



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology



Global
Bio-India
2024
Transforming Lives
Bioscience to Bioeconomy

बाइरैक
इन्क्यूबेट
इन्सिटिव
birac
Ignite Innovate Incubate

Exhibitor DIRECTORY



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology
Government of India



Biotechnology Industry Research
Assistance Council
Government of India Enterprises

GLOBAL BIO-INDIA 2024

12-14 September 2024

Hall no. 5, Pragati Maidan, New Delhi

Global Bio-India 2024 is a mega international congregation of biotechnology stakeholders, including international bodies, regulatory bodies, central and state ministries, SMEs, large industries, bioclusters, research institutes, investors, and the startup ecosystem. This annual event is organized by the Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Undertaking under the Department of Biotechnology (DBT) Ministry of Science and Technology, Government of India showcasing India's Biotech growth and opportunities to the world.






सत्यमेव जयते

DEPARTMENT OF BIOTECHNOLOGY

Ministry of Science & Technology
Government of India

DEPARTMENT OF BIOTECHNOLOGY

The Department of Biotechnology (DBT) is an Indian Government Organization set up in 1986 under the Ministry of Science and Technology facilitating research, capacity-building, technology, and enterprise development in the field of biotechnology. DBT has an Autonomous Body- Biotechnology Research and Innovation Council (BRIC) consisting of 13 Institutes, 2 Autonomous Institutes namely, Regional center for Biotechnology, Faridabad and International Centre for Genetic Engineering and Biotechnology, New Delhi; 2 PSUs namely BIRAC and BICOL. During the period of May 2014 to August 2023, DBT has supported 6518 institutes and 2480 NGOs resulting in about 18401 publications and patents over 1044 technologies. In attaining its mission, the DBT actively collaborates with more than 15 countries globally.





**Biotechnology Industry Research
Assistance Council**
Government of India Enterprises

BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL

BIRAC is a Section 8 "Not-for-profit Company" set up by Department of Biotechnology, under Ministry of Science & Technology, Government of India, as an interface agency to promote Industry-Academia interface. Mandate of BIRAC is to nurture and empower the Biotech Innovation Ecosystem in India. To serve various dimensions, BIRAC operates mainly in 3 verticals i.e. Investment schemes, Entrepreneurship Development & Strategic Partnerships. BIRAC works closely with all partners - National and International to leverage the strength and expertise, mobilize resources and extend the outreach of its activities for innovative affordable product development addressing the unmet need.

BIRAC IMPACT




Index

Sl. No.	Categories	Subcategories	Page No.
1	Start UP	Healthcare Therapeutics & Vaccines	7-43
		Healthcare Devices & Diagnostics	45-113
		Industrial Biotechnology	117-170
		Agriculture	173-177
2	Incubator		178-220
3	Industry	Sponsors	222-231
		Non-Sponsors	232-235
		SMEs	236-238
		CROs	239-242
5	Academia		244-265
6	States		266-271



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology



STARTUPS (Pg. No. 5-177)

**Healthcare
Therapeutics & Vaccine**

**Healthcare
Devices & Diagnostics**

**Industrial
Biotechnology**

Agriculture



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology

Global
Bio-India
2024
Transforming Lives
Bioscience to Bioeconomy

बाइरैक
इन्क्यूबेटर्स
बिरैक
Ignite Innovate Incubate



**Healthcare
Therapeutics & Vaccine**

HEALTHCARE- THERAPEUTICS AND VACCINES		
Sl. No.	Company Name	PAGE NUMBER
1	Aaarna Therapeutics Pvt Ltd	8
2	Abhignya Biotech Innovations	8
3	Acasta Health Pvt Ltd	9
4	Aerogene	9
5	Ahammune Biosciences Private Limited	10
7	Akrivis Health Care Pvt Ltd	10
8	Amar Biosystems Pvt. Ltd.	11
9	Amaterasu Lifesciences Llp	11
10	Apcegen Technologies Pvt Ltd	12
11	Apramitha Innovations Private Limited	12
12	Arnav Biotech Corp	13
13	Atreves Healthcare Pvt. Ltd.	13
14	Balman Eswaran Biomedicine And Materials Science Pvt. Ltd.	14
15	Bioacademia Nexus Technologies Llp	14
16	Bioagile Therapeutics Pvt Ltd	15
17	Bioconsort Consulting And Research Llp	15
18	Boltzmann Labs Private Limited Eviogen Discovery Private Limited	16
19	Bonji Naturals Private Limited	16
20	Breww Therapeutics Private Limited	17
21	Bycus Therapeutics Private Limited	17
22	Calm The Chaos	18
23	Cellogen Therapeutics Private Limited	18
24	Consyte Life Sciences Pvt Ltd	19
25	Cygenica	19
26	Descign Ai	20
27	Diverge Communications	20
28	Dr. Rituparna Sinha Roy	21
29	Dr. Shiroadkar's Health Solutions Pvt. Ltd.	21
30	Eaffocare Innovation Ltd.	22
31	Eviogen Discovery	22
32	Fejuice	23
33	Filamentech	23
34	Fitabeo Therapeutics Limited	24
35	Focelite Goodness (I) Pvt Ltd	24
36	Growdea technologies pvt ltd	25
37	Inger therapeutics pvt ltd	25

HEALTHCARE- THERAPEUTICS AND VACCINES		
Sl. No.	Company Name	PAGE NUMBER
38	Innaumation Medical Devices Private Limited	26
39	INTE-ELABS PRIVATE LIMITED	26
40	INVIGORATE BIOTECHNOLOGIES LLP	27
41	Jeeto Biocourier	27
42	KoshKey Sciences Pvt Ltd	28
43	Levim Lifetech Private Limited	28
44	Lorven Biologics private Limited	29
45	MESTASTOP SOLUTION PVT LTD	29
46	MG Biological Pvt Ltd	30
47	MOLDOC BIOTECH PRIVATE LIMITED	30
48	Molecule AI Private Limited	31
49	Nanic Ayurveda	31
50	Natural Solutions & Neutraceuticals Private Limited	32
51	Neothera Research Private Limited	32
52	nubiogenx private limited	33
53	OmniBRx Biotechnologies Pvt. Ltd.	33
54	Oncosimis Biotech Pvt Ltd	34
55	Orish J Bioworks Pvt. Ltd	34
56	Peptomer Therapeutics Pvt Ltd	35
57	POLYORBIT PVT. LTD.	35
58	Prescience Insilico Private Limited	36
59	Radiom Bioinnovations Pvt. Ltd.	36
60	Sangadak Technologies Pvt Ltd	37
61	Schrocken India Private Limited	37
62	Sravathi AI Technology Pvt Ltd	38
63	Suria Eye Products Pvt. Ltd.	38
64	SWALAVA ENTERPRISES PRIVATE LIMITED	39
65	Tech Cell Innovations Private Limited	39
66	Theracues innovation pvt ltd	40
67	Theraxcel Healthcare Private Limited	40
68	Tranalab Private Limited	41
69	Transcell Biologics Private Limited	41
70	Unicas Biotech Private Limited	42
71	VEGEN LABS LLP	42
72	WeTranslate	43
73	ZZWICK HYGIENE PVT LTD	43



Thematic Area: AAARNA Therapeutics Pvt Ltd., Dr. Pooja M. Tiwari



Founder and Co-founder(s):
Dr Pooja M. Tiwari,
Mr Subhash Bawage,
Mr Shyam Tiwari

Developed Under
(scheme):
BIG

Email:
info@aaarna.com

Product/Technology differentiation from Competitors

Its a broad spectrum antiviral against influenza and another for all 4 Dengue viral strains.

Brief Description of Product

Developed two antiviral therapeutics against influenza virus and dengue virus. 1. mRNA expressed antiviral therapeutics inhibit viral entry into the host cells. 2. Antiviral against Dengue virus targets viral RNA thus making it inactive.

Current Stage of Development

For both of our antiviral therapeutics, pre-clinical proof of concept data is complete.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Global

National/Societal Relevance

With the population density, India is constantly under economic and healthcare burden of influenza and Dengue cases have increased over last year, making antiviral therapeutics need urgent.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

mRNA expressed antiviral therapeutics against viral infectious diseases

IP Status

Provisional being filed

Thematic Area: Abhignya Biotech Innovations



Founder and Co-founder(s):
Dr Sambashiva Daravath

Email:
abhignyabiotech@gmail.com

Product/Technology differentiation from Competitors

Completely Herbal, Non-toxic and 100% Chemical free.

Brief Description of Product

ALSET is a product dedicated to quality and natural ingredients ensuring best in mosquito protection.

It is herbal mosquito repellent spray, with following features: 1.100% Chemical-Free and is crafted from natural ingredients, making it safe for your skin as well as for the environment. 2.Skin-Safe: ALSET protects without compromising your well-being. 3.Powerful Herbal Blend: formulation combines potent botanicals to keep mosquitoes at bay. 4. Indoor and Outdoor use: Spray ALSET near light sources, patios, and doorways to create a mosquito-free zone.

5. Effective protection: Long-lasting defense against mosquitoes along with anti-bacterial, anti-fungal and anti-viral properties.

Current Stage of Development

Ready to be launched in the market

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Telangana, India

National/Societal Relevance

Herbal, Non-toxic and 100% Chemical free mosquito repellant for Indian market.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

ALSET Mosquito Herbal Shield

Product Positioning

An alcohol free and chemical free composition gives it an edge from other competing products.

Import Substitution

Herbal ingredients

Export Potential

Good

Thematic Area: Acasta Health Pvt Ltd



Founder and Co-founder(s):
 Dr. Suresh Poosala

Email:
 suresh@acastahealth.com

Product/Technology differentiation from Competitors

Age-MAP™ stands out by using a unique combination of non-invasive methods and extensive questionnaires. We collect genomic and proteomic data through non-invasive techniques like buccal swabs and saliva samples, while also incorporating clinical and functional data from a detailed questionnaire. Thus, eliminating the need for invasive procedures and clinical validation, making it user-friendly. Our innovative Biomarker Predictive Screening platform uses advanced Proteomic, Genomic, Metabolomic, Clinical, and Functional Hallmarks of Aging to provide personalized, actionable health insights. This holistic approach empowers users to manage their health and wellness proactively, setting Age-MAP™ apart as a leader in accessible, cutting-edge health assessment technology.

Brief Description of Product

Age-MAP™ is a cutting-edge health assessment tool that utilizes an advanced in-house algorithm to analyse a comprehensive set of genomic and functional parameters. It is an innovative Biomarker Predictive Screening platform based on advanced Proteomic, Genomic, Metabolomic, Clinical, & Functional Hallmarks of Aging. This innovative product provides personalized insights into an individual's HealthSpan, enabling proactive management of health and wellness. Age-MAP™ is designed to help users make informed decisions to optimize their lifestyle, prevent age-related conditions, and enhance overall well-being. With a focus on precision and personalization, Age-MAP™ aims to revolutionize the way people approach aging and health management. Age-MAP™ Biological Age, leverages a comprehensive data collection process, including a combination of biological samples and clinical information. We use non-invasive methods to gather genomic, proteomic data, which are then analysed using our proprietary algorithm. This detailed and precise approach ensures that the insights provided are both accurate and actionable, empowering individuals to take proactive steps in managing their health and wellness.

Current Stage of Development

Age-MAP™ is in the advanced stages of R&D, having developed and validated proprietary algorithm, using a non-invasive buccal swabs and saliva collection for genomic and proteomic data. These methods allow for easy and efficient data collection, eliminating the need for clinical validation. The finalization of the user interface is currently under process along with expansion of dataset, and compliance with relevant health and safety standards. Establishing strategic partnerships for product distribution and market entry within the next 3-6 months following a full-scale launch are immediate future plans.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India

National/Societal Relevance

Age-MAP™ addresses national and societal needs by providing accessible, non-invasive health assessments that promote proactive wellness and aging management. Its personalized insights help individuals optimize their health, potentially reducing healthcare costs and improving quality of life across diverse populations.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

Age-MAP™ Bio Real Biological Age

Name of Startup: Arogene Biotech



Founder and Co-founder(s):
 Dr Subash Chandra Dadhich
 Dr Rekha Dadhich

Developed Under (scheme):
 SEED Fund

Email:
 dr_dsubashchandra@yahoo.com

Product/Technology differentiation from Competitors

Our technology is superior as it combines materials to give a cartilage with tensile strength equal to natural knee cartilage. We use autologous live chondrocytes which have least chance of rejection or immune reaction.

Brief Description of Product

Our product is hybrid knee cartilage made from natural gelatin and polymer added with live chondrocytes.

Current Stage of Development

Knee cartilage synthesis has been researched and well documented. It is being actively pursued in several countries. We have formulated the gel using hybrid materials and it is ready to be tested.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Initially we shall market it in India and gradually to the SAARC countries.

Product/Technology

Our product technology uses a combination of gelatin and polymer to form a bio ink. We add live chondrocytes to make it a viable knee cartilage.

National/Societal Relevance

Osteoarthritis is a common problem especially in women over the age of 50 years. Our product would be able to solve the chronic pain and disability.

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

Hybrid 3D Bio printed Knee Cartilage with live Chondrocytes

Product Positioning

We would be able to sell the product to patients are suffering from osteoarthritis. Most of our patients above 50 years of age.

IP Status

Application number 202441047738

Import Substitution

Our product would reduce the import of metallic knee joint prosthesis.

Export Potential

We shall be able to export to SAARC countries in about 2 years time

Thematic Area: Ahammune Biosciences Private Limited



Founder and Co-founder(s):
Ahammune Biosciences
Private Limited

Developed Under
(scheme):
BIPP

Email:
parul@ahammune.com

Product/Technology differentiation from Competitors

The current management options for vitiligo include steroids and immunosuppressants, drugs which are not targeted and cause generalized decrease in immunity. This leads to minimal efficacy along with several side-effects. At Ahammune, we have set-up a program specifically to target cellular pathways relevant for Vitiligo using easy to synthesize small molecules. Ahammune's small molecules target the causal pathways associated with the spread of depigmentation in vitiligo and thus are much safer and effective than repurposed immunosuppressants which are bound to have off-shoot effects.

Brief Description of Product

Vitiligo is the most common depigmenting disorder with a global prevalence of 1-2. Patchy white appearance of skin is a cause of great concern to patients as it causes change in their appearance and causes severe psychological stress due to underlying social stigma. Till now, there is no cure for this disease and all present options are symptomatic in nature. Ahammune has developed a new drug candidate with 'first-in class' mechanism of action for vitiligo treatment. This candidate has been developed as a topical product and has been demonstrated to be both safe and efficacious in animal studies. Phase 1 studies have further established the safety of the product in healthy human subjects. Phase II studies are now planned for this product in vitiligo patients. It has the potential to fulfil the lacuna that currently exists in vitiligo therapeutics arena and bring hope for millions of patients. In addition to this, we are developing a platform for small molecules which targets other autoimmune diseases such as atopic dermatitis.

Current Stage of Development

The current drug candidate has reached the stage of Phase II trials after rigorous testing in cellular and animal models in the discovery stage. The development stage involved optimization of synthetic process for API and formulation followed by GLP toxicity studies. Having completed these steps, currently the clinical development stage is ongoing

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

International geographies. Global patents filed

National/Societal Relevance

The impact of vitiligo goes beyond skin. Burden of Vitiligo is huge in India, with certain regions like Gujarat having an estimated 8 of population being affected. The fact that depigmentation is more apparent on darker skin and social stigma and exclusion associated in culture makes vitiligo of extreme relevance to the Indian society. We are providing new hope to vitiligo sufferers through our new treatment.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

AB1001: A new drug candidate for debilitating skin depigmentation disorder, vitiligo

Product Positioning

The product is positioned as a prescription product to be prescribed by dermatologists to patients.

Export Potential

The drug candidate is a proprietary new chemical entity with patent applications filed in several countries.

IP Status

Patent Applications: PCT/IB2018/056677
PCT/IB2019/053459 PCT/IB2019/059389
Granted Patent: 395240, US 11,739,082 B2,
IDP000084533, 278322, JP7520810B2,
AU2019260644B2.

Thematic Area: Akrivis Health Care Pvt Ltd



Founder and Co-founder(s):
Dr J Sarat Babu,
Mr. J Sampath kumar

Email:
sales@akrivis.in

Product/Technology differentiation from Competitors

Our exosome and nano technologies set us apart from competitors by offering a dual-approach to advanced regenerative solutions. Our synthetic exosomes deliver precise, targeted bioactive molecules for optimal cell repair and regeneration, while our nano-encapsulation technology ensures deeper, more controlled penetration of active ingredients. This combination provides faster, more effective results in skincare, hair restoration, and chronic wound healing, minimizing risks of immune rejection or contamination. Unlike others relying on traditional or stem-cell-derived methods, our innovative technologies enhance both safety and efficacy for superior, long-lasting outcomes.

Brief Description of Product

Akrivis Health Care provides cutting-edge solutions in regenerative skincare, hair restoration, and chronic wound healing, utilizing advanced exosome technology and biotechnology to deliver clinically proven, safe, and effective products that promote skin rejuvenation, hair growth, and accelerated tissue repair.

Current Stage of Development

Our product justifies a Technology Readiness Level TRL 8 designation because it has successfully undergone rigorous validation in an operational environment.

Are you willing to Transfer/Out-License your Technology No

Major Achievements

Awarded by the QCI for our contributions in exosomes and nano technologies, Board member for BIS GoI.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

Exosome and Nano Biologics

Unique Selling Point

Exosome technology harnesses the power of naturally occurring cell-to-cell communication systems, enabling targeted delivery of bioactive molecules for precise and efficient skin and tissue regeneration. This cutting-edge approach enhances healing, stimulates collagen production, and accelerates cell renewal, offering faster, safer, and more effective results in skincare, hair restoration, and chronic wound healing compared to traditional methods. With the ability to mimic the body's natural regenerative processes, exosome-based products provide superior outcomes with minimal risk of adverse reactions.

Product Positioning

Premium Skin Care

Export Potential

With few Countries having this technology, there is a huge potential

IP Status

In Progress



Thematic Area: Amar Biosystems Pvt. Ltd.



Founder and Co-founder(s):
Keerthi Renganathan and
Asrar Maqbool

Email:
info@amarbiosystems.com

Product/Technology differentiation from Competitors

Automation, variable flow rate, multiple chip use, in-built wash program.

Brief Description of Product

nanomake L™ is a user-friendly microfluidic platform designed for rapid optimization and formulation of nanomedicines. This fully automated system, utilizes both, single-use and multi-use microfluidic chips to enable reproducible scale-up of nano formulations, such as mRNA-lipid nanoparticles LNPs, polymeric nanoparticles, liposomes, etc while preserving their critical quality attributes. This instrument, based on controlled microfluidic mixing technology, ensures the production of uniform and reproducible high-quality nanoparticles. With an option to work with a wide range of flow rates on a single platform and using three configurable precursor pumps for a precise process control, Nanomake L™ ensures efficient and versatile formulation of a range of nanoparticles. Its built-in washing program keeps the microchips clean, while the systems versatility to accommodate microfluidic chips with different internal volumes, enhances the process flexibility and adaptability.

Current Stage of Development

The system is under 3rd party validation.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Worldwide

National/Societal Relevance

nanomake L is an indigenously developed microfluidic platform designed for application in the biopharmaceutical and vaccines industries for research and development. It will serve as an affordable alternative for both Indian and international laboratories and will be utilized in academia and industry for the creation of therapeutics, such as mRNA vaccines.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

nanomake-L

Product Positioning

nanomake-L technology is a simple to use microfluidic platform designed to enable rapid optimisation and formulation of nanomedicine with optimal setup and training.

Import Substitution

Yes

Export Potential

Yes

IP Status

Patent has been granted for the Microfluidic chip design under patent number: 308036 and 308037.

Thematic Area: Amaterasu Lifesciences LLP



Founder and Co-founder(s):
Founder and Managing Partner:
Maharukh Rustomjee

Developed Under
(scheme):
BIG

Email:
praveen@amaterasu.in

Product/Technology differentiation from Competitors

SiDMI will reduce side effects and development of resistance to the anti-malarial drugs ACTs as being single dose resolves the issue of patient compliance to treatment.

SiDMI, Single Dose Anti-Malari Injection, offers comprehensive malaria treatment with just single-dose of

Artemether+Lumefantrine Injection.

SiDMI has demonstrated 100% clearance of the malarial parasite from the blood, without recrudescence in the clinical simulation model in mice at significantly low doses providing 100% survival.

Brief Description of Product

Despite the proven efficacy of WHO recommended Artemisinin Based Combination Treatments, lack of patient compliance has proven detrimental and resulted in development of resistance. ACTs poses challenges such as undesirable side effects, incomplete dosing, unavailability of parenteral therapy and multiple injections leading to incomplete treatment. The strong possibility of emergence of artemisinin resistance globally will have serious adverse effects on malaria control program.

SiDMI, a novel Single Dose anti-Malaria Injection with a depot injectable formulation of the WHO recommended Artemether Lumefantrine combination. It has demonstrated 100% parasite clearance in preclinical malaria simulation model in mice. SiDMI ensures 100 patient compliance and significantly reduces side effects. SiDMI will bring radical shift in malaria treatment from 6 days to a single-dose. SiDMI could help in preventing transition from uncomplicated to complicated malaria thus saving lives, decreasing the need for hospitalisation and thereby reducing the healthcare burden.

Current Stage of Development

Proof of Concept has been established in P. berghei model followed by PK study in mice and GLP single dose toxicity study in mice and rats which established safety and efficacy. Current development plan includes PK study of SiDMI in rats, process scale-up at manufacturing site and ICH stability study with an objective to apply for approval of clinical studies to DCGI.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Africa, India and South East Asia

National/Societal Relevance

India has the largest population at risk from malaria. Further the strong possibility of artemisinin resistance in India reiterates the need for effective malaria control and treatment programs and new antimalarial drugs or formulations, with single-dose, broad therapeutic potential and novel mechanism of action. SiDMI is an important step in this direction.

Non-compliance to the 6-day anti-malarial treatment with ACT, due to associated side effects, is a major challenge in treating malaria. This is proposed as an important cause leading to disease progression towards severe or cerebral malaria, thus increasing the risk of death.

SiDMI proposes synergy of high efficacy with high patient compliance to provide immense social benefits through control of this disease.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

SiDMI - Single Dose Anti-Malaria Injection

Product Positioning

The Single Dose Anti-Malaria Injection SiDMI will ensure 100% patient compliance to anti-malaria therapy thus preventing uncomplicated Malaria and associated complications or hospitalisation thereby saving huge medical expenses. SiDMI will reduce side effects and development of resistance to the anti-malarial drugs ACTs.

Import Potential

As India is self-sufficient with respect to anti-malarial drugs the import substitution is not envisaged. Currently there is no direct competition to SiDMI.

Export Potential

Huge, Global anti malaria market is approximately USD1 billion with more than 40 share from ACT treatments. Considering the 100% compliance benefit, it is sure to penetrate existing ACT market and grab large market share from the available US\$ 400 million market opportunity.

IP Status

Indian Patent Application 201821041493- A liquid injectable composition - Assigned to Amaterasu by Institute of Chemical Technology ICT, Mumbai International Patent Application Number PCT/IN2019/050808 US Patent Application No.: 17/289008.



Thematic Area: Apcegen Technologies Pvt Ltd



Founder and Co-founder(s):
Amita Vyas Ashutosh Vyas

Developed Under
(scheme):
BIPP

Email:
amita@apcegen.com

Product/Technology differentiation from Competitors

1. PEGhFab is a novel fully human PEGylated Fab 2. Low dosing as compared to other available drugs like Humira, Remicade or their biosimilars, once in a month anticipated instead of twice a week injection which saves on doctor visits. 3. Subcutaneous injections are possible instead of IV dosing with currently available drugs. 4. The lack of complement fixation may impart less risk of intracellular infection than the monoclonal antibody agents, a potentially much safer drug. 5. Lower COGS. Lesser cost of production.

Brief Description of Product

Tumor necrosis factor alpha is a pro-inflammatory cytokine implicated in the pathogenesis of various immunological diseases including rheumatoid arthritis. Neutralizing TNF is an effective treatment strategy in RA. Currently, this requires the use of biological agents, such as mAbs and soluble receptor-human Fc fusion protein, which are expensive to manufacture. An optimal TNF neutralizing agent needs to bind TNF with high affinity and have a long plasma half-life, low antigenicity and high tolerability and safety. It also needs to be accessible to all patients with RA who would benefit from TNF blockade. Apcegen has developed a PEGylated anti TNF Fab, PEGhFab, the Fab of human anti-TNF antibody is site specifically conjugated with a 40-kDa polyethylene glycol molecule PEG. Unlike other anti-TNF agents our PEGhFab does not cause complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, apoptosis or necrosis of neutrophils thus it will be much safer. In in-vitro studies, the PEGhFab was shown to bind to and neutralize human TNF in a dose- dependent manner. The biological efficacy of PEGhFab was established in Transgenic mouse model Tg197 in comparison with Remicade.

Current Stage of Development

Activities completed: 1. Clone development, early stage shake flask runs and invitro TNF binding assay 2. Lab scale process development, both USP and DSP at 1L Fermentation level 3. PEGylation of purified Fab and invitro TNF binding assays to compare binding efficacy between native Fab and PEGylated Fab 4. Product Characterization by means of various analytical methods 3. In-vivo biological efficacy study in Tg197 mouse model in comparison with Remicade.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India and RoW to begin with

National/Societal Relevance

About 1% of the Indian adult population has Rheumatoid Arthritis with women having two to three times more often than men. Onset is most frequent during middle age, but people of any age can be affected. Rheumatoid Arthritis primarily affects joints however, it also affects other organs in 15 to 25 of individuals. Many anti TNF biosimilars are now available in India but the affordability is still an issue. We target to place our PEGhFab with similar or higher effectiveness as compared to the available mAbs like Adalimumab but at almost one tenth of its cost, making it widely affordable.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

At Apcegen we have developed indigenous Platform technologies for biologics development and have used our platform to develop following products: 1. Novel PEGylated Antibody Fragment PEGhFab for the treatment of Rheumatoid Arthritis 2. Biosimilar Pembrolizumab 3. Biosimilar Etanercept 4. Biosimilar Afibercept 5. Biosimilar Erythropoietin 6. Biosimilar tPA

Product Positioning

Alternate and first line of targeted treatment for Rheumatoid Arthritis and other TNF related autoimmune disorders.

Import Substitution

Yes

Export Potential

Yes

Thematic Area: Apramitha Innovations Private Limited



Founder and Co-founder(s):
Sreedharala Venkata Nookaraju

Developed Under
(scheme):
BIPP

Email:
vsreedharala@apramitha.com

Product/Technology differentiation from Competitors

Psoriasis is a chronic disease, impacts the quality of life of its patients and require long term treatment for its management. Current treatment options i.e. corticosteroids, vitamin D analogs etc. are associated with side effects and have restrictions to use 4-8 weeks. Proposed Apremilast is the first PDE4 inhibitor to be used in the topical treatment of mild to moderate psoriasis and can use for prolonged period without/ minimal side effects. Also addresses the oral side effects such as tolerability, GIT issues, suicidal tendency, etc. It greatly improves the quality of life of psoriatic patients by managing the disease for.

Brief Description of Product

Psoriasis is a very widespread chronic disease across the world and it will have a significant impact on the quality of life of the patients. Current available topical treatment options are either corticosteroids or vitamin D analogs. These products can be used only for 4-8 weeks as they are associated with side effects. Apremilast is a PDE4 inhibitor and the current proposed product will be the first PDE4 inhibitor to be used in the topical treatment of mild to moderate psoriasis. Also, the current oral apremilast tablets approved by DCGI, USFDA & several other regulatory agencies for the treatment of psoriatic arthritis & moderate to severe psoriasis are reported to have patient tolerability issues, side effects, and few suicidal alerts. Topical presentation of apremilast is supposed to reduce the tolerability issues, and side effects and provide a better treatment option for the treatment of mild to moderate psoriasis patient segment.

Current Stage of Development

An approved drug substance i.e. Apremilast, PDE4 inhibitor, has been repurposed to mitigate the side effects associated with its current oral dosage form by developing an alternative topical formulation. The developed innovative topical dosage form has successfully demonstrated 36 months shelf life. The safety and efficacy of this product have been validated through five distinct preclinical studies. A proof-of-concept POC clinical study was conducted against placebo and confirmed its therapeutic efficacy and safety. Based on the recommendations of the Subject Expert Committee of DCGI, a comprehensive Phase III clinical trial with positive outcome has been carried out.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

The product is targeted to Indian market as of now. Planning to submit the dossier along with clinical study report to the countries which accepts the Indian Phase III Clinical trial reports. Subsequently, the same report submitted to the boards of the regulatory markets and inputs will be taken about

National/Societal Relevance

Psoriasis is a chronic skin disease, if not addressed at the early stages leads to serious complications. The existing approved topical treatment options are restricted for 4-8 weeks and these treatment options are need to rotate regularly to avoid the side effects and to manage the disease. The patient needs to visit the dermatologist to manage the disease and is to the patients. This burden can be decreased with this product as it can be used for prolonged period without rotation which can increases the quality life of the patients.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

PDE4i Topical dosage forms

Product Positioning

The developed product will be popularized in the tire 1 cities to capture the top dermatology key opinion leaders. Then it will be taken to the tire II cities and rural areas by partnering with strong derma market players.

Import Substitution

The developed product is an innovative product and is not available in foreign countries. It will impact on the import substitution.

Export Potential

The developed product can be exported to all tropical countries where the skin will become dry.

IP Status

IN 301416 granted patent number

Name of Startup: ARNAV Biotech Corp



Founder and Co-founder(s):
Dr. Shree Ram Singh
Dr. Pooja M. Tiwari

Email:
info@arnavbiotech.com

Product/Technology differentiation from Competitors

One of its kind in the market that acts both as a protein and an mRNA therapeutic against two significant respiratory pathogens RSV and flu.

Brief Description of Product

Entry inhibitor delivered as mRNA or a protein that blocks entry of Respiratory syncytial virus RSV and influenza.

Current Stage of Development

We have US patent, license and full FTO with in-vitro and pre-clinical animal efficacy data.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Worldwide

National/Societal Relevance

In India, RSV infections severely impact infants to 16 year old children with diagnosis merely at 2-15 years of age, often leading to serious respiratory issues and hospitalizations. Our candidate offers hope by reducing these infections, improving early diagnosis outcomes, and easing the burden on families and healthcare, fostering healthier communities across the country.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

Broad spectrum antiviral against RSV and influenza

Product Positioning

Our candidate offers a targeted therapeutic approach to combat RSV and flu like two birds at one shot. Its designed for optimal efficacy and safety, disrupts viral fusion, reducing infection rates. It addresses an unmet need for RSV therapeutics with enhanced delivery systems, ensuring precision treatment across patient.

Import Substitution

Yes, we aim to make this in India for India and beyond and are interested in partnering with institutions that would enable us to realize the Make in India potential of this.

Export Potential

Even in US, there are no post-infection RSV specific treatment available. The approved prophylaxis are expensive and dont treat the symptoms after infection has started. Especially, rural population, uninsured face inaccessibility. Thus providing a huge export potential

IP Status

US Patent US8815295B1, licensed to ARNAV.

Thematic Area: Atraves Healthcare Pvt. Ltd.



Founder and Co-founder(s):
Dr. Akash Chaurasiya,
Ms. Kanan Panchal

Developed Under
(scheme):
BIG

Email:
dr.akashchaurasiya@gmail.com

Product/Technology differentiation from Competitors

The available products tablets are conventional formulations with high dose requirements. Our differentiated product offers various advantages which will be helpful in disrupting the market. 1. Novel patented self-emulsifying technology-based drug product 2. Lean manufacturing with existing facility for continuous supply 3. Improved stability eases the logistics transportation, distribution & storage 4. Helps overcome the global issue of anti-fungal/microbial drug resistance 5. Make in India with proprietorship & import substitution.

Brief Description of Product

Fungal infections are one of the leading causes of diseases in populated countries like India. The drug available for the treatment of fungal infection exhibits limited clinical benefits due to unfavorable pharmacokinetic properties, severe toxicities, and resistance. Posaconazole is orally approved for treatment of various fungal infections, however, because of its limited oral bioavailability, high-dose of 600-800 mg/day is required for several weeks, which results in severe side-effects, fungal resistance and high treatment cost. To address these issues, the current product is a novel posaconazole capsule formulation using biocompatible excipients. The formulation is designed to develop a stable drug product with enhanced clinical benefits and ease of manufacturing. This product offers enhanced bioavailability and thereby provides better clinical efficacy at reduced doses as compared to existing products. Also, due to in-house patents and simple manufacturing processes, our product can be offered at affordable prices. This, thereby, can be more effective in lesser doses and available to the majority of the population.

Current Stage of Development

The proof of concept work is completed with product development, stability and pharmacokinetic study on rodent model. The scaling up of this product at an approved facility is ongoing and will be followed by a pharmacokinetic study on dogs.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India and Rest of the world

National/Societal Relevance

Fungal infections are one of the leading causes of diseases in populated countries like India. Patients contracted with fungal infections are also victims of social stigma as these diseases reflect on their physical well-being and can also lead to societal trauma. The drug available for the treatment of fungal infection exhibits limited clinical benefits due to unfavourable pharmacokinetic PK properties, severe toxicities, and resistance. Considering these limitations, we are developing a novel posaconazole drug product with better clinical efficacy and affordability for the Indian population and the rest of the world.

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

Posaconazole Capsule

Product Positioning

The product will be positioned for the oral antifungal drug market. Approximately, 1200 Cr. in INR. Since posaconazole is a broad-spectrum antifungal drug, it is used for the treatment of various types of fungal infections, including black fungus.

IP Status

2 Patents Application filed - Application No. 202411002299 & 202211001449



Thematic Area: BALMAN ESWARAN BIO MEDICINE AND
MATERIALS SCIENCE PVT LTD



Founder and Co-founder(s):
M P Balakrishnan, P Manoharan,
Rajul Bhaskar

Email:
sv.eswaran@gmail.com

Product/Technology differentiation from Competitors

Most anti-cancer drugs are prohibitively costly and have many side effects e.g., Doxorubicin, most commonly used anti-cancer drug show high cardiotoxicity and nausea, hair-loss are known side effects. Their water solubility allows easy elimination from body combined with low dosage requirements and delivery as injectables for use intravenously. These are highly active against different cancer cell lines e.g. lung cancer, colorectal cancer and breast cancer. There are very few drugs available for treating triple negative breast cancer TNBC and these compounds show good activity against TNBC as well.

Brief Description of Product

New "Fullerazirman", SWCNT and rGO aryl aziridino-Mn II complex are water-soluble nanocarbon materials and their anti-cancer activity has been evaluated and found to be comparable to that of Doxorubicin, the most used anti-cancer drug, which is known to have many side effects, including high cardiotoxicity. These new conjugates overcome the major limitation of nanocarbon materials, viz. insolubility in most common organic solvents which leads to non-processability of these materials for industrial applications. Their mechanism of action involves Radical Oxygen Scavenging ROS which leads to its superior Anti-Cancer, Anti-Viral and Neuroprotective activity. Further, due to their high water solubility these exhibits no cytotoxicity. These also allows slow drug release and targeted drug delivery. In addition to the medical applications, these have efficient electrical properties make them excellent candidates for nanolithography, organic electronics, particularly in the development of Organic Field Effect Transistors OFETs, Organic Light Emitting Diodes OLEDs and Biosensors.

Current Stage of Development

These new water soluble nanocarbon materials have been prepared and shown to be highly anti-cancer active against A549, CT26, U937, MDAMB-231, FaDu, HeLa, HCT-116, MCF-7 cell lines. These results are based on in-vitro work. Formulation studies are being done currently along with in vivo studies in mice at NARFBR, ICMR, Hyderabad. All achieved more than 90 anti-cancer activity at 125-g/ml, and at the same concentration maintained more than 70 cell viability. All showed significant Anti-cancer activity.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Beginning with the Indian market and then expanding worldwide.

National/Societal Relevance

Cancer is a highly relevant killer disease in India and rest of the world. There is much pain and suffering and financial loss and families going bankrupt. There is thus a very urgent need for low-cost low dose efficacious anti-cancer drugs with high anti-cancer activity with little or Low effect on normal cells. The current work is an expected to benefit cancer patients all over India. All the materials required for this work are available within the country "Make in India" the product is thus purely indigenous. The products have potential applications in materials science, e.g. Nano-device fabrication with applications in diverse fields.

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

Water Soluble Nano carbon materials for cancer treatment. Fullerazirman, SWCNT and rGO aryl aziridino - Mn II complex have been prepared and carefully characterized by modern spectroscopic techniques. These are water soluble, nano- size , non-cytotoxic and highly active against different cancers [Breast cancer; Triple negative Breast cancer; Lung cancer; Colorectal Cancer]

Product Positioning

Since these are new chemical entities, these should attract worldwide attention as the drugs are low cost, nano, non-cytotoxic and these should be positioned as life-saving drugs which help prolonging life and help in longevity of human beings

Import Substitution

These new anti-cancer drugs will replace very costly imported drugs which are highly cytotoxic. These could in addition lead to considerable export worldwide and saving many lives and thus reducing the suffering of mankind.

Export Potential

The export potential is immense as these products are new anti-cancer drugs which are highly active against different form of cancers without any side effects as it is the case with the other drugs in current use e.g. Doxorubicin. Their easy and 'green' synthesis, nano size, easy delivery, high activity characteristics envisage export potential.

IP Status

1. Water soluble Fullerene C60 adducts for nano medicine & materials science Indian Patent No- 419806 granted on 31-01-2023.
2. Anti-Cancer Activity of a new water soluble reduced graphene oxide-Manganese II complex against three human cancer cell lines

Thematic Area: BIOACADEMIA NEXUS TECHNOLOGIES LLP.

Founder and Co-founder(s):
Mrs. KAMALA PAUL &
Dr. SAMRAT PAUL

Email:
paulsamrat.12@gmail.com

Product/Technology differentiation from Competitors

The medicated Biopatch was developed by incorporating bio-medicine derived from cultured cells. The dressing material is created using a sustainable derivative, with the primary component being cellulose extracted from sugarcane bagasse.

Brief Description of Product

BIOPATCH-D, an Innovative wound care material consists of two main components: 1: Medicated Biopatch: This component involves the preparation of a mitochondrial suspension-coated bi-layered polymeric scaffold. Mitochondria, crucial for cellular energy production and wound healing, are incorporated into the scaffold. This layer provides therapeutic benefits to promote wound healing 2: Sustainable Dressing Material: The second component comprises a sustainable derivative composed of silver nanoparticle-cellulose nanofiber composite material. This sustainable dressing material serves as the substrate for the Biopatch, providing a biocompatible and environmentally friendly base for wound coverage. The combination of these two components in BIOPATCH-D aims to create an effective and biocompatible wound dressing material with enhanced therapeutic properties for promoting wound healing.

Current Stage of Development

The prototype of the product, which comprises two subcomponents—a medicated patch and a dressing material—has been developed and is ready for demonstration. In vitro studies using cell culture systems have shown significant results, which were further validated through animal trials on a mouse model. The animal studies demonstrated that the product performed significantly better compared to the standard marketed product, Tegaderm. An e-filing for intellectual property rights IPR has been processed. The initial product is prepared for demonstration, pending the requirements for clinical trials.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India and Rest of the world

National/Societal Relevance

The innovative wound healing material offers significant national and societal benefits by improving healthcare outcomes, reducing treatment costs, and enhancing patient recovery. Utilizing sustainable materials like cellulose from sugarcane bagasse, it supports environmental sustainability and resource efficiency.

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

BIOPATCH -D Promoting wound healing with biocompatibility and sustainability.

Product Positioning

The prototype of the product, which comprises two subcomponents—a medicated patch and a dressing material—has been developed and is ready for demonstration. In vitro studies using cell culture systems have shown significant results, which were further validated through animal trials on a mouse model. The animal studies demonstrated that the product performed significantly better compared to the standard marketed product, Tegaderm. An e-filing for intellectual property rights IPR has been processed. The initial product is prepared for demonstration, pending the requirements for clinical trials.



Thematic Area: BioAgile Therapeutics Pvt. Ltd



Founder and Co-founder(s):
Divya C

Email:
divya@bioagiletherapeutics.com

Brief Description of Product

A CRO based in India providing an end to end clinical research services to pharmaceutical, nutraceutical, biotech, herbs, cosmetics and medical device industries. Services comprise of project management, site management, medical writing, data management and bio statistics.

Current Stage of Development

Currently developing our services for the pharmaceutical, nutraceutical, biotech, herbs, cosmetics and medical device industries for their clinical research needs.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India and USA.

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

Clinical Research services

Major Achievements

Awarded as Emerging Clinical Research Organization of the year 2017

Thematic Area: BioConsort Consulting and Research LLP



Founder and Co-founder(s):
Founder: Prof. Ena Ray Banerjee
Director: Dr. Shinjini Mitra &
Ms. Urbi Banerjee

Email:
shinjini.bioconsortllp@gmail.com

Product/Technology differentiation from Competitors

Currently there are no complete care packages in the market.

The product is a multidisciplinary enterprise combining different technologies together it in a package.

The incorporated technologies have been scientifically validated and will be made into nutraceuticals and lifestyle products.

Brief Description of Product

This product is a scientifically-backed package for complete self-care. BioConsort Consulting and Research LLP has several technologies in its kitty, including a probiotic formulation with therapeutic and preventive activity against inflammatory bowel disease, a patented camelid nanoantibody technology which can be used to generate antibodies against any antigen for therapy and diagnosis, and a plethora of phytochemicals with anti-inflammatory and anti-oxidative effects and effective in a number of diseases.

The package offers therapy for physical health issues, including gastrointestinal issues, diabetes, kidney issues, skin issues, lung issues, and others, in the form of probiotic therapy, phytotherapy and nanoantibody therapy, as required.

Offering customized diets, including health drinks containing probiotics and phytochemicals, as well as other services, like psychological counselling, legal advice, travel advice, lifestyle products including creams and face masks containing phytochemicals, and specialized courses, as and when needed by the client.

The package includes the following:

1. For regulation of diseases: a probiotic formulation for gastrointestinal disorders, phytotherapy for diabetes, kidney disorders, atopic dermatitis and lung disorders, and nanoantibody therapy for atopic dermatitis and lung disorders.
2. For proper food and nutrition: phytochemical- and probiotic-based health drinks and food products, along with a customized diet as needed by the client.
3. For wellness: liaising with partners for services psychological counselling, legal advice, travel advice, and provide lifestyle products face masks, creams, perfumes, and others and skill enhancement courses, in collaboration with other partners.

In a word, this is a complete package to keep oneself healthy, physically and mentally, especially for post-retirement clients.

Current Stage of Development

While the package itself is in an idea stage, the health drinks, therapies and diagnoses being proposed have passed lab-stage screening. Prototypes have been developed of the probiotic drink and the nanoantibodies, while the phytochemicals have been extensively validated in the lab. The nanoantibody technology has already been patented.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Pan-India

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

"Celebrate Me" Care Package- a one-stop shop for a healthy self.

IP Status

Patent for nanoantibody technology: Patent No. 380047 dated 27.08.2015, titled "Method of developing an antigen-specific library of novel format stable single chain antibody"



Name of Startup: Boltzmann Labs



Founder and Co-founder(s):
Kolli Sarath and Paritosh Prashar

Developed Under
(scheme):
BIG

Email:
kolliarath@boltzmann.com

Product/Technology differentiation from Competitors

Key Features & Benefits • AI-First Approach: Leverages AI and machine learning across the entire drug discovery process • Cloud-Based Platforms: Accessible and scalable solutions for seamless collaboration and data management • End-to-End Solution: Streamlines drug development from target identification to clinical trials • AI Agent-Based Workflows: Automates routine tasks and provides intelligent suggestions to enhance research efficiency • Integrated Electronic Lab Notebook: Facilitates efficient experiment tracking, data organization, and knowledge sharing.

Brief Description of Product

An end-to-end, AI-powered solution for accelerating drug discovery and development. Suite Components apps: • BoltChem: AI-driven platform for predicting molecular properties, aiding in hit identification, expansion, and lead optimization. • BoltBio: AI platform for novel disease target discovery, biomarker identification, off-target predictions, and multi-omics analysis. • ReBolt: AI-powered synthesis planning tool with an integrated Electronic Lab Notebook for streamlined experiment tracking and data management. • BoltPro: AI platform for protein engineering, including antibody, peptide, and enzyme design and optimization • ClinBolt: AI-driven platform utilizing digital twins to enhance clinical trials through disease progression forecasting and patient response simulation.

Current Stage of Development

The products have been validated in collaboration with industry partners.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, US and Europe

National/Societal Relevance

Make in India.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Boltzmann AI Drug Discovery Suite - An end-to-end, AI-powered solution for accelerating drug discovery and development.

Product Positioning

Boltzmann AI Drug Discovery Suite is positioned as a transformative, AI-driven solution that empowers the pharmaceutical industry to innovate faster, smarter, and with greater success.

Thematic Area: BONJI



Founder and Co-founder(s):
Ruchi Singh Neekhra, Tushar Bansal, Vipul Bajaj, Mehak Kapoor

Developed Under
(scheme):
BioNEST

Email:
support@bonji.in

Product/Technology differentiation from Competitors

Ruchi Singh Neekhra, Tushar Bansal, Vipul Bajaj, Mehak Kapoor.

Brief Description of Product

Personal care product by tackling urban stressors—pollution, radiation, and hard water with a groundbreaking fusion of natural ingredients.

Current Stage of Development

Currently developing our services for the pharmaceutical, nutraceutical, biotech, herbs, cosmetics and medical device industries for their clinical research needs.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Bonji targets urban areas globally, focusing on regions heavily impacted by pollution, radiation, and hard water. Our products address the specific needs of consumers in cities and industrial areas where environmental stressors significantly affect skin and hair health.

National/Societal Relevance

Bonji addresses the growing concern of urban-induced skin and hair damage, a pressing issue in increasingly polluted and industrialized environments. By providing effective, natural solutions that combat the harmful effects of pollution, radiation, and hard water, Bonji contributes to healthier communities and supports the well-being of modern urban populations.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

BONJI - beyond just natural

Import Substitution

Bonji reduces dependency on imported skincare by offering advanced, locally developed solutions that rival international brands. The product uses innovative technology and ECOCERT and USDA certified ingredients, provide high-quality, effective products that cater to domestic needs, fostering self-reliance and supporting local industry in the personal care sector.

Export Potential

Bonji has strong export potential, offering unique, scientifically advanced natural products that cater to the global demand for effective solutions to urban skin and hair challenges. Our innovative use of nanotechnology and commitment to ECOCERT and USDA certified ingredients position Bonji as a competitive brand in international markets, appealing to eco-conscious consumers worldwide.



Thematic Area: BREWW THERAPEUTICS PRIVATE LIMITED



Founder and Co-founder(s):
DR. SUDIP GHOSH AND
DR. MUNNA BHATTACHARYA

Email:
mysudip17@gmail.com

Product/Technology differentiation from Competitors

Fermented product range for Men.

Brief Description of Product

Fermenta is a world's first water based formula for mens care made from fermented fruits and vegetables. Fermenta solves unique need of mens rough skin through the patented technology. Fermenta solves Mens hair issues like dandruff, hair fall and hair growth and beard issues like beard dandruff and growth Fermenta is completely natural and has USFDA approved GRAS ingredients for safety purposes.

Current Stage of Development

Commercialized.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Punjab, Haryana and Delhi

National/Societal Relevance

Procurement from direct farmers increases their revenue.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Patented Men Care Product: Fermented Fruits and Vegetables.

Product Positioning

Men care.

Import Substitution

All products are made in India.

Export Potential

Huge market potential.

IP Status

Indian Granted Patent: 459674.

Thematic Area: Bycus Therapeutics Pvt. Ltd.



Founder and Co-founder(s):
Dr. Nageswara Rao, Dr. Cherish Babu,
Dr. Nishanth Pasaru, Rajeev Reddy

Developed Under
(scheme):
BIG, NBM

Email:
parao@bycusbio.com

Product/Technology differentiation from Competitors

Affordable biologics for India and global markets.

Brief Description of Product

1. Peg-Asparaginase: Therapeutic product used for treatment of acute leukaemia
2. rh-Epidermal Growth Factor rh-EGF: Topical product used for wound healing, diabetic foot ulcer, cosmetics
3. Endonuclease ByNase: Reagent used in biopharmaceuticals for nucleic acid clearance
4. Insulin Aspart: Fast acting treatment for Type-1 and Type-2 diabetes
5. Insulin Glargine: Long acting treatment for Type-1 and Type-2 diabetes
6. BT02: Therapeutic product used to treat chronic gout.

Current Stage of Development

Process development, optimization, demonstration of biosimilarity and generation of consistency data.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India and Global.

National/Societal Relevance

Healthcare equity, Ensuring medicine affordability for all.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Developing biosimilars for Affordable biologics

Import Substitution

Affordable biologics, substitutes expensive imported drugs.

Export Potential

Complies with international regulatory standards. Ability to be commercialized globally



Name of Startup: CALM THE CHAOS



Founder and Co-founder(s):
Founder - Dr. Mansi Gupta
Co-founder - Mr. Arjun Mahotra

Email:
calmtchaos@gmail.com

Brief Description of Product

Calm the Chaos is a brand of Ayurvedic products which are natural and pure. Our brand believes that skincare is utmost important and it should be of the purest form. The ingredients and its benefits are drawn from the ancient Indian Science of Ayurveda.

Technology readiness level (TRL)

TRL-2

Title/Name of the Product/Technology

CALM THE CHAOS Ayurveda Skin & Hair care

Thematic Area: CELLOGEN THERAPEUTICS PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Gaurav Kharya

Developed Under
(scheme):
NATO PHARMA

Email:
rikgangulybioinfo@gmail.com

Product/Technology differentiation from Competitors

Fermented product range for Men.

Brief Description of Product

Cellogen Therapeutics is biotech startup which is striving today to come up with innovative cell therapy-based solutions for a healthy tomorrow.

Technology readiness level (TRL)

TRL-1

Title/Name of the Product/Technology

CAR-T CELL THERAPY.



Thematic Area: Consytel Life Sciences Pvt Ltd



Founder and Co-founder(s):
Shubhendu Kumar Dash, Sandhyarani Dash
and Swagatika Satpathy

Developed Under
(scheme):
BIG

Email:
info@consytel.com

Product/Technology differentiation from Competitors

The stated national goals of malaria elimination by 2030 requires mass deployable safe anti-malarial formulation to reduce new infections and also block the transmission chain in the endemic areas. Currently, no suitable formulation is available in the market. Current formulation under development prevents progression to clinical stage of falciparum malaria and decreases transmission rates. It addresses all the limitations of current prophylactic agents and demonstrates a clear improvement over available options. The formulation therefore can be mass deployed to disrupt transmission and help eradicate malaria. It may also be a promising find to address malaria in pregnancy.

Brief Description of Product

A comprehensive malaria eradication strategy would call for a safe, mass deployable oral agent which could inclusively address the vulnerable population subset such as pregnant women, children, G6PD deficient population and people with concomitant neuropsychiatric illnesses. Owing to adverse effects profile of current anti-malarial drugs, the patient compliance remains poor hence not considered for mass rollout in malaria elimination programs. The company has developed a novel oral formulation capable of facilitating the malaria elimination objective by 2030. The potential usage extends over geographical boundaries and could be leveraged to eliminate malaria in addition to other interventions. This novel anti-malarial formulation is a polymeric nano encapsulation of Pgranatum extracts, suitably surface functionalized to suppress the liver stage development of human malaria cycle. Later the scope can be expanded to Pvivax parasites thereby providing a comprehensive therapeutic option to eliminate malaria.

Current Stage of Development

The PoC has been validated through in vivo mice model and the formulation under development has successfully impeded development of sporozoites at the liver stage with high margin of safety. Currently formulation optimization and preclinical studies are underway for submission to CDSCO under phytopharmaceuticals regulatory pathway as a new Drug.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Asia and Africa would be the geographical areas of focus for the antimalarial formulation.

National/Societal Relevance

Malaria is one of the major public health problems globally and impacts India as one of the High Burden-High Impact countries. Although India has made considerable progress in reducing its malaria burden and consequently formulated a National Framework for Malaria Elimination program in India, emphasis has to be placed on transmission elimination in addition to vector control. An important challenge identified is sanitization of the parasite pool harboured by human asymptomatic carriers facilitating continued transmission. A mass deployable prophylactic in endemic areas can tilt the balance decisively making dreams of malaria elimination by 2030 a reality.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Novel anti-malarial formulated on nano encapsulated botanical extracts with hepatic delivery for malaria prophylaxis. This aims to facilitate malaria elimination objectives by 2030. The product development is based on phyto pharmaceuticals regulatory pathway of CDSCO.

Product Positioning

Innovative formulation suitable for mass adoption across age groups and diverse population segments in endemic areas for malaria prophylaxis and decreasing transmission rates. This would support the malaria elimination by 2030 efforts.

Import Substitution

Today most of the anti-malarial APIs are imported and our formulation under development can play the role of effective import substitute.

Export Potential

There is a huge export potential as Africa and Southeast Asian countries suffer from resistant malaria cases. The product has been shown to be quite effective even in artesunate resistant malaria which is the mainstay of treatment currently. The formulation therefore shows global potential.

IP Status

A patent has been filed for our formulation under development under the title "Functionalised encapsulated compositions with hepatic delivery of antimalarial plant extracts" under application number 202241033791.

Thematic Area: CyGenica



Founder and Co-founder(s):
Dr Nusrat J M Sanghmitra, Founder
& CEO Dr Sk Fazul Haque Krishnan,
Cofounder & Director

Developed Under
(scheme):
BIG

Email:
nusrat@cygenica.com

Product/Technology differentiation from Competitors

GEENIE is differentiated because of its Novel cell entry mechanism ensuring the availability of 100 therapeutic cargo at the intracellular target side vs all other innovations in this space those are based on endocytosis based delivery leading to 2-3 availability at the intracellular target side Crossing blood brain barrier targeting brain and access to CNS therapeutics market Robust safety profile Recombinant nature of production and drug loading ratio leading upto 7 times reduction in manufacturing cost in comparison with liposomes top competing platform.

Brief Description of Product

GEENIE: An Efficient Targeted Delivery Platform GEENIE Guided, Efficient, Effortless Navigation for Intracellular Entry, is our core enabling platform, a molecular nanoneedle that crosses the living cell membrane barrier by tunnelling through it without doing any damage. Our patented technology can transport small molecule therapeutics, large proteins as big as CRISPR cas9, & nucleotide based therapeutics precisely into the target intracellular location bypassing the endosomes It is non toxic, non immunogenic and retains the drug efficacy at 40 less dose.

Current Stage of Development

Preclinical stage US FDA granted orphan drug designation for the treatment of glioblastoma 3 Pharma partnership with one paid POC.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Worldwide.

National/Societal Relevance

Cancer has affected all of us in one way or other. We lose 1130 of our loved ones every hour. Mainly because cancer therapy causes the pain. Our innovation can reduce that pain impacting more than 20 million patients worldwide. At CyGenica, we have revolutionized how drugs enter our cells. We have developed a novel molecular carrier technology platform for the efficient transport and targeted delivery of a broad range of intracellular therapeutics to enable safer, more effective, and affordable drugs to improve patient outcomes.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

Shaping the Future of Drug Delivery Platform at Molecular Scale by Delivering on the Promise of Safe, Efficient, & Targeted Intracellular Delivery to Transform Cancer and Genome Editing Therapies.

Product Positioning

First in class safe and targeted intracellular delivery platform for cancer drugs and genomic medicines

Import Substitution


Liposomal formulation of drugs.

Export Potential

First in class safe and targeted intracellular delivery platform having wide range of applications in making cancer drugs and genomic medicines safer and better impacting patients worldwide and this leads to high export potential.

IP Status

ACCEPTED Patents 1 in USA and 2 in EU 1. PCT/EP2018/072699 has entered national phase in USA, EU, China and India in July 2020 2. PCT/EP2020/055201 "Cell membrane penetrating conjugates for gene therapy" International publication number WO/2020/174070 entered national phase in USA, EU, India, China, Japan, Korea and Canada.





Thematic Area: DESIGN AI



Founder and Co-founder(s):
Vishal Gupta Kendrick Cetina

Email:
vishalgupta.bt@gmail.com

Product/Technology differentiation from Competitors

1. A patented Workflow design and management system which allows seamless data capture, management and collaboration across different stages of R&D in Life Sciences and Healthcare. The system automates documentation and bypasses the major bottleneck of manual documentation. 2. Single platform for end-to-end digitalization with a host of modules and features. Users will no longer need to buy, install, learn and manage multiple expensive and non-interoperable solutions. 3. AI enabled acceleration of R&D and organization productivity with the AI embedded directly into the user's workflow. AIRA - Artificial Intelligence Research Assistant, can answer questions, design experiments and write automated reports.

Brief Description of Product

Descign is a play on the words Design & Science. Descign is a cutting-edge cloud-based platform which enables Life Sciences and Healthcare organizations to: 1. Digitize, automate and scale their R&D workflows & data on a single platform 2. Collaborate seamlessly and securely with CROs/partners globally 3. Use Artificial Intelligence to optimize their workflows, enhance productivity and accelerate from discovery to market.

It is a holistic combination of Electronic Lab Notebook ELN, Lab Information Management System LIMS, Lab Execution System LES, Inventory Management, Order Management and Regulatory Compliance features CFR 21 P 11, ISO15189, GXP and more.

Current Stage of Development

The product is being used and implemented in multiple organizations across India & USA, spanning in academia, industry, pharma, biopharma and healthcare segments with a focus on CROs.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, USA and Europe.

National/Societal Relevance

Descign solves the problem of non-reproducibility of R&D. This will accelerate solving some of the biggest threats to humanity which are diseases, food shortages and climate change. Descign aims to enable a quick transition to a bio-based economy from a chemical-based economy.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Descign - AI powered data management and collaboration platform for Life Sciences and Healthcare.

Product Positioning

Digitalization platform for Medium and Large Enterprises in Pharma & Biopharma industry across India, USA and Europe.

Import Substitution

There are very limited Indian solutions available and they use legacy outdated technology. The foreign solutions are moderately advanced but are unaffordable for Indian Enterprises.

Export Potential

Descign is an R & D platform developed in India but built for the world. It has very high export potential with deep interest from MNCs. Descign aims to connect global R&D organizations and bring India's R&D to the forefront.

IP Status

Status - Granted Patent No.- 409078
Patent Name - A SYSTEM FOR ENTITY STATE-BASED STAGE-WISE FORMAL SPECIFICATION OF PROCESSES AND A METHOD THEREOF

Name of Startup: DIVERGE COMMUNICATIONS



Founder and Co-founder(s):
Founder - Aditi Bhardwaj

Email:
aditi@divergecommunications.com

Product/Technology differentiation from Competitors

A specialist marketing agency for biotech and life science sector above generic marketing and communication service provider.

Brief Description of Product

Biotech and life science companies communicate their technology and innovation without sacrificing scientific accuracy. As a marketing agency with a team of scientists-turned-marketers, the company has diverse skills to create and execute effective marketing strategies.

Current Stage of Development

Developed

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

India, USA, Europe

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Life Science Marketing and Communication Services



Name of Startup: DR. RITUPARNA SINHA ROY



Founder and Co-founder(s):
Dr. Rituparna Sinha Roy
Prof. Amit Kumar Dinda

Developed Under
(scheme):
BIG

Email:
rituparna@iiserkol.ac.in

Product/Technology differentiation from Competitors USP:

- i. non-immunogenic clinically safe ii thermostable
- iii does not depend on body's own coagulation method
- iv can be used for patients having inherent bleeding disorder and traumatic coagulopathy
- v forms clot only at injured sites

Problem addressed: Traumatic coagulopathy of wounded soldiers and accident victims cause huge no. of deaths worldwide. FDA-approved non-immunogenic sealants are not available. Widely used fibrin-based sealants cause immunogenic reactions and there is batch to batch variation and possibility of disease transmission is there, since it is prepared from biological sources. Certain FDA-approved sealants cause exothermic reactions and are difficult to apply. Patients having inherent bleeding disorder face life-threatening situation.

Brief Description of Product

The invention is focused on facilitating the formation of faster blood-clotting only at injured sites. At injured site, 3.14 cm 2, 30 L 1.5 mM such sealants form a physical barrier and absorbing fluid from the blood, it concentrates blood corpuscles and platelets and stop bleeding by forming hemostatic plug only at injured site. Sealant 5 exhibited ~82 sec 38.7 faster blood-clotting than fibrin and ~113 sec 53.2 faster blood-clotting than RADA-16.

Current Stage of Development

TRL-3 proof-of-concept stage

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Indian Organizations like DRDO, ICMR, Hospitals, Army, Pharma companies

National/Societal Relevance

Safe Sealant to treat bleeding disorder: Engineered peptide based clinically safe sealant. The current product is a designed fibrin and mussel foot pad protein- inspired non-immunogenic, thermostable, adhesive and efficient sealant for blood clotting. The designed sealant efficiently halts bleeding for both external and internal wounds, even for heparinized system overcoming the bacterial infection. In heparinized system, the sealant facilitates faster blood-clotting compared to fibrin ~82 s faster ~ 38.7 faster and blood-loss is ~ 4-fold less. Our sealant has exhibited ~ 53.2 faster ~113 sec faster blood-clotting than RADA-16. Both peptide based sealant RADA-16 and fibrin are FDA-approved sealant and RADA-16 was developed by a scientist from MIT, United States. The sealant has exhibited ~ 57 faster blood-clotting than DRDO's INMASEAL. Additionally, for this sealant, the process of clotting mimicry is like fibrin and the clotting mechanism is independent of body's own coagulation system. Thus, it can perform suture-free wound closure, which is extremely helpful for lung tissues and nerve tissues. Our product will save the lives of the injured individuals in the defence sectors, accidental victims and any other individuals especially having coagulation disorders without any harm in the system.

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

Clinically safe sealant for treating bleeding disorder for defense sector

Product Positioning

Axiostat, Fibroreal, Botroclot are the available products in the Indian market which are having different shortfalls. In India in 2015, hemostat demand market was valued at US\$ 54.1 million and in 2027, it will be past US\$ 105.

Import Substitution



Fibroreal Fibrin Sealant Kit

Export Potential

Axiostat, Fibroreal, Botroclot are the available products in the Indian market which are having different shortfalls. In India in 2015, hemostat demand market was valued at US\$ 54.1 million and in 2027, it will be past US\$ 105.1 Million valuation

IP Status

Indian patent granted entitled title: "Peptide based tissue sealant" Patent no. 527743 Date of grant: 15/03/2024 Application no.201831040193 Date of filing: 24/10/2018 Another Provisional patent filed patent no: 202431050925 Date of filing: 3rd July, 2024



Name of Startup: DR. SHIRODKARS HEALTH SOLUTIONS PVT. LTD



Founder and Co-founder(s):
Dr. Jyoti Shirodkar
Ajay Shirodkar
Shalmalee Shirodkar

Email:
ceo.blumark@gmail.com

Product/Technology differentiation from Competitors

- 1 Lowest Glycemic Index GI products in the World attracting Diabetic/Obesity/PCOS Foods Market
- 2 Optimum Glycemic Load for standard meal portion sizes ensuring adequate nutrition and yet with controlled sugar
- 3 Only company to have tested GI in-vivo as per ISO26642
- 4 Proven Heart-Healthy, as the micro-ingredient effective to reduce Lipids/Cholesterol to down CVD risk with the ingredient claim allowed by USFDA and European-FA
- 5 Amazing Probiotic gut friendly effectiveness
- 6 Balance of Carbs/Proteins/Good Fats/Fibre/Resistant Starch/Micronutrients/Anti-Oxidants/Phytochemicals
- 7 2-of-3 products are VEGAN and Gluten-free
- 8 Offers Sumptuous Tastes and variety
- 9 Needs of i Patients of Diabetics/Pre-Diabetics/PCOD/Piles/Constipation/Celiac/Obese/Celiacs/ Gluten-Wheat Allergies ii Those who practise prevention than cure concept

Brief Description of Product

1 BLUMARK Foods: BLUMARK is the brand of not only the lowest G.I. Foods, but also ensuring total health, marking the healthy journey of a user with foods perfectly fitting in the daily Indian meal habits.

1.1 Snack-Mix: A unique, clinically tested innovation of superfoods like wholegrain barley & millets with carefully chosen pulses blended with responsibly selected antioxidant spices, that offer a variety of benefits. Thalipeeth/Dosa/Uppma/ Utiapam/Cutlet/Chilla to perfectly fit Indian Snack Habits giving following benefits:

-Lowest G.I., far lower than that of Poha/ Uppma/ Idli/ Vada Pav/ Sandwich/ Paratha/ Polished Oats

-Soluble Fibre Beta Glucan Rich -Packed with Complex Carbs, Resistant Starch, Insoluble Fibre -Protein-Rich

-Gluten Free -Good source of Iron, Mg, P, Cu, Zn, Se responsible for good immunity

1.2 Shake-Mix: A unique innovation of superfood of wholegrain barley & millets infused with dates, almonds, pumpkin seeds & milk solids blended with responsibly selected popular flavours of Cardamom, Cinnamon, Chocolate that offers you the quickest energising health drink without any adverse effects, which normally all other energy drinks in market have due to added sugar & other ingredients.

Benefits Blumark offers are -

Soothing sweetness with G.I. 42

-Super Soluble Fibre Beta Glucan

-Resistant Starch, Insoluble Fibre

-Protein-Rich

-Gluten Free

-Good source of Ca,Mg,P,K,Cu,Zn,Se, responsible for good immunity and corrects Sodium-Potassium balance.

1.3 Roti-Mix: A unique, clinically tested innovation of superfood wholegrain barley & millets with scientifically chosen pulses, integrated with a patented process to derive the flour with improved taste while retaining health parameters. It offers to customer a variety of Chapati/ Phulka/ Bhakri/ Paratha from the same flour to perfectly fit lunch/dinner habits of Indians. They offer outstandingly unique benefits as follows: -G.I. as low as 30, significantly lower than Wheat/Jowar/ Bajra/Ragi/Polished Oats -Soluble Fibre, Beta Glucan Rich -Packed with Complex Carbs, resistant starch, insoluble fibre -Protein-Rich -99.997% Gluten Free -Good source of Iron, K, Mg, P, Cu, Zn responsible for good immunity and corrects Calcium-Magnesium balance.

Current Stage of Development

Products developed, Clinical Tests completed, manual process operations are in place ensuring quality.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

India (Pune/Mumbai/Nasik/Kolhapur) and abroad

National/Societal Relevance

Pandemic in has increased the cases of Diabetes/Heart/Obesity/PCOS/Child Obesity/Cancer post Diabetes in India. Current Diabetes treatments are called TTF by experts meaning Treating-To-Failure due to adverse side effects of drugs their ever-increasing doses, complications in spite of blood-sugar control. Ayurveda has immense potential to play effective alternatives.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

1.Clinically Proven, Patented BLUMARK Foods Ayurved /Modern Diet based: a Roti-Mix b Snack-Mix c Shake-Mix offering 7-Star Benefits:

- i Best Blood-Sugar Control via-Food without Hypoglycemia risk
- ii Heart-Healthy with Barley Beta-Glucan
- iii Gut-Friendly with Prebiotics
- iv 100% Natural, No Additives/Preservatives
- v Perfect Balance of Carbs/Good Fats/Fibre/ Proteins/Micronutrients/Anti-Oxidants/ Phytochemicals
- vi Gluten-Free
- vii Vegan

2. AI driven & Ayurved based Diabetes Risk Assessment Test

3. Health Consulting/Coaching Services

Product Positioning

BLUMARK gets positioned as "Super Niche Product" in the top-right quadrant with best health-value for customer

Import Substitution

For import Quinoa / Oats based products. The company has proven Swadeshi Therapeutic Food Technology, which can more effectively replace the existing fancy exotic products.

Export Potential

Diabetes/Obesity/PCOS/CVD are increasing all over the world. Hence, BLUMARK Foods have universal applicability/potential. The current products may appeal to Non-Resident-Indians. Target High- End Mkt:10Mn. with Indian-Style cooking/eating habits. Estimated export market potential of 3Mn.

IP Status

National and 2 International Patents Granted.





Name of Startup: EAFFOCARE PVT LTD



Founder and Co-founder(s):
Prof. Jyotsnendu
Dr. Baishakhi Chandra

Developed Under
(scheme):
BIG

Email:
j.giri251@gmail.com

Product/Technology differentiation from Competitors

Scientists have explored different silane derivative with positive charges as molecules to develop long-lasting hygiene products surface disinfectant and hand sanitizer. However, killing of the pathogen on the silane-coated surface normally takes a longer time, 15 min Zoono, New Zealand, Microban-24, USA. However, DuroKea technology is based on Nanotechnology with 100-200 nm particles, which will make coating and create nano-roughness on the surface. Unique positive charges needle on the nanoparticles, electrostatically attract pathogen negative charges and kill them instantly in around 60 sec by synergistic action of physical and chemical function. Particles customized for different surfaces of hospitals.

Brief Description of Product

Despite ongoing prevention efforts over the last decade globally, Health Care Associated Infections HAI are a serious problem where 10-19% of patient will acquire HAI during their hospital stay, resulting in morbidity, mortality, and increased costs. Antimicrobial resistance AMR is associated with HAI, and both issues are becoming a major threat to the country as cases have increased enormously. Maintaining 24x7 hygiene hand and surfaces is crucial and essential to control the transmission of pathogens and HAI. DuroKea Technology, self-disinfecting surfaces nanotechnology developed at the Indian Institute of Technology IITH, is a unique, one-of-a-kind, providing innovative, long-lasting hygiene products to stop the spreading of germs and prevent HAI.

Current Stage of Development

Developed and validated individual product in the lab setup as well as limited institutional setup like IIT Hospital, Primary health care setup. The validation in the different hospital environments such as AIIMS, Hyderabad, AIG, Hyderabad on HAI is under process.

- This technology is validated through extensive field trial and certified by Govt CCMB, Hyderabad and THSTI, Faridabad
- Certified by NABL accredited laboratories, SIMA Lab Sophisticated Industrial Materials Analytic Labs Pvt. Ltd.
- Using DuroKea technology, company has launched four innovative hygiene long-lasting antimicrobial/ antiviral products, that are: DuroKea S, DuroKea M, DuroKea H, DuroKea H Aqua, specially to fight against COVID-19 Virus and other germs in three different ways.

- Products e-launched by Honorable Minister of Education.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

The global surface sanitizer market is projected to reach \$3.6 billion by 2025. India will significantly share this market. Targeting India and the Indian healthcare sector and global markets later.

National/Societal Relevance

DuroKea Technology and its long-lasting DuroKea products are first in their kind in India as well as abroad. No products are available which is alcohol based with long lasting functionality. DuroKea Technology based products are superior in their efficacy and affordability. DuroKea technology provides instant killing on the pathogen including Covid-19 virus and with long-lasting action up to several hours to several days up to 35 Days. This self-disinfecting technology and products provide 24x7 and prolong hygiene and protection from germs which is essential to fight against health care-associated infections

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

DuroKea

Product Positioning

DuroKea Products is based on nanotechnology and unique technology for the fast and effective killing of pathogens on all possible surfaces in the hospital or healthcare sector. The DuroKea technology made our product unique, effective, and affordable to stop pathogen transmission and stop HAI

Import Substitution

Health Care Associated Infections HAI are a serious problem resulting in morbidity, mortality, and increased costs. Antimicrobial resistance AMR is associated with HAI. DuroKea, compared to conventional hygiene products, will certainly reduce the HAI burden on our society.

Export Potential

The HAI is a global burden. Due to its effectiveness and affordability, it has a high potential of export and selling in other countries after validation and appropriate certification in India.

IP Status

Granted Two Patents No:202041041760 and 202041055925. PCT Application No: PCT/IB2021/062204 US Patent Application No:18/258930



Name of Startup: EVIOGEN DISCOVERY PRIVATE LIMITED



Founder and Co-founder(s):
Paritosh Prashar

Developed Under
(scheme):
BioNEST

Email:
paritosh@evioegen.com

Product/Technology differentiation from Competitors

Hybridoma development or phage library preparation is the conventional method of generating antibodies against therapeutic targets. However, both the methods are time consuming, laborious and require humanization and can result in toxic side effects. B-cell cloning circumvent these issues by directly cloning antibody sequences from patient B-cells to discover therapeutic antibodies in less than 2 weeks

Brief Description of Product

High-throughput single B cell cloning combined with artificial intelligence AI offers a powerful approach to monoclonal antibody mAb discovery. This innovative methodology leverages the rapid advancements in next-generation sequencing and microfluidic technologies to isolate and analyse individual B cells from diverse immune repertoires. By capturing the genetic and phenotypic information of B cells at an unprecedented scale, researchers can efficiently identify candidate antibodies with high specificity and affinity for target antigens. AI algorithms further enhance this process by analysing complex datasets to predict antibody-antigen interactions, optimize antibody structures, and identify novel epitopes. Machine learning models can rapidly sift through vast datasets to highlight promising antibody candidates, significantly reducing the time and cost associated with traditional mAb development. This synergy of high-throughput technologies and AI-driven analysis not only accelerates the discovery pipeline but also expands the potential for identifying therapeutic antibodies against challenging targets, thus paving the way for advancements in treating a wide array of diseases. The current method integrates high-throughput and AI to identify high affinity antibody against various infectious and oncology target. High affinity antibodies against Sars-Cov-2 were cloned through high-throughput single B-cell sequencing. The affinity and other parameters for the top candidates was further improved through in-house developed AI platforms.

Current Stage of Development

The platform is currently validated using non-clinical samples. Validation of the antibody cloning platform using actual patient samples is further required.

Are you willing to Transfer/ Out-License your Technology YES

Geographical Region Targeted

India and Global

National/Societal Relevance

During a pandemic or any infectious disease outbreak, neutralizing therapeutic antibodies can be cloned directly from samples in less than two weeks. Such antibodies can be created against a panel of infectious diseases.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology


High-Throughput Single B Cell Cloning for therapeutic antibody discovery

Product Positioning

High-Throughput Single B Cell Cloning platform for discovery of novel therapeutic antibodies

Export Potential

The kit version of this platform that can be sold commercially is under development.



Name of Startup: FeJuice



Founder and Co-founder(s):
1. Dr Marija Lesjak, Co-founder /
CEO 2. Dr Natasa Simin,
Co-founder / COO 3. Bojana
Mumovic, Co-founder / CMO 4.
Biljana Munjiza, Co-founder /
Business Development Executive

Email:
bojana.mumovic@fejuice.eu

Product/Technology differentiation from Competitors

Iron is found in a variety of foods, but not all iron in food is equally bioavailable. Our novel discovery proved that certain compounds of foods can inhibit iron absorption. FeJuice is a 100 natural formula made of fruits and vegetables with highly absorbable iron and no iron inhibitors. FeJuice is the first natural, scientifically proven, and side-effect-free nutritional formula for Iron Deficiency Anemia treatment and prevention according to which numerous foodstuffs can be made, easily consumable on the go in various forms such as Porridge Powder, Freeze Dried Snack, Bar, Smoothie, Puree, Baby Food, Ice Cream.

Brief Description of Product

FeJuice developed and patented the first natural, scientifically proven, and side-effect-free nutritional formula for anemia prevention and treatment, according to which numerous foodstuffs can be made such as porridge powder, freeze-dried snacks, juice, smoothies, puree, bars, soup, baby food, ice cream, etc.

Current Stage of Development

TRL 7 We have a finalized prototype of product porridge powder ready to go into industrial level of production and entering B2C test market. We have an ongoing B2B partnership negotiations for production of another product smoothie / puree pouch. We have an international PCT patent pending PCT application - F&R Ref: 57539-0002W01 and we have a registered trademark. Raising a pre-series A investment to enter the market.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Europe, Asia

National/Societal Relevance

Iron-deficiency anemia (IDA) affects 27% of world's population, 29% of non-pregnant women, 38% of pregnant women and 43% of children globally. IDA in pregnancy and infancy has negative long-term health effects. WHO aims to reduce IDA in women by 50% by 2030. Treatment typically involves oral iron supplements, but high doses and side effects hinder compliance. Our plant-based formula offers bioavailable iron without side effects, addressing this challenge.

Technology readiness level (TRL)

TRL-7



Title/Name of the Product/Technology

FeJuice - Patented Functional Food Against Anemia

Product Positioning

Healthy Food Products, Functional Food, Pharma.

Export Potential

Wide

IP Status

PCT patent pending PCT application - F&R Ref: 57539-0002W01 and we have a registered trademark

Name of Startup: FilamenTech, Inc.



Founder and Co-founder(s):
Dr. Srbojib M. Mijailovich CEO
Momcilo Prodanovic COO &
Director of Belgrade office
Dr. Bohan Stojanovic CTO
Vladimir Vladimirov CPO

Email:
natasha@filonacci-ca.com

Product/Technology differentiation from Competitors

MUSICO differentiates itself by integrating multimodal biomedical data with physics-based modeling, offering predictive capabilities across molecular, cellular, and organ levels. Unlike competitors using traditional AI or lab-based methods, MUSICO excels at predicting drug efficacy with limited human data, cutting development costs by up to 60. Its multiscale digital twins provide precision for personalized therapies, and its simulations across all biological scales outperform lab-on-a-chip solutions. This makes MUSICO an ethically aligned, faster, and more comprehensive alternative to CROs and other technologies, driving efficient drug development for cardiac and skeletal muscle diseases.

Brief Description of Product

MUSICO Muscle Simulation Code platform is an advanced computational tool developed by FilamenTech, Inc. for in silico drug development and personalized healthcare targeting cardiac and skeletal muscle diseases. By integrating multimodal biomedical data—including genetic information, protein interactions, physiological experiments, and patient records hospital records and imaging data—with predictive physics-based modeling, MUSICO enables precise simulations to predict the effects of genetic mutations and drug interactions, offering unparalleled insights into human muscle behavior and drug efficacy at molecular, cellular, tissue, and organ levels. MUSICO significantly enhances the accuracy of preclinical and clinical predictions, allowing researchers and pharmaceutical companies to assess the potential effectiveness of novel therapies before advancing to costly and time-consuming clinical trials. By providing detailed multiscale simulations, the platform reduces clinical phase failures, accelerates development timelines, and cuts overall costs. MUSICO can reduce development costs by up to 60 and increase drug approval success rates from 10 to 50, providing faster access to treatments and minimizing the need for animal and human trials. The platform also supports personalized therapy development using multiscale digital twins for predictive analysis. Additionally, unlike traditional AI, MUSICO excels at making accurate predictions with limited human data, improving healthcare delivery, and enabling early interventions. With its scalability and high-performance computing capabilities, MUSICO efficiently handles large-scale simulations, providing timely, actionable insights. This platform is a game-changer, bringing new precision and efficiency to the development of treatments for muscle-related diseases.

Current Stage of Development

MUSICO modules were validated through experiments at leading academic institutions, with collaborations involving 12 research institutions and 2 biotech companies across the USA, EU, and Australia, with findings published in 65+ peer-reviewed papers. The platform underwent rigorous validation during the Horizon 2020 project for drug and mutation testing. Additionally, MUSICO played a key role in the MyoKardia and Bristol Myers Squibb project, helping unravel the mechanisms of FDA-approved mavacamten. Currently, the platform is in pre-clinical and early clinical validation with the University of Washington, Arizona State University, and ITT, placing it at TRL 5.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

MUSICO is targeting the USA, EU and Asia markets, focusing on early-stage biotech companies, research institutes, and pharmaceutical firms engaged in drug development for cardiac and skeletal muscle diseases. After initial market penetration, we aim to expand to APAC region and South America, supporting personalized therapies and precision medicine globally.

National/Societal Relevance

MUSICO addresses critical health challenges by transforming drug development for inherited heart diseases, reducing costs, and accelerating access to life-saving treatments. With regulatory shifts in the U.S., Europe, and increasingly in India recognizing the value of in silico models, MUSICO aligns with the "3Rs" principle, offering a more humane and predictive approach. It supports personalized therapies, enhances patient outcomes, and fosters faster recovery, contributing to societal well-being. By promoting sustainability and minimizing environmental impacts, MUSICO enables efficient, ethical drug development, benefiting healthcare systems and the economy across these regions.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

MUSICO Muscle Simulation Code platform

Product Positioning

MUSICO is positioned as a cutting-edge platform for in silico drug development and personalized healthcare. Targeting cardiac and skeletal muscle diseases, it offers precise multiscale simulations, reducing costs and time to market. Aimed at biotech firms and research institutions, it accelerates drug development and supports personalized therapies globally.

Import Substitution

MUSICO enables import substitution by reducing reliance on foreign pharmaceutical testing services and expensive clinical trials. By fostering domestic drug development and leveraging local resources, it lowers costs, accelerates time to market, and enhances healthcare innovation, empowering local industries to compete globally and promote national self-sufficiency.

Export Potential

MUSICO's export potential lies in providing advanced in silico drug development tools to international biotech and pharmaceutical markets. Its modular system caters to global demand for efficient, ethical, and cost-effective drug discovery solutions, particularly in cardiac and skeletal muscle diseases, offering strong appeal in the USA, EU, and APAC regions.

IP Status

FilamenTech has secured Copyright protection for the MUSICO Muscle Simulation Code platform, safeguarding the proprietary algorithms and software integral to its operation. Additionally, we leverage Secret Know-how to protect the unique methods and confidential processes underlying our platform, ensuring that our competitive edge remains secure.





Name of Startup: Fitabeo Therapeutics



Founder and Co-founder(s):
Mallikarjun Chityala
Prof Alex Mullen

Email:
mallikarjun.chityala@fitabeo.com

Product/Technology differentiation from Competitors

Fitabeo Therapeutics SpherionexT is the world's first controlled release thin film technology to combine multiple compounds and complex release them upto eight hours on a fast dissolving and single-layered film. Fitabeo Therapeutics Velocifilm is the single-layered fast-dissolving thin film technology for rapid bioavailability.

Brief Description of Product

Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Fitabeo Therapeutics pipeline consists of three development programs across Psychiatry, Neurology and Womens health.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted


North America, Europe, Asia and Africa.

National/Societal Relevance

The population of 'over 65 years' is expected to grow up to 1.5 billion people by 2050, consequently, healthcare costs will go up by a whopping \$2 Tn. This will result in a crisis-like situation in social care, compelling innovation towards healthy ageing and decentralising patient care. Medication non-adherence is estimated to cost global healthcare eyewatering \$420 bn annually. Over 50 of new drugs approved are expected to be biopharmaceuticals, most of which are delivered as injections costing healthcare dearly. Thin-film offer great value and significant cost savings.

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes.

Product Positioning

Oral thin films offer a great way of delivering medicine for elderly patients and children, as they alleviate dysphagia and fear of choking. Using proprietary technologies, we develop single-layered fast-dissolving oral films that are rapid release and controlled release respectively, offering substantial benefits to patients.

IP Status

Patent granted in Japan: JP7524185B2 Filed in the US, EU, UK, CA, KR and CN.

Name of Startup: Focelite Goodness I Pvt Ltd



Founder and Co-founder(s):
Vijay Kumar Ranka &
Komal Minhas

Email:
komal@focelite.com

Product/Technology differentiation from Competitors

It is first of its kind combination of drug and device with dual mode of action targeting viral inhibition and having faster recovery

Brief Description of Product

A drug and a wrist wearable light emitting device , an emerging technology for reating antiviral infection like dengue.

Current Stage of Development

Animal study- Toxicology/ safety being under discussion and evaluation

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

South Asia and globally impacted regions affected with dengue fever

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

Welblu- an emerging antiviral therapy for dengue serotypes

National/Societal Relevance

Treating the impacted people in developing or under developed countries as an easy to use, cost effective device

Export Potential

To be globally supplied

Name of Startup: Growdea Technologies Pvt. Ltd.



Founder and Co-founder(s):
Dr. Avinash Mishra
Dr. Anurag S Rathore

Email:
am@growdeatech.com

Product/Technology differentiation from Competitors

Analogue differentiates itself from competitors with comprehensive AI modules, validated algorithms, affordable pricing, and robust data security options. Its advanced AI/ML modules enhance predictive modelling, offering a technical edge. The platform's proven algorithm, tested in fee for service mode, provides a validation edge. Competitive pricing ensures accessibility to a broader research community, offering a price edge. Additionally, Analogue offers both SaaS and hardware-inbuilt options, ensuring data security and supporting computational infrastructure at the clients end. These features collectively provide a powerful, reliable, and cost-effective solution for computational drug design and optimization.

Brief Description of Product

Analogue is a revolutionary platform that integrates advanced computational techniques with artificial intelligence AI and machine learning ML algorithms to transform the field of computational drug design and optimization. This comprehensive solution consists of several critical modules, each specifically designed to address key aspects of the drug design process, ensuring fast, accurate, and cost-effective results while maintaining high standards of data security and scientific support. At the core of Analogue is the QSAR Quantitative Structure-Activity Relationship module, which aids in identifying new hits through ligand-based approaches by analysing the chemical structure and biological activity relationships. This module can predict the potential activity of new compounds, narrowing down vast libraries of compounds to those most likely to exhibit desired biological activities. The Drug Molecule Generator module complements this by generating new hits based on existing compounds, using sophisticated algorithms to modify known structures and create novel molecules with potentially improved properties. This capability is crucial for rapidly expanding the pool of viable drug candidates and discovering compounds with enhanced therapeutic efficacy. Another essential component of Analogue is the Drug Decoy Identification module, which can distinguish true hit compounds from a basket of potential candidates by employing advanced filtering techniques to identify active compounds, ensuring that only the most promising candidates proceed to further stages of development, thus saving time and resources. The Protein Drug Binding module is vital for predicting experimental binding affinities between proteins and small molecules, using computational docking techniques to simulate interactions between drug candidates and their target proteins. The data from this module on binding strengths and potential efficacy is critical for prioritizing compounds for further testing and development. The platform also includes a Protein Drug Interaction module that detects compatibility between protein sequences and small molecule structures, predicting how well a drug will interact with its target based on sequence and structural data, thereby aiding in the design of more effective and specific therapies. For antibody-based therapies, the Antigen-Antibody Interaction Predictor module is invaluable, predicting the experimental dissociation constant Kd for antigen-antibody interactions and providing insights into the strength and stability of these interactions, crucial for designing effective antibody therapies and vaccines. Molecular Dynamics MD Simulation is a cornerstone of Analogue, enabling researchers to perform detailed simulations of molecular systems to study the dynamic behavior of drug molecules and their interactions with biological targets over time. This module helps optimize drug candidates by revealing their stability and conformational changes during interactions. Finally, the Trajectory Analyzer module interprets the results of molecular simulations, providing detailed analyses of molecular trajectories, identifying key interactions, and structural changes during simulations, which is essential for refining drug designs. Together, these modules form a comprehensive and powerful platform for computational drug design and optimization. By integrating advanced computational techniques with AI/ML algorithms, Analogue enhances the drug discovery process, accelerates the identification of new drug candidates, and optimizes existing therapies. The platform's efficiency, cost-effectiveness, data security, and continuous scientific support help researchers and pharmaceutical companies develop more effective and targeted drugs.

Current Stage of Development

Analogue is now fully operational and ready to be commercially available. An extensive internal testing has performed and Analogue is now ready to be deployed to new users, from whom feedbacks will be gathered, and continuous refinement of the platform will be done to meet the evolving needs of the Indian biotech and pharma sectors.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted
Global

Technology readiness level (TRL)
TRL-8



Title/Name of the Product/Technology

Analogue: A Therapeutic Design Product

Product Positioning

Analogue is the leading digital platform empowering biotech and pharma researchers to accelerate discovery and development through cutting-edge in silico and ML based tools. By combining machine learning and biophysics-based technologies, we deliver unparalleled insights and predictions that streamline research, reduce costs, and drive innovation.

Import Substitution

This tool will reduce dependency of Indian Institutions on different imported tools like that of Schrodinger and Biovia.

National/Societal Relevance

Analogue can revolutionize Indian biotech and pharma research, by accelerating drug discovery and development while reducing costs. By harnessing advanced machine learning and biophysics, our platform empowers the researchers to tackle critical health challenges in our country, fostering innovation and contributing to a stronger scientific community. We are committed to improving public health outcomes in India, making medicines more affordable and accessible, and addressing unmet medical needs. Our computational approach also promotes sustainability, aligning with India's environmental goals.

Export Potential

Being a digital product Analogue has high export potential. Also, providing better results at an affordable rate can further enhance its demand in global market.

Name of Startup: Inger Therapeutics Pvt Ltd



Founder and Co-founder(s):
Bala Veshwanth Ram V
Surekha V

Developed Under
(scheme):
BIG, GCI

Email:
yeshwanth.v@ingertx.com

Product/Technology differentiation from Competitors

The biggest bottleneck of ligand discovery is the identification of high affinity and specific ligands that is rapid and economical. Most commonly used technologies are High throughput screening, Biological display systems and DNA encoded libraries. Suprbody and its generation methodology addresses the limitations of the existing technologies and still retains its strengths. The innovative elements in the suprbody scaffold include: i completely synthetic scaffold with a possibility to include unnatural moieties ii multiple loops aids in cooperativity iii introduce recombination in the selection process that helps in delivering a the best binders via multiple rounds of selection.

Brief Description of Product

At Inger Therapeutics, we are passionate about discovering such high affinity ligands called Suprabodies for therapeutic and diagnostic applications. Suprabodies are ligands that are synthetic and low molecular weight discovered using a stringent and robust Suprbody selection methodology. Suprbody and its generation methodology addresses the limitations of the existing technologies and still retains its strengths. The innovative elements in the suprbody scaffold include: i completely synthetic scaffold with a possibility to include unnatural moieties ii multiple loops aids in cooperativity iii introduce recombination in the selection process that helps in delivering the best binders via multiple rounds of selection. Eventually, these advantages reflect in smaller synthetic products that are scalable and favourable in tissue penetration.

Current Stage of Development

The proof of concept of the technology is already published in Nature Chemistry. The proof of concept for our technology has been successfully published in Nature Chemistry. The technology operates through three key phases: Selection, Synthesis, and Validation. Currently, both the Selection and Synthesis phases are fully functional, with the final Validation phase underway.


Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

The platform has the potential to serve global needs

Technology readiness level (TRL)

TRL-5



Title/Name of the Product/Technology

Suprbody Discovery Platform

Product Positioning

Suprabodies revolutionize diagnostics and therapeutics with a rapid, cost-effective in vitro selection process and advanced scaffold design. Inspired from natural antibodies, they offer exceptional binding properties, versatility, and scalability. Ideal for cutting-edge research and large-scale applications, Suprabodies set a new standard in biotechnology innovation.

Import Substitution

Possible but depend very much on the end application.

National/Societal Relevance

Ingers platform will facilitate the development of indigenous therapeutics and diagnostic probes, thereby enhancing the biotech ecosystem and bolstering the economy.

Export Potential

Yes. The technology once completed and validated will have global reach.



Name of Startup: Innaumation Medical Devices Private Limited



Founder and Co-founder(s):
Dr Vishal U S
Shahsank Mahesh

Developed Under
(scheme):
BIG

Email:
asif@innaumation.com

Product/Technology differentiation from Competitors

- The kit comprises of a Prosthesis made of platinum cured silicone - medical grade, Guidewires, Secondary inserter, brush • Low cost and high-quality device approved will help Govt. save significant amount.
- Training programs for surgeons and speech therapists at the hospital to help assist interested surgeons training
- Assistance to patients for procuring handicap smart card and certificate
- 6 months warranty on product. Western brands do not provide warranty - 10 of devices fail on day 1 or within a month
- Patient support program - online and offline
- Assistance to set up Lary clubs

Brief Description of Product

Our solution is the Aum Voice Prosthesis, an affordable voice prosthesis for throat cancer patients. It is a 'one size fits all device' that allows the patient to speak even in the absence of a larynx. Innaumation Medical Devices is connected with bringing back lost voices of laryngectomy patients. With the existing expensive devices available in the market, it is difficult for lower middle class and poor patients to afford it. With our device coming into picture, these patients will get a chance to get their voice back at an affordable price.

Current Stage of Development

Setting up a CDSCO approved manufacturing set up in Bangalore. Reaching out to regional cancer centres and govt hospitals for order through our distributor network.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted


Global

National/Societal Relevance

More than 10,00,000 patients undergo laryngectomy globally and majority of them end up losing their voice. Aum voice chain helps in reaching out to all patients and restore back their voice. With the objective to rehabilitate not only voice but rehabilitate their lives, actively engaged in pursuing the issuance of disability certificates and helping the patients get all the benefits under the Rights for Persons with Disabilities Act.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Aum Voice Prosthesis

Product Positioning

Our target customers are patients who have lost their voice due to laryngectomy.

Export Potential

With throat cancer already prevalent in more than 180 countries, Aum Voice Prosthesis can easily be supplied to these countries most of them having very low Purchase Power Parity. Of these countries at least 50 countries accept Indian regulations and the rest follow either USFDA or CE.

Import Substitution

The price of imported substitutes is extremely high when compared with Aum Voice Prosthesis. As the increase in price does not come with an element of improved quality or convenience to the patient or surgeon, import substitution is significantly high.

IP Status

Design Number- 304171 Filing Date- 29-03-2018 Issue date 30-09-2019 Tracheo Esophageal Voice Prosthesis Patent Number- 363275 Application Number- 5609/CHE/2015 Filing Date- 19-10-2015 Issue date- 26-03-2021 US Patent for Tracheo Esophageal Voice Prosthesis Patent Number: US 11,376,118 B2 Issue date: July 5th 2022

Name of Startup: INTE-E-LABS PRIVATE LIMITED



Founder and Co-founder(s):
Founder - Ms. Sonia Madan,
Co-founder - Dr. Devanand Kumar

Developed Under
(scheme):
BIG

Email:
sonia.madan@inteelabs.com

Product/Technology differentiation from Competitors

Production of highly active Recombinant Reteplase in pichia expression system :

- 100 % soluble protein -Low HCP, HcDNA, Endotoxins free due to extracellular expression
- Low cost Reteplase -Scale up & Commercial viability - potential to meet the unmet need of the market

Brief Description of Product

Cardiovascular disorders mortality reaching 17.6 million globally. A 2022 study showed that those with COVID-19 were at an increased risk of CVD's. Evidence indicates that 1.3 of individuals with COVID-19 experienced heart attack. Hence, early reperfusion therapy is critical for rapidly restoring blood flow. Reteplase, a third generation thrombolytic due to bolus administration, prolonged half-life and increased fibrin specificity provides this opportunity. The existing reteplase technologies have a complex process of 10-12steps, extremely low recoveries, 1:1000 refolding dilution ratio makes scale up and consistent production extremely challenging to meet the demand.

Due to its cost complex nature, this valuable candidate was not utilized fully upto its potential. Where big pharma companies are struggling, Recplase, FYSEC platform-based technology for production of highly functional low cost Reteplase offers lifesaving treatment accessible to 2.3 tier cities too. The current technology offers for production of highly active soluble Reteplase in pichia expression system with low HCP, HcDNA and endotoxin free system due to extracellular expression in pichia. Scalable & Commercial viability are few USP's of this technology which is sufficient to disrupt the existing thrombolytic drug market. Reteplase candidate upon successful completion will provide hope and healing by providing affordable life-saving treatments accessible. The company is first to report soluble expression of highly active low cost, scalable and commercially viable Reteplase candidate hence have strong IP potential. There is plenty of scope in market for getting a better priced candidate utilizing its potential as thrombolytic therapy because of ease of administration.

Current Stage of Development

Need identified, Basic principles observed and reported. Due diligence, strategy design has already been done. Genes are being synthesized. Hypothesis testing and initial soluble expression has been demonstrated. Preliminary Comparative analysis with commercially available standard done. Expression was done from 30ml plate to 500 shake flask and up to 5L bioreactor. As an initial assessment for its activity has been shown to be as good as available standards in the market.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India and Rest of world

National/Societal Relevance

The Estimated mortality & morbidity reaching 17.6 million by 2022 due to cardiovascular diseases is an alarming number. A 2022 study published in Nature Medicine showed that those with COVID-19 were at an increased risk of cardiovascular diseases. Reteplase, because of the possibility of bolus administration provides this opportunity. According to the National Center for Biotechnology, 2 out of 5 of patients with acute ischemic stroke received rTPA in the U.S. As per CDC; 38 of people were able to recognize the symptoms and were treated at the right time. Hence pre-hospital thrombolysis becomes important to save lives.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Production of Soluble Recombinant Tissue Plasminogen Activator tPA /RETEPLASE BIOSIMILAR Using Indigenously Developed FYSEC™ platform

Product Positioning

The existing Reteplase technologies have a complex process of 10-12steps, extremely low recoveries, 1:1000 refolding dilution ratio, making scale up and consistent production extremely challenging. Due to its cost and complex nature, this valuable candidate was not utilized fully upto its potential.

Import Substitution

Estimated mortality & morbidity reaching 17.6 million due to cardiovascular diseases 2. tPA Market Reports CAGR of 5.25 leading to US\$ 3,491.5 Mn market. There is enough space in market for a better candidate proposal. The proposed study is to demonstrate production of soluble Reteplase at a better price.

Export Potential

Estimated mortality & morbidity reaching 17.6 million due to cardiovascular diseases 2. tPA Market Reports CAGR of 5.25 leading to US\$ 3,491.5 Mn market. There is enough space in market for a better candidate proposal. The proposed study is to demonstrate production of soluble Reteplase at a better price.

IP Status

Provisional patent application no. 202111041221 filed for production of soluble recombinant tissue plasminogen activator rTPA has been filed.



Name of Startup: INVIGORATE BIOTECHNOLOGIES LLP



Founder and Co-founder(s):
JAINENDRA JAIN DAVENDER
KUMAR BHATI

Email:
jainendra@invigoratebio.com

Product/Technology differentiation from Competitors

Ours is Indigenous, safe, efficacious, and cost-effective viral vector system Lentivirus or AAV vector platforms that can be used to develop ATMPs Advanced Therapy Medicinal Products e.g. CAR-T, CAR-NK, tumor infiltrating lymphocytes TILs, marrow-derived lymphocytes MILs and many more.

Brief Description of Product

Cell and gene therapy CGT has the potential to transform medicine, providing long term and potentially curative treatment options for a wide range of diseases ranging from dreaded cancers to genetic disorders to autoimmune diseases and many more. Cell and gene therapy target DNA or RNA inside or outside the body to modify genetic material to improve functioning or fight disease. Specifically, gene therapy uses genetic material, or DNA, to manipulate a patient's cells for the treatment of an inherited or acquired disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, dendritic cells, and pancreatic islet cells. Cell therapies can use cells from the patients' own body autologous or from a donor allogenic. Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient's body. This technology may enable the development of an unlimited types of specific human cells needed for therapeutic purposes. In some cases, such as CAR-T, cells are genetically modified before being re-introduced into the patient. This is the intersection between gene and cell therapy. Gene therapy seeks to modify or introduce genes into a patient's body with the goal of treating, preventing or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body. Therapeutic genes are packaged in a delivery vehicle, often deactivated viruses such as adeno-associated viruses AAV, retroviruses or lentiviruses vector LJV. Gene therapy may be performed in vivo, in which the therapeutic gene is directly delivered to cells inside the patient's body, or ex vivo, in which the therapeutic gene is inserted into cells outside the body before being introduced into the body. Ex vivo gene therapy is a form of cell therapy. This approach includes several cell-based immunotherapies, such as chimeric antigen receptors CAR T-cell therapies, T-cell receptor TCR therapies, natural killer NK cell therapies, tumor infiltrating lymphocytes TILs, marrow-derived lymphocytes MILs, gamma-delta T-cells and dendritic vaccines. There is urgency to address and rapidly respond to global needs and pursue safe, low cost, easily administered, and rapidly scalable approaches. We propose to develop a safe, efficacious and cost-effective gene delivery system based on established Lentivirus or AAV vector platforms, which are easily scalable and can be accommodated into a multi-product manufacturing facility with lower biosafety requirements.

Current Stage of Development

Our team has established the PoC using adherent HEL293T cell line and optimized the LJV production with satisfactory titer value. the presence of GFP Green Fluorescent Protein has been identified using FACS Fluorescence Activated Cell Sorting , Fluorescent microscopy and qPCR. The scale up studies are underway to take the existing TRL to next level i.e. TRL 4-6.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

We as a start-up planning to take our technology to global scale with primary focus in India and other LMICs.

National/Societal Relevance

India, now is at advantageous position to offer robust, scalable, and cost-effective process/technology in CGT segment as offerings from western world are available at premium cost and limited accessibility. Technical competence and cost-effective solutions will give India an edge to become a potential force in Biotech world.

Technology readiness level (TRL)

TRL-3



Title/Name of the Product/Technology

Development of Scalable Technology for Gene/Cell Therapy Products Using Lentivirus/Adeno associate virus Vector System.

Product Positioning

The CGT market will be valued USD~ 92 billion by 2032. The potential of the technology and different products thereof is huge. ATMPs Advanced Therapy Medicinal Products expected India Market would be around USD 2.5 billion by 2030 thus opening an endless opportunity healthcare segment for CAR-T/CAR-NK TIL, MILs etc.

Import Substitution

Our technology/product will help India to be self-reliant in next 15 years in CGT segment and will reduce the dependency on western world in terms of technology and product.

Export Potential

With Such a huge market potential and India's advantageous position due to technical competence and cost-effective solutions in healthcare field creates greater possibilities for both technology as well products export in this segment.

IP Status

IP is under draft and soon the patent application will be filed By October 2024

Name of Startup: Jeeto BioCourier



Founder and Co-founder(s):
Dr Vinod Kumar Prajapati
Dr Manoj Bansode

Email:
vinod@jeetobiocourier.com

Product/Technology differentiation from Competitors

1. End to end logistic support by qualified staff.
2. Less rate for international shipments
3. Real time tracking of temperature and location.
4. IATA approved packaging

Brief Description of Product

Jeeto BioCourier has established its specialized operations, making it one of the most sought after and reliable names in national and international courier and logistics services in shipment of life Science and Pharmaceuticals & Biological Samples under controlled temperature and dry-ice packaging.

Current Stage of Development

Delivered more than 10000 shipment including domestic and international for private and govt organization such as RCB Faridabad, CSIR-IGIB, IISc Bangalore.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted


India, Europe, USA

National/Societal Relevance

1. We are importing several life saving drugs which are not available in India.
2. As global network scientific community is exchanging lots of research material, assisted several scientists in this starting from packing to export as well as import.

Technology readiness level (TRL)

TRL-9



Name of Startup: Koshkey Sciences Pvt. Ltd.



Founder and Co-founder(s):
Dr. Tanay Bhatt
Prof. Colin Jamora

Developed Under
(scheme):
BIG

Email:
tanaybhatt123@gmail.com

Product/Technology differentiation from Competitors

Through in-house research we have developed Antisense Oligonucleotide ASO based technology, we can target specific genes in skin cells to increase the local release of Antimicrobial Peptides at the infection and injury site. A key differentiator for our approach lies in the host-targeted nature of our RNAi therapy, as opposed to pathogen-targeted strategies pursued by existing competitors. KoshKeys comprehensive approach solves both the problems – non-healing ulcers and AMR infection – simultaneously, making it a perfect and unique solution for diabetic individuals at a higher risk of limb amputation or sepsis.

Brief Description of Product

Koshkeys RNAi-Based Therapy: A Promising Solution for Wound Healing and AMR Infections Koshkey Sciences Pvt Ltd is developing an innovative RNA interference RNAi-based therapy to address the pressing issue of chronic non-healing wounds and antimicrobial resistance AMR infections, particularly prevalent among diabetic patients. Our approach leverages the power of RNAi to stimulate the production of antimicrobial peptides AMPs by skin cells, promoting wound healing and combating infections.

Addressing a Critical Need: Chronic non-healing wounds, often complicated by AMR infections, impose a significant burden on patients and healthcare systems. These wounds are particularly prevalent among diabetic individuals, leading to impaired mobility, increased healthcare costs, and even amputations. Koshkeys therapy addresses this pressing issue by offering a novel approach to wound healing and infection control. Koshkeys therapy involves the topical application of Antisense Oligo molecules, which are designed to target and silence a specific gene that inhibits AMP production in skin cells. By downregulating this gene, the therapy enables skin cells to produce higher levels of AMPs, which are potent antimicrobial agents. These AMPs can effectively combat a wide range of pathogens, including those that are resistant to traditional antibiotics.

Key Benefits • Enhanced wound healing: The increased production of AMPs promotes a healthy healing environment, facilitating the closure of chronic wounds. • Combatting AMR infections: AMPs offer a broad-spectrum defense against various pathogens, including those that are resistant to antibiotics. • Reduced risk of amputation: By preventing the progression of infections and promoting wound healing, Koshkeys therapy can significantly reduce the risk of amputation, improving quality of life for diabetic patients. • Improved patient outcomes: The therapy has the potential to reduce healthcare costs, improve patient outcomes, and enhance overall well-being.

National Relevance India faces a significant challenge with chronic non-healing wounds and AMR infections, particularly among its diabetic population. Koshkeys therapy offers a promising solution that can address this pressing healthcare issue. The development and commercialization of this innovative therapy could have a profound impact on the lives of countless patients in India and beyond.

Future Outlook Koshkey is currently conducting preclinical studies to evaluate the safety of the RNAi-based therapy. If these studies are successful, the company plans to initiate clinical trials to further assess the therapy's potential. The development and commercialization of this innovative therapy could represent a significant breakthrough in the treatment of chronic non-healing wounds and AMR infections. In conclusion, Koshkeys RNAi-based therapy offers a promising approach to addressing a critical healthcare challenge. By stimulating the production of AMPs, the therapy has the potential to enhance wound healing, combat AMR infections, and improve the lives of patients suffering from chronic wounds. As the company continues to advance its research and development efforts, the future looks bright for this innovative therapeutic solution.

Current Stage of Development

KoshKey has shown the efficacy of the topical RNAi formulation on diabetic mice model of non-healing wounds and AMR infections. The formulation has also shown the similar activity on human skin explants Ex-vivo. With sufficient pre-clinical safety data on mice, rabbits, and guinea pigs, we can move forward to Phase-1 clinical trials.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

In addition to India, developed countries like USA, European nations, Australia.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

Topical RNAi Therapy for Diabetic Wounds and AMR Infections

Product Positioning

Current approaches to treat non-healing diabetic wounds and antibiotics that treat AMR infections are not efficacious enough. Often leading to limb amputation and sepsis led death of the patient.

KoshKeys solution provide comprehensive solution solving both the problems - AMR infections and chronic ulcers.

National/Societal Relevance


Considering growing diabetic population and incidents of AMR infections, KoshKeys RNAi technology offers a promising solution for a critical national health issue. Our approach has the potential to improve patient outcomes, reduce healthcare costs, and position India at the forefront of innovative wound care and AMR treatment.

Export Potential

KoshKeys aim to commercialize the therapy in key developed countries worldwide.

IP Status

PCT and Indian national phase application filed: PCT no.: PCT/IN2024/050330 Indian Patent Application No: 20234102225



Name of Startup: Levim Lifetech



Founder and Co-founder(s):
Jatin Vimal,
Nitin Vimal, Srikanth Raman

Developed Under
(scheme):
SBIRI, NBM

Email:
jatin@levim.in

Product/Technology differentiation from Competitors

1 First-to-Market Biosimilar: Levim launched India's first Liraglutide biosimilar, addressing GLP-1 receptor agonist shortages with up to 65 cost reductions, improving accessibility for diabetic patients. 2 Advanced Clinical Development: Romiplostim for chronic immune thrombocytopenia has reached Phase III trials, demonstrating Levim's dedication to innovative treatments for complex hematologic conditions. 3 Proactive ADA Management: The ADA project focuses on managing anti-drug antibodies to ensure therapeutic protein safety and efficacy through thorough analysis and risk management. 4 Patent Protection: Holds patents for breakthrough technologies, including antibody-biomolecule conjugates and peptide acylation, enhancing market competitiveness.

Brief Description of Product

Levim Lifetech: Pioneering Innovations with Liraglutide, Romiplostim, and Anti-Drug Antibody Our portfolio features groundbreaking products, including Liraglutide, Romiplostim, and ADA. Backed by patents in advanced antibody-biomolecule conjugates and peptide acylation, we set new industry standards with unmatched quality. Liraglutide is a GLP-1 receptor agonist designed to manage type 2 diabetes and obesity. Levim has introduced India's first Liraglutide biosimilar, marking a breakthrough in diabetes management. This glucagon-like peptide-1 (GLP-1) receptor agonist, known for enhancing glycemic control and weight loss in type 2 diabetes, is now more accessible. Supported by the National Biopharma Mission NBM, BIRAC, and in collaboration with Glenmark Pharmaceuticals, this biosimilar is priced at 35% of the original drug cost, significantly improving affordability. This development promises broader access, better disease management, and a positive impact on India's healthcare system and economy. Romiplostim, a thrombopoietin receptor agonist, is used to treat chronic immune thrombocytopenia (ITP). Levim is dedicated to advancing treatments for critical hematologic conditions. The Romiplostim molecule has progressed to Phase III human clinical trials. Anti-Drug Antibody (ADA) project is a critical initiative aimed at addressing the challenges on understanding ADA mechanisms and their impact on drug effectiveness. By identifying and managing ADA-inducing factors early, we enhance drug safety and performance. In summary, Levim's work on Liraglutide, Romiplostim, and ADA represents a convergence of scientific excellence and innovative solutions, reinforced by extensive publications and BIRAC grants. Our dedication to developing cutting-edge therapies ensures that we remain at the forefront of biopharmaceutical advancements, committed to improving patient lives through transformative treatments.

Current Stage of Development

Liraglutide Biosimilar: Recently launched in India, addressing GLP-1 receptor agonist shortages with cost-effective solutions. Romiplostim: In Phase III clinical trials for chronic immune thrombocytopenia, supported by SBIRI and NBM, BIRAC. ADA Project: Advanced research stage, focusing on managing anti-drug antibodies for enhanced drug safety. Patents Granted.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

• India: Enhancing local healthcare with affordable Liraglutide biosimilars and Romiplostim. • South Asia: Addressing drug shortages and healthcare needs in neighboring countries. • Developing Markets: Offering cost-effective therapies in regions with high demand. • Global Markets: Expanding internationally with advanced biopharmaceuticals, supported by research and strategic partnerships.

Product/Technology

Levim Lifetech excels in biopharmaceutical development with groundbreaking products like Liraglutide, Romiplostim, and Anti-Drug Antibody ADA therapies. Our Liraglutide biosimilar, India's first, enhances diabetes management with significant cost reductions. Romiplostim is advancing to Phase III trials for chronic immune thrombocytopenia. Our ADA project focuses on optimizing therapeutic protein safety.

National/Societal Relevance

Levim's Liraglutide biosimilar, priced up to 65% lower than the original, reduces daily treatment costs from 380-532 INR to 118-165 INR, significantly improving access for India's 77 million diabetes patients. Romiplostim, targeting chronic immune thrombocytopenia affecting 50,000 patients, is now in Phase III trials, demonstrating our dedication to clinical excellence. Patents for advanced processes, like peptide acylation, ensure high-quality biosimilars with enhanced purity and yield. Strategic partnerships with Glenmark Pharmaceuticals, and support from SBIRI and NBM, strengthen our research capabilities and market presence, underscoring Levim's impact on India's healthcare and biopharmaceutical innovation.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

"Levim driving innovation": The Key to a Strong Pipeline and Successful Products -Streptokinase, Peg-asparaginase, Liraglutide, Romiplostim and more coming soon

Unique Selling Point

1 Innovative Biosimilars: Launched India's first Liraglutide biosimilar, addressing GLP-1 shortages. 2 Advanced Clinical Development: Romiplostim is in Phase III trials for chronic immune thrombocytopenia. 3 ADA Research: Enhancing therapeutic protein safety by managing ADAs. 4 Affordability: Cut Liraglutide biosimilar costs by up to 65. 5 Patents: Holds patents

Product Positioning

1 Innovation and Patents: Utilizes patented processes, like novel peptide acylation, to ensure high-quality, cost-effective biosimilars. 2 Focus on Critical Therapies: Develops treatments for acute diseases, oncology, metabolic disorders, meeting significant healthcare needs. 3 Strategic Collaborations: Partners with Glenmark Pharmaceuticals to enhance research and market presence. 4 Affordability

IP Status

1 PCT/IB2019/052124: Antibody-Biomolecule Conjugates Linked Through Multifunctional Macromolecule And Uses Thereof - granted in IN 2 PCT/IB2019/055537: Acylation Process For Preparation Of N-Substituted Peptide - granted in US & IN

Import Substitution

Levim Lifetech's strategies reduce dependency on imported drugs by offering affordable biosimilars like Liraglutide, cutting costs by up to 65. Their focus on critical therapies, advanced clinical trials, patented innovations, and strategic collaborations enhance local healthcare access, improve patient outcomes, and strengthen India's biopharmaceutical industry.

Export Potential

Levim Lifetech Pvt. Ltd. is positioned for global expansion with cost-effective solutions like Liraglutide biosimilars, reducing costs by up to 65 and targeting the 422 million people with diabetes worldwide. Romiplostim addresses chronic immune thrombocytopenia, impacting 1.6 million patients globally, enhancing Levim's export potential.

Name of Startup: M/s. Lorven Biologics Private Limited



Founder and Co-founder(s):
Dr. Venkataramana Mudili

Email:
ra@lorvenbiologics.com

Product/Technology differentiation from Competitors

On Liraglutide, Semaglutide and Ranibizumab our major differentiation often comes from pricing. Our products are typically cost significantly less than branded counterparts, which can make them more accessible to a broader patient population.

Brief Description of Product

1.L-Asparaginase is an enzyme used primarily in the treatment of certain cancers, particularly acute lymphoblastic leukemia ALL . It works by depleting the amino acid L-asparagine, which cancer cells need to grow and divide. 2. Pegaspargase is a modified form of the enzyme L-asparaginase, used primarily as a chemotherapy agent in the treatment of acute lymphoblastic leukemia ALL . It works by breaking down the amino acid asparagine, which leukemia cells depend on for survival. Pegaspargase has a longer half-life than standard L-asparaginase because it is linked to polyethylene glycol PEG , allowing for less frequent dosing. 3. Human Albumin r-DNA is a form of albumin protein produced using recombinant DNA technology. Albumin is a naturally occurring protein in human blood, primarily responsible for maintaining oncotic pressure, transporting hormones, drugs, and other substances, and acting as a plasma volume expander. 4,5. Liraglutide and Semaglutide is a glucagon-like peptide-1 GLP-1 receptor agonist used primarily to treat type 2 diabetes and obesity. It mimics the action of the natural hormone GLP-1, helping to regulate blood sugar levels by stimulating insulin secretion and inhibiting glucagon release. It also slows gastric emptying and reduces appetite, contributing to weight loss. 6. Ranibizumab is a monoclonal antibody fragment used in the treatment of several eye diseases, particularly those involving abnormal blood vessel growth and leakage, which can lead to vision loss. It works by inhibiting vascular endothelial growth factor A VEGF-A , a protein responsible for the growth of abnormal blood vessels in the retina. 7. Bacillus clausii is a probiotic bacterium belonging to the Bacillus genus, known for its ability to survive in harsh environmental conditions, including the acidic environment of the stomach. It is a spore-forming, gram-positive, rod-shaped bacterium commonly used in medical and dietary applications to promote gut health. It helps balance gut flora by inhibiting the growth of harmful bacteria. Often prescribed to treat or prevent diarrhea, especially antibiotic-associated diarrhea, and improve overall digestive health. 8. Saccharomyces boulardii is a beneficial, non-pathogenic yeast strain widely used as a probiotic. Unlike bacteria-based probiotics, this yeast can survive harsh stomach conditions and is resistant to antibiotics. It has been shown to help maintain and restore gut health by inhibiting harmful pathogens, reducing inflammation, and supporting the intestinal barrier. S. boulardii is particularly effective in treating and preventing diarrhea, including antibiotic-associated diarrhea, infectious diarrhea, and diarrhea linked to irritable bowel syndrome IBS . It is also used to support overall digestive health and boost immune function. 9. Lactic Acid Bacillus is a type of beneficial bacteria that helps in maintaining gut health. It belongs to a group of lactic acid-producing bacteria, such as Lactobacillus, which are commonly found in the digestive and urinary tracts. These bacteria convert lactose and other sugars into lactic acid, creating an acidic environment that inhibits the growth of harmful pathogens. 10. Diagnostic devices using synthetic biology leverage engineered biological systems to detect specific molecules, pathogens, or biomarkers. These devices are designed to sense, process, and report information from biological samples like blood, saliva.

Current Stage of Development

We ensure that our all product portfolio Liraglutide, Semaglutide, Human Albumin r-DNA and Ranibizumab technologies are not only theoretically sound but also practically viable in conditions that closely resemble its intended use. By rigorously testing the integrated system in a relevant environment, developers can identify and mitigate risks, optimize performance, and build confidence among stakeholders.

Are you willing to Transfer /Out-License your Technology Yes

Geographical Region Targeted

Emerging markets like China, Brazil, and India.

National/Societal Relevance

We contribute to healthcare innovation, accessibility, and economic growth.

Major Achievements

Lorven Biologics has received several accolades and awards for its contributions to biotechnology and healthcare. Notably, Dr. Venkataramana Mudili, the Managing Director of Lorven Biologics India, has been honored with the Andhra Pradesh Academy Young Scientist Award and various Best Researcher awards at both international and national forums.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

1. L-Asparaginase 2. Pegaspargase 3. Human Albumin r-DNA 4. Liraglutide 5. Semaglutide 6. Ranibizumab 7. Bacillus clausii 8. Saccharomyces Boulardii 9. Lactic Acid Bacillus Tablet and Other Human and Aqua Probiotics 10. Medical Devices - Diagnostic Devices using Synthetic Biology etc.

Product Positioning

R&D Studies up to 100L pilot scale was done and process optimised. Pri-Clinical Toxicology Studies yet to start.

Import Substitution

New biopharmaceutical manufacturers can contribute to import substitution by producing APIs domestically, reducing external dependency and ensuring a more secure supply chain

Export Potential

We are potential for new drugs is substantial, with opportunities in both developed and emerging markets by our strengths such as cost-efficient production, regulatory compliance, a growing R&D ecosystem, and government support make India a leading hub for drug exports.

Unique Selling Point

High purity, safety profile, batch-to-batch consistent quality and supply and enhanced stability, consistency.

IP Status

Obtained Process Patents for Liraglutide Semaglutide and CRM197



Name of Startup: Mestastop Solutions Pvt. Ltd



Founder and Co-founder(s):
Dr. Arnab Roy Chowdhury
Dr. Debabani Roy Chowdhury

Developed Under (scheme):
BIG, LEAP Fund, SEED Fund

Email:
debabani@mestastop.com

Mobile No:
88976 40394

GBI Category

Startup exhibition

Product/Technology differentiation from Competitors

Translational and High-throughput

Brief Description of Product

Proprietary in vitro, in vivo and ex vivo platforms to fight metastasis.

Current Stage of Development

Retrospective and prospective clinical trials have been completed.

Are you willing to Transfer / Out-License your Technology No

Geographical Region Targeted

US and Europe

Technology readiness level (TRL)

TRL-7





Name of Startup: MG BIOLOGICAL PRIVATE LIMITED



Founder and Co-founder(s):
Varun Kumar

Email:
mgbiological@gmail.com

Product/Technology differentiation from Competitors

Entabor 2 L-glutamine is a new therapy/new drug pharmaceutical formulation for the treatment of Sickle Cell Disorder in India. The other therapy currently used in India is Hydroxyurea for the treatment of Sickle Cell Disorder. As a comparison to current therapy in India, Entabor 2, the new technology, has several below-mentioned key comparisons. 1. No need for laboratory monitoring 2. Indicated for all genotypes, whereas in hydroxyurea therapy is only indicated for HbSS and HbS-0-Thalassemia.

Brief Description of Product

Entabor 2 is a generic formulation for the treatment of Sickle Cell Disorder. Entabor 2 is pure prescription-grade L-glutamine crystals as oral powder.

Are you willing to Transfer/Out-License your Technology Yes

National/Societal Relevance

Glutamine is an amino acid made in the human body and is also the most abundant amino acid in the body. Glutamine is also found in food – meats, eggs, milk, yogurt, nuts, cabbage, beans, etc. Glutamine is considered as a conditionally essential amino acid for people living with sickle cell disease due to the depletion of L-glutamine in sickle cell patients. The clinical severity of SCD in India matches the African haplotype in many regions.

Geographical Region Targeted

Preferably India, Globally

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

L Glutamine Oral Powder 5 gm Entabor 2 - A Generic Formulation for Treatment of Sickle Cell Anemia- New Drug Formulation, First Time in India

Product Positioning

Much High Potential of the export of this product, Unique Therapy.

Name of Startup: MOLDOC BIOTECH PRIVATE LIMITED



Founder and Co-founder(s):
1: Dr. Ashwani Sharma
2: Mr. Sunil Kumar Verma

Email:
ashwansharma@gmail.com

Product/Technology differentiation from Competitors

1: MBPL stands out by offering advanced in vitro skin and liver tissue models that closely mimic human physiology, ensuring more accurate toxicology assessments. Unlike competitors, MBPL's models provide higher reproducibility and viability, with features such as Caucasian ethnicity skin tissues without scratch marks and hepatocytes with 95% viability. 2: Additionally, the MBPL-Miner tool leverages cutting-edge machine learning for comprehensive regulatory toxicological profiling, integrating diverse data sources for predictive modeling. This combination of high-quality tissue models and innovative data analysis tools provides a superior, cost-effective alternative for safety evaluations and regulatory compliance.

Brief Description of Product

Product Descriptions 1: Ex Vivo Human Skin Tissues for Chemical Testing EU OECD 428 Source: Insight BioSolutions, France Application: These skin tissues are specifically designed for chemical testing and skin absorption assays, compliant with EU OECD 428 guidelines. Our ex vivo human skin tissues offer a reliable and accurate model for assessing how chemicals penetrate and affect human skin. This model is critical for regulatory testing and research applications, providing an ethical and efficient alternative to in vivo testing. 2: Animal and Human Hepatocyte Cells for In Vitro Toxicology Methods Source: Insight BioSolutions, France, and leading suppliers from the USA Application: Our hepatocyte cell models, sourced from both animal and human origins, are ideal for in vitro toxicology testing. These cells play a crucial role in evaluating the metabolic and toxicological profiles of new drug candidates. 3: MBPL-Miner for Compounds Regulatory Toxicological Profile The MBPL-Miner is an innovative data and text mining tool designed to streamline the regulatory toxicological profiling of chemical compounds. Utilizing advanced algorithms and machine learning, MBPL-Miner integrates data from various sources, predicts potential toxic effects, and ensures compliance with international regulatory requirements. It features a user-friendly interface, predictive modelling, and continuous updates, making it an essential tool for toxicologists, researchers, and regulatory professionals. MBPL-Miner supports risk assessments, simplifies regulatory submissions, and aids in identifying potential toxicological issues early in the development process, enhancing the safety and compliance of chemical products.

Current Stage of Development

1: MBPL's Distribution of Skin and Liver Tissues MBPL has established a strong foothold in the Indian market by successfully distributing in vitro skin and liver tissues. These tissues are essential for compound toxicology assessments and are widely used by pharmaceutical, cosmetic, and chemical industries to evaluate the safety and efficacy of their products.

2: The MBPL-Miner tool has reached a significant milestone by being utilized for the safety assessment of hormonal products. This application showcases the tool's effectiveness in generating comprehensive regulatory toxicological profiles.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

All India

National/Societal Relevance

The distribution of advanced in vitro skin and liver tissue models in India supports local industries in conducting ethical, accurate, and cost-effective toxicology assessments, reducing reliance on animal testing. This aligns with global ethical standards and promotes humane research practices. Furthermore, the MBPL-Miner tool enhances the safety and regulatory compliance of pharmaceutical, cosmetic, and chemical products by providing comprehensive toxicological profiling. This contributes to public health by ensuring that products meet stringent safety standards, ultimately protecting consumers and fostering trust in these industries.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

1: In vitro Skin tissues and liver tissue cell models for compound toxicology assessments. 2: MBPL-Miner for compounds regulatory toxicological profile.




Product Positioning

MBPL provides advanced in vitro skin and liver tissue models for precise toxicology assessments and MBPL-Miner for comprehensive regulatory toxicological profiling, offering cutting-edge, reliable, and ethical solutions to the pharmaceutical, cosmetic, and chemical industries, ensuring compliance and enhancing safety evaluations.

IP Status

Trade mark

Ex vivo Human Skin Models: Structure & Product Code



Name of Startup: Molecule AI Private Limited



Founder and Co-founder(s):
Mr. Saurabh Singal &
Ms. Neeta Singal

Email:
info@moleculeai.com

Product/Technology differentiation from Competitors

1 The combination of state-of-the-art computational tools in drug discovery with novel AI tools developed in-house by leveraging our proven success in natural language processing. We expect the combination of these aspects to result in a solution that will outperform existing computational drug discovery tools. 2 A rigorous hit-to-lead screening process that will combine automation again, developed in-house and deep domain expertise through in-house personnel and partners to maximize the likelihood of clinical success of the AI-generated hits.

Brief Description of Product


MoleculeAI proudly introduces Molecule GEN, a revolutionary AI-driven software suite designed to transform the drug discovery process. Molecule GEN leverages advanced AI technology to simplify and expedite the discovery of new therapeutic candidates. This platform offers a unique combination of de novo molecule generation and lead optimization capabilities, ensuring that researchers can efficiently move from hit generation to lead development. The intuitive design of Molecule GEN makes it accessible to users of all backgrounds, including biologists, chemists, and AI researchers, facilitating the translation of research ideas into viable drug candidates with ease. As a Software as a Service SaaS platform, Molecule GEN eliminates the complexities associated with setup and maintenance, providing a seamless user experience. The platform includes a range of integrated tools tailored for rational and AI-based drug design. These tools include Protein Info for curated protein metadata and analyses which is used for visualizing protein-ligand interactions, and Leader for AI-driven lead optimization. Genie enables the generation of novel molecules, while Ligand Docking facilitates the docking of small molecules with target proteins. Additionally, ADME explores the absorption, distribution, metabolism, and excretion properties of molecules, and Screenie screens hits based on physicochemical properties. Protein Prep and Ligand Prep tools offer intelligent preparation for various applications. Molecule GEN stands out as an end-to-end solution for AI-driven drug discovery, embracing the future of AI to revolutionize the industry. With its comprehensive features and user-friendly interface, Molecule GEN provides researchers with the tools they need to accelerate drug discovery and innovation.

Current Stage of Development

Pre launched Market Ready

Geographical Region Targeted
Global

Technology readiness level (TRL)
TRL-9



Title/Name of the Product/Technology

Molecule Gen

Product Positioning

Pharmaceuticals, CROs and Research Institutes.

National/Societal Relevance

Reducing dependency on Western-led medicine and promoting indigenous drug development, this project will expedite the creation of novel, proprietary, and patentable therapeutic molecules. Additionally, create capabilities to focus on areas ignored by the west, but important for India.

Export Potential

High. Catering to pharmaceuticals across the globe, aiding their efforts in launching new drugs across all therapeutic areas.

Name of Startup: NANIC WELLNESS PRIVATE LIMITED



Founder and Co-founder(s):
R.Savuniya - CEO
R.Arun Kumar - Md

Email:
nanicayurveda@gmail.com

Product/Technology differentiation from Competitors

Menstrual Care Lotion stands out from competitors due to its unique application method and innovative formulation. Unlike traditional products that rely on oral intake, our lotion is applied directly to the navel, allowing for targeted absorption of natural oils and herbal extracts. This approach supports menstrual health without systemic side effects. The blend of Ayurvedic ingredients is carefully selected to regulate menstrual cycles, reduce white discharge, and alleviate perimenopausal symptoms, offering a holistic and convenient alternative to conventional treatments.

Brief Description of Product

Menstrual Care Lotion is an innovative Ayurvedic product designed to support women's health. Applied into the 'Navel', it combines natural oils and herbal extracts to help regulate 'Irregular Menstrual Cycles' and control 'White Discharge', alleviates symptoms of perimenopause such as heavy or frequent bleeding, and supports overall menstrual wellbeing without oral intake.

Current Stage of Development

Menstrual Care Lotion is at the Minimum Viable Product MVP stage. Successfully developed and tested the prototype, validating its effectiveness in addressing menstrual health issues. The product has completed the patent application process, with novelty confirmed and final approval imminent. Currently refining the product based on feedback, preparing for market launch, and scaling production to meet anticipated demand. Well-positioned to bring a validated, innovative solution to market, addressing a critical need for women's health.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

The initial launch of Menstrual Care Lotion will target all regions across India.

National/Societal Relevance

Menstrual Care Lotion addresses irregular menstrual cycles, a key factor affecting fertility and contributing to various health issues such as hormonal imbalance, weight fluctuations, PCOD, mood swings, hair loss, and infertility. In India, where these menstrual health challenges are prevalent, this product provides a natural, non-invasive solution by integrating Ayurvedic wisdom with modern techniques. By promoting menstrual regularity and supporting overall hormonal balance, it enhances reproductive health and well-being, helping to alleviate multiple related ailments and improving women's health care nationwide.

Technology readiness level (TRL)

TRL-6



Title/Name of the Product/Technology

Menstrual Care Lotion: Regulate Irregular Menstrual Cycle by navel application.

Product Positioning

Menstrual Care Lotion is positioned as a premium Ayurvedic solution for menstrual health. With its unique navel application method, it offers targeted relief for irregular cycles and white discharge. Combining traditional herbs with modern technology, it provides a holistic, non-invasive alternative for women seeking natural menstrual support.

Export Potential

Menstrual Care Lotion has strong export potential due to its unique Ayurvedic formulation and targeted approach to menstrual health. Its natural, non-invasive solution appeals to international markets seeking holistic and effective wellness products. The blend of traditional herbs with modern application methods positions it as a valuable product for global.

Import Substitution

Menstrual Care Lotion supports import substitution by offering a locally developed Ayurvedic solution for menstrual health, reducing reliance on foreign products. By providing an effective, natural alternative made from traditional Indian herbs, it promotes self-sufficiency and supports the domestic market for women's health solutions.

IP Status

Patent has been applied and have completed the publication and examination phases.





Name of Startup: NATURAL SOLUTIONS AND NEUTRACEUTICALS PRIVATE LIMITED



Founder and Co-founder(s):
Dr Anil Kumar Sharma

Email:
info@nsnpl2health.com

Product/Technology differentiation from Competitors

Virulina: Clinically tested product with a 95.9% inhibition activity against coronavirus. Virulina offers a broad-spectrum antiviral solution with potent immunomodulatory and anti-inflammatory properties, making it ideal for empirical therapy.

Hypercum and HepadetoX address prevalent post-pandemic health issues such as hypertension and liver injuries. Hypercum is a polyherbal formulation that safely relaxes smooth muscles by promoting endothelial NO release, alleviating hypertension-related symptoms and promoting overall well-being.

Brief Description of Product

Antiviral Innovation: Virulina is a polyherbal product designed to meet the urgent need for effective antiviral solutions in the post-pandemic era. It exhibits immunomodulatory and anti-inflammatory properties, enhancing its overall health benefits. Virulina, is distinguished by its broad-spectrum antiviral capabilities, demonstrating a 95.9 % inhibition activity against the Wuhan coronavirus, close to the 98.6 efficacy of remdesivir.

Hypertension Management: Hypercum is a polyherbal formulation that safely relaxes smooth muscles by promoting endothelial NO release, alleviating hypertension-related symptoms and thus effectively manage hypertension and its associated complications

HepadetoX: A polyherbal formulation used for liver damage, particularly in the context of post-COVID liver injuries, which affect more than half of the patients. In vitro studies have unequivocally demonstrated its significant potential in rejuvenating hepatic cells and facilitating the recovery of the liver. HepadetoX also contributes to the regulation of cholesterol levels, which are pivotal in maintaining optimal lipid levels. These lipid levels serve as vital markers for cardiac health. By aiding in liver healing, HepadetoX not only fosters liver recovery but also plays a crucial role in alleviating cardiac issues, which can be life-threatening. This dual impact emphasizes the pivotal role of HepadetoX in safeguarding both liver and cardiac health.

Current Stage of Development

The product is ready to be launched in the market. Pre-Clinical & Clinical studies are completed. Outsourced manufacturing facility which complies the market requirement. Received FDAQ licence to market the products.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Maharashtra and Karnataka, INDIA

National/Societal Relevance

Virulina can reduce the burden on healthcare systems and improve patient outcomes. Antiviral market in India is projected to reach \$2.8 billion by 2028, growing at a CAGR of 8.8. Virulina has significant market potential, contributing to economic growth and innovation in the healthcare sector.

As an effective treatment for hypertension, Hypercum can help reduce the incidence of heart disease and related complications, improving overall public health. The hypertension market in India is projected to reach \$1.6 billion by 2028, growing at a CAGR of 6.5.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

GODNESS OF NATURE Virulina: a polyherbal product with Immunomodulatory and Anti-inflammatory effects.

Product Positioning

Immunity Modulator with anti-inflammatory and anti-viral management Hypercum: Anti Hypertension and morbidity. Natural bronchodilator & Vasodilator Hepa Detox: Metabolism & Liver detoxification National/Societal Relevance Virulina can reduce the burden on healthcare systems and improve patient outcomes. Antiviral market in India is projected to reach \$2.8 billion by 2028, growing at a CAGR of 8.8. Virulina has significant market potential, contributing to economic growth and innovation in the healthcare sector. As an effective treatment for hypertension, Hypercum can help reduce the incidence of heart disease and related complications, improving overall public health. The hypertension market in India is projected to reach \$1.6 billion by 2028, growing at a CAGR of 6.5.

Export Potential

Global export market potential.

IP Status

1. Virulina Patent Application Number : 202021016940 Patent Application Date 20/04/2020 Patent Number 4040858
2. Hypercum Patent Application Number : 3507/MUM/2013 Patent Application Date 06/11/2013 Patent Number 352347



Name of Startup: Neothera Research Private Limited



Founder & Co-founder(s)
Dr. Abha Rishi G M Arif

Email:
neotheraresearch@gmail.com

Product/Technology differentiation from Competitors

Unique phyto-active principle-based formulation which is a therapeutic.

Brief Description of Product

Neothera Research has developed phyto-active principle-based formulation that has shown excellent results in preclinical studies for neurodegenerative conditions. This formulation leverages the power of natural plant-based compounds to address the underlying causes of diseases like multiple sclerosis.

Current Stage of Development

Extremely positive results observed in the animal studies conducted on the product.

Are you willing to Transfer / Out-License your Technology Yes

Geographical Region Targeted

India and Global market

National/Societal Relevance

Tackling Multiple Sclerosis: MS is a chronic autoimmune disease that affects the central nervous system. It causes inflammation and damage to the myelin sheath, disrupting communication between the brain and the body. Symptoms can vary greatly, but commonly include fatigue, weakness, numbness, vision problems, and cognitive changes. This debilitating condition presents a significant challenge the current product provides an innovative solution to improve the lives of those affected.

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

Phyto Active Principle-based Herbal Formulation for Treating Demyelinating Diseases of the Nervous System.

Product Positioning

Safe, unique herbal active principle-based formulation which is a therapeutic in demyelinating diseases.

Export Potential

Across the globe

Import Potential

Yes potential product to substitute import products

IP Status

Grant No.449959

Name of Startup: Nubiogenx Pvt. Ltd



Founder and Co-founder(s):
Saroj K Basak
Manoj K Basak

Developed Under
(scheme):
BIG

Email:
nubiogenx@gmail.com

Product/Technology differentiation from Competitors

The medical industry is in need of new treatment options for ever increasing population of people suffering from kidney diseases. As per US-CDC Medicare cost for people with CKD is over \$61.8 billion or \$23,700 per person and patient cost for ESRD only is \$36.6 billion or \$80,000 per person in the year 2018. In INDIA annual median haemodialysis cost of CKD patient is about INR 61,170 and median kidney transplantation cost is INR 392,920 and these patient can be treated with the proposed new therapy and their quality of life improved. These two option available till date.

Brief Description of Product

Mesenchymal stem cells expressing therapeutic protein transgene derived conditioned media for the treatment of chronic kidney disease CKD.

Current Stage of Development

Milestone completed : Expression of therapeutic protein from clonal selected cells was determined using ELISA and high expressing cells were identified. Cells were adapted to low serum model. Achieved up to 2 FBS media. Expression of transgene is robust and average yield is 80ng/ml. Studies were performed with or without antibiotic up to 6 passage. Collection of condition media ,lyophilization, characterization and quantification of bulk for functional study. Invitro functional assay using renal cell lines viz. NRK49F and NRK52-E in progress as cellular efficacy model for the study.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Global

National/Societal Relevance

Beneficial to the poor people and also improve the life style of the person that will reduce the social burden , affects old age people.

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

Stem Cell based treatment for Chronic Kidney Disease CKD

Product Positioning

This can be a standalone therapy or can be used with other mode of existing therapy to improve patient outcome.

Export Potential

High, as this technology is not available globally.

Import Substitution

NO

Name of Startup: OmniBRx Biotechnologies Pvt. Ltd.



Founder and Co-founder(s):
Mr. Ravindra Patel - MD, CEO

Developed Under
(scheme):
BIG, LEAP Fund, NBM

Email:
ravindra.patel@omnibrx.com

Product/Technology differentiation from Competitors

It offers 90% cost savings, 10X scalability, and 6X efficiency

a. Dynamic bed design ensures functional & geometrical scalability from 1L till 200L.

b. Efficiency: This design of the bioreactor ensured nutritional and gaseous homogeneity for good health of the grown cells at high cell density which increase the efficiency of the process output.

c. Affordability: The product is cheaper compared to available market products as it offers per unit of the surface area which decreases the product cost (vaccine, mAbs) and increase its accessibility.

Brief Description of Product

CellBRx® -IST. The proprietary world's first close-loop, integrated & automated single use bioreactor platform reduces manual interventions significantly and makes the whole seed expansion process robust & user friendly. miniBRx® - a small-scale high throughput allowing multiple runs at a time -bioreactor system for suspension cell culture applications. The perfusion-enabled automated bioreactor systems are used for small scale studies such as process development, characterization, etc. All these bioreactor product range are used for production & development of vaccines, viral vectors, biotherapeutics mAbs, cell & gene therapy products. OmniBRx Biotechnologies has commercially launched below mentioned products. 1 CellBRx®: Single-use bioreactor technology is the first-of-its-kind bioreactor device with complete automation, which makes it almost reliable platform for vaccine manufacturing. CellBRx® SUB's are developed upon the concept of Dynamic bed reactor DBR technology, which ensures nutritional & gaseous homogeneity across the cell carrier bed resulting in high-density cell culture. The innovative arrangement of cell carrier matrix, the cell carrier matrix is the area where cells will attach and grow to produce desired product. In the CellBRx®, single use bioreactor ensures nutritional and gaseous homogeneity across the cell carrier matrix, in all the scales of the CellBRx®. This design leads to high density and healthy cell growth for efficient process output. With linear scalability, our product ranges from 1L to 200L bioreactor volume with a surface area from 0.5 M² to 1500M² equivalent to 17,647 units of roller bottles. Accumulated USPs of the CellBRx® System are 90% cost savings, 10X scalability, and 6X efficiency. 2 "CellBRx® IST" - CellBRx® -Integrated Seed Train: The world's first Integrated Seed Train system, for viral vector & vaccine manufacturing. It integrates serially linear seed bioreactors 1 L SeedBRx - 5 L SeedBRx - 10 L SeedBRx and automates whole process of seed expansion in these bioreactors. This the close-loop seed expansion is done for large scale production. It is a fully automated, recipe-driven, aseptically connected system that grows the cells to the required numbers trypsinize the bioreactor vessel in automation according to the user defined process. USPs such as, least manual interventions, least facility foot print, full process automation, user friendly, regulatory compliances friendly, makes it one of its kind solution for vaccine manufacturers and viral vector producers.

Key Features: (a)Pre-Sterilized & Contamination Prevention - System incorporates pre-sterilized, inter-connected devices, significantly reducing the risk of contamination with fully closed-loop systems.

(b)Robust Automation - Achieve robust process controls with end-to-end automation.

(c) Compact Footprint - 85 reduction in footprint.

(d) Consistency & Cost Efficiency: Benefit from unparalleled process consistency and reduce upstream costs by up to 90, decreasing facility requirements, labor, and media consumption.

(e) High Cell Recovery: CellBRx®-IST consistently delivers more than 85 cell recovery for VERO and more than 92 for HEK-293 in 1L, 5L, and 10L SeedBRx bioreactors.

(f)Cell Viability & Growth: Achieve consistent cell viability of over 90 and seamless cell growth and recovery when transitioning to larger bioreactors.

(g) GAMP-5 Compliant IST Controller: Our GAMP-5 compliant IST controller generates invaluable process data for Process Analytical Technology PAT, enhancing product quality, cost-efficiency, safety, and consistency.

3 miniBRx®: It is small scale high throughput system for suspension cell culture application. The miniBRx® bioreactor platform is single use, fully automated and perfusion enabled, used for fed batch and perfusion-based process. Up to 16 fully-featured mini-bioreactors having 100ml/250ml bioreactor volume can be run simultaneously with the miniBRx® system. The bioreactor system has different applications such as process development, process characterizations, DOE & QbD experiments, scale down model studies, etc.

Current Stage of Development

OmniBRx's recent pipeline includes C> Compass, PerfBRx™, and StirBRx™, each at different Technology Readiness Levels TRL. C> Compass is a developmental device for cell and gene therapy, with validated concepts and integrated components. PerfBRx™ is a single-use bioreactor platform for perfusion bioprocesses, designed for both R&D and commercial scale, currently in the prototyping phase with identified components. StirBRx™ is another single-use bioreactor platform for suspension cell culture, also designed for R&D and commercial scales, and in the prototyping phase with identified components.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Domestic & Global Market, more emphasis on the USA and the Europe as more than 80% market of the single use clients are in these regions.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

1 CellBRx® - A patented single use bioreactor system for Adherent Cell culture applications.

Product Positioning

OmniBRx Biotechnologies leads in single-use bioreactor technologies for biologics, vaccines, cell and gene therapy, and biosimilars. The CellBRx® system offers automation and scalability, CellBRx IST provides vial-to-harvest platforms for vaccines, and miniBRx® offers high-throughput bioreactors for process development, ensuring cost savings and efficiency.

Import Substitution

1 2-D surface platforms such as roller bottles, multi surface flasks. 2 3-D surface platforms such fixed bed and packed bed bioreactors, 3 Conventional Stirred tank Bioreactors.

National/Societal Relevance

OmniBRx offers affordable process technologies with lower CAPEX and OPEX. It delivers improved process efficiency which helps to produce more biologics such as vaccines per unit and decreasing the cost of the same. These ultimately improve ease of access to biological drugs i.e. Vaccine, promoting equitable healthcare. Their streamlined drug development process enables faster availability of life-saving medications. By reducing manufacturing costs, OmniBRx contributes to efficient resource allocation in healthcare systems. Overall, OmniBRx plays a crucial role in making essential medications accessible, cost-effective, and impactful for the nations healthcare and economic well-being.

Export Potential

OmniBRx Products: CellBRx, CellBRx-IST, miniBRx® have strong export potential, with over 85 of clients globally, mainly in the USA and Europe. Their scalability, cost-effectiveness, and efficiency make them a top choice. Growing demand for biologics boosts their position as a key player in bioprocessing technology.



A proud moment for the recipient of BIG-BIRAC-22 grant award for Stem Cell based treatment for Chronic Kidney Disease (CKD)



NuBioGenx Private Limited - AIC-CCMB



Thematic Area: Healthcare - Therapeutics and Vaccines



Founder and Co-founder(s):
Sudarsana Reddy Lokireddy
Sridhar Rao Kunchala
Chandramohan Reddy Lokireddy

Developed Under
(scheme):
BIG, NBM

Email:
sreddy@oncosimis.com

Product/Technology differentiation from Competitors

The Unique Value Proposition of BacSec™ is to produce faster and higher quality Biologic therapeutic proteins at a lower cost using mainly, Proprietary Plasmid using rDNA technology enabling 'efficient' protein expression b. Proprietary line of genetically engineered E. coli cells enabling 'extracellular protein secretion' significant improvement from conventional 'intracellular expression' c. Proprietary growth media mix tailored to 'optimal biomass production' and also enable protein in its native conformation. d. Proprietary perfusion system - This technology facilitates continuous harvesting of the products of interest, in a relatively small fermenter.

Brief Description of Product

AcceTT® and BacSec® Technologies: Manufacturing of biopharmaceuticals is subjected to many changes, such as rising volume demands by meeting more stringent safety requirements. These prevailing conditions challenging conventional manufacturing platforms to re-think and re-innovate, which have not adapted sufficiently to these changes at low cost. Oncosimis AcceTT® and BacSec® technology is designed to meet these demands while keeping the yield biologics much higher level compared to current competitors. AcceTT® and BacSec® have established platform technologies at lab scale and would ideally suited for the development and large-scale manufacturing of a wide range of biologic drugs in both CHO cells and E. coli.

Current Stage of Development

Oncosimis Biotech products are at various commercial stages serving both local and international customers.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Worldwide

National/Societal Relevance

BacSec® is a fully indigenous technology offering a readymade platform for enabling development of the required molecules helping keep the costs low.

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

E. coli Secreted Recombinant Affinity Ligands, Enzymes & Growth Factors

Product Positioning

Technology transfer, B2B and B2C

Import Substitution

BacSec® will be a significant technology to help Indian companies depend on indigenously developed technology rather than in-license technologies from abroad.

Export Potential

BacSec® can be a crucial platform to enable India to achieve a leadership position in the Biosimilars market while retaining the cost advantage. Technology already out licensed to European countries.

IP Status

More than 30 patents filed all over world and also granted in countries like US, Europe, Japan, S. Korea, China, Singapore and India.

Name of Startup: Orish J Bioworks Pvt. Ltd.



Founder and Co-founder(s):
Rima Pandey & Shashikant Tewary

Email:
info@orishj.com

Product/Technology differentiation from Competitors

The key differentiators of nc-95x curcuminoid nano particles from the competition are i. Close to 95 purity of curcuminoid molecule ii. Nanotization without adding carrier particles or chemical modification iii. No taste and smell. This makes its suitable for various food formats like dairy products, beverages, chocolates, and gummies.

Brief Description of Product

Nanotechnology is being used to reduce the molecule size of natural curcumin to less than or equal to 200 nm. The natural curcumin curcuminoid extracted from Curcuma longa rhizome molecule has been reduced to nano size without using any carrier particle. The process is simple, safe, cost-effective, and food-grade compliant. The process accomplishes this molecular reduction without relying on any carrier particles. This innovation is significant because carrier particles can sometimes introduce unwanted characteristics or impurities into the final product, but by avoiding their use, this nanotechnology approach maintains the purity and integrity of natural curcumin. Natural curcumin size ranges between 1 - 20 micrometres. It has limited therapeutic effect because of poor bio-availability. The body removes almost 75% of the curcumin consumed. Also, the natural curcumin has a characteristic smell and a bitter after taste. nc-95x ~ 200 nm particle size is made from natural curcumin by using nanotechnology for particle size reduction. The smaller size helps in higher surface area, better absorption, increased bioavailability, and thereby more therapeutic effect. Compared to natural curcumin, it is 5x more bioavailable in mice model and stays in the blood for up to 8 hours. The advantage over the current similar technology available in the market is that the purity of curcumin molecule is more than 90% and the nanotization has been done without the use of carrier particles or any chemical modification. Additionally, nc-95x has no taste and smell.

Current Stage of Development

nc-95x curcuminoid nanoparticles have been characterized for their physical, chemical, and biological properties. Physically, nc-95x is different from natural curcuminoid but chemically it is the same. Pre-clinical studies have been done to understand its bio-availability and toxicity. Anecdotal studies in more than 100, stage 4 cancer patients show that it leads to better quality of life. In clinical trial CTRI/2018/04/013362, it was shown that the use of 0.1 percent nc-95x curcuminoid nano particles suspension reduced instantaneous risk of onset of Radiation Induced Oral Mucositis by 50 percent.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

B2B Phyto active Ingredient: India, Europe, US, UK, Japan, Middle East and South East Asia

National/Societal Relevance

INR 926 billion was the estimated harvest-post harvest losses in Indian agriculture 2023. A significant value addition gap exists in the value chain linking agriculture, manufacturing and health-wellness market. Phyto extracts have a significant role in bridging this value chain gap. India controls almost 80 of the global curcumin market. The government of India has recently constituted the National Turmeric Board. This will help in harnessing the potential and goodwill of turmeric and its derivative products. nc-95x with its USPs and pre-clinical and clinical validation can contribute to the well-being of the society and the economy of the nation.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

nc-95x: Natural Curcuminoid Nano Particles for Health and Wellness Applications

Product Positioning

nc-95x is a validated phyto active ingredient value added natural curcuminoid for nutraceutical products in health and wellness applications.

Export Potential

India controls almost 80 of the global curcumin market. Value-added curcumin is exported in the range of 150 - 200 MT per year. nc-95x has high export potential in its targeted geographical market.

IP Status

IP 298432 granted



Name of Startup: Peptomer Therapeutics Private Limited



Founder and Co-founder(s):
Dr Kantaraja Chandra - Co-founder, Director
Dr Manohar Mahata Co-founder, Director
Dr Ravindra P Veeranna Co-founder

Developed Under
(scheme):
BIG

Email:
info@peptometherapeutics.com

Product/Technology differentiation from Competitors

• Engineered antimicrobial compounds with adjustable lengths • Unique Mode of Action: less likely target for known bacterial resistance mechanisms. • Novel Antimicrobial Molecules for Clinical Use: We utilise cutting-edge platform technologies monomers/building blocks to design and synthesise new antimicrobial molecules, combining monomers with existing natural amino acid monomers. • Enhancement of Existing Antimicrobials: The membrane-permeating effects of the compounds can boost the effectiveness of current antibiotics against multidrug-resistant MDR pathogens. • Broad-Spectrum Activity: bacteria and fungi • Reduced Risk of Resistance: Current innovation is designed with multiple mechanisms to inhibit bacterial growth.

Brief Description of Product

Antimicrobial resistance AMR poses serious and escalating global health challenges. Over the past few decades, there has been a notable lack of new antibiotic classes introduced, even as the number of deaths directly or indirectly attributable to AMR has been increasing at an alarming rate. This situation underscores an urgent need for the development of novel alternative antimicrobials to address the growing threat of resistant pathogens. In response to this critical need, peptomer innovation is dedicated to inventing a platform technology designed to serve as a foundational tool for creating a new class of highly effective antimicrobials. This innovative platform aims to overcome the limitations of current treatments and offer robust solutions to combat a wide range of resistant microorganisms

Current Stage of Development

We have established and validated • Synthesis of the monomers • Use of monomer for controlled synthesis of antimicrobial oligomers, peptidomimetics and hybrids • Established that the design can be used to generate a series of antimicrobial compounds with broad-spectrum activity against Fungi, Gram-positive and Gram-negative bacteria. • The first generation lead candidates n=6 are well characterised by invitro assays, that can be used for chronic wounds complicated by persistent multi-drug resistant bacteria. The preliminary data to substantiate their application as antifungals is available. Based on the validation studies, the current technology has the potential to be a groundbreaking innovation for developing novel therapeutics to combat antimicrobial resistance AMR.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted
Global

National/Societal Relevance

The current Innovation addresses various socioeconomic issues associated with AMR by providing new therapeutics to combat drug-resistant infections.

Human Health: The new class of alternatives reduces morbidity, mortality, and healthcare costs.

Animal Health: Our innovation promotes clean milk production, vital for Indian dairy farming, which alleviates poverty, supports landless farmers, and improves rural nutrition.

Mastitis, a common mammary gland infection, causes significant milk loss 100-500 kg per cow per lactation and renders milk unfit for consumption. The current solution effectively treats mastitis from bacterial resistance, and also serves as dry cow therapy to reduce incidence, minimizing economic losses for rural farmers.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

A Platform for Generating New Antibiotic Alternatives

Product Positioning

Broad-spectrum alternatives to antibiotics effective against Gram-positive and Gram-negative bacteria, and fungi.

Import Substitution


Made in India novel alternatives to antibiotics to fight antimicrobial resistance.

Export Potential

The innovation address a major global health care crisis.

IP Status

*PCT Filed, published PCT/IN2023/050399 WO2023/209728A1 National phase filed in India 202417032489, to be filed in the EU/UK, USA by October 2024



Name of Startup: Polyorbit Private Limited



Founder and Co-founder(s):
Madan Sundar Dash,
Mamoni Dash, Biswa Ranjan Sahoo

Developed Under
(scheme):
BIG

Email:
info@polyorbit.org

Product/Technology differentiation from Competitors

The proposed product is an injectable graft based on exosomes from osteoblast cells of human donor patients, that will be encapsulated in a polymer matrix to promote extracellular matrix formation and subsequent bone regeneration. The current technology utilizes exosomes with regenerative capability that are isolated from human donor patients themselves, which is different from other products available in the market.

Brief Description of Product

Fractures, or broken bones, are extremely common. Furthermore, bone diseases such as osteoporosis or maxillofacial trauma can lead to broken bones thus impacting physical health and quality of life. The healing of bone fracture requires regeneration of bone at the fracture site resulting in bone tissue with similar biomechanical competence as bone. Bone defects of critical size have been traditionally treated with autografts, allografts and xenografts but the existing treatments suffer from limitations. The proposed product is an injectable graft comprising of exosomes from osteoblast cells of human donors patients that will be encapsulated in a polymer matrix. The polymer matrix will be capable of promoting extracellular matrix formation and subsequent bone regeneration. The encapsulated exosomes have a higher regenerative capability and will overcome the issue of donor rejection or any immunogenic reaction. The first product will aid in the regeneration of dental bone.

Current Stage of Development

The current stage of development is validating the product with human donor dental tissue. The POC is validated in a rat calvarial defect model using rat bone cell line.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted


India

National/Societal Relevance

The causes of dental bone loss, are various factors that may contribute to this medical condition. Bone loss in the teeth is related to damage to the jaw bone surrounding the teeth or roots. Bones are biologically active and sensitive, making them susceptible to conditions that have a negative impact on them. Infections are often the primary cause of teeth bone loss, which may involve infections in the nerve or gums. These problems affect in all age groups ranging from children to old age people. Restoring bone health is crucial for maintaining a healthy life.

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

Exosomes based bone graft material: A personalized product for Bone healing.

Product Positioning

The product is in the development stage.

Export Potential

The product has the potential for export since bone health is a global concern. In countries with a majority of senior citizens, this product can aid in bone regeneration where there is bone loss due to dental problems, accidents, sports-related injuries, or diseases.

IP Status

M. Dash, S. Samal, D. Barik, A 3D-EXTRACELLULAR MATRIX SCAFFOLD AND METHOD OF PREPARATION THEREOF, Indian Patent Application Number- 202331001486.



Name of Startup: Prescience insilico Pvt Ltd



Founder and Co-founder(s):
Prof. Jayant K
Dr. Sudip Roy

Email:
seema@prescience.com

Product/Technology differentiation from Competitors

The in-silico drug design market is now mostly dominated by North American companies like Schrodinger Inc, Nimbus Therapeutics, Chemical Computing Group etc. PIPL software platform PRinS3 performs high-throughput modeling and simulations by incorporating AI and cloud computing for designing/repurposing drug molecules for different therapeutics. This is the first such SW platform integrated with deep tech which could screen thousands of molecules. Unlike the AI drug design companies, the product emphasizes on validation of the AI using physics-based methods. This reduces the false positives, and fewer trial and error combinations are required on the experimental bench.

Brief Description of Product

Prescience has developed a state-of-the-art in silico technology platform PRinS3 that offers modular applications to design and repurpose drugs. Unlike the competing software, PRinS3 uses AI, cloud computing, and advanced physics-based modeling methods like molecular dynamics and enhanced sampling to calculate the free energy of binding of ligands to the targets.

Current Stage of Development

Already in the market.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

SaaS is being used across industry and academic labs in Asia.

For global pharma R&D projects, PRinS3 is extensively used in house to deliver service consultation projects.

National/Societal Relevance

Working on a product for R&D in drug design. The platform will reduce the time of drug development by 3-4 years and early-stage R&D cost by 2X. Thus impacting the success rate for new drugs. Therefore, we believe this will help small and medium size pharma organizations will be investing in drug discovery projects. The platform will also enable R&D institutions to create IPs more rapidly and help in scaling up the full process of drug development.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

PRinS3 SaaS PRESCIENCE in silico Solution SUITE

Product Positioning

Global pharma R&D - leveraging digital R&D tools in drug discovery and design, formulation design and optimization, drug repurposing, target validation and off target effect elucidations.

Name of Startup: Radiom Bioinnovations Pvt. Ltd.



Founder and Co-founder(s):
Dr. Priyanka Sharma
Mr. Pushker Dutt Sharma

Email:
radiombiinnovations@gmail.com

Product/Technology differentiation from Competitors

iColostrum is an omnipotent immunity booster and unique from other similar marketed products in that it is derived from 100% natural and authentic skimmed indigenous bovine colostrum with high IgG and very high protein content. It has no added preservatives, gluten and sugars. It is available in different forms as capsules, sachets and chewables.

Brief Description of Product

Radiom Bioinnovations has a range of Bovine colostrum based nutraceutical products. Its Finished product is available as Capsules, sachets and flavoured chewables:

1. iColostrum is a powerful nutraceutical intended to be used as wellness, healthcare & dietary supplement. • Omnihealth capsules with 20 to 30 IgG content • Gold standard 30 to 40 IgG content • Premium and Exclusive 60 Total IgG. • iColostrum milk Sachets for infants • iColostrum chewables in different flavours for kids and people unable to ingest capsules.

2. Raw Material/Ingredient product available as powder form in 5 kg and 20 kg packets: 1. a2Immunoglobulin, 95 with 80 to 90 IgG 2. a2Colestra Whole/Skimmed 40 IgG 3. a2Colestra Whole/Skimmed 30 IgG 4. a2Colestra Whole/Skimmed 20 IgG

3. iColostrum is an omnipotent immunity booster and unique from other similar marketed products in that it is derived from 100 natural and authentic skimmed indigenous bovine colostrum with as high as 60 IgG as main bioactive present and very high protein content. It has no added preservatives, gluten and sugars. Indigenous Bovine Colostrum contains most powerful prebiotics such as Iron binding Lactoferrin, Lactoperoxidase and bio-actives Proline-Rich Polypeptides, Growth factors, Vitamins, Minerals, casein, etc. in addition to Immunoglobulins. The product is also available as Whole colostrum, which contains phospholipids, sphingomyelins and MUFA, PUFA also suitable for infants and kids for brain development. Bovine Colostrum is the natural health treasure for all age groups and a blessing from mother nature. It has been successfully proved to be efficacious as the wellness and dietary supplement for malnourished, Anaemic patients, persons with digestive problems or gut issues, immunodeficiencies, respiratory problems, Alzheimers Disease and cognitive disorders as well as for skincare, bone repair, maintaining good health, overall growth and neuronal development in infants and children.

Current Stage of Development

Capsules, sachets, chewable and powders all developed and ready for selling and trials.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Nationwide and also intended for international market distribution

National/Societal Relevance

Product is highly recommended for person suffering from malnutrition, iron deficiency, digestive disorder and any immunodeficiency. For brain development & cognitive function in infants, kids. As bone repair and immunity booster for all including aged with metabolic disorders and immunocompromised person.

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

1. iColostrum 2. a2Immunoglobulin 3. a2Colestra

Product Positioning



iColostrum: Most omnipotent bioactive Natural Immunity booster as wellness & dietary supplement for all age groups.

Import Substitution

Made in India product will support Import substitution

Export Potential

Potential market for export



Name of Startup : Sangadak Technologies Pvt. Ltd.



Founder and Co-founder(s):
Amit Srivastava &
Ritika Srivastava

Developed Under
(scheme):
BIG

Email:
AMIT@SANGADAK.COM

Product/Technology differentiation from Competitors

Our drug safety data mining platform stands out with real-time AI-driven signal detection, integrating diverse data sources like clinical trials, patient records, and social media for a comprehensive safety view. Its intuitive interface enables easy use by both technical and non-technical teams. Automated compliance with global regulations streamlines reporting, while the platform's customizability and scalability suit organizations of any size. Additionally, proactive risk management through predictive analytics helps identify potential issues early, ensuring faster, more accurate safety monitoring and enhanced patient outcomes, setting it apart from competitors.

Brief Description of Product

Pharmacovigilance.dev: The drug safety data mining platform is a cutting-edge, AI-driven solution specifically designed for the pharmacovigilance industry, offering a smarter, faster way to manage and assess the safety of drugs and vaccines throughout their lifecycle. The platform empowers pharmaceutical companies, regulatory agencies, and healthcare organizations to identify and analyze adverse drug reactions (ADRs) by automating the process of signal detection, significantly reducing manual labor while increasing accuracy and speed in decision-making. In the rapidly evolving landscape of drug development, traditional methods of monitoring drug safety are often too slow, labor-intensive, and prone to human error. With the vast amount of data generated from clinical trials, patient reports, and real-world evidence, it is becoming increasingly challenging to track potential safety signals effectively. The platform solves this by leveraging advanced machine learning algorithms and artificial intelligence to continuously monitor large datasets, identify patterns, and detect safety signals in real-time. By integrating multiple data sources such as clinical trial data, patient health records, spontaneous reporting systems, and social media mentions, the platform offers a comprehensive approach to drug safety monitoring. This holistic view of drug safety helps users uncover hidden patterns that might indicate previously undetected adverse events, providing them with actionable insights to make informed, timely decisions. One of the key differentiators of this platform is its user-friendly interface, designed for both data scientists and pharmacovigilance experts. It offers an intuitive dashboard that presents safety signals clearly, making it easy for users to interpret results without needing advanced technical expertise. This allows for seamless collaboration across departments, ensuring that both technical and non-technical users can benefit from the platform's powerful capabilities. The platform also supports compliance with global regulatory requirements by helping users adhere to the latest safety monitoring and reporting standards set by agencies such as the FDA and EMA. This ensures that companies can respond quickly to potential safety concerns, avoiding costly delays and minimizing risks to patients. The platform's scalability allows it to accommodate organizations of all sizes, from emerging biotech companies to large pharmaceutical corporations. It is flexible enough to be customized according to specific pharmacovigilance needs, whether that involves monitoring a single drug, a portfolio of medications, or vaccines. In summary, our drug safety data mining platform is a game-changer for pharmacovigilance professionals looking to optimize their safety monitoring processes. By automating adverse event detection and analysis, it helps organizations stay ahead of potential risks, improve patient outcomes, and ensure regulatory compliance—all while saving time and resources. With its AI-driven technology, comprehensive data integration, and user-friendly interface, the platform is positioned as an essential tool for modern drug development and safety surveillance.

Current Stage of Development

Web Platform Launched for Demonstration - Available on Pharmacovigilance.dev

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

North America, South America and Europe

National/Societal Relevance

Highly socially and nationally relevant as it will help in safer, faster and cheaper drug, vaccine and device development.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology


Pharmacovigilance.dev - An AI and Data Mining Driven Platform for Analytics in drugs and vaccines safety.

Product Positioning

Our drug safety data mining platform stands out with real-time AI-driven signal detection, integrating diverse data sources like clinical trials, patient records, and social media for a comprehensive safety view. Its intuitive interface enables easy use by both technical and non-technical teams.

Export Potential

Very high export potential as drug safety intelligence is primarily needed by Life Science companies in North America, South America and Europe



Name of Startup: Schrocken India Private Limited



Founder and Co-founder(s):
Sanjay Kuberkar

Email:
sanjay.kuberkar@collabrix.co

Product/Technology differentiation from Competitors

Cell & Gene Therapies are an emerging offering in the life sciences industry. Globally, these therapies cost \$300,000 to \$3M per patient. Alpatia enables operation of these therapies on a digital platform thus reducing the overall cost to patients. This is highly applicable to the Indian context. There are 2 competitors in the industry, Trakcel & HyperTrust. Alpatia differentiates itself in 2 ways: a The completeness of the solution - includes quality, manufacturing, and enterprise integrations, and b The total cost of ownership - having built on scalable technologies, Alpatia is designed to scale to 100,000s patients.

Brief Description of Product

Alpatia is Collabrix software-as-a-service platform for execution of cell & gene therapies. It streamlines the orchestration of vein-to-vein therapy by establishing an integrated network of stakeholders and executing cross-enterprise workflows for autologous and allogeneic therapies. Alpatias functionality includes patient onboarding & ordering, slot management, collection management, transportation of biological material, manufacturing, quality management, infusion management, and post-infusion monitoring. Chain-of-Identity Col and Chain-of-Custody is a core built-in feature of the product. The software is built on a modern cloud platform, and leverages enterprise blockchain technology enabling robust cyber-security and data privacy.

Current Stage of Development

The product has been fully developed, and being evaluated for use by multiple Indian and global pharmaceutical corporations big pharma for deployment.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, EU, US

National/Societal Relevance

Alpatia is instrumental in enabling personalized therapies for difficult diseases such as cancer and autoimmunity for every patient, no matter where on this globe.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Alpatia

Product Positioning

Alpatia is targeted to Indian and global cell & gene therapy companies.

Import Substitution

100 import substitution for competing products.

Export Potential

Huge potential for exports, and we are already working on sales to global big pharma.

Name of Startup: Sravathi AI Technology Private Limited



Founder and Co-founder(s):
Dr. Kishan Gurram, Dr. Deepak
Agrawal, Dr. Rajappan Vetrivel, Dr.
Ramanarayanan G.V. Dr. Sivakumar S.

Email:
nagaraj.kulkarni@sravathi.ai

Product/Technology differentiation from Competitors

Key differentiators: State-of-the-art NCE generative models to generate and optimize diverse set of molecules. With more than 100 in-silico properties across ADMET, medicinal, synthetic feasibility, solubility, physicochemical. Advanced molecular dynamic methods for molecule refinement and candidate selection including Quantum Chemistry, Alchemical binding free energy. Able to differentiate in-silico between nM and μ M activity. Novel Chemistry AI in-silico platform for optimal routes of synthesis, yield optimization, impurity prediction, and solubility.

Brief Description of Product

Sravathi AI is focused on creating, discovering, and developing innovative advanced pharma and chemical products. Sravathi AI uses Hybrid Intelligence, combining the domain expertise with innovative AI technology to solve the most difficult problems in drug discovery and process research. Sravathi has developed in-house proprietary AI algorithms that can make accurate predictions involving the vast and unexplored space of molecules and chemical reactions.

Current Stage of Development

We have already developed platforms for drug discovery and chemistry AI and we are applying them for a number of internal and external projects. We have a lead molecule for an immuno-oncology target using our AI platform. Also, we are expected to file our first IND for a repurposed drug for the treatment of cancer. This was developed using our AI platform.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

All over the world.

National/Societal Relevance

The societal relevance of using our technology in drug discovery is that it can potentially improve the quality of life for millions of people who suffer from various diseases and conditions. Our technology can help researchers discover new drugs faster, cheaper, and more effectively by using data and algorithms to analyze biological and chemical information, generate novel molecules, and optimize drug designs.

Technology readiness level (TRL)

TRL-8

Major Achievements

Shortlisted as top 10 globally by Standard Industries USA for our Chemistry AI platform.

Sravathi AI Drug Discovery Capabilities				
Target Identification	New Chemical Entities (NCE)	Drug Repurposing (DR)	PROTACs / Glues	ADC
<ul style="list-style-type: none"> Druggable targets Crystal structure prediction Pocket identification 	<ul style="list-style-type: none"> In-silico design In-silico properties Hit-to-lead optimization Advanced Molecular Dynamics ROS and Rn conditions 	<ul style="list-style-type: none"> Ligand centric Target centric Advanced Molecular Dynamics 	<ul style="list-style-type: none"> In-silico design In-silico evaluation NCE E3 ligases NCE linkers 	<ul style="list-style-type: none"> In-silico design of payload ADC linker design

Title/Name of the Product/Technology

Artificial intelligence driven drug discovery and process development platform.

Product Positioning

Our AI driven drug discovery and chemistry AI platform can be a reliable partner for a pharmaceutical or biotechnology industry.

IP Status

Generated many IP for our immuno-oncology programs using our platform. Eg. WO2024028727A1, WO2024127343A1.

Name of Startup: Suria Eye Products Pvt. Ltd.



Founder and Co-founder(s):
Tamilvanan Shunmugaperuma &
Suriaprabha Marchen

Developed Under
(scheme):
BIG

Email:
tamilvanan1@yahoo.co.in

Product/Technology differentiation from Competitors

Commercially available are either single drug-loaded or drug-free lachrymal products. These formulations are mainly used to make hydrophilic ocular surfaces, minimize surface tension, and provide a density that allows the tear film to remain on the corneal surface for a suitable time. The main disadvantage of the product is repeated and frequent topical administrations, which lead to interruption in the production of normal tear volume, which results in further worsening the DES conditions. The prepared nanocapsule eyedrops are having bi-compartmental structure in which one half behaves like hydrophobic and another half acts as hydrophilic in the dispersed polymer-coated oil droplets.

Brief Description of Product

The nanocapsule eyedrops comprise bi-compartmental structures onto the dispersed polymer-coated oil droplets to accommodate two different drugs having dissimilar physicochemical properties but similar pharmacological activity. There is an increasing interest in preparing two drugs-loaded nanocapsules eyedrops to manage moderate to severe dry eye syndrome DES. Particularly in the case of DES, multiple benefits can be extracted from two drugs-loaded nanocapsules which include: 1. Co-delivery of two drug molecules 2. Prolonged drug action 3. Synergistic activity 4. Possible administration frequency reduction 5. Rapid relief from symptoms like inflammatory pain 6. Patient comforts since DES is always associated with inflammation due to inefficient coverage of tear fluid on the extra-ocular tissues such as cornea and conjunctiva, inflammation control/management becomes an integral part of symptomatic relief to patients suffering from ocular dryness conditions. The concept behind this proposal is mainly to address inflammation control/management of DES by exploiting/extracting the synergistic anti-inflammatory potential of two different drug molecules. Due to the low aqueous solubility of these two drugs, it is difficult to make aqueous-based eye drops and thereby opening the option of using colloidal drug delivery systems like emulsions, nanocapsules, nanoparticles and suspensions. Among these colloidal carriers, the nanocapsules possess the advantage of retardation in drug release because of the presence of polymeric coating onto the dispersed oil droplets. However, the polymer-coated oil droplets appear to be concentric or spherical in shape, and thus, a single drug molecule can be entrapped at a time into it. Therefore, the chances of adding one more cargo are not possible with the spherical-shaped dispersed oil droplets of the nanocapsules. To accommodate the additional cargo with or without the same pharmacological activity but dissimilar physicochemical properties to that of the originally entrapped drug molecule, it is pertinent to make architecture onto the dispersed oil droplets from spherical shape to the bi-compartmental structure. In the market, already a large number of low-viscosity and high-viscosity types of lachrymal products are available. For DES treatment actual marketed products are low-viscosity artificial tears (7 products), moderate-viscosity artificial tears (2 products), high-viscosity artificial tears (3 products), gel formulations (2 products) and lubricating ointments (4 products). These formulations are mainly used to make hydrophilic ocular surface, minimize the surface tension and provides a density which allows tear film to remain on the corneal surface for a suitable time. The main disadvantage of the product is repeated and frequent topical administrations which lead to interruption in the production of normal tear volume which in turn results in further worsening the DES conditions. The prepared nanocapsule eyedrops are having bi-compartmental structure in which one half behaves like hydrophobic and another half acts as hydrophilic in the dispersed oil droplets. Thus, the nanocapsule prototype is ready for accommodating two drug molecules having dissimilar physicochemical properties but similar pharmacological activity. Moreover, no marketed nanocapsule prototype is currently available.

Current Stage of Development

Currently, the project is at the technology readiness level TRL 4. The limited scale and laboratory validation including nanocapsules formula optimization through quality by design approach, in vitro corneal epithelial cell line viability assay, storage stability assessment of nanocapsule eyedrops, therapeutic efficacy checking in dry eye condition-induced rabbit eye model, etc. were completed. For clinical or field trials or large-scale validation required to be initiated after completing the toxicity tests of eyedrop formulations at GLP conditions.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Depending on the geographical location, climate and lifestyle of the people, the DES prevalence varies from 7.4 to 44.3. In India, it was found to be higher ranging from 18.4 to 54.3. Therefore, preserving healthy eyes becomes one of the most sensitive problems for all age-grouped people.

National/Societal Relevance

DES prevalence in India has been reported to be higher 18.4 to 54.3. In comparison to men, DES occurrence is more prevalent in women. This may be due to the decrease in the level of estrogen and androgen hormones in women at the menopause stage. If the DES remains untreated, then, it may result in blurred vision and possible vision loss. An increase in the usage of modern, user-friendly electronic gadgets, especially during the COVID-19 quarantine conditions, results in the worsening of eye health. Therefore, preserving healthy eyes becomes one of the most sensitive problems for all age-grouped people.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Ready to use Janus nanocapsules to manage dry eye syndrome

Product Positioning


The two drugs-loaded nanocapsule eyedrops will be used on the highly inflamed and disease-induced eyes for the rapid recovery into healthy condition. Therefore, our product will occupy the position of opening the treatment for dry eye syndrome.

Export Potential

Depending on the geographical location, climate and lifestyle of the people, the prevalence of DES in the world varies from 7.4 to 44.3. Moreover, our product is ready for accommodating two drug molecules and no marketed nanocapsule prototype is currently available.

IP Status

Patent filed on 24-02-2024, Application number: 202431013359



Name of Startup: SWALAVA ENTERPRISES PRIVATE LIMITED



Founder and Co-founder(s):
Dr. VIJAY KULKARNI
Mr. RAMESHWAR NALAWADE

Developed Under
(scheme):
BIG

Email:
vijay.kulkarni@swalava.com

Product/Technology differentiation from Competitors

Commercially marketed Albendazole products are poorly soluble in water and hence have lesser bioavailability, causing lower efficacy for systemic/ organ infection like liver, lungs and blood.

Hot Melt Extrusion (HME) technology has increased the bioavailability of product, overcome drug resistance and hence enhanced therapeutic efficacy.

Brief Description of Product

Manufactured using HME (Hot Melt Extrusion) technology, the product Albendazole (broad-spectrum Anthelmintic drug) offers enhanced bioavailability for ruminants (cattle, sheep and goat). This results in improved antiparasitic activity for gut/systemic or organ infections like of liver, lung and brain. The developed product can be self-consumed by animal as feed additive and hence does not require any specialized personnel or device for dose administration further assuring complete dosing and lower possibility of drug resistance.

Current Stage of Development

Product is ready for commercialization from an identified contract manufacturing site

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Europe, USA and New Zealand, Africa

National/Societal Relevance

1. Higher bioavailability with enhanced anthelmintic for systemic infection and gut infection thereby improving therapeutic activity.
2. Can be self-consumed by animal as feed additive and hence does not require any specialized personnel or device for dose administration, assuring complete dosing and lower possibility of drug resistance.
3. Help the dairy and meat industry in improving the health of farm animals
4. HME process for manufacturing solid dispersion product is environment friendly and as the process does not require a solvent, hence the batch-to-batch variations are minimized.
5. There has been a lack of new Anthelmintic drugs into the market for veterinary application since long.

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

Title: Development of commercial deworming product with enhanced bio-availability and animal Dosing compliance.
Name of the Product: Highly bioavailable Albendazole for Veterinary application
Technology: Hot Melt Extrusion.

Product Positioning

Through veterinary doctors and out target customer would be Dairy and Goat farms.

Export Potential

Can be exported to the countries with large number of farm animals i.e. Dairy and Meat industry.

Name of Startup: Tech Cell Innovations Private Limited



Founder and Co-founder(s):
Dr. Suchi Gupta
Mr. Vianayak Gupta

Developed Under
(scheme):
BIG

Email:
gupta.s1291@gmail.com

Product/Technology differentiation from Competitors

Exosome-based products are transforming the treatment of chronic wounds and osteoarthritis by targeting root causes, promoting tissue regeneration, and repairing cartilage—surpassing traditional therapies like hyaluronic acid and NSAIDs. These products are becoming more accessible as off-the-shelf solutions, with cost-effective production aided by using biowaste-derived materials, such as placental tissue. While exosome-based formulations are already advancing in Europe and the USA, with several in FDA-approved clinical trials and cosmetic applications, this is a new technology in India. We are pioneers in developing these innovative products, leading the way in this transformative healthcare field.

Brief Description of Product

We have developed a unique nano-formulation-based product harnessing the potential of stem cell exosomes for treating chronic wounds and osteoarthritis. The product can be easily tuned to multiple forms such as spray, powder, gel, etc., considering the patient's need. The major component of the product is well known for their therapeutic effects and have been established in various studies preclinical and clinical for their efficacious tackling of the wound chronicity such as inflammation, excessive levels of pro-inflammatory signals, tissue necrosis, etc. Thus, the novelty is highlighted by the first of its kind economical, indigenous Make in India regenerative product with versatile applications. Third-party validation of the product efficacy has been established in small and large animals. More investments are in plan for developing GMP grade products and obtaining regulatory approval for first in human clinical trials.

Current Stage of Development

TRL 4 completed.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, Europe and USA

National/Societal Relevance

Exosome-based products hold significant national and societal importance due to their potential to revolutionize healthcare and improve quality of life. Nationally, they offer advanced treatments for chronic conditions like osteoarthritis and chronic wounds, which are prevalent and costly to manage. Their ability to promote healing and potentially modify disease progression can reduce long-term healthcare costs and reliance on conventional, less effective therapies. Their use of biowaste-derived materials also supports sustainability and reduces medical waste. By advancing this technology, countries can lead in innovative healthcare solutions, improve patient outcomes, and contribute to the global shift toward regenerative medicine.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Non cellular regenerative nano-formulation
ExoAm

Product Positioning

Exosome-based products are positioned as advanced solutions for chronic wounds and osteoarthritis, addressing root causes and promoting healing at the cellular level. Unlike traditional treatments, they offer long-term benefits. Using biowaste-derived materials makes them cost-effective. While gaining traction in Europe and the USA, this technology is emerging in India.

Import Substitution

Exosome-based products can enable import substitution in India by reducing reliance on costly foreign treatments. Local production lowers costs and improves accessibility, while fostering job creation and economic growth. By leading in this innovative technology, India can enhance its healthcare industry, strengthen its global position, and improve patient outcomes.

Export Potential

With growing global demand for advanced therapies, the firms making exosome-based product can leverage cost-effective, high-quality solutions to enter international markets. India's competitive manufacturing advantages and emerging biotech reputation enhance the appeal of these products globally, positioning them well for export success.





Name of Startup: Theracues Innovations Pvt Ltd

theraCUES[™]
SIGNALS FOR LIFE

Founder and Co-founder(s):
Gopalakrishna Ramaswamy

Email:
gk@theracues.com

Product/Technology differentiation from Competitors

Unique solutions based on tumor and tumor micro environment.

Brief Description of Product

Signature and analytics-based solutions for therapeutics especially for cancer.

Current Stage of Development

We are in the initial stage of validation.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted


Global.

National/Societal Relevance

For oncology and other complex disease.

Technology readiness level (TRL)

TRL-2



Title/Name of the Product/Technology

OncoCUES - Signals for oncotherapy

Product Positioning

Useful for immunotherapy decisions

Import Substitution

Foundation medicine solutions

Export Potential

We are looking at Analytics and SAAS model.

Name of Startup: Theraxcel Healthcare Private Limited

THERAXCEL

Founder and Co-founder(s):
Dr. Vivek Ghate Mangalore, Director & Co-Founder
Jagdish Chandra Hilyar, Director & Co-Founder
Veena K. M., Director and Co-Founder

Developed Under
(scheme):
BIG

Email:
vivek@theraxcel.com

Product/Technology differentiation from Competitors

MucoPhyt Technology stands out from competitors through its unique integration of advanced scientific methods with natural botanical extracts. Unlike traditional mucosal care solutions, MucoPhyt leverages a blend of phytochemicals for enhanced soothing and protective effects, ensuring superior efficacy and safety. Its commitment to sustainability and ethical sourcing further differentiates it, combining environmental responsibility with cutting-edge innovation for optimal mucosal health.

Brief Description of Product

MucoPhyt Technology is a cutting-edge solution designed to enhance mucosal health using the power of nature and advanced scientific methods. This innovative product harnesses the benefits of natural botanical extracts to provide effective care for mucosal tissues, promoting overall wellness and comfort. The mucosal tissues, which line various body cavities and canals, play a crucial role in protecting against pathogens and environmental irritants. However, these tissues can often become irritated or compromised due to various factors, including environmental conditions, lifestyle habits, or underlying health issues. MucoPhyt Technology offers a unique approach to mucosal care by leveraging plant-based compounds known for their soothing and protective properties. Formulated with a blend of carefully selected phytochemicals, MucoPhyt Technology works by reinforcing the natural barrier functions of the mucosal tissues, helping to maintain their integrity and resilience. The active ingredients are derived from a variety of plants, each chosen for their specific benefits to mucosal health. These include anti-inflammatory agents that help reduce swelling and irritation, as well as antioxidants that protect the mucosal tissues from oxidative stress and free radical damage. Additionally, the formulation includes mucosal hydrating agents that ensure the tissues remain moist and healthy, preventing dryness and discomfort. What sets MucoPhyt Technology apart is its commitment to combining nature with science. By integrating phytotherapy principles with modern research techniques, this product offers a highly effective solution that is both gentle and powerful. The natural ingredients are meticulously processed to preserve their bioactive properties, ensuring maximum efficacy and safety. This approach not only enhances the therapeutic potential of the product but also minimizes the risk of adverse reactions, making it suitable for long-term use. Moreover, MucoPhyt Technology is designed to be versatile and can be used for various mucosal applications, including oral, nasal, and gastrointestinal care. Its formulation is adaptable, catering to the specific needs of different mucosal environments while maintaining a high standard of safety and effectiveness. Whether used as a preventive measure or as a response to mucosal irritation, MucoPhyt Technology provides a comprehensive approach to maintaining mucosal health. In addition to its functional benefits, MucoPhyt Technology is also committed to sustainability and ethical sourcing. The botanical ingredients are harvested from eco-friendly farms that prioritize environmental conservation and sustainable practices. This ensures that while users benefit from the natural properties of these plants, the impact on the environment is minimized. Overall, MucoPhyt Technology represents a fusion of nature and innovation, offering a robust solution for anyone seeking to maintain healthy mucosal tissues and overall well-being.

Current Stage of Development

MucoPhyt Technology is at Technology Readiness Level 4 TRL 4, meaning the core components and processes have been validated in a lab environment. At this stage, we have successfully demonstrated the basic functionality of our technology through controlled testing, showing promising results. This level indicates a transition from theoretical research to practical experimentation, laying the groundwork for more complex, real-world applications.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

MucoPhyt Technology primarily targets the Indian market, addressing the growing demand for advanced mucosal care solutions. With its focus on effective and sustainable health products, the technology aims to cater to India's diverse and expanding healthcare needs.

National/Societal Relevance

MucoPhyt Technology addresses significant national and societal health needs in India by providing advanced mucosal care solutions. Its focus on natural, sustainable ingredients aligns with the growing demand for eco-friendly health products, promoting overall well-being and supporting public health initiatives.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

MucoPhyt: Plant-Powered Mucosal Solutions

Product Positioning

MucoPhyt Technology is positioned as a premium solution for mucosal health, blending natural botanical extracts with innovative science. It targets health-conscious consumers seeking effective, eco-friendly care options, offering superior efficacy and sustainability in the competitive wellness market.

Import Substitution

MucoPhyt Technology supports import substitution by providing a locally developed, advanced mucosal care solution. By leveraging indigenous botanical extracts and innovative formulations, it reduces reliance on imported products, fostering self-sufficiency and promoting the growth of India's healthcare and pharmaceutical industries.

Export Potential

MucoPhyt Technology holds significant export potential, with its advanced, natural mucosal care solutions appealing to global markets. Its innovative formulation and commitment to sustainability align with international health trends, positioning it as a competitive product for export to regions seeking high-quality, eco-friendly wellness solutions.

IP Status

An Indian patent has been filed for MucoPhyt Technology under application number 202241040144



Name of Startup: TRANALAB PRIVATE LIMITED



Founder and Co-founder(s):
C. Ganesh &
Nitin Deshpande

Developed Under
(scheme):
NBM

Email:
nitin.deshpande@tranalab.com

Product/Technology differentiation from Competitors

Reduction of off-target effects and increasing efficacy. MTM conjugates are relatively smaller in size 1.5-4 kDa molecular weight, biocompatible and the combinatorial modular design enables diverse cargo to be delivered. It has in-built potential for quick turnaround time. Competing technologies are liposomal formulations and nanotechnology-based delivery systems. Liposomal formulations often have stability issues, difficult to handle and are expensive. Nanoparticles on the other hand possess safety/toxicity issues and fate inside the body, irrespective of cargo being used.

Brief Description of Product

Macrophage Targeting Molecules (MTM) technology addresses the problem of targeted delivery specifically to the inside of macrophages. Macrophages are target cells for both large molecule biotherapeutics and small molecule anti-infectives.

Gaucher Disease GD: Using protein engineering approaches, Tranalab is working to produce a biobetter Glucocerebrosidase (GCS) to reduce the frequency of drug administration from the current, twice a month to once in two months. The approach is two pronged, to improve GCS's uptake into macrophages through a particular receptor on macrophage cells, and/or improve GCS stability inside macrophages. For improved uptake of GCS into macrophages, specific small molecules Macrophage Targeting Molecules - MTMs have been identified which can bind to the endocytic receptor for GCS. The in-vitro experiments indicate a 2x betterment in GCS uptake which is further targeted to increase upto 4x uptake.

Macrophage related infectious diseases: The use of Macrophage Targeted Molecules (MTM) technology is being extended to deliver/target small molecule anti-infectives drugs inside macrophages for effectively eliminating intra-macrophage pathogens. Conjugates of MTMs with small molecule drugs have been made and their uptake into macrophage interior has been microscopically demonstrated along with designing of next generation conjugates. Conjugates will be assessed for their anti-viral/anti-bacterial potential using the intra-macrophage killing assay.

Current Stage of Development

Scaling up the production of Glucocerebrosidase from lab to clinic. Although produced using well known CHO cells, Glucocerebrosidase requires complex controlled enzymatic deglycosylation to convert it to a form which macrophages take up. The required three deglycosylation enzymes have been produced recombinantly and are being used to glycan-modify CHO-produced Glucocerebrosidase.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Global markets for both Glucocerebrosidase biobetter and MTM-drug specially focusing on India and other LMICs.

National/Societal Relevance

PROBLEM - MACROPHAGE RESIDENT INFECTIVE DISEASES PATHOGENS: many pathogens which cause diverse sets of infectious diseases infect, survive, replicate in and disseminate from macrophages. Most anti-infectives have limited reach to pathogens inside macrophages. Although macrophages constitute the primary first line of defence against pathogens, macrophages are subverted by pathogens in different ways. Hence, targeting effective drugs to the inside of macrophages is crucial for pathogen elimination and disease control. Current product focuses on few select pathogenic bacteria as per the WHO 2024 list and on flaviviruses especially dengue, all of which display macrophage-tropism. MTM-Drug conjugates are unique for precise treatment of infectious diseases

PROBLEM - RARE GENETIC DISORDER Gaucher Disease GD: It is characterized by non-functional genetically mutated Glucocerebrosidase GCS enzyme. Enzyme replacement using the glycoprotein enzyme i.e recombinant GCS (rGCS) is used as a therapy for Gaucher Disease. rGCS is taken-up by macrophages from circulation. rGCS clears toxic glucosylceramide deposits inside macrophages, which get accumulated when the body's own GCS is defective.

Current rGCS therapy is unaffordable as it is required to be given twice a month for the lifetime of individual. Approximately INR 30 Lakhs cost per 10kg child per year is required to be administered and this dose increases with weight.

There are many litigations on rare diseases, while India does have a rare disease policy. With the major aim of bringing affordability, the current technology addresses the need by decreasing the administration frequency of GD drug.

Technology readiness level (TRL)

TRL-2

Title/Name of the Product/Technology

Game-changing drugs using macrophage targeted delivery: Biobetter Glucocerebrosidase for Gaucher disease therapy and Macrophage targeted anti-infectives to kill macrophage resident infectious pathogens.

Product Positioning

Biobetter Glucocerebrosidase offers advantages such as lower frequency of administration and affordability. MTM-Drug conjugates are unique for precise treatment of infectious diseases with advantages such as dose reduction, shorter regimen, lower toxicity and better patient compliance

Import Substitution

Currently, the availability of Glucocerebrosidase in India is completely import dependent. Hence, biobetter Glucocerebrosidase is a potent novel biotherapeutic. MTM are novel set of molecules and hence import substitution is not applicable.

Export Potential

Products addresses global health problems not just locally in Indian market. The products would well fit as 'Make in India, for India and the globe too. We plan to follow differential pricing in economically weak LMICs vs. well-off markets.



Name of Startup: Transcell Biologics Private Limited



Founder and Co-founder(s):
Dr. Subhadra Dravida

Email:
suba.dravida@tran-scill.com

Product/Technology differentiation from Competitors

Testing safety or efficacy like concerns offered as Enterprise Solution AI-enabled Solution offering technology implementation from the existing workflows Anti-thesis to the CRO working model built on proprietary human Micro Physiological configurations.

Brief Description of Product

DART is a next gen Enterprise Solution that leverages human Micro Physiological Systems and Artificial Intelligence/Machine Learning tools in testing safety or efficacy concerns of the bio and pharmaceutical compositions. The end-user adopts DART during discovery stage till manufacturing the product stage through developmental stage, embracing cruelty-free operations.

Current Stage of Development

DART has clients in India and has a strong pipeline of end-user network created in the US and Europe.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted


India, USA, Europe, Japan

National/Societal Relevance

The technology supports cruelty free operations in the bio and pharmaceutical workflows aids in affordable drug development initiatives and thereby patient care.

Technology readiness level (TRL)

TRL-9





Name of Startup: Unicas Biotech Private Limited

Unicas
Biotech

Founder and Co-founder(s):
Anirudh Nishtala, Co-founder & CEO
Dr. Naveen Kumar D, Co-founder & Director

Developed Under
(scheme):
BIG, SEED Fund

Email:
anirudh@unicasbiotech.com

Product/Technology differentiation from Competitors

Unicas proprietary lipids have better stability, transfection efficiencies, and lower toxicity compared to current commercial lipids - Biology-driven lipid nanoparticle design leveraging active and passive targeting strategies and exploring different routes of absorption in vivo to achieve tropism to different target tissue and cell types Innovation in PEGylated lipids with and without conjugates to enhance specificity.

Brief Description of Product

Unicas Biotech is at the forefront of accelerating therapeutic development through innovative lipid and lipid nanoparticle LNP technology, addressing the critical challenge of targeted delivery. Our vertically integrated approach ensures a seamless workflow from the selection and development of proprietary novel lipids, based on ionization theory, to the creation of LNP formulations tailored for specific cells and tissues. With a strong emphasis on extrahepatic delivery, the current product target therapeutic and vaccine delivery beyond the liver, filling a crucial gap in the market. Traditionally, LNPs have been liver-tropic, limiting their application. Unicas breaks this barrier by developing advanced LNP formulations that achieve precise delivery to tissues outside the liver, expanding the therapeutic possibilities. Beyond R&D, we can provide comprehensive regulatory support to ensure smooth regulatory filings for any market. The Research Use Only RUO manufacturing capabilities are in the process of scaling up for commercial-scale production. Through end-to-end solutions, Unicas empowers the development of groundbreaking treatments, providing tailored delivery solutions that enhance the precision, safety, and efficacy of advanced therapies. By bridging the delivery gap, the company is paving the way for the next generation of targeted therapies, meeting the unmet needs of patients with unparalleled innovation and expertise.

Current Stage of Development

Unicas has conducted biodistribution studies at IICT on healthy mice demonstrating extra hepatic delivery with genetic payload, successfully de-targeting the liver We have completed immunohistochemistry IHC toxicity studies and are currently conducting safety studies and further optimizing the LNP formulations to target the kidney cell types.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

US, Europe, Japan, Korea

National/Societal Relevance

Unicas Biotech boosts India's biotech self-reliance by advancing local lipid production and genomic medicine support. By decreasing dependency on imports and promoting domestic innovation, Unicas enhances strategic autonomy, drives down costs, and aligns with India's vision for self-sufficiency in biotechnology.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Powering Precision: Targeted Delivery for Therapeutics with Breakthrough Lipid and Lipid Nanoparticle Technology

Product Positioning

Unicas is a vertically integrated partner in lipid and lipid nanoparticle technology, offering end-to-end solutions from novel lipid development and targeted LNP formulations to regulatory support and scalable manufacturing. The company accelerate therapeutic innovation with extrahepatic delivery, enabling targeted therapies and vaccines beyond the liver.

Import Substitution

Unicas Biotech could significantly reduce India's biotech imports, potentially substituting \$1.9 billion to \$3.25 billion annually. Key impacts include domestic lipid production, support for genomic medicine, cost savings in manufacturing, GMP compliance, enhanced strategic independence, and increased R&D investment, aligning with India's self-reliance goals.

Export Potential

Unicas Biotech's export potential could reach \$1.2 billion to \$1.9 billion annually by tapping into global markets for Lipid Nano Particles, custom lipids, delivery systems for advanced therapeutics, and contract manufacturing. Company's potential for GMP compliance and strategic partnerships further enhances opportunities in North America, Europe, and Asia.



Name of Startup: VeGen Labs

VeGen Labs
Redefining Drug Discovery

Founder and Co-founder(s):
Uday Kumar S., Prashant K. Bhavar
Co-Founder: Appaji Mandhare

Developed Under
(scheme):
BIG, BioNEST, BIPP,
SBIRI, SEED Fund

Email:
udays@vegen.in

Product/Technology differentiation from Competitors

No RAS inhibitor is approved in Asia or Africa including India. IND126 is the most potent inhibitor globally, that was developed as a differentiated product from products.

Brief Description of Product

IND126 is a 2nd Generation KRASG12C inhibitor being developed by VeGen for Non-Small Cell Lung Cancer.

Current Stage of Development

IND126 is being pursued for IND-Enabling Toxicology Studies.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Asia including India, Africa, and ROW

National/Societal Relevance

Lung cancer is the fourth most often diagnosed cancer and leading cause of cancer-related deaths worldwide. RAS is one of the most frequently mutated oncogenes in human cancer. KRASG12C mutation is most commonly found in 20 of non-small cell lung cancer patients.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

KRAG12C inhibitor for treatment of Non-Small Cell Lung Cancer NSCLC

Product Positioning

Product is expected to enter clinical trial testing in H1, 2025

Import Substitution

2 Novel KRASG12C have been approved in the west, but they are not expected to be available in India, given the unaffordable cost. VeGen IND126 is going to decrease the dependency of drug for this subpopulation of Lung Cancer patients.

Export Potential

An accelerated approval of the drug is expected to happen by 2028.

IP Status

202141046053 PCT Application no: PCT/IB2022/059630

Name of Startup: WeTranslate



Founder and Co-founder(s):
Akhil Shah
Ratnesh Jain

Email:
akhil.shah@wetranslate.science

Product/Technology differentiation from Competitors

WeTranslate is a platform where life sciences innovation led companies are onboarded for accessing right network and right strategy for rapid commercialisation.

Brief Description of Product

WeTranslate is a platform where life sciences innovation led companies are onboarded for accessing right network and right strategy for rapid commercialisation.

Are you willing to Transfer/ Out-License your Technology No

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Intellectual incubators/accelerators

Name of Startup: ZZWICK HYGIENE



Founder and Co-founder(s):
SHIRIDINADH V S
S NANDINI RAI

Developed Under
(scheme):
SEED Fund

Email:
nandini@padforher.com

Product/Technology differentiation from Competitors

Padforher differentiates itself from competitors through its focus on comfort, eco-friendliness, and affordability. The pads are designed with superior absorption and breathability, providing a rash-free experience that many other brands lack. By prioritizing both comfort and environmental sustainability, Padforher offers a unique value proposition that appeals to women seeking high-quality, budget-friendly period care solutions.

Brief Description of Product

Padforher Sanitary Pads are designed to provide women with a rash-free, comfortable period experience. These pads are crafted with soft, breathable materials that ensure maximum comfort while being gentle on the skin. Padforher focuses on eco-friendly options, making these pads not only kind to the body but also to the environment. They offer superior absorbency, leak protection, and an affordable price, making them an ideal choice for women seeking quality and value. With a commitment to empowering women through comfort and sustainability, Padforher is redefining what it means to have a worry-free period.

Current Stage of Development

Padforher is in a growth phase, having established a strong foundation with its high-quality, affordable, eco-friendly sanitary pads. After a successful year, the brand is expanding its product line and entering export markets. With a focus on innovation and customer satisfaction, Padforher is strategically positioned to scale operations and increase market share, while preparing for future growth.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Tier 2 and tier 3 cities in India and is expanding into international markets, including Seychelles, East Africa. This strategic focus aims to reach underserved regions with high-quality, affordable menstrual care products.

National/Societal Relevance

Padforher addresses national and societal relevance by providing eco-friendly and affordable menstrual care solutions, promoting hygiene and comfort for women across diverse socio-economic backgrounds. By focusing on sustainability and accessibility, it supports broader public health goals and environmental responsibility.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

BIODEGRADABLE SANITARY PADS

Product Positioning

Padforher is positioned as a premium yet affordable option in the menstrual care market. By combining advanced technology with natural fibers, it offers superior comfort, absorbency, and eco-friendliness. The product is designed to provide a high-quality, rash-free experience at a budget-friendly price, catering to women seeking both value and sustainability.

Import Substitution

Padforher supports import substitution by offering high-quality, locally produced sanitary pads that reduce reliance on imported products. By manufacturing domestically, it helps strengthen local industries, creates jobs, and contributes to economic self-sufficiency in menstrual care products.

Export Potential

Padforher has significant export potential, particularly with its entry into markets like Seychelles, Africa. The product's combination of advanced technology and eco-friendly materials positions it well for international markets, appealing to consumers seeking high-quality, sustainable menstrual care solutions. Expansion into additional countries could further enhance global reach and revenue.





DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology

Global
Bio-India
2024
Transforming Lives
Bioscience to Bioeconomy

बाइरेक
इन्क्यूबेटर्स
बिराक
Ignite Innovate Incubate



**Healthcare
Devices & Diagnostics**

HEALTHCARE-DEVICES & DIAGNOSTICS		
Sl. No.	Company Name	PAGE NUMBER
1	Aasya Healthcare Private Limited	47
2	Accelerd Sciences Private Limited	47
3	Adsys Medtech Pvt. Ltd.	48
4	Aindra Systems	48
5	Alfatcus Technology Pvt Ltd	49
6	Algorithmic Biologics Pvt. Ltd.	49
7	Ambinova Technologies Pvt Ltd	50
8	Amdus Technologies Pvt.Ltd.	50
9	Anymar Pvt. Ltd.	51
10	Anziam Bio Pvt Ltd	51
11	Arcapsis Techno-Solutions Private Limited	52
12	Ardor Biomed India Pvt Ltd	52
13	Assam Rifle	53
14	Aur Innovations Private Limited	53
15	Avay Biosciences Pvt Ltd	54
16	Avinya Infinity Solution Pvt Ltd	54
17	Avinya Neurotech Private Limited	55
18	Axion Meditech And Life Science Pvt Ltd	55
19	Babycue Private Limited	56
20	Beaable Health Pvt Ltd	56
21	Bearly Technovations Pvt. Ltd.	57
22	Bigohealth	57
23	Biodimension Technology Private Limited	58
24	Bioinnovatiq Lifescience Pvt Ltd	58
25	Bioestim Innovations Private Limited	59
26	Biotalent Search Private Limited	59
27	Biyani Bio Solution Pvt Ltd	60
28	Black Space Technology	60
29	Cambrian Bioworks	61
30	Canary Biosensors Private Limited	61
31	Caregenix Diagnostics Pvt Ltd	62
32	Cellseq Solutions Llp	62
33	Chrogene Aarogyam Biotech Private Limited	63
34	Cognidiagnoseai	63
35	Compass Healthcare	64

HEALTHCARE-DEVICES & DIAGNOSTICS		
Sl. No.	Company Name	PAGE NUMBER
36	Copious Dio Tech	64
37	Criador Design Labs Pvt Ltd	65
38	Curie Microelectronics Pvt. Ltd.	65
39	D2r Global Consulting	66
40	Deepfacts Private Limited	66
41	Define Bio.pvt.ltd	67
42	Denovo Bioinnovations Private Limited	67
43	Dessinrx Healthcare Private Limited	68
44	Dfine Bio Innovations	68
45	Dgrakahak Private Limited	69
46	Diasys Diagnostics India Pvt. Ltd	69
47	Digibooks Link4solution Private Limited	70
48	Dr.omics Labs Private Limited	70
49	Dxbidt Enzymes	71
50	Elevatronix Private Limited	71
51	Envisage Medtech Private Limited	72
52	Europeon Life Lechnologies	72
53	Evoreality	73
54	Femacare	73
55	Fides Medtech Private Limited	74
56	Genem Biotech Private Limited	74
57	Genes 2me Private Limited	75
58	Genespectrum Life Sciences Llp	75
59	Genomiki Solutions Private Limited	76
60	Glowvista Instruments Pvt. Ltd.	76
61	Haystackanalytics	77
62	Healyantra Medical Technologies Pvt Ltd	77
63	Helix Prevealth Healthtech Private Limited	78
64	Helo Health	78
65	Human Biogenesis	79
66	Icaltech Innovations Private Limited	79
67	Immugenix Biosciences Pvt Ltd	80
68	Immunitasbio Private Ltd	80
69	Incredible Devices Pvt Ltd	81
70	Infab Semiconductor Pvt Ltd	81



HEALTHCARE-DEVICES & DIAGNOSTICS		
Sl. No.	Company Name	PAGE NUMBER
71	Inochi Care	82
72	Intignus Biotech Pvt Ltd	82
73	Iota Diagnostic Pvt. Ltd.	83
74	Ismo Bio-Photonics Pvt. Ltd.	83
75	Itx Care Private Limited	84
76	Kumshungba Private Limited	84
77	Latent Heat2 Comfort Technology	85
78	Lifesenz Cancer Research Labs Pvt Ltd	85
79	Lumiguide Pvt. Ltd. (Lighting The Way To Independence)	86
80	Luxlighting Technology Private Limited	86
81	Manastik	87
82	Mars Healthtech Pvt Ltd	87
83	Medantrik Medtech Pvt Ltd	88
84	Medclinica Private Limited	88
85	Medevplus	89
86	Mediklik Webhealth Pvt Ltd	89
87	Medtra Innovative Technologies Pvt Ltd	90
88	MetamorF Art And Design	90
89	Mild Cares Private Limited	91
90	Miraqules Med Solution Pvt Ltd	91
91	Naisbrain Private Limited	92
92	Nemocare Wellness Pvt Ltd	92
93	Neuome Technologies Private Limited	93
94	Neuphony Pankhtech India Pvt Ltd	93
95	Noccarc Robotics Private Limited	94
96	Obront Biotech	94
97	Oko Icare Solutions Pvt. Ltd.	95
98	Oncoseek Bio Pvt Ltd.	95
99	Opti-Mode Diagnostics Pvt Ltd	96
100	Ostic Pharma Pvt Ltd	96
101	Papersens Pvt Ltd	97
102	Pictelai Pvt Ltd	97
103	Pistartech Private Limited	98
104	Plabs Solutions Private Limited	98
105	Plebc Innovations Private Limited	99

HEALTHCARE-DEVICES & DIAGNOSTICS		
Sl. No.	Company Name	PAGE NUMBER
106	Poccet Labs	99
107	Pragmatech Healthcare Solutions Pvt Ltd	100
108	Prakhar Innovations Llp	100
109	Prefecure	101
110	Primary Healthcare Pvt. Ltd	101
111	Procyto Labs Private Limited	102
112	Psaizi Technologies Private Limited	102
113	Ramja Genosenosr Pvt	103
114	Reprosci Biosciences Private Limited	103
115	Roundworks Technologies Private Limited	104
116	Rxone Care Private Limited	104
117	Sarbit Innovations Pvt. Ltd.	105
118	Sarsuag Enterprises	105
119	Shitashii Innovations Pvt Ltd	106
120	Shodh Clinical Solutions Llp	106
121	Silverynanos Innovations Llp	107
122	Smartqr Healthcare	107
123	Sparshacare Innovation Pvt Ltd	108
124	Startoon Labs Private Limited	108
125	Startup Incubated At Fitt, Iit Delhi	109
126	Tech Atriocare Private Limited	109
127	Techinvention Lifecare Pvt Ltd	110
128	Terra Blue Exploration Technologies Pvt Ltd	110
129	Tiny Prism Pvt Ltd	111
130	Ur Advanced Therapeutics	111
131	Vasmed Health Sciences Pvt Ltd	112
132	Vetdiag Genomix Pvt Ltd	112
133	Vgenomics India Pvt. Ltd.	113
134	Vphore Labs Pvt Ltd	113

Name of Startup: AASYA HEALTHCARE PRIVATE LIMITED



Founder and Co-founder(s):
Dr Kranti Kiran Reddy Ealla
Dr Vikas Sahu

Developed Under
(scheme):
BIG, SEED Fund

Email:
sahu88vikas@gmail.com

Product/Technology differentiation from Competitors

The proposed BacNo Gel formulation is unique in nature with its novelty components like: Silk based biomaterial as carrier and matrix, Phenomenon of drug induced hydro-gelation of silk, two in one approach of Tetracycline as antibiotic agent, and osteo-inductive properties using its anti-collagenase activity simultaneously. The Design approach for its applicability in extraction wound at clinical setting.

Brief Description of Product

Prescription of systemic antibiotics after tooth extraction is the most common practice by dentists around the globe. The most common reason for this practice is to prevent secondary infection in the wound that has been created after extraction. Administrations of systemic antibiotics causes side effects like gastric irritation, nausea, vomiting, and diarrhoea, which are uncomfortable to the patients. Further, excessive use of antibiotics leads to antibiotic resistance, which is the major threat that the medical science is facing. Dental treatment leading to extraction includes acute/chronic pulpitis, periapical inflammation/abscess, severe periodontitis, and alveolar bone loss leading to mobility of teeth. The associated bacterial infection is specifically localized in nature and confined to dental pulp tissue to periapical region within alveolar bone. The source of infection, which includes decayed tooth or root once removed, will heal the wound without secondary complication in a healthy individual. Antibiotics given to healthy people to prevent infections may cause more harm than benefit to both the individual patients and the population. We have prototyped an affordable solution for the localized delivery of antibiotic drug at the site of wound extraction socket which will be easy to place by the dentist and with sustained release for 3-5 days to prevent secondary infection at the site of post extraction wound, leading to decreased use of systemic antibiotics. We have got positive result for efficacy and safety of developed hydrogel in animal studies in academic lab. With initial prototype in hand, we wish to further validate the hydrogel gel in GMP and GLP settings and perform the safety and efficacy studies as per ISO 10993 protocol and optimize the gel for clinical use in case of post extraction wound. The developed gel can be easily placed in the extraction socket, retained in the specific anatomy of alveolar bone owing to its unique gel behavior and will provide suitable microenvironment to control bacterial secondary infection on one hand and augment the alveolar bone regeneration on the other.

Technology readiness level (TRL) TRL- 6

Current Stage of Development

We are currently doing GMP production of the hydrogel under Test license for ISO 10993 biocompatibility testing and for human Clinical Trials.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Asia Pacific Market



Title/Name of the Product/Technology

BacNo Gel: Antibacterial and Osteoinductive, Drug Induced Hydro-Gel formulation for Post Tooth Extraction Wound Management

Product Positioning

Localized drug delivery for management of dental extraction wound in clinical setting

Import Substitution

Currently there are no point of care screening device available for DS testing, and the present testing involves importing expensive multimode reader which costs above Rs. 50 Lakhs. Apart from this, genomic testing offers wide information, and the kits are imported and the testing costs upwards of Rs. 15000.

National/Societal Relevance

FIGHT AGAINST ANTI-MICROBIAL RESISTANCE In India, with a population of 140 Crore people where 65 population live in rural areas and 30 population in urban, unnecessary prescription of antibiotics is commonly being practiced irrelevant to rural or urban setup. This leads to increased risk of rise in Anti-Microbial resistance in the population.

Export Potential

Provisional Patent filed. Application No. 202441042009 Title: Lateral Flow Test Strip For The Quantitative Estimation of Analytes

Name of Startup: Accelerd Sciences Private Limited



Founder and Co-founder(s):
Dr. R. Raviprasadh
Prof. Dr. M. Rajasekaran

Developed Under
(scheme):
SEED Fund

Email:
celerdsciences@gmail.com

Product/Technology differentiation from Competitors

Our product is portable with a disposable test strip for testing different biomarkers of DS. Due to the incorporation of lateral flow assay principles, immunology and electrochemistry in a miniaturized strip with a portable device, the measurements can be done at the site of blood collection itself. This feature is absent in the current testing routine. The competitor technology includes expensive, huge equipment and requires skilled workforce and sophisticated infrastructure. However, our portable device will bring accessibility and affordability without sacrificing the accuracy of the testing.

Brief Description of Product

Chromosomal abnormality viz. Down Syndrome affects 1 in every 1000 children born in India. These children grow with physical and mental abnormalities. In the current standard of patient care at maternity clinics and hospitals initial risk categorization is done by the combined calculation of maternal age, ultrasound test and serum biochemical marker levels for i.e., PAPP and free? -hCG. For this biomarker testing, blood samples are usually sent to tertiary testing centers using cold chain logistics. This increases turnaround time for results, multiple hospital visits and it costs between Rs. 1800/- to Rs. 4000/- across India. All these factors adversely affect the accessibility and affordability of these tests to majority of the population particularly living in tier 2, 3, and 4 areas. We are developing cost-efficient point of care device and single-plex assay strips to achieve the detection rate of 95 with a false positive rate of 5 for screening the risk of Down Syndrome DS occurrence from patients' blood samples in less than 10 minutes irrespective of the location for measurements, serum from the blood should be separated and diluted in fixed volume of dilution buffer. The diluted serum should be applied on a test strip which will be already connected to the device. PAPP and free? -hCG proteins will be quantified as µg/ml and ng/ml respectively in two different test strips as single-plex measurements. The values will be measured and calculated as multiples of median. PAPP of 0.5 MOM and free? -hCG proteins of 2 MOM will be classified as high-risk likelihood ratio. Our device with built in algorithm will combine the ultrasound parameters, maternal age and the measured blood markers to report the risk score. This product will help in the rapid screening of expectant mothers and the patients classified with high-risk score will be given a prenatal counselling for further diagnostic confirmatory testing.

Technology readiness level (TRL) TRL- 3

Current Stage of Development

In our point of care assay, we combine immunology, electrochemistry and lateral flow assay principles. Hence, we validated the sensitivity and dynamic range of antibodies using recombinant proteins spiked in buffers and diluted serum samples. We have achieved good correlation between ELISA vs. electrochemical measurements with HRP based assays. To combine the electrochemistry and immunology in a lateral flow assays, we have identified enzyme assays and the suitable electrodes for further electrochemical measurements. At this juncture, we are at the TRL3 stage and are exploring further funding to develop the product.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Throughout India and especially the tier 2 and 3 areas.

Title/Name of the Product/Technology

Portable point of care device for screening Downs Syndrome risk occurrence in pregnant women in their first trimester

Product Positioning

Health care device to be deployed at primary health centres and small laboratories. This will be used as a screening device for risk categorization. National/Societal Relevance Currently, 1 in 1000 child birth occurring at the maternal age of 25 years and 1 in 30 child births at the maternal age of 40 years are born with DS. Yet, there are no mandatory screening programs to detect DS during pregnancy. Our PoCD will improve the affordability and accessibility which would facilitate efficient screening of large populations, and help decrease the incidence of DS. Apart from vital test results, this would also provide the current prevalence of the syndrome, and also benefit the government in the future and assist in the subsequent planning of the national health policy.

Import Substitution

Currently there are no point of care screening device available for DS testing, and the present testing involves importing expensive multimode reader which costs above Rs. 50 Lakhs. Apart from this, genomic testing offers wide information, and the kits are imported and the testing costs upwards of Rs. 15000.

Export Potential

Our PoCD will a disrupting innovation in the field of mass screening of protein-based biomarkers and hence it can be imported at huge volumes across the world, where screening of one or few biomarkers are needed at bench side of the patient for quicker decision making

IP Status

Provisional Patent filed. Application No. 202441042009 Title: Lateral Flow Test Strip For The Quantitative Estimation of Analytes



Name of Startup: Adsys Medtech Private Limited



Founder and Co-founder(s):
Hardik Sharma (CEO)
Apoorv Agarwal (CTO)

Email:
hardik@adsys.in

Product/Technology differentiation from Competitors

Here are the product differentiation points for Adsys One: 1. Minimal Blood Requirement: Uses only 0.015 ml of blood, reducing invasiveness and enhancing patient comfort. 2. Portability: Lightweight and compact, enabling easy transport and operation in various settings without additional setup. 3. Rapid Results: Provides complete blood count reports in under 10 minutes, significantly faster than traditional lab tests. 4. Advanced Technology: Incorporates AI and proprietary optical technology for precise and reliable diagnostics. 5. Reduced Biomedical Waste: Utilizes disposable test kits for safe and easy disposal.

Brief Description of Product

Adsys One is an innovative AI-powered, point-of-care device that delivers rapid Complete Blood Count CBC reports using just a finger prick. Designed to revolutionise blood diagnostics, this device utilizes cutting-edge robotics and deep learning technology to provide accurate results in under 10 minutes, making it ideal for environments that require quick and reliable testing. Key Features: 1. Minimal Blood Requirement: The device needs only 0.015 ml of blood, making it minimally invasive and reducing patient discomfort compared to traditional methods. 2. Portability: Its lightweight and compact design allows for easy transportation, enabling use in various settings, from clinics to remote locations, without requiring additional setup. 3. Easy Disposal: The device employs a disposable test kit, ensuring hygienic and straightforward disposal after each use, minimizing cross-contamination risks. 4. User-Friendly Interface: Controlled via a mobile app, Adsyes One offers an intuitive user experience, guiding users through the testing process and facilitating easy result storage and sharing. 5. Advanced Optics: Incorporating proprietary optical technology, the device ensures precise blood sample measurements, enhancing diagnostic accuracy. Adsyes One harnesses the power of AI to analyse blood samples effectively, using algorithms trained on extensive datasets to deliver consistent and accurate results. This capability allows healthcare providers to obtain reliable data swiftly, improving patient care and decision-making. Adsyes One aims to transform healthcare diagnostics by providing an affordable and accessible solution for point-of-care testing. Its innovative features and ease of use position it as a vital tool for expanding access to diagnostic services, especially in resource-limited settings, and improving healthcare outcomes through timely and accurate blood analysis.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

We currently have a working hardware prototype for the test kit and device which is capable of carrying out an end-to-end test. The report parameters and results accuracy, repeatability and correlation are currently at the late stage of development.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

The company is located in Jaipur, Rajasthan. Therefore, our primary market will be hospitals and clinics in Rajasthan. We will then expand to major cities using a Hub and Spoke distribution network. On acquiring the FDA approvals, we will export our product to South East Asia and African Countries.



Title/Name of the Product/Technology

Point of care Rapid Complete Blood Count
Adsys one.

Product Positioning

Currently we have no direct competitor in the Indian Market for the product and the technology involved. We do have competitors in the international market but the products available are unable to meet the requirements for the Indian Diagnostics Market.

National/Societal Relevance

Adsys One is highly relevant to the Indian market for several reasons: 1. Enhanced Accessibility: Facilitates remote monitoring, bridging gaps between urban and rural healthcare. 2. Improved Patient Outcomes: Provides real-time data for early detection and better treatment. 3. Support for Healthcare Infrastructure: Streamlines operations and reduces strain on overburdened systems. 4. Alignment with Digital Health Initiatives: Supports India's efforts to modernize and improve healthcare through technology. By addressing these needs, Adsyes One plays a crucial role in advancing healthcare delivery and accessibility across India.

Import Substitution

The products that can replace Adsyes One are Sight Diagnostics OLO and Pixcell Medical HemoScreen. These two products are available in the international market but are not available in the same price range as Adsyes One.

Export Potential

The device and test kit are manufactured in India and almost all the parts required are sourced locally. Hence the manufacturing costs are relatively lower compared to its competitors and the product can be exported to South East Asian and African countries.

Major Achievements

Winners - Amrit Grand Challenge, JanCare
Winners - TIECon Vadodra Finalist - IIMA
Healthcare Summit

IP Status

Indian Patent Application No. 202211048311

Name of Startup: Aindra Systems



Founder and Co-founder(s):
Adarsh Natarajan

Developed Under (scheme):
BIG, BIPP, SBIRI

Email:
adarsh@aindra.in

Product/Technology differentiation from Competitors

There currently does not exist any evidence-based, point-of-care systems that are reliable and aid in the screening of cervical cancer. This limitation has motivated us to develop diagnostic solutions that are relevant to the socio-economic situations in places like India. CervASTRA is the only Point-of-Care system that uses the evidence-based gold standard in cervical cancer detection which, while using an established modality, also eliminates the subjectivity-driven errors in the modality and therefore results in higher sensitivity and specificity at an affordable price. We use conventional PAP smears which is the most common way of screening for Cervical Cancer.

Brief Description of Product

Aindra is an Artificial Intelligence driven company focused on creating Point-of-Care diagnostic solutions for fatal illnesses. Our Vision is to save lives through early detection of critical illnesses at the point-of-Care by democratizing access to quality healthcare, through the use of deep technology. Our mission is to build innovative products and technologies to aid in Point-of-Care critical illness detection by using Computational Pathology. We're working on making healthcare more accessible, affordable and agile. We see a world where machines work along with humans in creating an equitable healthcare system. In our Artificial Intelligence based Computational Pathology platform, we are using a combination of state-of-the-art medical hardware devices and software algorithms for diagnosis. This platform enables faster and more reliable diagnosis of critical illnesses. Our Point-of-Care Computational Pathology system comprises of an Auto Stainer, a Whole Slide Imaging device, an AI engine and a Telepathology platform. The first of such products leveraging this computational pathology platform is CervASTRA, a point of care screening system for Cervical Cancer, that is quick, affordable and accessible to the low-income countries as well. Our intelligent screening system CervASTRA, tailwinds the development and striking benefits of computational pathology.

Technology readiness level (TRL) TRL- 9


Current Stage of Development

Deployed at a couple of customer locations

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

We are looking at a Pan India approach through the use of a combination of Direct and Indirect sales approach



Title/Name of the Product/Technology

AI-based full stack Computational Pathology
platform

Product Positioning

Our product is positioned as an affordable alternative to the extremely expensive options that are sold by the large MNCs.

National/Societal Relevance

With a growing burden of Cancer, it is imperative that there are more systems that are appropriate for smaller health care facilities. And our system does exactly that.

Import Substitution

It does fall under the ambit of import substitution as the slide stainers and scanners available are from large MNC companies like Leica, Aperio, Phillips and Hamamatsu.

Export Potential

Yes, it does have potential for exports as the slide stainers and scanners available globally are from large MNC companies like Leica, Aperio, Phillips and Hamamatsu which are at high-price points.

IP Status

Patents granted in India, South Africa, UK, France, Germany, Malaysia.

Name of Startup: Alfaleus Technology Private Limited



Founder and Co-founder(s):
Sandal Kotawala

Developed Under (scheme):
BioNEST, SEED Fund

Email:
sandal@alfaleus.com

Product/Technology differentiation from Competitors

The Intelligent Vision Analyser iVA stands out from competitors due to its innovative use of virtual reality VR for visual field testing, offering a more engaging, accurate, and patient-friendly experience compared to traditional methods. Unlike conventional perimeters, iVA is portable and more affordable, making advanced glaucoma diagnostics accessible to a broader audience, including clinics in remote or underserved areas. Additionally, iVAs integration of VR with advanced algorithms provides highly accurate and reliable results, reducing the likelihood of errors common in standard visual field tests. This combination of cutting-edge technology and user-centric design positions iVA as a game-changer in glaucoma care.

Brief Description of Product

Intelligent Vision Analyser iVA : The Intelligent Vision Analyser iVA is a cutting-edge virtual reality-based visual field perimeter designed to detect and monitor visual field defects, particularly in glaucoma patients. Developed in collaboration with Aravind Eye Care, iVA offers an accessible and patient-friendly alternative to traditional methods, providing accurate diagnostics through an immersive VR experience. As a vital tool in glaucoma management, iVA is poised to revolutionize eye care by making advanced diagnostics more widely available, especially in regions with limited access to conventional eye care facilities.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Product in market in India with 100+ eye doctors using it

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India/ Global

Title/Name of the Product/Technology

Intelligent Vision Analyser - Virtual reality based visual field testing for eyecare

Product Positioning

The Intelligent Vision Analyser iVA is positioned as a cutting-edge, affordable, and portable visual field-testing solution, ideal for ophthalmologists and eye care clinics. Targeted at enhancing glaucoma diagnostics, iVA is designed to serve both advanced healthcare facilities and resource-limited settings, bridging the gap in accessible eye care.

National/Societal Relevance

The Intelligent Vision Analyser iVA addresses a critical need in glaucoma care, a leading cause of blindness in India. By making advanced diagnostics accessible and affordable, even in remote areas, iVA contributes to early detection and better management of glaucoma, ultimately reducing the burden of preventable blindness in society.

Import Substitution

The Intelligent Vision Analyser iVA serves as an effective import substitution by providing a domestically developed, high-quality alternative to expensive foreign visual field-testing equipment. By offering an affordable, locally produced solution, iVA reduces reliance on imported medical devices, supports the local economy, and makes advanced glaucoma diagnostics more accessible across India.

Export Potential

The Intelligent Vision Analyser iVA has strong export potential due to its innovative design, affordability, and portability. As a cutting-edge solution for glaucoma diagnostics, it meets global demand for accessible eye care technology, making it an attractive option for international markets, particularly in regions with limited access to advanced medical devices.

IP Status

No Patents iVA product, however we have 3 design registrations and 4 trademarks for Alfaleus and other products. 1 Patent in process.

Name of Startup: Algorithmic Biologics Private Limited



Founder and Co-founder(s):
Manoj Gopalkrishnan

Email:
admin@algorithmicbiologics.com

Product/Technology differentiation from Competitors

Tapestry for NGS stands out from competitors through its innovative algorithmic pooling strategy, which significantly enhances throughput and reduces costs while maintaining high accuracy, sensitivity, and specificity. It's highly scalable, seamlessly integrates with existing sequencing platforms, and offers distinct advantages over traditional methods.

Brief Description of Product

Tapestry for NGS is an innovative solution designed to enhance next-generation sequencing workflows. Our product focuses on improving the accuracy and efficiency of sequencing by enabling simultaneous analysis of multiple samples in a single run multiplexing. This not only reduces costs but also speeds up the process, making it easier to obtain high-quality genomic data. It is ideal for applications requiring large-scale genetic screening. Tapestry for NGS is adaptable to various sequencing platforms and can be integrated seamlessly into existing laboratory processes.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

Tapestry has been successfully demonstrated in its final form and is operational within a relevant environment. Over the course of its development, our technology has undergone rigorous testing and validation to ensure its effectiveness and integration with existing workflows. Feedback from these deployments has led to refinements, confirming its readiness for commercial use. We are preparing for broader market entry, with final steps involving securing additional regulatory approvals, and expanding our customer base. Our readiness for these steps underscores our confidence in the technology maturity, justifying its classification at TRL 8.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

International

Title/Name of the Product/Technology

Tapestry for NGS

Product Positioning

NGS Library Prep Software

National/Societal Relevance

Tapestry addresses critical needs in genomic research and clinical diagnostics by offering a cost-effective, high-throughput solution for next-generation sequencing. Its ability to process a large volume of samples accurately and efficiently supports advancements in personalized medicine and public health initiatives. By improving the accessibility and affordability of genomic testing, Tapestry contributes to enhanced disease prevention, early diagnosis, and targeted treatments, thereby benefiting healthcare systems and society at large.

Import Substitution

Reduces library prep kit use which are imported

Export Potential

Yes





Name of Startup: Ambinova Technologies Pvt Ltd



Founder and Co-founder(s):
Mr. Susanta Paul, Mr. Subham Das

Email:
paul@ambinova.in

Product/Technology differentiation from Competitors

We are offering an alternative to well-established imported brands by making products having comparable features, functionality, quality and performance. Customer can get cost effective option without compromising on standards

Brief Description of Product

laboratory equipment includes Drybath, Incubators, Autoclaves, Laminar Air Flow, Shakers, and Laboratory Furniture

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Products are already in the market

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, South East Asia, Middle East Asia and Africa

Title/Name of the Product/Technology

laboratory equipment includes Drybath, Incubators, Autoclaves, Laminar Air Flow, Shakers, and Laboratory Furniture

Product Positioning

We are offering an alternative to well-established imported brands

National/Societal Relevance

By choosing Ambinova, you not only gain access to our well-designed and precisely crafted instruments, but you also support local manufacturing and innovation. Our Make in India ethos perfectly aligns with the broader vision of promoting self-reliance and technological advancement in our great nation.

Import Substitution

We are offering an alternative to well-established imported brands by making products having comparable features, functionality, quality and performance. Customer can get cost effective option without compromising on standards.

Export Potential

Can be exported to South East Asia, Middle East Asia and Africa

Name of Startup: AMDUS TECHNOLOGIES PVT LTD



Founder and Co-founder(s):
Mr. AMIT MALIK
Mr. DUSHYANT JINDAL

Developed Under (scheme):
BIG

Email:
ceo@amdustech.com

Product/Technology differentiation from Competitors

1. Simple operation 2. Compact thus uses less bench space 3. Open Source of Reagent, 4. High Throughput 24Slides in one cycle

Brief Description of Product

We have developed an automatic slide stainer for medical diagnostic laboratories which will automate the current process of manual slide staining.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

We are ready with final version of prototype and working on the outer body to give final shape to the product, which can be widely accepted in national and international markets.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

National and International IVD Laboratories

Title/Name of the Product/Technology

AUTOMATIC SLIDE STAINER FOR IVD LABORATORIES

Product Positioning

Target Customer: Medical Diagnostics Laboratories Hospital & Independent Laboratories, Govt. & Pvt. We are automating the process of manual slide staining without changing the existing protocol & reagent inventory of laboratory.

National/Societal Relevance

Indigenous Product, Lab Automation, Less dependency on skilled labor, Uniform Staining

Import Substitution

1. Elitech & Bio-Merieux France 2. RAL, Cellavision, Sweden 3. Hardy Diagnostics, USA All of the above uses different ways to stain the slides, our is unique and patented.

Export Potential

The Global Slide Stainer market Equipment, Reagents & Consumables is projected to reach \$7.87 Billion approx. 65K Cr by 2028 from \$3.44Billion approx. 28K Cr in Year 2020, registering a CAGR of 10.8. Global Equipment Market sales is doubling by year 2028. Source: www.emergenresearch.com

IP Status

Patent No. 390800 Patent Title: An Automatic Slide Staining Apparatus for Slide Staining Patent Assignee: Amdus Technologies Pvt. Ltd. Inventor Name: Amit Malik





Name of Start-up: ANYMAR PVT. LTD. Anywhere Mobility Access & Rehabilitation



Founder and Co-founder(s):
Dr. ANIMA NANDA (FOUNDER)
Mr. SHIVA SAI (CO-FOUNDER)

Developed Under (scheme):
BIG

Email:
animananda72@gmail.com

Product/Technology differentiation from Competitors

The ANYMAR wheelchair excels in stair-climbing capabilities with its advanced roller track mechanism, ensuring smooth and stable ascension and descent on various stair types, a feature that outperforms many competitors. Unlike the Kanishka Foldable Stair Climbing Wheelchair, the ANYMAR product requires no external assistance, allowing users to independently navigate stairs and other challenging terrains. This independence, combined with its unique features like seat rotation, rotation lock, and mechanical descent system, sets it apart from other stair-climbing wheelchairs. Additionally, its affordability and comprehensive functionality make it an unmatched choice for those seeking advanced mobility solutions in India.

Brief Description of Product

The ANYMAR wheelchair is an innovative all-terrain mobility solution designed to enhance accessibility and safety for users navigating diverse environments. Unlike traditional wheelchairs that rely on wheels, the ANYMAR features a cutting-edge adaptive height adjustable track mechanism, replacing wheels with durable tracks. These tracks provide a significantly larger surface contact area, improving traction and stability on both flat surfaces and stairways. The ANYMAR wheelchair is equipped with front and back track sets connected by two parallel rods, ensuring that the tracks remain aligned for balanced movement. This design minimizes the risk of slipping or losing balance, particularly when descending stairways. A linear actuator is integrated into the system to adjust the angle of the seat according to the height of obstacles or steps. This actuator, which automatically modifies the seat's angle, is crucial for maintaining a horizontal level during transitions, enhancing user comfort and safety. The actuator mechanism can be customized based on user requirements, allowing adjustments to the actuators length or size to match varying obstacle heights. Positioned between the seat frame and one of the track frames, this actuator ensures precise horizontal level adjustments. The ANYMAR wheelchair's motor, powered by a battery located under the seat, drives the actuator and other components. The seat assembly of the ANYMAR wheelchair is designed for user convenience and safety. It includes a seat frame, a 360-degree rotating seat with a safety lock at 180 degrees, adjustable armrests, footrests, and a joystick for motion control. The joystick is complemented by an actuator switch for adjusting the seat angle relative to obstacle height. For advanced user support, the ANYMAR wheelchair incorporates wearable sensors to monitor stress and anxiety levels. These sensors measure physiological indicators such as heart rate variability HRV and galvanic skin response GSR. HRV sensors are worn as wristbands to track heartbeat intervals, while GSR sensors are placed on fingers to assess skin conductivity. This data helps evaluate stress and anxiety levels, which are further analysed using the Canadian Occupational Performance Measure to gauge user performance in daily activities. To ensure the effectiveness and user-friendliness of the ANYMAR wheelchair, volunteers to be assessed for anxiety levels before and after using the device. The final design will focus on optimizing the wheelchair for all-terrain mobility, including stair climbing, quick direction changes, lightweight construction, minimal power consumption during descents, extended battery life and cost-effectiveness. The ANYMAR wheelchair combines advanced track technology with adaptive mechanisms and user-centric features to provide a safe, efficient, cost effective and anxiety-reducing mobility solution.

Technology readiness level (TRL) TRL- 4

Are you willing to Transfer/Out-License your Technology Yes

Current Stage of Development

The ANYMAR wheelchair is at an advanced stage of development, having integrated an adaptive height adjustable track mechanism and a sophisticated actuator system for automatic seat angle adjustment. Prototype testing is ongoing, including the incorporation of wearable sensors for real-time stress and anxiety monitoring. The focus is on optimizing the design for all-terrain mobility, including stair climbing and efficient power usage. The development includes feedback from over 100 users to refine performance and ensure cost-effectiveness. Final adjustments aim to enhance user safety, comfort, and overall functionality, positioning the ANYMAR as a cutting-edge solution for diverse mobility needs.

Title/Name of the Product/Technology

ANYMAR PVT. LTD -Staircase Climbing Automated Wheel Chair with Anxiety Control

Export Potential

The ANYMAR wheelchair has strong export potential due to its advanced all-terrain capabilities, customizable features, and unique stress-monitoring technology. Its innovative design meets global demands for inclusive mobility solutions, offering opportunities in both developed and emerging markets, provided it complies with international standards and regulations.

Geographical Region Targeted

The primary geographical region targeted for ANYMAR wheelchair launch is India, with potential expansion to other international markets based on demand.

Product Positioning

ANYMAR wheelchair is positioned as a premium mobility solution designed for individuals with physical disabilities who require reliable, advanced, and versatile stair-climbing capabilities. It is aimed at both the Indian market and potential international markets, targeting customers seeking enhanced safety, independence, and convenience in their daily mobility.

National/Societal Relevance

ANYMAR wheelchair holds substantial national and societal relevance in India, where accessibility remains a significant challenge for individuals with disabilities. With its innovative stair-climbing feature, ANYMAR directly addresses the difficulties posed by uneven terrains and non-wheelchair-friendly infrastructure, common in many parts of the country. By empowering users with greater independence and mobility, this product not only enhances the quality of life for individuals with physical disabilities but also contributes to broader societal goals of inclusivity and equal opportunity. ANYMAR Wheelchair's introduction aligns with national efforts to improve accessibility and support the rights of people with disabilities.

Import Substitution

The ANYMAR wheelchair, a domestic innovation, substitutes costly imports, supporting India's Make in India initiative. It fosters local innovation, promotes self-reliance in healthcare and assistive technology, and enhances accessibility for people with disabilities, benefiting both the economy and the nation's technological independence.



Name of Startup: Anziam Bio Private Limited



Founder and Co-founder(s):
Shrayaance Jain Sachin Kapoor

Developed Under (scheme):
BioNEST

Email:
shrayaance@anziam.com

Product/Technology differentiation from Competitors

ACUCLOT, has got the capability of stopping/controlling the traumatic bleeding immediately without the help/supervision of Medical Professionals Based on Chitosan, the product accelerates the blood coagulation effect and enhances the clotting mechanism

Brief Description of Product

AcuClot is an advanced hemostatic sponge, designed to stop Surgical/ Superficial bleeding. Based on ActClot Technology Activated Clotting Mechanism, the composition and structure accelerate blood coagulation cascade, resulting in faster bleeding control. Key Features: - Charge-based platelet aggregation, enhances blood coagulation - Due to its cationic nature, the sponge is bio adhesive and creates a mechanical seal at the wound and accelerates the natural process of blood clotting - Microporous honeycomb structure, supports in higher up to 40 times of sponge weight and rapid blood absorption

Technology readiness level (TRL) TRL- 9

Current Stage of Development

The Product is complete, manufacturing license has been obtained from CDSCO

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, South East Asia, CIS, Middle East



Title/Name of the Product/Technology

Biopolymer based Hemostatic Sponge for Control of Traumatic Bleeding

Product Positioning

The product is placed as a Life saving device with advanced technology to stop the bleeding The nearest competitor is Gauze, which is not effective

National/Societal Relevance

ACUCLOT is a life saving device which can find its use with the Armed and Police forces

Import Substitution

Haemostatic Products are imported from USA and Israel

Export Potential

CIS Region, Middle East, South East Asia

Name of Startup: Arcapsis Techno solutions Pvt Ltd



Founder and Co-founder(s):
Nitin Awasthi
Kishore GK

Developed Under (scheme):
BIG

Email:
awasthi@arcapsis.com

Product/Technology differentiation from Competitors

Xperthaler will be supporting the following features: 1.Vibration/Beep at Medication time 2.Vibration/Beep to find missing Inhaler 3.Shake pattern detection Accelerometer 4.Reuseable/Washable Mouthpiece design 5.1 Month battery life on a single charge 6.Data on the cloud 7.Bluetooth Communication between actuator and Mobile 8.Quick Dialing and auto ordering services 9.Reports/Graphs usage patterns generation 10.Alert if actuator and Phone not in the vicinity 11.Weather/Air Quality and associated alerts 12.Medication expiry alert 13.Graphical Backlit display 14.Android Application

Brief Description of Product

XpertHaler will be India's first and only holistic COPD and Asthma Management Solution. Studies show that control of asthma can be achieved in the majority of patients. However, surveys repeatedly show that this is not the case in real life. Current inhaler medications are highly effective in reducing the burden and risk of asthma, but nonadherence is not making it possible. Nonadherence in terms of inhaler techniques and also with the discipline with which it is used. This poor adherence contributes to uncontrolled symptoms, impaired quality of life, flare-ups, urgent doctor visits and also loss of life. XpertHaler, a COPD and Asthma Management Solution, which will address the above problem and many more, is a universal, easy to use product, which replaces the current plastic jacket of the inhalers commonly found in the market. XpertHaler will have two parts. i. Actuator ii. Mobile-based Management System. The Actuator has features like: Vibrate/Beep at time of medication, Shake Detection, Finding the Device by Vibration/Beeping, current balance dose count, Expiry Info display, Reusability, 1 month of battery life, etc. The user will need to simply buy the medicine prescribed by the doctor, remove the medication canister from original actuator and insert it into the actuator of XpertHaler. This device will be connected to a feature-rich, mobile app called the CAMS COPD and Asthma Management System. CAMS will have features like various reminders, quick Dial/SMS to Emergency Partners like Care Taker, Guardian, Doctor or a local pharmacist Medicine Expiry Warning, Reports/Graphs, Next doctor appointment reminder, real-time notes from the emergency partners etc. The future enhancements planned for the subsequent versions are features like Data Analytics for R&D, AI and ML-based Pattern determination and prediction analysis, Weather Updates and related alerts, Patient Ranking, auto re-ordering of medicine and adherence Game with points/patient score SOFTWARE AS A DRUG. Today out of 33.3 Cr. asthmatic patients world-wide, 2cr Asthmatic patients are in India alone. That's not only it, out of the 16 Cr kids with wheezing worldwide, 18 Lakhs are in India, to whom inhaler medicines like Levolin or Asthalin is prescribed every year. Presently, the work is being initiated towards creating the Actuator.

Technology readiness level (TRL) TRL- 6

Current Stage of Development

The mobile app and the actual hardware is ready. The information is going to the cloud and we are able to display it on the cloud. Currently we are in the process of creating thousand numbers of pieces so that they can be checked for their efficiency and efficacy on the field.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India and Asian Countries

Title/Name of the Product/Technology

Xperthaler - The One Stop Solution to Arrest Asthma Flare-ups and Inflammations

Product Positioning

Xperthaler - The One Stop Solution to Arrest Asthma Flare-ups and Inflammations

National/Societal Relevance

Reduced Economic Burden on Health. Reduced plastic and medicine wastage.

Import Substitution

Yes

Export Potential

To Asian Countries and to the world after the CE and FDA approvals

IP Status

Patent Number: 201741002256 - SMART INHALER - Published



Name of Startup: Ardor Biomed India PVT LTD



Founder and Co-founder(s):
Vivekananda (Founder)
Radhikarajan R (Co-Founder)

Developed Under (scheme):
BIG

Email:
k.vivekanand@gmail.com

Product/Technology differentiation from Competitors

Most Advanced Wound Care AWC products in the market are imported and quite expensive. Their cost factor is a major hurdle to be used by the common public. They are not available readily in most tier-2 cities and below. Current devices mostly require a clinician for application, which again is a strain on the current healthcare setup. They are not sustainably produced and add to medical waste management burden. Most AWC products require a secondary dressing. Our product is comparatively low cost, does not require secondary dressing, no maceration of healing wound, has autolytic debridement properties, requires less frequent changes, fully biodegradable, can be used for multiple type wounds, effective against wide range of infecting microbes. In fact, the experts at medical center we are involved with for our research see a great potential for our product especially applicable to very sensitive dermal procedures.

Brief Description of Product

We have developed an advanced wound healing bio-cellulose patch produced by the action of bacteria on primarily matured coconut water, which is an Agro-waste product. This moist cellulose patch is highly hydrophilic with over 98 percent moisture content and will incorporate monolaurin, a coconut derived compound to act as the anti-microbial agent. Monolaurin has shown to have anti-bacterial, anti-viral and anti-fungal properties. MTT cell proliferation studies have shown that monolaurin augments cell growth. This wound healing patch can be used to heal chronic infected wounds and burns. It also has application in drug delivery, cosmetics, surgical barrier films etc. Bacterial cellulose has all the properties that is required from an advanced wound healing device. Since it is derived from an Agro-wasted product, it will be sustainable to produce, more cost effective to patients and is an all-natural product.

Technology readiness level(TRL) TRL- 4

Current Stage of Development

Product has completed all pre-clinical studies including on animal models. Product has shown excellent promise in all the studies. We will be commencing clinical studies soon.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Product can be marketed globally and has high potential specifically in Asia-Pacific and African regions



Title/Name of the Product/Technology

Cellulose based Advanced wound care product made utilizing agro-waste with coconut extract as an antimicrobial agent

Product Positioning

Product is intended for healing chronic wounds such as diabetic foot ulcers, burns, pressure ulcers, ischemic ulcers etc. from a costing standpoint, we have positioned the product such that it is affordable to the vast segment of users in India. Our product is very price competitive when compared with competitors

National/Societal Relevance

Most advanced wound care products intended for treating chronic wounds in India are imported and quite expensive. Ultimately, the affordability for prolonged wound treatment becomes difficult. Our product is designed to be user-friendly and very cost effective. Since our product is utilizing an agro-waste for its production, it is a classic example of a circular economy product. The farmers from whom we are sourcing the matured coconut water are able make a revenue, which would otherwise be wasted

Import Substitution

India is the top importer of wound dressings globally. A 2016 report indicates import of wound care products into India to the tune of USD \$765 million. With the rise of many lifestyle related ailments, the demand for imported wound care product will rise to \$1 billion very soon.

Export Potential

It is well known that most developing countries in the Asia-Pacific and African regions depend heavily on imports for wound care. Also, these regions are majority suffering from chronic wound conditions such as diabetic ulcers, burns and venous conditions due to several socio-economic factors. We will export to such countries.

IP Status

Patent Application No. 202041045573

Name of Startup: Assam Rifles



Founder and Co-founder(s):
Government of India

Developed Under (scheme):
OTHERS

Email:
sidraina21@gmail.com

Product/Technology differentiation from Competitors

1 Most surgical dressing material is either cotton or collagen based - Lotus based materials are novel and have promising potential 2 Pineapple peel to my knowledge hasnt been used as bitumen extender

Other Scheme Name

Assam Rifles Battalion Fund Brief Description of Product 1 Lotus stem were bleached and processed to make cellulose rich dressing material and bandages 2 Pineapple peel were treated in basic medium and mixed with locally sourced material to prepare bitumen extender for road repair

Technology readiness level (TRL) TRL- 5

Current Stage of Development

Its a basic prototype of both projects and has been tested in field for demonstration of its practical feasibility

Product Launched / About to be Launched NA

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Bircac Yes

Product/Technology
Bleaching and extraction


Unique Selling Point

Made using minimal lab equipments during Manipur crisis by highschool students

Present Stage of Development

Basic prototype ready

Unique Acknowledgement No. GBI-SP/0057



Title/Name of the Product/Technology

Lotus stem based Green Bandages and Pineapple peel Based Bitumen Extender

National/Societal Relevance

Made using minimal lab equipments during Manipur crisis by high school students For development of product all communities of Manipur were engaged and it became a way of promoting education as well as national integration



Name of Startup: AUR INNOVATIONS PRIVATE LIMITED



Founder and Co-founder(s):
Dr Roshan U Saktharkar (FOUNDER)
Dr Madhuri M Waghmare (Co-FOUNDER)

Developed Under (scheme):
BIG

Email:
rusakharkar@gmail.com

Product/Technology differentiation from Competitors

Metal diamond bur will tear gingiva and damage tooth portion, our invented flexible bur will curette disease gingiva and polish tooth surface. Many patients are reluctant to pain, surgery, suturing, high antibiotic they will accept cost effective quality-based treatment with invented flexible bur. Flexible bur is very simple to use, so every dentist can work with saving time.

Brief Description of Product

Invented and Designed a Medical Plastic Flexible Bur which will debride periodontal pocket wall lining and clean tooth side wall when fitted in rotary instrument. The technique or approach to insert a dental bur into the periodontal pocket is also novel and inventive. Novelty of the product - Adaptation to tooth root anatomical curvature is possible even after every tooth root has different anatomy and curvature, this is due to flexibility of the Inventive Bur. Design of this bur is inventive with micro projection on its working surface. We are using medical grade plastic to manufacture invented flexible bur. Debridement and cleaning of tooth root, at the same time deriding disease soft tissue Lining is possible. Novelty of the process/ technique - Inserting rotating Dental bur into periodontal pocket i.e., space between tooth & gingiva to remove diseased pocket lining is a novel process. Existing Metal diamond bur tear gingiva and damage tooth portion, Invented Medical Plastic Flexible Bur, debride diseased soft tissue lining and clean tooth root surface without damaging it. Metal carbide burs, Metal diamond burs exist in the market, ceramic bur, polishing burs are also present in the market but all are designed to cut or polish the tooth surface. Metal diamond bur cannot be used to debride diseased gingiva because it is too hard and rigid, it will damage tooth & tear soft tissue. Fine polishing Ceramic burs cannot curette gingiva because the surface of ceramic bur has smooth surface All existing Dental burs are rigid and rigid burs are not able to adapt curved root surface, some teeth have complex root curvature. There is a requirement of a device which can do debridement of the tooth root surface and gingival pocket curettage our invented product is covering that gap. Invented Flexible Bur will provide quality based gingival treatment to the mass population specially people from lower socio-economic strata.

Technology readiness level (TRL) TRL- 3

Current Stage of Development

We have developed three Module of flexible bur, Product is in a Validation Stage, for clinical trials.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

We are an Indian manufacturer we will first practice in India and Asian countries, very soon we enter in the Global Medical device market with a focus on major markets such as USA, Japan, Germany, Mexico, Australia, Saudi Arabia, Nigeria, Malaysia, Canada.



Title/Name of the Product/Technology

AuriBur The Soft and Flexible Dental Bur for Periodontal Pocket Debridement.

Product Positioning

Many patients are reluctant to pain, surgery, suturing, high antibiotic, High cost they will accept cost effective quality-based treatment with invented flexible bur. Flexible bur is cost effective simple to use, every dentist can work with Saving time. Procedure requires only 15 minutes.

National/Societal Relevance

50 percent of GLOBAL adult population is suffering from mild to severe form of periodontitis. Periodontitis is major reasons for tooth loss in adults. India, with a population of over 1 billion, is bound to become a developed nation soon. This transition will require a population that is healthy, including in terms of periodontal health. Indian population is highly susceptible to periodontitis. According to National Oral health Survey, prevalence of periodontal disease increased with age. The prevalence was 57, 67.7, 89.6 and 79.9 percent in the age groups 12, 15, 35-44 and 65-74 years, respectively.

Import Substitution

Imported Laser machine is used to treat periodontitis, it can be substituted with the indigenous product of the Invention.

Export Potential

Flexible and soft dental bur for debridement do not exist in the world. 50 percent of GLOBAL adult population is suffering from mild to severe form of periodontitis. This product has a huge Export potential.

IP Status

Granted two Indian patents Application number: 2741/MUM/2015 Title of Application: A Periodontal Sheath Bur and File. Application Number: 4433/MUM/2015 Title of Application: A Periodontal Brush Bur and File. Trade Mark is Granted for product market Name "AuriBur"



Name of Startup: Avay Biosciences Pvt Ltd



Founder and Co-founder(s):
Manish Amin
Suhridh Sundaram

Developed Under (scheme):
BIG, BioNEST, LEAP Fund, PACE,
SEED Fund

Email:
manish@avaytech

Product/Technology differentiation from Competitors

The Liquid Xpert by Avay Biosciences stands out through its advanced automation capabilities, designed to streamline and enhance laboratory workflows. It integrates precise liquid handling with automated sample manipulation, including pick-and-place functions, tube handling, and cap management—all within a compact, space-efficient design. Its user-friendly interface and customizable workflows make it adaptable to a variety of diagnostic and research needs. Unlike competitors, Liquid Xpert offers seamless integration with existing lab infrastructure, ensuring high throughput and accuracy. This combination of features positions Liquid Xpert as a superior solution in the highly competitive liquid handling systems market.

Brief Description of Product

The Liquid Xpert is a state-of-the-art automated liquid handling system developed by Avay Biosciences. Designed for diagnostic labs, this system excels in precision liquid aspiration and dispensing, and features advanced capabilities such as pick-and-place operations within a biosafety cabinet. Additionally, it automates the opening and closing of screw cap tubes and microcentrifuge tubes. Liquid Xpert is engineered to streamline laboratory workflows, enhance efficiency, and maintain sterility during critical processes, making it a robust solution for complex diagnostic applications.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

The Liquid Xpert is in its final development stages, having progressed beyond prototyping to extensive validation and testing. This system has undergone comprehensive in-house trials to ensure precision, reliability, and seamless integration into existing lab workflows. Key features, such as automated liquid handling, sample manipulation, and tube handling, are fully operational. The current focus is on optimizing performance, user interface, and ensuring industry compliance. With commercialization plans underway, Liquid Xpert is poised to enter the diagnostics and biotechnology markets, offering a cutting-edge solution for lab automation and efficiency.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, North America, European Union, UAE



Title/Name of the Product/Technology

Liquid Xpert - A personal pipetting workstation

Product Positioning

Liquid Xpert is Avay Biosciences' cutting-edge automated liquid handling system. Engineered for precision and versatility, it automates liquid transfers with unmatched accuracy, improving workflow efficiency and reducing manual errors. Ideal for diverse scientific applications, it seamlessly integrates with existing lab setups, boosting productivity and reliability in research and clinical environments.

National/Societal Relevance

Liquid Xpert enhances national and societal impact by advancing scientific research, improving healthcare outcomes, and supporting public health through precise liquid handling. It boosts laboratory productivity, accelerates therapeutic development, and fosters economic growth, contributing to innovations and effective responses to health challenges.

Import Substitution

Liquid Xpert enables import substitution by providing a high-precision, automated liquid handling system locally, reducing reliance on foreign technology. This supports domestic manufacturing, lowers costs, and strengthens local industries, fostering self-reliance and economic growth within the scientific and healthcare sectors.

Export Potential

Liquid Xpert has strong export potential due to its advanced precision and efficiency in liquid handling. Its capabilities make it attractive to global research and clinical labs, offering opportunities to enter international markets, enhance global competitiveness, and meet growing demand for innovative lab technologies worldwide.

IP Status

Design patent has been filed for all the products of Avay.

Name of Startup: Avinya Neurotech Private Limited



Founder and Co-founder(s):
Sai Sowmya Darapaneni
Aniket Kumar

Developed Under (scheme):
BIG

Email:
avinyaneurotech@gmail.com

Product/Technology differentiation from Competitors

The traditional EEG machines are expensive 15 Lakh rupees and expert-dependent. It takes a longer time to apply on a patient's head, the clinicians need to spend hours to analyze and detect the abnormality. Due to this, the availability of EEG machines and technicians is scarce. The New devices like Ceribell are expensive and the headset is one-time usable. To address the above need and challenges we are developing our innovative solution NeuroPaahi which is an AI-powered Rapid Response Multimodal Neuromonitoring System, which is being developed to serve the urgency in Emergency and ICU departments at an affordable cost.

Brief Description of Product

To address the need to detect non-convulsive seizures effectively for better prognosis and to avoid Non-convulsive Status Epilepticus NCSE. We are developing an easily deployable flexible device to continuously monitor a critically ill patient's brain to check for seizure onset, especially non-convulsive seizures and alert nearby/connected caregivers to take quick action. Our solution includes innovative active sensors active shielding technology with flexible electronics to accurately capture the brain biopotentials and a cloud software backed with ML algorithms that helps in automatic interpretation and evidence-based diagnostics of non-convulsive seizure. Our flagship product NeuroPaahi is packed with an Active Dry Electrode system having capabilities to record 8 Ch EEG and 1 Ch EXG, EDA. Our software platform NeuroAstra is being developed to remotely capture, display, and interpret the live signals with the help of AI/ML trained on high-quality patient datasets.

Technology readiness level(TRL)TRL- 3

Current Stage of Development

As part of our milestones, we developed an algorithm to differentiate between the normal and abnormality of the EEG data which is further being displayed on a user-friendly Dashboard. The testing of different electrodes and integration with our active circuit is in progress. We are validating the prototype with the collaborated hospitals and diagnostic centers. After the successful development of dry/hybrid active sensors with the integrated software tool. We will be able to develop the wearable device which can be further tested using available amplifiers and if the accuracy matches the expectations, then we can also go for pre-clinical testing.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Our primary market includes India, Asia focusing on providing rapid EEG monitoring solutions for critical care settings, such as emergency rooms and intensive care units. We are planning to expand our presence internationally, reaching markets in Europe and parts of the USA.



Title/Name of the Product/Technology

Wearable Device for evidence-based diagnostics of Non-convulsive Seizures in critically-ill patients.

Product Positioning

We are developing our product as a rapid and accessible bedside monitoring solution, designed specifically for critical care environments such as emergency rooms, intensive care units, and neurocritical care. The key aspects include Speed and Ease of Use, Portable and Bedside Solutions, Real-Time Seizure Detection, Broad Accessibility, and Clinical Validation.

National/Societal Relevance

We are aligned with SDG 3 and SDG 9 as we are working with the vision of providing good health and well-being to the public by building innovative, affordable, accessible, and highly accurate medical-grade neuromonitoring solutions.

IP Status

Filed, Application No. 202341060387

Name of Startup: Avinya Infinity Solutions Private Limited



Founder and Co-founder(s):
Arijit Majumdar

Developed Under (scheme):
BioNEST

Email:
office@avinyainfinitysolutions.com

Product/Technology differentiation from Competitors

The UVM+ Dual-Action Disinfection Device offers key differentiators compared to competitors. It combines ultrasonic dry mist and UV-C light to disinfect both air and surfaces, unlike many single-method solutions. With the ability to disinfect 170 sq.ft in 15 minutes, it significantly reduces downtime, improving efficiency in healthcare settings. Safety is a priority, as the device uses non-corrosive, residue-free mist and automated UV-C light with human detection sensors, reducing health risks associated with harsh chemicals. Additionally, the UVM+ consumes only 250mL of disinfectant per hour, minimizing operational costs and environmental impact. Its patented technology ensures reliable performance, while the lightweight

Brief Description of Product

Avinya Infinity Solutions specializes in providing advanced disinfection technology for healthcare environments. The company's flagship product focuses on infection control by utilizing cutting-edge UV-C technology to disinfect hospital surfaces and equipment. This solution aims to significantly reduce hospital-acquired infections HAIs while ensuring regulatory compliance, safety, and operational efficiency for healthcare facilities.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

Current Stage of Development: Avinya Infinity Solutions is in the advanced prototype stage, having completed rigorous testing and validation of its disinfection product. The technology has been validated through trials in collaboration with healthcare professionals, and the product has undergone quality and safety assessments. We are in the process of obtaining necessary certifications and regulatory approvals. Furthermore, discussions with potential customers and early-stage partnerships are underway, positioning the company for imminent market entry and commercialization. This stage reflects both technical readiness and strategic alignment for scaling the solution.

Product Launched / About to be Launched

About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

The UVM+ Dual-Action Disinfection Device combines ultrasonic dry mist and UV-C light for comprehensive air and surface disinfection. It efficiently covers 170 sq.ft in 15 minutes, uses minimal disinfectant, and features a user-friendly, portable design with patented technology for superior performance.

Unique Selling Point

The UVM+ offers a unique dual-action disinfection with ultrasonic mist and UV-C light, covering 170 sq.ft in just 15 minutes. It combines efficiency, safety, and cost-effectiveness with a patented design, reducing operational costs and improving infection control in healthcare settings.

Present Stage of Development

The UVM+ is in the final stage of development, with a completed prototype undergoing rigorous testing and validation. It has received positive feedback from initial trials, and we are now preparing for pilot deployments and commercial launch.

Geographical Region Targeted

The UVM+ targets healthcare facilities across India and the broader South Asian region. We aim to address the growing need for advanced disinfection solutions in hospitals, clinics, and other medical environments where high standards of hygiene are crucial for patient safety and operational efficiency.

Major Achievements

Winner of National Startup Awards 2023

Developed Under(scheme) BioNEST

Bionest Center Name Bionest IIT Guwahati

Title/Name of the Product/Technology

UVM+

Product Positioning

Product Positioning: The UVM+ Dual-Action Disinfection Device is positioned as a cutting-edge solution for comprehensive, efficient, and safe disinfection in healthcare settings. Combining ultrasonic dry mist and UV-C light, it addresses both air and surface contamination, offering superior performance over single-method devices and ensuring a safer environment while reducing cost.

National/Societal Relevance

National/Societal Relevance: The UVM+ device addresses critical healthcare needs by enhancing disinfection practices, reducing healthcare-associated infections HAIs, and improving patient safety. Its efficient, cost-effective solution supports public health objectives, contributing to a healthier environment and better healthcare outcomes on a national scale.

Import Substitution

Import Substitution: The UVM+ device offers a domestically manufactured solution to replace costly, imported disinfection systems. By providing an advanced, locally produced alternative, it reduces reliance on foreign technology, supports local industry, and enhances economic self-sufficiency in healthcare equipment.

Export Potential

Export Potential: The UVM+ device, with its innovative dual-action disinfection and patented technology, is poised for global markets. Its efficiency, safety features, and cost-effectiveness make it an attractive option for international healthcare facilities, positioning it as a competitive export product with significant growth potential.

IP Status

Two patent filed 1. Name: An Automated Dual Disinfection System 2. Name: AN ADAPTABLE ROBOTIC DEVICE FOR DISINFECTION, CLEANING AND WAREHOUSE MANAGEMENT



Name of Startup: Axion Meditech and Life Science Pvt Ltd

Founder and Co-founder(s):
Pranav Dhumad

Email:
axionmeditech@gmail.com

Product/Technology differentiation from Competitors

Product is easy to use. It has very less coefficient of friction, it is compatible with both hydrophilic and hydrophobic type of lens. It's based on newer technology which gives better intra ocular lens delivery. It will also be available with patent protected automatic delivery.

Brief Description of Product

Intraocular Lens Guide is disposable device used to implant Intraocular Lens into eye during cataract surgery. These are disposable but critical product having high sales value due to technical criticality. There is no manufacturer of this product in India even though high demand with TAM 2.5 Cr units in India and 7.6 Cr units in the world. It's a process innovation with modifying polymer property to reduce friction between Intra ocular lens and the guide such that it does not damage or make scratch on intra ocular lens.

Technology readiness level (TRL) TRL- 8


Current Stage of Development

The product is ready for market. we tested received biocompatibility with accredited lab. and also tested our product with help of some ophthalmologist. we got awesome result. Our lens delivery load is minimum, and it's easy to use for surgeon. We have different models and sizes ready with us to sell as per clients demand.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

as there are very few players of this product, mostly from USA and Europe, their product cost is very high. So, we can supply product all over world.



Title/Name of the Product/Technology

Intraocular Lend Guide

Product Positioning

We are planning to reduce sales cost by 80 of existing sales price of imported equivalent product available the market.

National/Societal Relevance

As cataract is national issue, and Centre government is also sensitive on issue, certain reports from USA and Indian government indicates high blindness due to untreated cataract due to high surgery cost. Our product can address this national issue by reducing cost of surgery, as well as can reduce trade deficit by reducing import of this product as well as by exporting the product.

Import Substitution

Our product is 100 import substitute products, as there is no manufacturer of this product in India despite sales of approx. 2.5 Cr units per year

Export Potential

As there are approx. 10 manufacturers of this product worldwide with TAM 7.5 Cr units, we have excellent export potential. Moreover, all competitors are from USA and Europe, their cost is very high, which helps us to grab global market.



Name of Startup: BABYCUE PRIVATE LIMITED



Founder and Co-founder(s):
Manish Kumar Swain (FOUNDER)
Itishree Jali (Co-FOUNDER)

Developed Under (scheme):
BIG

Email:
manish.babycue@gmail.com

Product/Technology differentiation from Competitors

Our μ -PAD based diarrheal detection kit is non-invasive, rapid-on-site infection detection, cost-effective, bio-degradable, qualitative and quantitative measurement of biomarkers in fecal samples with color changing visualization. Increased levels of fecal biomarkers detected from diarrheal detection kit can further be correlated well with both endoscopic and histological assessment of disease activity. Since, the device is designed ergonomically with simple lateral flow assay technology, it requires low-throughput settings and eliminates the need of sophisticated instruments in affected areas. Measurement of responsible biomarkers using this rapid diarrheal detection kit can be considered as a reliable indicator of inflammation and can facilitate clinical decision-making.

Brief Description of Product

Our μ -PAD based diarrheal detection kit is non-invasive, rapid-on-site infection detection, cost-effective, bio-degradable, qualitative and quantitative measurement of biomarkers in fecal samples with color changing visualization. Increased levels of fecal biomarkers detected from diarrheal detection kit can further be correlated well with both endoscopic and histological assessment of disease activity. Since, the device is designed ergonomically with simple lateral flow assay technology, it requires low-throughput settings and eliminates the need of sophisticated instruments in affected areas. Measurement of responsible biomarkers using this rapid diarrheal detection kit can be considered as a reliable indicator of inflammation and can facilitate clinical decision-making. The μ -PAD-based detection kit will be a testing platform for early immuno-diagnosis of bacterial diarrhea among infants with fast turn-around time of 5-7 minutes under lower throughput requirements in clinics, hospitals and laboratories as a point-of-care option. Hence, this can support in clinical decision-making for treatment i.e., if viral diarrhea, ORS and nutrition therapy and if bacterial diarrhea, antibiotic treatment prescribed by clinicians. It will eliminate the need of sophisticated instrumentation that are non-available or less available in remote target regions, very cost-expensive, demands high-throughput setups, skilled manpower, complex procedures that can consume time and will take 24-48 hours to generate reports. This will be truly beneficial for the lakhs of rural and low-resource settings, where last mile health workers i.e., ASHA, Auxiliary Nurse Midwife Anganwadi Workers in India, they can administer drugs after conducting the test through this instant diagnostic kit.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

We have successfully validated the concept of our Lateral Flow Assay LFA strip prototype through laboratory-scale experiments, demonstrating a proof-of-principle for the detection of the target analyte in spiked stool samples. Preliminary data indicate a positive correlation between the presence of the analyte and the test line colorimetric response. While these findings are promising, significant technical challenges must still be addressed to advance the technology, including optimization of the assays sensitivity and specificity, and scale-up of the manufacturing process. Further research is needed to mature the technology and prepare it for more advanced testing and validation at higher TRLs

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

SAARC Countries



Title/Name of the Product/Technology

A DISPOSABLE PAPER ANALYTICAL PLATFORM FOR RAPID DIFFERENTIATION OF CHILDHOOD DIARRHEA

Product Positioning

Our diarrhea detection kit is a quick, non-invasive diagnostic tool for healthcare providers, enabling accurate differentiation between bacterial and viral diarrhea in children under 5. It's an affordable, eco-friendly, and easy-to-use alternative to traditional, time-consuming diagnostic methods, making it the ideal choice for hospitals, clinics, and community health workers.

National/Societal Relevance

In India, the prevalence is 3 times a year with mortality rate of 19.5, claiming 300 lives/day 1 lakh children/year. Thus, there is an urgent unmet medical need to combat increasing cases by introducing early diagnosis tool for differentiating diarrhea that will help in clinical decision-making to prescribe definitive treatment. Our device will be highly specific in detecting the responsible biomarkers directly from patient fecal samples. Economical pricing and practical use in treatment will ensure it a must have device and bring revolution in the field of PoC devices, and will help industries in attaining commanding position in the market.

Export Potential

Our product has strong export potential, especially in developing countries where childhood diarrhea is prevalent and access to advanced diagnostic tools is limited. The affordability, ease of use, and rapid results make our diarrhea detection kit highly suitable for global markets, particularly in Africa and SAARC countries.

IP Status

PCT/IB2023/052710 - Published

Name of Startup: BeAble Health Pvt Ltd



Founder and Co-founder(s):
Habib Ali Sreehari KG

Developed Under (scheme):
BIG, SBIRI

Email:
habib@beablehealth.com

Product/Technology differentiation from Competitors

ArmAble uniquely combines interactive therapeutic games with real-time movement tracking, enhancing patient engagement and promoting neuroplasticity through high repetition exercises. This integration of engaging software with advanced hardware differentiates it from traditional rehabilitation methods, making therapy more effective and enjoyable.

Brief Description of Product

ArmAble is an advanced upper limb rehabilitation device designed to aid in the recovery of individuals with motor deficits due to conditions such as stroke and spinal cord injuries. ArmAble offers an engaging and effective rehabilitation experience combining state-of-the-art hardware with interactive therapeutic games. The device tracks movement data to provide objective progress reports and promotes neuroplasticity through repetitive exercises, crucial for recovery. By making therapy enjoyable and motivating, ArmAble enhances patient adherence and outcomes, transforming rehabilitation into a dynamic and effective process. Ideal for rehabilitation centers, it is a lifeline to improved mobility and quality of life.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

In the market

Product Launched / About to be Launched Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

ArmAble is an advanced rehabilitation technology that leverages AI, gamification, and data analytics to enhance upper limb therapy. It features multiple handles for task-specific training, adjustable inclination for varied therapy needs, and real-time performance tracking to deliver personalized, efficient rehabilitation solutions.

Unique Selling Point

ArmAble is an AI-driven rehabilitation device that offers immersive, gamified therapy for upper limb mobility recovery. Its unique features include adjustable inclination, multiple task-oriented handles, and real-time data tracking, making it an innovative, engaging, and cost-effective solution for patients and therapists alike.

Present Stage of Development In market

Geographical Region Targeted

ArmAble addresses a vast global market in rehabilitation technology, responding to rising cases of strokes and spinal cord injuries. In India and globally, the increasing need for advanced, technology-driven rehabilitation solutions presents a significant economic opportunity for ArmAble's innovative approach.

Major Achievements

Most Innovative Product in Physiotherapy and Rehabilitation - PhysioTimes Startup of the Year - Rehabilitation Technology - NationWide Healthcare Awards Mercedes Benz - Business Mint Vilgro iPitch 2019 Winner Social Alpha Quest for Assistive Technology -Winner XPOMET Startup Award - Berlin Top 3 Silver Award

Title/Name of the Product/Technology

ArmAble - Game based Arm Rehabilitation Device

Product Positioning

ArmAble is positioned as a cutting-edge rehabilitation solution for stroke, TBI and spinal cord injury patients, offering affordable, data-driven, and AI-backed therapy. By combining gamified exercises with personalized treatment, ArmAble enhances recovery outcomes and bridges the gap in accessible, effective rehabilitation technologies.

National/Societal Relevance

ArmAble holds immense national and societal relevance for India by addressing critical healthcare challenges. With a high incidence of strokes and spinal cord injuries, India faces a pressing need for accessible and effective rehabilitation solutions. ArmAble's technology-driven approach enhances patient outcomes, promotes independence, and reduces healthcare costs, aligning with India's healthcare priorities of improving patient care and accessibility to advanced medical technologies. This makes ArmAble pivotal in addressing India's rehabilitation needs and contributing to enhanced quality of life for individuals with motor deficits.

Import Substitution

Yes

IP Status

Indian Patent Granted : 314299 US Patent Granted : 11,357,690 EU Patent Application filed : 18835236.3 PCT Application : PCT/IB2018/055332



Name of Startup: bEarly Technovations Pvt. Ltd



Founder and Co-founder(s):
Sathyanarayanan

Email:
ceo@bearlytech.com

Product/Technology differentiation from Competitors

Existing gait analysis instruments such as GAITRITE, F-Scan provide extensive parametric information about a patient's gait. The results are add-ons that need to be analyzed by doctors, but do not reduce the burden of the existing time-consuming manual examination. paceB leverages AI producing reports that can substitute the existing manual gait examination. This saves the complete examination time, allowing doctors to directly focus on treatment.

Brief Description of Product

paceB is an AI-integrated gait analysis device for the screening and prognostication of gait disorder such as Parkinsons Disease, Stroke, etc.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Product Market Fit Validation Phase

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India

Title/Name of the Product/Technology

paceB: AI-powered gait analysis device

Product Positioning

AI-powered gait analysis device: Screen and Prognose gait disorders

National/Societal Relevance

With over 20M cases and a predicted rate of increase of more than 200, movement disorders are a growing concern in India. The existing physical examination of gait disorders is time-consuming, not-data-driven thus inefficient. paceB will act as a time-effective, data-driven alternative to the existing approach saving almost entire gait disorder examination time, improving patient outcomes.

Export Potential

High export potential as movement disorders are a global problem and no solution exists to facilitate early diagnosis of the same.

IP Status

202341039134 - disposed

Name of Startup: BigOHealth



Founder and Co-founder(s):
Gaurav R
Shubham Shreyas

Developed Under (scheme):
SEED Fund

Email:
gaurav@bigohealth.com

Product/Technology differentiation from Competitors

We have myriad competitive advantages over them such as strong presence on the ground, robust engagement with both doctors and patients, high care quality delivery 24x7, and strong outreach into intervention areas through Digital Centres. The platform is vernacular in language, easy to use and has a voice-based interface that sets us apart from our competitors.

Brief Description of Product

BigOHealth is a vernacular healthcare platform that enables underserved & healthcare-deprived rural patients to get quality and affordable healthcare across primary, specialist, and tertiary care. Our simple-to-use integrated health platform and digital clinics in village in partnership with local pharmacies enables the vulnerable patients to do instant tele/video consultation with certified doctors 24x7, search and book in-person online doctor appointments in tier-3, tier-4 towns, get expert opinion from leading specialists across the country and access end-to-end specialist and tertiary care with curated doctors in metro cities.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

https://play.google.com/store/apps/details?id=com.patients.bigohealth&hl=en_IN

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Bihar

Title/Name of the Product/Technology

Artificial Intelligence

Product Positioning

Healthcare

Export Potential

In African and low-middle-income countries

National/Societal Relevance

BigOHealth innovation limits the patient's exposure to the local unlicensed medical practitioners and helps them to get high quality care at affordable rates. It significantly cuts down patient's clinic waiting times by 5-6 hours, alleviating the previous ordeal of traveling 30-40 km at 3 AM in the morning and standing in queues outside the doctor clinic for 3-4 hours to get an appointment with no surety of getting it. It lessens the mental stress on patients and their families, who previously faced the prospect of not being attended by doctors or being cheated. Moreover, it saves the families daily wages.



paceB



Name of Startup: Biodimension Technology Private Limited



Founder and Co-founder(s):
Ranjithkumar V Pradeep
Arunachalam Manojkumar S

Developed Under (scheme):
BIG

Email:
ranjith@biodimension.in

Product/Technology differentiation from Competitors
Product shipment and increased shelflife

Brief Description of Product

Reconstructed human tissue models are advanced in vitro systems that mimic the structural and functional properties of human tissues. These models have revolutionized biomedical research by providing more accurate and reliable platforms for studying human biology, disease mechanisms, drug efficacy, and toxicity. They bridge the gap between traditional cell cultures and animal models, offering a more human-relevant context for experimental studies. Composition and Design Reconstructed human tissue models are typically engineered using a combination of human cells and biomaterials. These models can be composed of primary human cells, stem cells, or cell lines, depending on the intended application. The cells are cultured in three-dimensional 3D matrices that simulate the extracellular environment of human tissues, allowing them to organize into structures that closely resemble those found in vivo. The biomaterials used in these models, such as hydrogels, scaffolds, and biocompatible polymers, play a crucial role in supporting cell growth, differentiation, and function. These materials are designed to mimic the mechanical and biochemical properties of the native extracellular matrix, facilitating the development of tissue-like architectures. Advanced tissue engineering techniques, including bioprinting and microfluidics, are often employed to create complex tissue models with multiple cell types, layered structures, and vascular networks. Applications in Biomedical Research One of the most significant advantages of reconstructed human tissue models is their ability to provide more physiologically relevant data compared to traditional 2D cell cultures and animal models. This is particularly important in the context of drug development, where these models can be used to predict drug efficacy and toxicity more accurately, reducing the reliance on animal testing and improving the translation of preclinical findings to human clinical trials. In disease research, reconstructed human tissue models offer a powerful tool for studying the underlying mechanisms of various conditions, including cancer, cardiovascular diseases, neurodegenerative disorders, and infectious diseases. By replicating the tissue microenvironment in which these diseases occur, researchers can observe disease progression, identify potential therapeutic targets, and test the effects of novel treatments in a controlled and reproducible manner. These models are also invaluable for studying the interactions between different cell types within a tissue, such as epithelial and immune cells in skin models or neurons and glial cells in brain models. This allows for a more comprehensive understanding of tissue-specific functions and responses to external stimuli, such as drugs, chemicals, or pathogens. Ethical and Regulatory Considerations The use of reconstructed human tissue models addresses several ethical concerns associated with animal testing. By providing a human-relevant alternative, these models help reduce the need for animal experiments, aligning with the principles of the 3Rs Replacement, Reduction, and Refinement in research. Regulatory agencies are increasingly recognizing the value of these models, and they are being incorporated into safety testing guidelines for cosmetics, chemicals, and pharmaceuticals. Future Perspectives The field of reconstructed human tissue models is rapidly evolving, with ongoing advancements in stem cell technology, tissue engineering, and computational modeling. As these technologies continue to improve, we can expect the development of even more sophisticated models that replicate the complexity

Technology readiness level (TRL) TRL- 7

Current Stage of Development

The reconstructed epidermis, vaginal epithelium, and full-thickness skin are already on the market.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted
Globally

Title/Name of the Product/Technology

Reconstructed human tissue models

Product Positioning

some of our products are in the market

National/Societal Relevance


Ethical relevancy

Import Substitution

animal models

Export Potential

European and USA people are ready to accept



Name of Startup: Bioinnovatiq Lifescience pvt ltd



Founder and Co-founder(s):
Sujan Chaudhuri
Ranjita Ghosh Moulick

Developed Under (scheme):
BIG

Email:
director@bioinnovatiq.com

Product/Technology differentiation from Competitors

1. No competitor has similar technology Patent filed to compete in the cost that the product can. 2. Microheater based heating and use of such controlled heating for PCR is new and unmatched Patent granted. the time of the reaction and cost of the product outperforms all the competitor in this field.

Brief Description of Product

1. A cell free transcription-translation system which can synthesize protein in less than 1.5 hours without any need of generation of cell-based clone for recombinant protein production. The applications are robust and provide solution as mentioned below: - No formation of inclusion bodies - Expression of Toxin Proteins - Cost effective and large-scale production possible - Very high yield - Can express active multimeric protein 2. A portable low-cost, chip-based PCR device with innovative Design which features a micro-heater for rapid PCR, integrated with an optical detection system for large-scale screening of disease samples. The micro heaters in the device can operate at different temperatures thus giving flexibility to do PCR with different program at the same time, surpassing the capabilities of standard gradient PCR machines.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

Product is undergoing rigorous manufacturing process flow and validation process.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted
India and abroad

Title/Name of the Product/Technology

1. TX-TL Cell-free protein expression system 2. PORTABLE HANDHELD POINT OF CARE RT-PCR AS REAL TIME MOLECULAR DIAGNOSTIC DEVICE

National/Societal Relevance

Our low-cost system has the potential to earn exponential growth by replacing conventional protein production technology Therapeutic-non-therapeutic that involves cell based or other cell free production system and increase the availability and affordability of biotherapeutics significantly.

Export Potential

The patented product has high potential for export.

IP Status

for 1: Filed: Applications Patent application no. 202111023575 dated 27th May 2021 for 2: Granted patent: Patent Application No. is 202011016082 dated 14th April 2020. Applied patent: 1. Indian Patent Application Number 201811004666 dated 7/02/2018. PCT Application PCT/IN2019/050090 Dated 05.02.2019

Name of Startup: Biostim Innovations Private Limited



Founder and Co-founder(s):
Mr. Kushagra Asthana
Mr. Prithu Prasad

Developed Under (scheme):
BIG

Email:
kushagra@biostim.in

Product/Technology differentiation from Competitors

There are few functional electrical stimulators available worldwide. In India, there are no products and all are imported from abroad. We are the first and only company to manufacture this company locally in India. Our product costs very low compared to our counterparts, leading to higher distribution. The movement detection algorithm has been designed according to Indian patients walking pattern. Our device is easier to set up and configure than the imported counterparts. Our user experience is better than the competitors.

Brief Description of Product

Biostep Plus brand name is intended to address the lack of ankle dorsiflexion in patients who have sustained damage to upper motor neurons or pathways to the spinal cord. During the swing phase of the gait, the device electrically stimulates the appropriate muscles that cause ankle dorsiflexion and may thus improve the patient's gait. Medical benefits of Functional Electrical Stimulation FES may include prevention/retardation of muscle atrophy, increased blood flow, muscle re-education, and maintained or increased joint range of motion.

Technology readiness level (TRL) TRL- 5


Current Stage of Development

Clinical Grade Device is ready. Quality management System ISO13485 and ISO9001 certification obtained. Device is currently being sent to various labs for tests like electrical safety and biocompatibility. Preliminary studies conducted with patients show positive results. After completion of tests, to go for full clinical validation.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Our initial target and focus region is India. Beyond India, we are open to exploring Asia and Middle East.



Title/Name of the Product/Technology

Biostep Plus - an external functional neuromuscular stimulator

Product Positioning

There are many ways the product can be fit into the market; our early target is physiotherapy and rehab centers. Most of our target patients visit such centers. We will incentivize physiotherapists to sell our product to patients who need it for the long term.

National/Societal Relevance

Stroke is a growing epidemic in India. Every year 150/10000 people suffer from stroke. It is found that the demographics of stroke is being shifted from older patients to younger patient. Rehabilitation of stroke often takes months. All the stroke patients suffer from some kind of mobility issues. Our device is an effective aid for stroke rehabilitation. Mobility is one of the most important activities of daily living ADLs. If a person is able to get back on feet early, he can become productive.

Import Substitution

This product can be 100 import substitution. The counterpart products are imported from western countries and China for up to 10X the cost that we are planning to launch. It is so expensive that doctors do not prescribe to patients who need it. Service is another issue.

Export Potential

There is a very strong export potential in the Asian and African markets. Regulations are not very strict and it is a price sensitive market. Exports are possible if we tie up with local distributors in those countries. In EU and US, there already are few big players.

IP Status

Applied Patent Published Patent
Application Number: 202311078953

Name of Startup: BioTalent Search Private Limited



Founder and Co-founder(s):
Mr. Prabuddha Daronde(Director)
Ms. Sneha Shelare(Director)

Email:
pd@biotalentsearch.com

Product/Technology differentiation from Competitors

Life Sciences Focus: Specializes exclusively in the life sciences sector, offering deep industry knowledge. Niche Expertise: Skilled in sourcing candidates for highly specialized roles. Extensive Network: Access to a vast network of professionals and exclusive job opportunities. Quality Assurance: Rigorous screening ensures only top candidates are presented. Customized Solutions: Offers tailored recruitment strategies and consultancy services. Global Reach: Combines global capabilities with local market expertise. Diversity & Inclusion: Strong commitment to equitable hiring practices. Tech-Driven: Utilizes advanced technology and data analytics for efficient talent engagement.

Brief Description of Product

We are a BioTalent Search® company dedicated to connecting top talent with leading companies in the Life Sciences & Biotechnology. With our in-depth knowledge of the industry and extensive network of qualified candidates, and rigorous screening methodology, we are able to identify and recruit the best people for key roles in biotechnology, pharmaceuticals, medical devices, diagnostics and engineering. Our goal is to empower companies within the Life Sciences & Biotech domain by providing them with the talented individuals they need to drive innovation and growth. We pride ourselves on our ability to understand the unique needs of each client and deliver customized solutions that meet their specific requirements.

Technology readiness level (TRL) TRL- 9

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Starting with the Indian market, then gradually expanding globally.

Title/Name of the Product/Technology

Life Sciences Recruitment & Business Consultancy

Product Positioning

BioTalent Search is a life sciences recruitment firm known for its deep industry expertise, extensive network, and advanced technology. It connects top talent with leading organizations, emphasizing quality, global reach, and diversity.

National/Societal Relevance

BioTalent Search is highly relevant nationally due to its specialized focus on the life sciences sector, extensive network of professionals, and tailored recruitment solutions. It effectively addresses the talent needs of organizations across various life sciences fields, providing crucial expertise and support within the national market.

Name of Startup: Biyani BioSolutions Pvt Ltd., Jaipur



Founder and Co-founder(s):
Dr. Manish Biyani

Email:
biyanirb@gmail.com

Product/Technology differentiation from Competitors

BioMuRun is a unique electrophoresis system that offers several advantages over conventional solutions. It combines all components, like power supplies, gel tanks, buffers, and Gel documentation systems, into a compact, simplified, handle-held unit. BioMuRun precast cassettes also eliminate the need for gel preparation and extra buffer. It integrates two ion exchange matrices, which allows a high-performance run of DNA/RNA in a 1 µL volume of sample. BioMuRun reduces the traditional process time from 1 hour to 5 minutes. Its space-saving design makes it ideal for point-of-care use. BioMuRun integrates real-time monitoring and recording, unlike conventional systems that rely on external manual documentation systems.

Brief Description of Product

BioMuRun is an all-in-one solution for polyacrylamide gel electrophoresis PAGE, offering rapid analysis of DNA and RNA in mere minutes. The product is a partial outcome of a BIRAC-supported project in the COVID Consortium BT/COVID0020/01/20 and the Japan Agency for Medical Research and Development AMED JP20HE0622020. The invention focused on the remote site electrophoresis facility, utilizing RICCA RNA Isothermal Co-assisted and Coupled Amplification technology for lab-free rapid testing of RNA viruses. This comprehensive system ensures precise separation and visualization of nucleic acids, empowering scientists with the tools for accurate data interpretation and discovery. From routine laboratory tasks to research applications, this unique device provides unrivalled simplicity of use and exceptional performance capabilities. BioMuRun delivers unmatched performance, making it the go-to choice for molecular biologists everywhere. The device uses LEDs instead of UV light to visualize DNA bands. The device visualizes DNA as blue-green-red fluorescence, making it 100 times more cost-effective and portable. The BioMuRun makes itself a unique choice due to its features, including no requirement for an external power supply real-time analysis of results no requirement for a gel documentation system no requirement for the addition of buffer no gel preparation pre-cast gel convenience no post-gel staining requirement and run time within 5 minutes. BioMuRun is a customizable pre-cast polyacrylamide 6 native gel cassette that makes it easy to separate DNA and RNA quickly and cheaply. The cassettes consist of a borderless acrylamide gel, embedded with two ion exchange matrices IEMs that come into contact with the gel and electrodes. The IEMs provide a continuous flow of ions throughout the precast gel, resulting in the required sustained electric field for gel operation. We package each ready-to-use precast gel in a transparent plastic cassette for improved resolution. It permits high-performance detection of 50–500 bp of sample DNA in 1 µL in only 5 minutes. With BioMuRun, researchers can streamline their workflow, gaining quick insights into molecular structures with unparalleled efficiency.

Technology readiness level(TRL) TRL- 9

Current Stage of Development

The 'BioMuRun' exist in its prototype cum product stage. The BioMuRun has consistently high resolution, sensitivity, and reproducibility of results in molecular biology applications. The technology's reliability and efficacy in real-world applications make it a suitable alternative to the current system for deployment in various operational environments, such as academic research institutions, biotechnology companies, and clinical laboratories. The technology has been well-received due to its robustness, simplicity of use, and integration into existing workflows. The technology is now commercially available accompanied by developing marketing efforts to target a wide range of clients.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

BioMuRun aims to optimize its market penetration and influence among academic research institutions, biotechnology companies, and clinical laboratories across India. Then, our focus will leverage our significant influence in Asian, North American, European, and Middle Eastern markets.

Title/Name of the Product/Technology

BioMuRun: All-in-one Polyacrylamide Gel Electrophoresis Device

Product Positioning

BioMuRun is a cutting-edge electrophoresis solution that prioritizes the needs of the global market by offering advanced, innovative, Customer-Centric sustainable high-quality solutions.

National/Societal Relevance

BioMuRun is a technological innovation that drives national and societal progress by fostering cross-border economic growth collaboration between Japan and India. BioMuRun enables to transformation of research organizations and academic curricula by creating educational opportunities and advancing scientific knowledge. It integrates an affordable electrophoresis system, supporting skilled workforce development and fostering innovation. BioMuRun in-built blue light illumination is non-toxic and eliminates the need for UV-protective equipment, ensuring user safety. Due to its rapidness and ability to handle 1µL sample, it may replace traditional electrophoresis from clinical diagnostic through genetic/ small biological samples testing, forensic analysis, and research into genetic disorders.

Export Potential

BioMuRun has significant export potential due to its innovative technology, affordability, sustainability, and alignment with global trends in research, education, and environmental responsibility. Our primary focus is to expand the export market in Asia, North America, Europe, and the Middle East by ensuring the necessary compliance.

IP Status

The Technology is recognized with international patents following patent ID JP-2024-082160-A Gel electrophoresis device and Indian Design 392015-001 Cassette design patent.



Name of Startup: Black Space Technology



Founder and Co-founder(s):
Dr David Morgan
(CEO & Medical Director)

Developed Under (scheme):
OTHERS

Email:
info@blackspacetechnology.com

Product/Technology differentiation from Competitors

Competitor differentiation: Rapid-EPR is faster, lighter, smaller and better value for money. The first hour after injury is known as the 'golden hour' when 80 per cent of deaths occur; therefore speed of reaction and care is crucial to help save lives. Traditional hardware monitoring comprises of heavy, expensive and restricted-use equipment with isolated data capture devices do not talk to each other. This results in emergency care suffering from delays hindering effective decision-making and timely medical intervention. Rapid-EPR overcomes these challenges by integrating advanced technologies into a robust, portable platform used by emergency responders whilst allowing expert clinical consultation.

Brief Description of Product

Electronic patient record EPR platform with wearable wireless vital sign monitoring devices providing real-time situational awareness and videoconferencing.

Technology readiness level(TRL) TRL- 9

Current Stage of Development

Rapid-EPR has achieved TRL9 status through successful commercialisation, demonstrating its readiness and proven performance in operational environments.

Product Launched / About to be Launched Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology Yes

Availability for showcasing at Birac Yes

Product/Technology

Electronic patient record EPR platform with wearable wireless vital sign monitoring devices providing real-time situational awareness and telemedicine videoconferencing. A Software as a Medical Device approach enables incremental data capture from the point-of-injury to role 1, 2 or 3 designated hospitals with real-time data transmission in any environment.

Unique Selling Point

Rapid-EPR is hardware agnostic, connecting with Bluetooth-enabled medical devices on patients to transmit vital signs to clinicians in real-time. From the point-of-injury to hospitals, Rapid-EPR captures incremental data, creating a comprehensive medical record. Rapid-EPR sends data over limited bandwidth using innovative encryption and compression technologies including GPRS, WiFi, mesh radio.

Present Stage of Development

Rapid-EPR is currently in the market, available for purchase and actively used in operational settings.

Geographical Region Targeted

Global

Major Achievements

Winner of Advances in Digital Healthcare at Medilink Midlands Business Awards. Silver in Healthcare Technology at the international Stevie Awards for Technology Excellence. Finalist for Health Tech Innovator at Technology Supply Chains Innovation Awards. Finalist for Health Technology at the Institute of Engineering and Technology's Excellence and Innovation Awards.

Other Scheme Name UK Ministry of Defences Defence and Security Accelerator DASA

Title/Name of the Product/Technology

Rapid-EPR Telemedicine Solution

Product Positioning

Rapid-EPR is strategically positioned in the pre-hospital emergency care space for IGO, NGO, military, and civilian sectors, catering to the unique demands of each with robust, bespoke telemedicine solutions for remote and challenging environments.

National/Societal Relevance

Rapid-EPR enhances pre-hospital emergency care by streamlining data management and communication between emergency responders and medical facilities, improving the speed and quality of care during critical situations, and positively impacting patient outcomes nationwide.

Import Substitution

Our software-focused, hardware-agnostic approach allows our electronic patient record system to seamlessly integrate with Made in India smartphones and connect to locally manufactured Bluetooth-enabled medical devices. This compatibility supports the Indian governments initiative to encourage domestic production and reduces reliance on imported technology to boost local industry and technological self-reliance.

Export Potential

Our telemedicine solution offers significant export potential, adaptable to various international standards and suitable for diverse environments, including battlefields, conflict zones and disaster relief areas, enhancing global healthcare services.

IP Status

Patent No. GB2493458: A PORTABLE DEVICE FOR RECORDING PATIENT DATA



Name of Startup: Cambrian Bioworks

**CAMBRIAN
BIOWORKS**

Founder and Co-founder(s):
 Vaibhav Hegde (CEO) and
 Rohit Asil, Raghav Sridhar (Co-founders)

Developed Under (scheme):
 SEED Fund

Email:
 himani@cambrianbioworks.com

Product/Technology differentiation from Competitors

Manta has a compact design that fits seamlessly into crowded workbenches. Manta's single-sample cartridges enable automation regardless of sample load, processing 1 to 32 samples at a time. This innovation makes automation accessible to low and medium-throughput labs, unlike existing high-throughput solutions.

Brief Description of Product

Manta is an automated DNA/RNA isolation device. It is renowned for its compact design, it weighs about 17 kg and versatility in processing various sample types including blood, tissue, saliva, FFPE blocks, viral, bacterial, pus, amniotic fluid, among others. Manta ensures high-quality, NGS-grade extraction with efficiency and compatibility for various molecular downstream applications. It is completely manufactured in India.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Manta is available in the market for sales.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Pan-India and international markets - The US, Europe, Southeast Asia



Title/Name of the Product/Technology

Manta, the automated extraction device

Product Positioning

Our solution targets a growing global market, with a total available market size of \$34 billion. This market encompasses key sectors including cancer diagnostics, reproductive health, infectious disease testing, and transplant medicine. To accommodate varying demands, we offer flexible acquisition options, including direct sales and a reagent rental model.

National/Societal Relevance

At the national level, adopting innovative technologies like Manta strengthens our country's commitment to research and education excellence. Proudly made in India, Manta also embodies the spirit of an Atmanirbhar Bharat.

Import Substitution

Manta aids import substitution by offering a domestically made, automated nucleic acid extraction device, reducing dependence on imports. It supports local manufacturing, creates jobs, and aligns with the Atmanirbhar Bharat initiative, fostering self-reliance and making advanced diagnostics more accessible to Indian labs and institutions.

Export Potential

Manta has strong export potential as a high-quality, cost-effective nucleic acid extraction device. Its advanced technology and competitive pricing make it attractive to international markets, especially in regions seeking reliable and affordable lab equipment. Exporting Manta enhances India's global presence in biotech, drives revenue, and supports economic growth.

IP Status

Application no: 202341055638 Title: METHOD AND COMPOSITIONS FOR ENRICHING HIGH MOLECULAR WEIGHT DNA

Name of Startup: Canary Biosensors Private Limited

**CANARY
BIOSENSORS**

Founder and Co-founder(s):
 Mr. Kaushik Suresh (Co-founder)
 Mr. Amar Vignesh S (Co-founder)

Email:
 kaushik@canarybiosensors.com

Product/Technology differentiation from Competitors

Competitive advantage of our product: 1. Proprietary sensing and immobilization scheme for higher sensitivity and precision 2. The analyzer has Wifi connectivity and own digital health stack

Brief Description of Product

The product is a test strip and handheld analyzer to measure creatinine from the blood drop of patients similar to glucometer and reports the eGFR value. The test can be performed in hospital, clinics, radiology, and dialysis centers under 2 mins. The handheld analyzer is connected to our Canary Cloud via Wifi.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

The product is under internal validation using commercial serum samples KPIs Linear range: 0.5 - 10 mg/dL Precision: CV = 1.9 Interference: 15

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, USA, Canada, Middle-East



Title/Name of the Product/Technology

Point-of-care Creatinine test

Product Positioning

Target markets: Hospitals, Emergency, radiology, nephrology, dialysis centers Pricing: premium segment

National/Societal Relevance

Acute kidney injury AKI alone occurs in around 40 - 50 of ICU-patients and 10 - 15 of hospitalized patients in India and rest of the world due to several causes such as medications, cardiac events, infections, etc. Also, around 13 of Indian and global population is affected by Chronic Kidney Disease CKD, which has been steadily progressing over the past few years. Considering their impact on health outcomes, there is a necessity for a creatinine device with low TAT that can accurately predict kidney health status and can be used as a screening device for AKI and CKD.

Import Substitution

Currently, POCTs for creatinine are being imported by Nova Biomedical stat-sensor and xpress meter and Abbott point-of-care i-STAT creatinine. So, this product is intended to be manufactured in India with same quality standards as imported meters and made available to the market.

Export Potential

Global point-of-care creatinine test market: 650 million USD Target markets for export: USA, Canada, Middle-East Point-of-care Creatinine test US Market: 7.5 million USD

IP Status

Provisional filing done application no: 202441031198



Name of Start-up: Caregenix Diagnostics Pvt Ltd



Founder and Co-founder(s):
Abhaya Kanoje (Founder)
Swapnil Shende (Co-Founder)

Developed Under (scheme):
BIG

Email:
abhaya4069@gmail.com

Product/Technology differentiation from Competitors

Unlike other LF, here we will be targeting 2 different strains of brucella to improve screening i.e. B. melitensis and B. abortus, both the strains are responsible for causing infection in both humans and animals. And also, we are detecting both the Antibodies in a single strip.

Brief Description of Product

In the given innovation we propose a simple, rapid, cost-effective point-of-care test device for the detection of brucellosis in humans as well as in animals. The developed test will be having high rapidity, sensitivity, and specificity which could be used anywhere in the field levels or the health care settings or even in households by occupationally exposed populations with minimum or low technical speciality. Here, we are detecting Antibodies Both IgM and IgG by using WCLIn methodology of work, the lateral flow kit will be conjugated by adding colloidal gold-based technology with the secondary antibodies IgG and IgM forming antigen antibody complex.

Technology readiness level (TRL) TRL- 2

Current Stage of Development

Currently, Prototype of the Lateral flow kit is ready and it is under validations.

Are you willing to Transfer/Out-License your Technology Yes

Availability for showcasing at Birac Yes

Present Stage of Development

Under Validation

Geographical Region Targeted

Overall, India

Title/Name of the Product/Technology

POCT for occupationally exposed population to Brucella Infection

Name of Startup: CellSeq Solutions LLP



Founder and Co-founder(s):
Mr. Ritesh Ranjan
Ms. Vandana Kumari

Developed Under (scheme):
SEED Fund

Email:
Ritesh@cellseq.in

Product/Technology differentiation from Competitors

We provide world-wide available innovative products in Cancer biology and Reproductive biology to our Indian scientists and researchers.

Brief Description of Product

We provide service in NGS, Bioinformatics, Computational biology and products for Saliva/Swab collection kit, Infertility, Cytokines, Antigens etc.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

We provide service in NGS, Bioinformatics, Computational biology and products for Saliva/Swab collection kit, Infertility, Cytokines, Antigens etc.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

All India

Title/Name of the Product/Technology

Cancer Genomics and Reproductive Biology

Product Positioning

NGS Customer and IVF Customer in India

National/Societal Relevance

Our offering will help in Cancer Diagnostics and will help in better IVF.

Import Substitution

Yes

Export Potential

Currently we are focusing more in India but we are open for Export.



Name of Startup: CHROGENE AAROGYAM BIOTECH PVT. LTD.



Founder and Co-founder(s):
DR. POONGOTHAI A.R
(FOUNDER & DIRECTOR)

Developed Under (scheme):
BIG

Email:
poongothaiar@gmail.com

Product/Technology differentiation from Competitors

Non-invasive less turn around time for data acquisition Affordable Reliable Ease of use by the local staff Rapid results delivery Notification of the patients and counselling of their relatives Reduction of the mortality& morbidity through therapeutic intervention

Brief Description of Product

Problem: A need for a Point of Care device for screening of Sickle cell disease Solution: To come up with a Non-Invasive device for Point of Care testing which could be more affordable and accessible. This technology makes use of measurement of blood parameters non-invasively, specially, the Sickle cell. Introduction: The Point of Care POC screening or testing shortens the time for clinical decision-making about additional testing or therapy, as transport and preparation of clinical samples no longer causes delays as the test results are available at the point of care rapidly. Hence, we are coming up with a NON-INVASIVE POINT OF CARE DIAGNOSTICS FOR SICKLE CELL DISEASE. Overall POC screening may improve medical outcome and lower costs. Keeping this in view, the POC for Sickle cell disease is being designed and developed. Technical details Up-to date: The device which is under development, the differential absorption properties of normal RBC's versus Sickle cell have been exploited. Biomarkers have been proven helpful in identifying different interconnected disease-causing mechanisms of SCD, including hypercoagulability, hemolysis, inflammation, oxidative stress, vasculopathy, reperfusion injury and reduced vasodilator responses in endothelium, to name just a few. Endothelial cells ECs line the inner surface of blood and lymphatic vessels, and play important roles in the development and remodelling of vasculature, maintenance of vascular tone, blood fluidity, coagulation, nutrient exchange, and organ development. Endothelial dysfunction is characterized by a shift of the actions of the endothelium toward reduced vasodilation, a proinflammatory state, and prothrombotic properties, which are quite prominent in SCD. Thus, this property of SCD is exploited along with the existing technique. Acute inflammation is characterized by marked vascular changes, including vasodilatation, increased permeability, and the slowing of blood flow, which are induced by the actions of various inflammatory mediators. Vasodilatation occurs first at the arteriole level, progressing to the capillary level, and brings about a net increase in the amount of blood present, causing the redness and heat of inflammation. To check the vasodilatory response, in the existing model, a heating mechanism is proposed, which will increase the temperature of the tissue to 41.0 C. With the photo plethysmography, the blood flow signal is obtained at one particular wavelength before heating the tissue, during heat application and also after removal of the heat. The vaso responses are monitored and normalized responses are calculated. The vascular response times are very high in the case of SCD, when compared to normal response. This technique has been used to substantiate and to correct the results in case of false readings.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

The Prototype underwent many versions and iteration to arrive at the present stage. Being a medical device for Non-Invasive screening at Point of care, it had to undergo numerous validation process, mechanical and software changes for a robust, and compact model with lesser data acquisition time.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Looking at an alarming prevalence of SCD in most of the parts of India, in the next one year we intend to capture the Indian market first as 8.5 of Indian population harbours tribal communities which includes the school children also in that area.

Title/Name of the Product/Technology

NON-INVASIVE POINT OF CARE
DIAGNOSTICS FOR SICKLE CELL
DISEASE

Product Positioning

Product specifications/uniqueeness of
SCD Device Non-Invasive SCD screening
Sensor based Portable Affordable User
friendly at PoC Remote data transfer

National/Societal Relevance

According to 2023 India healthcare policy, sickle cell disease needs to be eliminated by 2047 and we are definitely building in a medical device to eliminate SCD. India has a high prevalence of SCD Establish a protocol for Non-Invasive device for screening & diagnosis of SCD Mass Screening for Early detection and diagnosis, better disease management due to early detection by screening thereby decreasing the disease burden in the population

IP Status

GRANTED PATENT NUMBER-422171
FROM INDIAN PATENT OFFICE



Name of Startup: CogniDiagnoseAI



Founder and Co-founder(s):
Devyansh Gupta

Email:
gupta.devyansh99@gmail.com

Product/Technology differentiation from Competitors

Name What they do How is CogniDiagnoseAI different Brain Alive Measure user engagement, stroke recovery, neuromarketing, crypto CogniDiagnoseAI provides a score and auto generated brain health medical report Marbles Health Hardware provider, Stimulation tDCS Service provider, no stimulation, auto generated report BrainSight AI MRI based data collection EEG based data collection NEMA AI Targetting kids, not providing medical diagnosis Targetting adults, provide medical diagnosis NeuroLeap Focused on brain body enhancement Focused on measuring brain health and early diagnosis Neuphony EEG hardware provider. No medical grade analysis or report. EEG medical grade analysis service provider

Brief Description of Product

CogniDiagnoseAI offers a 30-minute cognitive assessment testing using EEG and AI software, facilitating early diagnosis and tracking of neurodegenerative diseases like Parkinsons and Dementia, complementing medical diagnosis and aiding precision medicine for patients.

Technology readiness level (TRL) TRL- 4


Current Stage of Development

Our MVP is complete and has been tested using five algorithms, achieving accuracy rates between 70-90. The basic GUI is functional, and our automated data processing pipeline is operational. We are currently enhancing the GUI to incorporate additional features, including cloud-based data access and collaborative capabilities. This will enable physicians to seamlessly view and share patient data and reports from anywhere. Additionally, we are heavily focused on EEG data acquisition through collaborations with hospitals, partnerships, and our own data collection campaigns to continually refine and validate our technology.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

We are targeting pan India, starting with pilot studies in partnership with hospitals and clinics in Delhi NCR. After successful results, we will expand nationwide. Additionally, we are building in India for the globe, with plans to enter international markets as part of our long-term growth strategy.



Title/Name of the Product/Technology

CogniDiagnoseAI: Biomarker-Driven EEG
Diagnostics for Neurodegenerative diseases and
Cognitive Decline, and aiding precision medicine

Product Positioning

Our product positions itself as a cutting-edge, cost-effective EEG-based diagnostic solution that seamlessly integrates with existing hardware. It provides rapid, auto-generated reports for early detection and personalized treatment of neurodegenerative diseases. Ideal for hospitals and clinics, it also supports drug discovery, making it a versatile tool in healthcare.

National/Societal Relevance

Our AI-driven brain health diagnostics aim to address the growing burden of neurodegenerative diseases in India, where millions remain undiagnosed. By offering an affordable, reliable, and non-invasive EEG-based solution, we provide better diagnostic tools to underserved populations, particularly in low- and middle-income regions. This technology enables early detection and ongoing monitoring of conditions like Alzheimer's, Parkinson's, and dementia, improving patient outcomes and easing the socio-economic strain on healthcare. Our solution empowers doctors with precision medicine capabilities, ultimately contributing to better brain health management across India's diverse demographic.

Import Substitution

Our diagnostics fill a critical gap in India, as no direct substitute for brain health assessments currently exists. Comparable to cancer probability detection tests that require sending blood samples to the USA, our solution eliminates the need for international services by providing advanced, AI-driven brain health diagnostics locally within India.

Export Potential

Our solution has significant export potential, as the algorithms are entirely software-based and compatible with a wide range of existing EEG hardware. This flexibility allows seamless integration into international healthcare systems without the need for additional equipment. By exporting our developed algorithms, we can provide scalable, AI-driven brain health diagnostics.

IP Status

Currently, no IP or patent has been applied for at this stage. However, the intellectual property is protected through Non-Disclosure Agreements NDAs signed with respective clients, collaborators, and interns. We plan to file a patent within the next 3 to 6 months for the algorithms and technology developed.



Name of Startup: Compass Enterprises Pvt. Ltd.



Founder and Co-founder(s):
Dr. Bhaskar Rao Ganni
Dr. Sandeep Ganni

Developed Under (scheme):
OTHERS

Email:
elakhattar@compasshealthcare.in

Product/Technology differentiation from Competitors

The company specializes in developing, manufacturing , production and marketing of IVD kits with primary focus on Gynecology, Cardiac, respiratory, tumors and various blood borne pathogens utilizing Immunochromatography technology, ELISA, Molecular Diagnostic tests

Brief Description of Product

The company specializes in developing, manufacturing , production and marketing of IVD kits with primary focus on Gynecology, Cardiac, respiratory, tumors and various blood borne pathogens utilizing Immunochromatography technology, ELISA, Molecular Diagnostic tests

Technology readiness level(TRL) TRL- 7

Current Stage of Development

The product are optimised and kept ready for scale up in manufacturing

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac No

Product/Technology

The company specializes in developing, manufacturing , production and marketing of IVD kits with primary focus on Gynecology, Cardiac, respiratory, tumors and various blood borne pathogens utilizing Immunochromatography technology, ELISA, Molecular Diagnostic tests

Unique Selling Point

The product are produced in state of art manufacturing facility with automatic assembly lines and minimum manual intervention. High Quality , Zero Defect Product

Present Stage of Development

The product are optimised and kept ready for scale up in manufacturing

Geographical Region Targeted

PAN India

Major Achievements

Constructed world class state of art manufacturing facility in AMTZ Campus with complete automatic assembly lines to manufacture High Quality, zero defect products

Title/Name of the Product/Technology

In Vitro Diagnostic Kits and Reagents

Product Positioning

In clinical Labs through channel partners, Hospitals etc Over the counter products

National/Societal Relevance

High Quality , Zero Defect product
Reduces Import burden Affordable

Import Substitution

Many Rapid card products which are imported from various countries will now be produced in state of art manufacturing facility

Export Potential

Yes, Compass manufacturing facility is WHO compliant facility and in near future export product to different countries

Name of Startup: COPIOUS DIO TEC PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Ashish Kumar Srivastava

Developed Under (scheme):
BIG, OTHERS

Email:
Director@copiousdiotec.com

Product/Technology differentiation from Competitors

Its an additive manufactured product through features of stimulus

Brief Description of Product

Orthopedic and dental Implants manufacturing through additive manufacturing.

Technology readiness level(TRL) TRL- 2

Current Stage of Development

We are at the development phase, and seeking regulatory and manufacturing licenses.

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac No

Product/Technology
IMPLANTS

Unique Selling Point
STIMULUS

Present Stage of Development TRL 2

Geographical Region Targeted

ASIA AND AFRICA

Major Achievements
none

Other Scheme Name

Application is under review for BIG 2024

Title/Name of the Product/Technology

An implant manufacturing company

Product Positioning

surgeons

National/Societal Relevance

ortho

Name of Startup: Criador Design Labs Pvt Ltd



Founder and Co-founder(s):
Abhishek Reddy Gujjala
Vidyaasagar Diyavath

Email:
abhishek@criadorlabs.com

Product/Technology differentiation from Competitors

The device comes with a built-in speculum attachment and a user-intuitive touch-based patient management application. This avoids the need for an external computer or tablet that is traditionally used for this purpose. Given the smartphone penetration in India, a trained health worker, such as a Nurse or other paramedical worker, can be trained to use the application easily, operate the device, and screen a patient. Our IoT ecosystem enables the remote diagnosis by doctors, unlike the existing colposcopes that require an on-site doctor. This can help screen and diagnose a lot more women in rural settings, thereby enabling mass screening.

Brief Description of Product

A Smart Portable Colposcope is a device with IoT and AI functionalities that is used as a screening tool for cervical cancer in low-resource settings.

Technology readiness level (TRL) TRL- 1

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted
India

Title/Name of the Product/Technology

Smart Portable Colposcope SPC

Name of Startup: Curie Microelectronics Private Limited



Founder and Co-founder(s):
Mr. Ayan Dutta
(Founder & CEO)

Developed Under (scheme):
SEED Fund

Email:
ayan.dutta@cmicro.in

Product/Technology differentiation from Competitors

1. Custom AI model developed, which can predict cardiac diseases with accuracy above 90. 2. Generative AI prompt provided in Android/iOS app for users personal Question-&-Answer session. Pure Silver Touchpads for hassle-free, accurate & cable-less ECG recording. 3. Generative AI prompt provided in Android/iOS app for users personal Question-&-Answer session. 4. Dual Mode Operation Touchpad & Conventional Cable modes supported 5. Supports both Android & iOS apps 6. Separately provided RLD cable improves ECG signal quality. 7. Detailed ECG reports A4+ Thermal Paper format. 8. Gold-plated 6-pin AAMI connector provided for improved signal quality.

Brief Description of Product

Salient Features of Rhythm ECG: Custom AI model developed, which can predict cardiac diseases with accuracy above 90. Generative AI prompt provided in Android/iOS app for users personal Question-&-Answer session. Pure Silver Touchpads for hassle-free, accurate & cable-less ECG recording. 12-Lead ECG. Dual Mode Operation Touchpad & Conventional Cable modes supported. Fully automatic. Portable, Ultra-light. Clinical-Grade ECG. Supports both Android & iOS apps proprietary. Separate RLD cable provided compulsorily & free of cost. This improves ECG signal quality drastically. Healthcare professional is not required to set up & operate the device & app. No need to use an additional USB Type-C cable to operate. Detailed ECG reports PDF files are automatically created & saved in your phone memory, in both A4 & ECG paper formats. It has Preview option, in which you can continuously monitor your hearts performance in Realtime. 'Voice & text prompts' guide the user to easily operate this device IEC 60601-1-2:2014, International standard Patient Safety: Compliance-tested & certified by NABL-approved lab of Govt. of India. The internal electronic system of this device complies with ISO 13485 protocol International Standard for Quality Management of Medical Devices Clinically investigated device. Small battery-powered device. Gold-plated 6-pin AAMI connector provided for improved signal quality. World's best-in-class semiconductor chips used.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

The complete product has been developed and thoroughly tested.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

At first India, then rest of the world.

Title/Name of the Product/Technology

Artificial Intelligence-Powered & Pure Silver Touchpad-Based Heart Monitor & ECG Electrocardiography Device

Product Positioning

Our product Rhythm ECG received good feedback from initial users regarding its build-quality & advanced features. It's expected to revolutionize the scenario of modern cardiac healthcare.

National/Societal Relevance


Rhythm ECG helps detect cardiac diseases early while sitting at home. It will save many lives in India and abroad.

Import Substitution

Currently most of the modern & advanced medical devices are imported in India from abroad. Our entire technology stack has been developed indigenously from scratch as a tribute to govt. of India's Make in India initiative. It will help reduce our country's electronics import bill.

Export Potential

This medical device has been developed for massive usage by people across the world. It will increase our country's export & US Dollar-reserve.





Name of Startup: D2R Global Consulting

AMAC

Founder and Co-founder(s):
Ms Seethalakshmi
(Founder)

Developed Under (scheme):
SEED Fund

Email:
info@d2rgc.com

Product/Technology differentiation from Competitors

We want launch our product named AMAC-Ask Me Anything on Compliance. AMAC is a rolling subscription service for Startups in Healthcare and MedTech space whereby our team of expert consultants will help you solve your day-to-day queries on Regulatory, Quality, Clinical, Product Development and Statutory Compliance on the Go. This program ensure start-ups are able to launch their products and services as per national and global expectations. AMAC is an agile and cost-effective way of having our consultants in your pocket. AMAC covers all the phases from R&D to Go-To-Market and it is only Rs.36K+ GST per annum

Brief Description of Product

D2R Global is a boutique consulting for biotech and medtech/health tech start-ups assisting in a New Product Development b. Quality Management System Implementation c. Regulatory Approvals d Clinical Studies e Setting up new facility f Digital Health and Information Security g Indian Market Entry Assistance

Technology readiness level (TRL) TRL- 1

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India and Rest of the World ROW

Title/Name of the Product/Technology

D2R Global is a boutique consulting for biotech and medtech/health tech start-ups assisting in a New Product Development b. Quality Management System Implementation c Regulatory Approvals d. Clinical Studies e Setting up new facility f Digital Health and Information Security g Indian Market Entry Assistance

Product Positioning

Positioned for all the health tech, medtech, biotech start-ups

National/Societal Relevance

Consulting charges for Health/MedTech/ Biotech startups always adds cost burden so we want to solve that problem, hence planning to launch this Consultant in a Pocket formally named as AMAC-Ask Me Anything on Compliance. This program will benefit the early stage startups in India to make them aware of the national and international regulations while their developing their devices, diagnostics, digital health products

Name of Startup: DEEPFACTS PRIVATE LIMITED

proRITHM

Founder and Co-founder(s):
Vamsi Karatam
Varun Chintha

Email:
ceo@deepfacts.io

Product/Technology differentiation from Competitors

A wireless medical device designed to monitor all five key vitals remotely, ensuring real-time tracking even when the patient is on the move. It offers ease of use, making it accessible for patients of all backgrounds. With robust data retention capabilities, the device preserves real-time patient information for continuous, uninterrupted care. Seamless monitoring is guaranteed, empowering healthcare professionals with timely, actionable insights for informed decision-making, ultimately enhancing patient outcomes.

Brief Description of Product

The proRithm IR platform features RPM proRITHM devices designed to monitor Heart Rate, Cuffless Blood Pressure, Skin Temperature, Respiratory Rate, Oxygen Saturation, and Heart Rate Variability. With ongoing additions of new devices and integrations, its capabilities continue to expand, enhancing patient care even further.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

We have received MD13 from CDSCO and are currently conducting trials across several hospitals.

Are you willing to Transfer/Out-License your Technology Yes

Availability for showcasing at Birac Yes

Title/Name of the Product/Technology

proRITHM - Smart Remote Patient Monitoring

Product Positioning

Specifically tailored for non-ICU settings such as high-dependency units HDUs, step-down ICUs, VIP rooms, and infection wards. It is designed to provide continuous monitoring and early detection of health changes in these environments, enhancing patient care beyond

National/Societal Relevance

proRithm holds national and societal relevance by helping reduce the governments burden in managing non-communicable diseases NCDs in rural areas through effective Remote Patient Monitoring, enabling better access to healthcare and improved disease management.

Import Substitution


Import substitution for the proRithm devices electronic components is currently not feasible, as we import all electronics from the US. However, the fabrication and assembly of the electronic PCB boards are done in India, while other components like the plastic enclosure and battery are sourced from Indian manufacturers.

Export Potential

Yes, we have the capability to export our product to various markets. Our planned production capacity is approximately 10,000 units per month, with the potential to scale up to 50,000 units per month.

IP Status

Patent Application Number:
202241065163 Patent Application
Number: 202441031630



Name of Startup: Define Bio Pvt. Ltd.



Founder and Co-founder(s):
A Joint Venture with Bio Valley Incubation Council, BIRAC BioNEXY Incubation arm of Andhra Pradesh MedTech Zone

Developed Under (scheme): SEED Fund

Email:
info@definebio.in

Product/Technology differentiation from Competitors

Define Bio Pvt. Ltd is committed for ethical and efficient collection, storage, management and distribution of biological samples such as blood, tissues, etc.. Define Bio P Ltd. aligns with the Make in India initiative by promoting research, manufacturing, and innovation in the field of In vitro diagnostics. This will contribute to the self-reliance and growth of the Indian healthcare sector

Brief Description of Product

Performance Panels Characterized biological panels designed to assess the accuracy and reliability of diagnostic kits across a wide range of diseases and conditions, including HIV Syphilis Sickle cell TSH Cancer Marker HCV Dengue Haemophilia T3 Cardiac Markers HBsAg Malaria Thalassemia T4 Umbilical Cord Derivatives Advanced solutions utilizing components from the umbilical cord, such as Whartons Jelly, Human Collagen, Lyophilized Plasma and PDRN, for various applications, including tissue repair and anti-aging treatments. Potential applications include joint and cartilage repair, wound healing, and cosmetic procedures PBMC & iPSC's High-quality Peripheral Blood Mononuclear Cells PBMCs and induced Pluripotent Stem Cells iPSCs to support cutting-edge research in immunotherapy, personalized treatment, development of cancer vaccines FFPE Panels Comprehensive Formalin-Fixed Paraffin-Embedded FFPE tissue panels, essential for cancer research and diagnostic advancements

Technology readiness level(TRL) TRL- 8

Current Stage of Development

Performance Panel Developed Working on PBMC Umbilical Cord Derivatives, Market Analysis in progress

Product Launched / About to be Launched Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac No

Product/Technology

Performance Panels Characterized biological panels designed to assess the accuracy and reliability of diagnostic kits across a wide range of diseases and conditions, Umbilical Cord Derivatives Advanced solutions utilizing components from the umbilical cord, such as Whartons Jelly, Human Collagen, Lyophilized Plasma and PDRN, for various applications, including tissue repair

Unique Selling Point

By fostering partnerships with IVD manufacturers, we aim to develop superior quality diagnostic kits and reagents, The Performance Panels are Characterized using various diagnostic tests and the technical data / values are provided along with panels

Present Stage of Development

Performance Panel Developed Working on PBMC Umbilical Cord Derivatives, Market Analysis in progress

Geographical Region Targeted

PAN India

Major Achievements

Successfully developed product under Make in India initiative

Title/Name of the Product/Technology

Performance Panel Umbilical Cord Derivatives PBMC FFPE Panel

Product Positioning

IVD Manufacturers, Research Institutes, Labs, Institutes Cosmetic, Ophthalmology, Bone and cartilage Therapy Personalized medicine, Therapeutics

National/Societal Relevance

By fostering partnerships with IVD manufacturers, we aim to develop superior quality diagnostic kits and reagents, Import substitution Cost reduction Personalized medicine, Therapeutics

Import Substitution

Yes, Currently there is no Bio Bank in India which provides diseased panel / biological samples for development of IVD kits and reagents Define Bio P Ltd. aligns with the Make in India initiative by promoting research, manufacturing, and innovation in the field of In vitro diagnostics. This will contribute

Export Potential

Yes, Collaboration with WHO, Research institutes, Labs, manufacturer, Clinician, cosmetologists etc.. for product distribution



Name of Startup: Denovo Bioinnovations Private Limited



Founder and Co-founder(s):
Dr Nikhil Mamoria, MBBS

Developed Under (scheme): BIG, LEAP Fund

Email:
dr.nikhilmamoria@denovobiinnovations.com

Product/Technology differentiation from Competitors

Key Differentiators: 1 Innovatively designed Smart Stitch technology, patented pre-loaded suture cartridge adaptable to all kinds of absorbable and non-absorbable sutures. Proprietary suture needle and needle driving mechanism. 2 Ergonomically designed handle resulting in decreased efforts and increased access protected by 8 registered designs. 3 Lapsure comes with 6 degrees of freedom making movements intuitive. 4 Smart Stitch technology can be adapted to all kinds of surgical procedures including surgical robotics. 5 Fully autoclavable and reusable devices reducing the cost per use significantly.

Brief Description of Product

Our product LapSure is a hand-held robotic device. Suture Sure is a multifunctional device that combines the advantages of a needle holder and grasper into a single instrument with the feature of automated needle driving. Surgeons can perform suturing with just 1 click using our novel needle driving mechanism. The articulation mechanism on the handle is designed to compensate for the limitations of surgeons and aid in dexterity enhancement by 6 degrees of freedom, manipulation, and precise needle localization & orientation. Surgeons get wrist-like freedom inside the body, to reach complex locations ergonomically just like the surgical robots, enabling them to perform complex surgeries minimally invasively. It will significantly reduce the suturing time up to 70 and increase the accuracy of suturing up to 80 resulting in decreased anesthesia used, early recovery, and reduced hospital stay.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

We have successfully patented and developed the functional prototype of the device in metal and have achieved TRL4 stage. We are currently working towards preclinical studies and aim to launch our product in early 2026

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, USA, Europe, Japan, China, Singapore



Title/Name of the Product/Technology

Revolutionizing Wound Closure – Making Suturing Easier, Faster & Safer

Product Positioning

A complimentary solution to the high cost, large footprint robotic surgery and superior to traditional laparoscopy and open surgery -addressing most of the market.

National/Societal Relevance

Currently, In India, there is no alternative present for imported quality surgical instruments. Most of the surgeons use imported basic laparoscopic needle holders and graspers. With the launch of Suture Sure in the market, surgeons will get premium quality and advanced laparoscopic instruments. Suture Sure will have a high impact on society. With the Induction of Suture Sure, the greater number of open surgeries will be converted to laparoscopic surgeries & surgeries will be completed precisely in less time and with less anesthesia. We will be able to train more surgeons in less time, making more surgeons trained and capable of MIS.

Import Substitution

Currently, most of the advanced laparoscopic instruments are imported in India

Export Potential

With our patented technology, Denovo aims to be strong contender to capture global automated suturing market

IP Status

Denovo's strong IP portfolio of 18 intellectual properties which includes 2 granted patents and 8 registered designs, protects our novel needle-driving mechanism and outperforms all the competitors in the market.



Name of Startup: DessinRx Healthcare Private Limited

Founder and Co-founder(s):
Dr. Rohith Gorrepati
Dr. Devyani Singhi

Developed Under (scheme):
BIG

Email:
dessinrx@gmail.com

Product/Technology differentiation from Competitors

A unique self-retaining, malleable design that offers uniform yet variable dynamic traction throughout the length of the skin flap. This ensures consistent vertical traction and supports various sizes and shapes of the breast without compromising the surgeons operating space. Additionally, the automated dynamic traction provided by the smart retraction coil in the Alpha version sets it apart by enhancing surgical efficiency and reducing complications. These features, combined with its adaptability and ease of use, make the M-Arc retraction system an effective solution for modern surgical procedures?

Brief Description of Product

An innovative surgical tool designed to enhance the precision and safety of surgical procedures, specifically in the context of mastectomy and other complex surgeries. The M-ARC system features a self-retaining, malleable arm that can adapt to various shapes and sizes, providing uniform traction across the surgical site. This reduces the need for additional surgical assistants, minimizes complications such as skin flap necrosis, and improves overall surgical outcomes by offering better control and visualization during procedures.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

The Malleable Arc Retraction system is currently at the minimum viable product stage. The initial prototype has been developed and validated using a mannequin, with subsequent collaboration for clinical validation and trials with various hospitals such as AIIMS, JIPMER, and NIMS. The development plan includes further iterations, prototyping, and clinical validation before moving towards market deployment?

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

M-Arc targeting for domestic and international markets. The primary geographical focus will be on major Indian metropolitan areas such as Delhi, Mumbai, Chennai, Bangalore, Kolkata, and Hyderabad. The secondary includes Tier 2 and 3 cities within India. In terms of global expansion, plans to target the UK, US and Southeast Asia.

Product Positioning

This innovation aims to patient outcomes by reducing postoperative complications, improving surgical precision, and shortening recovery times. Surgeons benefit from better operating space and reduced procedural complexity, while hospitals see improved doctor-patient ratios and cost-effective surgical processes.

National/Societal Relevance

Breast cancer is a significant health issue in India, with rising incidences necessitating improved treatment protocols. M-arc system for mastectomies aim to reduce complications, enhance surgical outcomes, and support better post-operative recovery, addressing a crucial need in breast cancer management?

Import Substitution

This would replace the traditional manual retractors available in the hospitals for the surgical space.

Export Potential

Its adaptability to various breast sizes and shapes makes it a valuable tool for international healthcare providers, ensuring broader access to advanced surgical care.

IP Status

Title: Skin Flap Retraction Device Indian Patent Application No. 202241021395 dated 10/04/2022.

Name of Startup: Dfine Bioinnovations Pvt Ltd



Founder and Co-founder(s):
Aifer Shariff (CEO), Divya Acharya (CMD)
Lokesh M (CTO), Prathap (Director Sales)

Developed Under (scheme): OTHERS

Email:
ceo@dfinebio.in

Product/Technology differentiation from Competitors

Our FibrTimer Zeta-1 stands apart from competitors through its patented dual technology, combining optical and mechanical methods for precise test verification, especially for critical samples. Unlike imported coagulation analyzers, it is cost-effective, being 25-30 cheaper, making it ideal for small to mid-size labs. Additionally, its indigenous design supports the Make in India initiative. The device also includes small reagent packs, reducing wastage and operational costs, and a built-in power backup, ensuring uninterrupted operation even in areas with unreliable electricity. This holistic solution provides better affordability, efficiency, and reliability compared to existing imported alternatives.

Brief Description of Product

The **FibrTimer Zeta-1** is India's first indigenous semi-automated coagulation analyzer, specifically designed to address the needs of small to mid-size labs. It provides cost-effective, accurate, and efficient diagnostic solutions, reducing dependency on expensive imported devices. The FibrTimer Zeta-1 features patented dual technology, combining optical and mechanical methods to enhance test accuracy and verification, especially for critical or difficult samples. This cutting-edge device is user-friendly, with a capacitive touchscreen and a simple interface, making it ideal for lab technicians of varying expertise levels. One of its unique features is a built-in power backup, ensuring uninterrupted operation in areas prone to power outages, a critical advantage for labs in rural and underserved areas. The device is designed to perform essential coagulation tests like PT, APTT, Fibrinogen, Lupus, and D-dimer, ensuring timely diagnosis for patients with bleeding disorders, particularly in surgical settings. FibrTimer Zeta-1 offers smaller, affordable packs of consumables, reducing reagent wastage and operational costs for labs that deal with lower patient volumes. By empowering labs with an economical, efficient, and reliable coagulation solution, the FibrTimer Zeta-1 ensures labs can provide in-house testing, eliminating outsourcing delays, and improving patient outcomes. Its development supports India's Make in India initiative, fostering local innovation and employment.

Technology readiness level(TRL) TRL- 6

Current Stage of Development

We are upgrading our device with a consumable counterfeit detection feature and implementing customer feedback to enhance the systems overall performance

Product Launched / About to be Launched Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

FibrTimer Zeta-1 is India's first indigenous semi-automated coagulation analyzer, designed specifically for small to mid-size labs. It features patented dual technology, combining optical and mechanical methods to ensure fast, accurate, and reliable diagnostic results, particularly for critical samples.

Unique Selling Point

1 FibrTimer Zeta-1 features patented dual technology, offering fast, accurate results for critical samples. 2 Its India's first indigenous semi-automated coagulation analyzer, designed to be 25-30 more affordable than imported alternatives. 3 It comes with small consumables packs which help small to mid size labs to optimise lab operational cost.

Present Stage of Development

We are upgrading our device with a consumable counterfeit detection feature and implementing customer feedback to enhance the systems overall performance

Geographical Region Targeted

India and Indian subcontinent.

Major Achievements

Dfine Bioinnovations has achieved significant milestones, including winning the prestigious Emerging SMB award at the Times ET-it4SMB Lenovo Business Awards 2023 and being recognized as an

Other Scheme Name Self

Title/Name of the Product/Technology

FibrTimer Zeta-1:- An India's first indigenous semi-automated coagulation analyzer.

Product Positioning

FibrTimer Zeta-1 is designed for small to mid size labs specially present in tier 2 & Tier 3 cities and rural labs/hospitals.

National/Societal Relevance

FibrTimer Zeta-1 addresses a critical national need by reducing India's reliance on costly imported medical devices, particularly coagulation analyzers, which are vital for surgeries and managing bleeding disorders. With over 80 of medical devices imported, small to mid-size labs in rural and underserved areas struggle with high costs and delays in patient treatment. By developing an indigenous, cost-effective solution, we are improving healthcare accessibility, reducing diagnostic delays, and supporting the Make in India initiative, fostering local employment, and enhancing the overall healthcare infrastructure in the country.

Import Substitution

FibrTimer Zeta-1 serves as a key import substitution for coagulation analyzers, which are largely imported into India. By offering an indigenous, cost-effective alternative, we reduce dependency on expensive foreign devices, lower healthcare costs for small to mid-size labs, and promote local manufacturing under the Make in India initiative.

Export Potential

FibrTimer Zeta-1 holds strong export potential, particularly in emerging markets across Asia, Africa, and South America, where affordable and efficient diagnostic solutions are in high demand.

IP Status

Indian Patent Granted



Name of Startup: DGRakshak Private Limited



Founder and Co-founder(s):
Dr Deepika Singh (Founder)
Dr Gaurav Singh (Co-founder)

Developed Under
(scheme):
SEED Fund

Email:
gauravsingh18091977@
gmail.com

Product/Technology differentiation from Competitors

Non-invasive Radiation-free Portable Low-cost Real-time or fast computation First-of-its-kind battery-based sensor to be placed guided by thermal image Highly sensitive sensor for breast with penetration depth in breast 2-10 mm Unique subscription based model for affordability and mass outreach Affordable Data management solution through mobile application Good performance in low-frequency range and noise Suitable for diagnostic centers/health centers in rural areas and Tier 2 and Tier 3 cities with limited medical facilities Multistep data security Patient breast health Follow up Multi-modal classification for sensor data value-based , thermal image-based data features , and patient's medical history-based data text-based

Brief Description of Product

The device with integrated mobile application works on the principal of multi-modal identification of breast abnormalities-thermal imaging based, optical spectroscopy based and medical history based.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

Testing and validation of prototype through preclinical trials post-ethical clearance in MLN Medical College, Prayagraj and Kirti Diagnostic Centre, Prayagraj Ethical clearance in process in King George Medical University KGMU, Lucknow, Uttar Pradesh

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Phase 1- Prayagraj Phase 2- Lucknow and Kanpur Phase 3- Across Uttar Pradesh Phase 4- Across India Phase 5- Low- and Middle-income countries across the globe

Product/Technology

The device with integrated mobile application works on the principal of multi-modal identification of breast abnormalities-thermal imaging based, optical spectroscopy based and medical history based.

Unique Selling Point

Low-cost Customized mobile app in multiple languages for follow-up Easy-to-use Portable Can be integrated with Ayushman Bharat Digital Mission Unique business model

Present Stage of Development

Pre-clinical testing of prototype



Title/Name of the Product/Technology

Low cost, portable, radiation-free and non-invasive breast health monitoring device to be used by minimally trained person, especially in places with limited medical facilities

Product Positioning

Routine breast health monitoring device to be used at pathology center's, physicians, gynecologists, primary health centers and community health centres.

National/Societal Relevance

Mortality due to Breast cancer in India GLOBOCAN 2022 -98337 • In India, less than 5 of women breasts screened per year due to poor medical infrastructure • 75 female population with breast cancer is asymptomatic around 1.5 Lakh for 2022 • Lack of easy-to-use device for routine screening • Lack of user-friendly interactive mobile app for routine breast cancer screening • The lack of quality control measures in mammography Gold standard centers • Delay in report generation in Tier 2 & Tier 3 cities in India • Non-portable

Export Potential

Export to Low- and Middle-income countries across the globe through WHO

IP Status

Provisional patent Application No- 202411033706 Ref.No.-E-45/12364/2024/ DEL

Name of Startup: DiaSys Diagnostics India Pvt. Ltd



Founder and Co-founder(s):
Vijaywanth Mathur
(CTO & Director)

Email:
vijaywanth.mathur@diasys.in

Product/Technology differentiation from Competitors

QDx InstaLab incorporates a Patented Electrochemical Biosensor / Immunosensor Platform Technology based single or multiplexed cartridge that can do common diagnostic tests in an inexpensive format. The QDx InstaLab cartridge has an on-board plasma separation with an in-built QC and thus this assures the integrity and reliability of the sample measurement. QDx InstaLab is a world's first device that can do clinical biochemistry and immunoassays and hence there is no competition to this device. However, individual, maintenance- intensive, expensive biochemistry and immunoassay analyzers are the closest competition but there is NO ALL- IN-ONE Device in the market so far.

Brief Description of Product

Background: Point-of-care testing for common clinical diagnostics tests immunoassays, clinical biochemistry, electrolytes require multiple dedicated instruments that are often unreliable, expensive and need frequent maintenance. It is not possible for small labs, clinics, remote health-care screening centers in 2nd tier/3rd tier and rural areas in developing countries to afford the instrument infrastructure needed to provide healthcare diagnostics. In order to provide healthcare diagnostics to ALL at affordable costs, there is a need for a device that can do all common diagnostic tests reliably and is cost effective device and consumable cost. We have developed the world's first electrochemical biosensor/immunosensor lab-on-cartridge platform technology-based portable point-of-care device QDx InstaLab for quantitative measurement of all common diagnostics tests typically used in lab. QDx InstaLab incorporates an innovative, high performance, inexpensive microfluidic cartridge for rapid quantitative measurement of diagnostic tests in whole blood /plasma/serum samples. Our proposed methodology utilizes patented on-board plasma separation and a novel, patented plastic electrochemical biosensor /immunosensor that uses chronoamperometry / differential pulse voltammetry technique to provide a sensitive and accurate result in ~1-3 min for clinical biochemistry tests and in ~10 min for immunoassays. The device is portable, simple, easy-to-use and reliable as the measurements are carried out at a constant temperature of 37 C. The QDx InstaLab can perform a single test or multiplexed tests from a fingerprint with 5-10 microliters of whole blood sample per parameter. Further the cartridge is barcoded, and the kit of cartridges has an RFID label to differentiate between different tests and to keep a tab on the shelf-life parameters. The QDx InstaLab has a 2.8-inch Touch screen with a 1- inch printer. Method: We have done preliminary evaluation of the QDx InstaLab using patient samples for linearity, precision and cartridge stability for the clinical biochemistry profiles such as metabolite profile glucose, lactate, kidney profile urea, creatinine, diabetic profile HbA1c, Hb, lipid profile total cholesterol, triglycerides, liver profile ALT, AST. Accelerated stability testing was done at 2-8 C and at 45 C for 2 weeks for the assays during which linearity samples were run on 0, 4, 7, 14 days respectively. Results: Preliminary data analysis indicates that the biochemistry assays have a CV = 5, with R2 0.95 and a shelf-life of 9 months at 2-8 C storage temperature based on preliminary extrapolated data. Conclusion: The QDx InstaLab has the potential to revolutionize healthcare diagnostics in rural areas in the developing countries.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

QDx InstaLab is world's first Patented device that can do ALL common biochemistry and immunoassay diagnostics tests in one electrochemical biosensor/immunosensor Platform Technology based Single / Multiplexed Cartridges. Hence, the development required to commercialize such a device is very challenging to say the least. We have shown the feasibility of the technology with on-board plasma separation of the device and cartridge concept. The next step is to take it forward for a detailed development and optimization phase before the scale-up and validations.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Developing countries in Asia, Africa and South America.

Title/Name of the Product/Technology

QDx InstaLab

Product Positioning

2nd tier/ 3rd tier cities, rural areas, remote health-care screening community centers, small labs, doctor's offices in developing countries.

National/Societal Relevance

QDx InstaLab has the potential to revolutionize, Improve and provide Quality Healthcare to ALL. It will also be a Make-in-India initiative.

Import Substitution

All the individual point-of-care biochemistry and immunoassay analyzers in the market.

Export Potential

QDx InstaLab has the export potential to Africa, South America continents and to other Asian Countries as well.

IP Status

1.WO/2016/030710 2. WO/2016/030711 3. WO/2015/198097 4.8308/DELNP/2014ES 5. Indian Patent 407866 6. Indian Patent 359423 7. Indian Patent 403247



Name of Startup: Digibooks link4solution Private Limited



Founder and Co-founder(s):
Anil Chadda

Thematic Area: Healthcare-
Devices & Diagnostics

Email:
contact@link4solution.com

Product/Technology differentiation from Competitors

Presently there are the companies who are providing the cloud accounting to the service receivers, but we are one step further to provide the virtual accounting to SME

Brief Description of Product

Virtual accounting solution is for small and medium enterprises developed by the company based on last 40 years of experience in the industry and business enterprises. Considering the need of the business, every company has to maintain the books of accounts. The need-based accounting requires the skilled persons with knowledge about the business model. In addition to this the timely preparation as well as submission of information is of utmost requirements. Since the technology is changing very fast and every business require the info on 24x7 basis in the secured environment. All these requirements are fitted into the solution offered by the company as virtual accounting. There are mid-sized companies who requires the CFO Chief financial officer services but either they do not have the jobs made available to CFO for engaging them on full time basis or could not afford to pay depending upon the financial setup and needs. Here the company offer Virtual CFO services to meet the requirements of mid-sized company without any barriers to the geographical constraints.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

The company has already in the business since 2022 and providing the services to over 100 SME. The systems developed by the company have been successfully implemented and applied to the running organizations and we are getting the good testimonials from the companies who are availing these services.

IP Status

Not required, However the company has duly registered its trade mark

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

All over India



Title/Name of the Product/Technology

Virtual Accounting and CFO services

Product Positioning

Presenting available

National/Societal Relevance

Ready to use

Export Potential

In future there is a lot of potential after stabilizing the domestic technology

Name of Startup: Dr.Omics Labs Private Limited



Founder and Co-founder(s):
Deepshikha Satish, PhD (Founder)
Dr. Hardeep Behnwal (Co-founder)

Email:
deepshikhasatish@dromicslabs.com

Product/Technology differentiation from Competitors

Dr. Omics Labs differentiates itself from competitors through a research-driven approach, continuous innovation, and comprehensive healthcare solutions. Unlike others who position diagnostics as luxury products, Dr. Omics Labs prioritizes accessibility and utility for all, especially the needy. By integrating all stakeholders—patients, healthcare providers, and researchers—on a single platform, the lab ensures a holistic cycle of care from diagnosis to treatment. This approach goes beyond merely providing information it fosters collaboration and actionable insights. Dr. Omics Labs is leading the change by promoting preventive and personalized healthcare, raising awareness among practitioners and the public, and driving a healthcare revolution.

Brief Description of Product

1. DNA Wellness Tests offer a personalized approach to health and well-being by leveraging the power of DNA analysis. Our microarray-based tests provide valuable insights into an individual's genetic predisposition to various health conditions and lifestyle factors. Our range of DNA Wellness Tests includes: Healthy Genie: This test focuses on overall health and well-being, providing insights into genetic factors that may influence metabolism, immune function, and other essential aspects of health. Fit Genie: Designed for individuals seeking to optimize their fitness journey, Fit Genie assesses genetic factors related to muscle development, exercise response, and weight management. Sporty Genie: Tailored to athletes and sports enthusiasts, Sporty Genie identifies genetic variations that may impact athletic performance, injury risk, and recovery. Little Genie: This test is specifically designed for children, providing insights into their genetic predisposition to various health conditions and developmental factors. In addition to these comprehensive DNA Wellness Tests, we also offer: 2. Trichogenie: A microarray-based test for predicting the risk of hair diseases, helping individuals take proactive steps to maintain healthy hair. 3. Microarray-based tests for diabetes and heart disease risk prediction: These tests provide valuable information for individuals at risk of these chronic conditions, allowing them to make informed lifestyle choices and seek early intervention. 4. Whole exome sequencing-based Pharmacogenomics tests: These advanced tests analyze the entire protein-coding region of the genome to provide precision medicine suggestions for various diseases. By understanding an individual's genetic response to different medications, these tests can help optimize treatment plans and minimize adverse drug reactions. The benefits of DNA Wellness Tests include: Personalized Health Insights: DNA Wellness Tests provide individuals with a deeper understanding of their genetic makeup and how it influences their health and well-being. Proactive Health Management: By identifying potential risks early on, individuals can take proactive steps to manage their health and prevent disease progression. Tailored Lifestyle Recommendations: Based on the genetic information obtained from the tests, individuals can receive personalized recommendations for diet, exercise, and lifestyle choices. Precision Medicine: DNA Wellness Tests contribute to the growing field of precision medicine, enabling tailored healthcare approaches based on an individual's genetic profile. By leveraging the power of DNA analysis, our DNA Wellness Tests offer a valuable tool for individuals seeking to optimize their health and well-being. Whether you are interested in improving your overall health, enhancing athletic performance, or understanding your child's developmental needs, our tests provide personalized insights and actionable recommendations.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

The technology has been demonstrated in an operational environment. This means the technology has been successfully tested and proven to work in real-world conditions, in a pilot project.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Tier 1 cities of India.

Title/Name of the Product/Technology

DNA tests

Product Positioning

DNA Tests are positioned as a comprehensive and personalized genetic health assessment tool. By offering extensive SNP coverage and identifying risks for a wide range of diseases, these tests empower individuals to make informed decisions about their health, preventative measures, and lifestyle choices.

National/Societal Relevance

Dr. Omics Labs' preventive molecular diagnostics services, powered by advanced bioinformatics, play a crucial role in early disease detection and personalized healthcare, thereby reducing healthcare costs and the overall disease burden in India. The lab's initiatives align with national healthcare goals by fostering innovation, empowering local talent, and tackling critical health challenges with precision diagnostics. Aimed at reducing uncertainties, fear, and pain in people's lives, Dr. Omics Labs strives to build a healthier and happier society. The lab contributes to a transformative impact on public health and national well-being by promoting awareness, knowledge, and conscious lifestyle changes.

Import Substitution

Dr. Omics Labs has effectively substituted imports by developing indigenous molecular diagnostics and bioinformatics solutions that meet global standards. By leveraging local expertise and cutting-edge technology, the lab provides advanced diagnostic services that were previously sourced from abroad. This reduces dependency on imported diagnostic tools, and lowers costs.

Export Potential

Dr. Omics Labs' services have immense export potential, offering advanced molecular diagnostics and bioinformatics solutions that cater to the global shift toward personalized healthcare and precision medicine. These innovations can transform the healthcare and pharmaceutical markets, particularly in genetically diverse, high-income regions like Europe and America.



Name of Startup: DXBIDT ENZYMES



Founder and Co-founder(s):
Vikrama N Prabhu Umesh T.G.

Developed Under(scheme):
BIG

Email:
vikram@rubizon.com

Product/Technology differentiation from Competitors

Most affordable - Novel formulation for room temperature shipments -- Novel formulation as mastermixes for customer ease.

Brief Description of Product

DX/DT is India's new destination for enzymes and mastermixes catering to the need of research and molecular diagnostics. We are one of the most affordable enzyme makers in the world and we have ISO 9001:2015 certified facility.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Our products are already in the market for more than 2 years now and scientists across the world just trust us for the quality and performance: www.dxbidt.com/testimonials

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

All India. Just recently started exporting our products to Europe as well.



Title/Name of the Product/Technology

Enzymes and kits for molecular biology applications

Product Positioning

Fast delivery Highly economical Global quality standards Made in India

National/Societal Relevance

Skill development to students/ individuals - Job opportunity to freshers
- Point of care diagnostic kits for easy deployment

Import Substitution

Yes, we make all the enzymes and master mixes, in our ISO certified facility.

Export Potential

YES. Since our quality meets global demand, outside India also we started getting queries

Name of Startup: ELEVATRONIX PRIVATE LIMITED



Dr. Shahshi Kumar Co-founder,
Partha Sarathi Mallick Co-founder

Email:
info@elevatronix.in

Product/Technology differentiation from Competitors

1. Prodent USA is a dental equipment manufacturer based in East Brunswick, United states. They produce different shapes of sharp spade tips to loosen the teeth from the gums for ease of manual extraction and prevent trauma to surrounding teeth and tissue. 2. Osseotouch is a dental equipment manufacturer based in Turbigo, Italy. They produce powered and controlled magnetic mallets for easy oral surgery based on Magnetic Dynamic Technology.

Brief Description of Product

The device's cutting-edge technology ensures design features that minimize discomfort and pain for the patient during the extraction process. Incorporated simple mechanisms within the existing elevators that provide unprecedented precision and control over the tooth extraction process. The requirement of extensive external force of greater magnitude by dentists during the extraction process is now eliminated by a to-and-fro motion of the tooltip that can cut the alveolar bone with adjustable frequency and amplitude as per cutting depth required in a single stroke. The high frequency of the tooltip cuts a small section of the alveolar bone through pericementum with minimal force which is almost one-tenth of the cutting force magnitude exerted by a dentist with manual elevator during extraction.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

The prototype of the device was developed. High-quality and biocompatible materials were selected to ensure the safety and durability of the prototype. In the present invention the tool tip is attached to the device by mechanical coupling. The powered dental elevator underwent a series of performance tests to assess its ability to efficiently extract teeth. Testing included hitting hard artificial teeth and soft object. Dental professionals participated in usability testing to evaluate the prototype's ergonomic design, ease of use, and overall user experience. Feedback from dentist played a crucial role in refining the device's interface.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

PAN INDIA



Title/Name of the Product/Technology

Powered Dental Elevator

Product Positioning

Position the powered dental elevator as a tool that offers superior precision and efficiency, reducing the time and effort required for extractions and minimizing patient discomfort. If the powered dental elevator includes unique features these should be prominently featured in the positioning strategy to set the product apart from competitors.

National/Societal Relevance

1. Powered dental elevators play a crucial role in dental surgeries, particularly in tooth extractions. They enable precise, efficient, and less traumatic procedures, which contribute to better overall oral health outcomes. 2. In many regions, especially rural or underserved areas, access to advanced dental care is limited. Powered dental elevators can facilitate more efficient and effective dental procedures. 3. The development and production of powered dental elevators can spur technological advancement within the country. This includes innovations in materials, design, and manufacturing processes that can have applications beyond dental care.

Import Substitution

1. Support the development of prototypes and pilot projects to test the feasibility of local production and identify any potential challenges 2. Encourage investment in R&D to develop innovative designs that can compete with imported products. This may include partnerships between universities, research institutions, and private companies.

Export Potential

1. With an aging global population, the demand for dental care, including advanced surgical procedures that require tools like automated dental elevators, is increasing. 2. Countries with developing healthcare systems are potential markets as they modernize and expand their dental care capabilities.



Name of Startup: ENVISAGE MEDTECH PRIVATE LIMITED



Founder and Co-founder(s):
Pijush Giri (Founder)
Devendra Verma (Co-founder)

Developed Under(scheme):
BIG

Email:
mepijushgirifirm@gmail.com

Product/Technology differentiation from Competitors

There are few products available in the market for the same application. Interceed and Seprafilm are two FDA-approved anti-adhesive devices. Interceed is effective only in the absence of blood contamination and Seprafilm has low mechanical properties, is brittle and difficult to handle. The success rate of the two is 48 and 50. The price of ALBOGEL would be at least 10 times less than Betamix. Anti-inflammation is a unique property of our product which is not available in any the market available products so far.

Brief Description of Product

Post-operative adhesions are formed between tissues with the other tissues or organs because of the injury or cut made by the medical procedure to the patients. The adhesions not only cause body complications but also increase therapeutic costs. The post-surgical adhesion causes pain to the patient and secondary surgery becomes hectic for the doctors as they have to remove the mesh first. ENVISAGE has built up a hydrogel to prevent post-surgical adhesions. With time the surgical wounds heal and the hydrogel degrades reducing the possibilities of any post-toxic effects

Technology readiness level (TRL) TRL- 4

Current Stage of Development

We have completed pre-clinical studies. Now, a trial in a large pre-clinical study is underway and a pivotal trial in Laparoscopy is planned.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India

Title/Name of the Product/Technology

Highly Biocompatible and injectable hydrogel for the prevention of post-surgical adhesions

Product Positioning

1. Biocompatible and biodegradable 2. Made of materials known to be safe for a long time 3. Anti-adhesive to cells and hence will prevent migration cell, which can form adhesions 4. Easy to use 5. Sufficient gelling time 6. Long self-life 7. Anti-inflammation 8. Self-healing properties 9. Injectable and sprayable

National/Societal Relevance

The incidence of adhesions following surgery is very high some estimate an incidence as high as 80. The prevention of adhesions has the potential to save the healthcare market billions of dollars and improve the lives of hundreds of thousands of patients.

IP Status

1. Patent Number: 202131036067
Title of Patent: INJECTABLE HYDROGEL FOR PREVENTION OF POSTSURGICAL ADHESIONS 2. Patent Number: 202131050171 Title of Patent: A HYDROGEL COMPOSITION AND IMPLEMENTATIONS THEREOF

Name of Startup: European Life Technologies



Előd Orbán, Lajos Haracska,
Lajos Pintér

Email:
lajos.pinter@eurolifetech.com

Product/Technology differentiation from Competitors

The product/service provides end to end solution from sample processing through bioinformatic analysis in a professional software environment in a cost effective manner

Brief Description of Product

The Breast Way is a unique complex oncology solution on the market that includes key genetic tests for breast cancer patient pathway. Breast Way with 4 pillars provide complex genetic support for the most effective anti-tumour treatment, which is supported by a strong bioinformatics knowledge base that enables more accurate and reliable interpretation of genetic data than ever before. It contains testing of the inherited genetic risk factors of breast cancer, the tumor tissue genetic testing for more accurate diagnosis and precise targeted therapy, a gene expression profiling test system for breast cancer?prognosis and a liquid biopsy test for the treatment monitoring and resistance mechanism detection. Together, this information enables a clear and detailed picture of patient's health, allowing the patient and the doctor to make informed decisions about disease risk, prevention and treatment.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

The service is currently actively provided for both public and private healthcare sector

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Europe, India, Indonesia, Singapore

Title/Name of the Product/Technology

Breast Way

Product Positioning

end-to-end full service solution with optional TT

National/Societal Relevance

The need for complex cancer diagnostic solutions in India is highly significant and urgent. The country, with a population of over 1.4 billion, faces unique challenges in providing comprehensive cancer care. Many cases are diagnosed at a late stage due to a combination of factors. In India, cancer has become a major public health problem, with more than 1 million new cases diagnosed every year and around 900,000 people dying from it every year. Our aim is to boost the Indian tumour diagnostics market by providing healthcare providers, physicians and pathologists with complex solutions that enable high quality oncology services

Product/Technology

Extremely high tech solution to monitor and follow the full journey of a breast cancer patient involving both molecular diagnostic, bioinformatic and high-end software solutions



Name of Startup: EvoReality Start-up



Founder and Co-founder(s):
Veeky Baths, Kashyap Mehta,
Ashwani Kottapalli

Email:
veeky@goa.bits-pilani.ac.in

Product/Technology differentiation from Competitors

Our competitors are generally those companies which are using VR based games for cognitive rehabilitation. Most companies are focused on rehabilitation rather than assessment. Still, others in the domain of cognitive testing are either mobile based, computer based and do not take into account the naturalistic and ecological validity of the game environments. Moreover, they do not provide the detailed scores that our games provide because our scores are based on analysis of decision making by each player. This is the first of its type in India and has already shown its efficacy in capturing age-related cognitive decline.

Brief Description of Product

Our product, which is a series of goal-oriented games in VR assess cognitive abilities of players in a holistic, multi-sensory and multi-modal manner. We have 2 games in immersive VR : Navigation game and the Hand-Eye coordination game. In the navigation game, the players have to navigate an environment which contains turns, obstacles and collect rewards on the way. A separate component in the navigation game has a fly-course during which players have to collect coins suspended in the air by providing proper direction to the controllers. In the hand-eye coordination game, participants have to hit the stimuli red and blue cubes using appropriate hammers blue and red in the direction specified on the cubes. Both these games measure attention, planning, processing speed, navigation abilities, motor abilities, and visuo-spatial abilities. In addition, we have 2 tablet-based games: one on memory which has four levels for semantic and visual short-term memory test. The other game is an activity of daily living game wherein the participant has to shop for the given items and make the payment. This is an end-to-end ADL game which assesses players ability to make decision in naturalistic settings.

Technology readiness level (TRL) TRL- 7



Current Stage of Development

We have finished two pilots young cohort and old cohort demonstrating the integrated system. Based on the feedback from both the pilots, we are now creating the complete system which can be administered to the participants without any external help. At the same time, we are also working on the smart-phone based app which can sync the user data from the games and help in visualization of scores at the client side, i.e., mobile.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India and abroad



Title/Name of the Product/Technology

Cognitive Assessments based on goal-oriented games in immersive VR and Mobile/Tablet

Product Positioning

We will position our products in two ways: B2B and B2C. In B2B, we will provide geriatric care centres, NGOs, hospitals, neurological clinics and therapy hospitals with the headset and pre-loaded games. In B2C, the customers can use their own headset and download or purchase our games and play.

National/Societal Relevance

Given the rising threat of dementia in India, and the current state of neuropsychologists and health care system in India, absence of policies for dementia care, and acute lack of awareness about dementia in India, it is important to take early stride in tackling dementia. Technology-based cognitive assessments open door for more accessible, scalable, and time-efficient means for cognitive assessment as opposed to traditional neuropsychological tests.

Import Substitution

Yes definitely. We can develop our own culturally sensitive, and suitable games for cognitive assessment and do not have to rely on external companies from abroad.

Export Potential

Yes definitely. Because these games are developed initially in the English language and are technology-based, they can be very well exported to markets in the US, UK and other English Speaking nations Canada etc.

IP Status

Title: Virtual Reality Game based Assessment Method with Performance Scoring for Cognitive Assessment and Tracking. Application Number: 202411044314

Name of Startup: Femacare Pvt Ltd



Founder and Co-founder(s):
Dr. Charu Sharma

Developed Under (scheme):
SEED Fund

Email:
charu@femacare.in

Product/Technology differentiation from Competitors

Femacares products and technology difference from other competitors lies in its innovative, full-stack approach to women's health, offering personalized care through cutting-edge, hormone-free solutions. Our key differentiators include proprietary MPT nanofiber technology, precision medicine, holistic care, and a robust network of 40,000+ doctors. These advantages position Femacare to revolutionize the FemTech industry and address the unmet needs of 1.2 billion women worldwide.

Brief Description of Product

Femacare is a women's healthcare company dedicated to providing innovative and personalized solutions for fertility, contraception, and menopause through our full stack care delivery platform. Our state-of-the-art research and development team has developed proprietary, non-hormonal, and multi-purpose prevention technologies MPTs using electro-spun nanofibers. Our unique strength lies in combining precision medicine, tailoring solutions to every woman's needs using advanced science, and holistic care, considering all aspects of health, including physical and emotional needs, with personalized plans and nutraceuticals. Key products include: VEGA IUD: A 4th gen IUD combining non-hormonal drug elution with MPT nanofibers, offering protection against pregnancy and STIs. MENOVIX: An innovative solution for vaginal atrophy and perineal prolapse during menopause. Personalized Fertility Care Plan: A tailored approach to fertility enhancement supported by our digital platform, providing comprehensive assessments, targeted nutritional support, and access to certified fertility experts. Our team has mastered the art of incorporating multiple drugs with varying physicochemical properties into a single nanofiber matrix. This enables us to create products that can address multiple health concerns simultaneously, providing comprehensive care for women in a convenient and efficient manner. For example, our VEGA IUD new generation contraceptive device leverages drug-eluting nanofibers to deliver both contraceptive agents and antimicrobial compounds, offering protection against unintended pregnancy and sexually transmitted infections. Similarly, our BABY BLESS vaginal gel uses nanofiber-encapsulated fertility-enhancing ingredients to support conception, while MENOVIX harnesses the power of nanofibers to alleviate the symptoms of vaginal atrophy and perineal prolapse during menopause. Femacare aims to address the unmet needs of 1.2 billion women worldwide by providing accessible, affordable, and effective solutions. With a strong focus on R&D and a commitment to transforming women's healthcare, we are positive to make a significant impact in the growing femtech market.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

Currently, our website is under development and it will be completed soon. Our website will be launched next month by September 2024. Femacare also recognizes the importance of intellectual property IP protection in maintaining its competitive advantage and attracting investments. For patent protection, we have actively filed for patent applications to safeguard our core innovations novel nanoemulsion gel-based composition Application number: 202321019394 and non-hormonal intrauterine device Application number: 202321039113.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Femacare targets both the Indian and global markets, focusing on addressing unmet needs in women's reproductive health. In India, the emphasis is on accessible, affordable solutions for a diverse population, while globally, the aim is to provide innovative reproductive health products to women around the globe at affordable prices.

Title/Name of the Product/Technology

Our products include baby bless, vega-iud, menovix . Our innovation is based on Multiple-Prevention Technology which revolves around electro-spun nanofibers. It creates highly customizable and versatile nanofiber matrices. By carefully engineering them, we can develop products that offer targeted, controlled release of active ingredients while maintaining excellent biocompatibility and biodegradability.

Product Positioning

Femacare positions itself as a pioneer in hormone-free women's health solutions, offering innovative products like the 4th Generation IUD, fertility gel, and menopause therapies. We stand out by combining advanced nanofiber technology with personalized, multi-purpose prevention, delivering superior efficacy and safety compared to conventional alternatives.

National/Societal Relevance

Femacares solutions address critical gaps in women's reproductive and hormonal health in India, where access to quality healthcare is limited, especially in rural areas. Our products, like the VEGA IUD and BABY BLESS, provide affordable, non-hormonal options for conditions such as infertility and menopause. Traditional hormone therapies pose significant health risks our nanofiber-based solutions offer safer alternatives. By partnering with healthcare providers and NGOs, we ensure widespread accessibility, empowering women with effective treatments and education to make informed health decisions, ultimately improving their quality of life and societal well-being.

Import Substitution

Gynoveda and PregaHope offer fertility solutions, they lack the full-stack, personalized care and novelty of Femacare. Ro provides a full-stack fertility solution but doesn't prioritize personalized care or innovative technologies. Menovex offers personalized care and novel solutions lacks Femacares full-stack approach. Paragard and Mirena focus primarily on IUD devices

Export Potential

Yes, we have a lot of export potential as people in Middle Eastern, African, European, North and South American countries who seek affordable and less expensive solutions for infertility, pcos, menopause and iud.

IP Status

Femacare recognizes the importance of intellectual property IP protection in maintaining its competitive advantage and attracting investments. For patent protection, we have actively filed for patent applications to safeguard our core innovations novel nanoemulsion gel-based composition Application number: 202321019394 and non-hormonal intrauterine device Application number: 202321039113.



Name of Startup: FIDES MEDTECH PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Gayathri Mandada
Dr. Muralidhar Ogoti

Email:
mandadagayathri@gmail.com

Product/Technology differentiation from Competitors

Non-invasive Biomedical Device Surface touch for FHR UC No touch for prediction of Cervical dilatation

Brief Description of Product

Helps in Intrapartum Process Non-Invasive Gives Information about the Changes During Delivery of the Baby Fetal Heart Rate, Uterine Contractions Intensity and Frequency, Maternal heart Rate by surface touch, and Prediction of Cervical Dilatation by AI ML Algorithm

Technology readiness level (TRL) TRL- 3

Current Stage of Development

The current stage POC is finished Got accurate results Software Technology 65 finished Got Industrial design for the device Waiting for the validation tests

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, Developing countries, and other developed countries

Title/Name of the Product/Technology

JANANYA

Product Positioning

We ensure that our device JANANYA will maintain the respect of the labouring women by avoiding painful physical examination. Being a non-invasive device, it reduces the infection and reducing the morbidity and mortality of both mother and child. The NOVELTY lies in predicting the cervical dilatation with ZERO TOUCH.

National/Societal Relevance

SDG 3: We believe our solution will have a positive impact on Good Health and Well-being of laboring women with the reduction of morbidity and mortality of both mother and child.

IP Status

PATENT NO. 346704

Name of Startup: GENEM BIOTECH PRIVATE LIMITED



Founder and Co-founder(s):
Mukesh Kumar, Sunita Kumari

Email:
info@genem.in

Product/Technology differentiation from Competitors

This is a kind of noble product in which we will be using color scale to estimate the vitamin B12 level in serum/whole blood

Brief Description of Product

Vitamin B12, also called cobalamin, is a water-soluble vitamin that has a key role in the normal functioning of the nervous system via the synthesis of myelin myelinogenesis, and in the maturation of developing red blood cells in the bone marrow. It is involved in the metabolism of every cell of the human body: it is a cofactor in DNA synthesis, fatty acid metabolism, and amino acid metabolism. It is added to many different food and drugs. Sensitivity: 200 - 700 pg/ml Stability: 24-month Accuracy: 95 Assay time: 15 - 20 min

Technology readiness level (TRL) TRL- 6

Current Stage of Development

At present we have optimized the device for Specificity and sensitivity and optimizing with scale to make it semiquantitative

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

PAN INDIA

Title/Name of the Product/Technology

Vitamin B12 Rapid Test Semi-Quantitative

Product Positioning


Pharma company and government institution to screen malnutrition

National/Societal Relevance

Screen malnutrition

Export Potential

Africa and middle east asia



Name of Startup: GENES2ME PRIVATE LIMITED



Founder and Co-founder(s):
Mr. Neeraj Gupta

Email:
sanjeevnagpal@gene2me.com

Product/Technology differentiation from Competitors

Magnetic Bead based extraction and RT-PCR based amplification in one device. Pre-filled cartridge-based technology Diverse test menu with 55+ assays catering to various therapy segments like Oncology, infectious disease, reproductive, genetic disorders etc. Compatible with compromised sample types and sample volumes. No special lab environment or temperature requirements. Most cost-effective, competitive and efficient system.

Brief Description of Product

A unique and fully automated Sample IN - Result OUT detection system that integrates nucleic acid extraction with RT-PCR based fluorescent detection of up to 20 targets in 1 sample. The capacity of the machine is to handle one sample at a time.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

The device has been launched globally after rigorous research and testing. The device is commercially available to be sold globally.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Global



Title/Name of the Product/Technology

OnePCR - Fully automated detection system

Product Positioning

Point-of-Care Testing Device National/ Societal Relevance The device is a standalone portable system for detection of disease targets which does not need specific lab environment and can be placed in fields or at remote areas with limited access to testing or diagnostic infrastructure.

Name of Startup: Gene Spectrum Life Sciences LLP



Founder and Co-founder(s):
Akshay Zaware

Email:
akshay@genespectrum.in

Product/Technology differentiation from Competitors

1 Cloud based application with no high-end infrastructure requirement 2 FASTQ to VCF in just hours 3 Eliminate command-line redundancy 4 Integrated interpretation and reporting of the variants

Brief Description of Product

Gene Assure is a cloud-based platform designed to make clinical next-generation sequencing NGS data analysis faster and more accurate. It uses advanced AI technology to speed up the process of identifying genomic variants, which are crucial for understanding genetic information in a clinical setting. Not only does GeneAssure quickly pinpoint these variants, but it also provides detailed annotations, offering valuable insights that help in making informed clinical decisions. The platform is built with the user in mind. Its intuitive interface makes the entire process of NGS data analysis straightforward and accessible, even for those who may not be experts in the field. From uploading raw data to generating a final report, GeneAssure streamlines each step, allowing users to complete comprehensive analyses without hassle. What really sets GeneAssure apart is its exceptional performance. It outshines traditional methods in variant calling by delivering faster, more reliable results. This makes it a must-have tool for clinical labs looking to enhance their genomic workflows, reduce turnaround times, and ensure the highest level of accuracy. GeneAssure is a homegrown solution, developed with innovation and practicality in mind. It's cost-effective, robust, and designed to handle large volumes of clinical NGS data efficiently. Whether you're working on a small study or a large clinical trial, GeneAssure scales to meet your needs, ensuring consistent, high-quality performance. In essence, GeneAssure is more than just a data analysis tool—it's a comprehensive solution that brings speed, accuracy, and ease to clinical genomics. By combining cutting-edge AI with a user-friendly design, it empowers labs to achieve better results, faster, and with greater confidence.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

GeneAssure has completed its development phase and has undergone thorough testing with public datasets, delivering strong performance. The interface and AI-driven pipeline function seamlessly together, ensuring smooth and efficient operation. The next step is to move forward with clinical validation and testing, which will be crucial in confirming the softwares effectiveness in real-world clinical applications.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Pan India



Title/Name of the Product/Technology

GeneAssure - Clinical Genomics Suite

Product Positioning

GeneAssure is positioned as a cutting-edge, cloud-based platform specifically designed to streamline and enhance the analysis of clinical next-generation sequencing NGS data. It is targeted towards clinical laboratories and hospitals that require rapid, accurate, and comprehensive genomic variant analysis.

National/Societal Relevance

Most clinical NGS data analysis tools on the market are offered by foreign companies. GeneAssure, however, stands as a proud testament to the Make in India initiative, delivering a solution that matches the performance of international competitors while offering a significantly more cost-effective alternative. It proves that cutting-edge technology can be homegrown, providing high-quality, reliable results without the premium price tag associated with foreign applications.

Import Substitution

GeneAssure is a direct alternative to foreign-made applications for clinical NGS data analysis.

Export Potential

The global NGS market is expanding rapidly and Gene Assure holds strong potential as a globally accepted application.

Name of Startup: Genomiki Solutions Pvt. Ltd.



Founder and Co-founder(s):
Dr. Deeksha Bhartiya

Email:
support@genomiki.com

Product/Technology differentiation from Competitors

We are proud to be India's first AI-enabled SaaS solution for analysing, interpreting and reporting genome testing data. The other competitors are not based in India so the patient data is electronically sent to other countries for analyses. Many of these are solely relying on AI driven predictions and does following recommended guidelines whereas our solution utilises scientific curations along with AI predictions. The other solutions are also very expensive as compared to our cost-effective solution.

Brief Description of Product

In India, approximately 800,000 babies are born with congenital disorders each year. Among these, 25,000 are diagnosed with inherited metabolic disorders. Genomics based personalized medicine is going to be the future of healthcare which will help in preventive screening, early diagnosis and possible therapeutic interventions. At Genomiki Solutions, we envision transforming healthcare by developing genomic diagnostic and screening solutions for these rare pediatric disorders. These solutions will focus on developing smart custom-made genome-informatics solutions enabled with big-data analytics and artificial intelligence, meticulously designed to pinpoint specific genetic variants linked to disorders and AI-enabled therapy recommendation platform which will not only identify any FDA approved therapy but also available clinical trials. Application Our solutions with will help in Better Efficiency: With our targeted approach, we will screen pathogenic variants and the AI enabled algorithms will help in improving sensitivity and specificity of the results. Accelerating the decision-making: The targeted sequencing approach and our highly optimised algorithms will accelerate the processing of large numbers of samples in a short span of time which will empower our customers hospitals and diagnostic labs in taking quick medical decisions.

Technology readiness level (TRL) TRL- 5


Current Stage of Development

Our diagnostic genome-informatics solutions have been validated and launched in service mode. The cloud-based platform is under testing stage. We are currently working on the screening solutions.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

We are targeting regions across the country. We already have paid clients from the North and East part of India. We have started discussions with clients in Dhaka and Kenya.



Title/Name of the Product/Technology

Diagnostics and screening solutions for paediatric disorders

Product Positioning

Diagnostic labs and hospitals providing genome testing are facing challenges in analysing and reporting massive genomics data. Our product is an indigenous, cost-effective solution that empowers them with accurate tailored insights and provides AI-enabled therapy recommendations.

National/Societal Relevance

Our initiative holds significant national and societal relevance by making genomic solutions customised for the Indian population. We recognize the unique genetic diversity in our population and we are dedicated to curating specialized gene panels tailored to the Indian context. By doing so, we ensure that our platform provides accurate and relevant insights into the genetic underpinnings of cancer susceptibility and treatment response specific to our population. This approach not only enhances healthcare outcomes for individuals but also contributes to the advancement of cost-effective precision medicine in India, addressing a pressing societal need for more targeted and effective medico-genomic solutions.

Import Substitution

The current platforms in the market are not made in India and thus the patient data is electronically sent to other countries for analysis. Our indigenous solution provides an alternative to these platforms and in turn is accurate and cost-effective.

Export Potential

Our SaaS solution is hosted on cloud and the algorithm can analyse global data; thus, we can provide this solution globally. We have had discussions with labs in Dhaka and Kenya about their requirements and working on it.

Name of Startup: Glowvista Instruments Private Limited



Founder and Co-founder(s):
Dr. Earu Banoth (founder); Dr. Bala Chakravarthy Neelapu & Dr. Puneet Kumar Jain (Co-founder)

Developed Under
(scheme): BIG

Email:
info@glowvistainstruments.com

Product/Technology differentiation from Competitors

Our AI-driven auto focusing technology stands out from competitors by offering unparalleled precision and speed in image analysis. Unlike traditional methods, our system integrates advanced AI algorithms to automate focusing, significantly enhancing image resolution and clarity. This results in more accurate and rapid disease diagnosis, reducing human error. Additionally, our technology streamlines laboratory workflows, enabling more experiments in less time. The integration of AI-powered predictive analytics provides deeper diagnostic insights, facilitating earlier detection and better patient outcomes. Ultimately, our solution democratizes access to cutting-edge microscopy tools, empowering global healthcare and research institutions.

Brief Description of Product

Our proposal focuses on developing an AI/ML-driven auto focusing technology for digital microscopy, tailored for applications in biological research and medical diagnostics. The project aims to integrate advanced AI algorithms with optical systems to achieve precise and automated focusing capabilities, enhancing the resolution and efficiency of microorganism visualization and cell structure analysis. This innovation addresses the current challenge of manual focusing limitations in microscopy, offering a solution that significantly improves imaging accuracy and speed. The proposed technology will enable researchers and clinicians to conduct detailed examinations of microorganisms, cell structures, and tissue samples with unprecedented clarity and automation. By leveraging AI/ML for autofocus functionality, the project seeks to streamline diagnostic processes, improve disease detection accuracy, and support predictive analytics based on image data. The project plan includes the development of prototype systems, algorithm refinement through extensive testing and validation in diverse biological contexts, and the eventual commercialization of the technology. We aim to advance this cutting-edge technology from concept to market, positioning it as a transformative tool at the intersection of electronics, AI, and biomedical sciences, with profound implications for healthcare and scientific research communities globally.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

Our AI-driven auto focusing technology stands out from competitors by offering unparalleled precision and speed in image analysis. Unlike traditional methods, our system integrates advanced AI algorithms to automate focusing, significantly enhancing image resolution and clarity. This results in more accurate and rapid disease diagnosis, reducing human error. Additionally, our technology streamlines laboratory workflows, enabling more experiments in less time. The integration of AI-powered predictive analytics provides deeper diagnostic insights, facilitating earlier detection and better patient outcomes. Ultimately, our solution democratizes access to cutting-edge microscopy tools, empowering global healthcare and research institutions.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

We aim to support leading medical institutions, research centers, and universities, enhancing their diagnostic capabilities and research efficiency with cutting-edge microscopy tools.



Title/Name of the Product/Technology

AI integrated Autofocusing System for Digital Microscopy

Product Positioning

Our AI-driven auto focusing technology revolutionizes digital microscopy by delivering unparalleled accuracy and speed. Designed for biological research and medical diagnostics, it enhances imaging efficiency and reliability, addressing common challenges in current systems. With advanced algorithms and seamless integration, it stands out as a superior, cost-effective solution.

National/Societal Relevance

Our AI-driven autofocus technology has significant national and societal relevance by advancing biomedical research and medical diagnostics. By improving imaging accuracy and efficiency, it accelerates scientific discoveries and enhances diagnostic precision, potentially leading to better healthcare outcomes. This technology supports the growing demand for advanced diagnostic tools, fostering innovation in research institutions and medical facilities nationwide. Its adoption can contribute to more effective disease detection, treatment, and overall public health improvements, aligning with national priorities for cutting-edge medical technologies and enhanced healthcare services.

Import Substitution

Import substitution for our AI auto focus technology boosts local manufacturing, reducing reliance on imported microscopy systems. This strategy fosters domestic industry growth, lowers costs, creates jobs, and enhances self-reliance in advanced biomedical technologies. We have IEC certificate to follow up the procedure.

Export Potential

Our AI-driven autofocus technology has significant export potential, offering advanced, reliable solutions to global markets in biomedical research and medical diagnostics. Its superior accuracy and efficiency make it a competitive and attractive option for international laboratories and healthcare facilities.

Name of Startup: Haystack Analytics Pvt Ltd



Founder and Co-founder(s):
Dr. Anirvan Chatterjee, Gaurav Srivastava,
Prof Kiran Kondabagi

Developed Under
(scheme): BIG

Email:
ranjan@haystackanalytics.in

Product/Technology differentiation from Competitors

Pan bacteria, pan fungal, covers major ARGs and respiratory viruses

Brief Description of Product

infexn™ caters to the needs of identifying the pathogen and its Antimicrobial Resistance AMR, as of now entire spectrum of bacteria and fungi in a single go and has 24 hours of analytical TAT analytical means from the time the sample reaches the lab to the time reporting is done. Any diagnostic laboratory or 300+ bedded hospital can work as a partner and we install our sequencers, provide our reagent kits, and connectivity to the cloud for interpreting the results. infexn™ - Our genomic technology has proven to be highly effective in the detection of all bacteria, fungi, and major ARGs, including various pathogens, scenarios, and sample types, demonstrating the diverse applicability in early infection detection

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Products are available to purchase through different B2B channels

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, GCC, SEA

Title/Name of the Product/Technology

infexn

Product Positioning

Go-to test for suspected infection

National/Societal Relevance

Screening of all kinds of bacterial & Fungal infections along with medically important AMRs

Export Potential

Yes

IP Status

Patent pending

Name of Startup: Healyantra Medical Technologies Pvt Ltd



Founder and Co-founder(s):
Dr. Varun Khandelwal, Divesh Kumar Awasthi,
Dr. Hardik Kothadia

Email:
management@healyantra.com

Product/Technology differentiation from Competitors

Soloject offers true single-handed operation, unlike the Safira System and Protek Adapter, which may complicate workflows. Its integrated design eliminates the need for external tools, reducing setup time. Soloject also provides superior tactile feedback, enhancing precision in delicate procedures, which is not matched by the automated systems in Safira, or the manual adjustments needed with Protek. Additionally, Soloject's ergonomic design minimizes hand fatigue, offering a more comfortable and efficient experience during long ultrasound-guided interventions.

Brief Description of Product

Soloject is an innovative smart syringe designed specifically for ultrasound guided injection/aspiration procedures. It enables single-handed operation, providing enhanced control, stability, and tactile feedback for clinicians. The device is engineered to improve the precision of injections or aspirations during procedures by integrating advanced ergonomic design with intuitive handling. Soloject aims to streamline the process, reduce procedure time, and increase safety, making it an essential tool for healthcare providers performing image-guided interventions.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

We have successfully tested the auto-aspirating feature of our device in animal studies, demonstrating its effectiveness and reliability in a controlled environment.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Initially, we will focus on the Indian market, followed by expansion into South Asia, ASEAN countries, Africa, Europe, and North America. This phased approach aims to establish a strong presence in diverse regions with varying healthcare needs and opportunities.

Title/Name of the Product/Technology

SOLOJECT – Single Operator Smart Syringe for Ultrasound Guided Procedures

Product Positioning

Soloject will leverage its affordability and advanced features to appeal to healthcare providers. Initial focus on the Indian market will be supported by targeted campaigns, demonstrations through education & training programs, and partnerships with medical facilities.

National/Societal Relevance

It aligns with national healthcare priorities by improving patient care and reducing healthcare costs. By streamlining procedures, it enhances efficiency, accuracy, and patient outcomes across various medical specialties, such as critical care, physical medicine & rehabilitation, orthopedics, and oncology. This innovation not only improves patient experiences but also reduces procedure times and potential complications. Additionally, it supports economic growth by fostering innovation in the healthcare sector, contributing to the country's global competitiveness in medical technology.

Import Substitution

Soloject offers a cost-effective alternative to existing ultrasound-guided devices like Safira System & Protek. By manufacturing locally, Soloject can reduce the dependency on foreign products, & could support domestic industry by an affordable, high-quality solution tailored to the needs of the Indian healthcare market.

Export Potential

Soloject's unique design and low cost make it a great candidate for global markets. After launching in India, we have a plan to expand to South Asia, ASEAN, Africa, Europe, and North America, meeting the growing need for affordable, advanced & specialized medical devices.

IP Status

Provisional Patent has been filed with application no. 202321066049





Name of Startup: Helix Prevealth Healthtech Private Limited



Founder and Co-founder(s):
Vikash Yadav Rimsha Khan Ehsan
Ahmad Davran Abdullah Hashmi

Developed Under (scheme):
OTHERS

Email:
eshan1691@gmail.com

Product/Technology differentiation from Competitors

Prevealth offers a research-driven approach focused on slowing ovarian aging and addressing fertility challenges. Our product, OVATRAK, is a diagnostic solution combining genetic risk assessments and lifestyle data to provide personalized insights into ovarian health. Using genomics specifically tailored for women, OVATRAK empowers women to make informed fertility decisions early, potentially avoiding invasive treatments like IVF. By integrating advanced genomics, AI, and holistic health factors—including genetic, metabolic, and emotional aspects—Prevealth ensures comprehensive, personalized care for women at every life stage, helping them maintain reproductive health and overall well-being.

Brief Description of Product

At Prevealth, we are building a comprehensive digital solution, empowered by a mobile app and home-based testing, that tracks vital health parameters such as ovarian health, providing personalized nutrition and genomics-based insights to individuals. Our focus is on empowering women to maintain healthy fertility from puberty to menopause, and extend their reproductive potential naturally. In line with our commitment to innovation, we are conducting research to develop OVATRAK, a cutting-edge product that monitors ovarian health and aging using the power of genomics and AI. Ovarian aging is a critical aspect of women's health, marked by a decline in the quantity and quality of oocytes, leading to fertility challenges and other health concerns. Our diagnostic solution will assess genetic risks associated with ovarian aging, offering personalized insights that enable women to make informed decisions regarding fertility planning and proactive healthcare strategies. By combining advanced genetic markers and lifestyle data, OVATRAK will help women take control of their reproductive health early, potentially avoiding invasive treatments like IVF.

Technology readiness level (TRL) TRL- 1

Current Stage of Development

We are developing a mobile app with features such as teleconsultation, vital tracking, home-based test booking and sample collection, and nutrigenomics-based diet and supplement plans. Simultaneously, we have begun gathering clinical, biochemical, and genomics data to develop AI algorithms for monitoring ovarian health and aging, proactively addressing fertility challenges.

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology Yes

Availability for showcasing at Birac No

Product/Technology

OVATRAK employs AI-driven algorithms and machine learning to analyze genetic markers identified through Genome-Wide Association Studies GWAS. By integrating this genomic data with metabolic and lifestyle inputs, it generates precise ovarian aging risk assessments, enabling predictive fertility management and personalized reproductive health insights.

Unique Selling Point

Prevealths USP lies in its personalized, DNA-based healthcare solutions that combine genomics with 360-degree care, offering tailored support from doctors, nutritionists, and fitness experts. We focus on extending fertility and improving ovarian health, providing proactive, non-invasive alternatives to traditional fertility treatments like IVF.

Present Stage of Development

Prevealth is in the early stage of development, with our mobile app nearly ready and operations already underway. We are actively building our team, advancing research technology, and working with clients to deliver personalized women's healthcare solutions. Key research areas have been identified for further innovation. Prevealth is a health-tech

Geographical Region Targeted

India

Other Scheme Name

Bootstrap

Title/Name of the Product/Technology

Prevealth OVATRAK

Product Positioning

Prevealth is a health-tech startup offering personalized women's healthcare from puberty to menopause. Its flagship product, OVATRAK, uses AI and genomics to assess ovarian aging risks, providing personalized insights for proactive fertility management. This innovative solution empowers women to make informed reproductive health decisions and avoid invasive treatments like IVF.

National/Societal Relevance

Prevealth's product has a profound national and societal impact by addressing critical women's health issues like PCOS, infertility, and ovarian aging, affecting millions of Indian women. With 28 million couples struggling with infertility and 1 in 6 women suffering from PCOS, we offer personalized, genomics-driven solutions that empower women to take control of their reproductive health. By integrating preventive care with genetic insights, we aim to reduce dependence on costly, invasive treatments like IVF, improving the overall health and well-being of women across India. Our product promotes long-term healthcare sustainability and contributes to healthier, happier families.

Export Potential

Prevealths ovarian aging product is a globally scalable solution, designed to address a universal need for fertility preservation and women's reproductive health. Our diagnostic kits, leveraging advanced genomics and personalized care, can be easily exported worldwide, providing cutting-edge fertility and ovarian health solutions to women across the globe.

Name of Startup: Helo Health



Founder and Co-founder(s):
Sandeep Bhatia
Aditya Sandeep Bhatia

Email:
sandeep@helohealth.in

Product/Technology differentiation from Competitors

Our competition and differentiators are listed below: 1. Culture of Low/No Testing Differentiator: Low CPT, Instant results, No travel for patient 2. Discrete POCT Devices How many discrete devices? Common EHR, Medical-grade vs. Consumer-grade 3. Health ATMs Lower price, Portable, Suitable for health camps 4. Mom & Pop Labs Zero wait for tests, Higher ROI for Doctors, Portable 5. Collection Centers of Lab Chains Zero wait for tests Higher ROI for Doctors No movement of samples

Brief Description of Product

Helo Health was founded on the principle of "Diagnostics for All," with a mission to provide innovative solutions in the realm of medical diagnostics. Our focus is on transforming the timeline and costs associated with testing vitals, blood, urine, infectious diseases, markers, and specialized parameters. Through our pioneering approach, we aim to bridge critical gaps in healthcare accessibility, particularly in rural areas, where diagnostic services are severely limited. In rural Bharat India, there are only about 25,000 laboratories available to serve a population of over 90 Crore people spread across 600,000 villages. This scarcity of diagnostic facilities forces doctors in these areas to prescribe general medications without the crucial support of test results, leading to potential health complications. Villagers often need to make multiple trips to towns for tests and later for the reports. This delay in diagnosis not only postpones necessary treatment but also imposes a heavy financial burden due to travel expenses. Furthermore, villagers lose daily wages when they travel for these tests, making diagnostics an unaffordable luxury for many. We are addressing this gap in rural diagnostic services through our innovative multi-parametric medical device. This device is designed to be simple, painless, and highly accurate, offering instant results for over 51 parameters. These include vitals, common blood and urine tests, specialized tests, infectious disease screenings, health tracking metrics, and markers. By utilizing our technology, we reduce the cost of diagnostics by more than 50 and cut down the processing cycle time by over 90. This rapid and affordable solution is transforming healthcare in rural communities. On-Ground Benefits: Immediate testing and instant results enable local general practitioners GPs to diagnose ailments quickly and take appropriate actions. This not only improves patient outcomes but also reduces the burden on patients who would otherwise face long waits and high costs for diagnostics in towns far from their homes. Our business model involves partnering with large corporates through our partner foundations to install these systems in Primary Health Centres. PHCs the first port of call for villagers do not have lab facilities except a collection service. Our system helps bridge this gap with instant results for most common tests especially diabetes, anemia, infectious diseases and markers as well as special tests like Hba1c, Lipid Profile and ECG, that are a luxury in villages, today. Our approach is not only improving access to diagnostic services but also enhancing the overall health of rural populations. In addition, by bringing diagnostics closer to home, we are making healthcare more accessible, affordable, and effective for everyone in rural Bharat.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Product developed and ready validation - done IEC 60601 and IEC 62304 - done Initial units - sold

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, under-served geographies in the world like Asia, Africa, parts of Eastern Europe and Middle East



Title/Name of the Product/Technology

Multi-parametric diagnostics device

Product Positioning

Helo Health is committed to Diagnostics for All, focusing on affordable, accessible healthcare in rural India. With our multi-parametric device, offering instant results for 60 parameters, we reduce diagnostic costs by 70 and cycle time by 90. Partnering with corporates, we enhance rural healthcare, bridging critical diagnostic gaps.

National/Societal Relevance

In rural Bharat, with only 25,000 labs serving 90 crore people across 6 lakh villages, access to diagnostics is severely limited, leading to costly delays and health risks. Our innovative device provides instant, accurate results for over 60 parameters, cutting costs by 70 and reducing diagnostic time by 90, significantly improving rural healthcare.

Import Substitution

Yes. We do substitute the need for importing multi-parametric diagnostics devices

Export Potential

under-served geographies in the world like Asia, Africa, parts of Eastern Europe and Middle East

IP Status

PCT/IN2024/050033 dated 12 January 2024 for A SMART AND PORTABLE HEALTH TESTING KIT, A SYSTEM AND A METHOD THEREOF

Name of Startup: Human Biogenesis Pvt. Ltd.



Founder and Co-founder(s):
Debabrata Mandal
Sachitanand Roy

Developed Under (scheme):
BioNEST

Email:
contact@humanbiogenesis.com

Product/Technology differentiation from Competitors

The SD Kit stands out with no direct competition in the consumer market. Unlike indirect forensic methods such as microscopic assays, RSID kits, PSA/ABAcad kits, which require high-end equipment and technical expertise, the SD Kit offers a user-friendly, portable solution. It eliminates the need for specialized laboratories or trained personnel, making semen detection accessible and immediate for both personal use and on-site forensic applications.

Brief Description of Product

The SD Kit is an innovative, rapid semen detection solution designed to address critical needs in both general sexual wellness and forensic science. This portable, user-friendly kit provides instant and accurate confirmation of semen presence, empowering women to make informed reproductive health decisions and enhancing forensic investigations in sexual assault cases. The SD Kit offers a non-invasive, reliable method to detect semen exposure, filling a gap in at-home reproductive health tools. Its dual application extends to crime scene analysis, allowing for immediate evidence collection and preservation. By combining cutting-edge biotechnology with practical design, the SD Kit aims to revolutionize personal health monitoring and support legal justice in sexual assault cases.

Technology readiness level (TRL) TRL- 6

Current Stage of Development

The SD Kit is currently in the clinical validation stage, a critical phase in its development. This stage involves rigorous testing on human subjects to confirm the kits accuracy, reliability, and safety in real-world conditions. Extensive trials are being conducted to verify sensitivity, specificity, and usability across diverse populations. This validation process is essential to ensure the product meets regulatory standards and performs as intended before market introduction.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Metro Cities in India at start.



Title/Name of the Product/Technology

SD Kit

Product Positioning

Innovative health tech bridging personal wellness and forensic science. Positioned as an essential tool for reproductive health management and a game-changer in sexual assault evidence collection.

National/Societal Relevance

Enhances women's reproductive autonomy and supports sexual assault victims. Contributes to public health and criminal justice advancements, addressing critical societal needs in sexual wellness and safety.

Import Substitution

Reduces reliance on imported forensic kits. Offers a domestically developed alternative to foreign products, potentially lowering costs and increasing accessibility in the Indian market.

Export Potential

High global demand anticipated in both consumer and forensic markets. Unique product with potential for widespread adoption internationally, offering significant export opportunities and revenue generation.

IP Status

Design Patent Granted: 387848-001
Provisional Patent Filed: 202331082183

Name of Startup: ICALTECH INNOVATIONS PRIVATE LIMITED



Founder and Co-founder(s):
Mr. Jayavanth Kamath
Dr. Rajeshri Kamath

Developed Under (scheme):
SPARSH

Email:
jay@icaltech.com

Product/Technology differentiation from Competitors

Our Product Model: Antlia uses Oscillometry technology to diagnose Pulmonary Diseases. This device used for early diagnosis of lung disorders. This helps in localizing the site of obstruction in the lung airways. It also helps in clear assessment of response to treatment & post bronchodilator reversibility.

Brief Description of Product

Antlia is a Pulmonary Function Test also known as Lung Function Test Device. This device used to diagnose pulmonary diseases such as Asthma, COPD, ILD, Emphysema, Bronchitis. This device is used for early diagnosis of lung disorders. It potentially localize the site of obstruction. It is used for the assessment of response to treatment & post bronchodilator reversibility. This device is used by Chest Physicians, Pediatricians and General Practitioners.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Market Launched in 2022. We are currently scaling up of our production.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, US, APAC, Europe



Title/Name of the Product/Technology

Pulmonary Function Testing Device using Oscillometry Technology. This is also known as Lung Function Testing Device.

Product Positioning

Low-Cost Import Substitute. Local technical and spare parts support.

National/Societal Relevance

Children and senior citizens find it difficult to breathe into the current available product spirometer. Our product Antlia can be used from Pediatric to Geriatric population. We are therefore addressing a use case issue. The lung diagnosis of children as well as senior citizens has become simpler and effective with our technology.

Import Substitution

Our product is cheaper to imports by 70.

Export Potential

We are in the process of applying for US FDA accreditation. The market size for exports is over 500 million dollars.

IP Status

Patent Awarded - Number 514951



Name of Startup: ImmuGenix Biosciences Pvt Ltd



Founder and Co-founder(s):
Dr Naveen Kumar Venkatesan Samyuktha
Vinayagam

Email:
md@immugenixbio.com

Brief Description of Product

Real-Time PCR based diagnostic kits for infectious disease - Virus/ bacteria/ fungi/AMR genes

Technology readiness level (TRL) TRL- 6

Current Stage of Development

We have validated the product and waiting for CDSCO approval

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

INDIA, USA, UAE and Europe

Title/Name of the Product/Technology

IGB MarabanX Real-Time PCR diagnostic kits for infectious disease

Product Positioning

Diagnostic labs and hospital labs

National/Societal Relevance

This kit will help in timely diagnose of the disease which will save patients life.

Import Substitution

Yes, 100 indigenous

Export Potential

Yes

Name of Startup: ImmunitasBio Private Ltd



Founder and Co-founder(s):
Dr.Sivasankar Baalasubramanian

Developed Under(scheme):
BIG

Email:
shiv@immunitasbio.com

Product/Technology differentiation from Competitors

While there are many tests available to identify an infectious or autoimmune disease once a patient has already fallen ill like antibody tests, there is no blood test to identify individuals vulnerable to diseases before they fall ill. There is also no routine test that provides a functional readout of T-Cell immunity. Our product measures T-cell immunity in an individual to determine their overall health and wellness and identify the diseases they are vulnerable to, enabling the timely adoption of preventive and protective health measures. As such, the kit is a first-in-class product and faces no direct competition at present.

Brief Description of Product

Our immune system protects us from disease, be it an infection or cancer or autoimmune disease. This protection comes from T cells and antibodies made by B-cells and is mostly enabled by vaccination. When our immune system fails, we fall ill. This occurs more often when we grow old or develop co-morbidities. It is already a well-established fact that this is due to a decrease in T-cell immunity, including the immunity we get from vaccination. This leaves a sizeable population vulnerable to diseases. Early identification of such populations can prevent the development of serious medical situations that place a huge health and financial burden on the patients and infrastructural burden on the health care system. Currently, there is no routine test to measure T-cell immunity in an individual to identify vulnerability to diseases. There is also no blood test that can give a functional readout of an individual's immune status. Our product is a first-in-class innovation. It is a simple blood test that is designed to measure T-cell immunity against the most common diseases in India. The kit detects the presence of CD4 and CD8 T-cells against a battery of diseases and their absence will identify the vulnerable individuals like the aged and co-morbid. The test will also provide an assessment of long-term immunity to vaccination and identify populations lacking such immunity. The test provides an accurate assessment of one's immunity status against various diseases to enable the timely adoption of preventive and protective health measures. It can act as a monitoring tool for long term immunity, health and wellness. It will increase the quality of life in the vulnerable and bring about true healthcare where we extend the health of a person as opposed to treat their diseases. We believe this kit can also aid the government in adopting initiatives like booster vaccination programs for adults. The kit can also be adapted for diagnosing specific disease conditions like Celiac Disease, monitoring immunotherapies and optimising gene therapies. The kit can be used in any routine diagnostic lab, is accurate, easy to use and stable. It is highly scalable and customizable. We have previously launched RUO a COVID-19 T-cell kit based on the same platform.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

The kit is being developed under BIRAC BIG funding. The kit has been assembled and its stability, repeatability and reproducibility has been established. A clinical trial is on-going in collaboration with AIIMS, New Delhi to establish its sensitivity and specificity. Following the trial, the kit can be launched for RUO. We plan to further commercialize our kit via a B2B model after performing larger clinical trials and obtaining regulatory approvals.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

We aim to launch the product first in India before entering the global immunity and wellness market.

Title/Name of the Product/Technology

Whole Blood T-cell Immunity and Wellness Kit

Product Positioning

We aim to launch this product under a B2B model, where we will target hospitals and diagnostic labs who can offer our test as part of their routine health checkups. We will also approach health & wellness companies who offer holistic healthcare and health insurance companies.

National/Societal Relevance

India has a significant population that is old and co-morbid and thus vulnerable to diseases and complications that are often expensive to treat and hard to access for rural populations. Early identification of these populations will benefit the individuals, the healthcare system and ultimately society by increasing the quality of life in the vulnerable, bringing about true healthcare where we extend the health of a person as opposed to treat their diseases. We believe this kit can also aid the government in adopting initiatives like booster vaccination programs for adults. It can also be adapted to monitor immunotherapies

Import Substitution

This product does not fall under import substitution

Export Potential

There is a significant demand for immunity and wellness tests in the international market. Being a first-in-class product, the competitive and IP landscape are to our advantage. Being Made-In-India, our product will be economically priced and require minimal support/service requirements. We have previously exported our infection related T cell kits

IP Status

Application No: 202441065645 Title: T CELL ASSAY KITS AND METHODS THEREOF Applicant: ImmunitasBio Pvt. Ltd.



Name of Start-up: Incredible Devices Pvt Ltd



Founder and Co-founder(s):
Vikram Goel (Founder)
Rajwinder Kaur (Co-Founder)

Developed Under(scheme):
SEED Fund

Email:
vikram@incredibledevices.in

Product/Technology differentiation from Competitors

CBRS uses a patented technique that thoroughly cleans, disinfects, and reconditions catheter balloons, extending their usable life while ensuring safety and functionality. Unlike manual reprocessing, CBRS automates the entire procedure, minimizing human error and maintaining consistent quality.

Brief Description of Product

Catheter Balloon Reprocessing System CBRS by Incredible Devices utilizes a patented cleaning process that employs Dynamic Fluid Cleaning technology, generating fluid pressure 74 times higher to effectively remove biofilms. The system also uses mechanical vibration to eliminate surface proteins. As a sophisticated machine, CBRS ensures safe catheter reprocessing, making treatments safer, more affordable, and accessible to millions of low-income patients. It prevents hospital-acquired infections, reduces the spread of antimicrobial-resistant bacteria, and ensures safe disposal, mitigating the risk of viral outbreaks. Additionally, CBRS decreases biomedical waste by 90 and guarantees the safe disposal of the remaining catheters.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Developed & Commercialized across 14 states in India

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

PAN India and Neighbouring Countries



Title/Name of the Product/Technology

CBRS: Catheter Balloon Reprocessing System

Product Positioning

Target Audience: Hospitals and Healthcare Facilities: Large hospitals and healthcare centres that regularly use catheter balloons and seek to optimize their reprocessing methods. Cost Efficiency: CBRS provides significant savings by extending the lifecycle of catheter balloons, reducing the need for frequent replacements. Enhanced Safety

National/Societal Relevance

1. Reduction in Medical Expenses: By extending the lifecycle of catheter balloons, CBRS helps reduce the overall cost of medical supplies, easing the financial burden on healthcare systems and institutions. 2. Improved Infection Control: CBRS's advanced cleaning and disinfection processes reduce the risk of infections associated with catheter use, contributing to better patient outcomes and safety. 3. Reduction in Medical Waste: By reprocessing catheter balloons rather than discarding them after a single use, CBRS significantly decreases medical waste, supporting environmental sustainability efforts.

Import Substitution

Import substitution for CBRS involves developing and manufacturing the Catheter Balloon Reprocessing System domestically, reducing reliance on foreign technology. This approach strengthens local manufacturing capabilities, enhances self-sufficiency, lowers import costs, and promotes innovation within the national healthcare sector, contributing to economic growth and job creation.

Export Potential

CBRS has strong export potential due to its advanced technology and cost efficiency. With global demand for sustainable, cost-effective healthcare solutions rising, CBRS's compliance with international standards and its innovation leadership position it well in global markets, offering significant economic benefits and showcasing national technological advancements.

IP Status

Patent No. 311157

Name of Startup: INFAB Semiconductor Pvt Ltd



Founder and Co-founder(s):
Muthuraman Swaminathan

Email:
raman@infab-tech.com

Product/Technology differentiation from Competitors

We use lithography to integrate sensors into our chip. Added to that we can produce complex chips with the minimum dimension ranging from 20um to 50um. We also have specialized glass-to-glass bonding expertise. Our pressure controllers are more precise compared to others in the market. We also offer a very competitive pricing for our customer.

Brief Description of Product

Microfluidics Chips for Organ on Chip, Droplet, mRNA. We also offer pressure controllers, Flow Sensors for the microfluidics precise flow controller

Technology readiness level (TRL) TRL- 5

Current Stage of Development

Our products are in the testing phase and shortly be commercialized

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India & Global Market

Title/Name of the Product/Technology

The INFAB Polymer-based Microfluidics platform enables development of Microchannel, Reservoirs and Microreactors. PDMS-based Device Thickness: ranging from 100um to 5mm & widths from 5um to 250um & SU8-based Devices Thickness: from 5um to 100um & Width 5um to 250um. INFAB Semiconductor Pvt Ltd is a pioneering Indian technology company that specializes in the design, development, and manufacturing of advanced sensors, actuators, and microfluidic devices based on MEMS Micro-Electro-Mechanical Systems technology. Our MEMS-based devices offer high precision and accuracy, making them ideal for use in a wide range of applications across various industries.

Product Positioning

Custom-made solution for microfluidics-based devices for multiple applications & Market • Biomedical Research cell culture, drug delivery, tissue engineering, and point-of-care diagnostics. Analytical Chemistry, Pharmaceutical, Food and Beverage Industry

National/Societal Relevance

Reduce the import dependency and make the diagnostic more affordable

Import Substitution

95 of microfluidics chips and Pressure Controller are currently imported from Europe and US.

Export Potential

High because of the advanced features and cost advantage



Name of Startup: Inochi Care



Founder and Co-founder(s):
Dr Shivani Gupta
Mr Suteerth Tripathi

Developed Under(scheme):
BIG, NBM

Email:
shivani@inochihealthcare.com

Product/Technology differentiation from Competitors

We realized currently available advance wound care devices are misaligned with the needs of the complete continuum of wound care. The key limitations of competing technologies include being expensive and limited accessibility, no multi therapeutic approach to cater wounds of different types, contraindicated to use in infectious wounds, bulky that restrict the user mobility, require technical trained personnel to use these systems. Our patented innovation influences the overall wound environment to assist in healing process. The unique features of the technology include multifold therapy, uniform therapy distribution, hypoxia and infection control, portable, affordable and intuitive design.

Brief Description of Product

Our multitherapeutic wound healing technology creates and maintains the optimum healing environment at the wound site that stimulates the biological responses, leading to faster wound healing. Our innovative system consists of an electronic medical device along with a specially designed patch to deliver multifold therapeutic effect. It maintains optimum pressure, temperature, oxygen, and moisture levels at the wound site and also facilitates exudates removal and infection control. It also provides a mobile app built on customized AI algorithm to track the healing progression of the wound over time. This highly effective therapy reduces the cost and healing time for chronic wounds like diabetic foot ulcers and pressure sores. It relieves overcrowded hospitals and economically benefits patients and their families without compromising safety and quality of care delivered.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

ISO 13485 certified from NABL and CDSCO approved agency Product registration completed with CDSCO IEC 60601-1&2 compliance done NABL certified for product performance Test license obtained from CDSCO Manufacturing license Obtained

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India



Title/Name of the Product/Technology

InoHeal

Product Positioning

Hospitals, Nursing homes

National/Societal Relevance

Non-healing wounds Chronic wounds including Diabetic Foot Ulcers, Pressure ulcers and Trauma Wounds are exhausting for the affected individuals and place a massive financial burden on the health care systems. Delayed healing of chronic wounds causes complications like pain, septicemia, infections, and amputations leading to lifelong disability. Chronic wounds are a debilitating condition for many individuals in different age group. However, elderly population is highly prone to get chronic diabetes foot ulcers and pressure ulcers. Chronic wounds diabetic foot ulcers, pressure ulcers and venous leg ulcers affect an individual's ability to perform daily activities, further contributing to social isolation.

Import Substitution

Yes

Export Potential

Yes

IP Status

Product patents: 02 01 patent already granted in India, Japan & US Design Patent: 01 Granted Trademarks: 04

Name of Startup: Intignus Biotech Pvt. Ltd



Founder and Co-founder(s):
Dr. Vaishnavi Kulkarni

Developed Under (scheme):
BIG, LEAP Fund, SBIRI

Email:
vaishnavikulkarni@intignusbiotech.com

Product/Technology differentiation from Competitors

There are three competing diagnostic kits viz. Roche Elecsys preeclampsia kit, Perkin Elmer DELFIA Plgf test and Lumella by Diabetomics But this disease warrants early screening, where all the pregnant women need to be screened for development of preeclampsia. Proposition of our innovation: 1. Cost efficient alternative 4 times cheaper than other tests 2. Screening test enables surveillance hence better medical intervention for healthier pregnancy 3. Easy to use platform like a pregnancy detection test 4. Quick results 15 minutes of wait time 5. Predicts risk of developing preeclampsia in patient

Brief Description of Product

PE screen, a screening test for all pregnant women which can predict preeclampsia development in the upcoming weeks of gestation based on circulating levels of a placenta specific preeclampsia biomarker. This test is to be performed when the women visit their gynecologist during the fixed, routine check-ups. Pe screen is an early screening test that is · Low cost Rs 1000 /test · Rapid 15 min · Early detection even before 13 weeks of pregnancy · Point-of-care, usable in low resource settings and be operated by unskilled person · Can enable surveillance and monitoring of high-risk pregnancies

Technology readiness level (TRL) TRL- 6

Current Stage of Development

ISO 13485 certificate received, pilot clinical investigation completed, pivotal clinical trial underway, product test license received and documentation for manufacturing license initiated

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, South-East Asia, Sub-Saharan Africa, Europe and USA



Title/Name of the Product/Technology

PE screen Preeclampsia Screening Test

Product Positioning

A point-of-care device designed to predict the risk of developing preeclampsia in pregnant women. This easy-to-use, rapid screening tool provides accurate, early detection, empowering healthcare providers to implement timely interventions and improve maternal and fetal outcomes.

National/Societal Relevance

Societal Relevance: Benefits women economically weaker sections and/or residing in rural India and doctors, Healthcare Workers, ASHA workers. Use of PE screen will reduce preeclampsia associated maternal deaths, prevent preeclampsia-induced fetal growth retardation and facilitate birth of healthy babies and improve the healthcare quality in low resource settings National Relevance. Global alignment with the following UN SDGs: a. 3: Good health and well-being - 3.1 and 3.2 b. 5 Achieve gender equality and empower all women and girls - 5.5 and 5.6 c. 10 Reduce inequalities within and among countries - 10.2 d. 17 Partnerships for the goals

IP Status

1. Indian Granted Patent 435647 2. Indian Applied Patent 202321082680

Name of Startup: IOTA DIAGNOSTIC PRIVATE LIMITED



Founder and Co-founder(s):
Vaibhav Shitole

Developed Under (scheme):
SITARE

Email:
vaibhav@iotadiagnostic.com

Product/Technology differentiation from Competitors

Conventional sampling methods from the lower genital tract, especially for diseases like cervical cancer and STDs, is invasive and uncomfortable with techniques like vaginal and cervical smears. Societal taboos further discourage women from seeking screenings and diagnostic testing. Additionally, conventional methods like cervical smears lack sensitivity and can lead to false diagnoses due to professional biases. M-Strip offers a non-invasive alternative, using menstrual blood, which collect complex fluid includes blood, menstrual secretions and unique biomarkers. Integrated into sanitary pads, it provides a painless, contamination-free, and effective way to diagnose diseases.

Brief Description of Product

M-Strip™ is a self-sampling menstrual fluid collection device designed for non-invasive collection, storage, and transportation of menstrual fluid for diagnostic and research purposes. It consists of hydrophilic porous materials arranged between upper and lower layers, along with a tail extension for easy handling. The device is intended to be used with a sanitary pad, and after collection, the M-Strip™ is stored in a provided storage case for transport to a laboratory. The M-Strip, developed by Iota Diagnostic, represents a significant leap forward in the field of women's health, particularly in the early detection and screening of cervical cancer. This innovative device is a menstrual fluid collection tool designed to transform how women approach cervical cancer screening, prioritizing non-invasiveness, privacy, and convenience.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

M-Strip has obtained approval from the CDSCO under Class A IVD device for the Indian market, owing to advancements in the company's marketed core Bio-Sampling technology and successful pilot clinical studies. Following the addition of sufficient clinical data covering comprehensive disease testing, including all STDs, and subsequent publication, our aim is to get USFDA approval for the United States market and CE approval for the European market.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

At present our focus is on the Indian domestic market, having approval from CDSCO. With the International free sale approval in hand, we plan to obtain regulatory clearance for the overseas market. Our future roadmap involves a sequential entry into Europe, followed by USA, MEA, and rest of the world.



Title/Name of the Product/Technology

M-Strip: Cervical Cancer Home Screening kit
BioSampler: Blood Micro sampler Device

Product Positioning

In the Indian market, we are strategically positioning the M-Strip to reach end-users and customers through a combination of B2B strategies. This includes partnering with authorized pathology chains, NGOs, and directly engaging with businesses for sales, and implementing our own sales and marketing campaigns.

National/Societal Relevance

The increasing prevalence of health issues like cervical cancer, infertility, STIs such as HSV-2, syphilis, and HIV poses a significant threat to women's health, leading to higher female mortality rates. Although conditions like cervical cancer are treatable if detected early, insufficient awareness, reluctance, and non-compliance with traditional diagnostic methods lead many women to neglect early signs. Socially, the M-Strip's non-invasive test offers a comfortable, private, and anxiety-free screening experience. Its cost-effectiveness eliminates the need for complex clinical setups, making it accessible to a broader population and ensuring timely diagnosis and care.

Import Substitution

M-Strip will be an import substitution with present vaginal swab and sampling consumables required for collection of bio-fluid and cell samples from pelvic region from women.

Export Potential

The M-Strip, a pathbreaking diagnostic method, presents significant global export potential. Manufactured in India, it offers a cost-effective alternative to traditional practices. It promises to greatly impact resource-limited healthcare, enabling remote screening and diagnosis of women and treatment in under developing regions like Africa and other regions across the globe.

IP Status

1. Indian Patent: Title MENSTRUAL FLUID SAMPLING DEVICE Application No: 202321067654 Status: Complete Specification
2. Design Registration: Title: MENSTRUAL FLUID SAMPLING DEVICE Application No: 409453-001 Status: Granted

Name of Startup: ISMO Bio-Photonics Pvt. Ltd.



Founder and Co-founder(s):
Ikram Khan .S.I and Prof.Shantanu Pradhan, IITM

Developed Under(scheme):
BIG, SEED Fund

Email:
ikram@ismobiophotonics.com

Product/Technology differentiation from Competitors

Novel technology and FDA has recommended organoid based drug screening

Brief Description of Product

An organ-on-a-chip technology to grow organoids on for pre-clinical trials drug screening and personalized drug screening

Technology readiness level (TRL) TRL- 6

Current Stage of Development

We have demonstrated the product by growing tiny organoid brain on a chip in collaboration with MIT, USA, and working on drug specific organoids models to meet customers demands.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

USA, India and UK

Title/Name of the Product/Technology

Organoid bioreactor

Product Positioning

As an organ on a chip product for drug screening with organoids

National/Societal Relevance

This pandemic has shown us the importance of preclinical trials. our product helps in accelerate the drugs to market with our innovative organ on a chip technology with organoids for pre-clinical trials

Import Substitution


Yes, we will have the first movers advantage in of organ on a chip technology

Export Potential

Our state-of-the-art technology has global market of around 200 billion USD.

IP Status

Granted





Name of Startup: ITX CARE PRIVATE LIMITED



Founder and Co-founder(s):
Shalendra B Sinha (Founder/Director)
Venkata Sarath Pulipati (Co-Founder/Director)

Developed Under
(scheme): OTHERS

Email:
corporate@itxcare.in

Product/Technology differentiation from Competitors

Product differentiates itself through comprehensive live consultation capabilities and acts as a platform for real-time monitoring. It supports multiple medical device connections, including invasive and non-invasive vitals, auscultation and visuals for examination. The portable design allows easy deployment in diverse settings, while live ambulance monitoring starts critical care during transit, adaptability for rural healthcare and allows immediate decision-making prescriptions or tests further set it apart from competitors, offering a versatile and impactful remote healthcare solution. Currently no other solution allows family members who are at a distance to join the consultation.

Brief Description of Product

We developed a medical diagnostic device and software cloud web-conference application that enables clinical consultation at a distance. Where doctor and patient can be apart but still with the help of a nurse, our device and cloud application, the patient can experience what all doctor does at a physical clinic or an OPD. Through this setup we enable doctor who is at a distance from the patient to access patient body information including invasive and non-invasive vitals, body sounds heart & lungs and stream & capture of patient body visuals for examination in real-time. And will be in a position to understand the patient problem and subsequently prescribe medication or recommend further tests for the patient.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

We have successfully moved from concept, design, and prototype stages to real-world demonstration, where its functionality has been validated under practical conditions. We are one step away from full commercial deployment or TRL 8.

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India - 2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

Product is a medical diagnostic device integrated with a cloud-based web-conference application that enables real-time remote clinical consultations. It allows doctors to access patient data such as invasive and non-invasive vitals, body sounds heart and lungs, and visuals of the patient in real-time, simulating an in-person examination.

Unique Selling Point

The device enables comprehensive real-time remote consultations with portable integration of invasive and non-invasive vitals, body sound analysis, and live video streaming. It connects multiple medical devices, supports live ambulance monitoring for critical care, and allows family members to participate, offering a versatile solution across diverse healthcare settings.

Present Stage of Development

Progressed from concept, design, and prototype stages to successful real-world demonstrations, validating the device's functionality. The final prototype will be ready this month, and the next steps include applying for a test license and initiating the regulatory process for commercial production.

Geographical Region Targeted

Our primary geographical target is the rural market, where the significant doctor-patient gap makes your solution highly valuable. By bridging this gap, your device enables remote consultations and quality healthcare in underserved areas, addressing a critical need for accessible medical services.

Major Achievements

1. Rising TV CGTSM award 2. Secured top 10 among selected 50 startups at Annual Global Convention IMT Ghaziabad 3. Secured INR 30 lakhs SISF fund 4. Secured INR 10 lakhs grant from IIT Roorkee 5. Successfully completed pilot at Sri Sathya Sai Institute, Muddenahalli. 6. Bharat Seva Ashram, WB

Other Scheme Name

Bootstrapped funding

Title/Name of the Product/Technology

Remote Monitoring Technology - A SYSTEM AND A METHOD FOR REMOTE MEDICAL ASSISTANCE IN REAL-TIME

Product Positioning

Our product is positioned as a comprehensive, portable solution for real-time remote clinical consultations, designed to transform healthcare delivery across multiple environments, including clinics, ambulances, rural areas, home healthcare, and corporate wellness centers. It targets healthcare providers seeking advanced diagnostic capabilities without geographical limitations.

National/Societal Relevance

Our product enhances healthcare accessibility in rural and underserved areas, providing real-time consultations and emergency care through live ambulance monitoring. It supports the rising demand for home healthcare and helps reduce hospital overcrowding, promoting healthcare equity and improving patient outcomes, making it highly relevant for national healthcare challenges.

Import Substitution

Our product offers a solution for import substitution by providing locally developed and manufactured components within our device. We have reduced reliance on foreign devices, it supports domestic innovation, strengthens local manufacturing, and helps mitigate supply chain vulnerabilities, contributing to self-sufficiency in the healthcare sector.

Export Potential

Solution can address needs in emerging markets with limited healthcare infrastructure, developed countries seeking enhanced remote care, home healthcare markets worldwide, and corporate wellness programs, making it a valuable addition to global healthcare solutions. It has strong export potential due to its versatility and advanced features.

IP Status

Status: Patent Published Application No: 202311004715 A Date of Filing of Application: Jan-24-2023 Publication Date: Feb-03-2023 Name of the Applicant: ITX CARE PRIVATE LIMITED Name of the Inventor: Shalendra B Sinha



Name of Startup: Kumshungba Private Limited



Founder and Co-founder(s):
Dr W angkheirakpam Sujata W
Amarjeet Singh

Developed Under(scheme):
BioNEST

Email:
kumshungbam@gmail.com

Product/Technology differentiation from Competitors

low cost, user friendly, portable, protected

Brief Description of Product

It is an Extractor for extracting bioactive and fractions from natural products. It consists of a chamber, lid, outlet and grid and a removable inner cylinder. The inner cylinder is for adjusting volume and creating pressure. The grid which is detachable is for filtering the extract from solid natural product used for extraction. There will be variants in size according to requirements. The natural product according to requirement for a specific species is put in the extractor as fresh, mashed, dried and powdered etc. in the chamber. Unlike the Soxhlet, Clevenger, supercritical fluid extractor extraction is made simple. It makes it possible to explore various conditions for optimization for a particular bioactive or fraction from the parent natural products.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

Higher TRL level is under construction

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

hilly and all region globally. It will save untapped or wasted bioresources



Title/Name of the Product/Technology

Sujata Apparatus /extractor

Product Positioning

extractor of low cost

National/Societal Relevance

it will decrease imports both in machine and bioactives

Import Substitution

it will decrease imports both in machine and bioactives

Export Potential

high export potential

IP Status

Design protection no 373068-001 in Kolkata patent Office in India. 5 Indian Patent Application No: 202431055676 dated July 22, 2024

Name of Startup: Latent Heat2Comfort Technologies Pvt. Ltd



Founder and Co-founder(s):
Dr. K Satyanarayana V.N. T

Developed Under (scheme):
SEED Fund

Email:
phaniram@heat2comfort.com

Product/Technology differentiation from Competitors

There are no similar products available in Indian markets as of now, general practice here is to give sitz bath or mild pain killers to mothers. It is proven globally that cold therapy is the most effective and efficient method for pain management in perineum region.

Brief Description of Product

Perineal Cold Pack - An instant cold pack integrated with maternity pad, primarily used by Postpartum mother's Natural deliveries for alleviating pain in the perineum region caused because of tear during the delivery

Technology readiness level (TRL) TRL- 8

Current Stage of Development

The product was tested multiple times and we have started exploring the market through sampling

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

USA, Middle East, Europe and India



Title/Name of the Product/Technology

Perineal Cold Pack

Product Positioning

Globally acknowledged alternative in Perineal Pain management is now available in India

National/Societal Relevance

Sitz baths and mild painkillers are not the best methods for such pain management hence people and government in India should shift to better alternatives like Perineal Cold Pack

Import Substitution

There is no market in India as of today, we will have to create market while focusing on Exports

Export Potential

We are planning to primarily exploring export market

IP Status

Patent granted for the technology and we are yet to apply for patent for the product

Name of Start-up: LifeSenz Cancer Research Labs Pvt Ltd



Founder and Co-founder(s):
Dr Arindam Banerjee (Founder); Hanskumar Shah, Kaushik Shah (Co-Founder)

Email:
arindam.banerjee@lifesenz.co.in

Product/Technology differentiation from Competitors

Ex vivo 3D model based clinical decision-making tool is relatively newer avenue in the personalized cancer medicine. Few companies around the globe presently working to provide clinical guidance to our knowledge none currently exist in India with supportive validation studies respective to their proprietary platform. a Kiyatec Inc. a US based company published scientific observational studies demonstrated the analytical and clinical validation of an ex vivo 3D assay to predict patient-specific response to chemotherapy across various cancers. b Curesponse Inc., an Israel based company working on an ex vivo 3D model to assist oncologists in prioritizing and selecting treatment options.

Brief Description of Product

In worldwide cancer treatment, we do not have any personalized predictive therapy platform. One Treatment Fits All approach in many instances not only causes non-responsive treatment but also bear with economic burden to the patient and community overall. In this respect, LifeSenz is currently working on to clinically validate patient biopsy derived functional 3D based therapy prediction platform that can assist both the clinician and the patient to identify the best possible treatment options within the standard of care choices chemo/targeted/ immuno-therapy within 10-12 days post biopsy before the actual clinical treatment begins. Moreover, utilizing LifeSenz translational R&D resources & facilities we are extensively working with several tertiary universities/ institutes/ colleges across India to train and upskill budding biomedical professionals/students to make them future ready for global perspective. We are also engaged with academia and industry and assist and/or collaborate as a service option to perform several R&D based scientific projects relates to molecular oncology, drug discovery & development, nutraceuticals, cosmeceuticals and pharmacology subjects. We do have our own inhouse R&D program where we are also developing products relates to oncology and nutraceutical supplements.

Technology readiness level (TRL) TRL- 3

Current Stage of Development

LifeSenz has already initiated a clinical validation study for the ex vivo 3D therapy prediction platform Ethical approval through Bhaktivedanta Hospital and Research Institute, Thane, Mumbai <https://www.bhaktivedantahospital.com/> . In this case target samples n=100 from neoadjuvant NAT Breast cancer patient and objective is to correlates LifeSenz prediction through ex vivo platform with actual therapy outcomes pCR and/or RCB within the NAT settings. Based on these observations, subsequent further similar sample analysis with multiple other cancers from multiple centres across the geography could be a possibility alongside clinical recommendations to avail this platform through clinicians/medical boards.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Pan-India and globally



Title/Name of the Product/Technology

Ex vivo patient biopsy derived 3D cancer therapy prediction platform

Product Positioning

1. LifeSenz 3D therapy prediction platform will be unique with India perspective and with governments support we can carry out further validation under government hospital jurisdiction to build a comprehensive data to make it useful to integrate into the National Health Mission to minimize treatment cost while improving therapy outcomes.

National/Societal Relevance

Cancer therapy prediction will assist millions of cancer patients in India and abroad. With government support LifeSenz technology has the potential to minimize cancer cost both at the individual and community level while improving therapy outcomes. Being an innovative and cost effective as compared to the currently available western counterparts, the same services can be exported elsewhere for the benefitting thousands of cancer patients worldwide, including India.

Import Substitution

Currently available similar technology/ platform are available at a premium cost in only selected western geography USA and Israel. Hence only a handful of affordable patients can avail similar technology through paying hefty amount overseas. LifeSenz platform can bring down this cost to an affordable range while providing quality clinical data.

Export Potential

LifeSenz 3D therapy prediction platform can definitely be exported or bring foreign revenue to India through therapy prediction platform-based services. Not only that, LifeSenz other verticles including scientific R&D services and technical training programs for Biomedical Students could further open up new potential of future collaborations and research-based incomes



Name of Startup: LUMIGUIDE PVT. LTD.
Lighting The Way to Independence



Founder and Co-founder(s):
Mr. SHIVA SAI (FOUNDER); Dr. BIJAVA KUMAR
NAVAK, Dr. ANIMA NANDA (Co-FOUNDER)

Email:
abshivasai04@gmail.com

Product/Technology differentiation from Competitors

The LUMIGUIDE smart shoe differentiates itself from competitors through its integration of Li-Fi technology with AI and ML for real-time, adaptive navigation. Unlike traditional assistive devices that rely solely on basic sensors or guide dogs, this system provides context-aware obstacle detection, personalized voice guidance, and continuous learning capabilities. The use of Li-Fi offers more precise indoor positioning and faster data transmission compared to GPS-based solutions. Additionally, its energy-efficient design, powered by ML-optimized algorithms, ensures longer battery life and reliable performance, making it a more advanced and user-centric solution for visually impaired individuals.

Brief Description of Product

The LUMIGUIDE Smart Shoe is AI-Enhanced Smart Navigation System for Visually Impaired Individuals, which is an advanced assistive device designed to revolutionize the mobility and independence of visually impaired persons. This intelligent system, embedded within a smart shoe, leverages the power of Artificial Intelligence AI and Machine Learning ML combined with Li-Fi technology to provide real-time, adaptive navigation and obstacle detection. The primary function of the LUMIGUIDE Smart Shoe is to guide visually impaired users safely and efficiently through their environments, both indoors and outdoors. The system utilizes Li-Fi technology, which transmits data and positioning information through light sources. By interpreting these light signals, the smart shoe provides accurate voice-guided navigation to the user, helping them to follow the designated paths. The LUMIGUIDE smart shoe is equipped with ultrasonic and water sensors, which are managed by an AI-powered microcontroller. Machine Learning algorithms enable the LUMIGUIDE smart shoe to learn and improve obstacle detection over time. The AI analyzes sensor data to classify obstacles—such as solid objects, water puddles, or other hazardous surfaces—and predict potential threats. This allows the system to deliver timely and context-aware voice alerts, enhancing the user's safety. By employing Machine Learning models, the LUMIGUIDE smart shoe adapted to the users walking patterns and preferences. Over time, the AI learns to anticipate the user's movements and environment, offering personalized navigation instructions. For instance, the system might optimize routes based on the user's speed or preferred walking paths, making the navigation process more intuitive and less disruptive. The integration of AI enables the shoe to interact with environmental data beyond simple obstacle detection. LUMIGUIDE smart shoe analyses lighting conditions or weather data through connected IoT devices to adjust its guidance accordingly. If the light source for Li-Fi transmission is compromised due to environmental factors, the AI can switch to an alternative mode, such as utilizing stored data or pre-learned routes, ensuring the continuous guidance. The LUMIGUIDE smart shoe could predict and classify obstacles in real-time and drastically reduces the risk of accidents. Unlike traditional systems, which merely detect obstacles, this smart shoe offers context-specific responses, like warning of different surfaces or guiding the user around large obstacles. With its adaptive learning capability, the LUMIGUIDE smart shoe provides a tailored user experience, adjusting its responses based on the individual's needs and the environment. This personalization increases user confidence and independence. The integration of the ML algorithms on LUMIGUIDE smart shoe optimize power consumption by intelligently managing the system's resources, such as switching off sensors when not needed or adjusting Li-Fi signal strength based on proximity to light sources. LUMIGUIDE smart shoe enhanced the smart navigation particularly beneficial for visually impaired individuals in urban environments, offering them greater independence. It can be deployed in smart cities, public transportation hubs and residential areas, improving accessibility and inclusivity for all.

Technology readiness level (TRL) TRL- 3

Current Stage of Development

At the current stage of development, the AI-Enhanced Smart Navigation System - LUMIGUIDE smart shoe is at a proof-of-concept level, with foundational technologies such as Li-Fi, ultrasonic, and water sensors integrated into a prototype. The system successfully demonstrates basic obstacle detection and navigation capabilities. The next steps involve refining the AI and ML algorithms to enhance obstacle classification, environmental adaptability and personalized navigation. Initial tests indicate strong potential but further development is needed to optimize the AI's predictive accuracy and ensure seamless real-world application in diverse environments, ultimately moving towards a fully functional, user-friendly product.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

The LUMIGUIDE smart shoe targets urban and semi-urban regions globally, with a focus on densely populated areas where visually impaired individuals face significant mobility challenges. Initial deployment is aimed at smart cities, public transportation hubs and metropolitan areas in India where technological infrastructure supports advanced assistive devices.

Title/Name of the Product/Technology

LUMIGUIDE Smart Shoe - AI-Enhanced Smart Navigation System for Visually Impaired Individuals

Product Positioning

LUMIGUIDE smart shoe is a premium assistive device for visually impaired individuals, featuring advanced AI, ML, and Li-Fi for superior navigation and obstacle detection. Targeting tech-savvy users, it prioritizes safety, independence, and convenience, positioning itself as a top alternative to traditional mobility aids.

National/Societal Relevance

The LUMIGUIDE Smart Shoe addresses a critical societal need by enhancing mobility and independence for visually impaired individuals. This AI-powered, Li-Fi-enabled device provides real-time navigation and obstacle detection, improving safety and confidence. By leveraging machine learning, it adapts to users walking patterns and environmental conditions, offering personalized guidance and reducing the risk of accidents. The integration of this technology in urban and public spaces promotes inclusivity, allowing visually impaired individuals greater freedom and accessibility. This innovation aligns with national goals of improving assistive technologies and fostering smart, inclusive cities.

Import Substitution

The LUMIGUIDE Smart Shoe represents import substitution by reducing reliance on foreign assistive technologies. By developing this advanced navigation system in India, it fosters local innovation, creates jobs and supports self-sufficiency in assistive devices, contributing to national technological advancement and economic growth.

Export Potential

The LUMIGUIDE Smart Shoe, with AI and Li-Fi integration, has strong export potential, offering adaptive learning and context-specific guidance for visually impaired users. Its unique features can secure a competitive edge in the global assistive device market, fostering partnerships and expanding international reach.

IP Status

The Indian patent titled AI-Enabled Smart Shoe for Visually Impaired Individuals, with application number 202431063396, is currently under review, pending final approval. Further updates will be provided as the status progresses.



Name of Startup: LUXLIGHTING TECHNOLOGY PRIVATE LIMITED



Founder and Co-founder(s):
Lux Med® and Labosys®
(enterprise)

Developed Under(scheme):
AcE Fund

Email:
cto@luxmed.in

Product/Technology differentiation from Competitors

Controlled Environment Chambers are used to create replicated environmental conditions for research sample growth and testing through temperature, humidity, Co₂, O₂ Gas and lighting control.

Technology readiness level (TRL) TRL- 1

Current Stage of Development

Cell Culture Equipment - Cell Research Equipment's The specific requirements of a cell culture laboratory depend mainly on the type of research conducted for example, the needs of mammalian cell culture laboratory specializing in cancer research is quite different from that of an insect cell culture laboratory that focuses on protein expression. However, all cell culture laboratories have the common requirement of being free from pathogenic microorganisms i.e., asepsis, and share some of the same basic equipment that is essential for culturing cells. This section lists the equipment and supplies common to most cell culture laboratories,

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Cross Globe



Title/Name of the Product/Technology

LuxMed® and Labosys® are provide one-stop solution, including Cleanroom and Biological safety product, Cell Culture Equipment, CSSD Equipment / sterilization, Climatic Condition and Stability Chamber design, manufacturing, project executions.

Product Positioning

* Multi-purpose Chamber Stability Testing. * Seed Germination. * Tissue Culture. * Algae. * Arabidopsis. * Plant Growth. * Bacterial Culturing. * Drosophila Research, Insect. * Reptile rearing and Research.

National/Societal Relevance

These Equipments got imported from global market and

Import Substitution

Indigenous product create local ecosystem and environmental

Export Potential

Indigenous product create local ecosystem and environmental proof product performance and scale manufacturing for global market.

IP Status

10 file and 4 nos Granted - Design Registration

Name of Startup: LUXLIGHTING TECHNOLOGY PRIVATE LIMITED



Founder and Co-founder(s):
Suraj Kumar
Hema Kumari

Developed Under(scheme):
AcE Fund

Email:
cto@luxmed.in

Product/Technology differentiation from Competitors

1. Manufacturing scientific and laboratory equipment indigenous and a leading manufacturers and suppliers. 2. Registered Brand - LuxMed® and Labosys® brand. 3. OEM - on Government e Marketplace GeM Portal. Easy Carting thru our Registered Brand and product on portal. 4. Our product Available online on Amazon, Indiamart, Alibaba, Biomall, GeM

Brief Description of Product

LuxMed® leading manufacturers and suppliers of LuxMed® and Labosys® brand laboratory equipment and instruments, to various Universities, College, R & D labs, Institutes etc. Since 2003 we have been manufacturing scientific laboratory equipment indigenously which were being imported till then. It has always been our endeavour to have customers convenience in mind which constantly compels us to modify and improve upon our products continuously so that they have better acceptance by the end user. 1. Cleanroom and Biological safety product and services. 2. Climatic Condition and Stability Chamber, Ultralow Deep Freezer. 3. Cell Culture Equipment - Cell Research Equipments 4. Hospital CSSD Equipment <https://www.labosys.in/>

Technology readiness level (TRL) TRL- 9

Current Stage of Development

LuxMed® is specialized in products of 8 areas including medical diagnosis, biosafety protection, disinfection and sterilization, water purification system, infant care products, cold chain products, software products, clean room project. 1. Cleanroom and Biological safety product and services. 2. Climatic Condition and Stability Chamber, Ultralow Deep Freezer. 3. Cell Culture Equipment - Cell Research Equipments 4. Hospital CSSD Equipment <https://www.labosys.in/>

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Cross the Globe



Title/Name of the Product/Technology

Cleanroom and Biological safety product and services in cleanrooms, precision counts. Environmental conditions need to be controlled precisely to minimize contamination risks and protect people and assets. With LuxMed® and Labosys® and our wide range of cleanroom and biological safety product and services.

Product Positioning

Carbon dioxide Co2 incubators provide optimal growing conditions and contamination prevention for valuable cell cultures. LuxMed® provides a wide range of Co2 incubators, ranging from a small capacity and volume to a large-scale capacity cabinet. All the Co2 incubators are built with the Water Jacket and Air Jacket systems,

National/Societal Relevance

We Ensure product and technology development to meet Indian climatic conditions and researcher requirement.

Import Substitution

Thermo, Biobased, Eppendorf are selling in India at high cost, and customer facing inline challenges 1. High cost of equipments. 2. Specific requirement for use case, that have limitation in Indian climatic conditions. 3. Service, warranty and spares parts availability.

Export Potential

CO2 incubators are commonly used for cell culture processes in the pharmaceutical industry and medical research labs. For instance, they are often used to maintain the temperature and humidity levels essential for culturing cells in a lab setting.

IP Status

Design Registration filed: 10nos Design Registration Granted: 4nos 1. Design No.: 374335-001 - AIR VELOCITY SENSOR. 2. Design No.: 373797-002 - BIOMEDICAL DEEP FREEZERS. 3. Design No.: 373797-001 - BOD INCUBATOR. 4. Design No.: 374333-001 - CO2 SENSOR

Name of Startup: Manastik Technologies Private Limited



Founder and Co-founder(s):
Pushkraj Marne
Soubhik Das

Developed Under (scheme):
BIG

Email:
lajos.pinter@eurolifetech.com

Product/Technology differentiation from Competitors

Manastik is a comprehensive dementia care ecosystem offering neurocognitive assessments, tele-rehabilitation, and personalized interventions like physiotherapy, CST, OT, SLT, and nutrition therapy. It enables patients and caregivers to manage everything from medication reminders to therapy sessions in one platform, ensuring seamless, clinically accurate, and holistic dementia management.

Brief Description of Product

Manastik is a one-stop solution for Dementia patients for diagnosis to multi-disciplinary rehabilitation without leaving the comfort of home, we cater to all needs with a ML-based app platform that is curated by the Indian Federation of Neuro Rehab professionals useful for a rural dominant country where Neuro professionals to patient ratio is skewed. Our app provides a Family based Expert guided TeleNeuroRehab which costs less and reduces the burden of traveling to Tier 1 cities for better facilities. We cover all neuro-rehab professionals which include physiotherapy, Cognitive Stimulation Therapy, Occupational Therapy, Speech Language Therapy, Yoga, Pranayam, Music Therapy, and Nutrition.

Technology readiness level(TRL) TRL- 7

Current Stage of Development

TRL 7, Commencing clinical trials

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event Yes

Are you willing to Transfer/Out-License your Technology Yes

Availability for showcasing at Birac Yes

Product/Technology

We are a ML based stage tracking and rehab recommending app for saving time of doctors and increasing adherence to rehab

Unique Selling Point

We are the only app created in partnership with Indian Federation of NeuroRehab by integrating family-based dementia care model which is the best way out for a developing country like India. Our platform will be available in all Indian languages and reduces rehab visits by 90

Present Stage of Development

Manastik is validating its technology through tele-rehabilitation pilots in rural settings and testing ML-based cognitive assessments in controlled and real-world environments. Discussions with leading hospitals are underway to implement family-based dementia

Geographical Region Targeted

Manastik targets rural India, urban hubs, and developing LMICs in Africa and ASEAN markets

Major Achievements

Indias first Tele-neurorehab app, felicitated by Indian Academy of Neurology. Invited to present our work at AOSNR conference, Thailand. Started first pan India awareness and screening camp for Dementia. Young Investigator award : Indian Federation of Neuro Rehab. Onboarded General Secretary of World Federation of Neuro Rehab as our Advisor

Title/Name of the Product/Technology

TeleNeuroRehab App for Dementia diagnosis and rehab

Product Positioning

Manastik is positioned as an ML-driven dementia care ecosystem tailored for care homes, medical institutions, and government agencies. It offers personalized therapeutic interventions, real-time cognitive monitoring, and remote tele-rehabilitation, automating care beyond human capabilities by understanding complex dementia patterns and providing comprehensive, scalable solutions for efficient patient management.

National/Societal Relevance

In India, 15 million elderly are at risk of dementia, with cases rising to 8.8 million in 2023. Manastik addresses this critical gap by enhancing dementia care access through AI-driven tele-rehabilitation and hospital partnerships, improving early detection, treatment, and support across underserved rural, and urban areas.

Import Substitution

Manastik provides an innovative, homegrown local language support solution for dementia care, replacing the need for imported technologies. By creating a new category that integrates neurocognitive assessments, tele-rehabilitation, and personalized therapies, we are addressing gaps in the domestic market, reducing dependency on foreign products while catering to local healthcare needs.

Export Potential

Our solution offers strong export substitution potential by addressing dementia care needs within LMICs, reducing reliance on foreign products. With no language barriers and advisory support from the president of the Asian Oceania Society of Neuro Rehabilitation, Manastik is well-positioned to expand across Asian markets and beyond.

IP Status

202321061336



Name of Startup: MARS Healthtech Pvt Ltd



Founder and Co-founder(s):
Mohini Rajendra Nikam (Founder)
Akash Rajesh Khairnar (Co-founder)

Developed Under(scheme):
SEED Fund, SPARSH

Email:
mohininikam8444@gmail.com

Product/Technology differentiation from Competitors

This is saliva base product and we don't have any direct competitor in India

Brief Description of Product

The pre-commercialization and fully functional prototype development activities for a novel saliva pregnancy detection test kit, designed to offer a non-invasive, user-friendly, and accurate alternative to traditional pregnancy tests. The test kit leverages advanced lateral flow immunoassay and ELISA technologies for reliable results, addressing the need for more convenient and hygienic home pregnancy testing and other health conditions in future.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

We have conducted laboratory studies for proof of principal and defining detection limit of biomarker in saliva. That is qualitative and quantitative biomarker detection using saliva samples of pregnant women. Phase one and phase two clinical trials are complete for MVP. Along with the market research studies for understanding the marketing strategy and enhancing value proposition

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Start from Maharashtra

Title/Name of the Product/Technology

SALIKNOW-Saliva Detection Test Kit

Product Positioning

Currently the prototype is at TRL 5 level and We have filed 2 patents for design and process. Applied for CDSCOs test license.

National/Societal Relevance

saliva sampling makes it easier, convenient and more hygienic but for societal relevance the advantage is that it negates the need of having a private space for testing or sampling. The tests can be carried out anywhere in case of an emergency, this active screening will lead to better management and early decision making.

Export Potential

Our product has 100 percent potential for Export because Market demand, minimum competition, Price Factor and product technology

IP Status

Indian Patent Application No.
202321034301 dated May 16th, 2023

Name of Startup: MEDANTRIK MEDTECH PVT LTD



Founder and Co-founder(s):
Priyaranjan Tiwari
Prikshit Hooda

Email:
info.medantrik@gmail.com

Product/Technology differentiation from Competitors

NODEX stands out from its competitors by offering a comprehensive respiratory health monitoring solution that integrates real-time air pollution data, personalized exercise routines, and advanced biomarker analysis. Unlike traditional spirometers, which are often limited to clinical use, NODEX is designed for personal and professional settings, providing users with actionable insights on lung health tailored to their conditions. The inclusion of features like exercise tracking and pollution impact assessment makes NODEX a unique and holistic tool for managing respiratory health.

Brief Description of Product

NODEX is an advanced respiratory health monitoring device that focuses on improving lung health through personalized exercise programs and pollution impact assessments. Designed to help users understand the effects of air pollution on their lungs, NODEX provides real-time data on lung function and guides users through customized exercises to enhance lung capacity and resilience. By offering insights into how pollution affects respiratory health and tailoring exercises to individual needs, NODEX empowers users to take proactive steps toward healthier lungs.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

The product is at an advanced stage of development and is fully ready for launch. After extensive research, development, and testing, NODEX has been refined to meet market demands and regulatory standards. The device's hardware, software, and user interface are fully integrated, ensuring a seamless user experience. All necessary certifications and validations have been completed, and the product has undergone rigorous quality checks. With a robust go-to-market strategy in place, NODEX is prepared to enter the market, providing immediate value to users and healthcare providers

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Delhi

Title/Name of the Product/Technology

NODEX: Revolutionizing Respiratory Health Monitoring Real-time respiratory health monitoring solution, NODEX aims to mitigate the effects of pollution on lung health, extending the lifespan and improving the quality of life for millions. Every feature of NODEX, from exercise modes to personalized medication guidance, is designed to protect and enhance the respiratory health of the Indian population.

Product Positioning

Online and offline

National/Societal Relevance

Traffic-related air pollution is contributing significantly to health issues across India. There is a critical need for a personalized, low-cost device like NODEX to monitor and mitigate the impact of pollution on respiratory health, helping to improve the well-being of the nation.

Import Substitution

NODEX is a Make in India product designed to reduce reliance on expensive imported respiratory health devices. By offering a locally developed, affordable solution, NODEX helps in substituting imports, fostering self-reliance, and promoting indigenous innovation in the healthcare sector.

Export Potential

Especially in regions facing high levels of air pollution and respiratory health challenges. Its affordability, portability, and advanced features make it an attractive solution for global markets, particularly in developing countries looking for cost-effective healthcare technologies.

IP Status

5 filed



Name of Startup: MedClinica Private Limited



Founder and Co-founder(s):
Pola Venkateshwarlu
D Sandhya Rani

Email:
venkat.pola@medclinicacro.com

Product/Technology differentiation from Competitors

Most of Clinical Research Organizations CRO are using conventional platform tools for Data Robustness, Security & Integrity Turbulent Site Management is being practiced

Brief Description of Product

The Objective and aim of the proposal is to develop a CDM software with AI and ML to ensure/ improve the validity and Regulatory compliance AI and ML algorithms can automatically identify and report any regulatory violations during the study. These algorithms can also help researchers to ensure that they are following Good Clinical Practice GCP guidelines, 21 CFR Part 11, GDPR, as well as other regulations, such as the Health Insurance Portability and Accountability Act HIPAA The impact would be in terms of the customer value creation and can be a one stop solution for any CRO and can cater the need of any Clinical Trail Professional It can improve the process of Clinical trials and can help industry and research for quick execution of projects thereby delivering any product in short time to companies and organizations, for eg in covid times vaccination clinical trials require quick analysis and this software can be the right platform.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

It can improve the process of Clinical trials and can help industry and research for quick execution of projects thereby delivering any product in short time to companies and organizations, for e.g., in covid times vaccination clinical trials require quick analysis and this software can be the right platform.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

US, Europe, India - USFDA, TGA, INDIA,

Title/Name of the Product/Technology

Building an AI and ML-based CDM software to comply with regulatory requirements

Product Positioning

Subscription model per month per project

National/Societal Relevance

early launch of medication

Export Potential

Highly regulated industry will need to comply with local global regulation -USFDA, TGA, INDIA,

Name of Startup: MedevPlus



Founder and Co-founder(s):
Dr. Ravi Kiran Manapuram,
Sweta Patnaik, Smita Patnaik

Developed Under(scheme):
BIG, SEED Fund

Email:
ravikiran@medevplus.com

Product/Technology differentiation from Competitors

IXanner® provides both portable and clinical setups with 40kHz speed, 9mm x 9mm FOV, 157 m lateral resolution, and 4.67 m axial resolution. It allows volumetric scans without software dependency, digital report sharing, and retinal red reflex capture, with manual control for precise alignment. The competitor, limited to clinical use, offers 50kHz speed, a larger FOV 12mm x 9mm, and 207 m resolution, but requires software for scan access and provides only printed reports. While the competitor features auto alignment, IXanner® delivers superior flexibility, advanced manual controls, and ease of handling for diverse ocular parameters.

Brief Description of Product

IXanner®7vn is a patented, clinically validated ophthalmic device designed for both portable and clinical use. It excels in screening and diagnosing blindness-causing diseases like glaucoma, AMD, diabetic retinopathy, and Alzheimer's at early stages, even in remote and primary healthcare settings. With advanced imaging capabilities, including high lateral and axial resolution, and features like volumetric scans without software dependency, IXanner® offers flexibility for pediatric and non-ambulatory patients. It allows ophthalmologists to capture retinal red reflex and share reports digitally. Currently piloted at prestigious institutions, IXanner® is set to revolutionize early eye disease detection and comprehensive diagnostic care.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

IXanner®7vn is a patented, trademarked, clinically validated product and completed CDSCO A registration, The R&D and Production facilities are ISO13485 certified. Early prototypes were installed at two locations and are currently in pilot runs at Narayana Netralaya and Chaitanya Eye Hospital. Three IDE orders were received two from the U.S., one from IIT Hyderabad. The device is seeking FDA 510 k Exempt status under Class 1, is registered under CDSCO Class A, and has submitted a test license. Versions include Ver 1.0 for portable pediatric/non-ambulatory imaging, Ver 2.0 for comprehensive remote diagnostics.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

first target- US, EU, India and Latin America.

Title/Name of the Product/Technology

IXanner 7vn: A Portable and handheld device for comprehensive screening of the eye using Optical Coherence Tomography

Product Positioning

IXanner 7vn Ver 1.0 currently fits in the pediatric, camp and home care markets. Ver2.0 fits in all primary health care centers, eye care centers and secondary and tertiary care hospitals.

National/Societal Relevance

IXanner®7vn supports the National Control of Blindness Program, aiming to reduce blindness to 0.3. Its social relevance lies in providing early screening and diagnosis of diseases like glaucoma, AMD, diabetic retinopathy, and Alzheimer's, particularly in underserved areas. With its portability and remote capabilities, it extends care to pediatric and non-ambulatory patients, ensuring timely interventions. Digital report sharing enhances access to medical expertise, contributing to better public health outcomes and aligning with national efforts to prevent blindness and improve eye care accessibility across diverse populations.

Import Substitution

IXanner 7vn Ver 2.0 is an import substitution.

Export Potential

We already signed agreements with distributors to distribute in EU region. Already exported 3 units. We are projecting 30-unit sale FY 2025, and 180 units FY2026 just as exports

IP Status

PATENT NO FOR GRANTED PATENTS: US8668336B2



Name of Startup: Mediklik Webhealth Pvt Ltd



Founder and Co-founder(s):
Vikramaditya Tirhani

Developed Under (scheme):
BIG

Email:
vikram@mediklik.com

Product/Technology differentiation from Competitors

Integrated Breathing Cassette - Our Integrated Breathing Cassette is an advanced pneumatic and sensory assembly that is completely autoclavable and reusable, ensuring patient safety without compromise. Currently, 95 of advanced ventilators are imported from developed countries, where disposable consumables are common as most of the expenses are borne by insurance companies. Whereas in India, high costs often lead to the reuse of consumables, risking patient safety. Our patented technology addresses this issue by eliminating consumable costs while maintaining strict safety standards. This innovation offers a sustainable, cost-effective solution without compromising the quality of care.

Brief Description of Product

Over 3.6 million people die each year from respiratory illness in India alone. Over 46 percent of these patients die due to a lack of Mechanical ventilators. Considering the situation, Ventilators global potential market size is over 1.7 Billion USD. Per WHO standards, India currently needs an additional 1 million ventilators. Still, over 12000 units, i.e. over 95 percent of devices bought annually, are imported into India due to the lack of indigenous ventilators of global safety standards. Basic ventilators are inadequate for usage in the majority of situations due to reasons such as a Patient Type Restriction b Limitation of modes c Limitation of Environment for specific usage d Expensive devices and Consumables e Limitation of Safety Features Considering the challenges stated above, we have developed an INDIGENOUS VENTILATOR that offers the following features a Suitable for all patient types b Availability of all high-end ventilation modes c Adequate for all environments i.e. transport / ICU / emergency d Affordable with low running cost e Compliant with international safety certifications

Technology readiness level (TRL) TRL- 6

Current Stage of Development

A fully functional clinical-grade device is ready with a regulatory dossier for use on human subjects/patients. Application for Quality assurance certification is under process.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Phase I - Domestic Indian Market Phase II - Other developing countries Phase III - Europe Phase IV - US and North America

Title/Name of the Product/Technology

Advance Ventilator

Product Positioning

VENSI offers advanced features at nearly half the price of comparable products from other manufacturers. Despite its superior technical capabilities, VENSI is more affordable than competitors with similar specifications.

National/Societal Relevance

The VENSI Ventilator by Mediklik is critically relevant for India, where respiratory illnesses claim over 3.6 million lives annually. The technology addresses key challenges such as the high cost of respiratory devices, limited availability, and adherence to international safety standards. In India, the prohibitive expense of disposable flow sensors and inadequate sterilization processes lead to significant cross-contamination risks. VENSI's Breathing Cassette technology, with its autoclavable unit and embedded sterilization monitoring system, ensures high sterility levels and reduces operational costs. This innovation enhances patient safety, making advanced respiratory care accessible and affordable, thereby significantly impacting public health outcomes in India.

Import Substitution

Our keen focus is to produce a better-quality import substitute for high-end respiratory devices. These devices are designed and developed on international safety standards so that, we can not only cater as an import substitute but also export the devices to developed and under-development markets too.

Export Potential

The device is developed on international safety standards and can be exported across the globe, which we are planning to execute in 3 phases as described above in a span of 3 years.

IP Status

1. Patent granted - 508250 - A BREATHING APPARATUS 2. Design Patents granted - A347994-001, 347995-001, 347993-001 3. Registered Trademark

Name of Startup: MEDTRA INNOVATIVE TECHNOLOGIES PVT LTD



Founder and Co-founder(s):
Rajesh Kumar s
Saj Sulaiman

Email:
rajesh@medtraworld.com

Product/Technology differentiation from Competitors

One - third price and only make - in - India product

Brief Description of Product

Veineux is the world's most affordable vein tracking device using Augmented Reality, which will reduce the failed attempts during different intravenous medical procedures. The portable, flexible, and hands-free imaging facilitates the difficult process of finding a vein in a much easier and faster way, without changing standard clinical terms and practices. The medical team can now accurately assess the real-time situation of peripheral veins before, during and after piercing, Veineux not only improves the success rate of venepuncture in the first attempt itself, but also the satisfaction and comfort of the patients, thereby creating a stress-free solution for the medical team

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Production of 120 units completed

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Asia Africa

Title/Name of the Product/Technology

Augmented reality based NIR vein finder

Product Positioning

The global Vein Finder market is valued at 91 million US\$ in 2017 and will reach 630 million US\$ by the end of 2025, growing at a CAGR of 27.4 during 2018-2025. 55 million \$ market is total for IV access procedure.

National/Societal Relevance

The delay in prompt venepuncture become very serious when one could not find the vein ON TIME. When the medical practitioners are treating traumatic patients, where, EVERY SECOND COUNTS. Yet bruises, burns, and other physical conditions often make it difficult to locate veins and to administer lifesaving drugs or solutions. Too often precious lives are lost due to the delay in the initiation of administering the medication, which goes unnoticed or not reported in general.

Import Substitution

yes, only make in India product

Export Potential

yes, already exported to 5 countries

IP Status

Patent Application no. 20204100977



Name of Startup: METAMORF Art and Design



Founder and Co-founder(s):
 Madhavaraj V Sirsi - Founder Sandhya Sirsi - Co Founder

Developed Under (scheme): OTHERS

Email:
 mvsirsi@gmail.com

Product/Technology differentiation from Competitors

We are in a space to create and develop by art and design for application or deployment with process developed by us in house. We provide alternatives to existing processes to accelerate on time for implementation and match / optimize on budget. To be specific our solutions of products, services and experience incl. 3D printing for Visual communication, Branding, Campaign, Events, Exhibitions, Projects and more. Our solutions are sector or domain agnostic.

Brief Description of Product

- Unique creative, crafting and curation client centric solutions of products, services and experience incl. 3D printing for Visual communication, Branding, Campaign, Events, Exhibitions, Projects and more. Our solutions are sector or domain agnostic Our solutions are result of process developed with decades of experience in art & design. Ready to use solutions for startups, institution, industry, corporate, and academia for evolving needs in Analog, Digital and Phygital incl. 3D printing art and designs Easy to implement solutions for your thoughts & plans with our expertise and detailing in sync with stake holder interests. We are open to collaborate, partner and / or co-work. Experience learning from our Inclusive, Nature, Expressive, or Tactile Art - learning for creativity and analytical thinking. A practice in self-expression and application by mind-body connection "Think like an Artist". Outcome of our experiential learning modules vary from person to person with no known side effects We work in the field of design & art - We apportion our time with keen interest with stake holders for children & challenged focus along with sponsoring and support of various forms of art and Tribal Art

Technology readiness level(TRL) TRL- 7

Current Stage of Development

We have ready to use creation from art source and development by design as concept to completion. Partnering with full fledged mechatronics facility to offer client.

Geographical Region Targeted

We are not limited to confines of geography as most of our business / work for client engagement can happen online except very few F2F meetings. We are targeting for clients in need of transformation of thoughts or innovative method of portraying ideas.

Product Positioning

A format of creating and developing products, services and experiences with minimum layers to offer integrated analog, digital, AI and humane touch. Catering to individual innovators, corporate, institutions and academia in various domains and sectors.

National/Societal Relevance

In this age of speedy requirements, AI - LLM or Image generator largely addresses requirements of creative content or visual with options. However the targeted outcome can be achieved better through humane touch and tolerance to time. Our country has rich heritage and culture sprinkled with element of creativity in every sphere of life or life in itself. We are innovating a process of harnessing creative ability and rich pool of talent with tools of technology to produce visually appealing, aesthetically pleasing and functionally relevant outcomes benefitting clients and creative fraternity impacting lives of many artists and designers.

Import Substitution

Develop indigenous - Atma Nirbhar - products, services & experiences in Bioscience, Life science, AgriTech, Medtech, Ayush & many more domains. aiding innovations in science & technology with better translation of user brief, timely outcome, quality output & cost-effective solutions. Tailor made & ready to use.

Export Potential

Potential to create and develop catering to ever growing requirements to deliver solutions to various countries. We have unmatched length of artistic talent, breadth of design capability and depth of technology, to usher in new era of our country being reliable source and leader in art and design.

IP Status

Our creatives are rights protected and we are planning to apply for design registration from time to time.



Name of Startup: Mild Cares Private Limited



Founder and Co-founder(s):
 Mrs. Rachna Vyas

Developed Under(scheme):
 LEAP Fund

Email:
 sandeep@mildcares.com

Brief Description of Product

Technology Solution: The Gyno Cup is a reusable menstrual cup made from 100 medical-grade silicone and compliance by the FDA. It serves as a sustainable, cost-effective, and chemical-free alternative to traditional sanitary napkins and tampons. Designed for long-term use, the Gyno Cup can be reused for up to 5 years, offering significant cost savings while also reducing the environmental impact associated with menstrual waste. By providing a hygienic and sustainable solution, Gyno Cup addresses both health and environmental concerns.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

In Market

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India



Title/Name of the Product/Technology

Technology Solution: The Gyno Cup is a reusable menstrual cup made from 100 medical-grade silicone and compliance by the FDA. It serves as a sustainable, cost-effective, and chemical-free alternative to traditional sanitary napkins and tampons. Designed for long-term use, the Gyno Cup can be reused for up to 5 years, offering significant cost savings while also reducing the environmental impact associated with menstrual waste. By providing a hygienic and sustainable solution, Gyno Cup addresses both health and environmental concerns.

Product Positioning

Gyno Cup is the premium choice for modern menstrual hygiene, designed for women who prioritize sustainability, comfort, and health. Crafted from 100 medical-grade silicone, the Gyno Cup offers a safer, eco-friendly alternative to traditional menstrual products.

National/Societal Relevance

India



Name of Startup: Miraques



Founder and Co-founder(s):
Sabir Hossain, Dr. Mubeen Mridha,
and Dr. Devendra Verma

Developed Under (scheme):
BIG, SEED Fund

Email:
sabrhmritk@gmail.com

Product/Technology differentiation from Competitors

Competitors include biomaterial-based and blood protein-based fibrin, thrombin products, each limited by accessibility, affordability, or efficacy. Thrombin and fibrin hemostats are restricted to OTs only as they need proper training & environment for application & also too expensive to use in large injuries. Biomaterial-based products like Celox, Axiostat, HemCon are almost 5X slower at blood clotting than StopBleed. These products are made of single biomaterials e.g., Chitosan having inherent clotting properties. StopBleed, however, combines various biomaterials into a novel dressing having a fibrous microstructure with a charged surface mimicking fibrin strands, thus ensuring rapid clotting.

Brief Description of Product

StopBleed is a patented hemostat developed to have a fibrous and porous microarchitecture posing structural and functional similarities with naturally occurring fibrin protein strands. This microstructure provides a very high surface-to-volume ratio, resulting in a higher absorption capacity which brings the blood components closer together helping the body to accelerate the normal blood-clotting cascade. Upon coming in contact with the blood, in combination with pressure and due to its rapid absorption capacity, StopBleed creates a hydrogel at the injured site and stops bleeding within a minute.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

We're at TRL 5 - Biocompatibility, Efficacy, packaging, sterilization, shelf-life study completed - ISO 13485 certificate in place - Waiting for SBIRI funds, for - Pilot scale production, physicochemical study, GMP study, followed by initiation of clinical study.

Product Launched / About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

Miraques has developed a hemostat, StopBleed®, that is almost 5 times more effective than the current standards. It is a combination of GRAS materials and achieves hemostasis by creating a hydrogel on the wound. The hydrogel then acts as a physical seal to stop the bleeding.

Unique Selling Point

StopBleed is the first hemostat in the world to have structural and functional similarities with naturally occurring fibrin. It is developed via self-assembly process without involving any costly equipment or solvents. That's why it is not only 5X more effective but also twice more affordable than the currently marketed products.

Present Stage of Development

We're at TRL 5 completing most of the studies needed in terms of design validation and verification to prove our products' safety and efficacy. Currently preparing dossiers for manufacturing license & pilot scale production.

Geographical Region Targeted

India, US & Israel

Other Scheme Name

BIG, SEED Fund

Title/Name of the Product/Technology

StopBleed

Product Positioning

StopBleed® will be introduced in two forms. The powder will be for large surface bleedings providing flexibility in use irrespective of the size of the wounds including control of external bleeding and exudate from sutures and surgical procedures. Alternatively, the pellet will be for junctional injuries or narrow entry wounds.

National/Societal Relevance

Bleeding is a serious problem affecting people worldwide and therefore the need for a hemostatic agent is undeniable. Post regulatory approval and market entry, StopBleed® will positively impact public health. By introducing StopBleed®, there will be a guaranteed reduction in blood loss occurring in pre-hospital management resulting in better clinical outcomes, a reduced number of blood bags required, a shorter hospital stay and reducing the economic burden of prolonged treatments and complications. StopBleed® will also help our EMS do a job where the risk is real & the sacrifice could be ultimate.

Import Substitution

Majority of the players are from outside India which compels our country to import wound care products to provide advanced treatment to the nation. Our intention is to make StopBleed widely available to the Indian armed forces & civilians, thus reducing foreign dependency.

Export Potential

Bleeding is a global problem and there are a limited number of startups offer solutions like StopBleed that satisfy all the requirements prescribed by the DRDO or US Army to be a good hemostat. We've already received accolades from several international organisations including LOI for Israeli Defence for piloting.

IP Status

Title: SELF-ASSEMBLED NANO-FIBERS AS HEMOSTATIC AGENT PCT Application No.: PCT/IN2020/050364 Indian Application Status: Granted Patent No.: 376918 Pending in US & IL Title: "NANO-FIBROUS POLYELECTROLYTE COMPLEX FOR RAPID CONTROL OF HAEMORRHAGE" PCT Application No.: PCT/IN2019/050965 Indian Application Status: Granted Patent No.: 547492 Pending in US, UK, IL, CA, CN, AU



Name of Startup: NaisBrain Private Limited



Founder and Co-founder(s):
Dr Manish Baldia (Neurosurgeon) and
Dr Sonika Baldia (Ophthalmologist)

Email:
manishh99@yahoo.com

Product/Technology differentiation from Competitors

As a neurosurgeon with over 10 years of experience, I have extensively studied various implants available in the market and known their complications, with a focus on their design and materials. Leveraging our novel technology, we have successfully reduced costs while enhancing implant quality. Each of our implants is customized and certified by a neurosurgeon after verifying the fit on the patient's skull model. Additionally, our implants are priced at two-thirds of the market rate.

Brief Description of Product

In head injury and during brain stroke as a life saving measure, a portion of skull bone is removed and this removed bone has a limited life during which if not replaced it loses its vitality and thereafter is rejected by the host body. Hence there is a need for an artificial bone flap which needs to be placed to protect the brain. The surgical procedure to replace this bone is called as Cranioplasty. Thus, the Cranioplasty Implant stands as a beacon of hope, a shining light of healing magic, to guide the way towards a brighter tomorrow. Due to the unique size and shape of each patient's skull defect, a customized implant is necessary to ensure a proper fit. Traditionally, the cost of such personalized cranioplasty implants exceeds 1.5 lakh rupees. However, we present a pioneering solution by streamlining the design process and utilizing cost-effective materials, thus significantly reducing expenses and making it accessible to all patients. Dr. Manish Baldia, the founder, has been working on this technology for the past 10 years and personally designed implants for approximately 100 patients and successfully conducted surgeries. The data from these cases has been published in reputed international journals like Neurology India, Acta Neurochirurgica, and Acta Biomaterialia.

Technology readiness level (TRL) TRL- 9


Current Stage of Development

With the experience of 100 patients, we are developing an ISO 13485 implant manufacturing facility and will obtain all the necessary certifications. The facility is to be operational by October 2024.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Southeast Asia and Middle East countries



Title/Name of the Product/Technology

Next-generation personalized cranial implant/Naiscranio/Low cost, high quality customized cranial implant

Product Positioning

Our product is a flagship in terms of quality and cost hence we will be making this available for all the class of people. Our product will be a tough competition to the existing market players

National/Societal Relevance

This surgery is typically the patients second, and the family has already depleted their financial resources during the first procedure. As a result, they often cannot afford expensive customized implants for this second surgery and are forced to opt for lower-quality, cheaper alternatives, which increases the risk of complications. This situation imposes a substantial socioeconomic burden on both the family and the nation. Our novel product addresses this issue by reducing the cost of the implant by two-thirds, thereby alleviating financial strain and benefiting the nation as a whole.

Import Substitution

There are various companies abroad that manufacture customized cranial implants but the cost is very high as the material used is expensive and is not certified by a Neurosurgeon. The price range from 1.5 lakhs to 3 lakh rupees

Export Potential

It has a good export potential hence we are trying to obtain all necessary certifications. I have received highly positive feedback from reputable medical institutions, such as Christian Medical College, Vellore.

IP Status

IP filed last year.

Name of Startup: Nemocare Wellness Pvt Ltd

nemocare

Founder and Co-founder(s):
Manoj Sanker
Pratyusha Pareddy

Developed Under(scheme):
BIG, OTHERS, SEED Fund

Email:
manoj@nemo.care

Product/Technology differentiation from Competitors

our USP is that we are affordable, accessible, have high accuracy, provide timely intervention and we provide Cutting Edge Deep Tech to augment Doctors Decision Making Skills. ML Platform for disease prediction, connected digital healthcare platform is new innovative technology with patent pending status Wireless wearable vitals monitor is Make in India product with affordability factor.

Brief Description of Product

Nemocare has developed an easy to use, wearable device "Raksha", that wraps around the foot and monitors 6 main vital signs - Blood-oxygen saturation, heart rate, respiration rate, temperature, perfusion index and heart rate variability, 24 x 7. The device/platform can accurately notify healthcare workers so that they can intervene before it's too late. In the back-end, vital signs are analysed by a deep learning algorithm. The entire system works as an intelligent platform that gives accurate notifications and alerts to healthcare workers to enable timely intervention when a distress condition is detected. The device and algorithms are patented US patent and Indian Patent granted. With no technology risk a hospital can make any of its beds into an ICU bed quickly. The simple and easy to use design allows it to be immediately deployable in a clinical setting. Our Flagship product the Nemocare Raksha is a First of its kind IoT enabled medical grade wearable for new born babies backed by our AI engine that monitors 6 key vital signs, identifies and pre emptively predicts critical distress conditions and gives the complete picture of the baby's health our USP is that we are affordable, accessible, have high accuracy, provide timely intervention and we provide Cutting Edge Deep Tech to augment Doctors Decision Making Skills.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

We have deployed and piloted Nemocare Raksha across 6 states in India. We have a strong IP portfolio We have clinical study on safety and functionality at Narayana Hrudyalaya Bangalore published in Indian Journal of Pediatrics.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, US, South East Asia



Title/Name of the Product/Technology

Nemocare Raksha

Product Positioning

Step down units and monitoring across care continuum Personalised care and resource optimization Zero mother and child separation

National/Societal Relevance

RMNCH+A Reproductive, Maternal, Newborn, Child and Adolescent Health - CHILD HEALTH In the next 3 years we intend to monitor and save 1 million babies our devices deployed. And soon we hope to be an integral part of India - where no child ever dies of a cause that is completely preventable

Import Substitution

100 made in India product and will reduce burden on import

Export Potential

US market pilot ongoing Telemedicine use case

Checkout Accommodation(2nd)

14-09-2024

IP Status

We have a strong IP portfolio with 6 global patents files 1 US patent and 2 Indian Patent granted and 6 trademarks all IP filings incentivized and subsidized through DPIIT support

Name of Startup: Neuome Technologies Pvt. Ltd.

Neuome

Founder and Co-founder(s):
Dr. Rajanikanth Vangala Ph. D
(Managing Director & CEO)

Developed Under(scheme):
BIG

Email:
jiny@neuome.com

Product/Technology differentiation from Competitors

In biobanking and genomics research the available products for the biospecimen storage at RT but are expensive and after a specific time frame 2 weeks must be stored in freezers for longer storage. There are a few products for specific specimen storage at RT but their applications are limited. In general, the available products are either non affordable or with limited utilities. instaPRESERVE® is an affordable product especially for Indian market and suitable for long term storage of biospecimens at RT. With cost and utility factors instaPRESERVE® with 6 different SKUs is unique than other products in the market

Brief Description of Product

instaPRESERVE® is an innovative and propriety product of Neuome technologies. This alcohol-based solution was developed to collect transport and store biospecimens at room temperature RT for biobanking. This eliminates the expensive infrastructure with ultra freezers and liquid nitrogen-based storage containers. instaPRESERVE® is suitable for tissue fixation, histopathology and immunohistochemistry in clinical pathology. Anatomy museum specimens can be stored in instaPRESERVE® at room temperature. InstaPRESERVE® is an apt solution for the replacement of formalin. The specimen stored in instaPRESERVE® are suitable for genomics, proteomics and metabolomics analysis. InstaPRESERVE® is being further validated in cadaver embalming and forensic toxicology. instaPRESERVE® is an appropriate solution for agriculture and veterinary diagnosis and research. Blood, faecal, saliva and tissue samples from animals and plant parts and soil samples in agriculture can be collected in instaPRESERVE® and transported at RT. instaPRESERVE® preserves the data pathogens, gene expression etc. at the point of collection, hence a valuable product in confirmatory diagnosis and molecular research.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

In biobanking instaPRESERVE® has been validated for the preservation of biospecimens Blood, Saliva and Tissue with genomics and proteomics study. The specimens were stored for 5 years, and their stability has been confirmed. In histopathology an animal study has been completed and published. The application of instaPRESERVE® based tissue fixation, histopathology and immunohistochemistry analysis is under validation in multiple clinical pathology laboratories. instaPRESERVE® has been found to be efficient in metagenomics studies like gut microbiome and soil bacterial analysis. Based on the applications instaPRESERVE® has 6 different SKUs.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Our product line is designed for global distribution, with a strategic, phased rollout. We target India and Asia as our primary markets to establish a strong presence and customer base. Following this, we plan to expand our reach to other regions worldwide, ensuring a methodical and impactful market entry.



Title/Name of the Product/Technology

instaPRESERVE®, solution for collection transport and storage of biospecimen at ambient temperature.

Product Positioning

instaPRESERVE® is positioned as an innovative and cost-effective solution for biological specimen preservation, offering superior quality over conventional methods. Tailored for research institutions, biobanks, and healthcare facilities, instaPRESERVE® combines affordability and user friendly making it an ideal choice for Indian and global markets.

National/Societal Relevance

instaPRESERVE® is a non-toxic and ecofriendly product which replaces the toxic chemicals formalin and environmental pollution cold storage with freezers. The clinical pathologists, anatomists, forensic toxicologist and the technicians are exposed to occupational hazards with formalin usage. InstaPRESERVE improves their healthcare by replacing formalin. The demand for biobanking is increasing and adding freezers will greatly impact on environmental pollution. The emission of the greenhouse gasses can be avoided by replacing the freezers by biospecimens storage with instaPRESERVE at RT. InstaPRESERVE will greatly influence the improvement of the healthcare of the end users and the environment.

Import Substitution

instaPRESERVE® is an innovative Indian product. Many of the competitive products are imported hence expensive. As part of Make in India program instaPRESERVE is expected to considerably contribute by preventing the import and serving the country with affordable price for diagnosis and research.

Export Potential

instaPRESERVE®, as a user friendly and non-toxic product will have a potential in biobanking, medical diagnosis and basic science research globally. This biocompatible product meets the export/import regulatory requirements of different countries. On commercial launch the export potential can successfully be explored.

Name of Startup: Neuphony Pankhtech India Pvt Ltd.



Founder and Co-founder(s):
Ria Rustagi
Bhavya Madan

Developed Under(scheme):
LEAP Fund, SEED Fund

Email:
ria.rustagi@pankhtech.eu

Product/Technology differentiation from Competitors

India's First wearable and portable EEG Device Most affordable device worldwide

Brief Description of Product

Neuphony's EEG Flex Cap addresses the challenge of accessible and accurate brainwave monitoring, providing real-time data and insights for mental wellness, cognitive behavior therapy, and neurofeedback training. The technology enables practitioners, researchers, and enthusiasts to monitor and analyze EEG data with precision and ease.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

The Neuphony EEG Flex Cap, now at TRL 9, has successfully launched in the market, proving its reliability through extensive real-world use. This cutting-edge neurotech product, featuring 19 EEG sensors, delivers high-precision brainwave monitoring, ideal for researchers and practitioners alike. With robust sales and growing market penetration, it exemplifies a mature technology fully validated by customers, generating consistent revenue and solidifying Neuphony's position as a leader in the neurofeedback and BCI landscape. The Flex Caps advanced features, including real-time monitoring and neurofeedback capabilities, make it indispensable in both clinical and research settings.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Asia Pacific, Europe, UK, North America, and South America

Title/Name of the Product/Technology

Neuphony EEG Flex Cap

Product Positioning

The Neuphony EEG Flex Cap is positioned as a premium neurotech solution for researchers and clinicians, offering unmatched precision in brainwave monitoring. Designed for advanced cognitive and neurological studies, it bridges the gap between accessibility and high-performance, making cutting-edge neurofeedback technology available for both academic and research use.

National/Societal Relevance

The Neuphony EEG Flex Cap holds significant societal relevance by advancing mental health and neurological research. By providing accurate brainwave data, it empowers researchers and clinicians to better understand cognitive functions, mental health disorders, and neurodegenerative diseases. This technology facilitates early diagnosis and personalized treatment plans, contributing to improved mental health outcomes and patient care. Moreover, its accessibility promotes widespread adoption in educational institutions, fostering innovation in neuroscience. By bridging the gap between cutting-edge research and practical application, the EEG Flex Cap plays a crucial role in enhancing brain health and overall well-being in society.

Import Substitution

The Neuphony EEG Flex Cap serves as a critical import substitution by offering a high-quality, domestically-produced alternative to expensive foreign EEG devices. It reduces dependency on imports, fosters local innovation, and provides affordable, advanced neurotech solutions, supporting India's self-reliance in cutting-edge brain health technology.

Export Potential

The Neuphony EEG Flex Cap has strong export potential due to its high precision, affordability, and advanced features, making it competitive in global markets. Its compatibility with international research and clinical standards positions it as an attractive neurotech solution for academic institutions, healthcare providers, and research centers worldwide.

IP Status

3 trademarks, 2 copyrights for software 1 design registration under 5 classes Europe and India 1 software patent India and US

Name of Startup: Noccarc Robotics Private Limited



Founder and Co-founder(s):
Nikhil Kurele, Harshit Rathore,
Tushar Agarwal

Email:
karishma.b@noccarc.com

Product/Technology differentiation from Competitors

Apart from the clinical offerings that competitor products have, Noccarc V730i comes with an impeccable operating system which allows over-the-air software upgrade, just like smart phones. New technologies, enhanced user interface, and integration of new features in the same machine happens with a single click on the ventilator.

Brief Description of Product

Noccarc V730i is a smart ICU ventilator with compressor-based technology that provides respiratory care to adult, pediatric, and neonatal patients. Powered by the in-house developed cloud-based digital platform HorizonView, Noccarc V730i has an in-built ability for real-time remote monitoring on remote devices and also wireless central monitoring system. Noccarc V730i is truly designed for the future! The design of the ICU Ventilator comes with expansion communication ports that can easily integrate hardware modules of future technologies and features. With over-the-air updates and easy hardware plugging, the ventilator can evolve with new advancements in medical technology.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Commercialized

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

All states in India. Export business targeted in African countries.

Title/Name of the Product/Technology

Noccarc V730i Smart ICU Ventilator

Product Positioning

Smartest ICU Ventilator, ever.

National/Societal Relevance

This project will reduce dependence on imports and support the governments healthcare initiatives like PM-JAY Yojana, HEALTH Stack, UHID, etc., while ensuring data privacy and strengthening healthcare in Tier-2 & Tier-3 cities.

Import Substitution

The total ICU Ventilator Market size in India is INR 1100 Cr per annum. Unfortunately, 85 of this market is dominated by imported products, which Noccarc, with its Made in India ICU Ventilator plans to contribute towards import substitution.

Export Potential

Considering the regulatory compliances in other countries, Noccarc is eligible for sales in African countries, Indonesia and other.

IP Status

Granted Related to Noccarc V730i: 434454, 456959, 473231, 479307, 483769, 507955, 515484, 501684, 483769, 460696 Granted Not related to Noccarc V730i: 490827, 349368, 424467 Filed Related to Noccarc V730i: 202121008713, 202221042868, 202221059421, 202221063690, 202221064462, 202321000413, 202321009431, 202321009602, 202321010501, 202321041778, 202321041777, 202321079376, 202221073058



Name of Startup: Obront Biotech

Founder and Co-founder(s):
 Sayid Islam Amirul Islam

Developed Under (scheme):
 BIG

Email:
 sayidislam@gmail.com

Product/Technology differentiation from Competitors

Improved Sensitivity and Specificity with an improved signal-to-noise ratio enables a larger target detection window thus improving the efficacy of the qPCR assays for various infectious diseases. It thus enables earlier detection of disease and end-of-disease prognosis thus improving treatment outcomes for patients.

Brief Description of Product

The developed qPCR technology platform, the LIBRA PCR assays, is a novel signal detection chemistry that bridges the sensitivity gap of the current gold standard qPCR TaqMan probes especially in clinical settings. Any attempt to improve sensitivity of a PCR assay leads to a drop in specificity or an increase in false positives - an unwanted outcome in clinical settings. This due to non-specific signals or noise, usually generated by PCR inhibitors in clinical samples. The novelty of the developed signal detection chemistry is in its design of labelled PCR primers and probes that optimizes for reduction of non-specific signals or noise, thus enhancing sensitivity and specificity simultaneously. This reduction in non-specific signals leads to a longer detection window and therefore a higher dynamic range along with improved performance in the presence of PCR inhibitors, like in sputum samples - thus significantly enhancing sensitivity. This enhanced sensitivity or detection limit is crucial in both primary care and point-of-care clinical settings. It enables earlier and more sensitive detection of disease while also enabling more accurate clinical decisions at the end of the treatment cycle. It helps bridge the gap of point-of-care applications with lab-based qPCR settings thus elevating current disease screening practices.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

LIBRA Hep-B assay was validated on a statistically significant clinical samples study against a comparable TaqMan assay and showcased improved sensitivity and specificity, thus showcasing the core value proposition of the technology.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India Market initially. Eventually US, European and Japanese Markets

Title/Name of the Product/Technology

LIBRA Assays - a next-gen qPCR technology platform

Product Positioning

Category Technology leader priced competitively against current market leaders.

National/Societal Relevance

Globally competitive, best-in-class PCR kits manufactured from India, perhaps further enhancing the relevance of Indian diagnostics ecosystem internationally - Improved rural health screening practices perhaps adopted for early screening of disease and post-treatment follow-ups

Import Substitution

The key, novel component of the developed technology platform - the qPCR primers and probes have now been fully developed locally including raw materials. Other components of the qPCR kit are in its early stages of indigenization.

Export Potential

Efficacy, once comprehensively established, has global relevance. Improved qPCR assays can be deployed in both the Global North and the Global South.

IP Status

Patents Filed in India, US, European and Japanese Patent Offices.

Name of Startup: Oko Icare Solutions Pvt. Ltd



Founder and Co-founder(s):
 Neha Lande
 Ashish Andraskar

Developed Under(scheme):
 SBIRL SEED Fund

Email:
 nehalande89@gmail.com

Product/Technology differentiation from Competitors

Accuway stands out from other glaucoma screening devices due to several key differentiators: Faster and More Efficient: Accuway provides rapid results, delivering a single IOP reading within 5 to 8 seconds, significantly reducing the time required for screening compared to traditional devices. Non-Invasive and User-Friendly: Unlike many glaucoma diagnostic tools, Accuway is designed to be non-invasive and easy to operate, requiring minimal training for healthcare professionals. Its portability and simplicity allow for use in a wide range of settings, including rural and underserved areas. Cost-Effective: Accuway offers a more affordable solution for glaucoma screening, making it widely accessible.

Brief Description of Product

Accuway is not just a solution—it's an urgent necessity in the fight against glaucoma, addressing a critical need that can no longer be ignored. As glaucoma continues to silently rob millions of their sight, the demand for rapid, accurate, and accessible screening has never been more pressing. Traditional methods are falling short, leaving vast numbers of people undiagnosed and vulnerable to irreversible blindness. Accuway steps into this gap with cutting-edge technology that makes early detection possible anywhere, at any time. In a world where timely intervention is the difference between vision and darkness, Accuway is the need of the hour, empowering healthcare providers to save sight and transform lives before it's too late.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

Accuway is at TRL 5 as it is undergoing clinical validation in real-world settings, including hospitals in tier I and tier II. The technology has moved beyond prototypes to functional testing, ensuring efficacy, accuracy, and regulatory compliance, positioning it for further development and market readiness.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Accuway is targeting both domestic and international markets, with a focus on regions where glaucoma remains a significant health concern. In India, the primary focus is on Maharashtra, including rural and urban areas. Internationally, Accuway aims to enter glaucoma-prevalent regions in Africa, where access to early detection tools is limited. These regions are chosen due to the high incidence of undiagnosed glaucoma and the need for affordable, accessible screening solutions.

Title/Name of the Product/Technology

Accuway- A Noninvasive, anesthesia-free Inta Ocular pressure monitoring device

Product Positioning

The product positioning of Accuway is as a cutting-edge, affordable, and non-invasive glaucoma screening device designed for rapid and accurate intraocular pressure IOP measurement. It is positioned as a user-friendly solution for healthcare providers, offering portability and ease of use, making it suitable for both urban hospitals and rural clinics.

National/Societal Relevance

Accuway addresses a critical national need in India by providing accessible, affordable, and efficient glaucoma screening. With millions at risk of undiagnosed glaucoma, especially in rural and underserved areas, Accuway enhances early detection, reducing preventable blindness and alleviating the burden on the healthcare system, contributing to national health goals.

Import Substitution

Accuway serves as a key import substitution by offering a locally developed glaucoma screening device, reducing dependence on expensive imported medical equipment. Its cost-effective and innovative design provides an alternative to foreign products, promoting self-reliance in healthcare technology and supporting the governments Make in India initiative.

Export Potential

Accuway has significant export potential, particularly in emerging markets and developing countries where affordable, accessible healthcare is crucial. Its portable, cost-effective glaucoma screening technology addresses a global need, especially in regions like Africa and Southeast Asia, where early detection tools are limited, offering a scalable solution for glaucoma prevention worldwide.

IP Status

3 Patent Granted 1 design patent filled
 DEVICE FOR DETECTING GLAUCOMA A
 DEVICE FOR MONITORING INTRAOCULAR
 PRESSURE RAPID PROTOTYPING ASSISTED
 FABRICATION OF A DEVICE FOR DETECTING
 GLAUCOMA Intra Ocular Pressure Monitor
 Device





Name of Startup: Oncoseek Bio Pvt Ltd.



Founder and Co-founder(s):
Dr. Suresh Poosala

Developed Under (scheme):
BIG

Email:
suresh@oncoseekbio.com

Product/Technology differentiation from Competitors

Our spheroid/organoid models have achieved a high level of development, demonstrating consistent and reproducible results across various research settings. They are commercially available and utilized by multiple academic and industrial entities, supported by established protocols and comprehensive support services. Positive user feedback highlights their effectiveness in meeting research needs and improving outcomes. The models are scalable and robust, ensuring reliable performance in diverse applications and facilitating their integration into research practices.

Brief Description of Product

Three-dimensional 3D cell culture systems are gaining traction in drug discovery and tissue engineering due to their ability to provide more physiologically relevant data, which can be more predictive of in vivo outcomes. The increasing demand for human-relevant models arises from the genetic differences between species and the ethical drive to reduce animal studies, aligning with the 3Rs principle: replace, reduce, and refine. At Oncoseek Bio, we develop spheroid, organoid, and patient-derived xenograft PDX models to better study disease biology, screen novel therapeutics for cancers and metabolic disorders, and repurpose existing drugs. These models closely mimic human tissues, making them highly relevant. The current drug discovery process reveals a stark reality where, about 90 of drugs that succeed in mice fail in humans, highlighting the limited predictive power of traditional pre-clinical models. This underscores the necessity for models that better emulate human responses to drugs. 3D in vitro modeling addresses this issue by creating cellular models that simulate living tissues, allowing for extensive research and drug discovery in vitro rather than in animals or humans. These models can be integrated at various stages of drug discovery, prior to clinical trials. Additionally, 3D cell cultures are pivotal in cell therapy and regenerative medicine, where cells are grown for transplantation to repair damaged tissue. Although still in its early stages, the 3D cell culture field is rapidly evolving and holds promise for bridging the gap in preclinical predictive models more effectively than animal models. Emerging 3D cell culture products are already being integrated into the drug discovery process, transitioning from academic disease modeling to pharmacological applications such as drug screening, toxicity testing, pharmacokinetics, drug delivery, stem cell research, and the development of cell therapies. This technology is crucial for advancing our understanding and treatment of diseases, providing a more accurate and human-relevant approach to preclinical research. We have developed in vitro disease models for a range of cancers, including lung, prostate, breast, and liver cancers, as well as for metabolic disorders like non-alcoholic steatohepatitis. Additionally, we have created oncolytic virus models and immunocompetent models for drug screening. These robust models are highly effective in analyzing various compounds and small molecules critical for cell therapy and are actively utilized in regenerative medicine.

Technology readiness level (TRL) TRL- 9

Current Stage of Development


The current stage of development for our in vitro spheroid and organoid models has reached Technology Readiness Level 9, demonstrating their advanced maturity and applicability in real-world scenarios. These models have successfully transitioned from laboratory research to practical, widespread use in drug discovery and disease modeling. They are now extensively implemented for high-throughput screening, toxicity testing, and understanding disease mechanisms, proving their robustness and reliability. These models effectively replicate complex tissue structures and functionalities, offering a significant improvement over traditional 2D cultures and animal models, thereby validating their readiness for full-scale deployment in biomedical research and therapeutic development.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted
India

Title/Name of the Product/Technology

3D Models for the Drug Screening of
Various Cancers and Metabolic Disorder



Name of Startup: OPTI-MODE DIAGNOSTICS Pvt.Ltd.

OPTI-MODE
DIAGNOSTICS
Pvt. Ltd.

Founder and Co-founder(s):
Prof. Dalip Singh Mehta, Dr. Veena
Singh, Mr. Siddharth Mehta

Developed Under(scheme):
BIG

Email:
veenasingh.lko@gmail.com

Product/Technology differentiation from Competitors

Developed smart-phone based field-portable auto-fluorescence, fluorescence spectroscopic & imaging device is point-of-care digital pathology device which can be operated by nurses/ non-skilled persons and can screen large number of patients quickly. Conventionally, all the techniques auto-fluorescence, fluorescence spectroscopy and imaging systems are made independently which are bulky, costly. We have integrated all the technologies into a multimodal system for consistent and cost-effective screening and diagnosis of cancer patients.

Brief Description of Product

We have developed a smartphone-based field-portable label-free multi-modal auto-fluorescence and fluorescence, spectroscopic & imaging device, which is a point-of-care digital pathology device for consistent, cost-effective screening of cancer patients. Device works on the principle of auto-fluorescence and fluorescence signal generated by cancerous tissues by means of illuminating the sample by UV/Blue light. Device consists of UV-LED, blue-LED for generating fluorescence, integrated into 3D-printed mount. Device also consists of housing for excitation & emission filters. First images of cancer patients can be recorded using UV-LED & smart-phone camera, thereafter spectra are recorded using fiber-optic probe directly. Images and spectral data are processed using AI/ML/DL software for diagnosis.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

We have developed the three prototypes which are placed in the hospitals for data collection and already completed 365 cases. The graphic user interface along with the AI model for data analysis has been also developed.

Are you willing to Transfer/Out-License your Technology No



Title/Name of the Product/Technology

Oral cancer screening and diagnostics

National/Societal Relevance

The proposed easy to use point-of-care device is useful for consistent and cost-effective screening and diagnosis of oral cancer patients, which has great potential for societal and market impact. This is important step towards advanced device development under make in India program which may lead to "Atam-Nirbhar Bharat". The device is field portable, can be operated by non-skilled persons and be used for effective medical care of patients in remote/rural areas. The device integrates non-contact, non-invasive techniques into one at very low cost.

IP Status

Patent no. 524377

Name of Startup: Ostic Pharma Pvt Ltd



Founder and Co-founder(s):
Dr. Vinay Saini
Dr. Kusum Saini

Email:
drvinays14@gmail.com

Product/Technology differentiation from Competitors

Competitors- Sickie SCAN® - Biomedomics, USA & Hemotype C, USA - Imported Gel Electrophoresis - Thermo Fisher Scientific - Imported, Time Consuming and Expensive Ion-Exchange HPLC Systems- Hemoglobinopathy Testing / HPLC Newborn Screening Test - Biorad Imported, Time Consuming and Expensive Proposed -OstiSickle SCANTM- Ostic Pharma Pvt Ltd, SINE, IIT Bombay

Brief Description of Product

Sickle cell disease SCD - Autosomal recessive & Most inherited & largely neglected inherited blood disorder Sickle Cell Anemia - Point mutations at 6th position of beta-globin chain - Valine replace Glutamic acid - Hb S Problem - Screening and Rapid diagnostic tools for Sickle cell Diseases SCD are limited Solution - Rapid and affordable tests - mass screening & diagnosis of SCD Goals - Development of visual, qualitative, rapid & affordable tests for SCD Prevalence - Sub-Saharan Africa, the Middle East, India, the Caribbean, South and Central America, some countries along the Mediterranean Sea, the United States, & Europe Worldwide 300,000 children - born annually with SCD India 20 million patients with SCD Highest in South Asia - Chhattisgarh, Odisha, Maharashtra, Gujarat, Madhya Pradesh, Telangana, Andhra Pradesh and some parts of Tamil Nadu and Kerala Opportunities - Vision of GOI - Eliminate Sickle Cell Anemia by 2047 The union budget -FY 2023-24 Focus - Awareness creation, universal screening of approximately seven crore people 0-40 years in tribal areas <https://pib.gov.in/PressReleasePage.aspx?PRID=1896039> Solution - Rapid and affordable tests - mass screening & diagnosis of SCD Goals - Development of visual, qualitative, rapid & affordable tests for SCD Objective 1- Visual test for mass screening of Sickle Cell Principle - Diseased Hb-S gets PPT turbid- insolubility of the HbS in presence of buffer soln while normal Hb doesn't Detect the presence of hemoglobin S Current Status - Test developed and internal evaluation done Current Status - TRL - 6 Objective 2 - Rapid Tests for SCD / Trait - Based on LFA Principle - Detect types of SCD qualitatively in blood marker hemoglobin beta S LFA - Polyclonal antibodies against hemoglobin S, hemoglobin A Labeling- Gold & Other particles Conjugate, Coating - Monoclonal / polyclonal Abs Current Status - TRL-6 Novel innovative step- Gold & Other particles - Higher sensitivity & Specificity Reducing False positive results USP- Improve diagnosis of SCD Suitable in rural / tribal areas & resource constraint areas Good import substitution Value Proposition - Mass screening & diagnosis

Technology readiness level(TRL) TRL- 6

Current Stage of Development

Steps - Test Licenses CDSCO - Done MFG/IVD/2023/103188 Test Development- Done Evaluation- Done / in process Stability Studies - To be done Scaling up for validation at FDA / CDSCO sites - To be done CDSCO Application MD-7 -Manufacturing, distribution & donation of tests [License- MD-9] - will be done Infrastructure- 650 Sqfeet area - Monash Building, IIT Bombay Scaling up facility- Dehumidifier- 360 CFM Bry Air - Control humidity 20 & temperature AC for scaling up of IVD, Program Strip Cutter, Sealer, Oven, incubator & tables and stools SS, Domino Pouch Printer, Dispenser Biodot, USA, U. V. Spectrophotometry,

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Sub-Saharan Africa, the Middle East, India, the Caribbean, South and Central America, some countries along the Mediterranean Sea, the United States, & Europe Worldwide 300,000 children - born annually with SCD India 20 million patients with SCD Highest in South Asia - Chhattisgarh, Odisha, Maharashtra, Gujarat, Madhya Pradesh, Telangana, Andhra

Title/Name of the Product/Technology

Scaling up, Validation and Regulatory Approval of Rapid Tests for screening & Diagnosis of Sickle Cell of Anaemia - An effort to align with NSCEM.

Product Positioning

Trade Name - OstiSickle Cell Scan has been registered.

National/Societal Relevance

Vision of GOI - Eliminate Sickle Cell Anemia by 2047 The union budget -FY 2023-24 Focus - Awareness creation, universal screening of approximately seven crore people 0-40 years in tribal areas

Import Substitution


The product will provide good import substitution.

Export Potential

We will export the product in Sub-Saharan Africa, the Middle East, the Caribbean, South and Central America, some countries along the Mediterranean Sea, the United States, & Europe

IP Status

Trade Mark - OstiSickle SCAN - Trademark Registered Patent application number - 202321058040 Date of filing - 30th August 2023 Title - Rapid Diagnostic Test RDT kits for Sickle Cell Anemia Type of application - Provisional



Name of Startup: Papersens Pvt Ltd



Founder and Co-founder(s):
Dr.K Sudhakara Prasad
Mrs. Sonia Joseph

Developed Under
(scheme)- BIG, OTHERS

Email:
ksprasadnair@yahoo.com

Product/Technology differentiation from Competitors

Noninvasive test for PD biomarker for early screening and drug titration

Brief Description of Product

Disposable paper electrodes for electrochemical biosensor developments and paper analytical devices for biomarker detection Parkinsons and leptospirosis . The medicated contact lens for glaucoma management by utilizing the reverse switching phenomenon of graphene quantum dots.

Technology readiness level(TRL) TRL- 7

Current Stage of Development

Clinical Trial Complete for PD dual sensor

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event Yes

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

Disposable dual PAD for Noninvasive PD biomarker detection.

Unique Selling Point

Novel Nanotechnology and Indigenous Technology.

Present Stage of Development NA

Geographical Region Targeted

All the sensors developed have national, international, and societal importance.

Major Achievements

Bangalore Tech Summit Best campus start-up SmartBio Award 2023

Other Scheme Name

DBT, BIRAC-ETA, ICMR, DHR, SERB-Core grant, and Startup Karnataka Idea2POC

Title/Name of the Product/Technology

Disposable Paper analytical devices, paper electrodes, and medicated contact lenses

National/Societal Relevance

All the sensors developed have national, international, and societal importance.

Export Potential

yes

IP Status

1, A Microfluidic device 201841034005, Granted on 01-02-2024 IN 506261 2, Electrochemical biosensor and method for diagnosing Leptospirosis 201941047489 3, Thermal biosensor based diagnostic kit for Leptospirosis 202041011481, granted on 31-07-2024 IN 546790 4, Diagnostic test for Parkinson's disease 202041032701





Name of Startup: PICTELAI PRIVATE LIMITED



Founder and Co-founder(s):
Sandeep Kulkarni Sagar
Deshmukh Chinmay Joglekar

Developed Under (scheme):
OTHERS

Email:
chinmay.joglekar@pictelai.com

Product/Technology differentiation from Competitors

Automation of image analytics, morphological characteristics, audit trail, FDA Compliance and more

Brief Description of Product

Microscopic Image Analytics, Particle morphology automation, Automated Microbial Colony Count, US FDA 21 CFR Compliance, Cloud Platform

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Product 1.0 version has been launched in India for Pharmaceutical Industry under IPV Product 1.1 will be launched in early Q1 2025 is for Biotechnology Domain

Product Launched / About to be Launched

Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event

Yes

Are you willing to Transfer/Out-License your Technology

Yes

Availability for showcasing at Birac

Yes

Product/Technology

Image Analytics and Automation in Biotechnology

Unique Selling Point

Automation, Audit Trail and Reports

Present Stage of Development

Product launched in Pharmaceutical domain. With further development, it can support biotechnology domain

Geographical Region Targeted

Global

Major Achievements

None

Bionest Center Name

N/A

Other Scheme Name

Bootstrapped

Title/Name of the Product/Technology

AI ML in Image Processing, Computer Vision Algorithm Development, Cloud Platforms

Product Positioning

Premium High Quality Product with precise and accurate performance

National/Societal Relevance

Useful for all biotechnology companies in automation, productivity improvement and improved accuracy

Import Substitution

NA

Export Potential

All biotech companies across globe

IP Status

Not applicable

Name of Startup: PiStarTech Private Limited



Founder and Co-founder(s):
Dr. Anis Fatema
Dr. Aftab M. Hussain

Email:
anis.fatema786@gmail.com

Product/Technology differentiation from Competitors

Major competitors include Tekscan, Kan innovations etc and other entities lacking comprehensive AI integration or relying on pricier equipment. Our differentiators include: Affordability: Our solutions are priced at 1/10th the cost of the closest competitors. Full-Stack Solution: We offer a comprehensive solution from screening to orthotics, unlike many competitors. AI Layer: Our AI technology not only constructs 3D foot models but also diagnoses foot conditions with unmatched precision.

Brief Description of Product

PiStarTech Pvt. Ltd. is a health-tech startup incubated at CIE-IIITH. We at PiStarTech manufacture foot medical image analysis devices. It is a digital automated foot scanning system that provides complete plantar pressure analysis. We aim to provide affordable and automated foot screening facilities in India and support medical professionals at different stages of clinical evaluation and medical treatment. It aids in identifying pathologies and making accurate diagnoses and objectively evaluating the effectiveness of orthotics and treatments.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

The product has been developed and we are testing it in the relevant environment. We have also applied for ISO 13485 certification of the product.

Are you willing to Transfer/Out-License your Technology

No

Geographical Region Targeted

Tier I, Tier II and III cities

Title/Name of the Product/Technology

Diabetic Podiascanner Mat

Product Positioning

Our product is for the doctors especially orthopaedic and podiatrist. We position our product to be sold to pharmaceutical companies that specializes in medical equipment so that they can distribute our product to doctors

National/Societal Relevance

The cost of our solution is 4x lower than the comparable product in the market which has to be imported. This has been achieved through thorough research on the sensor system, development of the complete solution from scratch, and in-house manufacturing. The cost differential is important for penetration in small town and rural areas where a majority of patients do not have such a facility.

Export Potential

It has a great export potential. We are planning of launching it in middle east countries like Saudi and Dubai

IP Status

Granted patent no: 202341035778 Title: SYSTEM AND METHOD FOR DETECTING POSTURE OF USER AT SMART CHAIR USING MACHINE LEARNING MODEL



Name of Startup: Plabs Solutions Private Limited



Founder and Co-founder(s):
Prashant Chaudhary Onkar Singh
Vikas Garg Dr. Rahul Sharma

Developed Under(scheme):
BIG

Email:
pchaudhary@predoc.ai

Product/Technology differentiation from Competitors

? Unique combination of AI based prediction in conjunction with well tested physical technique? Extremely low cost at 1/10th of traditional tests? Specializes on Indian skin pigmentations? Works even in offline mode low resource settings? No proprietary device or any additional equipment like calibration card /chart/formula/calculations required? Enables diagnosis on a simple mobile? Non-invasive, Painless, Accurate diagnosis? Remote jaundice level monitoring of newborns? At home test accessibility? Instant results within 30 seconds

Brief Description of Product

Low Cost, Non-Invasive, Skin Tone Agnostic, Neonatal Jaundice detection using Pressure method on AI enabled smartphone, which: 1. Specializes in Indian skin tones 2. Accurately measures bilirubin level 3. Non-invasively using a 5 second video 4. At 1/10th the cost 5. Within 30 seconds 6. Works in offline mode low resource settings 7. No proprietary device

Technology readiness level (TRL) TRL- 4

Current Stage of Development

1. Patent No. 202111010537 Status: Published 2. POC on 500 videos of neonates 3. Identified jaundice category levels in test set using integrated mobile application with an overall accuracy of 90

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Phase I: Delhi, UP, Haryana, Phase II: Maharashtra, Goa, Karnataka Phase III: Punjab, Rajasthan, Himachal, Uttarakhand, Madhya Pradesh Phase IV: Rest of India



Title/Name of the Product/Technology

PreDoc.ai: The Pre-Doctor Diagnosis Platform

Product Positioning

- Low-cost alternative to bilirubinometer
- Specialized jaundice test for Indian skin tone
- Recommended monitoring test for newborns treated for jaundice in hospitals

National/Societal Relevance

It will enable semi-urban/rural population to avoid life-threatening situations arising out of neonatal jaundice by using our low cost, mobile based screening solution. Thus, the new borns in such areas can be saved from permanent damages caused by jaundice like brain damage, paralysis, etc.

Import Substitution

Substitute Bilirubinometers will have to be Customized for darker skin tones before being effective on Indian population. Thus, raising average device cost from 2 lakh Rs. per device to 3-4 lakh Rs. per device.

Export Potential

Highly scalable as no hardware is required and software export can be globalized with a click of a button.

IP Status

Patent Application No. 202111010537
Status: Published

Name of Startup: PlebC Innovations Private Limited



Founder and Co-founder(s):
Dr. Krishna Prasad
Mr. Vivek Gorrepati

Developed Under(scheme):
BIG

Email:
admin@plebc.com

Product/Technology differentiation from Competitors

TORUS allows for a lateral application area without requiring the change in position of patient and required. It offers XYZ probe motion control, with a precise and automated adjustments, unlike some competitors who rely on manual adjustments by an assistant. The system is VR compatible, enhancing the diagnostic experience with a haptic curve pad, a unique feature that provides tactile feedback. It incorporates advanced data compliance measures, including biometric authentication, geo tagging and block chain. It is designed to safely apply pressure with feedback mechanisms and mechanical limits, enhancing safety. Genital masking for privacy and compliance with PCPNDT.

Brief Description of Product

Tele-Operated Robotic Ultrasound System enables the shortage of radiologists in rural regions by allowing doctors to perform ultrasounds remotely. Equipped with advanced features such as a 7-DOF probe positioning system, haptic feedback for precise control, and biometric security for data protection, our product ensures high-quality imaging and diagnosis without the need for a radiologist to be physically present. This system aligns with multiple Sustainable Development Goals SDGs, aiming to improve maternal health, reduce birth defects, and facilitate early cancer detection, thus enhancing overall healthcare outcomes in underserved areas? TORUS system consists of two primary stations: the Doctors Station and the Patient Station. The Doctors Station includes displays for ultrasound visualization, a joystick for controlling the probes position, and biometric authentication for security. This station allows radiologists to remotely operate the ultrasound machine and interact with the patient via video and audio feeds. The Patient Station, equipped with a camera, sensors, and a 7 Degrees of Freedom DOF robotic arm, positions and maneuvers the ultrasound probe on the patient's body.

Technology readiness level (TRL) TRL- 4


Current Stage of Development

The TORUS system is currently in Minimum Viable Product.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Targeting for small towns in India with populations between 36,000 and 60,000 for the deployment of the TORUS system. These towns are specifically chosen because they currently lack ultrasound facilities and have established broadband connectivity.



Title/Name of the Product/Technology

Tele-Operated Robotic Ultrasound system

Product Positioning

In rural areas, remote areas where there is no ultrasound facility. In territory care hospitals for intra hospital movement of ultrasound system

National/Societal Relevance

India's first tele-operated robotic ultrasound system, addresses critical healthcare gaps in rural areas, aligning with Sustainable Development Goal 3. It enables remote ultrasound scans, ensuring prenatal and cancer diagnostics accessibility. With only 13 of specialty doctors in rural areas, TORUS reduces the average 45 km travel needed for ultrasound access. It improves emergency care, decreases diagnosis time for heart diseases This innovative solution offers secure, efficient, and timely medical services, significantly impacting maternal and general healthcare outcomes in underserved regions.

Import Substitution

Can replace imports of gantry robots, high precision positioning systems

Export Potential

Can be exported to countries with low dense population, low doctor to patient ratio, third world countries and gulf countries

IP Status

202341084539 granted on December 11, 2023.



Name of Startup: Poccet Labs



Founder and Co-founder(s):
Dr. Abhinav Gupta

Developed Under (scheme):
OTHERS

Email:
abhinav@poccetlabs.com

Product/Technology differentiation from Competitors

Ultra-portable Handheld Lower Manufacturing Cost Made in India

Brief Description of Product

We are developing a handheld blood analyzer for Emergency Rooms & ICUs

Technology readiness level (TRL) TRL- 3

Current Stage of Development

Individual components such as Biosensors, Electrodes, PCBs are developed and tested. Functional device under development.

Product Launched / About to be Launched

About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

Microfluidic biosensors to test the blood sample

Unique Selling Point

Small Size Lower Capex Made in India

Present Stage of Development

MVP Development

Geographical Region Targeted

Global

Major Achievements

TIDE 2.0 Grant Award SISFS Grant Award

Bionest Center Name N/A

Other Scheme Name

TIDE 2.0

Title/Name of the Product/Technology

InstaDx - Handheld blood gas analyzer

Product Positioning

Blood Testing right at the bedside for Emergency Rooms, ICUs and Ambulances

National/Societal Relevance

Giving a push to the Atmanirbhar Bharat Mission, because Blood Gas Analyzers are imported from European Countries and we are substituting that by manufacturing in the country.

Import Substitution

Blood Gas Analyzers are imported from European Countries and we are substituting that by manufacturing in the country.

Export Potential

Very high potential for export all over the globe.

IP Status

Not yet filed.

Name of Startup: Pragmatech Healthcare Solutions Pvt. Ltd.



Founder and Co-founder(s):
Mr. Anirban Palit Dr. Sayantani Pramanik
Ms. Palna Patel Dr. Bhagirath Modi

Developed Under (scheme):
BIG

Email:
anirban.palit@pragmatech.co.in

Product/Technology differentiation from Competitors

CERVICHECK Self Sampling Kit is a First clinically validated self-sampling kit that is developed in India. Positive percent agreement established with clinician collected samples established not only for HPV at 95 but also for Liquid based cytology at 89 for Sample adequacy. Established nil/low invalid sample collection failures, established user acceptance on a large cohort. Self-sampling kits that are available in other countries, are Designed specifically for a population that has undergone pelvic examination/self-sampling earlier. Moreover, they Do not employ fail safes to ensure correct sample collection- documented evidences of high numbers of Invalid Results sampling failure reported

Brief Description of Product

Our Innovation: The CERVICHECK™ Kit The CERVICHECK™ Assay is a field deployable point-of-care solution that detects pre-cancerous lesions accurately and without subjectivity, thus enabling an immediate course of treatment with a clinically actionable result. The CERVICHECK™ Kit consists of two technological innovations: 1. The CERVICHECK™ Self-Sampling Kit - This method of sample collection has been extensively researched in the last few years and it has been strongly established that self-sampling increases participation for cervical screening. However, the self-sampling kits that are available presently in other countries are designed to be used only with a PCR based HPV test. The CERVICHECK™ Self sampling kit, owing to its unique design and features has the ability to collect cells from the surface of the cervix, unlike other self-sampling kits available globally. Current Status: The CERVICHECK™ Self Sampling Kit - Approved by regulatory for launch in India, B2B pilot sales initiated to create brand awareness, own manufacturing premises. 2.The CERVICHECK™ Screening Kit for Point-of-care Detection - The CERVICHECK™ Screening test - will detect the presence of an established human biomarker in the cervical cell lysate in a Lateral-flow Test. This biomarker has been validated globally to detect pre-cancerous lesions/ Cervical pre-neoplasia. The positive predictive value for CIN2+ stages has been reported to be 100 and a negative predictive value of 82.5. Thus, this technology is being developed to detect CIN1 stage that have high chances of progression. The CERVICHECK™ Screening Kit - Advanced of development, will be going into clinical trials by July 2025.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

The CERVICHECK Self Sampling: 1. Successfully completed Pivotal Clinical Evaluation, with 94 Equivalence with Clinician collected samples 2. Approved by CDSCO HQ under FORM MD26 - Permission to manufacture and sell non predicate medical device 3. ISO 13485 obtained from CDSCO notified body 4. Manufacturing license MD 5 obtained from State Licensing Authority of Gujarat

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India and Low-Middle Income Countries

Title/Name of the Product/Technology

The CERVICHECK Self-Sampling Kit India's first clinically validated Self-Sampling kit that enables self-collection of cervical cells for periodic cervical screening. TRL 7 The CERVICHECK Screening kit - for detecting pre-cancerous cervical lesions - that can be deployed in a rural setting and can enable at-the-site treatment, thus reducing dropouts. TRL 3

Product Positioning

In a rural location, instead of going to crowded VIA-based mass screening camps and losing a day's earnings, rural ladies are encouraged by the ASHA Worker to get themselves checked using the CERVICHECK™ kit whenever they get an opportunity to visit the nearest Community Health Officer CHO.

National/Societal Relevance

The severity of Cervical Cancer as a public health burden in India can be gauged by the fact that India alone accounts for one-quarter of the worldwide burden of Cervical Cancers. It is the one of the leading causes of cancer mortality, accounting for 17 of all cancer deaths among women aged between 30 and 69 years. These numbers are solely attributed to successful adoption of periodic cervical cancer tests. Success of a large-scale screening Success of a large-scale screening program extensively depends on an India-centric approach where the local barriers for adoption are addressed.

Import Substitution

At present, clinically validated Self Sampling Kits are only available/manufactured in US, EU.

Export Potential

High potential in Low- and Middle-Income Countries

IP Status

Utility Patent: 373245 Design No.: 377633-001 Date: 18/01/2023 Design No.: 319779-001 Date: 18/07/2019 Utility Patent of Addition, Under Review, Application No: 202323004747

Product 1 : Blood Na+ Sensor



Accurately detects the amount of Na+ in blood with 1 drop of sample put on the sensor (Part of the InstaDx™ System)

Product 2 : FLEXIBLE HEATERS



These heaters are low power consuming and can be integrated into any system.



Name of Startup: Prakhar Innovations LLP



Founder and Co-founder(s):
Dr Rajesh Mehta, Dr Hema Mehta,
Poorn Mehta, Harit Mehta

Email:
rajeshforhealth@gmail.com

Product/Technology differentiation from Competitors

As such no competitors in Market with this technology. Blood test is very costly.

Brief Description of Product

Even though there is wide spread vitamin A deficiency in population, no one has developed the instrument so far which can measure the minimum light required for eyes to identify the object on e-paper in terms of millilux. The instrument is handy, easily movable, easy to operate and able to give result in less than 5 minutes! The recurring cost will be less than Rs 1 per test except manpower cost. Once we get large scale production, product cost will be around Rs. 25000 + taxes + margins.

Technology readiness level (TRL) TRL- 5


Current Stage of Development

Functional Prototype developed by integration of different modules and safety, efficacy and performance of candidate device demonstrated in a defined laboratory.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India to start with. Then Africa and other countries.



Title/Name of the Product/Technology

Bright Vision Detector

Product Positioning

This is now open for investors and we have applied for Government support. In less than 2 years period product will become a must instrument all over the world, just like Blood pressure instrument.

National/Societal Relevance

It can prevent accidents occurring at night. Also, infections, morbidity, mortality and blindness. just by spending 500 Cr and use of existing health workers and teachers we can prevent more than Rs. 1 lac Cr. Productivity will increase in industry and accidents will get reduced.

Import Substitution

No necessity for dependence on foreign technology. We have our own indigenous programming.


Export Potential

Huge potential for export as there is no such technology available world over.

IP Status

Filed a provisional patent specification, in India, in respect of SYSTEMS AND METHODS FOR TESTING EYESIGHT Application No: 202421063022

Name of Startup: PrefeCure



Founder and Co-founder(s):
Vineet Narayan Prajapati and
Syed Azmaan Ali Madni

Developed Under (scheme):
OTHERS

Email:
info.prefecure@gmail.com

Product/Technology differentiation from Competitors

PrefeCures platform stands out by integrating Systems Biology with Artificial Neural Networks for health prediction. Unlike traditional diagnostic tools, it utilizes a wide range of data sources, including genomics and multi-omics data, to provide comprehensive health insights. The platform offers instantaneous assessment for lethal diseases, contrasting with the time-consuming manual analysis of general diseases in traditional tests. This approach enables early detection and personalized health management, addressing critical gaps in current healthcare practices.

Brief Description of Product

PrefeCure is developing an innovative in-silico health prediction platform that leverages Systems Biology-driven Artificial Neural Networks ANN to revolutionize the prevention of deadly diseases. The platform aims to address critical healthcare challenges such as late-stage disease diagnoses, a reactive approach to health management, and underutilization of health data and advanced technologies. The system integrates various data sources including structured knowledge bases, scientific data, genomics data, multi-omics data, user health data, digital biomarkers, diagnostic data, and therapeutic data. This comprehensive data integration allows for a holistic approach to health prediction and risk assessment. PrefeCures platform uses artificial neural networks to analyze this complex dataset, enabling pattern recognition and assessment. The system performs arithmetic risk assessment and pathological evaluation to provide in-silico health predictions. This approach allows for early detection of potential health issues, personalized health insights, and more efficient diagnostic processes. The platform is designed to be accessible through both a website and a mobile app, targeting tech-savvy, urban, health-conscious individuals as well as a broader population of healthcare-seeking individuals. PrefeCure offers a freemium model for direct-to-consumer D2C use, as well as a B2B2C model through tech-sharing agreements with healthcare providers. PrefeCures solution aims to address the significant problem of medical errors, which result in millions of preventable deaths each year. By providing early, data-driven health insights, the platform has the potential to improve patient outcomes, reduce healthcare expenditures, and create opportunities for early intervention and prevention of diseases. The company is targeting a substantial market, with the global screening market valued at \$43 billion and the Indian screening market at \$5.7 billion. PrefeCures pricing strategy is competitive, offering their service at \$799 for a year after a month of use in their D2C model, and 750 per test in their B2B model. PrefeCure has already gained traction in the startup ecosystem, winning competitions and receiving grants from prestigious institutions like IIT Delhi, IISc Bangalore, and IIT Guwahati. The company is seeking support in various areas including data acquisition, product development, industry connections, clinical validation, computational resources, and legal guidance to further develop and scale their innovative health prediction platform.

Technology readiness level (TRL) TRL- 2

Current Stage of Development

PrefeCure is in the early stages of development, having validated their concept through various competitions and grants. They have outlined a clear path to market integration, currently in the validation phase Q1 where they are answering key questions about market demand and pricing. The next steps include establishing partnerships Q2, releasing a beta version Q3, and initiating early sales Q4. This indicates a well-thought-out development plan with clear milestones.

Product Launched / About to be Launched NA

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac No

Product/Technology

PrefeCures product is an in-silico health prediction platform that uses Systems Biology-driven Artificial Neural Networks. It integrates diverse health data sources to perform pattern recognition, risk assessment, and pathological evaluation. The platform provides rapid, comprehensive health insights, enabling early disease detection and personalized health management through both web and mobile app interfaces.

Unique Selling Point

PrefeCures unique selling point is its ability to provide instantaneous, comprehensive health assessments for lethal diseases using advanced AI and systems biology. This contrasts sharply with traditional, time-consuming manual analyses. The platform offers early detection and personalized health insights, potentially revolutionizing preventive healthcare and improving patient outcomes while reducing costs.

Present Stage of Development

PrefeCure is in the early stages of development, currently in the validation phase. They have won several competitions and grants, validating their concept. The company is answering key questions about market demand and pricing, preparing for upcoming stages including partnerships, beta release, and early sales.

Geographical Region Targeted

PrefeCure is initially targeting India, focusing on three main segments: tech-savvy urban health-conscious individuals, urban health tech curious individuals, and rural healthcare-seeking populations. Their long-term plan includes expanding globally, as indicated by their 5-year financial projections mentioning global operations.

Major Achievements

PrefeCure has achieved notable recognition: 1. Top 10 selection for incubation grant at IIT Delhi 2. Second Runner-up with incubation grant at IISc Bangalore 3. Top 50 selection for UNICEF-backed incubation 4. Winner of Business-Plan competition at IIT Guwahati with 80k INR grant

Bionest Center Name N/A

Other Scheme Name

ThinkStartup incubation grant

Title/Name of the Product/Technology

PrefeCure

Product Positioning

PrefeCure positions itself as an innovative, accessible health prediction platform for both consumers and healthcare providers. It offers a freemium D2C model through a website and app, targeting health-conscious individuals. For B2B2C, it provides a tech-sharing model with standalone API, allowing integration with existing healthcare systems.

National/Societal Relevance

PrefeCure addresses critical healthcare challenges in India, including high rates of medical errors and late-stage disease diagnoses. By enabling early detection and prevention of deadly diseases, it has the potential to significantly improve health outcomes, reduce healthcare costs, and enhance the overall quality of healthcare delivery in India.

Import Substitution

PrefeCures technology could potentially reduce reliance on imported medical diagnostic equipment and software. By developing an indigenous AI-driven health prediction platform, PrefeCure could decrease the need for expensive foreign medical technologies, contributing to import substitution in the healthcare sector using Electronic Health records EHRs, and embracing a population-specific approach.

Export Potential

While initially focused on India, PrefeCures technology has significant export potential. The global nature of healthcare challenges addressed by their platform suggests opportunities for international expansion. Their 5-year plan mentions global operations, indicating intent to export their technology and services to other countries, potentially generating foreign exchange.

IP Status

NA





Name of Startup: Primary Healthtech Private Limited



Founder and Co-founder(s):
Sahil Jaisani Founder & CEO, Ankit Chowdhury Co-Founder & CDO, Dr. Pooja Poddar Co-Founder & CMO

Developed Under (scheme): BioNEST, OTHERS, SBIRI

Email:
anushmita@mobilab.in

Product/Technology differentiation from Competitors

Mobilab targets primary care with its affordable, battery-powered, portable multi-diagnostic device, ideal for use in remote areas. Unlike multinational companies like Quidel, Abbott, and Roche, which focus on secondary and tertiary care, Mobilabs device addresses rural healthcare needs

Brief Description of Product

Mobilab is a portable diagnostic solution specifically designed for healthcare professionals who need fast and accurate test results in diverse environments, including clinics, mobile health camps, emergency response scenarios, and remote areas. It is capable of testing over 25 vital parameters essential for diagnosing diseases related to key organs such as the heart, liver, kidneys, and blood.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Mobilabs Technology Readiness Level TRL-9 is justified as Mobilab devices have already been deployed in various markets, including Nepal, Australia, and Venezuela. These devices are operational, fully functional in real-world environments, and actively serving healthcare professionals. With its ability to test over 25 critical health parameters, real-time error detection, and global market expansion, Mobilabs products demonstrate maturity and effectiveness, aligning with TRL-9 criteria.

Product Launched / About to be Launched Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

Mobilab, an innovative healthcare technology company, has developed a portable, battery-operated, IoT-enabled, AI/ML-powered device that tests over 25 critical health parameters, including kidney, liver, heart, pancreas, diabetes, and anemia from blood samples. This breakthrough enhances accessibility, efficiency, and accuracy in medical diagnostics.

Unique Selling Point

Mobilabs portable, battery-operated device breaks barriers in rural healthcare by offering affordable, accessible diagnostics without reliance on electricity. Its ability to store test results digitally for remote access enhances efficiency. Compared to costly Semi Auto-Analyzers, Mobilab is both cost-effective and accurate, providing strong market positioning.

Present Stage of Development

Technology Readiness Level - 9 TRL-9 - has been applied in its final form, is operational, and in the market.

Geographical Region Targeted

We aim to enhance healthcare accessibility in remote and underserved areas across India and similarly challenging regions worldwide. Our focus includes rural zones with limited medical infrastructure and countries facing significant healthcare access barriers, ensuring support reaches those most in need for better health outcomes.

Major Achievements

Primary Healthtech Pvt. Ltd. has won the Invent National Competition for Best Upcoming Healthcare Startup, received top honors in the NIRMAN Accelerator Programme, was a ZS Prize finalist, and earned the National Startup Award and TiE50 Award, becoming the first North East company to achieve these accolades.

Bionest Center Name

Centre for Nanotechnology, IIT Guwahati

Other Scheme Name

ICMR, Meity, SWASTHA, IIT Guwahati, SIIC - IIT Kanpur, DRISTHI CPS - IIT Indore

Title/Name of the Product/Technology

Mobilab - A portable diagnostic Solution

Product Positioning

Mobilab positions itself as a cutting-edge provider of portable, AI-powered diagnostic solutions designed for accessible, rapid, and accurate health testing. Its devices cater to both remote and urban healthcare settings, offering comprehensive, user-friendly diagnostics that empower healthcare professionals and enhance patient outcomes globally.

National/Societal Relevance

Mobilab's innovations hold significant national and societal relevance by addressing India's critical healthcare challenges. Its portable diagnostic devices enhance access to quality healthcare, particularly in remote and underserved regions, aligning with national priorities of improving primary health services. By enabling early detection of diseases and reducing dependence on large labs, Mobilab supports the government's vision of affordable, universal healthcare. Its AI-powered diagnostics contribute to better public health outcomes, lower healthcare costs, and reduced disease burden, promoting healthier communities and supporting national health goals.

Import Substitution

Mobilab's innovations support import substitution by offering domestically produced, advanced diagnostic devices that reduce reliance on costly imported medical equipment. By fostering local manufacturing and innovation, Mobilab strengthens India's healthcare technology sector, enhancing self-reliance and contributing to the nation's goal of reducing healthcare imports.

Export Potential

Mobilab has strong export potential, offering innovative, AI-powered diagnostic solutions tailored to global healthcare needs. With customers bases in Nepal, Australia, and Venezuela, its portable, cost-effective devices are well-suited for international markets, particularly in regions seeking affordable, high-quality medical diagnostics for underserved communities.

IP Status

Grant Numbers: 526299, 372924, 374832.
Application Numbers: 202331025899, 202331030326, 202331009162, 202431008115, 202331040709



Name of Startup: ProCyto Labs Pvt. Ltd.



Founder and Co-founder(s):
Dr. Neera Singh
Mr. Ajay Verma

Developed Under(scheme):
BIG, SBIRI

Email:
procytolabs@gmail.com

Product/Technology differentiation from Competitors

- Preservative-Free Gel: An allergen blocker eye gel prepared in situ gelling systems.
- Multi-Polymer Formulation: Contains three different combination of polymers such as tamarind seed polysaccharide, D-trehalose dihydrate, gellan gum, sodium hyaluronate, and other polymers at concentrations ranging from 0.1 to 2 w/v.
- Physiological Compatibility: Forms a gel upon application to ocular surface, maintaining osmolality between 150-350 mOs/kg.
- Comprehensive Protection: Use of FDA approved ophthalmic polymers that form a protective barrier and potentially blocks allergens, pollutants, prevents moisture loss, and restores epithelial integrity.
- Non-Irritating: Ensures compatibility with ocular tissues without impairing visual transmission.

Brief Description of Product

This innovative technology involves a preservative-free allergen blocker eye gel designed to prevent chronic eye allergies. The formulation transitions into a gel upon contact with tears, creating a protective layer over the ocular surface. This gel is drug-free, ensuring compatibility with ocular tissues without impairing vision or causing irritation. It effectively blocks allergens and pollutants, prevents moisture loss, and helps restore epithelial integrity. The formulation has a proven safety profile, making it suitable for long-term use in protecting eyes from environmental irritants.

Technology readiness level (TRL) TRL- 5

Current Stage of Development

The formulations have been characterized in the lab for the desired properties of an ophthalmic formulation. All the three formulations were found safe and effective in animal studies

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Allergic conjunctivitis has a global prevalence. This novel eye drop will be targeted for use in the countries where allergic conjunctivitis is highly prevalent. For example, Temperate zone of Mediterranean areas, Central Africa, Middle East, Japan, India, South America, Western Europe, Australia and North America.



Title/Name of the Product/Technology

Novel preservative-free allergen blocker gel

Product Positioning

Individuals suffering from dry eyes and chronic eye allergies

National/Societal Relevance

Eye allergies affect up to 30 of the world population because of the changing climate and increasing industrialization. Vernal keratoconjunctivitis VKC is a severe eye allergy that predominantly affects children aged of 5-15 impacting their quality of life with symptoms like watery, itchy, red, sore, swollen eyes. In India, VKC is more perennial with seasonal exacerbations and affecting higher age groups. Many cases remain undiagnosed or self-treated, leading to complications. Preventive eye drops are crucial for managing and preventing chronic eye allergies and dry eyes.

Import Substitution

There is no eye drop or gel available in the current market for prevention of allergic conjunctivitis. The eye drops available in the market only treat the condition. Our product can be used for both prevention and management of allergic conjunctivitis.

Export Potential

This is a novel preservative free barrier eye gel that block the allergen entry into the eye for up to 6 hours. The product can be used globally for prevention of allergic conjunctivitis and also for relief in dry eyes as it has unique components that helps in existing inflammation.

IP Status

Patent filed for all three formulations
Application no. 2023310244 PCT
Application filled Patent title:
Preservative-free allergen blocker eye gel

Name of Startup: Psaizi Technologies Private Limited



Founder and Co-founder(s):
Rajat Anand, Deepti Mathur

Developed Under(scheme):
BIG

Email:
psaizi@gmail.com

Product/Technology differentiation from Competitors

Our solution stands out by incorporating a feedback loop involving experienced clinicians. The backend algorithms generate initial reports and treatment recommendations based on EEG data and patient symptoms. These reports are reviewed and refined by our team of neurologists, ensuring accuracy and relevance. This dynamic feedback loop not only enhances patient care but also allows our algorithms to continuously learn and adapt based on new data, giving us a competitive edge over other solutions in the market.

Brief Description of Product

Our solution addresses the critical need for remote patient monitoring in tier 2 and 3 cities, where access to advanced EEG machines is often limited. Psaizi's remote EEG device, combined with our network of in-house clinicians, enables local doctors to receive actionable insights and personalized treatment plans for their patients. The EEG data is transmitted in real-time to our cloud-based platform, where expert neurologists analyze it and generate detailed reports. This data-driven approach allows doctors in underserved areas to offer high-quality care comparable to that found in major urban centers. In addition to the remote monitoring solution, we are conducting clinical trials in collaboration with medical institute to develop an AI algorithm that predicts seizures in epileptic patients in advance. This technology will be crucial in hospital settings, enabling timely intervention and improved patient outcomes. By integrating cutting-edge AI with remote monitoring, we aim to revolutionize the care and management of epilepsy, making advanced neurological care accessible to all.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

Our remote monitoring tool is fully developed and is currently being integrated with clinical workflows in partnership with healthcare providers. The AI algorithm for seizure prediction is in the clinical trial phase, showing promising results in predicting seizures with high accuracy.

Are you willing to Transfer/Out-License your Technology Yes

Title/Name of the Product/Technology

Digital Health Technologies for Epileptic Patients Monitoring and Care.

National/Societal Relevance

Our solution addresses the significant healthcare disparity in neurological care across India, particularly in tier 2 and 3 cities. By providing affordable, high-quality remote EEG monitoring and AI-driven seizure prediction, Psaizi empowers healthcare providers in these areas to offer advanced care, improving patient outcomes and quality of life for those with neurological disorders.

Import Substitution

Our technology reduces reliance on expensive imported EEG devices, offering a cost-effective, locally-developed alternative that meets the needs of Indian healthcare providers.

Export Potential

With proven effectiveness, our solution can be adapted and exported to other developing countries facing similar challenges in neurological care, making advanced EEG monitoring accessible worldwide.

Name of Startup: RAMJA Genosensor Pvt.Ltd.



Founder and Co-founder(s):
Pooja Goswami
Raghavendra Kumar Goswami

Developed Under(scheme):
BIG

Email:
poojagos@gmail.com

Product/Technology differentiation from Competitors

Existing technologies, gives results in 3 days with 35 sensitivities however Our device gives result in 90 minutes with 85 sensitivities. It is portable, and user-friendly. Using this technology will reduce the antimicrobial resistance rate, saving patients' lives and the economic burden of customers and consumers. Our Genosensor, will not only reduces the time of infection detection but will also reduce the cost of infrastructure by up to 95 and almost 80 reductions in staff. It can be done in a small room, with just technician help.

Brief Description of Product

RAMJA Genosensor is word first company who is providing first time ever ultra-fast, rapid, easy, and cost-effective solution: a novel paper-based device that can detect any infection and antimicrobial resistance in just 90 minutes. Our device is sensitive, specific, portable, and user-friendly. Using this technology will reduce the antimicrobial resistance rate, saving patients' lives and the economic burden of customers and consumers. Our Genosensor, will not only reduces the time of infection detection but will also reduce the cost of infrastructure by up to 95 and almost 80 reductions in staff. It can be done in a small room, with just technician help. We successfully conducted our Clinical trial at AIIMS Delhi, at department of Haematology, whereas now We are performing PAN India clinical trial with USAID Support.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

Manufacturing Licenses from CDSCO Granted, ISO-13485-2016 Approved, Export -Import Certificate. Patent granted Clinical Trial granted

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

PAN India

Title/Name of the Product/Technology

A novel paper-based device that can detect any infection and antimicrobial resistance in just 90 minutes

Product Positioning

Objectives: A electrochemical DNA Biosensor, which can detect patient, infection and antimicrobial resistance in 90 minutes, which will help physician to prescribe right antibiotic at right time. No more waiting of 3 days culture to revise the antibiotic treatment. Applications: Initially, all the ICU, Oncology

National/Societal Relevance

This technology can be used to detect epidemiology of AMR, which can give an information about the bugs and superbugs geographically It will also increase the Indian GDP, as everything is Indian origin Kits, Device, Software. This segment requirement is in masses. Government can create low-cost infection and AMR detection set-up from community label up-to tertiary care center anywhere in India. As of Now, Culture facility is the only facility, that too, is less in number due to higher maintenance. However, Genosensor technology need only 2 technician and 6/6 room with basic instrument Biosafety, centrifuge and Incubator.

Export Potential

Already Launching in PAN India

IP Status

Indian Patent granted- 391913, US- Patent accepted 17/782,352





Name of Startup: Reproscl Biosciences Private Limited



Founder and Co-founder(s):
Vijaygopal Rengarajan (Founder)
Dr Ravi Shankar Swamy (Co-Founder)

Email:
vijay@reprosci.health

Product/Technology differentiation from Competitors
Worlds first ESHRE-guideline compliant AI and VR Simulator

Brief Description of Product

Our flagship product, a multi-award-winning high-fidelity medical training simulator for Assisted Reproduction, adheres to the European Society of Human Reproduction and Embryology ESHRE s rigorous Recommendations for Good Practice in Ultrasound: Oocyte Retrieval.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Our Fertilator has already seen successful domestic implementations in the early stages of commercialization, with plans for significant international deployment underway.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Globally



Title/Name of the Product/Technology

Fertilator Medical Training Simulator

Product Positioning

Medical Training Simulator

National/Societal Relevance

An advanced medical education platform deployed as a high-fidelity medical training simulator featuring: Custom Build Hardware for Transvaginal Medical Procedures Haptic System for Tactile Feedback AI-powered Learning Experience Platform Ultrasound Generation & Simulation System To revolutionize the training, deployment, and performance of clinicians and healthcare workers.

Import Substitution

Accurate PickUp Sim

Export Potential

Global healthcare systems face a critical shortfall of clinicians and healthcare workers and significant challenges in education, employment, deployment, retention, and performance, hindering universal healthcare access. Fertilator provides a solution for accelerating training for healthcare workers/ professional across the globe.

Name of Startup: Roundworks Technologies Private Limited



Founder and Co-founder(s):
Dr Prashant Patel (Founder CEO) Sunil Kumar
Singh, Devendra Prasad (Co-Founder Director)

Email:
vaibhav@alveo.fit

Product/Technology differentiation from Competitors

Our solution aims to make holistic, quality respiratory care affordable and accessible across the full care continuum—from screening and diagnosis to follow-ups and rehabilitation. We've developed a handheld, US FDA-approved spirometer for use in healthcare settings and at home, paired with cloud-enabled apps for storing patient data and maintaining care continuity. This enhances medication adherence and helps patients live symptom-free lives. Our population health management dashboards enable policymakers to target specific areas, addressing the rise in respiratory diseases due to post-COVID-19 and air pollution, benefiting general practitioners, diagnosed patients, and at-risk populations.

Brief Description of Product

alveofit: is brand of Roundworks Technologies and also Patient Facing Home Care Mobile Platform. which connect with alveoair Digital Spirometer alveoair: A user-friendly spirometer for accurate lung health monitoring. It connects via Bluetooth, providing real-time data, and is ideal for hospitals, clinics, and home use. alveoair® MD Premium: A clinical-grade spirometer with unlimited data storage, advanced lung function metrics, pre-post bronchodilator tests, and ATS/ERS guidelines compliance. US FDA approved.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

At the current stage of development, alveofit® and its product line, including alveoair® and alveoair® MD Premium, are positioned for growth and market expansion. With regulatory approvals, such as the CDSCO, and US FDA 510K for clinical-grade products, the company has validated its technology and ensured compliance with international standards. The products are market-ready and already Commercialised, with advanced features tailored to meet the needs of healthcare professionals, making them competitive in both local and global markets. The focus is now on scaling operations, expanding distribution channels, and forming strategic partnerships to penetrate new regions.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

We are targeting pan-India with a comprehensive marketing strategy that includes partnerships with healthcare providers, regional outreach, and digital campaigns. Our focus is on reaching diverse healthcare settings and patient communities to promote our spirometer and enhance respiratory care across the country.



Title/Name of the Product/Technology

alveofit, alveoair, alveoMD, alveoair Clinical Grade

Product Positioning

Our spirometer is positioned as an advanced, FDA-approved device for both clinical and home use. It offers precise diagnostics and continuous monitoring with cloud integration, providing a comprehensive solution for effective respiratory care for healthcare professionals and patients alike.

National/Societal Relevance

Our spirometer addresses the national and societal need for improved respiratory health management. By offering accessible, accurate diagnostics and continuous monitoring, it helps combat rising respiratory diseases due to air pollution and post-COVID-19 conditions, supporting public health initiatives and enhancing overall quality of life.

Export Potential

Our FDA-approved spirometer has strong export potential in the US, Philippines, Vietnam, Malaysia, Australia, Nepal, and Bangladesh. Its global certification and advanced features make it well-suited for diverse healthcare settings, addressing respiratory health needs effectively across these regions.

IP Status

Patent No: 409921 Application No: 202121004108 Status: Granted Successfully

Name of Startup: RxOne Care Private Limited



Founder and Co-founder(s):
Mr. Nitin Guru
Mrs. Shruti Guru

Email:
cto@rxone.app

Product/Technology differentiation from Competitors

Patient 360° features like IoT based remote patient monitoring, AI powered Smart Reports and Medical Records Summarization, helps us stand ahead of the competitors.

Brief Description of Product

At RxOne, our mission is to accelerate the journey from care to cure. In India, where there is only one doctor for every 1,000 patients, it's no surprise that 82 of care providers face mounting stress and burnout. This not only affects the health of care providers but also impacts patient care outcomes. Every year, over 5.2 million people in India are affected by medical errors. While increasing the number of care providers and facilities is one solution, the faster option to meet rising care demands is technology. RxOne is revolutionizing healthcare with an AI and IoT-powered Electronic Medical Records EMR platform for hospitals, clinics, medical specialists, and more. Our platform offers smart features like Smart Calendar, Smart Prescription, Smart Report, Patient360°, health data summarization, online consultation, and more, helping care providers gain efficiencies, reduce operational costs, scale services, and improve diagnostic accuracy. For patients, RxOne offers a holistic Patient Health Records PHR app, enabling them to take control of their health with a secure, user-friendly way to manage medical data, track vital signs, and access a comprehensive directory of care services. With RxOne, every player in the care ecosystem—providers, physicians, and patients—benefits, ultimately leading to better outcomes.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

Our base EMR solution is commercially available in the market, we are currently building a IoT based ecosystem to be integrated with our EMR offerings. Simultaneously, we are introducing medical specialty specific EMR solutions for Cardiology, Dentistry and Paediatrics.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

RxOne Care is targeting a Pan-India market, focusing on urban and rural healthcare providers across Tier 1, 2, and 3 cities, aiming to bridge the healthcare gap with advanced AI and IoT-powered solutions, ensuring quality care accessibility throughout the nation.

Title/Name of the Product/Technology

RxOne Electronic Medical Records EMR Platform

Product Positioning

RxOneCare positions itself as a next-generation healthcare platform that empowers providers with AI-driven tools for efficient patient management and enhanced care delivery. By integrating smart technology with a focus on personalized care paths, RxOneCare stands out as the comprehensive solution for modernizing healthcare in India.

National/Societal Relevance

RxOneCare addresses critical national healthcare challenges by leveraging AI and IoT to bridge the gap between patient demand and provider availability. With India facing a shortage of medical professionals and rising incidences of chronic diseases, RxOneCares technology-driven approach enhances care quality, improves patient outcomes, and reduces healthcare costs. By making advanced medical care accessible across urban and rural areas, RxOneCare contributes to the nation's healthcare goals, supporting a healthier population and reducing the strain on the healthcare system. This aligns with India's broader vision of achieving universal health coverage and improving public health standards.

Import Substitution

N. A

Export Potential

RxOneCares AI-powered platform has strong export potential, offering scalable, cost-effective solutions for global healthcare. Its adaptability and ability to integrate with existing systems make it ideal for emerging markets with underdeveloped healthcare infrastructure, positioning RxOneCare as a leader in healthcare innovation worldwide.

IP Status

Application No. - IN202411032823

Name of Startup: Sarbit Innovations Pvt. Ltd.



Founder and Co-founder(s):
Sambit Kumar Keshi (CEO), Sarvar Singh (CTO),
Prof. Ajay Agarwal (Director)

Developed
Under(scheme): BIG

Email:
sarbit.innovations@gmail.com

Product/Technology differentiation from Competitors

There are different tests available for fungal diagnosis, but most of them require fungal culture growth, which prolongs the testing time and cannot accurately identify fungal genus or species. So, Conventional methods like Culture and Histopathology are not suitable for rapid detection. Although PCR and Serological Immunoassays reduce testing time, but they have a high turnaround time due to waiting for large sample batches and unable to detect multiple species in single run. MALDI-TOF, NMR methods require cultured samples and are also costly. Here, our product aims to deliver results within minutes, providing precise identifications at a very low cost.

Brief Description of Product

Our Product incorporates nanosensors and a Raman reader for the rapid and precise detection of various fungal species. Utilizing AI and data analysis, our method aims to identify multiple fungal species within minutes directly from blood or serum samples, eliminating the need for fungal culture.

Technology readiness level(TRL) TRL- 3

Current Stage of Development

At present, we can identify pure fungal biomarkers in our nanosensor under controlled conditions at very trace levels. Our next step is to initiate a pilot study to detect these biomarkers from blood serum.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

In regions heavily affected by fungal infections, such as India with 57 million cases, the impact of this technology could be particularly significant.

Title/Name of the Product/Technology

Kavak Sensorium: Identifying Invasive fungal infections within minutes.

National/Societal Relevance


In regions heavily impacted by fungal infections, such as India with its 57 million cases, this technology could be particularly transformative. Furthermore, the product's capability to detect other pathogens enhances its societal value, allowing for early identification of various infectious diseases and improving public health outcomes. Overall, the adoption of this product has the potential to significantly advance disease detection, treatment, and reduce healthcare costs.

Import Substitution

Import substitution involves replacing imported diagnostic devices such as PCR, MALDI-TOF, various immunoassay with our Indigenous product Kavak Sensorium alternatives to reduce reliance on foreign products.

Export Potential

The export potential for domestically produced pathogen detection devices is significant, especially considering the global demand for advanced healthcare technologies. With over 1 billion individuals infected with fungi and 1-2 million deaths occurring annually due to fungal infections, the products advantages can be a gamechanger in detection and diagnosis.





Name of Startup: Sarsuag Enterprises



Founder and Co-founder(s):
Dr. Prabhakar

Developed Under(scheme):
BIG

Email:
prabhakar@sarsuagenterprises.com

Product/Technology differentiation from Competitors

There is no diagnostic kit available in the market which detect dengue, malaria and chikungunya in single test. Brief Description of Product Sarsuag Enterprises developing diagnostic kit for detection of Malaria, Dengue and Chikungunya in single test. Our kits will detect seasonal outbreak of these disease and reduce cost of diagnostic and treatment. This is first of this kind of diagnostic kit in India.

Technology readiness level (TRL) TRL- 1

Current Stage of Development

Sarsuag Technology is in validation stage and well as all the raw material required manufacturing these kits is under development. This is indigenous kits where all raw materials manufactured inhouse.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, South Asia and South Africa

Title/Name of the Product/Technology

Single Diagnostic kit for Dengue, Malaria and chikungunya

Product Positioning

This kit helps in detecting all three diseases such as malaria, dengue, and chikungunya simultaneously. So, it will reduce cost of the diagnosis and save human lives.

National/Societal Relevance

There is loss of human lives because of misdiagnosis and wrong treatment during seasonal outbreak. There is loss of productivity at national level because of disease outbreak

Import Substitution

Currently this kit is not available for import but India is importing separate kit/raw material for each disease. So, once product is ready this imported will be substituted by make in India product.

Export Potential

Product can be exported to Middle east and African countries

Name of Startup: Shitashii Innovations Pvt Ltd



Founder and Co-founder(s):
Sunita Mehta
Meenu Mehta

Developed Under(scheme):
BIG

Email:
enigmaxy256@gmail.com

Product/Technology differentiation from Competitors

a novel form-factor and data reliability

Brief Description of Product

Myokeigo is a soft, flexible and wearable device for converting the muscle signals to speech potentially to be as an assistive device for patients with speech disorders or post-laryngectomy.

Technology readiness level (TRL) TRL- 4

Current Stage of Development

Developed first Prototype

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

North India

Title/Name of the Product/Technology

Myokeigo

Product Positioning

wearable

National/Societal Relevance


The developed product can prove to be a game changer for patients with speech disorders or post laryngectomy

Export Potential

yet to be explored

IP Status

202411030495



Name of Startup: Silverynanos Innovations LLP



Founder and Co-founder(s):
Dr. Divya Rathod (Founder & CEO)
C.A Jeenal Rathod (CFO)

Email:
jeenalrathod21@gmail.com

Product/Technology differentiation from Competitors

We are customizing nanocomposites according to different surfaces for making them bacteriostatic, water and stain repellent up-to 6 months like toilet surfaces to prevent UTI and microbiological services to check for contamination and growth of harmful bacteria at affordable prices compared to the market with intention of preventing infections, saving water and replacing PFAS forever chemicals from cleaning industries. Nanotechnology companies focusing on water and stain repellency at high cost 100X cost and not focusing on microbiological aspects.

Brief Description of Product

Hapitoprotect surfaces are customized nanocomposite coatings making different surfaces bacteriostatic, water and stain repellent for up-to 6months to prevent infections, upcoming pandemics, reduce Multidrug resistance, saving water up-to 55. replacing forever chemicals PFAS from environment polluting soil and water bodies leading to climate change. Focusing on UNDP SDG 3 and 6 We also give microbiological services with our products.

Technology readiness level (TRL) TRL- 8

Current Stage of Development

Currently we are at Pilot Sales for clothing and toilet surface protectors for up-to 500 liters/ month and for other surfaces we are customizing Development and research

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Asia pacific, Europe, UK, Canada, Africa, US, Latin America, Australia

Title/Name of the Product/Technology

Hapitoprotect surfaces

Product Positioning

Facility management replacing PFAS cleaning chemicals., Nanotechnology revolution at affordable prices almost equal to cleaning chemicals used in one month.

National/Societal Relevance

Preventing upcoming pandemic by preventing infections like UTI, bacterial, viral infections communicating through surfaces, saving water up-to 55 Pilot done under Amrut 2.0 Warangal, decrease in Multidrug resistance by replacing PFAS cleaning chemicals in hospitals, other surfaces and also saving soil and water bodies from PFAS forever chemicals.

Import Substitution

Nanoparticles

Export Potential

100 across globe with customization and microbiological services

Name of Startup: SmartQR Technologies Pvt. Ltd.



Founder and Co-founder(s):
Sambit Ghosh (Co-Founder)
Rohit Bajaj (Co-Founder)

Developed Under (scheme):
OTHERS

Email:
rb@healthledger.co.in

Product/Technology differentiation from Competitors

Others available in the market require devices for quantification purpose unlike our technology making it more cost-effective and market penetrable with ease-of-use.

Brief Description of Product

1 Novel system for detection of Hemoglobin in whole blood using deviceless strip detection app using AI/ML for colorimetric quantitative result display. 2 Novel system for detection of vaginal pH value using deviceless strip detection app using AI/ML for colorimetric quantitative result display.

Technology readiness level(TRL) TRL- 9

Current Stage of Development

Already in the process of commercialization.

Product Launched / About to be Launched NA

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

1 Novel system for detection of Hemoglobin in whole blood using deviceless strip detection app using AI/ML for colorimetric quantitative result display. 2 Novel system for detection of vaginal pH value using deviceless strip detection app using AI/ML for colorimetric quantitative result display

Unique Selling Point

Deviceless. Accurate. Ease-Of-Use.

Present Stage of Development

Commercialization.

Geographical Region Targeted

Pan India.

Major Achievements

AIM Congress, UAE - Runner up

Bionest Center Name N/A

Other Scheme Name Self

Title/Name of the Product/Technology

HemoQR - Hemoglobin detection kit
PrePapQR - Vaginal pH detection kit

Product Positioning

Government.

National/Societal Relevance

Hb detection for Anaemia Screening. RTI/ STI Screening.

Import Substitution

N/A

Export Potential

Humungous.

IP Status

NA



Name of Startup: SPARSHACARE INNOVATIONS



Founder and Co-founder(s):
Dr. Parikshit Sahatiya (Founder)
Dr. Chandra Sekhar Reddy (Co-Founder)

Email:
parikshit@hyderabad.bits-pilani.ac.in

Product/Technology differentiation from Competitors

The Sparsha Care mattress is designed with cutting-edge technology to enhance health and well-being. It features non-wearable sleep time monitoring, allowing users to track their sleep patterns without wearing any device. Personalized care options cater to various health needs, including vitals monitoring and support for conditions such as cardiovascular disease, diabetes, depression, insomnia, and immunity issues. The mattress also provides critical movement tracking, ensuring that even subtle movements are detected. With machine learning capabilities, it can predict future health trends based on current data. Technologies like Dozee, Smart-Watch, Sleepon, and Muse are integrated, making it a comprehensive health solution.

Brief Description of Product

Our Sparsha Mat Care product will be used for real-time sleep monitoring, tracking both individual movements and breath rate, making it highly promising for personal healthcare diagnosis. The Sparsha mat has a direct societal impact on elderly individuals, healthcare professionals, and family structures. It enhances the quality of life for the elderly, provides improved safety and security, increases independence, and reduces the burden on caregivers. With India's rapidly growing aging population and limited healthcare resources, providing hospital-based health services poses a significant challenge. The Sparsha mat can play a crucial role in the initial diagnosis for the elderly, thereby reducing reliance on hospital-based medical care. Sparsha mat takes care of your elderly while you are away.

Technology readiness level (TRL) TRL- 3

Current Stage of Development

1. The initial small working prototype 4 x 4 array of the Sparsha mat has been developed with the front end 2. The large area fabrication of 20 x 10 sensors have been developed 3. The sensors have been tested and calibrated and the linear response of the sensor is achieved for 4 x 4 4. The sleeping posture and the sleep pattern are successfully recorded for 4 x 4

Are you willing to Transfer/Out-License your Technology Yes

Title/Name of the Product/Technology

Sparsha Mat

National/Societal Relevance

There is a direct societal impact of the Sparsha mat on elderly people, healthcare professionals, family structures. This includes improved quality of life for elderly, enhanced safety and security, increased independence and less guilt for the caretaker. Further, with the exponential increase in the ageing population of India and with limited resource environment, it would be a huge task to provide hospital-based health services. Sparsha mat will play a huge societal role in the initial diagnosis for the elderly people thereby reducing the dependence for hospital based medical care.

IP Status

Indian Patent Filed 1: 202211030997 2: 202211008833

Name of Startup: STARTOON LABS PRIVATE LIMITED



Founder and Co-founder(s):
Mythreyi Kondapi
Suresh Susurla

Developed Under(scheme):
BIG

Email:
mythreyi@startoonlabs.com

Product/Technology differentiation from Competitors

Phzeeze is first of its kind of device which helps research concepts in EMG and movements, is brought into market to address daily needs of the Patients from musculoskeletal and neuromuscular disorders. Phzeeze sets itself apart from traditional companies through its unique combination of sEMG and ROM for real-time, accurate assessment of muscle and joint function. Unlike traditional methods, Phzeeze provides quantifiable data, enhancing diagnostic accuracy and treatment personalization. Its cloud-based platform allows for continuous monitoring and detailed reporting, offering a comprehensive solution not found in other devices.

Brief Description of Product

Phzeeze is an advanced digital health device designed to revolutionize the field of musculoskeletal rehabilitation and physiotherapy. Developed by Startoon Labs, Phzeeze leverages cutting-edge technology to provide real-time assessments of joint and muscle function. The device uses surface electromyography sEMG and Range of Motion ROM to measure muscle activity and joint movement, offering precise, quantitative data that aids in diagnosing musculoskeletal disorders and tracking patient progress over time. This data is transmitted to a cloud-based platform, where detailed reports are generated, providing actionable insights for clinicians and patients. Phzeeze's user-friendly interface and comprehensive analytics facilitate informed decision-making, personalized treatment plans, and enhanced patient outcomes. Its portability and ease of use make it suitable for a variety of settings, including clinics, hospitals, and home care, ensuring that high-quality rehabilitation is accessible to all. By bridging the gap between traditional physiotherapy methods and modern technology, Phzeeze stands at the forefront of innovation in healthcare, improving the standard of care and empowering patients in their recovery journey.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

We are in commercialization stage, currently in 13 states in India. We have physiotherapy clinics, hospitals, diagnostic centers and corporate wellness programs running in India.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Middle east, US

Title/Name of the Product/Technology

Phzeeze

Product Positioning

Phzeeze, a one-of-a-kind medical wearable device, tracks ROM and EMG of joints and muscles, offering unique advantages over traditional pain management and physiotherapy methods. It provides real-time data on various physiological parameters, can be used remotely, and generates detailed reports with Phzeeze grading and recommendations, revolutionizing patient care.

National/Societal Relevance


Musculoskeletal disorders MSDs impact 30 of India's adult population, with severe financial strain on 53 of rural households. Phzeeze addresses this critical need by offering a portable, cost-effective solution for early diagnosis and monitoring, significantly improving healthcare accessibility and outcomes in underserved areas.

Import Substitution

Phzeeze, developed under the Make in India initiative, reduces reliance on imported medical devices by providing a high-quality, domestically produced solution for musculoskeletal assessment. This not only enhances national self-reliance in healthcare technology but also supports local innovation and manufacturing.

Export Potential

As an ISO 13485:2016 and ISO 9001:2015 certified company, Startoon Labs has produced Phzeeze, India's first USFDA-listed medical device. This certification opens significant export opportunities, enabling the distribution of Phzeeze to global markets and showcasing India's capacity for high-quality medical device production, initiating with US and Middle-East Markets.



Name of Startup: Tech Atriocare Private Limited



Founder and Co-founder(s):
Tarun Adarsh

Developed Under (scheme):
OTHERS

Email:
techatriocare@gmail.com

Product/Technology differentiation from Competitors

Our platform offers a precision and personalized wellness solution by combining proprietary voice-based technology for health risk assessment, patent-pending proprietary formulation for optimizing body's defense, and personalized recommendations, setting us apart from competitors. Our holistic approach enables early intervention, proactive wellness and addresses the impact of environmental factors on heart and lung health.

Brief Description of Product

Haal Chaal Pravartak is a comprehensive preventive healthcare platform that integrates AI-powered health risk assessments, personalized wellness recommendations, and a groundbreaking amino acid formulation serving as a host-directed therapy. This proprietary formulation enhances the body's natural defenses, preventing infections and promoting overall well-being. Haal Chaal Pravartak is a pioneering preventive healthcare platform that revolutionizes the way individuals approach their health and wellness. Our platform empowers users to take control of their health, detecting potential health risks before they become chronic conditions. Our platform's core features include: - AI-driven health risk assessments - Personalized wellness recommendations - Novel amino acid formulation for immune system support - Mindfulness techniques and stress management - Community support and forums - Integration with wearable devices and health data platforms The amino acid formulation, a key differentiator, works by: - Boosting nitric oxide levels, exhibiting antiviral and immunomodulatory effects - Enhancing the body's natural defenses against pathogens - Supporting immune system function, reducing the risk of infections By incorporating this innovative formulation, Haal Chaal Pravartak offers a holistic approach to preventive healthcare, addressing physical and mental well-being while empowering individuals to take control of their health.

Technology readiness level (TRL)- 5

Current Stage of Development

We have conducted extensive alpha testing on the technology to ensure that it works seamlessly with all components of the existing system. Our proprietary formulation received favorable evaluations from healthcare practitioners and individuals throughout real-world trials and pilot studies, leading to improved health outcomes.

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event Yes

Are you willing to Transfer/Out-License your Technology Yes

Availability for showcasing at Birac Yes

Product/Technology

Haal Chaal Pravartak is a precision & personalized wellness platform that combines AI-driven health risk assessments, proprietary voice-based technology, and personalized wellness guidance with a novel amino acid formulation, serving as a host-directed therapy to boost the immune system and prevent infections. It provides predictive insights, thus enabling early interventions.

Unique Selling Point

Haal Chaal Pravartak's unique selling point lies in its user-engaging AI-powered, convenient voice-based health risk assessment, combined with personalized recommendations & host-directed therapy, mindfulness techniques, and community support. Our platform's holistic approach, focusing on both physical and mental well-being, sets us apart from traditional healthcare solutions, offering a user-centric approach.

Present Stage of Development

Haal Chaal Pravartak's MVP is tested, and ready for pilot commercial launch, with future expansion plans for immune system optimization program.

Geographical Region Targeted

India, specifically densely populated states with high vulnerable population like Delhi. We do have future plans for global expansion

Major Achievements

• TIDE 2.0 EIR grant by MeitY, Govt. of India • NIDHI-EIR grant by DST • DST ignition fund • Exhibitor at: Startup Mahakumbh 2024, GBI 2023 BIRAC, BECon 2024 eDC IIT Delhi, IISF 2023 Faridabad, Bihar Innovation Challenge '23, Life Science Startup Summit 2023 by DBT-ILS, SIB conference THSTI

Bionest Center Name N/A

Other Scheme Name

MeitY TIDE 2.0, DST

Title/Name of the Product/Technology

Haal Chaal Pravartak: A Precision & Personalized Wellness Platform

Product Positioning

Haal Chaal Pravartak is positioned as a comprehensive, AI-driven preventive healthcare platform that bridges the gap between healthcare services and individual well-being. Our platform caters to the growing demand for personalized, predictive, and preventive healthcare solutions, targeting health-conscious individuals, corporates, and healthcare providers seeking to improve health outcomes.

National/Societal Relevance

Haal Chaal Pravartak addresses India's significant healthcare challenges, including the rising burden of chronic diseases, inadequate healthcare infrastructure, and limited access to preventive care. By empowering individuals to take control of their health, our platform contributes to the nation's health and wellness goals, aligning with initiatives like Ayushman Bharat and National Health Mission.

Import Substitution

Our wellness platform reduces reliance on imported wellness solutions, expiry of their IP & instead it offers personalized recommendations catering the domestic market.

Export Potential

Our wellness platform has high potential for global export, addressing worldwide health concerns related to climate changes, pandemics and unhealthy lifestyle

IP Status

1.Copyrights 2. Patent draft is prepared for filing 3. Patent for the formulation is under examination



Name of Startup: TechInvention Lifecare Pvt. Ltd.



Founder and Co-founder(s):
Mr. Syed S Ahmed
Ms. Nazneen Hamid

Email:
syed@techinvention.biz

Product/Technology differentiation from Competitors

Unlike traditional methods like rectal palpation, the kit does not require specialized veterinary professionals or expensive screening methods such as Ultrasonography which the farmers cannot afford in low resource settings. Current detection methods utilize blood or milk sample for detection of Pregnancy associated glycoproteins PAG and Progesterone hormone respectively which are all imported having high cost and need veterinarians for interpretation. There is need of indigenously developed pregnancy kit in India. Our kit is non-invasive and give easy results in less than 3 minutes. The portable kit includes all necessary reagents and instructions for ease of use.

Brief Description of Product

The Bovine - Urinary Pregnancy Detection Kit is India's first of its kind an innovative diagnostic tool designed to detect early pregnancy buffaloes using fresh urine samples. This kit is highly sensitive and capable of diagnosing pregnancy as early as 28 days post-artificial insemination or natural mating. It offers a cost-effective, non-invasive, and easy-to-use solution for farmers, particularly beneficial in rural areas where availability of veterinary professionals' and other veterinary services are limited. Using digital detection method, the kit provides accurate results that are easy to interpret in the form of Pregnancy Detected or Pregnancy Not Detected. This early detection allows for timely resynchronization and rebreeding, ultimately contributing to better herd management and increased profitability for dairy farmers.

Technology readiness level (TRL)- 8

Current Stage of Development

We have received Test license to manufacture the product from CDSCO and the Pilot batches are under production for in-house testing and external evaluation.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Garb Jaanch technology primarily targets rural and urban milk union and co-operatives in India, focusing on areas with significant dairy farming activities. The aim is to support small farmers and milk unions to get early pregnancy detection to improve livestock reproductive management



Title/Name of the Product/Technology

Garbh Jaanch: Bovine - Urinary Pregnancy Detection Kit

Product Positioning

Garbh Jaanch is positioned as an affordable, non-invasive urine-based early pregnancy detection kit for livestock, targeting rural India. It provides smallholder farmers and dairy producers with an accurate, easy-to-use solution, enhancing reproductive management and productivity without requiring specialized skills or expensive equipment.

National/Societal Relevance

Garbh Jaanch technology holds significant national and societal relevance for India, particularly in rural and agricultural sectors. By providing an affordable, non-invasive method for early pregnancy detection in livestock, it supports smallholder farmers and milk unions and co-operatives in improving reproductive management and productivity. This leads to increased milk production, contributing to the nation's dairy industry, which is vital for food security and rural livelihoods. The technology helps reduce economic losses from missed pregnancies and improves herd management efficiency. Additionally, it promotes animal welfare by minimizing stress and invasive procedures, aligning with the broader goals of sustainable and humane livestock.

Import Substitution

Garbh Jaanch technology substitutes expensive imported pregnancy detection methods with a cost-effective, locally-developed solution. This enhances self-reliance in India's dairy sector, reduces dependence on foreign technology, and supports the Make in India initiative, fostering domestic innovation and boosting the rural economy.

Export Potential

Garbh Jaanch technology, with its affordability, ease of use, and effectiveness, has significant export potential to developing countries in Africa, Southeast Asia, and Latin America. Its non-invasive, cost-effective approach appeals to smallholder farmers, enhancing India's agricultural innovation reputation and contributing to global food security.

IP Status

Application number 202411050036, filed on June 29, 2024, is for the Colorimetric Urine Test for Early Pregnancy Detection in Livestock by ICAR-Central Institute for Research on Buffaloes and TechInvention Lifecare Private Limited. The provisional application is filed, with the complete specification due by June 29, 2025.



Name of Startup: TerraBlue XT



Founder and Co-founder(s):
Dr. Rajlakshmi Borthakur

Developed Under(scheme):
BIG, SEED Fund

Email:
raji@teblux.com

Product/Technology differentiation from Competitors

Current diagnostic standards for mental health largely rely on questionnaires and subjective assessments, which can vary in accuracy and consistency. These traditional methods often miss subtle, early signs of mental health issues, leading to delayed or inadequate intervention. Many competitors in the market offer solutions that are either device-dependent or focus solely on these conventional, symptom-based assessments. In contrast, Xaant differentiates itself by leveraging device-agnostic AI to automatically screen and continuously monitor mental health. This approach allows for more objective, real-time insights, enabling proactive, personalized interventions that go beyond the limitations of subjective assessment, setting a new standard.

Brief Description of Product

Xaant is a cutting-edge, device-agnostic AI platform designed to transform how mental and behavioral health is monitored and managed. In a world where nearly a billion people suffer from mental health issues, the need for innovative, scalable, and precise solutions has never been greater. Xaant stands at the forefront of this revolution, offering an evidence-based, clinically validated approach that ensures accuracy, accessibility, and impact. At its core, Xaant integrates multiple advanced technologies to deliver a comprehensive mental health solution. Xaant leverages a combination of advanced technologies to provide a comprehensive mental health solution. It begins with state-of-the-art biomedical sensors that collect real-time physiological data, such as heart rate variability HRV and electrodermal activity EDA, offering an objective, continuous assessment of an individual's mental state—something traditional methods struggle to achieve. This data is complemented by standardized, evidence-based self-report questionnaires that allow users to provide personal insights into their emotional and mental well-being. By integrating subjective self-assessment with objective physiological data, Xaant ensures a balanced approach to mental health monitoring. The platform's Natural Language Processing NLP capabilities then interpret this data, generating personalized, actionable insights delivered through interactive, real-time reporting. This helps users understand their mental health status clearly and take proactive steps toward improvement. Additionally, Xaant features an AI-driven chatbot that provides immediate support, answers questions, and guides users through their mental health journey, ensuring that assistance is always within reach. This combination of technologies makes Xaant a powerful, constant companion in managing mental health effectively.

Technology readiness level (TRL) TRL- 9

Current Stage of Development

Completed paid pilots with Indian Defence forces for 1000 individuals

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Global



Title/Name of the Product/Technology

Xaant - AI Platform for Mental Health Management

Product Positioning

An evidence-based platform offering objective mental health assessments and targeted psychological services, designed to accurately identify and address mental health needs. By leveraging advanced analytics and personalized interventions, our solution ensures optimal mental well-being, enhancing productivity and overall therapeutic success.

National/Societal Relevance

Our solution tackles the growing national challenge of mental health by offering precise, objective assessments and targeted psychological services, benefiting individuals and organizations alike. On a personal level, it empowers employees with early intervention, reducing the stigma and helping them lead healthier, more fulfilling lives. For organizations, it means a more resilient, productive workforce, with improved morale and reduced absenteeism. By fostering a culture of mental well-being, we contribute to societal progress, creating a ripple effect that enhances both individual lives and the broader economy, aligning with national goals for a healthier, more productive population.

Import Substitution

Our product leads to import substitution by providing a domestically developed, comprehensive mental health solution that reduces reliance on foreign psychological assessment tools and services. By leveraging local expertise, advanced technology, and culturally relevant interventions, we enable a practical solution to address mental health needs.

Export Potential

With nearly a billion people worldwide facing mental health challenges, our product has immense export potential. Its scalability, cultural adaptability, and proven effectiveness make it a powerful solution for global markets. By addressing diverse needs, we can lead the charge in improving mental health care across the world.

IP Status

Patent granted

Name of Startup: Tiny Prism Labs Pvt



Founder and Co-founder(s):
Errol Joshua
Mahesh Nayak

Developed Under (scheme):
BIG

Email:
maheshnayak2810@gmail.com

Product/Technology differentiation from Competitors

Competitors are either on Diagnostic or Rehabilitation and our device plans to do both on the same device on need basis.

Brief Description of Product

Sensor based wearable device with capability of measuring movement and sound to diagnose or give subjective data during rehabilitation activities. Currently the device is capable of running for a swallowing disorder called dysphagia, The device is also capable of onboarding other disorders through the software based approach.

Technology readiness level(TRL) TRL- 3

Current Stage of Development

Pre-clinical Validation

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology Yes

Availability for showcasing at Birac Yes

Product/Technology

The device uses embedded ML based approach to run a tiny ML based model to recognize patterns of physiological significance in sensor based data in a battery based device.

Unique Selling Point

Portable and compact non invasive device.

Present Stage of Development

We have the MVP ready.

Geographical Region Targeted


Indian sub continent is the current target.

Major Achievements

Basic model of classifying a patient or normal swallow built and running on the device successfully

Bionest Center Name N/A

Other Scheme Name N/A



Title/Name of the Product/Technology

Non invasive sensor based device for diagnosis, biofeedback and rehabilitation.

Product Positioning

We are currently trying to build it and sell in India and further extend it to other countries.

National/Societal Relevance

The device would help in better and faster screening at the primary healthcare centers and help in early detection of underlying higher diseases.

Import Substitution

True Angle - MobilIT

Export Potential

To countries like Canada and USA

IP Status

Provisional Patent filed

Name of Startup: UR Advanced Therapeutics



Founder and Co-founder(s):
Jaganmohan Reddy

Developed Under(scheme):
BIG, SEED Fund

Email:
JJMREDDY@GMAIL.COM

Product/Technology differentiation from Competitors

1. DAD can be used in 3D cell cultures, organoid cultures and in animals immune compromised or non-immune compromised animals. Being a small molecule DAD can penetrate into deep tissue very easily and also is stable for long periods of culture 2. Unlike Annexin V, which requires High Calcium presence, DAD do not require any external buffer. Thus, DAD can be used native cell culture media. 3. DAD clearly demarcates live cells and early apoptosis, late apoptosis and necrotic cells as Annexin V.

Brief Description of Product

Artificially designed miniature topographical and functional mimics as alternatives to native proteins. Currently we developed 15 amino acid alternative peptide for 320 amino acids Annexin V. Based on this expertise we are developing AI/ML programming tools to predict such miniature peptides for large variety of proteins. The current market product is a generic 350 amino acid Annexin V protein detects cell death in the presence of Calcium buffer and thus is difficult to use in native culture media of cells. Annexin V also have the issue with the deep penetration into the 3D culture spheroids and organoids that are fast growing as replacement for drug screening and toxicology studies. Our kit does not require external buffer and distinguishes the cell death effectively in 2D and 3D cultures and even in vivo in native conditions. It does not generate any immunogenicity and thus can be used in wild type animals multiple times. The provisional patent has been filed and we are filing for complete patent internationally covering North America, Europe and Asia Pacific. Currently There is no product from India and even globally we are the second product that can replace Annexin V. Every year, India imports 50,000 Kits of annexin V at a cost of 35,000 Rs per each kit amounting to 175 Crore. Our product not only provides technical advantage over Annexin V is also simple to use in a single step reaction and cost effective. Along with this we are launching Cell proliferation kit and Cell counting kit based on similar technology. In the next phase, as we develop our AI/ML based high throughput put prediction models we aim to generate peptide mimics in its application in Tissue Engineering, Cell and Gene therapy and drug delivery.

Technology readiness level (TRL) TRL- 8



Current Stage of Development

Product is validated and is in the revenue stage

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Europe, North America, Asia Pacific



Title/Name of the Product/Technology

Dynamic Apoptosis Detection Kit

Product Positioning

Positioned as Research Use consumable for the CROs and academic researchers globally

National/Societal Relevance

Only product from India completely made in India using AI/ML from discovery to production

Export Potential

Very high because 95 of market is outside India especially North America and Europe

IP Status

Indian Patent filed Patent Pending - Appl No: 202341048749. PCT application in the process

Name of Startup: VASMED HEALTH SCIENCES PVT LTD



Founder and Co-founder(s):
JAYAPRASAD PILLAI

Developed Under(scheme):
NBM

Email:
sales@vasmed.in

Product/Technology differentiation from Competitors

The current FFR system available in India is limited to 2 imported devices, the Vision FFR system will provide similar performance at a substantial value to the customers allow acceptance of the product as benchmark for intermediary lesion evaluation.

Brief Description of Product

FFR is the gold standard for determining the significance of a lesion during coronary angioplasties especially for the intermediary lesion. Currently these products are 100 imported into the country at a high cost. The suggested solution included an active medical device with disposable 0.014 guidewire incorporating a MEMS pressure sensor designed and developed within the country, in association with Indian Institute of Sciences, guidewire design and developed by Vasmed. The integrated electronics are tested and compliant to various IEC standards. The main components of the system include 1. 0.014 FFR guidewire with integrated 0.150 x 0.150 mm Piezo resistive MEMs pressure sensor 2. Vision FFR VFS2.0 Console system with screen 3. Vision FFR VFD1.0 Dongle system with integration to 0.014 guidewire The separate patent is applied for MEMs sensor, and Guidewire design The national importance of product is that coronary artery disease is a significant cause of morbidity and mortality in the community, currently more than 800,000 angiographies are done in India majority leading to stenting, with a cost-effective tool, the number of stents can be limited to clinically significant lesions, giving a valuable tool to the end-user. The Vision FFR system will be affordable, available and hence can be used in all use cases, including economically deprived sections, the social relevance is the affordability of the equipment to all afflicted with a common morbid disease

Technology readiness level (TRL) TRL- 9

Current Stage of Development

System is under IEC certification; Animal testing is planned and CDSCO submission to be applied.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Asia Pacific, Middle east



Title/Name of the Product/Technology

0.014 guidewire with MEMs pressure Sensor Guidewire wire FFR system

Product Positioning

Affordable, MEMS based FFR system

National/Societal Relevance

The national importance of product is that coronary artery disease is a significant cause of morbidity and mortality in the community, currently more than 800,000 angiographies are done in India majority leading to stenting, with a cost-effective tool, the number of stents can be limited to clinically significant lesions, giving a valuable tool to the end-user.

Import Substitution

currently 100 of FFR devices are imported

Export Potential

Under study

IP Status

1. A UNIQUE GUIDEWIRE DESIGN FOR MEASUREMENT OF ONE OR MORE PHYSIOLOGICAL VARIABLE IN A HUMAN BODY" - 201941010987 2. ULTRA-MINIATURE PRESSURE SENSOR WITH INTEGRATED TEMPERATURE COMPENSATION - 202041015485 3. AN INTRAVASCULAR GUIDEWIRE SYSTEM FOR INVASIVELY MEASURING BODY FLUIDS OR BLOOD - 202241053585



Name of Startup: VETDIAG GENOMIX PRIVATE LIMITED



Founder and Co-founder(s):
Dr. G. Mohana Sheela (Founder & Managing Director)
Mr. S. Raja Dileep Kumar (Co-founder & Director)

Developed Under (scheme):
OTHERS

Email:
vetdiaggenomix@gmail.com

Product/Technology differentiation from Competitors

DNA testing labs user-friendly Customizes kits according to geographic region Accurate and reliable results Precision diagnostics

Brief Description of Product

PCR & RT-PCR kits to diagnose tick fever in canine and Mastitis in cattle. This product provides accurate medicine. Targeted antibiotics can be given to the animal once the disease is diagnosed.

Technology readiness level(TRL) TRL- 8

Current Stage of Development

We currently provide molecular diagnostic services for cattle, cats, and dogs. We offer services in pathology, hematology, biochemistry, microbiology, and molecular biology. We intend to soon design and manufacture goods for the corresponding and wide range of veterinary fields, such as aqua, poultry, etc. We are looking for support and chance to prove ourselves

Product Launched / About to be Launched Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event Yes

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

PCR & RT-PCR KITS TO DIAGNOSE CANINE TICK FEVER & MASTITIS

Unique Selling Point

DNA testing labs user-friendly Customizes kits according to geographic region Accurate and reliable results Precision diagnostics

Present Stage of Development

Currently we are providing molecular diagnostic services. We are planning for manufacture unit in our near future. Prototype is ready.

Geographical Region Targeted

Entire PAN India Level & also looking forward for global extension

Major Achievements

Best Healthtech solution providers 2024 Startup Dangal Season 1 title winners Best emerging Startups at Bharat Pitchathon 3.0

Bionest Center Name N/A

Other Scheme Name

Startup India SEED Fund Scheme

Title/Name of the Product/Technology

Vetdiag Gene Pro mix : Precision Diagnostics for Veterinary.

Product Positioning

Veterinary molecular diagnostic kits are positioned as cutting-edge tools that provide highly accurate genetic insights, enabling veterinarians to detect diseases early, tailor treatments, and enhance preventive care for pets and livestock. These kits offer personalized veterinary care through customized health plans based on each animal's genetic profile, addressing disease risks.

National/Societal Relevance

Veterinary molecular diagnostic kits are crucial for animal health, food security, public health, and economic development. They enable early, precise disease detection, reducing pathogen spread and improving animal welfare. By sustaining livestock productivity, they help ensure stable food supplies and reduce production losses. These kits also support public health by controlling zoonotic diseases and reducing antibiotic resistance. Economically, they protect farmers, boost the veterinary industry, and foster job creation and innovation. Additionally, they safeguard trade by meeting international standards, help combat emerging diseases, and promote sustainable practices, while driving scientific research and advancing veterinary education and capacity.

Import Substitution

Global wide IDEXX Laboratories. It is our major and only competitor. We want to prove ourselves to withstand along with that company.

Export Potential

Total Addressable Market TAM Global Veterinary Diagnostic Market - US\$ 3.5 Billion Serviceable Available Market SAM Projected Market Value - US\$ 81.60 Million Serviceable Obtainable Market SOM Projected Market Value- US\$ 16.32 Million

IP Status

Application number: 202441033893A
Date of filling the application: 29/04/2024
Publication date: 03/05/2024 Title of the invention: A METHOD OF DETECTING TICK-BORNE PATHOGENS ASSOCIATED WITH TICK FEVER AND KIT THEREOF Name of Applicant: VETDIAG GENOMIX PRIVATE LIMITED Address of Applicant: DONKA ROAD, PATAMATA, VIJAYAWADA, ANDHRA PRADESH -520010



Name of Startup: Vgenomics India Private Limited



Founder and Co-founder(s):
Dr. Rahila Sardar Dr. Preeti Gupta Lal Mr. Sameer Malik

Developed Under (scheme):
OTHERS

Email:
support@vgenomics.co.in

Product/Technology differentiation from Competitors

Genetic test reports lack accuracy, reproducibility, and adherence to international standards. We are building an AI-powered platform designed to significantly enhance the diagnosis of rare diseases, while also supporting researchers in rare disease research. Unlike competitors that are primarily focused on selling genetic tests, our goal is to create a tool that sets the benchmark for accuracy and reliability in the genetic testing market, ultimately becoming the industry standard.

Brief Description of Product

Vgenomics offers a one-stop solution for diagnosing rare diseases, starting with advanced tools like RgenX. RgenX is a cutting-edge technology that traces the journey from phenotype to genotype, enabling the identification of underlying genetic disorders. This powerful tool enhances the early and accurate diagnosis of rare diseases, empowering clinicians to develop personalized treatment plans that significantly improve patient outcomes. In addition to this, our platform also includes newborn screening and genetic tests, providing a holistic approach to rare disease management.

Technology readiness level(TRL) TRL- 6

Current Stage of Development

The product is in an one-stop prototype stage TRL 6 , with the model undergoing clinical validation to ensure high accuracy and reliability.

Product Launched / About to be Launched About to be Launched

Do you want to Launch your Product in Global Bio India -2024 Event No

Are you willing to Transfer/Out-License your Technology No

Availability for showcasing at Birac Yes

Product/Technology

RgenX is a cutting-edge technology that traces the journey from phenotype to genotype, enabling the identification of underlying genetic disorders. We have an AI-driven solution utilizing machine learning and proprietary algorithms for rare disease detection and genetic disorder diagnosis.

Unique Selling Point

A complete diagnosis solution for rare genetic diseases.

Present Stage of Development

Advanced prototype TRL - 6 with clinical validation in progress

Geographical Region Targeted

Global market, with an initial focus on India

Major Achievements

IIM Nagpur SISFS Awardee Selected as an Impact Startup at WebSummit Qatar Illumina Accelerator Grant Secured seed funding from investors like Mumbai Angels, O2 Angels, and others. Built a multi-dimensional team that includes PhDs, technologists, AI Developers, and Business Experts.

Bionest Center Name N/A

Other Scheme Name

Others

Title/Name of the Product/Technology

Comprehensive Solution for Rare Diseases: Predicting and Unveiling Genetic Disorders

Product Positioning

Innovative platform for diagnosing rare and genetic diseases

National/Societal Relevance

Helps reduce the financial burden by enabling timely diagnosis of rare diseases, allowing individuals to begin management and treatment at an earlier stage, ultimately improving patient outcomes and reducing healthcare costs.

Import Substitution


Provides a homegrown solution, reducing reliance on foreign diagnostic tools while promoting the Make in India initiative and fostering local innovation.

Export Potential

Yes

IP Status

NA





Name of Startup: Vphore Labs Pvt Ltd

VPHORE LABS

Founder and Co-founder(s):
Priyank Saxena

Developed Under(scheme):
NBM

Email:
priyank@vphore.com

Product/Technology differentiation from Competitors

* Indigenous, Designed and Made in India * True Video Laryngoscope - live view of the glottis area unique curve for minimal manipulation reusable blades * Guided Channeled intubation

Brief Description of Product

Vphore Labs has developed a video laryngoscope product which offers support for adult as well as pediatric and neonatal subjects. Also, the design offers a complete guided operation helping in the critical cases. The product will be useful for anesthesiologists and clinicians in emergency setups and in operation theaters. It will be especially beneficial for patients with difficult anatomy.

Technology readiness level (TRL) TRL- 7

Current Stage of Development

* Final product has been successfully demonstrated and tested. * Product has also been validated for Electrical, Bio-compatibility, and safety tests * A Clinical Study has recently concluded, proving the product to be at par with the current industry standards * System level details and components are now being worked on along with the marketing plan.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India and Southeast Asia

Title/Name of the Product/Technology

Video Laryngoscope for use in Emergency Rooms, Operation Theaters and Surgeries

Product Positioning

A True Video Laryngoscope larynx is a quality, affordable, home-grown tool for easing the problems faced by clinicians in emergency rooms and operation theaters.

National/Societal Relevance

The benefits of video laryngoscope offer are as listed below: * Quicker time to medication especially in trauma cases * Improved success rate * Less trauma for patients * Lesser efforts from the clinician

Import Substitution

Currently all the video laryngoscope products are imported. We aim to give a quality, affordable, home-grown alternative to the clinicians

Export Potential

Video Laryngoscopes are being used worldwide now and have a huge export potential

IP Status

Design Patent - 326457-001





DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology

Global
Bio-India
2024
Transforming Lives
Bioscience to Bioeconomy

बाइरैक
इन्क्यूबेटर्स
बिरैक
Ignite Innovate Incubate



**Industrial
Biotechnology**

INDUSTRIAL BIOTECHNOLOGY (INCLUDING SECONDARY AGRICULTURE)		
Sl. No.	Company Name	PAGE NUMBER
1	3r Zerowaste	119
2	Aathma Pranavaayu Pvt Ltd	119
3	Acsen Agriscience Pvt Ltd	120
4	Adis Technologies Pvt Ltd	120
5	Agrifood Tech Private Limited	121
6	Agua14 Ventures Private Limited Company	121
7	Anabio Technologies Pvt Ltd	122
8	Andragogy Life Sciences	122
9	Arkashine Innovations Private Limited	123
10	Arthro Biotech Pvt Ltd	123
11	Asthraivi Global Services (P) Ltd	124
12	Aves Foodtech Private Limited	124
13	Axenic Agritech Private Limited	125
14	Bhojpatta Agripreneur Private Limited	125
15	Bhoomi AI Solutions Private Limited	126
16	Bio-Aryavedic Naturals Pvt Ltd	126
17	Biomakerz	127
18	Biopioneer Private Limited	127
19	Biopol Biosciences	128
20	Biosouk Life Sciences Llp	128
21	Bomlife Private Limited	129
22	Busan Tech	129
23	Cellzyme Life Sciences Private Limited	130
24	Chimertech Private Limited	130
25	Chrissron Biomass Solutions Pvt. Ltd.	131
26	Circular Ecotech Pvt Ltd	131
27	Clear Meat Pvt Ltd	132
28	Compositech Greensol Pvt. Ltd.	132
29	Cosmos Bio Pvt Ltd	133
30	Cowbit Technologies Pvt Ltd	133
31	Declutter Solutions Private Limited	134
32	Devigere Biosolutions Pvt Ltd	134
33	Earthtech Innovations Pvt Ltd	135
34	Edna Biolabs Private Limited	135
35	Ekosight Technologies Private Limited	136

INDUSTRIAL BIOTECHNOLOGY (INCLUDING SECONDARY AGRICULTURE)		
Sl. No.	Company Name	PAGE NUMBER
36	Elmentoz Research Pvt. Ltd.	136
37	Elvikon India Pvt Ltd	137
38	Ensoverse Private Limited	137
39	Exquinz Life Sciences Pvt Ltd	138
40	F3 Biotechnology	138
41	Famnutra millet foods pvt ltd	139
42	Fermentech GSV Private Limited	139
43	FIB-SOL Life Technologies Pvt. Ltd.	140
44	FisHealth14 AI Ventures Private Limited Company	140
45	Flowmatrix Polymers Pvt Ltd	141
46	Fluoresight Bioprobes Private Limited	141
47	FOAB SOLUTIONS PRIVATE LIMITED	142
48	Farm-fresh-fruits	142
49	Freshily19 Agri-Tech Private Limited	143
50	Gene Prospera Biotech Pvt. Ltd.	143
51	Genexis Biotech Private Limited	144
52	GPS Renewables Pvt ltd	144
53	GreenShift Energy Private Limited	145
54	HasiEco Ventures Pvt Ltd	145
55	IBioM	146
56	IPSUM LIFESCIENCES LLP	146
57	JASS Biologics Design Center	147
58	Kcat Enzymatic Private Limited	147
59	KisaanSay	148
60	KR Bioproducts (OPC) Private Ltd	148
61	Kwaklei and Khonggunmelei Orchids Pvt. Ltd.	149
62	Lab Iconics Technologies LLP	149
63	LANKA GREENOVATION	150
64	Masuu Organic Private Limited	150
65	Medic Tech Private Limited	151
66	MICROBIAL FARM RESEARCH AND CONSULTANCY	151
67	MrBiologist LLP	152
68	Nanosafe Solutions	152
69	Nap life sciences	153



INDUSTRIAL BIOTECHNOLOGY (INCLUDING SECONDARY AGRICULTURE)		
Sl. No.	Company Name	PAGE NUMBER
70	Neat Meatt Biotech Private Limited	153
71	NOPS foods pvt. ltd.	154
72	ONEOMICS PRIVATE LIMITED	154
73	Operon Technologies	155
74	Orchard Farm Fresh Vacuum Dried Fruits (India) P Ltd.	155
75	OrouEX Biological pvt ltd	156
76	Pequirel Technologies Private limited	156
77	Pherobank Technologies pvt ltd	157
78	ProteinNext India Pvt. Ltd.	157
79	Quaestio LLP	158
80	Quarks Innovation Lab Pvt Ltd	158
81	Reinste Nano Ventures Private Limited	159
82	REVV Environmental Solutions Pvt. Ltd.	159
84	RIGEL BIOENVIRON SOLUTIONS PVT. LTD.	160
85	RNA BIOTECH PVT LTD	160
86	Ronds Technologies Pvt Ltd	161
87	Sah Astitva	161
88	Sanovaskale Technologies Pvt Ltd	162
89	Scitechesy Research & Technology Private Limited	162
90	Scylene Wellness Private limited	163
91	SearchMyTenders	163
92	Serione	164
93	SM Biologics Consultants	164
94	Sodhani Biotech Pvt. Ltd.	165
95	SRIGPAVENS LIFE SCIENCES PVT. LTD	165
96	SUDHIN BIOTECH PRIVATE LIMITED	166
97	Testright Nanosystems Pvt. Ltd.	166
98	TMJ FOODS INDIA PVT LTD	167
99	Trishveda Naturals Pvt. Ltd.	167
100	Unbubble	168
101	UNXG Technologies Private Limited	168
102	VFL Sciences Private Limited	169
103	WIDE MOBILITY MECHATRONICS PVT LTD	169
104	Within clouds	170

Name of Startup: 3R ZEROWASTE PVT LIMITED



Founder and Co-founder(s):
Shiv Rao Challa - CEO
Dr Simi Mishra - CSO
Sanjiv Singh - CMO

Email:
ceo@0waste.co.in

Product/Technology differentiation from Competitors
Rewards and gamification for B2C Consumer

Brief Description of Product
Rewards Platform for Sustainable Gestures.

Current Stage of Development
Mobile application is in Playstore and being used by Citizens

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted
PAN India

National/Societal Relevance
It will promote sustainable practices across India and LIFE Mission will be targeted .

Technology readiness level (TRL)
TRL-7

Title/Name of the Product/Technology

Waste Management for Food Waste

Product Positioning

Unique in the world as on date

Import Substitution

Many items as Local SDG will be targeted

National/Societal Relevance

It will promote sustainable practices across India and LIFE Mission will be targeted

Export Potential

Yes

IP Status

Indoor bio air purifier patent was granted and we wish to file the extension for our outdoor bio air purifier. Grant No. 543505 Patent Application No. 202241026126

Name of Startup: Aathma Pranavaayu Pvt Ltd



Founder and Co-founder(s):
Dr Rajalakshmi S
Mr UmaMahesh B

Developed Under
(scheme):
SEED Fund

Email:
raji@pranavaayu.com

Product/Technology differentiation from Competitors

None of the competitors have liquid solution to do air purifying. All the conventional air purifiers have chemical filters which in turn pollute the soil and pollute the soil. We have a biomass solution which does the process of complete air purification.

Brief Description of Product

We are a clean tech company working towards the air pollution monitoring and mitigation solution. We work in the concept of bio air purifier which defies the concept of conventional filter-based air purifier which absorbs pollutants and creates soil pollution whereas here we use biomass which mimics photosynthesis where gas exchange processes take place. All the pollutants are eaten by biomass which gives out only enriched oxygenated air. We work in 3 verticals. The first indoor air purifier GardenAir has been granted patent recently and we are in the pre-commercial stage. The second one is Prana Green Wall, where any wall can be converted into a breathable wall using biomass. The third is outdoor air purifier which is in collaboration with Tamilnadu pollution control board. We have done a Paid pilot in Bangalore Bioinnovation Center, Bengaluru.

Current Stage of Development

In the current pilot state, we are able to demonstrate complete working of the system and its capacity to do air pollution mitigation. To commercialise, a few more sensor integration and automation is required to maximise the efficiency.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Most polluted cities like Delhi, Kolkata, Chennai, Mumbai.

National/Societal Relevance

Air pollution is the major cause for respiratory ailments like COPD and Asthma. Therefore, we recommend to have a bio friendly air purifier in every house. This product is the mandate for the one who wants fresh oxygen for long life

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

Prana Tree - A BioAir purifier for outdoor and carbon sequester

Product Positioning

Product is positioned to corporates and Government where there is a requirement for carbon sequestration and lack of space for additional trees. The product is well suited for traffic signals where the carbon built up is high due to vehicle idling.

National/Societal Relevance

Air pollution is the major cause for respiratory ailments like COPD and Asthma. Therefore, we recommend to have a bio friendly air purifier in every house. This product is the mandate for the one who wants fresh oxygen for long life


Export Potential

High potential as it is need of the hour to fight against climate change and will contribute to climate actions and carbon credits in a great way

IP Status

Indoor bio air purifier patent was granted and we wish to file the extension for our outdoor bio air purifier. Grant No. 543505 Patent Application No. 202241026126

KarmaCoins – Features of the Mobile Application



Name of Startup: ACSEN AGRISCIENCE PVT LTD



Founder and Co-founder(s):
Sengottuvelu Senthilnathan
Abishiek Senthilnathan

Developed Under
(scheme):
BIPP

Email:
arunagarwal@acsen.in

Product/Technology differentiation from Competitors
None of the INDIAN bred broccoli is available.

Brief Description of Product

Biofortified rich in glucoraphanin, indol-3-cabolin, FRAP and CUPRAC, DH lines have been developed and not their conversion into CMS is processing and finally will get utilize in hybrid production

Current Stage of Development

Biofortified rich in glucoraphanin, indol-3-cabolin, FRAP and CUPRAC, DH lines have been developed and not their conversion into CMS is processing and finally will get utilize in hybrid production

Are you willing to Transfer/ Out-License your Technology YES

Geographical Region Targeted

All over INDIA.

National/Societal Relevance

All seeds of broccoli in INDIA are imported till now. So will be helpful for our farmers to provide them broccoli seeds at very discounted price.

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

Waste Management for Food Waste

Product Positioning

All over INDIA and export to Europe also

Import Substitution

None of the available hybrid claims for biofortification.

Export Potential

Too high. Worldwide, seeds of biofortified broccoli can be sold.



Name of Startup: ADIS TECHNOLOGIES PVT LTD



Founder and Co-founder(s):
SUJIT HUKKERIKAR PRASAD
KRISHNA DESAI

Developed Under
(scheme):
BIG, SEED Fund

Email:
prasad@adis.co.in

Product/Technology differentiation from Competitors

Advanced RFID Integration: Unlike standard systems, our solution integrates advanced RFID technology with IoT, enabling precise tracking of animal health and productivity in real-time. Unique Identification and Analytics: We utilize a proprietary algorithm for unique animal identification and detailed analytics, including behavior and environmental conditions, which other systems lack. Comprehensive Data Handling: Our system captures and processes data seamlessly, with robust features for automated data analysis and reporting, enhancing decision-making for farmers and insurance companies. Scalability and Flexibility: The technology is designed to be easily scalable and adaptable, accommodating different farm sizes and types, and integrating with various existing farm management systems.

Brief Description of Product

Product Name: ADIS SmartID System Product Description: The ADIS SmartID System is an advanced digital solution designed to revolutionize livestock management and animal identification through the use of IoT technology. Combining RFID Radio-Frequency Identification tags, smart readers, and cloud-based analytics, ADIS SmartID provides farmers, insurance companies, and government agencies with a seamless and efficient way to track, monitor, and manage livestock health, productivity, and overall welfare. This system not only enhances animal identification but also contributes to digital insurance processes, enabling a more streamlined and transparent approach to livestock management. Key Features: RFID Animal Tags: The ADIS SmartID System uses durable, lightweight RFID tags designed for attachment to the ears of livestock such as cattle, sheep, goats, and even dogs. Each tag contains a unique identifier, which enables precise identification of individual animals. The tags are weather-resistant, ensuring reliable operation in various environmental conditions. Additionally, these tags are capable of capturing vital health data, such as body temperature and activity levels, which are critical for monitoring the health and behavior of the animals. Smart IoT Readers: Complementing the RFID tags, the ADIS SmartID System incorporates smart readers that are capable of long-range data scanning. These portable and easy-to-use readers are designed for both on-field and in-stall use, capturing data from multiple tags simultaneously. The readers aggregate the collected data and transmit it securely to cloud servers for further analysis. They are equipped with high-accuracy sensors to ensure reliable data collection, and their battery-operated design makes them suitable for use in remote areas without access to power. Cloud-Based Data Management: Once the data is collected by the smart readers, it is sent to the ADIS cloud platform. This platform provides secure storage, real-time processing, and advanced analytics capabilities. Farmers and other stakeholders can access this data via a user-friendly mobile or web application, allowing them to track the health, location, and productivity of their livestock in real-time. The cloud-based approach ensures scalability, enabling the system to handle large volumes of data as the number of monitored animals grows. Digital Insurance Integration: A key differentiator of the ADIS SmartID System is its integration with digital insurance processes. By providing accurate and real-time data on livestock health and identification, the system helps streamline the insurance claim process. This reduces fraud, enhances claim accuracy, and speeds up settlement times. Insurance companies can use the data provided by the system to validate claims, track animal history, and assess risk more effectively. Animal Health and Welfare Monitoring: The ability to continuously monitor vital signs and behavior patterns allows for early detection of diseases, stress, or other health issues. The systems analytics can alert farmers and veterinarians to potential problems before they become critical, enabling timely interventions. This proactive approach not only improves animal welfare but also boosts farm productivity and reduces costs associated with animal healthcare. Compliance and Traceability: The ADIS SmartID System ensures compliance with government regulations related to animal tracking and food safety. By maintaining accurate records of animal movements and health, the system

Current Stage of Development

The ADIS SmartID System is in a well-advanced stage of development. We have successfully moved from concept validation to prototype testing and field trials, with positive results demonstrating its effectiveness in livestock management. Pilot projects with international organizations and regulatory approvals are underway. Our system is actively used by major insurance companies and agricultural stakeholders, proving its commercial viability. Continuous enhancements are being made based on user feedback and technological advancements. We are now focused on scaling operations and expanding our market presence, supported by proven technology and successful implementation in real-world settings.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

ADIS Technologies targets global markets with a primary focus on emerging economies and regions with significant agricultural and livestock sectors, including India, Saudi Arabia, and the USA.

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

Prana Tree - A BioAir purifier for outdoor and carbon sequester

Product Positioning

Product is positioned to corporates and Government where there is a requirement for carbon sequestration and lack of space for additional trees. The product is well suited for traffic signals where the carbon built up is high due to vehicle idling.

Import Substitution

ADIS Technologies solutions contribute to import substitution by offering advanced, locally developed animal management technologies that reduce dependence on foreign systems. By providing high-quality, cost-effective tools for animal identification and management, the company supports domestic agricultural innovation and strengthens local industry, thereby lowering the need for imported technology and fostering self-reliance in the agricultural sector.

National/Societal Relevance

ADIS Technologies product addresses critical national and societal issues by enhancing livestock management and animal welfare. By providing precise animal identification and real-time data analytics, it supports improved food security, boosts agricultural productivity, and promotes sustainable farming practices. Its impact extends to economic benefits through increased efficiency and better resource utilization in the agricultural sector, contributing to national food security and rural development.

Export Potential

ADIS Technologies has significant export potential due to its innovative animal management solutions, which address global needs for efficient and effective animal identification and management. Our advanced technology, including unique animal identification systems and comprehensive management tools, positions us well in international markets. We have already engaged with international clients and are involved in projects with organizations such as the FAO and partners in Saudi Arabia. Our solutions are adaptable to various regions, offering scalable and customizable options that cater to diverse agricultural practices worldwide, thereby enhancing our potential for global expansion.

IP Status

The PCT application with the number PCT/IN2022/051036 for our process titled A PROCESS FOR IDENTIFICATION OF A SNUOTED ANIMAL. Copyright: The Application titled "REGISTRATION CERTIFICATE FOR UNIQUE IDENTIFICATION OF ANIMAL" was filed on 7th May 2024, with application number 14643/2024-CO/L. Trademark: device mark "Device of ADIS" number 6430329.

Name of Startup: AGRIFOOD TECH PRIVATE LIMITED



Founder and Co-founder(s):
Sushil Shelke Priyanka Shelke
Sindhu Shelke Sarjerao Shelke

Developed Under
(scheme):
BIG

Email:
agrifoodtech@gmail.com

Product/Technology differentiation from Competitors

We offer Processing Technology for rhizomes to powder with Complete In-House Operations that Reduces the Time of Processing to 24 Hours by eliminating sun drying 30 Days Required using combination of Biotechnology & Special Engineered Equipments such as Bio Reactor Vessel, Vacuum Evaporate System and Cabinet Air Dryer to arrive at dehydrated rhizome suitable for quality powder products. We are offering Proprietary Technology that will help farmers organisation to overcome these hurdles and make market ready products with complete inhouse processing. The end consumer products obtained from this technology has higher retention of bioactive elements like curcumin in turmeric.

Brief Description of Product

Technology providers of Innovative Rapid Rhizome Processing, Post Harvest Technology that Drastically Reduces Processing Time of Fresh Rhizomes such as Turmeric, Ginger etc. to Powder products that helps farmers to overcome their primary processing pains No dependency on weather conditions, eliminating sun drying by offering most efficient way to dry rhizome crops and prepare value added products for the market.

Current Stage of Development

We are expecting a Commercial Launch in less than a year. Following that we make proposal to the Ministry of Agriculture and Farmers Welfare Government of India to officially enlist this technology in the Government records, IIT Kanpur will help in this objective. Our INFRASTRUCTURE / TECHNOLOGY Solutions appeals to the Farmers Community on the following benefits. BUYING CENTERS are PRIMARY MANUFACTURERS & PROCESSORS and Farmers Producer Organisations seeking Projects in Value Addition in domain Fresh Produce to Finish. VALUE MATRIX offered by our technology QUALITY CONTROL and SCALE. 50 days of demos to the Farmers community have been completed.

Are you willing to Transfer/ Out-License your Technology YES

Geographical Region Targeted

Regions of Maharashtra, Telangana, Andhra Pradesh, Karnataka, and Tamil Nadu. Further MEKONG Region in International Target Market.

National/Societal Relevance

Social Impact: Our business model promotes Farmers Community in their Entrepreneurial Journey. We offer support from setting up Food Processing unit as a MSME Micro Small Enterprise from production and marketing and sales assistance. Economical Impact: The technology ensures zero waste production with no losses due to monsoon threat during sun drying Environmental Impact: Water Saving in comparison to Traditional Processing is 80! Lesser Biomass Burning/Consumption.

Technology readiness level (TRL)

TRL-5



Title/Name of the Product/Technology

Rapid Rhizome Technology

Product Positioning

Almost Efficient Underground Stem Processing Technology for Farmer Producer Organizations and food processors who are looking to undertake projects in Food Processing. Want to Process large Quantities of Underground Stems Having Financial Capability to Invest 110 Lakhs INR Wanting to enter Business of Primary Processing sell Value Added FMCG Products

Import Substitution

In 2023, India imported 13,134,500 kilograms of turmeric curcuma for a total value of \$15,413,120 this essentially is due to the non-capability to Process the Primary Fresh Produce, our Technology ensures Rapid Production and will help in bridging this Gap.

Export Potential

Rapid Rhizome Technology End Products Achieved 30 times faster processing while ensuring export quality and compliance with EU norms. The Technology targets MEKONG Region for International Launch.

IP Status

Technology Demonstration & Patent Filing: Indian Patent Application No. 202321063166

Name of Startup: Agua14 Ventures Private Limited Company



Founder and Co-founder(s):
Abhishek Deshmukh: Founder & Director
Principal Investigator for BIG

Developed Under
(scheme):
BIG, SPARSH

Email:
abhishek@agua14v.com

Product/Technology differentiation from Competitors

Fishgrade sets itself apart by offering a versatile AI-based system capable of grading over 25 commercial seafood species with a single device, unlike competitors who rely on mechanical sorters designed for specific species. Our automated system not only reduces operational costs by up to 60 but also provides superior accuracy, consistent quality, and faster sorting speeds. Additionally, Fishgrade's future roadmap includes innovative features like microplastics detection and hands-free operation, positioning us to surpass international grading standards and redefine industry benchmarks.

Brief Description of Product

Fishgrade: AI-based Fish Sorting and Quality Detection is an advanced, AI-driven system designed to revolutionize the seafood industry by providing precise and reliable sorting and grading for a wide variety of seafood, including fish, shellfish, and other marine products. The system employs cutting-edge computer vision and machine learning algorithms to evaluate multiple quality parameters, such as size, weight, color, texture, and overall freshness, in real-time. Fishgrade is designed to integrate seamlessly with conveyor belt systems at landing centers and export facilities, automating the sorting process to reduce labor costs significantly. Beyond the traditional grading standards set by international bodies like the FAO, Fishgrade aims to establish new benchmarks by developing proprietary grading criteria that better meet the specific needs of global importers and the seafood industry. One of the systems future capabilities includes the potential to detect microplastics in seafood—a groundbreaking feature that would set a new standard in the industry. The system also plans to incorporate additional sensors, such as X-ray and electronic noses e-noses, to further enhance the accuracy and comprehensiveness of the quality detection process. Fishgrade offers several key benefits to its users: Improved Profitability: By ensuring that only high-quality seafood is exported, Fishgrade helps businesses achieve better price realization and reduces the risk of product rejections at international markets. Enhanced Reliability: The AI-based grading system is far more consistent and reliable than manual grading, reducing human error and bias. Prevention of Catch Degradation: By grading and sorting the catch immediately after landing, Fishgrade helps prevent spoilage, ensuring that one substandard batch doesn't affect the overall quality of the stored seafood. This is similar to the concept of a single rotten apple spoiling the entire basket. Sustainability and Compliance: The system helps exporters comply with international quality standards while also supporting sustainable fishing practices by reducing waste and improving the efficiency of the supply chain. Fishgrade is not just a tool for today it is a platform designed to evolve with the industry, anticipating future needs and setting new standards for seafood quality and safety. This makes it an indispensable asset for seafood exporters who are looking to stay ahead in a highly competitive market.

Current Stage of Development

We have developed an alpha prototype to demonstrate the proof of concept for our seafood quality detection unit, capable of accurately assessing fish quality using AI. Currently, we are in the process of developing our MVP, which involves integrating this quality detection system with a conveyor belt to enable automated sorting. This MVP will not only detect the quality but also efficiently sort seafood based on various parameters, setting the stage for full-scale deployment.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Fishgrade targets coastal cities across India, serving seafood exporters, processors, fisheries cooperative societies, and fishermen. Internationally, we aim to reach exporters in developing nations and importers in major markets like the US and Europe, focusing on profitable trade routes and global expansion.

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

FishGrade: AI-based Fish Sorting and Quality Detection

Product Positioning

Fishgrade is uniquely positioned as a premium, scalable AI-powered solution for seafood exporters, processors, and fisheries cooperative societies in India and globally. Designed to meet stringent EU and US import standards, it enhances profitability by providing precise sorting across diverse markets, including developing countries.

Import Substitution

Fishgrade significantly reduces the need for imported grading machinery by providing a domestically developed, AI-powered seafood sorting system. This fosters local innovation and supports the Make in India initiative, while offering a cost-effective and high-quality alternative to foreign equipment.

National/Societal Relevance

Fishgrade supports the Indian government's goal to double fish exports from \$8 billion to \$15 billion by 2030 by providing advanced, AI-driven sorting technology. Our system improves grading accuracy, enhancing the quality and competitiveness of Indian seafood in global markets. By reducing reliance on imported grading machinery, Fishgrade fosters local innovation. In the future, we aim to offer direct export services to fishermen and cooperative societies, empowering them with increased profitability and fairer trade practices.

Export Potential

Fishgrade supports India's goal of doubling seafood exports from \$8 billion to \$15 billion by 2030. With strong export potential in Southeast Asia, South America, and compliance with EU and US import standards, it enhances global competitiveness by ensuring high-quality, precisely sorted products.

IP Status

Patent Application number:
202421003438



Name of Startup: Anabio Technologies Pvt Ltd



Founder and Co-founder(s):
Dr Rajalakshmi S
Mr UmaMahesh B

Developed Under
(scheme):
BIG, LEAP Fund

Email:
mithun.shah@anabio.in

Product/Technology differentiation from Competitors

Anabio Technologies is a 7-year-old startup focused on scaling sustainability. They have a built a revolutionary product, a flushable and biodegradable sanitary pad. Anabio's pads dissolve and disintegrate in the toilet eliminating need for disposal in a responsible and sustainable manner.

Brief Description of Product

Anabio Technologies is a 7-year-old startup focused on scaling sustainability. They have a built a revolutionary product, a flushable and biodegradable sanitary pad. Anabio's pads dissolve and disintegrate in the toilet eliminating need for disposal in a responsible and sustainable manner.

Current Stage of Development

We are now in advance stages of design finalization and consumer trials.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India First and then launch Globally.

National/Societal Relevance

Social Stigma- Women will have a dignified way of disposing the pads without fear of someone seeing them dispose a pad. It protects their privacy. Sanitation Employees- Currently, there is no dignity in labor, our sanitation employee are forced to handle this waste stream, and in most cases, without gloves and masks. In many cases, kids perform manual scavenging. Our solution will improve the dignity of labor Health and safety- used sanitary pads are classified as hazardous waste. Our solution will prevent spreading of diseases and prevent contamination of land and water bodies by making sure this stream is eliminated.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

Flushable Sanitary Pads

Product Positioning

The flushable pad will eliminate the need to go out to dispose a pad. It won't even leave the bathroom, no one needs to know. Our solution will prevent spreading of diseases.

Unique Selling Point

Our Product dissolves

IP Status

2 patents filed

Export Potential

Yes

Name of Startup: ANDRAGOGY LIFE SCIENCES



Founder and Co-founder(s):
SAMRAT CHATTERJEE

Email:
infochatto@gmail.com

Product/Technology differentiation from Competitors

Existing kits are very costly More than one buffer and time consuming.

Brief Description of Product

ANDRAGOGY LIFE SCIENCES specialises in providing comprehensive solutions in the Biotechnology/Life Sciences domain. Our Flagship Product Rapid Soil Genomic DNA Extraction Kit integrates seamlessly with existing research workflows to enhance accuracy, efficiency, and reproducibility in scientific investigations. Weve recently ventured into personal care products offering science-backed solutions such as our anti-fungal foot cream.

Current Stage of Development

Our Rapid Soil Genomic DNA Extraction kit is currently in the commercialisation stage. It has successfully been adopted by Calcutta University for their course practical classes and exams, demonstrating its practical application and value in an academic setting. The product is fully developed, extensively tested and have received positive feedback from users. We continue to refine and enhance the product based on user feedback to ensure it meets the evolving needs of the life sciences community.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Pan India.

National/Societal Relevance

Andragogy Life Sciences is dedicated to advance in biotechnology in India by providing low-cost molecular biology kits and buffers. Our affordable and high-quality products support education and research ensuring accessibility to a broader audience by innovation.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

Developer of Low-Cost Molecular Biology Kits And Ready To Use Buffers

Product Positioning

Most Efficient Underground Stem Processing Technology for Farmer Producer Organizations and food processors who are looking to undertake projects in Food Processing. Want to Process large Quantities of Underground Stems Having Financial Capability to Invest 110 Lakhs INR Wanting to enter Business of Primary Processing sell Value Added FMCG Products

Export Potential

Yes



Name of Startup: Arka Shine Innovation in Agriculture



Founder and Co-founder(s):
Asudha Ramesh Karbari Ramesh Karbari

Developed Under
(scheme):
BIG

Email:
karbari.rudha@gmail.com

Product/Technology differentiation from Competitors

Portable & Lightweight Complete Automation Ease of Operation Ease of Cleaning after the test Ease of replacement of Modules Ease of charging the device Ease in understanding results One chemical handling per test On-spot printed results Life Span ~ 0.5 Lac tests Technical Details: Complete Automation for a Soil Test, IOT-based operation of device, AI/ML algorithms and Platform, Innovative and patented Sensory Platform. Value Proposition: Affordable and Easy to Use, Detailed and all results of soil parameters, User Friendly Interface, 1 Lac tests per Device per cartridge.

Brief Description of Product

SoilSaathi is revolutionary AI-integrated product that delivers reliable, effortless, and accurate complete 13 parameters soil analysis directly on farm. This portable device, designed like backpack, allows entire miniature testing lab to be easily transported to remote and challenging locations where traditional soil testing labs are inaccessible.

Current Stage of Development

Validating with Soil Testing Laboratories.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Karnataka, Telangana, Kerala, Tamil Nadu, Maharashtra, and Madhya Pradesh.

Technology readiness level (TRL)

TRL-8

IP Status

387972- apparatus and method for soil testing,419926- apparatus and method for soil testing,202341001891 apparatus and method for optical analysis,202341072887 system and device for analysis perishable item,202341001892 apparatus for electrical analysis,202141028625 recommendation system,202341069355 apparatus for testing soil,369092-001 portable soil testing apparatus,397147-001 portable soil testing apparatus.



Title/Name of the Product/Technology

SoilSaathi

Product Positioning

Partnering with following for larger network and distribution. 1. Agri Incubators 2. Agri Universities 3. Agri businesses 4. Agri Corporates 5. Retailers 6. FPOs Positioning it as a portable product that can be carried to farm and provide results in 30 minutes.

Import Substitution

SoilSaathi can be easily customized to meet the specific needs of different regions and crop types within India, offering a competitive edge over standardized imported solutions. Relying on domestic production reduces vulnerabilities associated with international supply chain disruptions.

National/Societal Relevance

SoilSaathi provides real-time soil health monitoring supports sustainable agriculture. SoilSaathi provides real-time soil health monitoring, enabling farmers to make data-driven decisions that can increase crop yields by 20-30. Efficient Resource Use: Optimizing the use of fertilizers and water resources reduces wastage, ensuring sustainable farming practices. SoilSaathi represents a significant advancement in agri-tech, showcasing India's capability in developing cutting-edge agricultural technologies. It contributes to the Digital India initiative by integrating advanced technology into traditional farming practices. Empowering Small and Marginal Farmers.

Export Potential

Growing global emphasis on sustainable farming practices aligns with SoilSaathi's benefits of optimized fertilizer use and improved soil management. Many developing countries in Africa, Asia, and Latin America face similar soil health challenges as India, presenting a significant market for SoilSaathi. In developed markets, there is a strong focus on precision agriculture.

Name of Startup: ARTHRO BIOTECH



Founder and Co-founder(s):
Dr. Praveen K Sappa - Founder & CEO Dr. S A Vardhan Kishore Nalam - Co-Founder & Head of R&D Mr. Manikanth Injapur - Co-Founder & COO

Developed Under
(scheme):
SEED Fund

Email:
contact@arthrobio.com

Product/Technology differentiation from Competitors

The Arthros BSF meal stands out in the market due to its superior qualities. With a protein content ranging from 58 to 60 and an appealing golden-brown colour, it is highly desirable for pet food companies. The raw materials used for growing the BSF larvae are plant-based, ensuring traceability and compliance with European and American regulations. Arthros facility is committed to adhering to all European regulations, including Good Manufacturing Practices GMP, Hazard Analysis and Critical Control Points HACCP, obtaining plant approval from export certifying authority, and registering the facilities within TRACES EU regulatory.

Brief Description of Product

Arthro Biotech leverages black soldier flies as an efficient means to convert low-value organic residues derived from agricultural processing industries into valuable resources. Our internally developed advanced technologies enable us to breed these insects on a large scale. As a feed stock, we formulate specialized diets using traceable, plant-based, low-value organic residues. The larvae upcycle the nutrients into high quality insect ingredients such as Insect protein meal and insect oil. Once the larvae reach maturity, they are harvested and processed into protein-rich meal and oil, which serve as essential ingredients in animal feed production fish, shrimp, and pet food industries. Our strengths Furthermore, the organic residues that undergo conversion are transformed into nutrient-rich substances abundant in nitrogen, phosphorus, and potassium NPK, providing valuable inputs for agriculture. Arthro Biotech's circular and sustainable process ensures minimal to no waste, as every component is efficiently harnessed and utilized. In addition, we have developed entomopathogenic nematode based biopesticides. Our proprietary technology ensures scalable biopesticide production with reduced production costs. We also plan to develop insect-based plant bio stimulants leveraging on BSF larvae.

Current Stage of Development

BSFL products are already being exported to petfood and aqua feed companies across India and abroad. The biopesticide is currently in the field trials.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Currently- Petfood markets in Europe, SE Asia and Americas.

National/Societal Relevance

Produced on agriculture industry residues.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Black soldier fly larvae derived Protein meal, Fat and Flakes. Black soldier fly derived Entomopathogenic Nematodes.

Product Positioning

The products are derived from insects that are grown on agriculture industry residues. They have a low carbon footprint with a high nutritional profile. Added FMCG Products

Export Potential

Currently exporting

Import Substitution

Fishmeal & soy meal import substitution

IP Status

Provisional patent applied for Entomopathogenic Nematode production

Name of Startup: AsthraVi Global Services P Ltd

AsthraViTM

Founder and Co-founder(s):
Aniruddh Vaidya Srinivasulu K

Developed Under
(scheme):
BioNEST

Email:
info@asthravi.com

Product/Technology differentiation from Competitors

Portable & Lightweight Complete Automation Ease of Operation Ease of Cleaning after the test Ease of replacement of Modules Ease of charging the device Ease in understanding results One chemical handling per test On-spot printed results Life Span ~ 0.5 Lac tests Technical Details: Complete Automation for a Soil Test, IOT-based operation of device, AI/ML algorithms and Platform, Innovative and patented Sensory Platform. Value Proposition: Affordable and Easy to Use, Detailed and all results of soil parameters, User Friendly Interface, 1 Lac tests per Device per cartridge.

Brief Description of Product

AgriMORE+P stands as a multipurpose carrier-based bio-fertilizer sourced entirely from natural origins, free from synthetic chemicals. It offers advantages across a diverse range of agricultural and horticultural crops. The bio-compounds within this product possess non-pathogenic and environmentally friendly attributes, coupled with a distinctive capability to enhance soil stability by permeating soil pores, rocks, and minerals, prompting structural and size-related transformations. FowlMORE+ is a bio-meal derived from fermentation approach and enriched with biochemical precursors. This innovative feed supplement promotes cellular nutrition and boosts the growth performance of chickens, specifically designed for broiler chicken. It incorporates SSF based bio products with a high content of ARA and secondary metabolites sourced from diverse plants. A diverse array of essential nutrients, polyunsaturated fatty acids PUFAs, proteins, dietary fibre, lipids, vitamins, minerals, and secondary metabolites sourced from plant extracts. HerbiMore+, an advanced feed supplement blend, harnesses potent benefits to enhance both the health and productivity of cattle. This cutting-edge blend effectively manages stress levels during transition periods, significantly reducing the risk of abortion and supporting healthy pregnancies to ensure the reproductive well-being of your herd. Moreover, it facilitates improved nutrient exchange between mother and calf, fostering optimal growth and development in new-borns.

Current Stage of Development

Tested at field level, Field level validation has been completed.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

All India.

Technology readiness level (TRL)

TRL-6



Title/Name of the Product/Technology

AgriMORE, FowlMORE HerbiMORE

Product Positioning

Chemical FREE We would like to promote our product using various marketing models like B2B and B2C.

Import Substitution

As per the import and export data there are two Indian based companies importing these products and reselling in India.

National/Societal Relevance

Using our product, we aim to improve the nutritional profiles for Human and animal health by boosting immune function and reducing the incidence of certain diseases. Healthier animal can lead to better quality of animal derived foods.

Export Potential

PUFA based feed ingredients are completely import dependent as on date, as per our knowledge we see a huge potential in exporting to Middle East and African countries.

Name of Startup: Aves FoodTech Pvt Ltd



Founder and Co-founder(s):
Dr. Mahesh Patil Ms. Tejaswini Patil

Developed Under
(scheme):
BIG, SPARSH

Email:
avesfoodtech@gmail.com

Product/Technology differentiation from Competitors

• Unlike HCA, phytofit has multiple targets such as reduction in subcutaneous fat, gut Firmicutes and oxidative stress which makes it unique. • The natural yeast strains are specific for Garcinia fermentation and it is a novel combination in the process. • The process designed for phytofit making is unique in terms of technique, inoculum, substrate and end product. • Increase in yield of polyphenols is the key feature over existing products where loss in bio-activity and biomolecule yield is observed due to heat treatment. Therefore, phytofit is unique in terms of efficacy.

Brief Description of Product

This technology has been developed as a part of BIRAC- SIIP and BIG program. We have completed cell line and animal model studies for the product. We have registered under FSSAI to sale this product as a Food product with known health benefits as per FSSAI. Currently the beverage variant of this product is ready to launch in the market. We are also working on the other variants of this product and those will be ready soon.

Current Stage of Development

The present invention discloses a composition comprising yeast fermented Garcinia fruit pulp. The composition has increase in concentration of catechin, p-coumaric acid and chlorogenic acid achieved up to 1.5-3-fold during fermentation. In an embodiment, increased anti-obesity property of the Garcinia is achieved by fermenting the said fruit pulp using yeast.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Obesity is major pandemic worldwide, therefore acceptance and selling demand in overseas markets is high for the product. Due to awareness of preservatives, side effects in the society, this product may have great demand since it is chemical free with maximum shelf life. Therefore, acceptance in world market is easy.

National/Societal Relevance

Majority Indians are suffering from abdominal obesity. Therefore, scientifically validated, multi-targeted and easily acceptable solution is required for real and lasting impact on individuals, communities and on nation. Phytofit is a functional food concentrate which has easy daily acceptance, India's second most preferred taste, and easy to have consistency for Indian population which helps to reduce conversion of extra energy into fat. This solution can help to reduce the burden of increasing overweight, obesity and related secondary diseases in the society.

Technology readiness level (TRL)

TRL-5



Title/Name of the Product/Technology

PHYTOFIT

Product Positioning

This is functional food can be used as beverage, powder, tablet form. It can be used in water, curries or in salad topping. We have completed cell line and animal model studies for the product. We have registered under FSSAI to sale this product

Export Potential

Obesity is major pandemic worldwide, therefore acceptance and selling demand in overseas markets is high for the product. Due to awareness of preservatives, side effects in the society, this product may have great demand since it is chemical free with maximum shelf life. Therefore, acceptance in world market is easy.

IP Status

1 Indian Patent Application Number: 202121056669 • Title of Patent Application: Composition And Method Based on Fermented Concentrate Of Garcinia For Anti-Obesity • Priority Date: 7th Dec 2021 • Complete Patent Filed: 7th Dec 2022 • Name Of Applicant: Aves Foodtech Private Limited 2 Trademark Phytofit Registered Under Class 29.

Name of Startup: Axenic Agritech Private Limited



Founder and Co-founder(s):
Dr. Arpan Modi and Mrs. Ritu Modi

Developed Under
(scheme):
BioNEST

Email:
axenicagritech@gmail.com

Product/Technology differentiation from Competitors

1. Plant production can be expected after 6th month of the culture initiation. 2. Up to 3 times higher production with the same laboratory space.

Brief Description of Product

Production of uniform planting material in the plant tissue culture industry requires 9-12 months to generate a minimum of 2,50,000 ex-agar plants a year. We aim to reach the same target within 4-5 months. The process involves basic cell culture techniques and management of the cell clumps to develop plantlets. Generation of tissue culture-raised Banana plantlets is a primary scope in most commercial plant tissue culture industries. Starting from the collection of suckers to the production of uniform planting material the micropropagation technique involves a lot of manpower, resources, and time. The process starts in July-August and plant production can be expected after April of next year. In vitro leaves are generated and thrown out at every sub-culture cycle during the process. However, these leaves can be utilized to produce new planting material. We are aiming to develop sustainable solutions for the plant tissue culture industries. Our targets are small industries producing fewer than a million plants annually.

Current Stage of Development

Currently, we have procured the starting material from which in vitro leaves are generated. The plants are under cultivation.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Gujarat, Maharashtra

Technology readiness level (TRL)

TRL-2



Title/Name of the Product/Technology

Plant Tissue Culture and Plant Molecular Biology Services

Name of Startup: BHOJPATTA AGRIPRENEUR PRIVATE LIMITED



Founder and Co-founder(s):
NITISH KUMAR GURIYA KUMARI
NANDLAL KUMAR

Developed Under
(scheme):
OTHERS

Email:
bhojpatta@gmail.com

Product/Technology differentiation from Competitors

1. Tuffen Glass, Stainless Steel 304 Food Grade 2. Buy Back Facility 3. Storage Facility 4. Hand Holding Support for Loan and Training.

Brief Description of Product

It is a fruit and vegetable drying machine that takes heat from sunlight and dries the product. It uses a prism to control the temperature, and a cloth made of natural fibers to filter the air.

Current Stage of Development

Early stage.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

ALL INDIA.

Technology readiness level (TRL)

TRL-6



Title/Name of the Product/Technology

ZERO CARBON EMISSION DRYER WITH PRISM TECHNOLOGY

Export Potential

Yes

IP Status

Design Patent No 394780-001 Dated 25/10/2023 Trade Mark Registered 5855800 Dated 08 / 03/2024

Name of Startup: Bhoomi AI Solutions Private Limited



Founder and Co-founder(s):
Anant Kumar, Anupam Kumar,
Amit Kumar Singh, Janit Anjaria,
Ajay Garg

Email:
team@bhoomiai.com

Product/Technology differentiation from Competitors

We are differentiated from our competitors in terms of higher accuracy in crop disease prediction as well as real-time advisories to the farmers. Data directly collected from the farmers helps in higher accuracy.

Brief Description of Product

Bhoomi AI is an innovative agricultural technology platform designed to empower farmers with data-driven insights and solutions. Leveraging artificial intelligence and machine learning, Bhoomi provides a comprehensive suite of tools to optimize crop management, improve yields, and enhance overall agricultural productivity. Key Features: 1. Identification of crop diseases and pests in real-time using Image Analytics. 2. Farm advisory in Indian languages, 3. Crop yield estimation for the farmers, 4. Micro credit/government credit advisories, 5. Organic fertilizers production 20-30 TPD for promotion of sustainable agriculture.

Current Stage of Development

We have more than 3000 farmers as users. We have resolved more than 8000 queries from the farmers in real time.

Are you willing to Transfer/Out-License your Technology Yes

National/Societal Relevance



Pests, diseases and improper use of agricultural inputs like pesticides, herbicides, and low-quality seeds result in a significant crop loss of 20-25 in India. This translates to a staggering annual economic impact of up to 1 Lakh crore per annum. Our solution can reduce it by 30-40

Geographical Region Targeted

We have focussed our product on B2B segments in the regions of Karnataka, Uttar Pradesh and Bihar

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

Crop Advisory Solutions for AI

Product Positioning

We are focussing on B2B segments for Agri-drone and Agri-tech companies

Export Potential

Our product has the potential to tap the international markets in the USA and Canada.

Import Potential

We will replace foreign companies like Plantix from the Indian market.

Name of Startup: Bio-Aryavedic Naturals Pvt Ltd



Founder and Co-founder(s):
VINEETHA A K ARUN B

Developed Under
(scheme):
PACE, SEED Fund

Email:
aryavedic.in@gmail.com

Product/Technology differentiation from Competitors

We developed a natural polymer, known for its biodegradability and non-toxicity character. This natural polymer compound possesses versatile properties making it suitable for applications such as forming films for textile, food and pharmaceutical purposes, including edible coating and drug-eluting carriers. It also exhibits inherent antibacterial and antifungal properties and can serve in environmental applications owing to its absorbent capacity during photocatalytic processes. This compound effectively improves the technological and mechanical properties and enhances the interfacial charge transfer thereby restricting electron-hole combinations and improving photocatalytic properties. This non-toxic, biodegradable composite is the most cost-effective solution compared to silver, gold, copper, zinc NPS.

Brief Description of Product

Introducing our ground-breaking product, the albedon Instant Fabric Stiffener Spray. This innovative 3-in-1 solution acts as an instant stiffener, fabric conditioner, and antimicrobial agent, all packaged in an eco-friendly manner. Infused with active BIO Shield Technology and sustainable starches, it ensures your clothes stay fresh and protected throughout the day. These products cater to a diverse range of sectors, including working professionals worldwide, the hospitality industry, the public sector, and the healthcare sector. Whether its simplifying fabric care for busy professionals or ensuring durability and exceptional performance in hospitality and public sector uniforms, our products are designed to meet the highest standards. Our water-based formula ensures that the particles are safe for spraying, making it gentle on fabrics and safe for your family. The eco-friendly packaging and photocatalytic activity help reduce air pollution, making Albedon a responsible choice for your household. Albedon revolutionized the traditional starching method, which involved dipping clothes in starch water and then drying them—a time-consuming process. With Albedon, you get the same crispness and cleanliness instantly, without the hassle. Simply spray and go, saving you precious time and effort. What makes Albedon even more special is our commitment to supporting local farmers. We source our cassava starch directly from small-scale farmers, ensuring they receive fair prices and sustainable livelihoods. By choosing Albedon, you're not only caring for your clothes and the environment, but also contributing to the well-being of farming communities. Every spray of Albedon is beneficial for your fabric and the environment. It's our way of supporting you, so you can confidently step into each day with freshness and ease. We hold certifications from reputable institutions such as the South Indian Textile Research Association SITRA and the Sree Chitra Tirunal Institute for Medical Sciences and Technology SCTIMST Biomedical Technology Wing, ensuring long-lasting antimicrobial protection, skin-friendly formulations, and freedom from toxic chemicals.

Current Stage of Development

Prototype developed.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Products cater to a diverse range of sectors, including working professionals worldwide, the hospitality industry, the public sector, and the healthcare sector. Whether its simplifying fabric care for busy professionals or ensuring durability and exceptional performance in hospitality and public sector uniforms, our products are designed to meet the highest standards.

National/Societal Relevance

The albedon Instant Fabric Stiffener Spray not only enhances fabric appearance with its long-lasting stiffness and antimicrobial protection but also aligns with broader societal benefits. By reducing greenhouse gas emissions, it supports environmental sustainability. Furthermore, its antimicrobial properties contribute to improved hygiene, helping mitigate communicable diseases that affect school-going children. Additionally, the spray's commitment to sustainability resonates with our support for farmers by promoting eco-friendly practices, thereby contributing to the well-being of communities and the environment.

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

Albedon Sustainable Instant fabric ironing stiffener spray that provides long-term antimicrobial protection for up to 30 days, made without using any harmful chemicals or toxic minerals.

Product Positioning

Albedon Instant Fabric Stiffener Spray provides immediate, long-lasting stiffness with antimicrobial protection and a sustainable formula. Ideal for individuals, corporates, and public sectors seeking high-quality, eco-friendly fabric care solutions that enhance garment appearance while supporting environmental responsibility.

Export Potential

With its high-performance, antimicrobial protection, and eco-friendly formula, Albedon Instant Fabric Stiffener Spray has strong export potential. It meets the growing global demand for sustainable, effective fabric care solutions, offering significant opportunities in international markets

Import Potential

It represents a strategic move towards import substitution by providing a high-quality, locally produced alternative to international fabric stiffeners. By manufacturing this product domestically, we reduce reliance on imported goods, support local industry, and contribute to the country's economic self-sufficiency. This approach enhances product accessibility and affordability & aligns with sustainable practices.

IP Status

Patent application filed Application Number: 202341039637



Name of Startup: Biomakerz



Founder and Co-founder(s):
Kabilan S - Founder

Email:
biomakerz@gmail.com

Product/Technology differentiation from Competitors

Enterokinase technology differentiates itself through Pichia pastoris-based production, ensuring high purity, specific activity, and scalable yield. This yeasts efficient expression system and post-translational modifications enhance cost-effectiveness and regulatory compliance, crucial for pharmaceutical and biotechnological applications. Innovative formulations and stringent quality control further set it apart, catering to diverse industry needs with superior performance and safety assurances compared to competitors.

Brief Description of Product

Enterokinase is a pivotal enzyme in protein digestion, crucial for cleaving trypsin-sensitive linkages in proteins. Its production in Pichia pastoris holds promise due to the yeasts robust expression system, offering scalable and efficient enzyme production. Isomaltulose, a disaccharide with low glycemic index properties, can also be synthesized in Pichia pastoris. This yeasts genetic manipulability and ability to perform post-translational modifications make it an ideal host for industrial bioprocesses, facilitating cost-effective production of both enterokinase and isomaltulose.

Current Stage of Development

The current stage of technology transfer for enterokinase indicates that the enzyme has successfully transitioned from research and development to a phase where efforts are focused on adapting and scaling its production for industrial applications. This phase involves transferring the know-how and processes developed in the laboratory to commercial settings, ensuring robust production, quality control, and regulatory compliance. Such a stage signifies a significant advancement towards practical applications in biotechnology, pharmaceuticals, and other industries reliant on enterokinases enzymatic activity.

Are you willing to Transfer/Out-License your Technology Yes

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Recombinant Protein Production

Name of Startup: BioPioneer Private Limited



Founder and Co-founder(s):
Dr.Bijayananda Panigrahi
Ms. Soumya Surajita

Developed Under
(scheme):
BIG, SBIRI, SEED Fund

Email:
biopioneer2020@gmail.com

Product/Technology differentiation from Competitors

Protease inhibitors pi available in the market are expensive, sensitive to temperature, less effective, and limited inhibition activity. The major key player of protease inhibitors such as MP biomedical, Roche, Calbiochem, Thermo scientific, etc. are transporting the materials in cold chain conditions, in addition, all are providing cocktail protease inhibitors and majority of the pi are insoluble in water. Biopioneer is addressed all these issues and come up as NexGEN HM Protease inhibitor.

Brief Description of Product

Biopioneer Pvt. Ltd. offers a new generation protease inhibitor that is highly efficient and has several strong USPs. Currently, there are several protease inhibitors in the market, and India imports almost all of them which makes them very expensive. Also, the popular commercial protease inhibitors have some drawbacks such as requiring cold storage because they don't have stability in RT, are mostly toxic in nature, and water insolubility, and are quite costly. NexGen HM Protease Inhibitor tackles all the mentioned problems with its outstanding USPs that include it being completely water-soluble, non-toxic, thermally stable up to 95°C, effective against several classes of proteases, stable at a wide range of pH, can be stored at room temperature and is ten times more cost-effective than similar products in the market.

Current Stage of Development

We have field trail data, where we got excellent feedback from various institute such as Institute of Life Sciences, IICT, AIIMS, NISER, IIT, Indore, IIT Kanpur, ICGEB, Utkal University, Imgenex, etc. beside this we generate few revenues around 20Lakh. Last year we got around 43 of repeat orders. further looking to expand our business pan India, especially biotech industry.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Globally the protease inhibitor market size is expected to hit 8 billion dollars by 2030. Considering our USPs, we ultimately want to export our product globally starting with Europe and the USA as they are the major players in the same with Roche, Sigma-Aldrich, and ThermoFisher.

National/Societal Relevance

Most protease inhibitors in the Indian market are imported from other countries which makes them very costly to be used while protein isolation and purification, ultimately making the protein of interest costlier for the market. Biopioneer is the first start-up in India to manufacture protease inhibitors and focuses on mitigating the requirements for the import of protease inhibitors. Through our product, we aim to provide an effective and affordable protease inhibitor to the life sciences research sector of our country which will ultimately help the pharma and aligned industries in producing more cost-effective products for the people of this country.

Technology readiness level (TRL)

TRL-6



Title/Name of the Product/Technology

Lunched 1st thermally stable protease Inhibitor for global Markets.

Product Positioning

B2B, Especially Biotech, cosmetic, diagnosis, and biopharma industries.

Export Potential

As NexGen HM Protease Inhibitor has been validated with protein isolates of several species such as mammalian cells, bacteria, yeast, nematodes, and plants. It is stable at RT, so no need any cold chain logistic support to export the materials globally.

Import Potential

Biopioneer offer a 1st made in India novel protease inhibitor that mitigates the gaps currently residing in the protease inhibitor market such as toxicity, insolubility n water, inhibitors available in cocktail form, require cold storage, and not being stable across a wide range of pH.

IP Status

Application number 202131010934,
Controller General of Patents, Designs & Trademarks, India Granted Tread mark
5974988 and 5974987

Name of Startup: Biopol Biosciences



Founder and Co-founder(s):
Founder - Akash S
Co-founder - Vidhyasagar D

Developed Under
(scheme):
BIG

Email:
akash@biopolbiosciences.com

Product/Technology differentiation from Competitors

There are a few companies globally and in domestic market producing Vitamin k2-7 through chemical and biological methods. With respect to the organism, all the companies use bacillus subtilis natto. As raw materials are concerned companies use yeast extracts, peptones, and soya peptone. Whereas we are trying to use soya bean waste, optimizing to match the nitrogen content. In terms of production costs, companies are producing at a cost of 4-6 rupees per mg, we have working towards a target of rupees 1 per mg. And finally with a target of increasing production capacities to 180 -200 mg/L.

Brief Description of Product

Mk-7 namely Menaquinone-7 is a highly valuable member of the Vitamin K family has a significant effect on preventing osteoporosis and cardiovascular diseases besides its positive effects on blood coagulation. The likely therapeutic dose of MK-7 for treatment of osteoporosis and cardiovascular diseases from MK-7 rich dietary sources that is blue cheese, meat and fermented soybean would require the consumption of impractically large quantities. It is, therefore, desirable to develop a rich source of MK-7 as a dietary supplement. Bacillus subtilis natto is used for production of MK-7. The current challenge for MK-7 fermentation involves increasing the yield of fermentation to make large scale production viable. We have developed a bacterial strain that is capable of giving us high yields of MK-7 of 180 - 200 mg/L at a span of 7 days. We have optimized the substrate feeding strategy that in turn enhances the formation of Mk-7 and finally a simpler downstream process to extract the product.

Current Stage of Development

Product demonstration.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Domestic and International markets

National/Societal Relevance

Our vision on this project is see and provide an opportunity for every Indian to consume Vitamin k2-7 thereby reducing the problems of osteoporosis, CVD and Hemophilia.

Technology readiness level (TRL)

TRL-6



Title/Name of the Product/Technology

Efficient production of Vitamin K2 - 7 through improved upstream and downstream process

Product Positioning

Vitamin k2-7 belongs to High value low volume product and our Target customers are Nutraceutical and pharmaceutical industries.

Import Substitution

Yes, Globally Vitamin K2-7 is imported around 100 kgs per month. We believe that we will capture 10 of the current import market.

Export Substitution

Since Vitamin K2-7 global increment is increasing with a CAGR of 29.7, we will always have the potential to export at larger scales.

Name of Startup: BIOSOUK LIFE SCIENCES LLP



Founder: Ms. Kauser Banu
Co-Founder: Mr. Mohammed Asif

Email:
kauserbio@gmail.com

Product/Technology differentiation from Competitors

Milk-O-Mak stands out as a highly competitive product in the market due to its unique combination of affordability, simplicity, and comprehensive functionality. Unlike many other milk adulteration detection solutions, Milk-O-Mak is a single paper microfluidics device that offers rapid, on-site, colorimetric detection of 12 major milk adulterants. This broad detection capability, combined with its low cost and ease of use, makes it exceptionally accessible to a wide audience, including small-scale dairy farmers, vendors, and consumers. Its ability to provide quick, reliable results directly at the point of use gives it a significant edge over traditional chemical test strips.

Brief Description of Product

Milk-O-Mak is a low-cost, simple-to-use, Single Paper device for a rapid on-site colorimetric detection of 12 major milk adulterants with a vision of "One in every home". Milk-O-Mak addresses critical dairy industry challenges caused by milk adulteration, which threatens safety and quality. Traditional methods are complex, costly, and require specialized equipment, creating barriers for small-scale operations and consumers. Our low-cost, single-paper device provides immediate, affordable results, transforming quality assurance by making reliable testing accessible across farms, processing plants, retailers, and households. Adulterated milk poses health risks, erodes consumer trust, and impacts market competitiveness. Milk-O-Mak overcomes these issues with straightforward testing, safeguarding health, enhancing efficiency, and strengthening industry integrity. Our solution empowers stakeholders to maintain high milk quality and safety standards by simplifying the process and reducing costs. Milk-O-Mak opens new market opportunities, facilitating widespread adoption across the dairy supply chain. Milk-O-Mak's innovative technology not only enhances health and safety by providing affordable, accessible milk testing but also supports responsible consumption and production practices. By aligning with SDG 3 and SDG 12, Milk-O-Mak contributes to the broader global efforts to improve public health, promote sustainability, and ensure that dairy products are safe and responsibly produced. Our solution represents a meaningful step towards achieving these goals, creating a positive impact across the dairy industry and beyond.

Current Stage of Development

We have field trail data, where we got excellent feedback from various institute such as Institute of Life Sciences, IICT, AIIMS, NISER, IIT, Indore, IIT Kanpur, ICGEB, Utkal University, Imgenex, etc. beside this we generate few revenues around 20Lakh. Last year we got around 43 of repeat orders. further looking to expand our business pan India, especially biotech industry.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Starting in high-growth regions like India and Asia, then expand to North America and Europe, emphasizing cost-effectiveness.

National/Societal Relevance

Milk-O-Mak has significant relevance as it addresses critical public health issue. Milk, dietary staple worldwide, especially in developing countries, is often adulterated with harmful substances like urea, detergents, starch. This adulteration not only reduces milk's nutritional value but also endangers health, particularly among vulnerable groups such as children and elderly. Milk-O-Mak offers an accessible and affordable solution by allowing consumers, small-scale dairy farmers, and local vendors to swiftly and accurately detect milk adulterants. This is vital in areas with weak food safety regulations. By enabling self-verification of milk purity, Milk-O-Mak enhances public health, food trust, fostering higher dairy quality standards.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

Milk-O-Mak: low-cost, simple-to-use, Single Paper Micro fluidics device for a rapid on-site colorimetric detection of 12 major milk adulterants with a vision of "One in every home".

Product Positioning

Milk-O-Mak targets a critical segment of the dairy industry by providing accessible, reliable milk quality testing. Our solution serves dairy farms, processing plants, retailers, and consumers, each facing challenges with milk adulteration and needing cost-effective, on-site testing.

Export Potential

Global dairy industry is valued at approximately \$800 billion, with the milk testing market growing due to increased food safety concerns. Market for on-site milk testing is estimated at over \$5 billion annually. Milk-O-Mak's cost-effective, user-friendly technology is well-positioned to capture a significant share by enhancing quality assurance throughout dairysupplychain.

Import Potential

By fostering local research, production, & innovation, it reduces dependence on imported technology. This advancement not only lowers costs& creates jobs but also tailors solutions to specific local needs. Widespread adoption of Milk-O-Mak can lead to greater accountability within dairy supply chain, encouraging producers to adhere to higher standards of quality.

IP Status

2 Product IP generated



Name of Startup: Bomlife Private Limited



Founder and Co-founder(s):
Amlan Datta Manibrata Paul

Email:
mail@bomlife.in

Product/Technology differentiation from Competitors

We have isolated and ascertained combination of particular strains of each microbe which achieve maximum synergy with our IP protected bio-fertilizer formulation so that they can reproduce faster and supply balanced NPK. Most competitors offer inoculums of individual microbes whereas we offer a consortium with established synergy. Our bio-organic inputs can exclusively achieve optimal yield whereas most others supply as supplement to conventional.

Brief Description of Product

Bio-fertilizer: Our innovation involves a carrier-based consortia of microorganisms identified and isolated through 2 decades of research, the novelty of our IP protected formulation Patent No: WO2013098856A3 is in its design to obtain maximum synergy between the microbes so that they can reproduce faster, grow rapidly, and perform efficiently to supply the plant system with balanced NPK diet. We offer our biofertilizer in both liquid and solid form. Bio Stimulants: We've designed humic acid-based bio-stimulants with natural chelators and botanical extracts which optimize absorption of micronutrients and boost overall health & growth of the plant. Bio Pest & Fungal control agents: We have designed inoculums of singular or mixture of antagonistic and entomopathogenic fungi & bacteria as bio-control agents which prevents target pests and fungal diseases. We also offer neem oil based botanical extract & natural alkaloids which can control common pests upon infestation.

Current Stage of Development

Individual products are developed as well as their doses and application protocols have been established. We have developed package of practices for target crops namely tea, cotton, sugarcane, common vegetables etc through successful trials. At present we are conducting institutional validation of our package of practices on sugarcane, tea & cotton with funding support from BIRAC IKP Agri Grand Challenge. We are at early sales stage. Post validation we would like to strike partnership with industry.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Assam, West Bengal north for tea MP, Maharashtra, Tamil Nadu, Telangana, Odisha for cotton, Uttarakhand, Uttar Pradesh, Haryana, Tamil Nadu for sugarcane

National/Societal Relevance

In order to meet sustainable development goals, it has become imperative to accept Bio-organic inputs and its management will take the lead role in the agri-input space. Farmers can get higher return on investment with reduction of overall cost of production and a better price realization for the residue free produce. Farmers get healthy life without toxic chemical. Consumers gets toxin free products with lower carbon foot print. Environment gains with reduction of greenhouse gas emission, land restoration, bioremediation, and rejuvenation of the farm ecology. Social impact - health and happiness for all.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

Agri-tech - Bio-organic inputs for crop nutrition, protection & soil modulation

Product Positioning

Bio-organic inputs that can exclusively meet the requirement of commercial agriculture.

Import Substitution

Our nutritional inputs can completely replace chemical fertilizers like Urea, MoP, DAP which requires huge amount of energy during manufacturing. Nearly half of countries petroleum import goes for manufacturing urea. So, in an indirect way it is capable of reducing import of energy fuel.

Export Substitution

Internationally the demand for bio inputs is growing as replacement of chemical fertilizers. There is less price competition in the international market in comparison to domestic due to absence of subsidy for chemical inputs. Our products have good market potential in South East Asia, Africa & Middle East.

IP Status

Biofertilizer is IP protected.



Name of Startup: BUSAN TECH



Founder and Co-founder(s):
AALFIN EMMANUEL S

Email:
eaalfi@gmail.com

Product/Technology differentiation from Competitors

Meerkat Pro stands out by using three types of data—vibration, sound, and heat—to predict motor health more accurately than competitors. It uses smart AI to provide clear insights, making it easy for anyone in bioindustries to understand and act on. The product's design also prioritizes integration with existing industrial IoT frameworks, enabling seamless adoption without extensive retrofitting.

Brief Description of Product

Meerkat Pro is an advanced predictive maintenance solution designed to optimize motor performance within bioindustry applications by leveraging a sophisticated IoT-ML integration framework. The system deploys an array of precision-engineered sensors, including MEMS-based accelerometers, high-sensitivity microphones, and infrared thermal sensors, to capture multi-modal data streams encompassing vibration, acoustic, and thermal parameters. These real-time data inputs are transmitted wirelessly to an edge computing module, where initial signal processing and feature extraction are performed. Subsequently, the processed data is relayed to a cloud-based analytics engine that employs state-of-the-art machine learning algorithms, such as gradient boosting and LSTM networks, to predict motor health status with high accuracy. The AI model identifies potential anomalies, degradation trends, and failure precursors, translating complex data patterns into actionable insights. These insights are then visualized through an intuitive dashboard, enabling bioindustry professionals to make informed maintenance decisions without requiring deep technical expertise in data science or AI. Meerkat Pro represents a convergence of cutting-edge technologies, engineered to provide a seamless, scalable solution for maintaining operational efficiency and minimizing downtime in biologically sensitive environments.

Current Stage of Development

The Meerkat Pro prototype has successfully completed the build phase, incorporating all hardware and software components. The system is fully integrated, with functional sensor networks, data acquisition pipelines, and the predictive analytics engine in place. Extensive internal validations have been conducted, ensuring system stability and data integrity. The prototype is now ready to enter the testing phase, where it will undergo rigorous field trials to validate performance in real-world bioindustrial conditions.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Meerkat Pro targets global bioindustrial markets, focusing on regions with strong manufacturing sectors such as South-east Asia, North America, and Europe where operational efficiency is crucial.

National/Societal Relevance

Meerkat Pro supports national initiatives for smart manufacturing and sustainable industry, enhancing the reliability and efficiency of critical bioindustrial infrastructure, which is vital for economic stability.

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

[Meerkat Pro] Enhancing bio-based machinery longevity with cutting-edge predictive maintenance and AI integration.

Product Positioning

Meerkat Pro is positioned as a premium predictive maintenance solution for bioindustries, offering advanced technology at a competitive price point, ensuring high ROI for industrial customers.

Export Potential

Meerkat Pro has strong export potential, offering a competitive edge in international markets by addressing the global need for advanced, reliable, and cost-effective predictive maintenance solutions.

Import Potential

By offering a locally developed, high-tech solution like Meerkat Pro, the reliance on imported predictive maintenance systems is reduced, fostering domestic technological innovation and self-reliance.



Name of Startup: Celldzyne Life Sciences Private Limited



Founder and Co-founder(s):
Dr. M. Anantha Barathi Founder and
CEO Dr. Guhan Jayaraman Co-founder
and chief scientific advisor

Email:
ananthabarathim@gmail.com

Product/Technology differentiation from Competitors

Currently, animal sources and pathogenic bacteria are the major sources of Hyaluronic acid, which is cruel, non-safe, and also non-sustainable. Further, their properties are fixed as they are natural sources. We can produce Hyaluronic acid from engineered safe organisms in a sustainable manner and we can customise the properties of Hyaluronic acid by metabolic engineering and synthetic biology strategies.

Brief Description of Product

Hyaluronic acid HA is a naturally occurring biopolymer, specifically a glycosaminoglycan. Distinctive properties: Viscoelastic and moisturizing properties, paired with decreased toxicity levels, HA-based products have numerous applications in the pharma and cosmetic industries. Examples: Knee arthritis injections and derma fillers.

Current Stage of Development

Process development including downstream processing for isolation/enhancement/ extraction of the product at bioreactor level at less than 100 L.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

International market

National/Societal Relevance

Petrochemical-based products are essential however, the associated processes are non-sustainable and toxic to health and the environment. Animal/natural microbe-based products are natural however, animal sources pose a risk of viral and other infections in addition to limited supply and natural microbes if pathogens cause immunotoxicity. Plant extracts are a very potential source of biochemicals however as raw materials, they are considered unreliable for supply and need sophisticated processing to concentrate and improve specificity as bioactive compounds. Proposed solution: We create cell factories and employ bioprocess technologies as an alternative source for scalable, sustainable, natural-identical, and enhanced biochemical substances.

Technology readiness level (TRL)

TRL-5



Title/Name of the Product/Technology

Designing microbial cell factories for sustainable manufacturing of biochemicals. Our first cell factory is for producing hyaluronic acid.

IP Status

PROCESS FOR PRODUCTION OF CONSTANT MOLECULAR WEIGHT HYALURONIC ACID BY RECOMBINANT MICROBIAL FERMENTATIONS*
Patent Grant NO: 201841036041
PROCESSES FOR PRODUCTION OF HIGH MOLECULAR WEIGHT HYALURONAN IN A RECOMBINANT LACTOCOCCUS LACTIS USING ACETATE CO-UTILIZATION FED-BATCH STRATEGY* Patent Grant NO: 201941025143.

Name of Startup: CHIMERTECH PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Ragul Paramasivam
Dr. Karthik Deekonda

Developed Under
(scheme):
BIG, SEED Fund

Email:
ragul.paramasivam@chimertech.com

Product/Technology differentiation from Competitors

Meerkat Pro stands out by using three types of data—vibration, sound, and heat—to predict motor health more accurately than competitors. It uses smart AI to provide clear insights, making it easy for anyone in bioindustries to understand and act on. The product's design also prioritizes integration with existing industrial IoT frameworks, enabling seamless adoption without extensive retrofitting.

Brief Description of Product

NIRAMM, developed by Chimertech, is a revolutionary cloud-integrated Near Infrared NIR Spectroscopy-based adapter designed for milking machines. This technology aims to address critical challenges in dairy farming by providing real-time monitoring of 24 essential milk and cattle health parameters during every milking session. NIRAMM's comprehensive approach covers a wide range of categories including rumen health, milk quality, animal wellness, estrous, pregnancy, antibiotics, and disease management, making it an indispensable tool for modern dairy farms. Key Features: 24-In-1 Monitoring: NIRAMM is equipped to monitor 24 different parameters related to milk quality and cattle health. These parameters include somatic cell count SCC, milk urea nitrogen MUN, pH, milk solids, and more. The ability to track these metrics in real-time enables farmers to detect and address health issues like mastitis, ketosis, and antibiotic residues as they arise, preventing potential losses and ensuring the well-being of the herd. Artificial Intelligence AI Integration: NIRAMM's AI capabilities significantly enhance its functionality. The AI algorithms analyze data collected by the NIR sensor to detect subtle changes in milk parameters that may indicate emerging health issues. This proactive approach allows for early intervention, improving animal welfare and overall farm productivity. Furthermore, AI supports predictive maintenance of milking equipment, reducing the risk of unexpected breakdowns, and ensuring continuous operation, which is critical for large-scale dairy farms. User-Friendly Web Application: The NIRAMM system includes a robust web application designed to be intuitive and user-friendly. The application features a dashboard that centralizes all critical data, allowing farmers to easily monitor and manage their herd's health. It provides visual representations of key metrics, making it easier for farmers to make informed decisions quickly. This application also includes features for tracking reproductive health, managing cattle profiles, and monitoring milk quality, all of which are crucial for optimizing farm operations. Validation and Performance: NIRAMM has undergone rigorous testing under laboratory conditions, where it was benchmarked against traditional gold-standard methods like the Gerber method for milk fat and the Kjeldahl method for true protein. The results demonstrated that NIRAMM's performance is on par with these established methods, validating its accuracy and reliability. Additionally, NIRAMM was compared with leading technologies such as Lactoscan and PortaCheck, showing strong correlations across key parameters, further establishing its credibility as a superior alternative to existing solutions. Impact on the Dairy Industry: NIRAMM is poised to have a transformative impact on the dairy industry. By offering a non-invasive, cost-effective, and highly accurate solution for monitoring milk quality and cattle health, NIRAMM addresses several critical challenges faced by modern dairy farms. Its real-time monitoring capabilities allow for immediate responses to health issues, reducing the risk of severe diseases and improving overall herd management. The integration of AI into NIRAMM enhances its predictive capabilities, allowing farmers to anticipate and prevent equipment failures, thus minimizing downtime and optimizing farm efficiency. This contributes to greater operational efficiency and profitability for farmers. For consumers, NIRAMM ensures access to higher-quality, safer dairy products, which are produced under more responsible and sustainable farming practices.

Current Stage of Development

A high-fidelity prototype of the NIRAMM adapter has been developed, which integrates advanced Near Infrared NIR Spectroscopy technology with real-time monitoring capabilities. This prototype is not merely a conceptual model but a fully functional system that accurately measures 24 critical milk and cattle health parameters during the milking process. Laboratory Validation: The NIRAMM prototype has undergone rigorous testing in controlled laboratory conditions, a crucial aspect of TRL-6. It has been benchmarked against, demonstrating its accuracy and reliability. showed strong correlations, further validating its readiness for real-world application.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

NIRAMM primarily targets the Indian dairy market, with potential for expansion to other regions with large-scale dairy operations such as Southeast Asia, Africa, and Europe.

National/Societal Relevance

NIRAMM holds significant national and societal relevance by addressing key challenges in India's dairy sector, such as undetected cattle illnesses, low milk yield, and compromised milk quality. By providing real-time, AI-driven monitoring of critical health and milk parameters, NIRAMM ensures healthier livestock, safer dairy products, and enhanced farm productivity. This technology supports the government's initiatives for improving food safety and animal welfare, while also empowering small and marginal farmers with advanced tools to increase profitability. NIRAMM contributes to a more sustainable and resilient agricultural ecosystem, aligning with India's broader goals of food security and rural development.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

[NIRAMM – Near Infrared NIR Spectroscopy-based Adapter for Milking Machines.

Product Positioning

NIRAMM is positioned as an advanced, Sensor- AI-integrated solution for modern dairy farms, offering an all-in-one platform for milk quality monitoring and herd health management, aiming to elevate farm productivity and product safety.

Export Potential

With its comprehensive and innovative approach, NIRAMM has significant export potential, particularly in developing markets where dairy farming is evolving from small-scale to industrial operations, seeking efficient and reliable monitoring solutions.

Import Potential

NIRAMM reduces dependence on imported dairy monitoring technologies by offering a domestically developed, cost-effective solution, aligned with India's focus on self-reliance and boosting local innovation in agriculture.



Name of Startup: Chrissron Biomass Solutions

CHRISSRON
MAKE LIFE SUSTAINABLE

Founder and Co-founder(s):
Dr. Shereena P. Joy &
Aryamaan Singh

Email:
shereenajoy@gmail.com

Product/Technology differentiation from Competitors

Primary competitor for Our Product is FR4. We are differentiated as: - Higher Electrical Resistance: Our Product offers 11G ohms vs. FR4's 103-105 Megaohms, ensuring superior insulation. - Comparable Dielectric Strength: Both Our Product and FR4 have a dielectric strength of 2-5. - Equal Fire Resistance: Our Product matches FR4s V0 fire resistance rating, ensuring safety. - Low Moisture Absorption: Our Product offers the same low moisture absorption as FR4, ensuring stability in humid conditions. Ideal Choice: Our Product is perfect for applications requiring higher electrical insulation without compromising on performance or durability.

Brief Description of Product

We manufacture biodegradable resins from plant wastes. With prototypes for natural circuit boards in electronics, Insulation for EV batteries and thermal insulation for ceilings ready and under testing, we are constantly innovating for new applications.

Current Stage of Development

We have developed and patented sustainable resin technology by processing plant-waste. We generated functional MVPs for applications in diverse industries like electronics, construction, packaging, disposable crockery etc. We are now in the process of acquiring initial clients to validate the products in market.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

We are currently targeting clients based out of Chennai, Bangalore, and Mumbai with a plan to span entire India over the next 2 years. We have leads to countries like France, Norway, Germany, Taiwan and Singapore, the position for which will be clarified over a years time.

National/Societal Relevance

The societal relevance of our technology is: - Promote circular economy & reduced reliance on non-renewable resources - Additional revenue for farmers and small startups - Reduced carbon footprint - Reduced GHG emissions by 80 - Reduced E-Waste - Easily biodegradable.

Technology readiness level (TRL)

TRL-5

Title/Name of the Product/Technology

Natural Printed Circuit Board PCB - EV Battery Insulation Natural - Fire Resistant Ceiling Insulation - Disposable Crockery - Medicine and Food Packaging

Product Positioning

We plan to position our product as: - Sustainable alternative to pollution causing fossil-based plastics - Solution for Indias cause of 40 air pollution, stubble burning - Additional income for farmers.

Export Potential

FR4 based PCBs for magnetic sensors used in fuel gauges in automotive industries of Norway, Germany and France are exported from India. Our eco-friendly product can replace FR4 and provide a better functionality with higher profit margins and therefore holds immense export potential.

Import Potential

Our product has a substantial potential to be an import substitution by replacing below goods entirely for their respective applications: - FR4: India is the largest importer of FR4 in the World - Polyurethane Foam: India is the second largest importer of FR4 in the World.

Name of Startup: Circular Ecotech Pvt Ltd



Founder and Co-founder(s):
Founder - Shardul Narde

Developed Under
(scheme):
BIG

Email:
shardul.cetpl@gmail.com

Product/Technology differentiation from Competitors

Our technology has advanced rapid heating solutions capable of energy-efficient heat transfer and reducing emissions significantly. Apart from this, our technology is completely electrically powered without any extra fuel requirement, more automation possibility, lesser area footprints and cost-effective at the same time.

Brief Description of Product

The microwave-assisted reactor is a new-age heating technology applied to the industrial sector with a scaling-up vision. Our technology can fit in multiple domains from the activation of charcoal, the carbonization of agricultural waste to get biochar, or simply for drying purposes. Our technology provides a wide range of working temperatures from room to 1000 degrees Celsius, in less time. This is because of unique radiative heating principles. In this type of heating the heat is transferred via microwaves and it heats the core of the particle. Due to this, the heat losses are reduced and hence the heat transfer becomes rapid and more efficient. The technology can be customized as per the process needs. It can be worked in batch, continuous or semicontinuous mode. Our prototype stands at 100kg/day capacity for the carbonization process. As the technology is electrically powered, it can make the process easily automated and mobile. Also, it cuts down the point source emissions significantly.

Current Stage of Development

We have developed the prototype and now we are looking forward to the application-specific scale-up of the technology. For that, we are looking for possible collaboration.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Primarily our region to target is India but we are open to working globally.

National/Societal Relevance

With this technology, we can convert agricultural waste into biochar, which is a new-age material for soil remediation. Through this process, we can also target processes like torrefaction and pyrolysis in a much more sustainable way which can reduce carbon emissions and sequester carbon in a better way.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

The microwave heating technology is applied to a higher range of heating applications like carbonization and activation along with drying. This technology has a temperature working range from room temperature to 100 degrees Celsius.

Availability for showcasing at Birac

No.

Unique Selling Point

Microwave Heating Less Start up and Shut down time More Operational Control More Sustainable and energy-efficient

Import Substitution

We can substitute the heating technologies imported from abroad with this current technology.

Export Potential

We currently rely on rotary kilns as conventional heating reactors for high-temperature working ranges. These rotary kiln technologies are well established globally, but we can establish as well as export this innovative technology.

IP Status

We have already filed a provisional patent and now are moving towards filing the complete patent in India





Name of Startup: Clear Meat Pvt Ltd



Founder and Co-founder(s):
Dr Siddharth Manvatl

Email:
neerajv@clearmeat.com

Product/Technology differentiation from Competitors
Made in India 60 Cheaper Antibiotic free Hormone Free Kill free.

Brief Description of Product

Cell Growth Media ClearX9 is a serum-free complete cell culture media. Cultivated Meat Chicken Keema: This is kill-free cell-based cultivated meat.

Current Stage of Development

Cell Growth Media is commercialized and we have a client globally.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Globally.

National/Societal Relevance

Serum-free cell culture media are crucial for reducing animal use and enhancing scientific consistency in biopharmaceuticals. Environmentally it contributes to sustainability by lessening dependence on livestock farming.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Cell Growth Media and Cultivated Meat

Product Positioning

Globally.


Export Potential

Yes.

Import Potential

Yes.

Name of Startup: Compositel Greensol Pvt Ltd



Founder and Co-founder(s):
Dr. Manish Kumar Lila,
Founding Director

Email:
director@compositel.in

Product/Technology differentiation from Competitors

The developed technology is Indigenous, and No direct competition is there in the market. The developed granules are cost-effective with comparable mechanical and thermal properties. Its Manufacturing waste is also recyclable up to 6 times.

Brief Description of Product

The composite granules are developed using agro-waste and are Partially Biodegradable, a Green Alternative to Traditional Plastic.

Current Stage of Development

The granules are supplied to 3-4 Companies to validate for their product.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

PAN India.

National/Societal Relevance

The use of the developed granules can reduce plastic consumption by a considerable quantity as well as incineration of bio-mass, which are two major reasons for pollution. Therefore, the produced granules are relevant for the Nation as well as Society.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

Natural Fiber Reinforced Thermoplastic Composite Granules.

Import Substitution

No import required for any component as well as no substitution is currently available at the price, we are offering.

Export Potential

India polymer market available for composite application 2400 kT/PA US\$ 2.82 Billion. Global natural fiber composite market US\$ 9.82 Billion 2023 and increasing at a CAGR of 11.8, therefore, there is a huge potential for export also.



Name of Startup: COSMOS BIO PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Bharat Somireddy, Co-founder
Sowjanya Venkata, Co-founder

Developed Under
(scheme):
BIG

Email:
bharat@cosmosbiotech.com

Product/Technology differentiation from Competitors

Cosmos Bios key differentiations from competitors include being the first to produce affordable, biologically active ingredients like ectoine entirely in India. Traditionally, ectoine is produced through bacterial milking, which requires multimillion-dollar investments in custom bioreactors and high salt concentrations that can corrode fermenters. However, Cosmos Bio leverages recombinant DNA technology to produce ectoine in standard, cost-effective bioreactors without the need for high-salt media. Our innovative approach is not only cost-effective but also ethical, focusing on vegan and cruelty-free methods. Additionally, we prioritize sustainability, minimizing environmental impact while delivering high-quality products at competitive prices.

Brief Description of Product

Cosmos Bio Private Limited is at the forefront of producing recombinant ectoine, a compound renowned for its protective properties against environmental stressors like UV radiation, dehydration, and extreme temperatures. Originally derived from halophilic microorganisms, ectoine is highly valued in skincare, pharmaceuticals, and other industries requiring cellular protection. Leveraging advanced recombinant DNA technology, Cosmos Bio has successfully identified and cloned the key biosynthetic genes from halophilic bacteria, expressing them in a host organism using a bacterial vector. Our R&D efforts have focused on optimizing both upstream and downstream processes, yielding promising results in ectoine production. Compared to traditional extraction methods, our recombinant approach offers significant advantages. It is sustainable, scalable, and cost-effective, meeting the rising demand for natural, cruelty-free, and eco-friendly products. Additionally, this method ensures consistent quality and a reliable supply, addressing common challenges in ectoine production. Currently, ectoine production at Cosmos Bio remains in the R&D phase. We are dedicated to further improving yields and refining our processes to achieve industrial viability. As part of our commitment to ethical and regulatory standards, Cosmos Bio will secure all necessary licenses and approvals before commercializing recombinant ectoine. The project has been financially supported by the Biotechnology Industry Research Assistance Council BIRAC through the Biotechnology Ignition Grant BIG. This support has been instrumental in advancing our research and development efforts, positioning us to make a significant impact in the market. Our innovative approach positions us to contribute to a healthier and more sustainable future with our cutting-edge ectoine production.

Current Stage of Development

Cosmos Bio Private Limited is in the advanced R&D phase for recombinant ectoine production. Weve successfully cloned the biosynthetic genes and expressed them using a bacterial vector, focusing on optimizing upstream and downstream processes. Currently, were refining these methods to achieve industrial-scale viability and consistent yields. While significant progress has been made, no commercialization has occurred yet. We are committed to securing the necessary licenses before any market rollout. Supported by BIRACs Biotechnology Ignition Grant BIG, this project is progressing toward bringing sustainable and innovative ectoine to market.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

India, USA, Europe, and South Korea.

National/Societal Relevance

Cosmos Bios work in producing biologically active ingredients like ectoine has significant national and societal relevance. By developing a first-of-its-kind, made-in-India product, we contribute to the nations self-reliance in biotechnology, reducing dependence on costly imports. Our ethical and sustainable production methods align with national goals of promoting green technology and environmental stewardship. Additionally, our focus on affordable, high-quality products addresses the growing demand for safer, non-toxic skincare solutions, benefiting public health. Through innovation and responsible manufacturing, Cosmos Bio is poised to make a meaningful impact on both the Indian economy and society.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Production of recombinant ectoine for human skin anti-aging

Product Positioning

Cosmos Bio positions its ectoine as a premium yet affordable biologically active ingredient for the cosmetic and pharmaceutical industries. Targeted at consumers and businesses seeking high-quality, ethically produced alternatives, our ectoine stands out for being vegan, cruelty-free, and manufactured using sustainable biotechnology methods.

Export Potential

Cosmos Bios ectoine has strong export potential due to its unique positioning as an affordable, high-quality, and ethically produced active ingredient in the global cosmetic and pharmaceutical markets. With increasing demand for vegan and cruelty-free products worldwide, our ectoine meets the growing consumer preference for sustainable and natural skincare solutions.

Import Potential

Cosmos Bio's ectoine production reduces reliance on imports, cuts costs, and boosts local economies by fostering domestic biotechnology. Using advanced fermentation techniques, it provides affordable, high-quality ectoine for skincare, pharmaceuticals, and agriculture, promoting self-sufficiency, innovation, and environmental sustainability in line with Indias Make in India initiative.

IP Status

Application number:202441050897
Applicant: Cosmos Bio Private Limited
Inventors: Somireddy Venkata Bharat Kumar Reddy



Name of Startup: COWBIT TECHNOLOGIES PRIVATE LIMITED



Founder and Co-founder(s):
Ananda Kumar Mishra /
Diptimayee Mishra

Developed Under
(scheme):
BIG

Email:
cowbitinc@gmail.com

Product/Technology differentiation from Competitors

Internet-Free Functionality: Unlike competitors who rely heavily on constant internet connectivity, Cowbit's devices work offline, storing data locally and syncing when a connection is available. This makes it ideal for rural areas with limited or unreliable internet access. Comprehensive Health Monitoring: Cowbit offers a broader range of health metrics compared to competitors, including vital signs, behavioural patterns, and early disease detection, providing a more holistic view of cattle health. User-Friendly Interface: The Cowbit platform is designed with simplicity in mind, making it accessible to farmers with varying levels of tech literacy. This ease of use is crucial for widespread adoption.

Brief Description of Product

Cowbit is developing a line of connected products and solutions to optimize the health of the cattle for farmers welfare. This includes facilitating the right kind of infrastructure and housing for cattle, tracking each individual animal's health and yield through a wearable device, measuring parameters such as heat cycle, mastitis, foot and mouth disease and monitoring health conditions.

Current Stage of Development

We are conducting market trials on indigenous breeds to promote and help dairy farmers.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Odisha, India.

National/Societal Relevance

Cowbit Technologies addresses a critical need in rural India by improving cattle health and dairy productivity. By enhancing precision farming and supporting dairy farmers, our solution contributes to national goals of agricultural advancement, food security, and rural economic development.

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

Natural Fiber Reinforced Thermoplastic Composite Granules.

Product Positioning

Cowbit Technologies positions itself as a pioneering provider of affordable, low-powered IoT solutions for rural dairy farmers. Our product ensures continuous cattle health monitoring without internet dependency, offering reliability and ease of use, especially in remote areas where traditional solutions fail.

Import Substitution

Cowbit Technologies reduces reliance on expensive, imported cattle health monitoring systems by offering a locally developed, cost-effective alternative. This innovation supports India's Make in India initiative, promotes self-reliance, and contributes to the growth of the domestic agricultural technology sector.

Export Potential

Cowbit Technologies has strong export potential, particularly in developing countries with large dairy industries. By providing affordable and scalable cattle health monitoring solutions, Cowbit can tap into international markets, enhancing precision farming practices globally and contributing to sustainable agricultural development.



Name of Startup: Declutter Solutions Pvt Ltd



Founder and Co-founder(s):
Nitu Joseph, Co-founder and CTO Sreechanth
Sundaram, Co-founder and COO

Developed Under
(scheme):
BIG, SPARSH

Email:
nituj@decluttersolutions.in

Product/Technology differentiation from Competitors

Aquacol stands out with its use of fishery byproducts, reducing waste and promoting a circular economy. It features an advanced eutectic solvent-based extraction process that takes up to 18 hours, ensuring high bioavailability and purity with no harmful solvent residue. The production is not energy-intensive, and the decentralized, low-cost approach makes Aquacol 30% cheaper than competitors. Emphasizing sustainability and local economic support, Aquacol meets the demand for eco-friendly, high-quality health solutions.

Brief Description of Product

Aquacol is a premium, eco-friendly collagen extracted from fishery byproducts using advanced, sustainable methods. By repurposing what would otherwise be waste, Aquacol not only delivers high-quality collagen with superior bioavailability but also supports environmental sustainability and local fishing communities. Its innovative extraction process ensures minimal environmental impact while promoting a circular economy.

Current Stage of Development

Aquacol is at Technology Readiness Level TRL 4, indicating successful lab-scale validation of its collagen extraction process using natural deep eutectic solvent DES technology. The process has demonstrated zero waste and zero liquid discharge capabilities, with effective collagen extraction and recovery. Piloting is underway with consultancy from CSIR Central Leather Research Institute, Chennai.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

India, Asia Pacific.

National/Societal Relevance

It offsets 4.1 tons of carbon emissions per ton of waste processed. It creates 4 green jobs created for women-led self-help groups per ton of waste processed. Cost to the urban local body for waste management reduced by 30%.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Aquacol: Transforming Fish Waste into Community Wealth: Pure, Powerful, and Sustainable Collagen from the Sea

Product Positioning

Aquacol is positioned as a premium, eco-friendly collagen for health-conscious and environmentally aware consumers and brands.

Export Potential

From March 2023 to February 2024, India imported 1,567 collagen shipments, a 23% increase from the previous year. These were supplied by 281 foreign exporters to 167 Indian buyers. The main sources of India's collagen imports are the United States, South Korea, and Germany.

Import Potential

The global fish collagen market is projected to reach USD 1,473.9 million in 2024, and USD 2,664.5 million by 2034.

IP Status

Provisional patent filed- 202341085995

Name of Startup: DEVIKERE BIOSOLUTIONS PVT LTD

Founder and Co-founder(s):
SMITHA D P, Founder and CEO
Abhishek D P, Co-founder

Email:
smithadevikere28@gmail.com

Product/Technology differentiation from Competitors

Single ingredient as egg replacer from plant source.

Brief Description of Product

Highly functional, water soluble, clean label plant protein concentrates from mung beans and Black-eyed peas for Food and Nutrition applications, Plant based egg replacer in baking applications Mung bean hydrolysates for cell culture media applications.

Current Stage of Development

Plant protein extraction from Mung bean is tested for nutritional and safety studies and ready for scale up.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India and USA.

National/Societal Relevance

value addition and innovation of inhouse pulses for global market.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

PLANT PROTEIN CONCENTRATES AND PEPTIDES FOR NOVEL APPLICATIONS.

Product Positioning

Cowbit Technologies positions itself as a pioneering provider of affordable, low-powered IoT solutions for rural dairy farmers. Our product ensures continuous cattle health monitoring without internet dependency, offering reliability and ease of use, especially in remote areas where traditional solutions fail.

Import Substitution

99% of all the plant protein consumption in India is imported. We are selling our pulses for 50 to 80 INR/ kg and importing proteins for the cost range 500 to 2000 INR / kg

Export Potential

only egg replacer in baking application itself is billion dollar potential. Including innovation in food and nutrition, biotech applications as media ingredient, cosmetic ingredient if Multibillion dollar potential.



Name of Startup: EARTHTECH INNOVATIONS PVT LTD



Founder and Co-founder(s):
Dr. Nishant Gopalan, Toyam Sharma, Raj
Lodhari, Mohammad Bharmal,
Khojema Makda

Developed Under
(scheme):
BIG, SPARSH

Email:
earthtechinnovations@gmail.com

Product/Technology differentiation from Competitors

1. Requires 30 to 50 less space compared to any other plant. 2. Moreover, It Consumes around 50 less water. 3. More efficient due to IoT and AI proposed Technology. 4. Furthermore, our plant has All season stability and boosted gas output no change in gas generation due to seasonal changes. 5. Committed to safety, its equipped with pressure sensors that ensure safety from leaks. 6. The plant design is modular and scalable and does not require underground construction. 7. IN HOUSE DEVELOPED Gas Enrichment by CO2 Scrubbing. Pressurized Storage for flexible User usage.

Brief Description of Product

This pain of restarting old biogas plants is what we intend to solve, with a scientifically designed reactor, for predictable regular gas output of biogas for the user. Our Smart Biogas Plant monitors and controls other critical parameters like the pH and mixing intervals of the reactor, for preventing microbial population collapse. The innovation allows for treating the biogas reactor as a complex multi-species mixed fermentation process, with process control, and user notifications to minimize the downtime of the biogas and the requirement to restart the reactor. Compared to traditional biogas plants, the proposed solution occupies 30 to 50 less space and consumes up to 80 less water. The proposed technology is up to 60 more efficient, providing stable and boosted gas output throughout all seasons, with no variation due to seasonal changes. The reactors temperature is controlled throughout the year, ensuring optimal output and better overall microbial health. The plants pressure monitoring systems guarantee safety from leaks, with a modular and scalable design that can even fit into smaller spaces in various urban landscapes. The plants IoT system nudges/ notifies the user to move away from behaviours that lead to plant failure.

Current Stage of Development

The product is commercialized. We had successfully installed a 0.5 TPD waste treatment plant at Rolex Rings Ltd. in Rajkot. This advanced technology is currently operating efficiently and has achieved over 60 savings on the company's canteen gas bills.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Pan India and abroad.

National/Societal Relevance

The Cleanignite plant significantly impacts urban waste management by reducing 35-45 of Organic Fraction of Municipal Solid Waste OFMSW loads on dumping sites by treating waste near its source. This decreases transportation costs, saving fuel and money. The technology offers a clean, hygienic alternative to composting, efficiently converting waste into green fuel, and reducing reliance on fossil fuels like LPG and coal-based electricity. It also produces organically rich fertilizers, cutting the need for chemical alternatives. Importantly, the plant curbs methane emissions, a potent greenhouse gas, by converting waste into clean energy, supporting climate action and sustainable urban living.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

AI and IoT-based Smart Biomethanation Plant for Community-Scale Organic Waste Management.

Product Positioning

Our biogas plant transforms organic waste into reliable energy with 60 greater efficiency and 80 less water use than traditional systems. Designed for urban environments, it ensures consistent gas output year-round, is space-efficient, and features IoT-driven controls for optimal performance and safety, supporting sustainable urban living.

Export Potential

The Cleanignite plant has strong export potential, offering advanced waste-to-energy technology that addresses global challenges in waste management and renewable energy. Exporting this technology can help other countries achieve sustainability goals, reduce reliance on fossil fuels, and improve urban waste management, positioning India as a leader in green technology innovation.

Import Potential

The Cleanignite plant reduces reliance on imported fossil fuels like LPG by converting organic waste into locally produced renewable energy. This fosters energy independence and supports national efforts to reduce imports, strengthen domestic industries, and promote sustainable growth, aligning with India's push for self-sufficiency and economic resilience.

IP Status

Yes. Patent: 202221072352.
Awaiting to be granted.

Name of Startup: Edna Biolabs Pvt. Ltd.



Founder and Co-founder(s):
Dr. Nikhil Kateja

Developed Under
(scheme):
IIT DELHI FIRE Grant

Email:
info@ednabiolabs.com

Product/Technology differentiation from Competitors

We have leveraged our expertise in molecular biology, fermentation process development, and intensified downstream purification to produce a range of enzymes and kits reliably at low cost. Our USP is high quality coupled with affordability. Our extensive expertise in purification and analytical characterization has enabled us to match/exceed the activity and purity of the enzymes offered by international companies.

Brief Description of Product

The aim of this venture is to produce and market high-value enzymes and kits for research and in-vitro diagnostics applications. The company is one amongst the few to domestically produce specialty enzymes and kits with comparable or better activity to international standards.

Product/Technology

We have leveraged our expertise in molecular biology, fermentation process development, and intensified downstream purification to produce a range of enzymes and kits reliably at low cost. Our USP is high quality coupled with affordability.

Current Stage of Development

Edna is currently selling its products to different research labs and diagnostic centers. We are fortunate to have many established clients already - IIT Delhi, IIT Roorkee, AIIMS Delhi, AIIMS Rishikesh, JNU, Delhi University, Regional Centre for Biotechnology, Banaras Hindu University, Maharshi Dayanand University, Ashoka University, and Vel Tech University. NIPGR, NII, RCB.

Are you willing to Transfer/ Out-License your Technology YES

Geographical Region Targeted


Pan India.

National/Societal Relevance

The domestic production of enzymes and kits for research and in-vitro diagnostics applications will improve the accessibility of millions of Indians to reliable diagnostics information, which contributes up to 70 to disease identification by doctors and is the backbone of curative and preventive medicine.

Technology readiness level (TRL)

TRL-9



Name of Startup: Ekosight



Founder and Co-founder(s):
Dhiraj Choudhary, Founder and
CEO Saumya Rawat,
Co-founder and COO

Developed Under
(scheme):
SEED Fund

Email:
dhiraj@ekosight.com

Product/Technology differentiation from Competitors

Ekosight Soil Doctor stands out by offering a portable, real-time soil testing device that delivers rapid, accurate results directly in the field. Unlike competitors, it uses proprietary powdered reagents and advanced optical sensors for high precision with minimal chemical use. This makes it more affordable, user-friendly, and efficient, enabling farmers to make immediate, data-driven decisions for better crop management.

Brief Description of Product

Ekosight Soil Doctor, an innovative, portable soil testing device designed to revolutionise soil health management. It's a budget-friendly device that measures 12 essential soil parameters providing farmers with comprehensive soil health data on-the-go. Within an hour, farmers receive a holistic report, enabling them to make immediate and informed decisions required to optimise their crop yield and soil health. Our device also offers a customised fertiliser recommendation for the next crop to be sown on the farm, further enhancing its value and utility for farmers.

Current Stage of Development

Ekosight Soil Doctor is at TRL 9 because it has been successfully used by farmers on-ground, works reliably, meets all necessary standards, and is ready for large-scale production and widespread adoption.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Andhra Pradesh, Telangana, Tamil Nadu, Uttar Pradesh, Haryana, Punjab.

National/Societal Relevance

Ekosight Soil Doctor has significant national and societal relevance by empowering farmers with affordable, real-time soil health insights. It helps optimize fertilizer use, boost crop yields, and promote sustainable farming, directly addressing food security and agricultural productivity. This technology supports rural livelihoods, enhances resource efficiency, and contributes to the nation's agricultural sustainability.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Ekosight Soil Doctor.

Product Positioning

It's targeted at small to medium-scale farmers and agricultural professionals who seek to optimize crop yields, reduce input costs, and adopt sustainable farming practices. The device offers an affordable, accessible solution for enhancing soil management and optimising crop yields.

Import Substitution

Ekosight Soil Doctor contributes to import substitution by providing a domestically developed soil testing solution, reducing reliance on expensive, imported soil analysis equipment. By offering a cost-effective, locally manufactured alternative, it supports the Indian economy, promotes self-reliance in agricultural technology, and decreases the need for imported products.

Export Potential

Ekosight Soil Doctor has strong export potential due to its innovative, portable design, and affordability, especially in developing countries facing similar agricultural challenges. Its real-time, accurate soil analysis can meet global demand for sustainable farming solutions, positioning it as a valuable tool for improving agricultural productivity worldwide.

IP Status

202341012329 202341047657

Name of Startup: Elmentoz Research Pvt. Ltd



Founder and Co-founder(s):
Founder - Dr. Jayashankar Das
Co-Founder - Dr. Padmaja Mohanty

Developed Under
(scheme):
BIG

Email:
anurag@elmentoz.com

Product/Technology differentiation from Competitors

Elmentoz Research is strategically positioned to lead the growing insect-based alternative protein and biodiesel industry. With strong biotechnologist leadership, Elmentoz is innovating precision animal health nutrition supplements fortified with protein meal. These supplements offer sustainable feed formulations for poultry, shrimp, and salmon. Elmentoz Low Free Fat Technology enhances oil quality for feed industries, ensuring better nutritional value. Additionally, the development of AMP-fortified meal sets Elmentoz apart, reducing competition with existing insect-based protein companies by offering a unique, high-quality product. This focus on innovation and sustainability positions Elmentoz competitively in the alternative protein and biodiesel sectors.

Brief Description of Product

Elmentoz is addressing two major challenges concurrently. Firstly, the current reliance on animal feed protein, which occupies a staggering 83 of agricultural land from the 16 of crop land available for human food production, presents pressing environmental concerns. This production process contributes approximately 6.44kg of CO2 equivalent emissions per kilogram, takes 4 to 5 months to complete, and consumes approximately 87 gallons of water per kilogram, significantly threatening food security. Additionally, food waste exacerbates economic losses, amounting to a staggering \$1 trillion, and contributes approximately 9-10 of the global carbon footprint, highlighting the urgent need for sustainable solutions for alternative protein for animal feed and circular economy innovation. Elmentoz is focusing a circular economy solution for animal feed industries, offering highly scalable, cost-effective, and sustainable protein sources for poultry, aqua and pet industry. Our approach achieves remarkable environmental benefits, including a 6-fold reduction in carbon footprint, a 207-fold decrease in water footprint, and a 107-fold reduction in land space utilization compared to conventional methods. By integrating food waste management into our process and industrializing insects Black soldier Fly we enhance climate resilience while providing rich, digestible and sustainable protein with essential amino acids. At scale, our circular economy model, empowered by IoT technology, aims to reduce 300,000 metric tons of CO2 equivalent emissions annually and manage 2,400,000 metric tons of organic waste per year.

Current Stage of Development

The ongoing poultry feed trial has shown promising results, including reduced Feed Conversion Ratio FCR and increased bird weight, highlighting the effectiveness of our feed formulation and management practices. The decentralized IoT data acquisition system is now operational and ready for demonstration.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Regional, National, and International.

National/Societal Relevance

Resource Efficiency: Utilizes organic waste, transforming it into valuable alternative protein and biodiesel, turning waste management into a profitable venture. Energy Independence Reduces India's dependency on imported fossil fuels, enhancing energy security with domestic biofuel production. Protein Security Reduces India's dependency on soya, enhancing protein security with domestic alternative protein production. Waste Reduction Addresses India's waste management issues by converting organic waste into alternative protein and biofuel, reducing landfill use and pollution. Food Security & Crop Dependency Reduction*: Using BSF larvae that do not compete with human food crops for land reduces pressure on agricultural resources Rural Employment.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

Elmentoz Research, a B2B biotech startup, addresses protein and energy security with a circular economy model. Aiming to cut CO2 emissions by 300,000 tons annually, manage 2,400,000 tons organic waste. Elmentoz expertise in fostering BSFL technology through patented IoT based platform, producing alternative protein for feed & Oil for Biodiesel.

Product Positioning

Poultry Feed Industry Shrimp Feed Industry
Pet Food Industry Biofuel Industry.

Export Potential

India's strategic position and cost-effective manufacturing capabilities make it highly suitable for export. Leveraging these advantages, Elmentoz can offer competitive pricing and quality products on the global stage, enhancing its position as a key player in the international market.

Import Potential

By fostering a completely Make in India approach, we can eliminate external import reliance for feed and biodiesel production. This strategy aims to reduce dependence on soya and palm, enhancing self-sufficiency and promoting sustainable domestic sourcing within Indian feed and biodiesel manufacturing sectors.



Name of Startup: ELVIKON INDIA PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Rambabu Atluri
Dr. Sree Lakshmi Latha A

Developed Under
(scheme):
BIG

Email:
rambabu.a@elvikon.com

Product/Technology differentiation from Competitors

The resin business has been a competitive sector and most suppliers are by large companies from Europe and the USA. Sadly, 100 of the chromatography resin used by Indian pharma companies today is imported and hence it is expected that the cost of the resin is very much depend on the international market as well as economical fluctuations. At Elvikon, we want to be the first manufacturer of Ultrapure chromatography resin in India and sale it under the trade mark of "Make in India".

Brief Description of Product

The silica resin is a flexible and easy-to-use protein purification resin and can be adapted to many protein purification techniques including column chromatography, batch chromatography and automated methods such as FPLC. The silica resin developed by Elvikon is substantially spherical and have a size within the range of 5 to 60um, pore volume greater than the 90, and are further characterised with an alkali metal content below 100ppm. The method is based on sol-gel transformation and consists of emulsion technology for drop formation. The method increases the possibilities of controlling physical properties of resin such as particle shape, and pore characteristics, which is not possible with the state-of-the-art technologies or classical process such as spray drying, or fused silica process. Different sizes of silica gel mesh are utilized in various column chromatography techniques for distinct purposes such as compound identification, separation, and purification. Typically, smaller mesh sizes result in higher-resolution separations, while larger mesh sizes lead to faster separations. For bulk scale separations, mesh sizes ranging from 30 to 400 are commonly used, with prices typically falling between \$1 to \$3 per kilogram. Suppliers offering silica gel mesh sizes between 30 to 400 include Sigma-Aldrich, Sorbent India, Sorbent Technologies, Sisco Research Laboratories Pvt, Material Harvest, Shimadzu Corporation, SiliCycle, Fuji Silysia Chemical Ltd, Alfa Aesar, Thermo Fisher Scientific, and Osaka Soda. It is worth noting that no manufacturer currently offers silica gel resin with mesh sizes above 400, particularly 1250 and 2500 mesh sizes, which are often employed in high-quality purification processes. Currently, there is a lack of silica resin manufacturers in India capable of producing high-resolution separations above 400 mesh, specifically 1250 and 2500 mesh sizes used for the purification of insulin and peptides. Importing such small particles can cost between \$3000 to \$7000 per kg. Elvikon aims to fill this market gap by locally producing high-quality silica resin, reducing the country's import dependency on this specialized material. By utilizing locally sourced raw materials, Elvikon ensures a self-sustainable production process. Furthermore, the average lead time for importing such silica resin is approximately 6 weeks, creating a significant delay in meeting demand.

Current Stage of Development

Silica resin or silica microspheres were prepared using a water in oil emulsion technique. The silica precursor is in hydrolysed form and it goes through polymerisation via hydrolysis and condensation reactions. Drying the precipitate under ambient conditions followed by classification leads to silica resin of different mesh sizes. Various mesh sizes have been produced and SOPs for repeatability has been established. Especially SOPs for 5um, 10um and 30 to 60um have been established which has consistent repeatability.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

The chromatography industry is in continuous need for improved particles and there is a global demand for porous silica particles. In fact controlled by only a handful of suppliers and Elvikon would market not only in India but rest of the world where full population of Pharm. companies.

National/Societal Relevance

The rising prevalence of diabetes in India is bound to escalate the demand for recombinant insulin therapeutics. The production of human insulin involves a multi stage purification using low pressure HPLC technique with silica gel columns. Unfortunately, all the silica resins used for preparative and analytical chromatography are being imported and no manufacturer in India, implies the reliability on imports and its costly affair. Setting up a manufacturing unit for preparative chromatography silica resin would certainly minimizes the import dependency as well as cost effective, leads to influence the cost of insulin in India.

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

Silica-based chromatography resin for protein purification.

Product Positioning


It's targeted at small to medium-scale farmers and agricultural professionals who seek to optimize crop yields, reduce input costs, and adopt sustainable farming practices. The device offers an affordable, accessible solution for enhancing soil management and optimising crop yields.

Import Substitution

First of its kind manufacturing unit in India, it is estimated that, about 10 to 15 of the imports will be reduced in the first year of sales followed by 25, the following year. By reducing import dependency, production cost of peptides and insulin can be cheaper.

Export Potential

Due to affordability of the silica resin, there is a huge scope for export to developing countries such as Africa.



Name of Startup: Ensoverse Private Limited



Founder and Co-founder(s):
Founder-Vasundhara Sharma
Co-Founder- Ajay Sangwan
Co-Founder- Vasundhara Sharma

Email:
vasundharasharma2308@gmail.com

Product/Technology differentiation from Competitors

Made only in India with 100 indigenous contents. Organic Product compared to currently available synthetic Fiber/ Fabric Entirely novel product- No such Product has been made of yet- this will make India a forerunner in Protech Technology Availability Time-1-1.5 months made to order v/s 5 months. Cost efficient -cheaper than competitor price. Sustainable and biodegradable with inherent FR properties made from Fungal Mycelium Waste to Value.

Brief Description of Product

There is a huge growing need and demand for indigenous sustainable fiber/fabric, having inherent protective functionalities. Our product is sustainable, biodegradable, indigenously made- from waste while being an entirely novel product across the globe. I have uses across Defense industry as well as civil industries including but not limited to- Oil & Gas, Metal, Chemical, Maritime, Power, Pharmaceutical etc.

Current Stage of Development

Currently we are at fiber development stage, we have already achieved empirical and practical results based on various tests and analysis of the same.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Global target Market.

National/Societal Relevance

Resource Efficiency: Utilizes organic waste, transforming it into valuable alternative protein and biodiesel, turning waste management into a profitable venture. Energy Independence Reduces India's dependency on imported fossil fuels, enhancing energy security with domestic biofuel production. Protein Security Reduces India's dependency on soya, enhancing protein security with domestic alternative protein production. Waste Reduction Addresses India's waste management issues by converting organic waste into alternative protein and biofuel, reducing landfill use and pollution. Food Security & Crop Dependency Reduction**: Using BSF larvae that do not compete with human food crops for land reduces pressure on agricultural resources Rural Employment.

Technology readiness level (TRL)

TRL-3



Title/Name of the Product/Technology

Indigenously made, inherently Fire-Retardant sustainable Fibre/Fabric/Protech Product, from mycelium using Agri waste.

Product Positioning

Sustainable Protech, Indigenously made, Novel Technology, Will make India Forerunner in Protech Technology.

Export Potential

Across the Globe in Defense Industry as well as state defense in civil industries, such as Oil & Gas, Metal, Chemical, Maritime, Power, Pharmaceutical etc. In Textile Industry Maritime Industry.

Import Potential

Protech Fibre / Fabric / Apparel Sustainable Textile



Name of Startup: Exquinz Life Sciences Pvt Ltd

EXQUINZ
LIFESCIENCES

Founder and Co-founder(s):
Mr. Krishna Chaitanya Battula Dr.
Sree Lakshmi Latha A
Dr. Rambabu Atluri

Developed Under
(scheme):
BIG

Email:
info@exquinz.com

Product/Technology differentiation from Competitors

Currently, Temptime, is the sole supplier of VVMs worldwide. Temptime VVM works on the color shade of the inner square of the VVM, where it is very difficult for a health worker to read the different color shades of the inner circle and match with the outer. However, ExviT label comes with a display window shows not only the temperature breach but also the time remaining to use the vaccine, thereby alarming the healthcare workers to use it before to discard. Self-adhesive backing for easy attachment to any packaging types, and comparatively low cost.

Brief Description of Product

About 25 of vaccines reaching their destination have degraded efficacy due to failures to maintain the cold-chain. Vaccine vial monitors VVMs are currently been used, which are small stickers that adhere to vaccine vials and change color as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used for immunization. Temptime is the sole supplier of VVMs worldwide and playing a monopoly in the vaccine market. VVMs are being are being imported into India and adding 100 of the vaccine cost. Recently, Niti Aayog has initiated a roadmap to help development of VVMs for non-dependability and made it a national project. At Exquinz, we take up the challenge of making VVMs for India and make in India. A VVM label referred ExviT has been developed. ExviT not only shows the temperature breach but also shows remaining time to expiry, which is unique feature compared to Temptime VVM. The current TRL of the ExviT label is 3, where it is demonstrated under laboratory conditions and validated production viability.

Current Stage of Development

Currently, we are validating the technology in house under various conditions as specified by different stake holders. Minimum Viable Product 1.0 and demonstrate the product in real-time conditions, ensuring with third-party certification are the ongoing activities.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

WHO and GAVI Alliance specifies that all new vaccines funded through its vaccine fund be labelled with VVMs.

National/Societal Relevance

Recently, Niti Aayog has initiated a roadmap to help development of VVMs for non-dependability and made it a national project.

Technology readiness level (TRL)

TRL-3



Title/Name of the Product/Technology

Vaccine Vial Monitors VVMs.

Product Positioning

If ExviT fulfills the WHO prequalification standards, it will enable direct sales per unit to vaccine manufacturers who possess the necessary supply capacity for WHO and GAVI.

Import Substitution

TEMPTIME Corporation acquired by Zebra Technologies, the American company licensed by the WHO to manufacture VVMs, is the SOLE supplier of VVMs worldwide. Exquinz is set to establish itself as the pioneering competitor, marking a significant milestone in its industry.

Export Potential

Other than TEMPTIME, there are no competitors in the market and hence the export potential is very high as India is the second-largest vaccine exporter in terms of volumes 24.7 of total global exports.

Major Achievements

DPIIT Nidhi Prayas BIG-23 SISFS GI grant.

Accommodation Required

Yes.

Name of Startup: F3 Biotechnology



Founder and Co-founder(s):
Rajani Amrendra

Developed Under
(scheme):
BIG

Email:
f3biotechnology@gmail.com

Product/Technology differentiation from Competitors

Organic solution for feed conditioning and starch gelatinization, based on emulsion technology, Nano size, capillary action-based travel of salts, Nano size droplets.

Brief Description of Product

Emulsified salts.

Current Stage of Development

Large scale trials.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Pan India.

National/Societal Relevance

The social relevance of animal feed is multifaceted, encompassing critical aspects of food security, rural livelihoods, environmental sustainability, public health, and economic development. By ensuring the quality and profitability of animal feed, we support the well-being of livestock and the livelihoods of farmers, contribute to environmental conservation, enhance public health, and drive economic growth. The continued focus on improving animal feed through innovation and sustainable practices is essential for addressing the global challenges of food security and sustainable development.

Technology readiness level (TRL)

TRL-5



Title/Name of the Product/Technology

Indigenously made, inherently Fire-Retardant sustainable Fibre/Fabric/Protech Product, from mycelium using Agri waste.

Product Positioning

B2B.

Export Potential

South east Asia.

Import Potential

Yes

IP Status

202021039566, Granted

Name of Startup: Famnutra Millet Foods Private Limited



Founder and Co-founder(s):
Sailash Ganduri,
Lakshmi Praneetha

Developed Under
(scheme):
BIG

Email:
famnutra@gmail.com

Product/Technology differentiation from Competitors

Blissbody stands out with its unique sugar-free, millet-based fermented beverage, offering superior gut health benefits. Unlike competitors, it uses nutrient-rich millet, supports sustainable local sourcing, and features eco-friendly packaging. Blissbody is positioned as part of a holistic wellness lifestyle, providing educational content and engaging marketing campaigns. Its diverse flavors cater to varied tastes, and the brand emphasizes ingredient transparency and authentic storytelling. With both online and offline availability, including subscription models, Blissbody ensures convenience and fosters loyalty. This comprehensive approach sets Blissbody apart as a healthier, more sustainable, and trustworthy beverage choice.

Brief Description of Product

Discover the refreshing taste and health benefits of Blissbody, a revolutionary sugar-free millet fermented beverage designed to enhance your gut health. Crafted with natural probiotics, Blissbody supports digestion and overall wellness. Perfect for those seeking a healthy alternative to sugary fizzy drinks, Blissbody is gluten-free, vegan, and free from artificial flavors and preservatives. Each 200ml bottle is packed with the goodness of fermented millet, offering a light, tangy flavor that's both delicious and nutritious.

Current Stage of Development

The product is being manufactured and marketed in a pilot scale of 100 litres per day.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

All over India and export in the long run.

National/Societal Relevance

Blissbody addresses several societal trends and needs, making it highly relevant today. With increasing awareness of health and wellness, it offers a sugar-free, nutrient-rich alternative that supports digestive health, catering to the growing demand for functional beverages. By using millet, it promotes sustainable agriculture and reduces reliance on common grains, aligning with the push towards food diversity and environmental responsibility. Additionally, Blissbody's commitment to eco-friendly packaging appeals to the environmentally conscious consumer. By supporting local farmers and promoting a holistic approach to health, Blissbody not only benefits individual well-being but also contributes positively to community and environmental sustainability.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Blissbody: Revolutionizing Wellness with Sugar-Free, Fermented Millet Beverages for Optimal Gut Health.

Product Positioning

Blissbody positions itself as a holistic wellness beverage, emphasizing gut health and sustainability. Targeting health-conscious consumers aged 30-55, it offers a unique, nutrient-rich alternative to sugary drinks. Through educational content and authentic storytelling, Blissbody fosters trust and promotes a healthy, eco-friendly lifestyle.

Export Potential

Blissbody's export potential is high due to global trends favoring health-conscious, sustainable products. Its unique, sugar-free, millet-based formulation meets international demand for functional beverages. With strong branding and eco-friendly packaging, Blissbody can appeal to diverse markets seeking innovative and nutritious beverage options.

IP Status

Trade mark obtained 6148958

Name of Startup: Fermentech GSV Private Limited



Founder and Co-founder(s):
Dr. G.R.Gopi and
Mr. P. Sathyavathian

Developed Under
(scheme):
BIPP

Email:
gopi@fermentechgsv.com

Brief Description of Product

Nisin is a biological shelf-life enhancer replacing chemical preservatives. It finds applications in food processing and permitted by regulators across the globe for wide category of food types.

Current Stage of Development

The project is in the verge of pre-commercialization and undergoing regulatory filing.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted


India, EU and USA.

National/Societal Relevance

1. Consumer Demand: Consumers increasingly prefer natural and organic products, driving demand for nisin as a natural preservative. 2. Sustainable Agriculture: Nisin can be used to reduce antibiotic use in agriculture, promoting sustainable farming practices. 3. Global Health: Nisin's antimicrobial properties can help address global health challenges, such as antibiotic resistance and foodborne illnesses.

Technology readiness level (TRL)

TRL-8





Name of Startup: FIB-SOL life technologies Pvt Ltd



Founder and Co-founder(s):
Dr. Kavitha Sairam

Developed Under
(scheme):
SBIRI, GCI

Email:
pramal.biswa@gmail.com

Product/Technology differentiation from Competitors

Agri-gels and Fertilizer Carrying Membranes: FIB-SOL does away with the bulky carrier by introducing bioactives in polymeric gel solutions/membrane giving a highly stable, light weight and super-efficient Bioactive formulation Functional Seed coating Primers: single component soil stimulator Functional Biodegradable mulch sheets: aimed to reduce soil pollution and enhanced sustainability Metagenome based Soil Amendments: Area and variety agnostic core microbe formulation Artificial Nodules: mimic the protective advantages of a nodular environment.

Brief Description of Product

IB-SOL is proud to introduce a new range of stabilized Agri-tech formulations based on State-of-the-art innovations. Agri-gels TRL-9: Patented technology confers, a highly compact 1000 X and efficient way to deliver soil bacteria that provides macro nutrients and increases availability of other nutrients. Product is quality certified for performance by several governmental university trials such as GKVK and ANGRAU. Product, being water soluble, can be applied via all modes: including drip, spraying, broadcasting as well as seed-coating and seedling dip Implemented over 200000 acres across various crop segments and agro-geoclimatic zones in India. A 25 improvement in crop productivity and a reduction of 30 in chemical input can be achieved. The product also improves quality features of the harvest as well as the at 100ml/acre single dose, the product is extremely light weight this gives an obvious advantage in logistics cost reduction for bulk transport and ease of storage. The product also has an enhanced shelf life of over 1.5 years. Fertilizer Carrying Membranes TRL-8: Light weight Membranes Patented Encapsulation technology that increases the shelf life and efficacy of bioactives both Biological and chemical. Large scale effectiveness proven with biofertilizer encapsulation with improved shelf life of over 2 years. Looking for commercial partners. Functional Seed coating Primers TRL-4: Patented technology involving covalent stabilization of Microbial signals to polymer backbones, which are then used as seed coating. These products functionalize the rhizosphere improve seed survival and crop development. Looking for partners to develop and commercialize. Biodegradable mulch sheets TRL-2: Mulch sheet with enhanced biodegradability to reduce synthetic polymer associated pollution. To be developed under Grand Challenge India Scheme Metagenome based Soil Amendments TRL-4: Revolutionary bio amendments developed by utilizing Targeted metagenomics to harness the core microbiome. First product developed for Traditional paddy. Currently under field evaluation for efficacy. Artificial Nodules TRL-2: A multicomponent formulation to Create and maintain a nodule like environment around roots to provide the advantages of symbiosis in non-leguminous target crops.

Current Stage of Development

Agri Gels Products have been implemented over 200000 acres generating a revenue of over 5 crores 3 years 22-25%.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Geographical Region Targeted *: Targeting 8 Lakh acres in the next 2 years towards sales of Agri Gels in 5 states namely Tamilnadu, Andhra Pradesh, Telangana, Maharashtra and UP through various channel partners, such as FPO, FPA, Dealers, Agri Ecommerce portals.

National/Societal Relevance

FIB-SOL products provide a powerful solution to the excessive use of fertilizers and therefore the growing problem of agricultural land degradation, water pollution through runoff, falling yields, and food security issues. FIB-SOL's Products/technology reduces fertilizer usage by 30-50, increases yield/crop health by 1.3- 2 times, and overall margin per acre by 1.5-4X. This reduction in the use of fertilizer can result in a saving of import costs borne by the Indian government It also has a significantly longer shelf-life, reducing the need for deep discounting or product dumping and is highly cost effective. It can also significantly reduce Carbon footprint.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Product 1: Agri gels Product 2: Fertilizer Carrying Membranes Product 3: Functional Seed coating Primers Product 4: Biodegradable mulch sheets Product 5: Metagenome based Soil Amendments: Product 6: Artificial Nodules.

Product Positioning

The product aims to reduce the logistics burden of various stakeholders in the Agri retail chain. It also helps in easy application and reduces the use of Chemical inputs and also improves soil quality. Customer Benefits: cost input benefit, improved yield, and improved soil quality.

Import Potential

India's import of urea rose 22 to 91.23 lakh tonnes during the last fiscal year. A good biofertilizer will be able to substitute for 25 of this value. FIB-SOL Agri Gels stands to be an eligible product for the same.

Export Potential

The Indian biostimulants market was valued at USD 266.58 million in 2022 and is expected to grow to USD 849.76 million by 2030, with a compound annual growth rate CAGR of 15.61. With an edge over the existing commercial formulations the product has huge potential in export markets.

IP Status

AGRI GELS: "Polymeric gel-based agrobiological composition" India Patent No. 421141 Granted PCT/IB2023/053573 FERTILIZER CARRYING MEMBRANE An ultra-light weight nanofiber polymer carrier for use in agricultural and industrial applications" India Patent No. 428596 Granted. PCT/IN2016/000181. FUNCTIONAL SEED COATING PRIMERS" India Patent No.298859 Granted , U.S. Patent US20200031989. ARTIFICIAL NODULES: 202441013730. Provisional Filed

Name of Startup: FisHealth14 AI Ventures Private Limited Company



Founder and Co-founder(s):
Shraddha Bhasetti, Founder & Director
Principal Investigator for BIG

Developed Under
(scheme):
BIG

Email:
shraddha@fishhealthai.com

Product/Technology differentiation from Competitors

FishBuddy distinguishes itself by offering real-time fish health status detection and fully automated environmental management, features absent in competing systems. Unlike competitors, FishBuddy seamlessly integrates advanced AI-driven fish behavior analysis, water parameter monitoring, and IoT-based automation into a single system capable of supporting diverse fish species. While currently focused on aquariums, future iterations of FishBuddy will be designed to manage even the most sensitive marine and brackish water species, with tailored algorithms to maintain optimal conditions, setting a new standard in the industry.

Brief Description of Product

FishBuddy is an innovative AI-powered system that brings a new level of automation to fish health monitoring and management, initially tailored for aquarium environments. Utilizing advanced computer vision and machine learning technologies, FishBuddy offers real-time, automated analysis of fish behavior and critical water quality parameters, including pH, temperature, dissolved oxygen, and ammonia levels. The core strength of FishBuddy lies in its ability to operate autonomously, significantly reducing the need for manual intervention. The system is designed to continuously monitor and detect any deviations from optimal conditions, whether related to fish behavior or changes in water quality. Upon detecting such deviations, FishBuddy automatically triggers IoT-based actuators integrated within the system to make real-time adjustments. These adjustments may include regulating pH levels, controlling water temperature, or activating filtration systems, all aimed at maintaining an ideal environment for the fish. This level of automation not only ensures a healthier and more stable environment for aquarium fish but also simplifies the management process for owners and breeders. The system's AI-driven analytics offer actionable insights, which are delivered through an intuitive dashboard accessible on smartphones or computers. Users are kept informed with real-time alerts and detailed reports, allowing them to track the health of their fish and the status of the aquarium's environment effortlessly. While the system is robust in its autonomous capabilities, it is also designed to recognize scenarios where manual intervention may be necessary. In cases where the system cannot rectify an issue, or if the fish's health is critically compromised, FishBuddy alerts the user, providing guidance on the necessary steps to take. This ensures that the health and wellbeing of the fish are always prioritized, even in situations where technology alone may not suffice. The current focus of FishBuddy is on aquarium settings, but the technology is designed with scalability in mind. Future iterations will extend its application to larger and more complex environments, such as aquaculture farms. Not only aquaculture farms but also offshore aquaculture or dam-based aquaculture, where daily monitoring and management are either impractical or uneconomical, will benefit greatly from our system. In these challenging environments, FishBuddy's autonomous capabilities will offer a significant advantage, ensuring that fish health is maintained even in remote or difficult-to-access locations, providing unparalleled support to aquaculture customers. As development continues, FishBuddy will expand its capabilities to include more sophisticated health indicators and broader species compatibility. By integrating AI with IoT-driven automation, FishBuddy sets a new benchmark in fish health management, ensuring that aquatic life is cared for with precision, efficiency, and minimal manual intervention.

Current Stage of Development

We have developed an alpha prototype with a data collection assembly that detects fish health and monitors water parameters, supported by a preliminary algorithm for goldfish. The system includes actuators to adjust water conditions, though full automation is in progress. We are refining algorithms for more species and integrating automation for an MVP focused on aquariums. After successful pilots, we plan to launch FishBuddy for home aquariums and retail settings, with future versions targeting ornamental aquaculture, farms, and offshore aquaculture.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

FishBuddy targets the Indian market and major developed regions, including the US and EU. The system is designed for scalability across diverse environments, from home aquariums to large-scale aquaculture operations in these key global markets.

National/Societal Relevance

FishBuddy aligns with the United Nations Sustainable Development Goal 14, focusing on improving underwater life by enhancing the health and longevity of aquarium species. Our system supports India's goal to double aquaculture production by 2030, contributing to sustainable practices and reducing dependency on imported technologies. By providing an advanced, locally developed solution, FishBuddy promotes better fish welfare and environmental sustainability, while also fostering economic growth within the aquaculture industry, ultimately supporting the nation's broader ecological and economic objectives.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

FishBuddy: AI-based Fish Health Monitoring and Management System.

Product Positioning


FishBuddy is positioned as a premium, AI-driven solution for real-time fish health monitoring and automated water management. Targeted at aquarium owners, retailers, and aquaculture operators, it offers unmatched precision and scalability, ensuring optimal conditions with minimal manual intervention across various environments.

Export Potential

FishBuddy supports India's goal to double fish exports from \$8 billion to \$15 billion by 2030. Our advanced AI and IoT systems, designed for global aquarium and aquaculture markets, including offshore setups, offer strong export potential in developed markets like the US and EU.

Import Potential

FishBuddy, developed entirely in India, supports the Make in India initiative by eliminating the need for imported hardware and software in fish health management. Our advanced AI algorithms and locally manufactured hardware provide a comprehensive, homegrown solution, fostering self-reliance and reducing dependency on foreign technologies.



Name of Startup: Flowmatrix Polymers Private Limited



Founder and Co-founder(s):
Founders: Dr. Shruti Gurbaxani,
Chief Product Development
Officer MSC. Material Science and
Engineering, 8+ years of experience
in NPD b Rti Gurbaxani, Chief
Marketing Officer BBA DAVV, 5+
Years of experience in Digital
Marketing, Social Media Influencer
60K followers' Co-founders - Dr.
Anup K Ghosh, R&D Head Senior
Consultant Ex-HOD, Dept. of
Material Science and Engineering,
IITD b Ayush Kshirsagar, Business
Development manager, Masters
of Foreign Trade, DAVV +14 years
of experience in the areas of
international sales

**Developed Under
(scheme):**
BIG

Email:
sgurbaxani17@gmail.com

Product/Technology differentiation from Competitors

Punarvasu: Our closest competitors are Brown Living sustainable Office stationery, EarthHero sustainable washing and cleaning solutions, Humanscale Sustainable office furniture, Brands are selling sustainable products made from wood, metals, ceramics but not from upcycled plastics. Additionally, office decor items are largely required but very limited options are available. Green-Craft PLA filament- Our closest competitors are in Europe and USA like Prusament FormFutura, Filamentive, Reflow, GreenGate3D. We are unique in APAC and Australia Demographic region in terms of Material, cost, and geographical location.

Brief Description of Product

Punarvasu: Elevate Your Workspace with Sustainable Elegance Transform your office space with Punarvasu's innovative range of upcycled decor and technological gifts. We blend modern design with the timeless appeal of India's rich cultural heritage, crafting unique office essentials from upcycled plastic waste. Our collection includes beautifully crafted pen stands, mobile stands, office planters, and more—each meticulously designed using advanced 3D printing technology. Every item is more than just a functional accessory it is a statement of sustainable luxury. Our pen stands are perfect for organizing your desk and serve as conversation starters, showcasing your commitment to eco-conscious living. The mobile stands combine style and utility, offering a sleek, stable rest for your devices. Our office planters add greenery, enhancing your environment with natural beauty and sustainable craftsmanship. Whether you are looking for the perfect corporate gift or aiming to enhance your workspace, Punarvasu offers products that blend practicality, elegance, and a commitment to environmental stewardship. Elevate your lifestyle with pieces that stand out for their beauty and purpose—one print at a time. Understanding the need for change, we offer a unique provision: return your decor items and well provide new ones at a discounted rate. Choose Punarvasu to make a statement about your taste, values, and vision for a better world. Green-Craft PLA Filament: Eco-Friendly 3D Printing Excellence Elevate 3D printing projects with Green-Craft PLA Filament, the perfect blend of sustainability and performance. Made from biodegradable, plant-based materials, Green-Craft PLA is designed for eco-conscious creators who demand both quality and environmental responsibility. Our filament offers exceptional print precision, vibrant colors, and smooth finishes, ensuring professional-grade results every time. With its low warping and easy-to-use properties, Green-Craft PLA is compatible with a wide range of 3D printers, making it ideal for hobbyists, educators, and professionals alike. Choose Green-Craft PLA Filament to reduce your carbon footprint and embrace a greener approach to 3D printing without compromising on quality.

Current Stage of Development

TRL Level 6 – Punarvasu and Green-Craft PLA- We have fabricated products worth 10 kgs and repeated the process to establish product stability and process repeatability.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Our customers base for first two years resides and works in North, west and central India for Punarvasu and we are targeting Pan India customers for Green-craft PLA filament.

National/Societal Relevance

FIB-SOL products provide a powerful solution to the excessive use of fertilizers and therefore the growing problem of agricultural land degradation, water pollution through runoff, falling yields, and food security issues. FIB-Sol's Products/technology reduces fertilizer usage by 30-50, increases yield/crop health by 1.3- 2 times, and overall margin per acre by 1.5-4X. This reduction in the use of fertilizer can result in a saving of import costs borne by the Indian government It also has a significantly longer shelf-life, reducing the need for deep discounting or product dumping and is highly cost effective. It can also significantly reduce Carbon footprint.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

Punarvasu: Elevate Your Workspace with Sustainable Elegance b Green-Craft PLA Filament: Crafted from upcycled plastic.

Product Positioning

Punarvasu 3D-printed office decor is perfect for eco-conscious professionals, making a bold statement about commitment to quality and environmental responsibility. Green-Craft PLA filament is positioned as an eco-friendly, high-performance material designed for creators who prioritize sustainability. Perfect for hobbyists and professionals seeking reliable, earth-conscious filaments for innovative, responsible 3D printing.

Import Potential

Our products are supplementary reservoirs for Imported raw material. By developing a circular economy and building reverse supply chain we are reducing the import of the raw materials and adding to "Make in India".

Export Potential

We want to build brand "Punarvasu" supporting India's promise of Innovation and Sustainability to the world. All our products can be exported internationally with Certifications like ISO 9001:2015 RoHS Compliance, Global Recycled Standard GRS, Customs and Export Documentation, FSC Certification and adhering to Compliance with International Trade Laws.



Name of Startup: FLUORESIGHT BIOPROBES Pvt. Ltd.



Founder and Co-founder(s):
Dr. Nivedita Sarkar and Prof.
Subhadeep Banerjee

**Developed Under
(scheme):**
BIG

Email:
fluoresightbioprobes@gmail.com

Product/Technology differentiation from Competitors

Our products have longer fluorescence lifetimes and larger Stokes shifts as compared to commercial dyes. Both these properties are crucial for long duration fluorescence imaging, especially of live cell samples, where laser induced photobleaching is a major issue.

Brief Description of Product

Molecular dyes with blue absorption and green to yellow emission for bioimaging precisely for labeling of cell organelles like lysosomes, mitochondria, and endoplasmic reticulum in eukaryotic cells. The main area of applications is in fluorescence and confocal microscopy, for cell painting, cell tracking, for microscopic study of cell organelle behavior under different experimental conditions.

Current Stage of Development

Successful lab scale preparation of the dyes has been achieved with correct structural characterization. Fluorescence spectroscopic behavior has been studied and analyzed in terms of spectral position in the visible region. Fluorescence quantum yields, fluorescence lifetimes were measured and all of which have been benchmarked against known commercial standard dyes and found to be comparable or better. Confocal microscopic analysis was successfully performed using these dyes and a comparative known commercial dye, which shows a very good overlap, thereby establishing a comparative value with commercial standards. Provisional IP has been filed and further scientific studies are underway with external validators.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted


All of India.

National/Societal Relevance

Our bioimaging products are well-aligned with our societal and national goals of Atmanirbhar Bharat and upskilling of our workforce for generation of employment and to be vocal for local brands. Currently, under the BIG funding, we have provided employment to two technical assistants.

Technology readiness level (TRL)

TRL-5



Title/Name of the Product/Technology

Fluorescent molecular probes for cell organelle bioimaging

Product Positioning

Our products are locally produced high quality bioimaging probes with good benchtop stability, featuring sustained intracellular glow and high target specificity inside cells. Our products are readily available locally with short lead times.

Export Potential

These dyes have comparable fluorescence spectral properties and bioimaging capability like the imported commercial dyes. If there can be acceptance initially in the Indian market and scientific validation through strong publication support, then the export potential will be significant, given that biotechnology research globally depends hugely upon fluorescent small molecules.

Import Potential

We are the 1st of its kind Indian startup making these molecular dyes for bioimaging, all of which are at present imported from foreign brands. Therefore, there is huge import substitution potential in the form of savings of import costs for customers and reduction of product lead times.

IP Status

Indian Patent Provisional Application No.: 202421049434 filed on June 27, 2024



Name of Startup: FOAB SOLUTIONS PRIVATE LIMITED



Founder and Co-founder(s):
Founders:
RAJEEVU GEORGE SREEKUMAR M
DR. SUNNICHEN V GEORGE SAJI
THOMAS MANJULA B

Developed Under
(scheme):
BIG

Email:
foabsolutions@gmail.com

Product/Technology differentiation from Competitors

Geebin is a multi-layer aerobic composter for solid wastes management. Most of the products in this segment are single layered and facing lots of issues. Also, our shape of the composter is cylindrical and our competitors doesn't have such shape and structure.

Brief Description of Product

GEEBIN: A novel system for home composting at source. It is the first ever multi-layer aerobic bin composter in India for composting household wastes. It is a registered bin having a total capacity of 90 liters. This will be enough for a normal family which have 4 to 5 members. It is a 3-bin system. When one bin filled with bio-waste, it will take around 30 to 35 days for getting proper compost. • Geebin designed to keep both inside and outside • Composting process will finish in 30-35 days, once it filled • It is the biggest home composter in capacity wise 87 ltr • No foul smell, faster decomposing • Leachate holding tray for each bin • Dcom & Flourish is our own inoculum for waste processing We have another product called EYC BIO Composter. It is a Single layered composter with cylindrical shape.

Current Stage of Development

We are currently selling our product all over Kerala State. Major client of our product is Local Self Government Bodies across Kerala. We sold over 60000 units till date. Our open market client strength comes around 10000 nos.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Currently targeting Kerala selling at a price of 5500. Started to work in Tamilnadu and Puthucherry. Now we are planning for All India distribution. The price will vary according to distance of delivering location.

National/Societal Relevance

It is a green technology product. We are actively giving support to government of Kerala for keep our surroundings clean and healthy. As we know at least 60 of the wastes comes out from each family are food wastes and if we compost it at the source means, our premises will be clean at least 60. This is the relevance of our product.

Technology readiness level (TRL)

TRL- 9



Title/Name of the Product/Technology

GEEBIN - MULTI LAYER AEROBIC BIN FOR HOUSEHOLD BIO WASTES MANAGEMENT.

Product Positioning

Top product in Kerala in the field of household waste management.

Import Potential

We have 3 Bin system and Two bin system for GEEBIN. in EYC Bio Composter we have 3 Bin system and Twin Bin system.

Export Potential

We are making each Geebin as parts and it can assemble to its final state at customer level. So, we can export it for those who are willing to purchase. Till date we didn't try this level

IP Status

We have design patent for our product Reg No 326783-001 as per Designs Act Trade Mark Registration Number for Geebin - 4011266

Name of Startup: Farm-fresh-fruits



Founder and Co-founder(s):
Ravindra Raghuvanshi

Email:
info@farm-fresh-fruits.com

Product/Technology differentiation from Competitors

Traditional drying methods often lead to a significant loss of nutrients can affect the aroma, color, taste, and overall quality. The shelf life of dried products may not be optimal. While freeze-drying is better at preserving nutrients compared to traditional drying, it still can cause changes in color, taste, and texture, especially when rehydrated. This method is not suitable for drying leafy vegetables and fruits like oranges and sweet lemons & the drying process is lengthy, and it consumes a significant amount of power. The Orchard vacuum dryer has been developed to address all the above issues.

Brief Description of Product

The Orchard Vacuum Dryer OVD patent application pending appears to offer a promising solution by addressing the shortcomings of existing drying technologies for fruits & vegetables. Here are its key advantages: 1. Preservation of Quality: Nutrients: Maintains the nutritional content of the fruits and vegetables. Aroma and Taste: Ensures that the original aroma and taste of the produce are preserved. Colour: Keeps the natural color of the produce intact. Texture: When rehydrated, the produce retains its original texture and taste. 2. Versatility: Capable of effectively drying a wide variety of fruits and vegetables, including those that are typically challenging to dry, such as leafy greens and citrus fruits. 3. Efficiency: Cost-Effective: More economical compared to freeze-drying in terms of both equipment and operational costs. Time and Energy: Reduces drying time and energy consumption, making it a more sustainable option.

Current Stage of Development

We have been working on this project for more than four and a half years. We are already drying fruits, vegetables in a pilot plant of around 12 kg of fresh fruits or 2 kg of vegetables and started selling to test the market acceptance.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

India, USA, Canada and Middle East.

National/Societal Relevance

Our vacuum-dried fruits and vegetables address critical social issues by tackling post-harvest food waste, a major challenge for farmers and the environment. By sourcing directly from local farmers, we ensure fair pricing and a sustainable income for rural communities. Our eco-friendly vacuum-drying process minimizes energy usage while preserving vital nutrients, promoting healthier eating habits without additives or preservatives. As we contribute to reducing global food waste, we also make nutritious, long-lasting food accessible, helping combat food insecurity. This approach aligns with growing consumer demand for sustainable, ethical products, fostering a deeper connection between producers, consumers, and the planet.

Technology readiness level (TRL)

TRL-9



Name of Startup: FRESHLY19 AGRI-TECH PRIVATE LIMITED



Founder and Co-founder(s):
AMAN KUMAR SUSHANT BARMA

Developed Under
(scheme):
SEED Fund

Email:
care@nuttyvillage.in

Product/Technology differentiation from Competitors

Our Main Competitors are Whole Truth Food, Yoga Bar, as they are doing clean label products while targeting health conscious consumers. We are working with small farmers at grassroot level which stands us apart from our competitors in terms of solving small farmers challenges related to post harvest losses, maximizing their crop produce value as well as integrating source traceability to authenticate their natural farming practices which makes us a clean label brand while creating impact on grassroot level and offering better value to end consumers.

Brief Description of Product

We are working with small farmer on grassroot level to solve the challenge of ensuring sustainability, to do this we are implementing blended finance as a model, so we made producer group of small women farmers to build primary infrastructure so they can do de-shelling, sorting and grading of groundnut after that it comes to our processing unit where we are working with SHG women's to do the value-addition and making peanut butter which are preservative and palm oil free which is great source of plant based affordable protein for the end consumer.

Current Stage of Development

The proposed project aims to address the nutritional limitations of traditional peanut butter by reducing the phytic acid content in peanuts. Phytic acid, an antinutrient present in peanuts, binds essential minerals, making them less bioavailable and harder for the body to absorb. Our solution involves developing an innovative processing method that combines optimised soaking, fermentation, and enzymatic treatments to significantly decrease phytic acid levels. This will enhance the bioavailability and digestibility of proteins and minerals in the final peanut butter product. The project plan includes optimising these processes over a 12-month period, followed by scaling the method for commercial production.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Mumbai, Kolkata, Delhi, Chennai, Lucknow.

National/Societal Relevance

We are working with small farmer on grassroot level to solve the challenge of ensuring sustainability, to do this we are implementing blended finance as a model, so we made producer group of small women farmers to build primary infrastructure so they can do de-shelling, sorting and grading of groundnut after that it comes to our processing unit where we are working with SHG women's to do the value-addition and making peanut butter and energy bars which are preservative and palm oil free which is great source of plant based affordable protein for the end consumer.

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

Bringing Post Harvest Value addition at farm gate level in groundnut value chain near ganga river of Unnao.

Product Positioning

Our offerings appeal to those advocating for a sustainable lifestyle, mirroring the global trend of conscious consumerism. Working professionals seeking convenient and nutritious on-the-go snacks form another significant segment. Our Millet Protein Bars and Energy Bars cater to this demographic, providing a solution that aligns with their busy lifestyles.

Export Potential

Affordable Protein Substitute to whey protein which is more bioavailable as India is second largest exporter to USA in Peanut Butter.

Import Potential

Affordable Protein Substitute to whey protein which is more bioavailable.

Name of Startup: Gene Prospera Biotech Pvt. Ltd.



Founder and Co-founder(s):
Founders:
Dr. Goutam Mukherjee &
Mrs. Misty Mukherjee

Developed Under
(scheme):
BIG

Email:
goutam.cumicrobio@gmail.com

Product/Technology differentiation from Competitors

The "Single Buffer RNA Isolation Kit" stands out for its simplicity and versatility, using a single buffer for various samples, including soil with minor modifications. It delivers high RNA yield with minimal genomic DNA contamination, ensuring purity for downstream applications like qPCR and sequencing. Cost-effective and user-friendly, the kit provides significant savings without compromising quality. Positive feedback from beta testing highlights its reliability and ease of use, making it a compelling choice for researchers seeking an efficient, affordable, and adaptable RNA isolation solution.

Brief Description of Product

The "Single Buffer RNA Isolation Kit" is a versatile and innovative tool designed to streamline RNA extraction from a wide range of biological samples, including bacteria, biofilm, cell lines, plant tissues, and tissue homogenates. Utilizing a single buffer system, this kit simplifies the isolation process, ensuring consistency and reliability across different sample types. Notably, with very minor modifications, the same buffer can effectively isolate RNA from soil samples, highlighting its adaptability and versatility. Engineered for high performance, the kit provides substantial RNA yields, making it a dependable choice for researchers who require large quantities of RNA for their experiments. Furthermore, the Single Buffer RNA Isolation Kit is cost-effective, offering a more affordable alternative compared to many existing RNA isolation kits on the market. This affordability makes it accessible to a broader range of users, from academic researchers to commercial laboratories. Another critical advantage of this kit is its ability to minimize genomic DNA contamination, ensuring the purity of the isolated RNA and making it suitable for various downstream applications, such as qPCR, sequencing, and other molecular biology techniques. Overall, the Single Buffer RNA Isolation Kit stands out as a safe, efficient, and economical solution for RNA isolation needs across diverse sample types.

Current Stage of Development

The "Single Buffer RNA Isolation Kit" is nearing market readiness, validated through extensive lab testing for efficiency and reliability across various samples, including bacteria, biofilm, cell lines, plant tissues, and soil with minor modifications. It offers high RNA yield with minimal DNA contamination, making it suitable for qPCR and sequencing. Cost-analysis shows it to be more affordable than existing kits. Positive beta testing feedback highlights its ease of use and consistent performance. Regulatory compliance and safety evaluations are complete, with the focus now on scaling production and securing certifications for a successful commercial launch.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted


Pan India.

National/Societal Relevance

The "Single Buffer RNA Isolation Kit" holds national and societal relevance by providing an affordable and efficient solution for RNA extraction. It supports a wide range of research applications, including disease research and agricultural studies, enhancing scientific capabilities in diverse fields. Its cost-effectiveness and ease of use make it accessible to academic institutions and research facilities, contributing to advancements in biotechnology and public health.

Technology readiness level (TRL)

TRL- 7



Title/Name of the Product/Technology

Single Buffer RNA Isolation kit.

Product Positioning

The "Single Buffer RNA Isolation Kit" is positioned as a cost-effective, versatile solution for RNA extraction. It simplifies the process with a single buffer, ensures high yield and minimal DNA contamination, and is suitable for diverse samples. Ideal for researchers seeking efficiency and affordability in RNA isolation.

Import Potential

The "Single Buffer RNA Isolation Kit" supports import substitution by providing a domestically developed, cost-effective alternative to foreign RNA isolation kits. By reducing reliance on imported products, it strengthens local manufacturing capabilities and promotes self-sufficiency in biotechnology, helping to retain resources and stimulate economic growth within the country.

Export Potential

The kit has significant export potential due to its innovative design, cost-effectiveness, and versatility. Its high performance across various sample types and minimal DNA contamination makes it attractive to international research institutions and biotechnology companies. Its affordability compared to existing kits also enhances its competitive edge in global markets.

Name of Startup: Genexis Biotech Private Limited



Founder and Co-founder(s):
Mr Vipul Kumar
Dr Jitendra Wagh

Developed Under
(scheme):
SEED Fund

Email:
vipul.083@gmail.com

Product/Technology differentiation from Competitors

Our serum alternative formulation differentiates itself by utilizing animal-origin-free recombinant proteins, providing a cost-effective solution compared to both traditional FBS and other serum-free formulations. Leveraging advanced strain engineering, we significantly reduce production costs while maintaining high-quality standards. Our proprietary platform technology ensures the high-level expression of essential FBS proteins, including validated production of bovine FGF2 and TGFβ1. This innovative approach offers a reliable and affordable alternative, making it a true replacement for FBS in various applications, setting us apart from competitors in the market.

Brief Description of Product

At Genexis Biotech, we are developing an innovative serum alternative formulation using animal-origin-free recombinant proteins. Our product offers a reliable and cost-effective substitute for traditional fetal bovine serum (FBS), which is widely used in cell culture applications but comes with ethical and economic challenges. Our formulation stands out by leveraging advanced strain engineering and precision fermentation, enabling the high-level expression of key FBS proteins, such as FGF2 and TGFβ1. Our proprietary platform technology ensures consistent yield and quality, making our serum alternative not only affordable but also scalable. This approach significantly reduces production costs, making our product a practical choice compared to other serum-free formulations, which are often more expensive than FBS. Our serum alternative includes essential components such as growth factors, attachment factors, carrier proteins, and iron-binding proteins, tailored to meet the diverse needs of various research and industrial applications. The development of our growth factors—specifically FGF2 and TGFβ1—demonstrates our commitment to providing high-quality bioactive proteins. These components are crucial for cell proliferation, differentiation, and overall cell health, making them vital for research in regenerative medicine, pharmaceuticals, and cosmetic applications. Additionally, we have produced specialty proteins like SIRT6 and rTEV protease, which further enhance the versatility and functionality of our product range. Our serum alternative formulation aims to replace the use of FBS in the market, offering a sustainable and ethical option that aligns with the growing demand for animal-free products. With our focus on innovation and cost efficiency, we are poised to set a new standard in the biotechnology industry, providing researchers and industries with a superior alternative to traditional cell culture media.

Current Stage of Development

The proposed project aims to address the nutritional limitations of traditional peanut butter by reducing the phytic acid content in peanuts. Phytic acid, an antinutrient present in peanuts, binds essential minerals, making them less bioavailable and harder for the body to absorb. Our solution involves developing an innovative processing method that combines optimised soaking, fermentation, and enzymatic treatments to significantly decrease phytic acid levels. This will enhance the bioavailability and digestibility of proteins and minerals in the final peanut butter product. The project plan includes optimising these processes over a 12-month period, followed by scaling the method for commercial production.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Genexis Biotech targets global markets, focusing on North America, Europe, and Asia-Pacific. These regions have a strong demand for innovative biotechnology solutions, particularly in research, pharmaceuticals, and industrial applications, making them ideal for our growth factors and serum alternatives.

National/Societal Relevance

Genexis Biotech's growth factors, such as bFGF2 and TGFβ1, hold significant national and societal relevance. They offer sustainable, animal-origin-free alternatives to fetal bovine serum sourced growth factors, addressing ethical concerns and reducing reliance on animal-derived products. Our innovations support the growing demand for advanced biotechnological solutions in regenerative medicine, pharmaceuticals, and cellular agriculture. By promoting sustainable practices, we contribute to environmental conservation and ethical research, aligning with societal values and national priorities for scientific advancement and sustainability. Our work also supports job creation and economic growth within the biotech sector, further enhancing our societal impact.

IP Status

202221057717



Title/Name of the Product/Technology

Bringing in 100 Animal-Free Proteins and FBS Alternative for a Sustainable Future.

Product Positioning

Our growth factors, including bFGF2 and TGFβ1, are positioned as high-quality, animal-origin-free alternatives to traditional fetal bovine serum proteins. Our products offer cost-effective, scalable solutions for applications in biotechnology, cellular agriculture, and regenerative medicine. We emphasize sustainability, innovation, and ethical production, catering to global markets seeking advanced biotechnological.

Export Potential

Our innovative growth factors and serum alternatives have strong export potential due to their high quality, cost-effectiveness, and broad applicability in global biotech markets. Targeting regions like North America, Europe, and Asia-Pacific, we aim to meet the growing demand for sustainable and ethical biotechnological solutions.

Import Potential

Genexis Biotech's animal-origin-free growth factors, like bFGF2 and TGFβ1, provide a domestic alternative to imported growth factors and other high-cost specialty proteins. By offering locally produced, cost-effective growth factors, we reduce dependency on foreign imports and support national self-sufficiency in biotechnology.

Name of Startup: Gps Renewables



Founder and Co-founder(s):
Mainak Chakraborty
Sreekrishna Sankar

Developed Under
(scheme):
BIG

Email:
vikraman@gpsrenewables.com

Product/Technology differentiation from Competitors

GPS has filed 7 patents, 3 granted for equipment design and process efficiency GPS has bacterial consortium to quick start the CBG plants Team size of over 800 led by strong management team and technology entrepreneurs.

Brief Description of Product

GPS Renewables builds and operates Biogas plants that utilize multiple types of feedstock agri-residue, MSW, etc. Biogas plants have a capacity of 1TPD to 500 TPD of feedstock. GPS began its journey with BioUrja bioreactors for large corporates. Today GPS offers plants with a feed capacity of 100-500TPD of feedstock. GPS also offers specialized equipment for biogas production, scrubbing and purification under the Optimaxx brand.

Current Stage of Development

Multiple plants over 120 are already running. The largest Biogas plant in Asia located in Indore was setup and made operational by GPS. GPS has several smaller biogas plants developed for corporate clients. GPS offers and exports specialized equipment for biogas production, scrubbing and purification under the Optimaxx brand.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

India, Europe, SE Asia, Middle east, Africa.

National/Societal Relevance

The following SDGs are addressed by GPS SDG 3 Good health and well-being SDG 6 Clean water and sanitation SDG 7 Affordable and clean energy SDG 8 Decent work and economic growth SDG 9 Industry, innovation and infrastructure SDG 10 Reduced Inequalities SDG 11 Sustainable cities and communities SDG 12 Responsible consumption and production SDG 13 Climate action SDG 15 Life on land SDG 17 Partnerships for the goals.

Technology readiness level (TRL)

TRL- 9

Thematic Area

Industrial Biotechnology (Including secondary Agriculture)



Title/Name of the Product/Technology

Compressed Bio-Gas plants and specialized equipment for biogas production and upgradation.

Product Positioning

GPS provides reliable, low-cost solutions for conversion of biomass to biogas. GPS aims to be the leader in other sources of renewable energy, such as ethanol and sustainable aviation fuels.

Import Potential

Biogas production helps reduce the import of natural gas. GPS is also working on bio-coal, 2G ethanol, and sustainable aviation fuels to further reduce the fossil fuel import. GPS also has equipment that help avoid import of machinery and tools for the industry.

Export Potential

GPS exports specialized equipment to Europe. GPS will also export sustainable aviation fuels by 2027.

IP Status

1817/CHE/2014 AUTOMATIC TITRATION SYSTEM 201741000448 PRE-DIGESTER UNIT FOR EFFECTIVE TREATMENT OF BIODEGRADABLE FRACTION OF SOLID WASTE 1816/CHE/2014 TWIN BALLOON BIOGAS COMPRESSION SYSTEM 202441011214 MISTURE REMOVAL SYSTEM FROM BIOGAS 202441019824 BIOCOMPLEX OF LIGNOCELLULOSIC MATERIAL, ANAEROBIC FUNGI 202441019825 PROCESS FOR CONTINUOUSLY PRODUCING ANAEROBIC FUNGAL BIOMASS 202441019826 CONTINUOUS PRODUCTION OF ANAEROBIC FUNGAL BIOMASS.

Name of Startup: Greenshift Energy Private Limited



Founder and Co-founder(s):
Founder: Kunal K Godambe
Co-Founder: Dakshata K Godambe
Co-Founder: Saurabh C Patankar

Developed Under (scheme):
BIG

Email:
greenshiftnrg@gmail.com

Product/Technology differentiation from Competitors

The project's innovative approach offers several key features that set it apart from conventional methods. Notably, the process does not use any binders, either organic or inorganic, which could cause environmental hazards during burning. The manufacturing process remains unaffected by moisture, making it suitable for operation even during the monsoon season. The versatility of the process allows it to accommodate any type of biomass, providing flexibility in creating materials of various shapes and sizes for different applications. Furthermore, the recycling of solvents used in the process contributes to lower operational costs, enhancing the overall sustainability of the project.

Brief Description of Product

A key intermediate product is Bio Clay, which possessed properties similar to clay. Bio Clay hardened when moisture dried up and softened when moisture was added, offering end customers the flexibility to create their own products with their own quality standards. This innovation allowed the entire process to be divided into two parts: one handled at the source and the other at the market, thereby reducing transportation costs. This BioClay can be converted into products for various applications, including bio pellets/biospheres for bioenergy, biobased idols, and artifacts, biodegradable, and aroma diffusers. These diverse applications showcase the versatility and broad market potential of the technology.

Current Stage of Development

Reached a Technology Readiness Level TRL of 6, indicating a well-developed and viable technology ready for further commercialization. We are currently focused on bioenergy to address the dual problem of disposal of crop residues and non-availability of biomass pellets/spheres of required size for thermal power plants to complete the mandate of government to use 5 biomasses in Thermal power plants. Along with this we are committed to penetrate this technology into as many applications as possible while continuing to develop novel solutions to address waste material challenges with our pilot project.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Pan India.

National/Societal Relevance

Bioenergy has been attributed as carbon neutral form of energy that can be produced through local carbon resource. It gives dual benefit of energy security and carbon neutrality. The biomass densification technology can be scaled at high tonnage as a continuous process to operate in all weather conditions without requirement of drying biomass before pelleting process. Smaller size of pellets or biomass spheres ensure that higher surface area is available for combustion which is an oxidation reaction.

Technology readiness level (TRL)

TRL- 6



Title/Name of the Product/Technology

Densification of Biomass - Giving shape to Biomass Sustainable lignocellulose-based materials


Export Potential

Opportunity of exports for biobased products.

Import Potential

There is a strategic advantage of energy security when compared to Grade 1-5 coal which is the imported coal. The technology helps in power ministry mandate of use of 5 biomass pellets in thermal power plants.

Name of Startup: HasiEco Ventures Pvt. Ltd



Founder and Co-founder(s):
Ekshikha Bhagtani

Developed Under (scheme):
BIG, SPARSH

Email:
ekshika.bhagtani@gmail.com

Product/Technology differentiation from Competitors

Our Product is different from those plastic based and even Bioplastic based tableware coated with chemicals not suitable for the health and environment. It is completely made of food grade matrix and polymers which are safe for food to be served and safe to be ingested by animals. Life cycle of our product either ends in animal consumption or as manure for the soil leaving no danger or traces to the mother earth.

Brief Description of Product

We are offering the safe servings for the food as the health of yours and planet matters. We are addressing the dual challenge of waste management and sustainability in the food and beverage industry. Agrofood residue as waste, contributing to environmental degradation. By repurposing this waste material, we are reducing landfill waste and providing an innovative and sustainable alternative to traditional tableware and packaging materials. Additionally, our solution addresses the increasing demand for eco-friendly products in the market specifically microplastic free. Consumers are becoming more conscious of their environmental and health impact and are actively seeking sustainable alternatives. Our venture not only offers a unique and innovative product which is animal edible and microplastic free but also aligns with the growing sustainability movement.

Current Stage of Development

Proof of concept stage.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Global.

National/Societal Relevance

Our product addresses national sustainability goals by reducing plastic waste, promoting the circular economy, and supporting local industries. It contributes to environmental preservation, creates jobs, and fosters economic independence, aligning with societal efforts to build a greener, more self-sufficient future.

Technology readiness level (TRL)

TRL- 4

Title/Name of the Product/Technology

Sustainable tableware & packaging material from agrofood waste approaching circular economy.

Product Positioning

Our product, crafted from upcycled agrofood waste, provides an eco-friendly, durable alternative to plastic disposables. Ideal for environmentally conscious consumers and businesses, it combines sustainability with performance, supports the circular economy, and offers a cost-effective solution that aligns with modern values of responsible consumption and waste reduction.

Import Potential


Made from locally sourced material, replaces imported disposables, supporting local industries, reducing environmental impact, and fostering economic resilience. By promoting a circular economy, creating jobs, and enhancing cost competitiveness, it appeals to consumers and businesses seeking sustainable, high-quality, and locally produced alternatives to imports.

Export Potential

It has strong export potential due to its sustainability and innovation. It offers global markets a high-quality, eco-friendly alternative to plastic disposables, aligning with international trends towards green products and supporting global sustainability while showcasing local industry advancements.



Name of Startup: IBioM



Founder and Co-founder(s):
Dr. Raja Mugasingam Founder
Dr. Jagadish Mittur Co-Founder

Email:
info@ibiom.in

Product/Technology differentiation from Competitors
Wider reach and network among startups and MSMEs.

Brief Description of Product
IBioM Indian Biotech and MSME Association is an entity that assists entrepreneurship in Life Sciences / Biotechnology Sector. The aim is to chaperon startups from their early stages to steadily move along to the stages of MSME and beyond where possible. Furthermore, IBioM offers a chance to explore channels for Governments and various funding agencies to help move startups literally from the street levels to scaleups as well as to sustain MSMEs in various areas of Life Sciences across India. IBioM, now as a registered organization, is set to take off as a formal "Entity" by enterprising Biotech innovators, students, and angel investors seeking guidance and help in various ways. IBioM is the result of efforts from an informal group BBS- "Bengaluru Biotechnology StartUps" started in mid-2019 by a few bio-technocrats representing start-ups as well as SMEs. BBS currently, grown with an informal membership of 250+ has become a highly vibrant group helping each other in various forms and means. Partnerships between startups has resulted in many successes. BBS has provided impetus to graduate ideas, launch several products, constructive feedback, exchange of knowledge, reagents, equipment, use of laboratory space and much more. The intent behind the setting up of IBioM has been to collaborate, develop and maintain a relationship with experienced stakeholders, top scientists and leading individuals, and media to create a favorable public environment for further growth and development of Life Sciences / Biotechnology in India. IBioM would focus on augmenting the knowledge and understanding of biosafety and regulatory systems, scientific concepts, methods and technology of risk assessment, risk management and risk communication of biotechnology to various stakeholders. This is a novel attempt at building capacity for StartUps situated in different verticals of the Life Sciences/ Biotechnology sector. IBioM looks forward to working with established entities such as ABLE, BCIC, FKCCI, Government Departments of Industry and Commerce and other departments for collective progress and complementarity.

Current Stage of Development
Having partnered key industry events, including the Bangalore Tech Summit BTS 22, 23 and Genomics India Conference GIC 22, 24, our profile has been significantly raised as a facilitator and influencer in the biotech community. IBioM has partnered along with BIRAC for the upcoming GBI 2024 Conference as well as with IISC for the IMMUNOCON 2024.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted
National Level.

National/Societal Relevance
Highly relevant in the startups and MSME sector in Biotech field.

Technology readiness level (TRL)
TRL- 9

Title/Name of the Product/Technology

Foundation for Indian Biotech Startups & MSMEs IBioM.

Name of Startup: IPSUM LIFESCIENCES LLP



Founder and Co-founder(s):
Dr. Bhavin Patel - Founder
Dr. Meghna Vanza - Co-founder

Email:
bhavin@ipsumlifesciences.com

Product/Technology differentiation from Competitors

Ipsum is the only company in India to produce High Purity 90 natural tocopherols. This grade gives more safety and efficacy to the end consumers as the contaminants are removed from the product, as a natural preservative this also gives more efficiency and thus lesser dosages. The Continuous Purification of Natural and Pharmaceutical Ingredients is the unique technology which needs lesser foot print since the operations are in a continuous mode, it has low CAPEX compared to other manufacturers. This technology needs hardly 9 people to run the plant including QA, which makes the RoI more sustainable.

Brief Description of Product

Natural Tocopherols are superior in terms of quality, bioavailability and safety as compared to its synthetic counterpart or other oil based synthetic anti-oxidants. Ipsum has developed the technology to remove the impurities like free fatty acids, sterols, squalene from the deoderised distillate of Sun Flower as well as Soy oil. Ipsum is the only company in India to produce High Purity 90 natural tocopherols. This grade gives more safety and efficacy to the end consumers as the contaminants are removed from the product, as a natural preservative this also gives more efficiency and thus lesser dosages.

Current Stage of Development

Continuous Purification of Natural and Pharmaceutical Ingredients - High Purity Natural Tocopherols is already commercialized technology. The Manufacturing plant is set up at Talaja MIDC, Navi Mumbai, which is operational and delivering with the real product being delivered to the customers with repetitive orders. Current installation capacity is for 1500 Kgs of 90 pure tocopherols on monthly basis.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted
Indian Market as of Now.

National/Societal Relevance

The raw material is a waste of edible oil refinery. India being agricultural producer for Soy and Sunflower, gives us immense opportunity to have this renewable raw material. In India there are refineries of Soy and Sunflower oil, which generates this waste in quantum. By implementing this technology, we are able to save this by product to be discarded as waste, and are generating value out of it.

Technology readiness level (TRL)
TRL- 9



Title/Name of the Product/Technology

Continuous Purification of Natural and Pharmaceutical Ingredients - High Purity Natural Tocopherols.

Product Positioning

In Natural Ingredients domain natural Tocopherols Vitamin-E has its own space as food preservative and human health application. Since we have made this product available in the highest purity levels, consumer preference will be more in terms of more safer, efficient and bio-available products compared to existing synthetic versions.

Import Potential

Since, Ipsum is offering same Ex-Works price as the Chinese manufacturers, importers from India are preferring Ipsum as preferred supplier, as it saves costs arriving due to logistics, import duty, forex conversion. This is also helping to protect our forex reserves.

Export Potential

On Global Markets, product derived from this technology can compete with the Chinese manufacturers in terms of the costs. We believe because of geo-political concerns and trust issues buyers from Europe and North America will be preferring Indian origin products as compared to Chinese origin.



Name of Startup: Jass Biologics Design Center



Founder and Co-founder(s):
Kiruba.S, Sumaya, Nancy

Email:
kiruba.s@jassbiologics.com

Product/Technology differentiation from Competitors

Home grown expertise with international experience and would be trusted and provide consistent partnership.

Brief Description of Product

Engineering design consultant for the single use and Stainless-steel facility from the feasibility stage to GMP hand over. Also specialised in Equipment sourcing, skilled resource provider as consultant. In addition to that we have team for Technical document drafting services.

Current Stage of Development

Already executed the Base and detailed design for Single use facility and stainless steel facility.

Are you willing to Transfer/ Out-License your Technology

Geographical Region Targeted

Asia, Europe.

National/Societal Relevance

When design comes with quality and lean approach it leads overall cost reduction which ultimately helps the user end in several instances it is the patients who consume Biopharmaceutical process-based drugs.

Technology readiness level (TRL)

TRL- 8


Title/Name of the Product/Technology

Engineering design consultant for the single use and Stainless-steel facility from the feasibility stage to GMP hand over. Also specialised in Equipment sourcing, skilled resource provider as consultant. In addition to that we have team for Technical document drafting services.

Product Positioning

Shall execute Process economics to analyze it for market viability.

Name of Startup: KCAT



Founder and Co-founder(s):
Mr. Pravin Kumar - Director -
Chief Scientific Officer Mr. Gladstone Sigamani -
Director - Chief Executive Officer
Ms. Roopa L. - Director- Chief IP Officer

Email:
ankita.s@kcat.co.in

Product/Technology differentiation from Competitors

Kcat Enzymatic offers cutting-edge biocatalytic solutions with proprietary enzymes like Transaminase Greenaminase® and Hydroxylase Greenhydroxylase®, among others. These enzymes are engineered for exceptional robustness and thermodynamic stability, ensuring faster reaction rates and higher specificity compared to traditional methods. Leveraging advanced AI and quantum chemistry, our 7D Grid Technology enhances enzyme performance for pharmaceutical API and drug production. Designed for sustainability, these enzymes operate under mild, eco-friendly conditions, significantly reducing carbon footprints, waste, and energy consumption. Kcat Enzymatic provides cost-effective, biodegradable alternatives, enabling efficient, greener industrial-scale production.

Brief Description of Product

Biocatalysis, a process powered by biological catalysts such as enzymes, has become a game changer in modern chemical production. In fact, 30 of API intermediates for leading pharmaceutical drugs now rely on biocatalytic processes. These enzymes operate under milder conditions compared to traditional chemical catalysts, making them eco-friendly, biodegradable, and cost-effective. With fewer conversion steps, simplified purification processes, and reduced capital investment, biocatalysis offers clear advantages over conventional synthetic methods. Kcat Enzymatic has pioneered innovative biocatalytic solutions using proprietary engineered enzymes Transaminase Greenaminase® & Hydroxylase Greenhydroxylase®. These enzymes are designed to reduce carbon footprints, support sustainability, and provide cost-effective solutions for the production of APIs, and drugs. Leveraging artificial intelligence and proprietary quantum chemistry algorithms, Kcat Enzymatic has developed thermodynamically stable enzymes that catalyze chemical reactions in bioreactors at faster rates and with higher specificity than conventional methods. Our cutting-edge 7D Grid Technology, an AI-based enzyme engineering platform, has successfully engineered enzymes that are now integral to the production of pharmaceutical API and drugs. With our innovative approach, we are ushering in a new era of greener, more sustainable, and highly efficient biocatalytic processes.

Current Stage of Development

The enzymes have been meticulously engineered, designed, and optimized at the lab scale, achieving successful validation for product conversion at a 1 kg scale. These robust and thermostable enzymes demonstrate over 90 conversion efficiency at this level. Currently, the enzymes are undergoing further validation at pilot scale 100 to 200 kg and are being optimized to meet industrial-scale requirements. Commercialization is anticipated by May 2025.

Are you willing to Transfer/Out-License your Technology

Geographical Region Targeted

US, Europe and India.

National/Societal Relevance

These enzymes operate under milder conditions compared to traditional chemical catalysts, making them eco-friendly, biodegradable, cost-effective and support sustainability. With our innovative approach, we are ushering in a new era of greener, more sustainable, and highly efficient biocatalytic processes.

Technology readiness level (TRL)

TRL- 7

Title/Name of the Product/Technology

Revolutionizing Biocatalysis with Engineered Enzymes for Sustainable API and Drug Production.

Product Positioning

Product is currently in Pilot scale validations and is positioned to be commercialized by May 2025.

Export Potential

Huge Export Potential to US & European markets.



Name of Startup: KisaanSay



Founder and Co-founder(s):
Nitin Puri Manoj Karki Vaishali Puri

Email:
manoj.karki@kisaansay.in

Product/Technology differentiation from Competitors

All food products come from a certain place of India where it grows best Authentic Single Origin food products Direct from farmers No multiple handlings/ intermediaries.

Brief Description of Product

KisaanSay is a collaborative initiative of Indian farmers and food professionals. KisaanSay brings authentic food products directly from the finest farmer enterprises across India. Food products are sourced from natural farming sources- mountain, valley, forest, foothill, tribal areas across India. Built on a unique model where farmers get fair share of profits. Categories include Pulses, Millets, Rice, Honey, Ghee, Oil, Juices, and Spices.

Current Stage of Development

Already executed the Base and detailed design for Single use facility and stainless steel facility.

Are you willing to Transfer / Out-License your Technology No

Geographical Region Targeted

Pan India.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Indias First Place-of-Origin Grocery Brand

Name of Startup: KR Bioproducts OPC Private Ltd



Founder and Co-founder(s):
Dr Ranjita Biswas

Email:
kr.bioproducts@gmail.com

Product/Technology differentiation from Competitors

1. KRcordy mushroom- Grown through the unconventional method in a bioreactor in a liquid medium so significant improvement in productivity and cost reduction due to design of special media under patent. 2. KRclean biosurfactant- An innovative method for product recovery was developed to reduce the cost of biosurfactant production under patent.

Brief Description of Product

1. KRcordy mushroom- Cordyceps militaris is a high-value medicinal mushroom known for hypoglycaemic, hypolipidemic, anti-inflammatory, antitumor, antibacterial, antifungal, antiviral, antimalarial, prosexual, neuroprotective, antioxidant, and immuno-protective activities. It is rich in nutritional components like cordycepin, adenosine, cordycepic acid, aminoacids and sterols. The global market size was valued at USD 1.02 billion in 2023. It is growing at a CAGR of 11.7 and is expected to reach USD 3.11 billion by 2033. This mushroom is becoming popular as nutraceuticals fortified in wellness and preventive healthcare products. The Company grows the mushroom at the bioreactor scale in a liquid medium. The active component cordycepin is produced in high concentration, yield and productivity compared to the wild-type fruiting bodies which takes 90-120 days. Such innovations can help to reduce the wide demand and supply gap in the future. 2. KRclean biosurfactant- The household cleaning and disinfecting agents are a health and environmental hazard due to the toxic and non-degradable nature of the chemical surfactants used. While the biosurfactants are biodegradable non-toxic, bactericidal, anti-fungal and active under a wide range of temperatures and pH. The Company produces biosurfactants obtained from non-pathogenic Bacillus sp. It can be sprayed on soiled surfaces to clean fat and oil-based dirt and kill bacterial and fungal cells. In 2020, the market for green surfactants was estimated to be worth close to USD 2.54 billion. The global green surfactants market is projected to expand at a CAGR of 5.7 from 2022 to 2027, reaching a value of \$3.56 billion by 2026.

Current Stage of Development

1. KRcordy mushroom- Lab scale bioreactor process development is complete 100 L and above bioreactor facility is unavailable for further scale-up. 2. KRclean Biosurfactant- Lab scale bioreactor process development is complete 100 L and above bioreactor facility is unavailable for further scale-up.

Are you willing to Transfer /Out-License your Technology No

Geographical Region Targeted

Global.

National/Societal Relevance

1. KRcordy mushroom- It will support the health and general wellness of the people at an affordable price. 2. KRclean Biosurfactant- It will support health and safeguard the environment.

Technology readiness level (TRL)

TRL- 5

Title/Name of the Product/Technology

1. KRcordy mushroom- Cordyceps militaris biomass 2. KRclean Biosurfactant- Biosurfactant as household cleaner and disinfectant.

Product Positioning

1. KRcordy mushroom- The priced Cordyceps militaris will be available at an affordable cost for preventive healthcare with mention of active compound Cordycepin concentration 2. KRclean Biosurfactant- The biodegradable household cleaner and sanitizer at an affordable price will be attractive for the consumer in the post-covid era.

Export Potential

1. KRcordy mushroom- Yes, the market projections for Cordyceps militaris are very promising CAGR-11.02 from 2023- 2033. 2. KRclean Biosurfactant- Yes, the market projections for Biosurfactants are very promising CAGR- 5.7 from 2022-2027.

Import Potential

1. KRcordy mushroom- Import of Cordyceps militaris biomass from other countries can be reduced by further scaling up the process. 2. KRclean Biosurfactant- Import of surfactants/biosurfactants can be reduced by promoting such products.



Name of Startup: LANKA GREENOVATION



Founder and Co-founder(s):
Ms.R.Ananthi Founder,
Dr.S.Karthikumar Co-Founder,
Dr.R.Shyam Kumar Mentor

Email:
skarthikumar@gmail.com

Product/Technology differentiation from Competitors

This first-of-its-kind food analyzer is designed for home use, capable of monitoring key quality parameters in both water and various food products, including solids, semi-solids, and liquids. Leveraging IoT, it integrates multiple biochemical sensors with smart devices, enabling easy operation without specialized training. The device offers comprehensive multi-parameter monitoring, using innovative enzymatic and chemical detection methods. Its modular, energy-efficient design allows for customization, expansion, and cost-effective fabrication. Tested for high accuracy and reliability, this versatile analyzer is suitable for a wide range of applications, from homes to small businesses, bridging professional and personal food safety.

Brief Description of Product

This innovative food analyser is designed to be the first of its kind, capable of monitoring key quality parameters in both water and a wide range of food products, including solids, semi-solids, and liquids. The device utilizes the Internet of Things IoT to integrate multiple biochemical sensors with smart devices, enabling it to be used by individuals without specialized training. This technology is designed to be both reliable and energy-efficient, offering a viable alternative to complex equipment and the need for skilled personnel. The method for detecting microbial contamination, food contaminants and adulterants FCA in this device is based on a combination of enzymatic and chemical reactions, along with the colorimetric and spectrophotometric analysis of analytes. The device will feature key hardware components such as a microcontroller with IoT capabilities, various sensors, membrane-based biosensors for detecting different FCA, a cuvette, a Pi camera for capturing images, and a touch screen display monitor. The sensors will be housed in a 3D printed base support.

Current Stage of Development

Microcontrollers, sensors, pumps, and valves were sourced from local and online markets. The food analyzer was designed, fabricated, and assembled with sensors fitted into 3D-printed PLA supports. Custom Python code was used to test each sensor, and results were cross-validated with laboratory equipment. The prototype was successfully developed, with accurate direct measurements of pH, TDS, and temperature, and spectral data from NIR and photovoltaic sensors normalized. Some sensor outputs are still under analysis. The thermal analysis process using a thermal camera has been registered for copyright.

Are you willing to Transfer / Out-License your Technology No

Geographical Region Targeted

Recommended for all.

National/Societal Relevance

Enables real-time, at-home testing of food and water safety, addressing a critical national concern over food safety. Reduces the risk of consuming contaminated or adulterated food, significantly contributing to public health and safety. Supports national goals of improving food safety standards, raising public awareness, and promoting preventive health.

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

AI-Based Multiplex Food Analyzer

IP Status

Protocol for selected tests have been registered under Copyright L-146788/2024. The design component has been submitted for Design Act

Name of Startup: Masuu Organics



Founder and Co-founder(s):
Dr. Ramesh pennamareddy and
Swarna Priya Pennamareddy

Email:
ramesh.pennamareddy@gmail.com

Product/Technology differentiation from Competitors

The unique microbial blend can offer distinct advantages over generic formulations. The product incorporates an advanced delivery system that improves the stability and viability of the microorganism. This customized formulation providing more targeted approach compared to one size fits all solutions.

Brief Description of Product

AZOS LIQUID Azospirillum is a fascinating genus of plant growth-promoting rhizobacteria PGPR that has gained attention for its beneficial effects on crop growth and productivity. Azospirillum species are known for their ability to fix atmospheric nitrogen, making it available to plants. This nitrogen fixation process contributes to improved plant growth and development. Azospirillum produces growth-promoting substances, including auxins such as indole-3-acetic acid, gibberellins, and cytokinins. These phytohormones influence plant growth, root development, and stress tolerance. Azospirillum Liquid Biofertilizer is a highly effective, organic plant nutrient solution designed to enhance soil fertility and promote healthy plant growth. Formulated with beneficial microorganisms, it helps improve nutrient uptake, stimulate root development, and boost plant resistance to environmental stress. The liquid form ensures easy application and quick absorption, making it ideal for various crops and garden plants. Its natural composition supports sustainable agriculture by enriching soil health without the use of synthetic chemicals. DOSAGE: 1 BILLION CFU/ml Soil application Dissolved 50 - 100 ml in 10 Liters of water Foliar application Dissolved 25 - 50 ml in 1 liter of water Seed Treatment Dissolved 100 ml in 1 litre of water *Nanosized biofertilizers 1-100 nm is encapsulated in a suitable nanomaterial covering, and then the resulting product is manufactured.

Current Stage of Development

R&D: The product is likely in a mature stage of development if it has undergone extensive research and formulation, ensuring that it contains a well-balanced mix of beneficial Microbes optimized for plant growth and soil health. The availability of scientific data, case studies, or testimonials supporting the products benefits helps justify its development stage, confirming its reliability and performance.

Are you willing to Transfer /Out-License your Technology No

Geographical Region Targeted

The regions where soil nutrient deficiencies are common, Where Natural and organic farming is more practiced in India and globally.

National/Societal Relevance

Biofertilizers are significant at a national level as they promote sustainable agriculture by enhancing soil fertility, improving crop yields, and reducing dependence on chemical fertilizers. Liquid biofertilizers have national relevance due to their impact on agricultural productivity, environmental sustainability, economic development and alignment with broader policy goals. Liquid fertilizers ensure much higher bioavailability of fertilizer nutrients, as they are dissolved and highly assimilable.

Technology readiness level (TRL)

TRL- 9

Title/Name of the Product/Technology

NANO & LIQUID BIOFERTILIZERS:
Nanotechnology is being explored to enhance biofertilizer efficiency. Nano-sized carriers such as nanoparticles can improve nutrient uptake by plants and protect microorganisms from environmental stress. Liquid biofertilizer is a type of fertilizer made from natural or organic materials that enhance soil fertility and plant growth.

Product Positioning

The Indian biofertilizer market is growing, driven by rising chemical fertilizer costs and environmental awareness. Formulated with beneficial microorganisms, it helps improve nutrient uptake, stimulate root development, and boost plant resistance to environmental stress. This customized formulation providing more targeted approach compared to one size fits all solutions

Export Potential

High-quality, locally adapted products can offer a competitive edge in global markets, catering to specific agricultural needs. Exporting demonstrates local technological advancements and attracts further investment and collaboration opportunities.

Import Potential

Import substitution in the context of liquid biofertilizers offers economic, environmental, strategic benefits and reducing dependence on chemical fertilizers. It supports the development of local industries, enhances supply chain security, aligns with sustainability goals, and contributes to broader national objectives.

Name of Startup: Medic Tech Private Limited



Founder and Co-founder(s):
Dr. Inder Kumar Gupta,
Dr. Ishu Singhal,
Dr. Ravi Singhal

Developed Under (scheme):
BIG

Email:
support@medic.net.in

Product/Technology differentiation from Competitors

The NanoScience Lab™/ANUVRAT OUTSIDE™ stands out due to its exceptional customization capabilities, precision, and cost-efficiency in nanoscale material synthesis. Unlike traditional systems, it offers a flexible platform that can be tailored to various industrial needs, reducing operational costs and manpower while ensuring high safety standards. Our technology's advanced features and global IP rights provide a competitive edge in delivering innovative solutions across diverse applications.

Brief Description of Product

NanoScience Lab™/ANUVRAT OUTSIDE™ is a revolutionary nanoscale material synthesis machine designed for versatile and precise material creation. It enables the production of nanoscale materials for a wide range of applications, including healthcare, automotive, and advanced materials and many more. This cutting-edge platform offers unparalleled customization, efficiency, and cost-effectiveness, positioning it as a leader in nanotechnology. The intangible product, with global IP rights and Indian patents, is ready for commercialization and monetization through technology transfer and collaboration.

Current Stage of Development

Tangible: The NanoScience Lab™/ANUVRAT OUTSIDE™ has successfully completed the proof-of-concept phase, showcasing its effectiveness in nanoscale material synthesis. We are currently advancing to the prototype stage, with ongoing refinements based on internal testing results. Pre-commercialization trials are in progress, preparing the technology for real-world application and market introduction. Intangible: Our intangible product, represented by global IP rights and Indian patents, is fully developed and ready for commercialization. We are prepared to engage in technology transfer and collaboration, leveraging our intellectual property to drive innovation and facilitate broad deployment across various industries.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted


Global, with specific focus on markets in North America, Europe, and Asia, leveraging international IP rights and regional demand for advanced nanotechnology solutions.

National/Societal Relevance

The NanoScience Lab™/ANUVRAT OUTSIDE™ drives national innovation by advancing India's capabilities in nanotechnology. It supports key industries such as healthcare and automotive, fostering technological self-reliance and contributing to economic growth.

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

NanoScience Lab™/ANUVRAT OUTSIDE™ - Nanoscale Materials Synthesis Machine

Product Positioning

Leading-edge nanoscale material synthesis machine positioned as a high-performance, customizable solution for diverse industries, offering superior precision and cost-efficiency compared to traditional systems.

Import Substitution

The NanoScience Lab™/ANUVRAT OUTSIDE™ provides a domestic alternative to imported nanoscale material synthesis equipment, reducing dependency on foreign technology and supporting local manufacturing capabilities.

Export Potential

The NanoScience Lab™/ANUVRAT OUTSIDE™ has significant export potential due to its advanced technology and global IP rights. Its versatility and high performance cater to international markets, positioning it as a competitive solution in global nanotechnology sectors.

IP Status

IPO---NANO MATERIAL SYNTHESIS MACHINE Patent granted 482995 TITLE and Jurisdiction application App no. PCT APPLICATION, WIPO NANO MATERIAL SYNTHESIS MACHINE PCT/ IN2022/050175 USPTO 18/261,669 CANADA 3207985 EPO COVERING ABOU 44 COUNTRIES 22762753.6 BRAZIL BR 11 2023 017492- 9 JAPAN 2023-553536 RUSSIA 2023124631 AUSTRALIA 2022230334

Name of Startup: Microbial Farm Research and Consultancy



Founder and Co-founder(s):
PRAVEEN XAVIOR PANDIAN

Email:
praveen.xavior@microbialfarm.com

Product/Technology differentiation from Competitors

1. Low Cost Production, 2. Diversity Of Species, 3. Enhanced Molecular Formulation.

Brief Description of Product

Arbuscular Mycorrhizal AM fungi are a crucial component of sustainable agriculture and ecosystem management. These symbiotic fungi form a mutually beneficial relationship with the roots of most terrestrial plants, enhancing nutrient uptake, particularly phosphorus, while receiving carbohydrates from the host plant. Understanding AM Fungi: AM fungi belong to the phylum Glomeromycota and form arbuscules within plant root cells. These specialized structures facilitate nutrient exchange between the fungus and the plant. The fungi extend their hyphae into the soil, increasing the root surface area and improving access to water and nutrients, particularly phosphorus, nitrogen, and micronutrients. This symbiosis also enhances plant resistance to pathogens and environmental stressors, such as drought and salinity. Benefits of AM Fungi Products: Enhanced Nutrient Uptake: AM fungi improve the plants' ability to absorb essential nutrients, particularly phosphorus, which is often limited in soils. The extensive hyphal network of AM fungi accesses nutrient pools beyond the root zone. Improved Soil Structure: The hyphae of AM fungi contribute to soil aggregation by binding soil particles together, enhancing soil structure and porosity. This improved structure facilitates root penetration, water infiltration, and reduces erosion. Stress Tolerance: Plants inoculated with AM fungi exhibit increased tolerance to abiotic stresses like drought, salinity, and heavy metal contamination. The fungi improve water uptake and maintain plant hydration under adverse conditions. Disease Resistance: AM fungi can enhance plant resistance to root pathogens by inducing systemic resistance and competing with harmful microbes for space and nutrients. Sustainable Agriculture: Using AM fungi reduces the dependency on chemical fertilizers and pesticides, promoting environmentally friendly farming practices. This not only lowers input costs but also mitigates the negative environmental impacts associated with excessive chemical use. carbon sequestration: Arbuscular Mycorrhizal AM fungi play a significant role in carbon sequestration, which is the process of capturing and storing atmospheric carbon dioxide CO₂ to mitigate climate change. Their symbiotic relationship with plants not only enhances nutrient uptake and plant growth but also contributes to the storage of carbon in the soil.

Current Stage of Development

Since 2017, Microbial Farm has been transferring technology to private fertilizer manufacturers, successfully completing four projects in India and one in Brazil. Our technology customers have achieved a production capacity of 15 tons of product per day. Additionally, Microbial Farm produces its own advanced technology products in limited quantities.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

The regions where soil nutrient deficiencies are common, Where Natural and organic farming is more practiced in India and globally.

National/Societal Relevance

Mycorrhizal fungi products hold significant national and societal relevance due to their wide-ranging benefits for agriculture, environmental sustainability, and public health.

Technology readiness level (TRL)

TRL- 9

Title/Name of the Product/Technology

NANO & LIQUID BIOFERTILIZERS: Nanotechnology is being explored to enhance biofertilizer efficiency. Nano-sized carriers such as nanoparticles can improve nutrient uptake by plants and protect microorganisms from environmental stress. Liquid biofertilizer is a type of fertilizer made from natural or organic materials that enhance soil fertility and plant growth.

Product Positioning


Mycorrhiza products are positioned as a natural and sustainable solution for enhancing soil health, improving nutrient uptake, and boosting plant growth. Their unique ability to form symbiotic relationships with plant roots offers significant advantages over traditional chemical and organic fertilizers. This positioning highlights their role in promoting sustainable agriculture.

Export Potential

The mycorrhiza market is projected to be valued at USD 1.18 billion in 2024 and is anticipated to grow to USD 1.87 billion by 2029, with a compound annual growth rate CAGR of 14.14 during the forecast period from 2024 to 2029.

Import Potential

Mycorrhizal fungi products offer a compelling alternative to both chemical and organic fertilizers, particularly in the context of import substitution.





Name of Startup: Mr. Biologist



Founder and Co-founder(s):
Amrit Pritam Bhuyan

Email:
mrbiologist2017@gmail.com

Product/Technology differentiation from Competitors

It is a unique tea blended prebiotic formulation.

Brief Description of Product

A tea based prebiotic formulation.

Current Stage of Development

Currently we are evaluating toxicity studies.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

India.

National/Societal Relevance

Gut health care for all.

Technology readiness level (TRL)

TRL-1

Title/Name of the Product/Technology

A tea based prebiotic formulation

Product Positioning

India

Name of Startup: Nanosafe Solutions



Founder and Co-founder(s):
Dr. Anasuya Roy & Mr. Nirav Mehta

Developed Under
(scheme):
BIG

Email:
care@nanosafesolutions.com

Product/Technology differentiation from Competitors

Nanosafe Solutions sets itself apart from competitors like Microban, Biocote, and Resil through its proprietary active copper technology, which is a safer and more effective antimicrobial solution. Unlike conventional silver or chemical-based coatings, our technology leverages copper, a naturally occurring micronutrient, which not only offers broad-spectrum antimicrobial action but also aligns with sustainability and food safety standards. Furthermore, our focus on cost-effective, indigenous production for import substitution gives us a strategic edge in the market, ensuring both affordability and scalability.

Brief Description of Product

1 Active copper based antimicrobial technology formulations for coating, plastics, textiles, foam and cosmetics, construction chemicals 2 Copper fortification of water and other edible liquids via plastic packaging 3 Leaching copper, as a replacement for preservatives, through plastic packaging 4 Shelf-life extension using copper ingredients in flexible film 5 Organic, partially-import substituting antimicrobial formulation for application in medical devices coating, paints & polyurethane foam

Current Stage of Development

The technology, formulations and applications are all well tested, commercialised and launched in the market either by Nanosafe itself or by its collaboration brand partners like Supreme Industries, Sheela Foam, Uflex, Sika and lot of other brands which are currently at testing stages.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Asia, Europe, Africa, South America, Middle East.

National/Societal Relevance

Our active copper technology addresses critical public health issues in India by preventing microbial contamination in water, textiles, and polyurethane foams. It helps combat waterborne diseases in rural areas and reduces health risks from everyday products. By producing cost-effective antimicrobial solutions locally, we decrease reliance on imports, supporting India's goal of self-sufficiency and economic growth. This technology aligns with national health priorities and sustainable development goals.

Technology readiness level (TRL)

TRL- 9

Title/Name of the Product/Technology

1 Active copper based antimicrobial technology formulations for coating, plastics, textiles, foam and cosmetics, construction chemicals 2 Copper fortification of water and other edible liquids via plastic packaging 3 Leaching copper, as a replacement for preservatives, through plastic packaging 4 Shelf-life extension using copper ingredients in flexible film 5 Organic, partially-import substituting antimicrobial formulation for application in medical devices coating, paints & polyurethane foam.

Product Positioning

Our technology is positioned in critical markets such as water storage and purification, textiles, and now extends to polyurethane foam and water fortification sectors. These markets benefit from our active copper technology, which delivers broad-spectrum antimicrobial protection against bacteria, viruses, fungi, and algae thus ensuring enhanced hygiene and safety

Export Potential

Humungous export potential of active copper technology and formulations as well as other export-friendly accessories soon to be introduced.

Import Potential

Active copper technology by Nanosafe is 100 made in India antimicrobial technology, thereby giving an option to substitute import of silver based antimicrobial formulations



Name of Startup: NAP Life Sciences



Founder and Co-founder(s):
Dr. Asim Azhar, Dr. S Khan, and
Mr. M Alam

Email:
azharasim@gmail.com

Product/Technology differentiation from Competitors

We have developed these products in-house and economically viable so that it can be used to impart basic knowledge to even college students at affordable prices.

Brief Description of Product

Under Govt. of India's initiative MAKE IN INDIA, we are developing these products to present it to the end user scientist of R&D institutes as well as colleges. Our products are economically cheaper and yield-wise it is far better than the various international brands.

Current Stage of Development

After years of R&D and technical calibration, we are now at stage to launch our products to the market.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Our plasmid Miniprep kits deliver superior DNA yield and purity, outperforming international brands at half the cost. Ideal for researchers seeking cost-effective, high-quality solutions for molecular biology applications, our kits ensure reliable results without sacrificing performance, making them the preferred choice for efficient and affordable plasmid DNA extraction.

National/Societal Relevance

By manufacturing high-quality and affordable plasmid Miniprep kits locally, we are empowering the nation's scientific community to advance research in molecular biology without the financial burden of expensive imports. This democratization of essential research tools fosters innovation across academic and industrial sectors, enhances educational opportunities, and contributes to economic growth. Ultimately, our initiative strengthens national self-reliance in biotechnology, promoting a more robust and resilient scientific infrastructure.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Easy Gel Extraction, DNA Clean-Up, and Concentration Kit, 2. Easy Plasmid DNA Miniprep Kit, 3. Easy Genomic DNA Purification Kit: Animal, 4. Easy Genomic DNA Purification Kit: Bacteria, 5. Easy RNA Isolation Kit, 6. 5X SDS Sample Buffer, 7. NAPzol Trizol equivalent, 8. NAPtiter Cell Viability Assay Kit, 9. Easy Nuclei Preparation Kit, 10. GC Enhancer

Name of Startup: Neat Meatt Biotech Private Limited



Founder and Co-founder(s):
Dr Sandeep Sharma
Mr Sourabh Sobti

Developed Under
(scheme):
SEED Fund

Email:
sandeep@neatmeatt.in

Product/Technology differentiation from Competitors

Chicken cells are non-genetically modified -In-house developed -45 -50 passages & 25-30h doubling time as compared to competitors, these figures are superior -None of the organization has yet developed spontaneously immortalized chicken cells -Can be used for scale up studies using precision fermentation.

Brief Description of Product

Neat Meatt Chicken Primary Cell 1 NMCP1, premium primary cells isolated from 12-day fertilized chicken egg. These high-quality cells are meticulously extracted to ensure optimal viability and performance for various research and development purposes in the burgeoning field of cultivated meat. NMCP1 offers a robust and reliable foundation for your innovative projects, enabling groundbreaking advancements in sustainable and ethical meat production. Ideal for scientists and developers, NMCP1 cells are your essential tool for pioneering the future of food. Neat Meatt Chicken Immortalized cells 1 NMCL1, a specialized line of chicken cells isolated from 12-day fertilized egg that have surpassed 40 passages, achieving spontaneous immortalization. This unique characteristic makes NMCL1 an exceptional resource for research and development in the field of cultivated meat. These cells offer unparalleled stability and longevity, providing a reliable and efficient model for innovative studies aimed at advancing sustainable and ethical meat production. NMCL1 is the perfect choice for scientists seeking robust and reproducible results in their quest to revolutionize the future of food. Our premium In-House Chicken Serum CS, a meticulously crafted, nutrient-rich supplement designed to elevate your avian cell culture research and production. Sourced from healthy chickens and processed with the highest standards, our serum delivers essential growth factors, proteins, and hormones to support robust cell growth and viability. Ideal for applications in cultivated meat, poultry science, and avian biotechnology, our chicken serum ensures consistent, high-quality results, empowering your research with the reliability you need.

Current Stage of Development

Neat Meatt has developed in house chicken serum and primary & spontaneously immortalized chicken cells which are non-genetically modified. The cells have been well characterized utilizing fluorescence microscopy, marker studies, RT-PCR & other relevant analytical tools, the cells have been sold to a start-up organization too to carry forward their R&D activities. MCB's & WCB's have been prepared and cells have reached to a passage level of 45-50 with a doubling time of 25-30h, these are the first of its kind in India.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India/UK/USA/Malaysia/Israel/Singapore.

Do you want to Launch your Product in Global Bio India -2024 Event

Yes

National/Societal Relevance

The national and societal relevance of primary and spontaneously immortalized chicken cells is profound, with potential impacts on food security, sustainability, public health, and economic development. By advancing the use of these cells in cultivated meat, biotechnology, and research, nations can address critical global challenges while fostering innovation and ethical practices.

Technology readiness level (TRL)

TRL- 5

Title/Name of the Product/Technology

Neat Meatt Chicken Primary Cells 1 NMCP1
Neat Meatt Chicken Immortalized 1 NMCL1
Chicken Serum CS.

Product Positioning

Contacted brands like Sartorius, Hi-media, start-ups & R&D organizations working on different aspects of cultured meat across the globe

Export Potential

The export potential of primary and spontaneously immortalized chicken cells is vast, particularly in the burgeoning fields of cultivated meat, biotechnology, and sustainable agriculture. Nations that invest in developing these technologies can tap into growing global markets, contributing to economic growth, enhancing food security, and promoting environmental sustainability.

IP Status

Provisional application filed

Product Launched

Product Launched





Name of Startup: Nops foods pvt ltd



Founder and Co-founder(s):
Dr. Sandeep Kumar,
Mrs. Neeru Bala

Email:
nops.ikh@gmail.com

Product/Technology differentiation from Competitors

The product will deliver high throughput sugarcane peeling 20 X in comparison to available machines. It will peel the sugarcane rather than rubbing which available peelers do using metal brushes. Multiple by-products such as wax, dye and skin can be extracted using this machine. It can be scale-able to any size meeting the demand of sugarcane juice vendors, beverages companies to quality jaggery manufacturer. From sugarcane feeding to peeling and by-product segregation will be completely automated with minimal human intervention.

Brief Description of Product

The impurities present on the sugarcane surface are the key hurdles to produce drinkable sugarcane juice and good quality jaggery. The quality of these products is determined based on impurities concentration. Along with this, production of quality jaggery is majorly dependent on human skill and the methodology used to produce the jaggery is same from centuries and no breakthrough have been done by anyone to transform the jaggery making. In standard procedure, whole sugarcane is crushed to extract the juice but the extracted juice got mixed with impurities lies on sugarcane surface and inside the core. Then, in boiling pan, juice is cleaned using chemical or herbal Clarificant. The extent of cleaning describes the quality of the jaggery. This is major process drawback that initially impurities are allowed to mix with juice and in next step those impurities are extracted. Cleaning of sugarcane is essential to get the good quality of jaggery but unfortunately there is no sustainable practice available to clean the huge quantity of sugarcane. Therefore, we are developing commercial sugarcane peeler for jaggery producers so that quality of jaggery could be enhanced significantly. Also, the peeler can be used by sugarcane juice vendors and beverages companies to get the best quality of the juice without any additional process. The peeler comprises four peeling units arranged in such a way that they can clean the sugarcane in single run. Each peeling unit comprises two blades one is used to scrap the wax, dies and roots from the surface and another will peel off the hard skin. Instead of twin blades, single blades can also be used if someone wants to skip the scraping. The sugarcane never remains straight and also varies in diameter from top to bottom. In order to sort this issue, two of the blades will be attached with hydraulic to provide smooth to and for movement so that blades can peel the variable diameter sugarcane. The peeling units will be fixed at a position and the sugarcane will be passed through it by using high speed motor and rollers.

Current Stage of Development

A thorough market research has been done to evaluate the product need along with discussions with many scientists from ICAR-IISR Lucknow, ICAR - CIPHET Ludhiana and ICAR - CIAE, Bhopal. As per the discussion and product design research, multiple CAD models have been developed during last 12 months. Now, we are clear about the machine features and CAD modelling is in final stage. Also, funding remains a major hurdle to continue a steady growth in product development. However, as per our own funds we are speeding the product development and trying to develop the prototype very soon.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

India, USA, Canada and Middle East.

National/Societal Relevance

These products have medicinal value as per Ayurveda so have multiple health benefits. It will improve the well-being of the people and reduced burden on healthcare facilities. Only concern is the quality of the product which we are improving consistently with the help of technology.

Technology readiness level (TRL)

TRL-3

Title/Name of the Product/Technology

Efficient & High throughput sugarcane peeler

Product Positioning


A healthy sugar-based products for health-conscious people.

Export Potential

Post Covid-19 people are more aware about the health all around the globe and they are adopting healthy products. There is a huge demand of quality raw sugar products in foreign countries which we can meet out.

IP Status

Provisional patent for the technology filed bearing patent application number 202411060745. Trademark IKH of the company has been registered.



Name of Startup: ONEOMICS PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Kesavan Markkandan
Mrs. Elavarasi Balasubramanian
Mrs. Brindha Senthilkumar

Developed Under
(scheme):
BIG

Email:
sales@oneomics.in

Product/Technology differentiation from Competitors

RNAguard stands out from its competitors through its unique combination of ambient stability, ease of use, versatility, cost-effectiveness, and high-quality results. Its innovative technology, robust customer support, regulatory compliance, and market readiness further differentiate it as a leading RNA stabilization solution. By addressing the limitations of existing products and offering clear advantages, RNAguard is well-positioned to become the preferred choice for RNA stabilization in research, clinical diagnostics, biotechnology, and pharmaceutical industries.

Brief Description of Product

RNAguard is an innovative RNA stabilization solution designed to preserve RNA integrity at room temperature for up to 14 days. This product is ideal for use in research laboratories, clinical diagnostics, biotechnology companies, and pharmaceutical industries, providing a reliable and cost-effective alternative to traditional cold storage methods. RNAguard is a transformative product that redefines RNA stabilization, offering unparalleled convenience, reliability, and cost-efficiency. It eliminates the need for dry ice, Styrofoam packaging, and overnight shipping. RNAguard is designed to stabilize RNA by stopping the nuclease activity and protect against oxidation as soon as RNA is added. With RNAguard, laboratories and research institutions can confidently manage their RNA workflows, knowing their samples are protected and ready for any downstream application.

Current Stage of Development

RNAguards current pre-commercialization stage is justified by the completion of critical development milestones, including thorough product validation, regulatory preparations, production readiness, and strategic market planning. These achievements demonstrate that RNAguard is well-positioned for a successful market entry, offering a reliable and innovative solution for RNA stabilization that meets the needs of research laboratories, clinical diagnostics, and biotechnology companies globally.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

RNAguard's innovative RNA stabilization solution has significant potential across multiple geographical regions. By tailoring strategies to the unique needs and regulatory landscapes of North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, RNAguard can achieve widespread adoption and become a leading solution for RNA stabilization globally.

Do you want to Launch your Product in Global Bio India -2024 Event

Yes

National/Societal Relevance

The national and societal relevance of primary and spontaneously immortalized chicken cells is profound, with potential impacts on food security, sustainability, public health, and economic development. By advancing the use of these cells in cultivated meat, biotechnology, and research, nations can address critical global challenges while fostering innovation and ethical practices.

Technology readiness level (TRL)

TRL- 8

Title/Name of the Product/Technology

RNAguard - Complete Solution for Ambient Shipping of RNA Tagline: Protecting RNA Integrity, Anytime, Anywhere.

Product Positioning

RNAguards innovative approach to RNA stabilization positions it as the preferred choice for researchers, clinicians, and biotech professionals. By offering a reliable, cost-effective, and easy-to-use solution for RNA preservation at room temperature, RNAguard empowers users to achieve high-quality results without the complexities of traditional cold storage methods. This strategic positioning

Export Potential

RNAguard has substantial export potential due to its innovative features, global market demand, regulatory preparedness, and scalable production capabilities.



Name of Startup: Operon Technologies



Founder and Co-founder(s):
1 Dr. Nameet Kaur Founder & CEO 2
Sartaj Singh Co-founder & CTO

Developed Under
(scheme):
BIG, SEED Fund

Email:
info@operon.in

Product/Technology

Products: Laboratory Chemicals, Reagents & Kits, Analytical Equipment and Laboratory Consumables Services: Molecular Biology, Proteomics Services, Mutagenesis, Genomics, Services, Plasmid DNA Preparation, Computational Biology, Technical Writing, Industrial Consultation and Trainings

National/Societal Relevance

Operon Technologies plays a crucial role in advancing India's scientific, healthcare, and industrial sectors. By facilitating cutting-edge research and innovation, they contribute to significant breakthroughs in disease understanding and treatment. Their support enhances diagnostic capabilities and ensures high standards in quality control and safety across various industries. Additionally, they play a key role in professional education and training, which strengthens the scientific community. Through these efforts, Operon Technologies not only drives progress and improvement in public health and industry but also supports broader socio-economic development in India.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

PAN India.

Technology readiness level (TRL)

TRL-7



Title/Name of the Product/Technology

Research Facilitation

Unique Selling Point

We provide one-stop solutions for all sorts of research products and services.

Name of Startup: OxonEx Biological Private Limited



Founder and Co-founder(s):
Dr. Muniasamy Neerathilingam
Founder Dr. Prince Jayabal
Co-Founder Dr. Kumar Raju
Co-Founder Dr. Anand Krishnan MR.
Vasanth Mr. Ram Kasipatla

Developed Under
(scheme):
Friends and Family

Email:
mneerathilingam@gmail.com

Product/Technology differentiation from Competitors

One Media: Patented vegan formulation supports high biomass for over 40 microorganisms. One Media-Y: Enhances microbial growth with a nutrient-rich, dual-use liquid and agar medium. Expression Media: Auto-induction system eliminates extra inducers, reducing labor and costs. Irri-Saver: Boosts drought resistance and plant growth more effectively than conventional fertilizers. SipPro: Offers essential vitamins and fiber with low sugar, a healthier sports drink alternative. Green Yeast: Promotes optimal yeast growth for bakery products, probiotics, and biofuel.

Brief Description of Product

Oxonex aims to develop environmentally friendly products from the natural sources for global needs. One Media: One Media is a ready-to-use microbial liquid medium designed to support the uniform growth and high biomass production of over 40 microorganisms. With its patented, plant-sourced vegan formulation, One Media is ideal for culturing commercially important bacteria like probiotics and yeast. In addition, it can be used for manufacturing metabolites and other applications like tissue culture. One Media-Y: One Media-Y is a sterile liquid culture medium that promotes faster microbial growth, high biomass production, and overexpression of recombinant proteins. One Media-Y contains essential nutrients like sugars, amino acids, mineral salts, and vitamins, with a pH range of 4-5. One Media-Y supports the growth of various microorganisms and can be used as both liquid and agar media, making it suitable for diverse research and industrial applications. Expression Media: Expression Media, also known as Auto-induction Media, is a cost-effective solution designed for the efficient production of recombinant proteins. It incorporates proprietary molecules that release inducers at specific intervals, eliminating the need for continuous culture monitoring and the manual addition of substances like IPTG. This media has been successfully validated in numerous laboratories, providing consistent and positive results. Irri-Saver: Irri-Saver® is a natural biofertilizer developed to address water scarcity and rain-dependent farming challenges in agriculture. By colonizing plant roots and fixing atmospheric nitrogen, Irri-Saver significantly enhances plant growth and health, promoting drought resistance and increasing crop yields. Plant drought-resistance bacteria PDBS in Irri-Saver improve water use efficiency and nutrient uptake, helping plants survive under water-limited conditions. Green Yeast Green Yeast is a nutrient-rich formulation designed to support the excellent growth of yeast, making it ideal for various applications. It is widely used in bakery products, as a source of yeast extract in food products like Marmite and Vegemite, in probiotics, and for biofuel production, particularly ethanol removals in molasses and this technology drive the health of bakery products. It has huge application in US, Europe and other nations SipPro SipPro is a refreshing beverage enriched with vitamins B1, B2, and C, designed to boost immunity and provide dietary fiber without raising sugar levels. It is recommended for athletes to enhance energy levels and hydration during and after workouts. Available in natural flavors like Kiwi, Pineapple, Grape, Mango, and lemon, SipPro is set to make a global impact by promoting a healthier lifestyle.

Current Stage of Development

All Oxonex products are fully developed and market-ready. These innovative solutions, including biofertilizers, microbial media, biofuel-supporting yeast, and health-focused beverages, have undergone rigorous testing and validation. They are poised to meet global market demands, offering sustainable, eco-friendly alternatives across industries like agriculture, biotechnology, and health.

Are you willing to Transfer / Out-License your Technology YES

Geographical Region Targeted

Drought places, Farmers or agricultural places for procuring the raw materials, Biotech hub places and boost to have a branches in abroad- because it is global demanded products.

National/Societal Relevance

Oxonex's products have significant national and societal relevance by addressing critical challenges such as water scarcity, sustainable agriculture, and health. Irri-Saver supports resilient farming practices especially drought-prone areas like Rajasthan, Bihar, UP, North Karnataka, South Tamil Nadu. One Media and One Media-Y advance local research and industrial capabilities, and Expression Media enhances biotech efficiency for recombinant protein expression. SipPro promotes public health with low-sugar hydration, while Instant LB and Green Yeast Clean-Green technology and industry growth. Collectively, these innovations support environmental sustainability, improve food security, and foster economic development with use of natural raw materials for a huge biotech manufacturing.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

One Media, One Media-Y, Instant LB, Auto-Induction Expression Media, Irri-Saver Green Yeast Bakers yeast, SipPro Energy drinks to children to Adult.

Product Positioning

Oxonex offers vegan-based eco-friendly solutions including Irri-Saver for drought resistance, One Media and One Media-Y for efficient microbial culture, Expression Media for cost-effective protein production, SipPro for healthy hydration, Instant LB for easy bacterial culturing, and Green Yeast for diverse applications in baking and biofuel.

Unique Selling Point

Oxonex's unique selling point lies in its vegan-based eco-friendly, natural product range designed to address global challenges like climate change, Universal Microbial media. Our innovative solutions, from biofertilizers to microbial media and biofuel-supporting yeast, promote sustainable practices across industries. SipPro offers a health-conscious, vitamin-rich beverage, further promoting well-being and environmental responsibility.

Import Substitution

Oxonex's products, including Irri-Saver, One Media, and Green Yeast, offer viable alternatives to imported goods. By providing eco-friendly biofertilizers, efficient microbial media, and high-quality yeast locally, we reduce dependency on foreign imports, support domestic industries, and strengthen national self-reliance in critical sectors. Substitutes many imported chemicals for media and others.

Export Potential

Oxonex's innovative products, such as Irri-Saver, One Media, and Green Yeast, have strong export potential due to their advanced technology and eco-friendly features. With global demand for sustainable agriculture, efficient microbial media, and high-quality yeast, our products are well-positioned to penetrate international markets and drive growth.

IP Status

International Application No.: PCT/IN2024/050326 Indian Patent Application No. 202341022068

Major Achievements

Monopoly and sustainable, avoiding chemical usage boost to the farmers sectors- First Prize Poster Presentation - One Week One Lab at CSIR - CFTRI. Shortlisted and Selected for funding. However, we look forward to start manufacturing.





Name of Startup: Pequirel Technologies Pvt. Ltd.



Founder and Co-founder(s):
Kiran Baddi
Michael Machala
Mohan Bentur

Email:
kiran@pequirel.com

Product/Technology differentiation from Competitors

No one is offering year-round usage, nor are they building out seed-to sale platforms and community drying or growing services. We are able to produce better output quality, greater product usability and lowest pricing as per our competitor analysis.

Brief Description of Product

Problem: Small farmers are the backbone of Indian agriculture, comprising 78 of the farming community and contributing 41 to food production. However, they face significant challenges, with post-harvest losses PHL reaching 15-20, and in commercial crops like red chili and pulses, PHL can soar to 20-40. These losses, compounded by a staggering 40 degradation in quality due to climatic uncertainties and pests, mean farmers often receive only 16-32 of the produce cost despite their hard work. Solution: Pequirel Technologies addresses these challenges with the Advanced Adaptable Agriculture System A3S, an innovative IoT-based solar seedling growing and drying unit. By drying produce 2.6 times faster reducing drying time from 21 days to just 6 days A3S significantly cuts time and labour costs while enhancing the quality of grade 1 chili from 40 to an impressive 80, with zero losses. A3S offers small and marginal farmers a flexible, zero-capital investment option that enhances income and affordability. Its year-round usage ensures greater ROI with a shorter break-even period to the owners. Business model: Our business model targets farmers, FPOs, FPCs, rural women entrepreneurs, NGOs, and the food industry, utilizing B2C, B2B2C, and B2G2C sales strategies. Revenue is generated through direct sales of A3S units and stacked services, including agro-input advisory and market linkages, particularly benefiting rural youth and women. The market potential for drying agricultural products is immense, with a total addressable market TAM of 77 lakh crore, a serviceable available market SAM of 76,000 crore for spices, dried fruits, and nuts, and a serviceable obtainable market SOM of 76,000 crore specifically for dried chili. A3S stands out with unique selling propositions USP : year-round infrastructure for diverse crop growing and drying, additional farming services from seed to sale, automation for precision and cost efficiency, remote performance monitoring, and reliance on solar energy. Our innovative approach provides a competitive edge over existing solutions like Raheja, Aadhi solar dryers, catering to individual farmers and community-operated designs that leverage economies of scale. With its IoT-enabled controller, A3S adapts to various drying and growing needs across geographies, ensuring flexibility, enhanced ROI, and a lower payback period. We seek your support to empower small farmers and transform the agricultural landscape in India.

Current Stage of Development

Pequirel installed more than 10 A3S infrastructure in many parts of India. The major segment includes FPO and Food processing companies.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Karnataka, Maharashtra and Madhya Pradesh.

Do you want to Launch your Product in Global Bio India -2024 Event

Yes

National/Societal Relevance

So far we have egenerated following impact among farming community • 85+ farmers benefitted by A3S. • 50+ Tons for leafy vegetables dried • 44,815+ kg of chilli dried. • 50,200+ Kg of green gram dried • 9,000+ Kg Lemon peel dried • 3,20,000+ seedlings produced. • 5,24,444 INR revenue generation by pilots • 17,81,632 INR additional revenue to the farmers due to improved quality.

Technology readiness level (TRL)

TRL- 7

Title/Name of the Product/Technology

A3S Advanced adaptable agriculture Systems.

Product Positioning

At farmer level: Increasing the income of the farmers while reducing food losses at the farm gate itself. Industries: Helping food processing companies to reduce drying time by 2.5time and retaining required quality parameters essential for export market

Export Potential

The outcome of A3S is dried fruits and vegetables, The currently exported using electrical dried fruits and vegetables, Using A3S, exporter will be able to reduce the operation cost drastically.

Import Substitution

Yes. Dried tomato being imported from China because of quality parameters and price, now this can be addressed at Pequirel A3S.



Name of Startup: Pherobank technologies Pvt.Ltd



Founder and Co-founder(s):
Prof. Barkat Hussain

Developed Under (scheme):
BIG

Email:
bhatbati@rediffmail.com

Product/Technology differentiation from Competitors

Unique product Trapping both partners, no competition. another unique and cheapest product on houseflies.

Brief Description of Product

Fruit borer is a menace and directly bores into the fruit and render it unfit for consumption. The unique product which both male and female not only won the BIG grant but contain the pest still in the incursion area which has now entered into apple fruit bowl of India. from 2019, i have contain the pest still in the incursion zone by using this technology. I am using mass trapping approach and other green technologies.

Major Achievements

BIG Award Citi grant through social innovation Lab, IIT-Kanpur Vice chancellors appreciations NIT, Srinagar grant by JKDST& innovation cell and other felicitations while showcasing the technology to LG of , J&K and other administrators. Showcasing technology to Dr. Jitender Singh, Honble minster in PMO office while visiting our campus.

Current Stage of Development

Being a scientist, i have a versatile lab and other good support from all the departments.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

JK, Ladakh and few vendors to other states of India.

National/Societal Relevance

Yes

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

FishGrade: AI-based Fish Sorting and Quality Detection

Product Positioning

Excellent and great.

Product/ Technology

Cool , green and cheap too Very well aligned to BEEE Mission launched by the prime Minster of India Sustainable management of insect pest.

Unique Selling Point

20 40

Import Substitution

Yes.

Export Potential

Great scope in both developed and developoing countries.

IP Status

Yes

Name of Startup: ProteiNext India Pvt. Ltd.



Founder and Co-founder(s):

1. Founder: Mr. Debjit Saha M.Sc. Zoology with specialization in Applied Insect Science, NIDHI EIR Fellow 2021-22, BIRAC Innovation Fellow 2023-24 2. Co-founder: Dr. Amlan Das Associate Professor, Applied Insect Science Laboratory, Department of Zoology, University of Calcutta 3. Mentor: Dr. Saptarshi Chatterjee Chief Coordinator, E-YUVA Centre, Adamas University

Email:

proteinxindia@gmail.com

Product/Technology differentiation from Competitors

We farm insects as a sustainable source of protein, minimizing environmental impact. Our Insect-Pro Fish Food offers a natural, nutrient-rich alternative to low-quality conventional feeds, with essential proteins, vitamins, minerals, and good fats, mirroring fish's natural diet. We also recycle farm waste into Fertifrass, an eco-friendly biofertilizer.

Brief Description of Product

1. Live Insect: Mealworm and superworm larvae for feeding various animals, available in different sizes. 2. Protimeal: Dried mealworm larvae with added vitamins and minerals for pets. 3. MiniProti Bites: Non-insect-shaped, easy-to-handle pelleted treats made from mealworm larvae, suitable for fishes, amphibians, small mammals, and reptiles. 4. Fertifrass: Organic biofertilizer made from mealworm-based manure, environmentally friendly and easy to use for plant growth. 5. Insect-Pro Fish Food: Specialized, nutrient-rich fish food made from insect ingredients, promoting fish health, color, and growth.

Current Stage of Development

Our product has been validated in the lab and is now in the pilot phase across Kolkata, South 24 Parganas, and surrounding areas. Its available in 100+ retail stores and to 200+ individual consumers. We plan to expand distribution throughout West Bengal and nationally via online platforms after further validation.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

Currently focused on Kolkata, South 24 Parganas, and surrounding areas due to their high concentration of urban customers reliant on ready-made fish feed for their pet fish. Following this, we plan to expand distribution nationwide through online platforms.

National/Societal Relevance

With 19-25 of households owning aquariums, fish are the third most commonly kept pet. Our product addresses the need for nutritious, high-quality fish food, enhancing fish health and color. By developing an Indian brand and reducing reliance on low-quality imports, we promote Made in India for India.

Technology readiness level (TRL)

TRL-6



Title/Name of the Product/Technology

Insect-Based Solutions for Pet Nutrition and Plant Growth

Product Positioning

Positioned as an affordable, sustainable fish food alternative, offering superior nutrition and enhancing the overall well-being of pet fish.

Import Substitution

Our mealworm-based fish food replaces conventional, less nutritious feeds often imported into India, including top brands from Taiwan and Indonesia. By reducing dependence on foreign products and promoting domestic innovation, we embrace the Made in India motto and provide high-quality, locally-produced solutions for pet fish.

Export Potential

Potential to export to markets with high aquarium ownership and demand for premium, sustainable pet foods, leveraging India's expertise in insect farming.

Name of Startup: QUAESTIO LLP



Founder and Co-founder(s):
Nohid Chougale, Client solution & Product specialist Zuzer Chougale, Lead researcher

Email:

nohid.chougale@thequaestio.com

Product/Technology differentiation from Competitors

Competitors solutions to platform intelligence is usually on big industry like automotive and further the focus is on market intelligence side of the research. We uniquely combine technology and commercial intelligence seamlessly and invest in developing platforms for upcoming industry field like synthetic biology.

Brief Description of Product

Knowledge Hub - is a one-stop shop to be cognizant of industry trends and to stay abreast of technological developments. Our aim is to accelerate the adoption and development of synthetic biology. The platform offers consolidation of knowledge with newest and highly reliable trend, technology, application, expert, and market information. The next phase of product would include learning platform for educating interested students & researchers on critical basics of synthetic biology and help them stay updated on the most recent innovation and development of technology. Future iteration may also include - talents scouting, expert connect, industry events, geographical mapping of productions, consumer research, prototyping & testing connect, and more.

Current Stage of Development

We have completed the back end & front-end development of the platform in research we have reached maturity for launch, however, the comprehensiveness would be an on-going exercise.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted



Global

National/Societal Relevance

Accelerate the adoption & advancement of technology with one-stop shop solutioning approach. Also, be an enabler for student & researchers.

Technology readiness level (TRL)

TRL-8



Name of Startup: QUARKS INNOVATION LAB PVT LTD



Founder and Co-founder(s):
Dr Priyabrata Rautray Ar Avik Roy

Developed Under
(scheme):
BIG

Email:
priyabrata.rautray@gmail.com

Product/Technology differentiation from Competitors

Bio-Bricks comprise 80 agro-waste thus, they can readily convert the huge agro-waste generated after each harvest season into valuable building material. Bio-Bricks are fire-resistant and heat-resistant materials as shown by the initial tests done at KIIT University. The manufacturing process is easy and does not require any burning or heavy machinery. They have good sound-absorbing and acoustic properties due to their physical attributes. Versatile building material that can be used for different building purposes like partition walls, insulation panels, acoustic walls, etc. Bio-Bricks are economical and cost almost half the price of burnt clay bricks.

Brief Description of Product

Agricultural waste burning is a significant source of pollution in India, especially after harvesting. Bio-Brick was developed as a sustainable building material. Made out of 80 agro-waste by volume, it has the potential to create wealth from waste and also solve the issue of air pollution caused by stubble burning. This material has good thermal and sound insulation it is breathable and helps maintain comfortable living conditions during harsh summers or cold winters. Bio-Bricks are versatile and can be adapted to be used for various building types. Following are a few highlights of the project: Reducing air pollution, improving farmers income, making villages self-sufficient Atmanirbhar in building materials, and creating new jobs at the grassroots level.

Current Stage of Development

Initial testing and development of Bio-Bricks were done jointly at IIT Hyderabad and KIIT University, Bhubaneswar, Odisha. We have also won the Special Recognition Trophy for sustainable building material at the Rural Innovators Start-Up Conclave 2019, organised by the National Institute of Rural Development and Panchayati Raj NIRDPR, Hyderabad. We have received an Indian patent for Bio-Bricks and have also published three international peer-reviewed research papers. Presented Bio-Bricks at New Urban India—India@75 Conference-cum-Expo, organised by MoHUA on October 5-7, 2021. India's first Bio-Bricks based building was designed and developed at IIT Hyderabad, and inaugurated in September 2021.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Preferably the northern plains, such as Punjab, Haryana, and UP. But as India has diverse agriculture patterns, Bio-Bricks can be developed in most of the rural agriculture belts.

National/Societal Relevance

Reducing air pollution caused by stubble burning and improving the health and wellbeing of people? Create sustainable building materials from agro-waste waste to wealth? Circular economy? Create new employment at the grassroots and reduce migration? Reduce soil degradation, as they can substitute burnt clay bricks? Affordable building materials for low-cost housing in rural and peri-urban areas? Fire, heat-resistant sound-absorbing building materials

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

Bio-Bricks, a sustainable building material

Product Positioning

Bio-Bricks are sustainable building materials that can be effectively used as a brick substitute in load-bearing construction. Versatile building material that can be used for different building purposes like partition walls, insulation panels, acoustic walls, etc. Bio-Bricks are carbon-negative materials and can reduce the burden on natural resources.

Import Substitution

Bio-Bricks can be effectively used for sound and heat insulation, thereby reducing the need for synthetic PU foam. Bio-Bricks material can be used for packaging, thereby reducing the demand for petroleum-based thermocol.

Export Potential

Bio-Bricks due to their excellent heat and sound insulation properties, can be exported to European countries for construction purposes. As there is rise in the demand for sustainable construction material it can be readily exported as green building material.

IP Status

Patent No. - 361280 Patent Title - Eco-Friendly Bio-Bricks and Process of Preparation Thereof Inventors - Priyabrata Rautray, Avik Roy and Nibedit Dey.

Name of Startup: REINSTE NANO VENTURES PRIVATE LIMITED



Founder and Co-founder(s):
Puneet Mehrotra
Dr Archana Mehrotra

Email:
info@reinste.com

Product/Technology differentiation from Competitors

The product covers more surface and are 2100 cost effective compare to the other products available.

Brief Description of Product

Warrior Coatings are Nanotechnology based coatings which are 99.9 effective on wide range of pathogenic Microorganisms including Virus. The product is tested & certified from different government bodies like National Forensic Science University, Shree Chitra Trimul Institute. The product is Non toxic to humans and has 99.9 killing rate of pathogenic microbes. The coating works 24*7 and neutralizes the microbes which come in contact with this coating. The Coatings are extremely cost effective and are ideally suited in wide situations, surfaces and environments and are available for all kind of surfaces.

Current Stage of Development

Ready for Commercialisation.

Are you willing to Transfer / Out-License your Technology YES

Geographical Region Targeted

All over the world.

National/Societal Relevance

Warrior TM Coatings are Nanotechnology based coatings which are 99.9 effective on wide range of Pathogenic Microorganisms including Virus. The product is tested & certified from different government bodies like National Forensic Science University, Shree Chitra Trimul Institute. The product is Nontoxic to humans and has 99.9 killing rate of pathogenic microbes. The coating works 24*7 and neutralizes the microbes which come in contact with this coating.

Technology readiness level (TRL)

TRL-8



Thematic Area: RESOLVE BIOTECH PVT. LTD.

RESOLVE

Founder and Co-founder(s):
MR. RAM KHANNA - FOUNDER
DR. RITWIK DAHAKE - CO-FOUNDER

Developed Under
(scheme):
BIG, SEED Fund

Email:
ram.k@resolvebiotech.com

Product/Technology differentiation from Competitors

Patented design and made in India using industrial 3D printing technology Two independent heads, with option for different heads and separate volumes, liquid and configurable programs Zero down time as second pump can act as a backup in case one break downs specially during critical transfers Ideal for aseptic, sheer sensitive, viscous, corrosive liquids and for low pulsation requirements Designed to save critical cleanroom space with option of cascading multiple stations Ability to double production without any additional capex GMP compliant with activity data log and blue tooth printer

Brief Description of Product

BioDuo is a patented peristaltic pump allowing for multi-head simultaneous solutions for low and high volumes. It also allows for low pulsation modes specially required for tablet coating in pharma industry. FillBot is an Automated Liquid Handling and Filling system is designed to bring in industrial automation and production efficiency in bioprocessing and pharma industry. Indigenous designed, developed and made in India using industrial 3D printing technology, the BioDuo peristaltic pump and FillBot Filling Stations can be widely used for multiple applications in biotechnology, vaccines & diagnostics, pharmaceutical, lab chemical industry. They provide accuracy, repeatability and a failsafe solution for achieving zero downtime where continuous fluid transfer is of utmost importance. Equipped with dual head pump, compact and ergonomic design, and touch screen interface, the product is extremely user-friendly. The FillBot station is configurable for small batches 0.5 ml to 5000 ml of aseptic & non-aseptic fill/finish system and it uses BioDuo peristaltic pump to bring in precise accuracy, aseptic filling and no contact with equipment parts and hence no risks of cross-contamination. The combination of both the products, BioDuo and FillBot makes them extremely suitable for various applications such as fluid transfers, buffer and culture media filling, fermentation, harvesting cell media, purification and filtration, metering, dosing and dispensing, liquid filling, tablet coating in Biotech and Pharma industries. The system can handle viscous liquids without causing cleaning issues, prevention of frothing and can also be mounted on existing lines. The filling speed and volume can be programmed and saved to meet the specific requirements of the application. BioDuo Versions: Transfer Mode: Variable RPM, Flow Rate Dispensing Mode: Single Dose, Multi-Dose Flow Rate: Up to 2000 ml/min Pump Head Options: Small: H200 0.01 ml/min to 200 ml/min Large: H2000 0.5 ml/min to 2000 ml/min Both heads can be different in single pump FillBot Versions: FillBot 1 Standalone - Flow rate based with single /double/triple axis FillBot 2 Standalone - Weight Based with single/double/triple axis FillBot Retro Customizable solution for existing lines Key Features of BioDuo Pump & FillBot: Two independent pumps in One for multiple applications Zero Production Downtime with in-built redundancy Achieve doubling of production in no time without additional capex Automated system based on weight / volume fills Avoids shearing of biomolecules and substance damage Drip-less operation with no-vial no fill sensor to prevent miss filling and contamination of the filling environment Maintain Continuity and Prevent Disruptions by enabling Auto Resume Feature Activity logging for GMP compliance along with separate user profiles for different access levels Ergonomic design to save precious clean room space Easy to Operate, Auto-Calibrate, Low maintenance and Higher productivity Visual Cues and Led Indicators, Screen Lock, Sensor based Safety lid Digital Vial Counter for counting production output Ensures user safety and prevents accidents using sensor-based lid Anti-slip feature to avoid tube sliding, CE and IP31 Rating ready, 2 Bar pressure.

Current Stage of Development

Product has been commercialized in April 2024. Website: www.resolvebiotech.com / www.bioduo.in / www.resolvebiotech.com/fillbot.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Domestic India: FillBot and BioDuo Peristaltic Pump International: Europe, USA and other countries for Peristaltic BioDuo Pump.

Product/Technology

BioDuo is designed using industrial 3D printing where frothing, shearing of molecules and substance degradation is a major issue for continuous operation in bioprocess. Designed to be mounted on existing conveyor or separately, the FillBot system caters to Biopharma industry where industrial automation can achieve higher efficiency and reduced wastage.

Unique Selling Point

Ultra compact 2-in-1 for optimum use of critical cleanroom space Can be mounted on existing lines Precision filling Accuracy of ± 0.5 with multiple programs Compatible with abrasive and corrosive liquids No shearing of biomolecules and no tube slipping Manufactured using industrial 3D printing technology.

Technology readiness level (TRL)
TRL-9

Title/Name of the Product/Technology

BIODUO Peristaltic Pump & FILLBOT Automated Liquid Handling & Filling Stations

Product Positioning

Designed, developed and Made- in- India using industrial 3D printing technology, the BioDuo Peristaltic Pump and FillBot Liquid Filling Station cater exclusively to Biotech and Pharma Industry for various applications with in-built redundancy, automation and host of multiple features at a price substantially lower than global players.

Import Substitution

Reduced dependency on chinese and expensive imported peristaltic pump by providing more features and superior quality with local after sales service and updates.

National/Societal Relevance

Key product in Bio processing and Pharma application, requiring regular calibration is used for all liquid transfers and aseptic filling for zero cross contamination. Most of the pumps and filling lines are imported with very little after sales support.

Export Potential

BioDuo Pump can be exported to all major biotech companies in Europe, USA and other leading Biotech hubs across multiple countries.

IP Status

Design Patents filed and their status: India: 383449-001 - Status Approved Europe: 015036318-0001 - Status Approved USA: 29904432 - Status: Awaiting approval Filed on 6th October 2023 Functional patent: Provisional Patent filed on 12th September 2024 - Application no: 202321062277

Name of Startup: REVY ENVIRONMENTAL SOLUTIONS PVT. LTD.



Founder and Co-founder(s):
Dr. Vanita Prasad Founder & CTO
Mr. Rajneesh Prasad Director & CEO
Mr. Bhavik Kathrani Co-Founder & CFO

Developed Under
(scheme):
BIG, SPARSH

Email:
vanita.prasad@revy.co.in

Product/Technology differentiation from Competitors

REVV product contains 10-15 of right Archea micorbes than the closest global competitor Paques and 90 more as compared to Indian competitors, hence requires lesser time and effort to commission and maintain anaerobic reactors.

Brief Description of Product

REVV has developed "Designer Bio-culture" using IP protected combinations of bacteria/microorganisms in form of Anaerobic Granulated Sludge - containing 650 different microbes and Biomass Growth Enhancement Formulations BGEF that can treat organic waste/wastewater. REVV has also developed unique consortia for converting organic waste to Bio-Hydrogen. These bio-cultures can treat hard effluents like petroleum, chemicals, dyes, etc. and convert waste into re-usable products such as Bio-methane and Bio-Energy. REVVs innovation helps to reduce downtime for Bio-methane plants which inturn helps to solve the global crisis of food, water and energy and aid in reduction of total global carbon footprint. To support this product application and to create a better user experience the company has also developed an App called R-EMAPP which can track day-to-day performance of these biologicals in reactors remotely.

Current Stage of Development

Ready to License

Are you willing to Transfer/ Out-License your Technology YES

Geographical Region Targeted


PAN India further extending across international borders Nepal and Bangladesh and going global having already granted patents for USA, Malaysia, South Africa, Europe.

National/Societal Relevance

Waste management and sewage treatment are a part of public health and sanitation entrusted to municipal government for execution. Presently, the systems are assuming larger importance due to population explosion in municipal areas, legal intervention, emergence of newer technologies and raising of public awareness towards cleanliness. Only 21 of wastewater generated is treated. Around 60 of the effluent generated by the industries goes untreated into ecosystem. Thus, there is being an urgent need for efficient water resource management through enhanced water use efficiency and wastewater recycling. The problem can be mitigated by the adoption of cost-effective eco- friendly technologies for wastewater treatment.

Technology readiness level (TRL)

TRL-7



Title/Name of the Product/Technology

130 of 500 words limit 3 of 100 words limit Production and providing scientifically proven products Anaerobic Granulated Sludge and Biomass Growth Enhancement Formulations and services Customized APP service - R-EMAPP for end-to-end microbial health management in anaerobic reactors and enabling optimized organic waste/wastewater treatment along with renewable energy generation

Product Positioning

PEPSICO, Grasim Industries, Reliance Industries, Banas Dairy, GESCSL CETP Vatva, Transpek, Stagot Potatoes LLP, Xeon Waste Managers, DCM Sugar Mills, SampurnEarth, Sumul Dairy, Rajkot Dairy, YashPakka, Municipal STPs, Industrial ETPs, etc.

Import Substitution

The present innovation offers substitution to both a the available AGS products which are not only costly but also use artificial polymers in process of granulation. b To the Import of engineered biomass which is highly regulated/restricted.

Export Potential

Technology has potential for export. The company has started scouting for potential partners for creating offshore JV.

IP Status

Patent granted in India, USA, South Africa, Malaysia, and Europe for an economical process for preparation of anaerobic granules for waste water treatment



Name of Startup: Rigel Bioenviron Solutions Pvt Ltd



Founder and Co-founder(s):
Dr. Partha Chakravarty
Dr. Sanchita Mukherjee

Developed Under
(scheme):
BIG

Email:
send2sanchita@gmail.com

Product/Technology differentiation from Competitors

There is no competitor in India who has demonstrated the waste to PHA bioplastic production. Globally there were two consortiums in EU, the Phario project and Afterlife, who has worked on the similar technology building. Currently there are very few PHA producers globally who use pure feedstock for production instead of waste. We are producing PHA from waste only.

Brief Description of Product

A single technology addressing two waste streams A valorizing agro wastewater, to produce a bioplastic which reduces B plastic waste pollution, by substituting non-renewable, fossil based petrochemical plastics of recalcitrant nature in various applications and getting completely biodegraded in the environment at the end of its useful life. 1. Produce PHA at low cost in agro WWTP 2. Use up WWTP waste biosludge in PHA harvesting, thus eliminating hazardous sludge disposal problem 3. Single input points contrary to other processes with multiple input points/accompanying side stream reactors 4. Significant cost saving in large scale - continuous mode bio processing Polyhydroxyalkanoates PHAs are a family of bioplastics that are synthesized and intra-cellularly accumulated as a carbon and energy storage material by various microorganisms. It is completely non-toxic and currently the most sought-after bioplastic having very high price in pure form. Our breakthrough in PHA production technology is for producing PHA from wastewater in continuous mode reactor systems. With the BIG16 grant we have successfully run industrial pilot plant for PHA production from bacterial biomass from waste water based on the above concept at a large grain-based distillery.

Current Stage of Development

We have demonstrated the PHA biodegradable plastic production with a 200lp capacity industrial pilot plant at the actual industrial effluent treatment plant facility using the waste water from the ETP.


Are you willing to Transfer /Out-License your Technology Yes

Geographical Region Targeted

India, Mauritius started and any other region having high waste potential.

Technology readiness level (TRL)

TRL-6



Title/Name of the Product/Technology

Polyhydroxy alkanate PHA based bioplastic from agro waste water - technology for production of bioplastics from waste organics

Product Positioning

PHA today is a highly sought biopolymer globally because it is naturally biodegradable and having similar properties of PP. This polymer has its high-end usage for bio medical applications already, also being accepted as a very good packaging product. Already RIGEL has signed an NDA with food and sugarcane manufacturers.

Import Substitution

India's bioplastics market is presently dependent on import of raw granules / products from various developed countries. With stringent Indian Govt. norms on usage of conventional plastics, the present technology to produce PHA indigenous will definitely be an Import substitute.

National/Societal Relevance

- Bioplastic market price is 1.5 - 2 folds high PHA blend 7-10 times higher than conventional plastics - RIGEL's approach is to use wastewater/ agro wastes to drastically reduce substrate cost as well as utilizing waste minimization cost offset - thus dipping down at least 30 - 40 of total production cost of the bioplastics.
- PHA being the best-in-class bioplastic, completely non-toxic and biodegradable, can replace the conventional plastic in all areas
- Huge global demand as single use conventional plastics are being banned slowly in global perspective including India.

Export Potential

Demand for PHA as on 2022 was USD 81 Million. The Global PHA market is projected to reach USD 167 million by 2027 at a CAGR 15.3. Source: Market & markets

IP Status

1. Already granted patent: No. 288052: Process for Production of Polyhydroxy alkenoates from industrial wastewaters in continuous mode reactor system
2. Patent Application-202431004257, filing date 22-01-2024 under review.

Name of Startup: RNA BIOTECH PVT LTD



Founder and Co-founder(s):
Dr. Amaresh C. Panda

Email:
rnabio.pvt.ltd@gmail.com

Product/Technology differentiation from Competitors

Most companies use silica-based columns for RNA purification, which often results in genomic DNA contamination. In contrast, our kits use magnetic silica beads, ensuring DNA-free long RNA and microRNA. Additionally, our RNA isolation kit is efficient and providing a quick solution for isolating DNA-free total RNA, including mRNAs.

Brief Description of Product

Current RNA purification methods widely use silica-based columns that allow quick isolation of high quality and right quantities of RNA. However, the major limitations include high cost, the requirement of different kits for small RNA isolation, genomic DNA gDNA contamination, and not being flexible. To overcome the expensive and time-consuming DNase digestion issue, we use silica column to deplete the gDNA from the cell lysate before isolating high-quality DNA-free total RNA using magnetic silica beads. Furthermore, our proposed magnetic bead-based total RNA isolation kit provides an option to isolate DNA-free long RNA and microRNAs separately for microRNA studies which usually needs a special kit.

Current Stage of Development

Prototype development for other kits.

Are you willing to Transfer / Out-License your Technology No

Geographical Region Targeted

All over India

Technology readiness level (TRL)

TRL-6



Name of Startup: Ronds Technologies Pvt Ltd



Founder and Co-founder(s):
Sijo Joseph

Developed Under
(scheme):
SEED Fund

Email:
sijo.joseph@rondstech.com

Product/Technology differentiation from Competitors

1.Multi-Crop and Growth Stage Management: GrowMate is designed to handle multiple crops and growth stages simultaneously, allowing for efficient farm operations in diverse environments. 2.Self-Learning Optimization: GrowMate continuously collects data and employs self-learning algorithms to develop the most effective growth models for each crop. Over time, it refines these models, adapting to the unique needs of different plants and environments, leading to improved yield and efficiency. 3. All-in-One Solution for Smart Farming: It automates and optimizes nutrient dosing, irrigation, climate control, and overall greenhouse management. It is capable of handling multiple crops and growth stages.

Brief Description of Product

GrowMate is an advanced automation device leveraging AI and IoT to optimize plant growth and enhance farming efficiency. It offers a complete solution for smart farming, combining automated nutrient dosing and intelligent farm management. GrowMate harnesses cutting-edge technology to provide real-time insights, dynamic decision-making, and comprehensive farm control. Key Benefits: 1.AI-powered automated nutrient dosing tailored to plant growth stages 2.Real-time monitoring of critical growth parameters 3.Greenhouse monitoring and full automation 4.Smart irrigation management for precise water usage 5.Daily reports and alerts for key events 6.Growth stage tracking with adaptive dosing 7.Data-driven decisions with AI and IoT integration 8.Remote farm management via cloud platform

Current Stage of Development

GrowMate transforms farming by maximizing productivity, promoting sustainability, and simplifying farm operations. The product is developed, pilot installation is running at multiple locations. We are focussed on pre commercialisation activities and data collection now.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Middle East

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

GrowMate: Revolutionizing Smart Farming with AI and IoT

Product Positioning

Our product offers a fully automated solution for greenhouse management, featuring continuous monitoring and dosing precisely tailored to your plants needs. With advanced machine learning algorithms, it fine-tunes best practices, optimizes performance, and takes proactive action when critical levels are detected.

Import Substitution

As a domestically developed and manufactured product, GrowMate fosters self-reliance by offering advanced greenhouse automation, irrigation management, and nutrient dosing systems tailored to local farming needs. By promoting local innovation in agri-tech, GrowMate helps replace expensive foreign products, and boosting India's economy. It supports the "Make in India" initiatives.

National/Societal Relevance

The automated greenhouse system boosts agricultural productivity and sustainability in India by optimizing crop conditions with precise monitoring and dosing. It conserves water and resources, reducing manual labor and enhancing crop yields. Leveraging machine learning, it fine-tunes best practices, making agriculture more efficient and resilient in the face of climate challenges

Export Potential

The system's ability to manage diverse environments and crop types makes it appealing in international markets, especially in regions where greenhouse automation and precision farming are growing. By offering a cost-effective and innovative product, GrowMate positions itself as a competitive player in the global agri-tech industry.

Name of Startup: Sah Astitva



Founder and Co-founder(s):
Meet Joshi, Suhani Patel,
Dr. Madhukant Patel,
Kartik More, Poorav Shelat

Email:
info@sahastitva.org

Product/Technology differentiation from Competitors

Precision beekeeping leverages Internet of Things (IoT) devices to enhance hive management and monitoring. By integrating IoT sensors into beehives, beekeepers collect real-time data on environmental factors and hive conditions, enabling precise and proactive management. These devices monitor parameters like temperature, humidity, hive weight, and bee health indicators. Integrated systems analyze this data, offering advanced analytics and decision support, predicting hive behavior, and recommending interventions. Precision beekeeping improves bee health, reduces colony losses, and increases productivity, marking a significant advancement in modern beekeeping by optimizing hive management and supporting the conservation of vital pollinators.

Brief Description of Product

An Integrated Hive Management System (IHMS) that utilises advanced sensors, edge computing, and IoT to monitor in-hive and peripheral environmental conditions in real-time. A handheld spectrometer for non-invasive honey quality assessment, focusing on detecting adulteration and moisture levels. This will lead to a fully functional Apicary Management System with real-time data processing, operational smart hives, a portable honey quality assessment device, and AI models for hive anomaly prediction and crop management. Our solution is a combination of in-hive sensors and an on-field real-time honey testing device: Real-time Data Transmission: The data collected by the sensors would be transmitted in real-time to a centralized platform accessible to beekeepers via a smartphone app or web interface. This enables remote monitoring and management of hive conditions. Alert System: An alert system would be implemented to notify beekeepers of any deviations from optimal hive conditions, such as temperature fluctuations, unusual bee behavior, or signs of disease or pest infestation. Data Analytics: Advanced analytics tools would analyze the collected data to provide insights into hive health, productivity trends, and potential issues, empowering beekeepers to make informed decisions. Environmental Insights: Data collected from environmental sensors benefits beekeeping practices and contributes valuable insights into local ecosystem health and biodiversity. Non-Destructive Sampling: A honey testing device utilizes non-destructive methods to extract small samples for analysis, minimizing disruption to the bees and hive operations. Quality Assurance: Honey testing ensures that harvested honey meets quality standards, fostering consumer trust and satisfaction. Instant Feedback: Results from honey testing are transmitted in real-time to the beekeepers interface, providing instant feedback on the quality and purity of the harvested honey. Historical Data Analysis: The system stores historical data on honey quality, allowing beekeepers to track trends over time and make informed decisions regarding hive management practices. Educational Tool: This technology serves as an educational tool, helping beekeepers deepen their understanding of bee behavior and honey production processes. Apiculture Marketplace: An Apiculture Marketplace with an integrated network of data-yielding beehives could revolutionize the beekeeping industry by providing a centralized platform for beekeepers to manage their operations and sell various bee products such as honey, beeswax, propolis, pollen, royal jelly, and even live bee colonies.

Current Stage of Development

The project is at TRL 3, with successful development and lab testing of the IoT-enabled Smart Hive prototype and the handheld spectrometer for honey quality assessment. These prototypes include essential sensors and have demonstrated accurate data collection and initial analysis capabilities in controlled settings.

Are you willing to Transfer/ Out-License your Technology Yes

Geographical Region Targeted

We are working with farmers who grow crop impacted directly by honey bees, the geographical region enclosed by such crops are our target regions starting from Gujarat and Uttarakhand. We aim to cover every farmer in India that grow crops pollinated by honey bees.

National/Societal Relevance

Beekeeping is vital for rural livelihoods in India, and IoT-enabled beehives can significantly boost honey yields and incomes. This technology introduces opportunities for skill development, empowering communities with modern knowledge and enhancing their employability. Bees are essential for pollination and environmental health, and improved beekeeping practices through IoT can help preserve biodiversity and promote sustainable agriculture. Additionally, real-time honey testing devices ensure product quality, addressing concerns of adulteration and fostering consumer trust. This initiative not only supports economic empowerment but also contributes to environmental conservation and a more transparent honey industry.

Technology readiness level (TRL)

TRL-3



Title/Name of the Product/Technology

Smart Beehive Management System with Integrated Sensors, AI, and Spectrometry for Sustainable Apiculture and Honey Quality Assessment

Product Positioning

To Farmers, NGOs, Agri-Scientists/Agri Universities, End Users, Beekeeping experts, Beekeeping Organisation Heads, and Honey factories, Sah Astitva is the Agri-technology brand that simplifies data gathering and provides actionable outcomes to the farmer, beekeeper, and other stakeholders. It also simplifies and organises quality assessment of products. The cost is tentative cost.

Export Potential

This technology enhances productivity, ensures honey quality, and improves bee health, making it valuable for sustainable beekeeping markets. Its real-time testing boosts traceability and competitiveness in international markets, meeting global standards for purity and sustainability, and positioning it for expansion in established and emerging beekeeping regions.

Import Substitution

Weve developed a non-invasive honey spectrometer,leveraging Indian expertise and resources. We designed software, IoT technology, Bio-software models, machine learning, AI optics, PCB, and embedded hardware & avoiding imports. Our innovative solution is uniquely tailored for honey analysis, demonstrating our commitment innovation.

Name of Startup: Sanovaskale Technologies Pvt Ltd



Founder and Co-founder(s):
Dr. Smita Kale

Email:
director@sanovaskale.com

Product/Technology differentiation from Competitors

Chemo-enzymatic process, continuous process and over 60 conversions in single step.

Brief Description of Product

We have developed indigenous process technology for production of Lactose and Lactulose from milk whey or permeate. Lactose is a sugar found in milk that has many applications in food and pharmaceutical industries. Lactose is used as an excipient in oral, solid-dose formulations and in tablets, inhalations etc. Lactulose is a prebiotic disaccharide, and is used as an essential medicine as per WHO in the treatment of encephalopathy and constipation both in humans and animals. Both Lactose and Lactulose have a great demand worldwide. There are very few players in India making Lactose and Lactulose and are mostly imported to India. Therefore, India being the largest milk producing country, our new technology for continuous production of Lactose and conversion of Lactose to Lactulose by chemo/enzymatic method will be a very important process technology for the Country and even worldwide.

Current Stage of Development

We have successfully developed and performed pilot level scale up of the lactose and lactulose technology. Technology has been licensed to one company and can be transferred with engineering to others.


Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Europe, US and Australia

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

Lactose and Lactulose Production process Technology

Import Substitution

Today, India imports over 80 of lactose and over 90 of lactulose from Europe, US and Canada. Therefore, our improved and new technology will enable substantial import substitution.

Export Potential

Both lactose and lactulose demand is increasing globally and milk is only starting material for both lactose and lactulose. Therefore, India has great potential to export both products to many countries.

Major Achievements

Team has successfully transferred 4 commercial scale processes and helped with commissioning of full commercial plants for health supplement products and essential medicines

Name of Startup: Scitechsey Research & Technology Pvt. Ltd.



Founder and Co-founder(s):
Dr. Fanindra Pati Pandey Founder
Mr. Ashish Dubey Co-founder
Mr. Laxman Kumar Nasarpuri Co-founder

Developed Under (scheme):
BIG, BioNEST, SEED Fund

Email:
director@scitechsey.com

Product/Technology differentiation from Competitors

Scitechsey Research & Technology Private Limited, founded in 2021, distinguishes its products and technology through several key elements. Specializing in high-quality silver nanoparticle-based products like silver powder, conductive paste, nanoparticles, and metal nano powder, the company is known for its precision, compact design, and flawless finish. Scitechsey consistently launches new products tailored to client requirements and adhering to international standards, reflecting its dedication to innovation and market needs. With a modern production base, skilled workforce, and ethical business practices, the company provides value-added and efficient products within client's budgets.

Brief Description of Product

Silver nanoparticles AgNPs have become an important area of research in biotechnology due to their unique physical and chemical properties. The biological synthesis of AgNPs using microorganisms like bacteria, fungi, and algae is considered a green and environmentally friendly approach, as it avoids the use of harsh chemicals. These biologically synthesized AgNPs have shown promising applications in antimicrobial therapy, anticancer treatment, wound healing, biosensing, and more. The size, shape, and stability of the AgNPs can be controlled by using different capping agents, which is crucial for optimizing their biological activities. Overall, the development of efficient and sustainable methods for AgNP synthesis, along with a deeper understanding of their mechanisms of action, is an active area of research in the field of biotechnology.

Current Stage of Development

Scitechsey Research & Technology Private Limited, established in 2021, is currently at a stage of rapid development. The company is involved in the manufacture and supply of silver nanoparticles-based products, including silver powder, conductive paste, nanoparticles, and metal nanopowder. These products are highly demanded due to their dimensional accuracy, compact design, and seamless finish. The company has grown significantly by offering value-added and effective products within client's budgets, and it continues to introduce new products according to client needs and international quality standards.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

PAN India then exports

National/Societal Relevance

Appreciated by Doctors

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

Nanotechnology is the science and engineering of designing, producing, and using structures, devices, and systems by controlling matter at the nanoscale, which is typically defined as 1 to 100 nanometers nm in size. This scale is significant because it allows for the manipulation of matter where surface area and quantum mechanical effects become dominant, leading to unique properties not observed in larger structures.

Product Positioning

In the market

Name of Startup: Scylene Wellness Pvt Ltd



Founder and Co-founder(s):
Amit Kumar Sahu
Shrestha Patel

Developed Under
(scheme):
BioNEST

Email:
care@wishfit.in

Product/Technology differentiation from Competitors

Superior Protein Blend: Pea and brown rice proteins. No Added Sugars, Colors, or Artificial Additives: Pure and natural. Enhanced Bioavailability: Maximizes nutrient absorption. All Essential Amino Acids: Comprehensive muscle support. Gut Friendly: Contains digestive enzymes and probiotics. Allergen-Free: Free from gluten, dairy, and soy. Superfoods: Includes Moringa and Spirulina for added nutrition. Sustainable and Ethical: Eco-friendly packaging and responsibly sourced ingredients. Culinary Versatility: Ideal for smoothies, cooking, and baking.

Brief Description of Product

WishFit Plant Protein Powder stands out as the pinnacle of innovation in the realm of plant-based nutrition. Unlike conventional protein powders, WishFit harnesses the power of cutting-edge science and nature's finest ingredients to deliver a product that is unrivaled in quality and efficacy. Key Features: Superior Protein Blend: WishFit combines a unique mix of plant proteins, including pea, brown rice, and superfoods like Moringa and Spirulina, ensuring a complete amino acid profile present for optimal muscle recovery and growth. Enhanced Bioavailability: Our proprietary formulation enhances nutrient absorption, making WishFit more effective than standard protein powders. Natural and Pure: Made from 100 natural ingredients, WishFit is free from artificial additives, preservatives, and GMOs. It is also allergen-friendly, catering to a wide range of dietary needs. Advanced Digestive Support: Enriched with digestive enzymes and probiotics, WishFit promotes gut health and maximizes nutrient uptake. Sustainable and Ethical: Committed to sustainability, WishFit sources its ingredients responsibly and uses eco-friendly packaging, making it a choice that benefits both you and the planet. Delicious and Versatile: Available in a variety of flavors, WishFit can be seamlessly integrated into smoothies, shakes, and recipes, adding a nutritious boost to your daily diet. Culinary Versatility: WishFit's versatility extends beyond traditional protein shakes. It can be used in cooking, baking, and more, transforming everyday meals into protein-rich delights without compromising on taste or texture.

Current Stage of Development

We introduced MVP to the market 10 months earlier to gather consumer feedback and validate the concept with minimal investment. After refining the product based on feedback from the MVP stage, we are about to launch the product in its best form to a pan india market within a month.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

WishFit Plant Protein Powder is strategically targeted at the global market, with a primary focus on India, North America, Europe, and Other countries of Asia. These regions are experiencing significant growth in the health and wellness sector, with increasing demand for high-quality, plant-based nutrition products.

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

GrowMate: Revolutionizing Smart Farming with AI and IoT

Product Positioning

E-commerce sites and Own Website.

Import Substitution

WishFit Plant Protein Powder exemplifies import substitution by sourcing, extracting, and developing entirely within India. Utilizing locally sourced plant proteins and advanced extraction methods, such as cold-press technology, WishFit minimizes reliance on imported ingredients. This approach enhances self-sufficiency, supports local industry, and drives economic growth.

National/Societal Relevance

WishFit Plant Protein Powder addresses critical societal trends by reducing human dependency on animal protein sources and leveraging the full potential of plant superfoods. It supports sustainable, health-conscious lifestyles and meets growing demand for allergen-free, ethical nutrition. This product fosters healthier diets and promotes environmental sustainability.

Export Potential

WishFit Plant Protein Powder offers strong export potential with its unique formulation and advanced extraction methods. Targeting health-conscious markets in North America, Europe, and other countries of Asia, it meets global demands for Vegan, sustainable protein sources, allergen-free nutrition, ensuring competitiveness and broad appeal in international markets.

Name of Startup: SearchMyTenders



Founder and Co-founder(s):
Niraj Rani Founder & CEO,
Kumar Skand Co-Founder

Developed Under
(scheme):
NAT

Email:
ginny@searchmytenders.com

Product/Technology differentiation from Competitors

End-to-end, holistic tender services and solutions provider, having launched industry's first L1-bid value prediction tool.

Brief Description of Product

An aggregation platform connecting and supporting the MSMEs and the Government to increase their efficiency in doing business together. We support MSME businesses based in India in growing their topline by providing them end-to-end, holistic tender solutions so that they gain a competitive edge in bidding and winning tenders.

Current Stage of Development

Product launched and tested successfully in the market with 1000+ paid customers and 4000+ freemium customers.


Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Pan-India B2B and B2G levels

Technology readiness level (TRL)

TRL-9





Name of Startup: Serione



Founder and Co-founder(s):
1. Jayant Bhoopalam
2. Akhila Jayaram

Email:
jayant@serione.com

Product/Technology differentiation from Competitors

We are a first of its Kind Made in India, Circular Economy, High Value, Low Environmental Impact Silk Protein Manufacturer out of India. Our process is clean, eco-friendly & sustainable. We have also been able to match our prices Internationally and hence a great alternative to China Silk Proteins.

Brief Description of Product

Silk proteins, derived from silkworms, are versatile biomaterials with applications in cosmetics, agriculture, biomaterials, and food industries. In cosmetics, silk proteins moisturize, protect skin, and provide anti-aging benefits. They form a protective film, retaining moisture and improving skin elasticity. For agriculture, silk-based coatings extend the shelf life of produce by reducing moisture loss and gas exchange. As biomaterials, silk proteins are biocompatible, biodegradable, and have low immunogenicity, making them ideal for tissue engineering, wound dressings, and drug delivery systems. In food, silk proteins can improve texture, nutritional value, and act as natural emulsifiers and stabilizers. Key properties enabling these applications include: 1. Biocompatibility and biodegradability 2. Tunable mechanical strength 3. Antioxidant and antimicrobial properties 4. Film-forming ability 5. Versatility in processing These properties, along with eco-friendly production, make silk proteins promising for sustainable innovations across industries.

Current Stage of Development

We have successfully extracted high-quality silk proteins from various sources and identified the most effective ones for specific applications. Our current focus is on refining these proteins into specialized ingredients tailored for cosmetics, agriculture, biomaterials, and food industries. By understanding and leveraging the unique properties of silk proteins, we are transitioning from generic raw materials to industry-specific solutions. This targeted approach enhances the efficacy and benefits of silk proteins, allowing us to meet the distinct needs of each sector and position ourselves as leaders in silk protein innovation.

Are you willing to Transfer/Out-License your Technology Yes

National/Societal Relevance

India, the world's second-largest silk cocoon producer, generates 35,000 tons annually, with over half used in textiles. The silk processing industry faces sustainability challenges, particularly in water usage and protein waste. During production, sericin, a protein-rich material comprising 25 of the cocoons weight, is discarded, leading to significant water waste and loss of a valuable resource. This practice exacerbates India's water scarcity issues and overlooks potential applications for sericin in agriculture, cosmetics, and biomaterials. Developing innovative sericin recovery systems is crucial for India's sustainable development, offering opportunities to conserve water, create new revenue streams, reduce pollution, and promote circular economy principles in the textile industry.

Geographical Region Targeted

India, USA, Korea, Europe & Japan

Product Launched / About to be Launched

Product Launched

Do you want to Launch your Product in Global Bio India -2024 Event Yes

Technology readiness level (TRL)

TRL-7



Title/Name of the Product/Technology

Silk Protein raw ingredient for Cosmetics, Agriculture, Biomaterials, Textile & Food applications.

Product Positioning

Silk proteins are premium biomaterials offering versatile applications: as bio stimulants or nitrogen sources in agriculture, enhancing post-harvest food preservation, serving as active ingredients in cosmetics, and as bioinks for 3D printing. Their multifunctionality and natural origin make them ideal for innovative, sustainable solutions across diverse industries.

Name of Startup: SM Biologics Consultants



Founder and Co-founder(s):
Palanivel - Founder

Email:
palanivel.sm@smbcsing.com

Product/Technology differentiation from Competitors

Home grown expertise with international experience and would be trusted and provide consistent partnership.

Brief Description of Product

Engineering design consultant for the single use and Stainless-steel facility from the feasibility stage to GMP hand over. Also specialised in Equipment sourcing, skilled resource provider as consultant. In addition to that we have team for technical document drafting services.

Current Stage of Development

Already executed the Base and detailed design for Single use facility and stainless-steel facility.

Are you willing to Transfer / Out-License your Technology No

Geographical Region Targeted

Asia, Europe

National/Societal Relevance

When design comes with quality and lean approach it leads overall cost reduction which ultimately helps the user end in several instances its the patients who consume Biopharmaceutical process based drugs

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

Engineering design consultant for the single use and Stainless-steel facility from the feasibility stage to GMP hand over. Also specialised in Equipment sourcing, skilled resource provider as consultant. In addition to that we have team for technical document drafting services

Product Positioning

Shall execute Process economics to analyze it for market viability

Name of Startup: Sodhani Biotech Pvt. Ltd.

**SODHANI
BIOTECH** PVT. LTD

Founder and Co-founder(s):
Founder: Sidhant Sodhani
Co-Founder: Krishna Devi

Developed Under
(scheme):
BioNEST

Email:
info@naturaldyes.in

Product/Technology differentiation from Competitors

We utilize wild microbes to produce our dyes and operate an in-house dyeing facility that simplifies the fabric dyeing process. This integrated setup addresses a common challenge faced by other industries.

Brief Description of Product

Microbial dyes are eco-friendly pigments produced through the fermentation of wild microorganisms. We have worked on yellow, pink, and blue dyes that offer a sustainable alternative to synthetic dyes, providing vibrant colors with minimal environmental impact. Microbial dyes are biodegradable and free from harmful chemicals that replace synthetic dyes overcoming shade limitation and improving light fastness with a greener process.

Current Stage of Development

Scientific experimental design was applied to systematically optimize dyeing parameters such as dye concentration, temperature, and time. The growth conditions of bacteria are also optimized. We have successfully produced a blue pigment in 2000 ml shake flasks and are now scaling up production to 20L-50L flasks. This pigment is derived by cultivating bacteria in shake flasks at 20-25°C for 5-7 days in a medium with peptone, glucose, and common salt at a pH of 6-7. We have tested the microbial dye on various fabrics, including cotton, wool, and silk. However, the blue-producing bacteria have a long growth period

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Our primary focus is on expanding our market in India

Technology readiness level (TRL)

TRL-4



Title/Name of the Product/Technology

Decarbonizing Textile Dyeing using Microbial Dyes

Product Positioning

Our main focus is to work on blue highlighting men's fashion. Unlike traditional dyeing methods that rely on synthetic chemicals, microbial dyes offer sustainable alternative with minimal environmental impact. Wild microbes are used to produce vibrant, eco-friendly dyes. The unique in-house dyeing facility ensures superior color consistency and quality control.

National/Societal Relevance

The UN World Water Development Report 2024 says 2.2 billion people worldwide have no access to clean water. Textile dyeing and processing are major contributors to water pollution. Minimizing the use of synthetic dyes will help to cut down on the untreated discharge of water bodies in rivers. By reducing exposure to synthetic dyes in the production process, we contribute to the improved health and well-being of both workers, people living near to textile hubs and consumers.

Import Substitution

By producing bacterial dyes, we can decrease reliance on imported dyes by developing and utilizing local sources. Hence, by promoting domestic production of natural dyes, supporting local businesses and creating jobs.

Export Potential

Increasing consumer and industry preference for sustainable and eco-friendly products is driving demand for natural dyes globally. Expanding markets in regions such as Europe, North America, and Asia, where there is a strong interest in green and ethical products.

Name of Startup: SRIGPAVENS LIFE SCIENCES PVT LTD



Founder and Co-founder(s):
Dr. Gajula Prabhakar, Founder
Dr. Papathodi Narendra Kumar, Co-founder

Developed Under
(scheme):
BIG

Email:
gajulaprabhakar@gmail.com

Product/Technology differentiation from Competitors

Pest Control Solution for Thrips Parvispinous • Targeted Pest Control: Bacillus pseudomycoides microbial surfactants disrupt Thrips parvispinous cell membranes for effective pest management. • Environmental Safety: Biodegradable, minimal risk to non-target organisms. • Resistance Management: Unique mode of action reduces Thrips parvispinous resistance. • Sustainable Farming Practices: Compatible with organic farming and sustainable agriculture. • Cost-Effective Solution: Long-lasting effects reduce application frequency. • Ease of Application: Optimized formulation for practical use. • Proven Efficacy: Research supports superior or comparable effectiveness against Thrips parvispinous on chili plants.

Brief Description of Product

Biosurfactant-BP offers a sustainable solution for controlling Thrips parvispinous on chili plants. Derived from Bacillus pseudomycoides, this eco-friendly biosurfactant effectively reduces pest damage and enhances crop yield. It provides a safe alternative to chemical pesticides, promoting healthier farming practices and ensuring environmental sustainability. By addressing key challenges in agriculture such as pesticide resistance and environmental impact, Biosurfactant-BP supports farmers in improving productivity while meeting consumer demand for safe and residue-free produce.

Current Stage of Development

Biosurfactant-BP is a sustainable alternative to conventional chemical pesticides in India's agricultural sector, addressing issues like pesticide overuse, environmental degradation, and food safety. This eco-friendly technology reduces dependency on harmful chemicals, supporting environmental stewardship and farmer welfare. It improves crop productivity and quality, leading to healthier crops and higher yields. By minimizing pesticide residue, it also contributes to improved food safety, reducing health risks for consumers. Biosurfactant-BP is a key contributor to India's efforts towards sustainable agriculture and long-term food security.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

National: Initially focused on regions across India where chili cultivation is prevalent, addressing local agricultural challenges and regulatory environments. International: Potential expansion to regions with similar agricultural needs and sustainability goals, leveraging global interest in eco-friendly farming practices and pesticide alternatives.

National/Societal Relevance

Biosurfactant-BP is particularly relevant for India's agricultural sector, where issues like pesticide overuse, environmental degradation, and food safety are significant concerns. By offering an eco-friendly alternative to chemical pesticides, it promotes sustainable farming practices that align with national goals for environmental stewardship and farmer welfare. This technology not only enhances crop productivity and quality but also reduces health risks associated with pesticide exposure for farmers and consumers alike. In addressing these challenges, Biosurfactant-BP supports India's drive towards sustainable agriculture and food security.

Technology readiness level (TRL)

TRL-7



Title/Name of the Product/Technology

Biosurfactant-BP: Eco-friendly Pest Control for Chilies

Product Positioning

Prospective Users/Buyers: • B2B: Agricultural cooperatives, large-scale chili producers, and organic farming associations seeking sustainable pest control solutions. • B2C: Individual farmers and growers interested in eco-friendly practices and consumers looking for residue-free chili products. Value Proposition: • Environmental Sustainability: Reduces chemical pesticide usage, minimizes environmental impact, and promotes biodiversity. • Crop Health and Quality: Enhances chili yield and quality by effectively controlling Thrips parvispinous without residues. • Health and Safety: Ensures safer working conditions for farmers and delivers safer, healthier produce to consumers.

Export Potential

Biosurfactant-BP holds significant export potential, especially to markets emphasizing sustainable agricultural practices and organic products. Countries in Europe, North America, and Southeast Asia, where eco-friendly farming methods are valued, present promising opportunities. Its ability to meet stringent environmental and food safety standards enhances its appeal. By offering a natural alternative to chemical pesticides, Biosurfactant-BP can cater to the growing demand for residue-free and environmentally sustainable agricultural products worldwide. This positions it as a competitive player in the global market for eco-friendly pest control solutions in agriculture.

Import Substitution

Biosurfactant-BP offers a viable import substitution solution by reducing reliance on imported chemical pesticides. As an indigenous, eco-friendly alternative derived from Bacillus pseudomycoides, it supports India's goal of self-sufficiency in agricultural inputs. By replacing imported chemicals with a locally produced, sustainable option, it enhances agricultural resilience, reduces dependency on foreign supplies, and promotes economic savings. This technology contributes to India's drive for self-reliance in agriculture while fostering sustainable practices that benefit both farmers and consumers through safer, high-quality produce.

IP Status

Re: Indian Patent Application No. 202441031721 Indian Filing Date: April 22, 2024 Type of Application - Indian Provisional Application Applicant: Srighavens Life Sciences Pvt. Ltd Title: "Bacillus Surfactants for Thrips Control in Chili"



Name of Startup: SUDHIN BIOTECH PRIVATE LIMITED



Founder and Co-founder(s):
Dr. Dhinakar S. Kompala, Ph.D. Chairman &
CEO, Sudhin Biopharma & Sudhin Biotech

Email:
khishore@sudhinbio.com

Product/Technology differentiation from Competitors

There are a few companies globally and in domestic market producing Vitamin k2-7 through chemical and biological methods. With respect to the organism, all the companies use bacillus subtilis natto. As raw materials are concerned companies use yeast extracts, peptones, and soya peptone. Whereas we are trying to use soya bean waste, optimizing to match the nitrogen content. In terms of production costs, companies are producing at a cost of 4-6 rupees per mg, we have working towards a target of rupees 1 per mg. And finally with a target of increasing production capacities to 180 -200 mg/L.

Brief Description of Product

BioSettlers are novel bioprocessing devices based on our novel patented technology using inclined / conical settling surfaces. BioSettlers are available in a variety of sizes, with three cylindrical diameter sizes of 75mm, 150mm, or 300mm and different heights resulting in internal liquid volumes ranging from about 250 ml up to 24L. Larger sizes can be fabricated according to customer specifications.

Current Stage of Development

System tested and launched for operations.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Global

National/Societal Relevance

Our vision on this project is see and provide an opportunity for every Indian to consume Vitamin k2-7 thereby reducing the problems of osteoporosis, CVD and Hemophilia.

Checkout Accomodation(2nd)

14-09-2024

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

SUDHIN BioSettlers

IP Status

17 patents

Name of Startup: TestRight Nanosystems Pvt. Ltd



Founder & Co-founder(s)
Shubham Rathore

Developed Under
(scheme):
BIG

Email:
testright.in@gmail.com

Product/Technology differentiation from Competitors

Our technology stands out from our competitors because we have developed a cutting-edge digital reader that serves as a more affordable and efficient alternative to the existing luminometers used for bacterial count in the market. Traditional luminometers are not only costly but also less advanced compared to our high-tech solution. Our digital reader is the first of its kind, offering precision, reliability, and ease of use at a fraction of the cost, making it accessible to a broader range of users. This innovation redefines the standard for bacterial counting technology, providing both superior performance and exceptional value.

Brief Description of Product

MBscan - a revolutionary device that automates the MBRT test and records accurate data on a cloud server for transparency. Simply insert the dye-mixed milk sample and forget - MBscan takes care of the rest! It senses the sample every 30 seconds and gives an alarm once the samples are decolorized. Key features of MBscan include: - Temperature Controlled Dry Bath for 16 Samples - Real-Time Decolorization Progress on Display - Automatic Test Tube Inversion for Proper Mixing Cloud Dashboard for Trend Analysis

Current Stage of Development

We are already in the market and sold 300 units in just 3 months

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Our primary geographic focus is on regions with a strong dairy industry presence, including countries known for large-scale dairy production and advanced agricultural practices. By targeting these areas, we aim to address the specific needs of dairy professionals, ensuring our product is accessible where it can have the most significant impact.

National/Societal Relevance

The national and societal relevance of our product lies in its potential to significantly enhance the efficiency and productivity of the dairy industry, a crucial sector in many economies. By improving measurement accuracy and operational transparency, our product supports sustainable agricultural practices, contributing to food security, economic growth, and the well-being of rural communities.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

MBscan

Product Positioning

MBscan is a high-tech, measurement gadget tailored for the dairy industry. It delivers precise, transparent results you can trust. While not positioned as a luxury or like China market product, MBscan sets a new standard for practicality and reliability, offering cutting-edge performance with ease of use for dairy professionals.

Export Potential

Our product has strong export potential, particularly in regions with growing dairy industries and a demand for high-quality, innovative solutions. With its unique blend of accuracy, transparency, and practical design, it is well-positioned to compete in international markets. By leveraging global distribution channels, we can expand our reach, driving growth and establishing a solid presence.

Import Potential

Our product plays a key role in import substitution by offering a high-quality, locally manufactured alternative to imported dairy industry gadgets. By providing a reliable and technologically advanced solution, we reduce dependency on foreign products, support domestic industries, and contribute to the local economy, all while ensuring competitive pricing and maintaining high standards of performance.

IP Status

Patent Number: 311760 Application
Number: 201611033997



Name of Startup: TMJ Foods India Private Limited



Founder and Co-founder(s):
T J Thankachan & Anto T Joseph

Developed Under
(scheme):
PACE

Email:
coonfresh124@gmail.com

Product/Technology differentiation from Competitors

The process involves harvesting the mushrooms, cleaning them, subjecting them to a blanching step, applying UVB to enhance vitamin D content, and then subjecting them to a dehydrated drying process using heat pump technology, which retains their inherent properties. The dried mushrooms are then powdered and mixed with millets to obtain the nutritional health mix from mushrooms. The specific formula adopted for mixing the various ingredients especially the millets with mushroom powder is unique and elicit the maximum vitamins and minerals.

Brief Description of Product

This invention relates to a nutritional health mix from mushrooms and a process for the preparation thereof. This invention particularly relates to a powdered nutritional health mix hailing from mushrooms. Beyond the inherent advantages of mushrooms, it also serves as a comprehensive source to meet the daily Vitamin D needs, coupled with an array of essential vitamins and minerals especially the Complete Protein with all nine amino acids. This concoction, combined with millets, is further elevated with natural flavouring agents. It retains its premium quality over a long period under standard storage conditions.

Current Stage of Development

Objective of this invention to propose a nutritional health mix from mushrooms and a process for the preparation, it is prepared from simple, readily available materials, a remarkable shelf life under standard storage conditions., a health supplement with a prominence of vitamin D, a completely vegan product.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Global

National/Societal Relevance

VIT D deficiency is addressed

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

COONVITA - Mushroom Millet Nutri Energy Drink In Powder Form

Product Positioning

Nutri Health Drink VIT D supplement

Export Potential

Vitamin D deficiency is a global issue and it has a high potential for export.

IP Status

202341073882 dated 30.10.2023 patent application filed and its processing is being done through TIMED as appointed by Kerala startup mission.

Name of Startup: Trishveda Naturals Pvt. Ltd.



Founder and Co-founder(s):
Mr. Shail Vinayak - Founder

Email:
rajat@trishvedanaturals.com

Product/Technology differentiation from Competitors

Manufacturing the same quality products at an affordable cost

Brief Description of Product

Founded in 2020, Trishveda Naturals Pvt Ltd is a Life science-based company located in Ludhiana, Punjab that aims to serve specialty ingredients to Personal Care, Food, Pharmaceutical, and Nutraceutical Industries. We are focused on utilizing the vastly unexplored Indian Tradition of Medicine i.e. Ayurveda along with Modern Science and Technology to provide industries solutions through the means of Biochemistry, Green chemistry and Biotechnology-based concepts and methodologies. We aim to create high-end but niche ingredients that can serve businesses to create extraordinary products for the human mankind. Value addition is a term that can be correlated with our company. We specialize in developing and producing ingredients only using local indigenous plant-based raw materials. We source these raw materials only from organic certified vendors thus promoting overall sustainable development. Our prime focus is on organic, natural, and certified-based ingredients, allowing us to create opportunities that respect mother nature and not tamper with the resources provided to us. Our portfolio Includes: - Carrier Oils - Exfoliators / Scrubs - Hydrolysate Proteins - Ferment Filtrate - Herbal Extracts & Molecules

Current Stage of Development

Currently producing and manufacturing at Pilot Scale level and ready to commercialize.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

APAC

National/Societal Relevance

Value addition Minimize the Import Substitution

Product/Technology

Plant Chemistry & Fermentation

Unique Selling Point

Upcycled Ingredients Science-backed ingredients Affordable Cost Clean Natural Ingredients Improving Farmers Livelihood Waste Utilization Circular Economy

Technology readiness level (TRL)

TRL-8





Name of Startup: UnBubble



Founder and Co-founder(s):
Akash Singh - Founder and CEO

Email:
akash@unbubble.in

Product/Technology differentiation from Competitors

UnBubble packaging stands out with rapid production, taking just 2 days to manufacture compared to 3 to 4 weeks for alternatives. It is competitively priced, unlike other materials that are 300 costlier. UnBubble also fully biodegrades within 48 hours, while others take 2 months, offering a faster, more sustainable solution.

Brief Description of Product

We create entirely plant-based, fully biodegradable protective packaging materials that are a replacement for non-sustainable harmful materials like plastic, foam, bubble wrap, thermocol, etc. Our packaging keeps products safe during shipping and also helps promote responsible production, consumption, and waste management. Once used, our packaging dissolves completely in water and is safe if accidentally ingested by pets or wildlife. Once it reaches the land, it acts as a natural compost and enhances soil fertility. Our packaging materials minimize environmental impact by reducing reliance on non-biodegradable materials and fossil fuels. Plus, its unique design and structure provide complete cushioning to the product by preventing product movement and hence preventing breakage offering robust protection during transit. Our goal is to completely replace plastic protective packaging and offer eco-conscious brands a reliable and sustainable solution that leaves zero carbon footprint.

Current Stage of Development

We have developed our product and have recently got a pilot opportunities to replace styrofoam packaging for some of their startups. We are planning to conduct pilots with a few startups to replace their current packaging with our sustainable plant-based packaging.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

South Asia

National/Societal Relevance

We make packaging that puts planet first. Our plant-based materials hold potential to reduce global plastic production by 40. Our materials are made of locally grown corn & agri waste. We empower farmers and rural women by giving them employment opportunities. Our manufacturing requires 70 less energy, emits 15 times less CO₂, and produces 80 less greenhouse gases than petroleum-based materials. We aim to replace polystyrene, polyurethane, and polyethylene in single-use packaging applications.

Technology readiness level (TRL)

TRL-7



Title/Name of the Product/Technology

UnBubble Sustainable Packaging Material

Product Positioning

UnBubble positions itself as a sustainable alternative to conventional packaging materials like foam, bubble wrap, etc, offering eco-friendly, fully biodegradable, and cost-competitive solutions. Targeting businesses prioritizing environmental impact, UnBubble emphasizes responsible production and waste management while providing protective, customizable, and affordable packaging for diverse needs.

Import Substitution

Yes

Export Potential

Yes

IP Status

We have pursued intellectual property protection for our proprietary manufacturing processes and design elements. We are in the process of securing patents and registering trademarks.

Name of Startup: UNXG TECHNOLOGIES PRIVATE LIMITED



Founder and Co-founder(s):
Deepak Ranjan Sethi Director and founder
Manas Ranjan Sethi Director and Co-founder
Biswa Ranjan Sethi Director and Finance
management
Santoshi Sethi Director and CSR
Activity Manager

Email:
unxg.biotechnology@gmail.com

Product/Technology differentiation from Competitors

Our colour will be human health and environment friendly, our product will not be toxic or carcinogenic.

Brief Description of Product

Natural colour for applications in food, feed, Pharma, and textile colour applications

Current Stage of Development

Research and Development is undergoing, we will be filing the patent and launching the product within 12 months time.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

USA, European Union and the United Kingdom

National/Societal Relevance

Socioeconomic development, large scale production of spirulina for the benefit of villages and villagers

Technology readiness level (TRL)


TRL-4

Title/Name of the Product/Technology

Spirulina biorefinery applications for healthy and wealthy life

Product Positioning

Natural colour for food, feed, Pharma and textile colours





Name of Startup: VFL Sciences Pvt. Limited



Founder and Co-founder(s):
V. Sankaranarayanan K.K.
Ramasubban V. Vaidyanathan

Email:
sankar.v@vflsciences.com

Product/Technology differentiation from Competitors

India imports over 90 of the laboratory instruments. With the Indian manufacturing and technologies are improving it is possible to make several of these instruments locally in India. At VFL Sciences, our core focus is on developing cutting edge instruments in India.

Brief Description of Product

Freeze dryers and Lyophilizers Our Penguin Classic series of freeze dryers and lyophilizers are designed with operational flexibility, operator convenience, and safety in mind. Available in two versions, -80°C and -50°C, these systems cater to a variety of freeze-drying needs. Whether you are working with pharmaceuticals, biological samples, or food products, the Penguin Classic series offers reliable performance and user-friendly features to streamline your lyophilization processes. Centrifuges Our Great Spin series features advanced centrifuges designed for a wide range of applications in research and clinical laboratories. These centrifuges offer precise control, high speed, and exceptional reliability, making them ideal for sample separation, cell culture, and more. With user-friendly interfaces and robust construction, Great Spin centrifuges provide consistent performance and longevity. Fermenters and Parallel Bioreactors Experience unparalleled versatility with our fermenters, available in capacities up to 10 litres and offered in both autoclavable and in-situ sterilizable versions, these cutting-edge solutions empower you to combine ease of operations with best in its class performance. Equipped with modern interfaces, expansive touch screen displays, and SCADA systems, the GreatFlo fermenters ensure intuitive operation and precise control at your fingertips. Meticulously engineered to excel in microbial and cell culture applications, The GreatFlo range of parallel bioreactors are better alternative to existing systems. Unlock the potential for robust process development and enhanced productivity as you harness the power of parallel experimentation

Current Stage of Development

We are in the instrumentation business and developed instrumentation as per customer requirements. The products are already sold to leading laboratories in India

Are you willing to Transfer/Out-License your Technology

No

Geographical Region Targeted

Currently focusing on India. Will look at global markets from 2026

National/Societal Relevance

India imports over 90 of all the laboratory instruments. By developing and manufacturing these products in India the Government can save lot of foreign exchange. This will also create lot of job opportunities India especially for skilled labours. The overall imported instrument market in India is over 10000 crores. Even if we can replace 10 of the instruments made in India there will be a huge potential to save!

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

Laboratory Instruments, Reagents and Consumables

Product Positioning

The Better Alternative to the imported technologies.

Import Substitution

The product developed are better alternative to the leading global players. At VFL Sciences we are focusing on competing with the global brands.

Export Potential

The global market for scientific instruments is very high. We would like to focus on the global market from 2026

Name of Startup: Wide Mobility Mechatronics Pvt. Ltd.



Founder and Co-founder(s):
Shekhar Basavanna & Rohini
Ghatpande

Developed Under
(scheme):
BIG

Email:
shekhar@widemobility.com

Product/Technology differentiation from Competitors

As of now, Conrad-G does not have competitors.

Brief Description of Product

India is the largest exporter of gherkins, contributing over Rs.2,000 crore to the country's export revenue. The crop is mainly cultivated in Karnataka, Tamil Nadu, and Telangana. However, fruit fly infestations pose a significant threat to this thriving market, as infested gherkins often show minimal or no external signs, making visual segregation difficult. Wide Mobility has developed a cutting-edge solution to address this issue—the CONRAD-G, an X-ray-based inspection system designed specifically to detect fruit fly infestations in gherkins. With an accuracy of over 95, CONRAD-G can currently handle up to 1,200 kg per hour. As the first-of-its-kind Make in India system, it is set to revolutionize the inspection process for Indian gherkin exporters. CONRAD-G is a fully automated system that feeds gherkins, generates X-ray images, classifies and segregates the infested gherkins. Post classification, the system pneumatically separates the infested produce, ensuring only the highest quality gherkins are selected. Prior to the introduction of CONRAD-G, manual inspections were labor-intensive, error-prone, and inefficient. Exporters had tried various methods to address the challenge, but CONRAD-Gs advanced technology offers significant advantages. It detects infestations of any size or orientation, even when no visible signs are present. Leakage radiation of Conrad-G is below 1 µSv/h, and the same is certified by the Atomic Energy Regulatory Board AERB. CONRAD-G has also been approved for subsidies by the Agricultural and Processed Food Products Export Development Authority APEDA after a detailed evaluation by ICAR-CIPHET.

Current Stage of Development

20+ machines on the field running for almost 24/7 during the season Most the customers have more than 1 machine, some of them have upto 4

Are you willing to Transfer/Out-License your Technology

No

Geographical Region Targeted

India

National/Societal Relevance

Fruit fly infestation was problem to Indian Gherkin Exporters affected Indian export value.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Conrad-G X-Ray Based Food Inspection Machine

Product Positioning

Conrad-G is a first of its kind, commercially successful product in separating fruitfly infested gherkins from the input.

Import Substitution

There is no import substitution

Export Potential

We are exploring opportunities to export to Sri Lanka. Also exploring possibility of detecting internal cavities in cucumber pickles for US companies.

IP Status

Application: 202041018995



Name of Startup: WithinCloud



Founder and Co-founder(s):
Harish Kumar & Deepak Sharma

Developed Under
(scheme):
Bootstrapped

Email:
mushfiq@withincloud.com

Product/Technology differentiation from Competitors

WithinCloud differentiates itself by offering industry-specific solutions that blend deep expertise in cloud computing, AI, and automation with a strong focus on data security. Our platform is customizable, allowing biotechnology firms to leverage specialized modules for research optimization, regulatory compliance, and secure data management.

Brief Description of Product

WithinCloud offers advanced cloud and IT consulting services that help biotechnology companies embrace digital transformation. Our solutions leverage AI, automation, and data analytics to optimize research processes, enhance operational efficiency, and ensure data security. We aim to drive innovation in bioinformatics, laboratory automation, and real-time data processing through scalable cloud infrastructure.

Current Stage of Development

Our solutions are currently being used by companies in the healthcare, pharmaceutical, and IT industries. We are now expanding our services to the biotechnology sector, focusing on delivering tailored digital transformation solutions to drive innovation.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Primarily targeting biotech hubs in India, Middle East Southeast Asia, and Africa, with plans to expand into Europe and the Americas.

National/Societal Relevance

In India's growing biotech sector, digital transformation is key to accelerating research and development, improving healthcare outcomes, and ensuring data security. Our solutions enable biotech firms to leverage technology for faster innovation and more precise research outcomes, contributing to the nation's progress in biotechnology.

Technology readiness level (TRL)

TRL-4

Title/Name of the Product/Technology

Cloud-Based Digital Transformation
Solutions for Biotechnology

Product Positioning

We position our solution as the go-to platform for biotechnology companies looking to optimize research, reduce time-to-market, and ensure compliance through cloud-based digital transformation solutions..

Unique Selling Point

Our unique offering is a fully customizable, secure cloud infrastructure that enhances data-driven research and operational efficiency while ensuring compliance with biotechnology regulations. We also offer end-to-end IT services, making it easier for biotech companies to integrate and scale cutting-edge digital tools.

Import Substitution

Our platform reduces the reliance on foreign digital transformation services by offering a home-grown, highly specialized IT infrastructure solution for biotech companies.

Export Potential

With an international outlook, we aim to export our technology solutions to biotech firms, particularly in under-developed markets like the Africa & Southeast Asia, which demand advanced digital tools to enhance their biotech research and operations.







DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology

Global
Bio-India
2024
Transforming Lives
Bioscience to Bioeconomy

बाइरैक
इन्क्यूबेटर्स
बिरैक
Ignite Innovate Incubate



Agriculture



AGRICULTURE		
Sl. No.	Company Name	PAGE NUMBER
1	Biopesticide Ltd	174
2	ClimateCrop Ltd	174
3	Sargenic Ventures Private Limited	175
4	Soil2Plant	175
5	Jfermi Biotechnology ltd	176
6	Proofminder	176
7	Water & Soil ltd	177
8	QTLomics Pvt ltd	177

Name of Startup: Biopesticide Ltd.



Founder and Co-founder(s):
Tamas Kovacs, Arpad Laszlo
Kovacs, Gabor Rakhely, Hiventures
Inc., Bonitas Inc., Environinvest
Corp., Creative Accelerator Ltd.

Email:
t.kovacs@biopesticide.eu

Product/Technology differentiation from Competitors

No other bacteriophage-biopesticides are available. This product is an efficient, environmentally sustainable solution against the rice BLB disease. XOOphage is absolutely specific against the targeted phytopathogen bacterium XOO. This biopesticide can also be used in bioproduction.

Brief Description of Product

XOOphage is a novel biopesticide against *Xanthomonas oryzae* pv. *oryzae* XOO, the causative agent of rice bacterial leaf blight BLB. BLB is a devastating disease of rice, causing significant economic losses and food security issues, especially in Asian countries. The bacterium *Xanthomonas oryzae* pv. *oryzae* XOO is listed as a possible tool for bioterrorism by the U.S. Food and Drug Administration FDA since, so far, no effective solution exists to control it. Biopesticide Ltd. has developed a biopesticide against this bacterium, proven to be efficient both in laboratory trials and field applications. The product contains bacteriophages phages as its active compounds. Phages are parasites of bacteria infecting and killing the target bacterium species in this case, XOO exclusively. Their application means minimal intervention in nature because only the target bacterium species XOO will be controlled, while other microorganisms and life forms will remain unaffected. When the host bacterium is not present, phages completely decompose and mineralize thus, they have no environmental impact. It should be highlighted that the phages are not genetically modified they were isolated from natural samples, then characterized, and selected to maximize their efficacies against XOO. The application of bacteriophages can provide an effective, environmentally conscious, and natural/green solution against XOO. In a series of field trials conducted by Tamil Nadu Agricultural University Tamil Nadu, Bidhan Chandra Agricultural University West Bengal, and University of Agricultural Sciences Dharwad Karnataka, the company's best-performing phage cocktails achieved 60-80 disease reduction and a 10-15 increase in crop yield over control.

Current Stage of Development

Seven successful field trials were conducted. The registration dossier will be submitted within 2-3 weeks.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

India, Vietnam. Potential market: Asia excluding Japan and the western part of Africa.

National/Societal Relevance

India is the second largest rice producer globally, with more than 120 million metric tons of paddy produced annually. According to The Hindu, XOO affects Asia's annual rice production by 60, but severely infected areas can see up to 80 crop losses. In the financial year 2018-19, India exported around 12 million tons of rice, primarily to EU countries thus, having the ability to defend against XOO with non-GMO products is an essential aspect to Indian farmers. XOOphage provides a cost-effective, reliable, and sustainable solution to a problem that India is one of the primary sufferers of.

Technology readiness level (TRL)

TRL-8

Title/Name of the Product/Technology

XOOphage - A novel, efficient and sustainable biopesticide against rice BLB disease

Product Positioning

It is a premium product. XOOphage is a biopesticide, with high efficacy and low environmental impact.

Import Substitution

No pesticides could be imported to India.

Export Potential

This biopesticide could be exported to all Asian rice production countries excluding Japan and to the western part of Africa. There are no direct competitor products registered in these countries.

IP Status

A patent application was submitted.

Name of Startup: CLIMATECROP Ltd. Israel



Founder and Co-founder(s):
Dr. Vivekanand Tiwari,
CSO and Co-Founder

Email:
vivek@climate-crop.com

Product/Technology differentiation from Competitors

A single target multiple trait enhancement in crops was identified and conserved in higher plants, thus providing enormous opportunities for work.

Brief Description of Product

Using our innovative technology, a few nucleotides of the commercial crop variety will be mutated so that the new product will be non-GM and have improved genetic potential. The new crop variety will store more energy in plants to support better survival under abiotic stresses and produce higher yields.

Current Stage of Development

Improved varieties of Yellow peas and Durum Wheat have already been developed and are getting ready for field trials in Europe. Since the tools we used to create this enhanced variety were non-GM, the new product does not require regulatory approvals.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

USA, South America, India, South East Asia

National/Societal Relevance

Global Impact on agriculture by reducing the carbon footprint of the crop produce.

Technology readiness level (TRL)

TRL-5



Title/Name of the Product/Technology

Climate-smart crop varieties with improved genetics

Product Positioning

An alcohol free and chemical free composition gives it an edge from other competing products.

Import Substitution

Import is not required the product will be developed locally

Export Potential

The product will be developed locally in the target market with a suitable partner

IP Status

Patented: US11254947B2

Name of Startup: jFermi biotechnology Kft.



Founder and Co-founder(s):
Krisztian Guttman CEO Gyula
Guttman CTO Mariann Kovacs

Email:
szabolcs.petri@jfermi.com

Product/Technology differentiation from Competitors

Unique selling proposals USPs of jFermi bioreactors: - Modularity & low-cost maintenance thanks to its USB Port compatibility - Flexible Parameterization thanks to its highly customizable software and open-source environment - No license fee thanks to its Mini Server Technology.

Brief Description of Product

jFermi is a Hungarian biotech company manufacturing innovative, user-friendly, flexible, and multi-purpose benchtop bioreactors with USB compatible - plug & play - accessories.

Current Stage of Development

Our bioreactors are used at different customers: universities and companies, now we finetune the system.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India

National/Societal Relevance

jFermi bioreactor holds national and societal relevance by enhancing the capacity for local research communities and industries to innovate within the biotechnology sector. These bioreactors enable more efficient and precise development processes in fields like pharmaceuticals, agriculture, and environmental management. By facilitating advanced research and production of biologically-based products, they contribute to public health, food security, and sustainable industrial practices, aligning with societal goals of improving quality of life and fostering scientific advancement.

Technology readiness level (TRL)

TRL-7

Title/Name of the Product/Technology

New-generation, innovative modular benchtop bioreactors.

Product Positioning

Pharmaceutical-agro- and circular economy companies and their R&D laboratories and institutions, such as universities and start-ups currently underserved.

Import Substitution

By adopting jFermi bioreactors, India can retain capital within the country, foster local innovation, and create high-tech jobs, aligning with government initiatives like Make in India that encourage local production and technological advancement.

Export Potential

jFermi bioreactors have substantial export potential, particularly targeting global biotech markets focused on research and development. With features tailored for versatility and efficiency, these bioreactors are well-suited for countries investing in biotechnology, healthcare, and sustainable agriculture. Exporting to regions with robust R&D infrastructure, such as Europe, North America.

Name of Startup: Proofminder



Founder and Co-founder(s):
Levente Simon, Anbrus Vancso,
Norbert Havas

Developed Under
(scheme):
SEED Fund

Email:
hello@proofminder.com

Product/Technology differentiation from Competitors

Highest resolution, most precise insights on the market that can be applied to large areas. Support of multiple crops, highly extensible to new vegetation. End-to-end support and integration.

Brief Description of Product

Proofminder provides precise analysis of vegetation from drone and satellite data. Our technology transforms value chains in seed production, food production, helping growers to optimize production, save costs and improve yields. From spot spraying till tree counting of large areas Proofminder provides super precise insights for agriculture.

Current Stage of Development

We are operating in 5 continents and process thousands and thousands of hectares of customer projects.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

Global

National/Societal Relevance

Help farmers to meet sustainability goals.

Technology readiness level (TRL)

TRL-9

Title/Name of the Product/Technology

AI based plant level farming

Product Positioning

Precision agriculture platform.

Import Substitution

Not relevant. We are operating from an Indian entity.

Export Potential

Relevant for the APAC region.

IP Status

The entire application and the AI models are our IP.



Name of Industry: QTLomics Technologies Pvt Ltd



Contact Person:
Krishna Prasad (PhD)

Email:
krishnaprasad@qtlomics.com

Description of Exhibit

Our genomics lab is in Bengaluru with molecular biology, sequencing lab and bioinformatics lab with 4 scientists. We help Agri universities, Ag biotech, aquaculture, veterinary and seed companies in India using our sequencing technologies helping in their research/breeding/QA/QC programs.

Organization Profile

QTLomics Technologies Pvt Ltd., a genomics Company in India, pioneers a transformative era in agriculture and stands as a new frontier in advanced genomics services. With a commitment to excellence, we provide a comprehensive suite of services spanning wet lab experimentation to bioinformatics support, all aligned with rigorous quality standards.

Website URL

<http://qtlomics.com/index.html>

Social Media Links

www.facebook.com/qtlomics/

<https://www.linkedin.com/company/qtlomics/>

Differential pricing model implemented in providing services

Our pricing depends on Project mode and part fixed fees and part success fees. Special prices for startups.

National/Societal Relevance

Our joint collaboration work should pave way to answer these questions: 1 Increase productivity and farmers income 2 Enhance resilience of livelihoods and ecosystems 3 Improve productivity in aqua culture and veterinary.

Future Plans and Initiatives

To increase our collaborations with ICAR, AICRP in crop improvement programs and also joint collaborations with other countries.

Address

First Floor, Arasu Complex, 4, 80 feet Road, Ashwath Nagar, RMV 2nd stage, Bengaluru, Karnataka 560094

Year of establishment

10-08-2006

Unique value proposition of the facility

Developed pipelines to apply genomics especially sequencing technologies to multiple institutes and companies in their research and developmental programs using cutting edge sequencing instruments which are new in the market. The areas include transgene characterization, GWAS, QTL, Trait specific marker discovery, parental and hybrid genome characterization, epigenetics and metagenomics.

Current Status of Facility

Functional

Accreditations received (if any)

Approximately 30 companies

Name of Startup: SARGENIC VENTURES PRIVATE LIMITED



Founder and Co-founder(s):
Rupesh Pawar

Developed Under
(scheme):
SPARSH

Email:
rupesh92pawar@gmail.com

Product/Technology differentiation from Competitors

Our innovative business model transcends conventional approaches in its holistic commitment to socio-economic empowerment and environmental sustainability. Unlike traditional cosmetic enterprises, our core product, derived from mahua tree products, stands as a testament to indigenous wisdom. Our approach combines cutting-edge technology, such as advanced cold press machines, with time-tested traditional practices. This convergence not only ensures the highest product quality but also fosters sustainable livelihoods for tribal women. Moreover, our model pioneers a comprehensive ecosystem, from procuring raw materials to manufacturing the final product.

Brief Description of Product

Our business, rooted in the heart of tribal communities, unlocks the transformative potential of mahua tree products. By seamlessly integrating traditional wisdom with modern technology, we empower indigenous women, offering skill development, sustainable livelihoods, and a direct market for their resources. Through our luxury cosmetic brand, we redefine beauty by showcasing the richness of nature while creating global impact and awareness. We exist to bridge the gap between ethical entrepreneurship and the socio-economic empowerment of tribal communities, crafting a beauty narrative that is not just about products but a profound and sustainable connection with the earth and its custodians.

Current Stage of Development

About to launch.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Africa, India and South East Asia

National/Societal Relevance

Tribal impact.

Technology readiness level (TRL)

TRL-6

Title/Name of the Product/Technology

Novel butter Technology for cosmetic technology

Product Positioning

Weve forged strategic partnerships with tribal communities for raw material sourcing, creating a symbiotic relationship that empowers indigenous women. Collaborating with the National Skill Training Institute facilitates skill development, aligning with our commitment to socio-economic empowerment. Our Beauty and You Global Impact Award from Nykaa strengthens our distribution network.

Import Potential

Yes

Export Potential

Yes

IP Status

Applied provisional patent



Name of Startup: Soil2Plant

Soil2Plant

Founder and Co-founder(s):
Ritesh Sanu

Email:
riteshsanu@gmail.com

Product/Technology differentiation from Competitors

Current industry practices rely on an in-vivo strategy involving cultivating crops and infecting them with mycorrhizal propagules spores, roots, hyphae that are later harvested for multiplied propagules/spores in the roots. While this method adds value to agriculture and horticulture, contamination is a significant concern that needs attention. Our modified Root Organ Culture ROC methodologies meet this requirement and contribute to large-scale production in a sophisticated monoxenic in-vitro setup for species-specific, clean VAM.

Brief Description of Product

Vesicular arbuscular mycorrhiza VAM are important organisms that form symbiotic relationships with 80 terrestrial plant species by colonizing their roots. They play a vital role in promoting nutrient uptake, especially phosphorus, as well as water uptake, and protecting plants from various types of stresses. Unlike other commonly commercialized biofertilizers, mass-producing contamination-free spores of VAM is a challenge due to its endophytic nature and its requirement for plant roots to infect, reproduce, and propagate. Current industry practices rely on an in-vivo strategy involving cultivating crops and infecting them with mycorrhizal propagules spores, roots, and hyphae that are later harvested for multiplied propagules/spores in the roots. While this method adds value to agriculture and horticulture, contamination is a significant concern that needs attention. Our modified Root Organ Culture ROC methodologies meet this requirement and contribute to large-scale production in a sophisticated monoxenic in-vitro setup for species-specific, clean VAM.

Current Stage of Development

Extensive studies have been conducted on optimising media and signalling molecules in root organ culture ROC-based monoxenic culture for spore production. These experiments have contributed to the understanding of vesicular-arbuscular mycorrhizal VAM reaction to different media compositions and the exploitation of ROC for efficient spore production. Additionally, extensive Plant Growth-Promoting PGP Bioassays have been conducted to understand the formulation of the eventual product for higher efficacy and infectivity. The datasets and learnings from these experiments are valuable assets for our progress in VAM production and formulation technologies for commercialization.

Are you willing to Transfer/Out-License your Technology Yes

Geographical Region Targeted

India, Europe, Malaysia, North America, South America, Indonesia

National/Societal Relevance

Organic farming and natural farming are essential today. India's soil health is deteriorating due to the excessive use of chemical fertilizers and pesticides. Adopting biological methods with moderate use of chemicals or complete reliance on biologicals for agriculture and horticulture will ensure improved soil health, efficient crop production, and nutritious food.

Technology readiness level (TRL)

TRL-8



Title/Name of the Product/Technology

Biological Plant Nutrition and Pest Management Solutions In vitro production of Vesicular Arbuscular Mycorrhiza VAM

Product Positioning

The product targets the Integrated Nutrient Management and organic/natural farming market, emphasizing the vital role of biologicals. Pure VAM spores can enhance infectivity and improve crop productivity compared to VAM produced in vivo on plants.

Import Potential

Only a handful of microorganisms are currently being cultured on a commercial scale. Both American and European markets have a few efficient biofertilizer strains, but strict quarantine regulations in India make it extremely difficult to introduce new organisms. This gap can be easily filled with Indian R&D and products.

Export Potential

The export of biological materials may be challenging, but common species can be exported to Europe, Malaysia, North America, South America, and Indonesia to meet the demand in their respective biologicals markets. The global agro-biological market is projected to reach USD 43.53 billion by 2035.

IP Status

Patent Pending

Name of Startup: Water&Soil Ltd.

water&soil

Founder and Co-founder(s):
Antal Vattay Richard Vattay

Email:
info@waterandsoil.eu

Product/Technology differentiation from Competitors

The Water Retainer is unique because it reduces the evaporation loss of the soil while it organically degrades in the soil without any remedies.

Brief Description of Product

The Water Retainer is an organically degradable liquid soil conditioner, which retains the already existing humidity in the soil by reducing the evaporation loss. Effective both in rain-fed and irrigated cultivation. It can provide 10-20 higher yield or reduce up to 30 - 50 of the irrigation water use.

Current Stage of Development

The Water Retainer is widely tested by scientific institutions on 4 continents in 14 countries. FAO has recognised the Water Retainer recently by incorporating the product into the recommended technologies and issued official publication. The Water Retainer is actively traded in Hungary, Morocco, Kenya, Tunisia, Algeria, Albania, Greece, Iraq, Kazakhstan, Uzbekistan, Chile, Peru.

Are you willing to Transfer/Out-License your Technology No

Geographical Region Targeted

Asia, Africa, South America, US, Australia

National/Societal Relevance

Climate change means rising temperature and more frequent droughts which can last longer for the agriculture. We need water in order to survive any of them. Our Water Retainer technology reduces the water use/need in irrigation. The result is that more land can be irrigated without increasing the water consumption. We keep the soil moist for longer in not irrigated cultivation. This is the key for reducing or surviving the consequences of the drought. Both the rising temperature and drought can be disastrous. Unfortunately there are several examples exist. Ethiopia, Kenya, India, Pakistan, Australia, California, etc.

Technology readiness level (TRL)

TRL-9



Title/Name of the Product/Technology

Water Retainer

Product Positioning

Good for high value crops.

Import Substitution

Water&Soil Ltd is ready to provide license for local production.

Export Potential

If local production is set-up and the license gives possibility for it the export potential is many 10s of millions of dollar

IP Status

Patented



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology



INCUBATOR EXPO

(Pg. No. 178-220)

INCUBATOR NAME		
Sl. No.	Company Name	PAGE NUMBER
1	AgHub- Agri Innovation Hub, PJTSAU	181
2	AIC Banasthali	181
3	AIC NIPER Guwahati Foundation	182
4	AIC RAISE Business Incubator	182
5	a-IDEA	183
6	ASPIRE-BioNEST	183
7	Association for Bio-inspired Leaders &Entrepreneurs at SASTRA-TBI	184
8	Atal Incubation Centre - Centre For Cellular and Molecular Biology	184
9	Bannari Amman Institute of Technology - Technology Business Incubator	185
10	Bhubaneswar City Knowledge Innovation Cluster (BCKIC)	185
11	BioNEST Agri Innovation Center, UASB	186
12	BioNEST DMIHER	186
13	BioNEST, Panjab University	187
14	BioNEST-Banaras Hindu University (BHU)	187
15	BioNEST-UDSC, University of Delhi South Campus	188
16	BIRAC E-YUVA Centre, UAS Dharwad	188
17	BITS Goa Innovation Incubation & Entrepreneurship Society (BGIIES)	189
18	BITS Pilani Hyderabad campus TBI Society	189
19	BSC BioNEST Bio-Incubator BBB , RCB	190
20	Career College Autonomous , Bhopal	190
21	Centre for Cellular and Molecular Platforms (C-CAMP)	191
22	Centre for Medical Innovation and Entrepreneurship, All India Institute of Medical Sciences, Delhi	191
23	Clean Energy International Incubation Centre	192
24	Crescent Innovation and Incubation Council	192
25	CSIR-CFTRI Incubation Centre	193
26	CSIR-IIIM BioNEST Bioincubation Centre (IIIM-TBI)	193
27	CSIR-IITR	194
28	DBT-ILS BIOINCUBATOR INSTITUTE OF LIFE SCIENCES	194
29	DERBI Foundation	195
30	DPSRU Innovation Incubation Foundation	195
31	Dr.Moopens iNEST	196
32	Entrepreneurship Development Center, Venture Center	196
33	E-Yuva Center, Anna University	197

INCUBATOR NAME		
Sl. No.	Company Name	PAGE NUMBER
34	E-YUVA Center, GIET University	197
35	E-YUVA Centre, Adamas University	198
36	E-YUVA Centre, Panjab University	198
37	E-YUVA Centre, PSGR Krishnammal College for Women	199
38	E-YUVA Centre, University of Rajasthan	199
39	Federation of Asian Biotech Associations (FABA)	200
40	Foundation for CfHE	200
41	Foundation for Innovation & Research in Science & Technology FIRST, IIT Kanpur	201
42	Foundation for Innovation and Technology Transfer	201
43	Golden Jubilee Biotech Park for Women Society	202
44	iDeaNA-CDFD Technology Incubator	202
45	IIT Guwahati Technology Innovation & Development Foundation BioNEST	203
46	IIT Madras HTIC MedTech Incubator	203
47	IIT Mandi Catalyst	204
48	IIT Ropar - Technology Business Incubator Foundation	204
49	IITM Bioincubator	205
50	IKP Knowledge Park	205
51	Incubation Centre IIT Patna	206
52	Innovation and Incubation Centre for Entrepreneurship	206
53	Institute of Advanced Study in Science and Technology - BioNEST - IASST	207
54	i-RISE TECHNOLOGY BUSINESS INCUBATOR, IISER Mohali	207
55	JSSATE Science & Technology Entrepreneurs Park	208
56	KIIT Technology Business Incubator	208
57	MakerVillage	209
58	Manipal Government of Karnataka Bioincubator - BioNEST	209
59	Mazumdar Shaw Medical Foundation TBI	210
60	Padmashree Research and Innovation center	210
61	Parul Innovation and Entrepreneurship Research Centre PIERC	211
62	Pilani Innovation and Entrepreneurship Development Society	211
63	PSG-STEP BioNEST	212
64	RISE Foundation IISER	212
65	Runway Incubator UPES, Dehradun	213
66	SCTIMST-TIMed	213



INCUBATOR NAME		
Sl. No.	Company Name	PAGE NUMBER
67	Siddaganga Incubation Foundation	214
68	Society for Innovation and Entrepreneurship SINE, IIT Bombay	214
69	Sona Incubation Foundation	215
70	SPMVV- Women Biotech Incubation Facility	215
71	Sri Ramchandra Institute of Higher Education and Research (SRIHER)	216
72	Startups Valley TBI	216
73	TIDES, IIT Roorkee	217
74	TNAU E-YUVA Centre	217
75	Translational Oncology Council - TRON	218
76	Venture Studio, Ahmedabad University	218
77	Veterinary Incubation Foundation @ TANUVAS	219
78	VIT-Technology Business Incubator (VIT-TBI)	219
SN No	International Incubator Name	Page No.
1	Innovation Starter (Bulgaria)	220
2	Poznan Science and Technology Park (Poland)	220

Incubator Name: AgHub- Agri Innovation Hub, PJTSAU

Focus Area: AgriTech

Location: AgHub, State Bank of India road,
Professor Jayashankar Telangana State
Agricultural University campus

Website:
<https://ag-hub.co/>

Email:
ceo@ag-hub.co


Contact No.:
99899 28773

About Incubator:

AgHub is a pioneering Innovation Hub, designed in a Hub & Spoke model, dedicated to fostering an inclusive ecosystem for Agritech startups, student entrepreneurs, and rural innovators. Funded by NABARD and MOFPI, AgHub has been promoting startups and student entrepreneurs across India since its inception in 2021. AgHub supports Agritech startups through four flagship programs: Incubation, Agritech Innovation Pilots AIP, Co-Innovation, and the Enterprise Acceleration Programme EAP. These programs have nurtured over 103 startups across various sectors, validated 10+ Agritech startups, facilitated INR 850+ million in fundraising for 30+ startups, and provided INR 8 million in grants to 22 startups. For student entrepreneurship, AgHub offers Design Thinking programs, Ideation Programs, and Student Incubation Programs. These initiatives have created 2,350+ design thinkers, pooled 650+ ideas, and nurtured 9 student-led enterprises. AgHubs rural entrepreneurship efforts are driven through three Rural Innovation Spokes in Telangana, supporting rural youth, women, FPOs, and grassroots innovators. The programs have nurtured 15+ rural enterprises, skilled 380+ rural youth and women, and connected 250+ farmers and FPOs to Agritech startups through the AgriTech Market Access Program AgMAP.

Total Space Sq. Ft.: 13000

IMPACT



5 most successful incubatees:

- Marut Dronetech Private Limited
- TRST01 TrayamBhu Tech Solutions Pvt Ltd
- Renkuba Private Limited
- Bharat Rohan Airborne Innovations Private Limited
- EF Polymer Private Limited

General Infrastructural Services:

AgHub spans 3,158 sq. meters 34,000 sq. ft.: 10,000 sq. ft. of Innovation Hub at PJTSAU, Hyderabad, India, and 8,000 sq. ft. each at three centers Jagtial, Warangal, and Tandur for Agri and Food Rural Innovation Spokes in the state of Telangana, India. The AgHub location at PJTSAU Hyderabad includes a co-working space for startups, pod rooms for client and mentor meetings, a space for board meetings, a podcast room with a smart board setup for training, and a thinkers lab for student innovators. As part of PJTSAU University, AgHub also provides access to the university's laboratories, research space, and field space for piloting technologies for startups.

Scientific Support Services:

AgHub has 250+ scientific mentors from PJTSAU with expertise in agriculture, research, education, and extension 50+ agribusiness mentors and business support service providers specializing in agribusiness industry legal matters, intellectual property, and finance and a network of 50+ investors, including VCs, HNIs, angels, funding institutions from the government, and industry.

Advisory and Mentoring Services:

AgHub provides advisory and mentoring services in scientific, industry, IP & legal matters, agribusiness, biotech, Agritech, research, agri-food, allied sectors, and more.

Incubator Name: AIC Banasthali

Focus Area: MedTech, HealthTech, BioTech, AgriTech, Lifesciences

Location: AIC Banasthali,
Nav Mandir,
P.O. Banasthali Vidyapith, Tonk, Rajasthan 304022

Website:
<https://aicbanasthali.org/>

Email:
binnykhanna@banasthali.in


Contact No.:
9820058823

About Incubator:

AIC Banasthali is India's first and largest women-centric business incubator. Over the last 6+ years it has supported 153 startups, 77 of these have raised over Rs. 1453 Mn in funding, registering 61 IPs and creating more than 2000 jobs.

Total Space Sq. Ft.: 38000

IMPACT



5 most successful incubatees:

- Dr Sarika Gupta
- Ms Kirti Vaishnav
- Ms Nidhi Pant
- Ms Jayshree Harak
- Ms Shriti Pandey

General Infrastructural Services:

AIC Banasthali offers a dedicated space for the social innovators. The incubator offers a state-of-the-art 38000 Sq Ft. dedicated space having co-working space, conference rooms, cubicles, auditorium, ideation room, etc. The innovators will also have complete access to the world-class lab-facilities at the Vidyapith. Along with infrastructure support, the innovators can also take guidance of faculty mentors at the Vidyapith. Over the years, the Incubation Centre has developed policies like IP Policy, Startup Policy, etc. for smooth functioning and usage of operational facilities at the University.

Scientific Support Services:

AIC Banasthali has access to its host institutes' in-house Krishi Vigyan Kendra KVK, Green house size = 10 m x 30m=300 sq meter, Animal House size = 34'-3"x 24'-3"= 833.49 sq feet, Botanical garden size = 17876.91sq feet, in-house hospital with 180 beds with ICU facilities, Diagnostic Centre, 5 Residential Doctors, nursing school, Department of Automation, Biotechnology, Pharmacy, Lifesciences, Physical Sciences, Robotics, Artificial Intelligence, Engineering workshop, among other facilities which will be available to the innovators helping them to fasten the process of development.

Advisory and Mentoring Services:

AIC Banasthali has a 10 member advisory board comprising of experienced mentors & Industry experts. Atal Incubation Centre has over the years built a strong pool of over 200 mentors across industries, has a good network of corporates and can leverage the network of Banasthali Vidyapith which comes handy with its long legacy.



Incubator Name: AIC NIPER Guwahati Foundation

Focus Area: Health and Pharmaceuticals, Biotechnology, Agriculture and allied fields, Water, Sanitation and Soli

Location: AIC NIPER Guwahati Foundation,
Sila Katamur Halugurisuk
PO : Changsari, Dist: Kamrup, Assam

Website:
<http://aicniper.org>

Email:
aic@niper.org


Contact No.:
9398875465

About Incubator:

NIPER-Guwahati is the sole National Institute of Pharmaceutical Sciences in the entire North Eastern Region of our country. It was established in 2008 to provide high-quality pharmaceutical education and research with a focus on the exploration of natural and synthetic products in this region for drug discovery and development. Atal Incubation Centre AIC NIPER-Guwahati Foundation is a Section-8 Company as per the Govt. of India Companies Act 2013 being established on 08th March 2022 under the Atal Innovation Mission AIM, a flagship initiative of NITI AAYOG, Government of India. The Centre is funded by the Atal Innovation Mission AIM, NITI Aayog, Government of India. AIC NIPER-Guwahati Foundation aim to foster and support world class innovation, dynamic entrepreneurs who want to build scalable and sustainable enterprises in the field of Healthcare, Lifesciences etc. OUR MISSION 1. Our mission is to cultivate and fortify the startup ecosystem across various industries including pharmaceuticals, healthcare, waste management, secondary agriculture and biotechnology. 2. We provide guidance and support to aspiring entrepreneurs, assisting them in establishing their businesses within the Indian ecosystem. 3. Our focus is on mentoring startups towards the optimal path to successfully bring their products to market.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Mr. Krishnarjun Das
- Mr. Bapan Das
- Dr. Prem Mathi Maran
- Ms. Dibyajyoti Borgohain
- Mrs. Monalisha Sengupta

General Infrastructural Services:

Exclusive incubation suits, Office space for incubatees, Common lab, Co-working space, Culture room, Meeting room, Advanced instrumentation, Animal house, Cafeteria, Library, Internet facility, 24 hours power backup, Analysis laboratory, Computer Centre

Scientific Support Services:

Access to equipment of NIPER-G with discounted charges Use of common facilities Pro-Bono scientific advisory from NIPER-Guwahati faculty members and the external members of the Technical Advisory Committee and Networking and scientific support from the institutions under MoU with Host Institute NIPER-Guwahati and Incubation Centre AIC across India.

Advisory and Mentoring Services:

Incubation Support: To provide incubation space, Appropriate mentorship, and enabling services for start-ups and entrepreneurs, including technical, legal, financial, and commercial support. • Knowledge Exchange: To connect industry and academia, facilitating efficient exchange of knowledge and technical and business mentorship. • Traditional Knowledge: To encourage and provide a platform for traditional healers of North-East India to market their goods with appropriate scientific validation and regulatory compliances.

Incubator Name: AIC RAISE Business Incubator

Focus Area: Healthcare

Location: AIC Raise Startup Incubation
Centre Rathinam Techzone,
Eachanari, Coimbatore, Tamilnadu - 641 021

Website:
<https://aicraise.com/>

Email:
suriyaraj@aicraise.com


Contact No.:
8870697986

About Incubator:

AIC RAISE creates a holistic ecosystem for social startups for maximizing profits and benefits to society and the environment. It is established under the prestigious Atal Innovation Mission AIM of NITI Aayog, Govt. of India. AIC RAISE encourages and backs innovative startups with suitable physical infrastructure in terms of capital equipment and operating facilities, key domain knowledge support, coupled with the availability of sectoral experts for mentoring, business planning support, access to seed capital, market information, management, business strategy, industry partners, training and as well as critical networking.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Atom6 Technologies Private Limited
- Nanospark Innovations India Private Limited
- Pattuthadam Private Limited
- Vaangal Enterprises
- Chrissron Biomass Solutions Private Limited

General Infrastructural Services:


AIC Raise boasts a centralized in-house testing and characterization facility, supervised by experts from Arts and Science, Engineering, and Pharmacy disciplines. The facility is equipped with major instruments such as a Bioreactor, Cooling Centrifuge, Tissue Culture Facility, Microbial Technology Lab, and Lyophilizer, among other modern equipment. This state-of-the-art setup is designed to support innovators and startups, enabling them to conduct high-level research, development, and testing in various scientific fields.

Scientific Support Services:

AIC RAISE offers robust scientific support to innovators and startups in fields like microbiology, tissue culture, medical research, biosensors, food tech, agriculture, and nutraceuticals. With guidance from IIT and NIT faculty, in-house experts, and industrial collaborators, AIC RAISE assists in research, product development, and business planning, fostering innovation through access to advanced resources and a strong network of sectoral experts.

Advisory and Mentoring Services:

AIC RAISE offers comprehensive support for innovators and startups, especially in life sciences and related fields. The center provides access to expert mentors, business planning assistance, and sector-specific knowledge to help startups navigate innovation challenges. Additionally, AIC RAISE facilitates access to seed capital, market insights, and networking opportunities, aiming to enhance both profitability and societal impact.



Incubator Name: a-IDEA

Focus Area: AgriTech

Location: Technology Bhawan ICAR-NAARM
Campus Rajendranagar Hyderabad
Telangana-500030

Website:
<https://aidea.naarm.org.in/>

Email:
ceo.aidea@naarm.in

Contact No:
04024581326


About Incubator:

The center is surrounded by agricultural institutions and is also known as the 'The Gurukul of ICAR institutes'. The incubator has supported many start-ups like AgNEXT, BharatRohan, Fermentech, Delmos, and Intello Labs through hand holding or seed funds. The center has a strong foresight study and is managed technically and technologically to establish a solid base for entrepreneurship. The ICAR-funded Agri-Business Unit provides initial support to foster an institutional culture in entrepreneurship. The center for agri-innovation operates through the Technology Business Incubator TBI hosted at ICAR-NAARM, Hyderabad, with financial backing from the ICAR-National Agriculture Innovation Fund NAIF, Department of Science & Technology DST, Government of India GoI, Department of Biotechnology DBT, National Bank for Agriculture and Rural Development NABARD, and Startup India. Since our inception, over the past 10 years, we have supported 300+ startups in agriculture and allied sectors through incubation and accelerator programs, and have seed funded 32+ portfolio startups through various a-IDEA seed funds.

Total Space Sq. Ft.: 14000



IMPACT



5 most successful incubatees:

- Drakon Innovations Private Limited
- Chimertech Pvt. Ltd
- Aumsat Technologies LLP
- Dhi Sathi Robotics Pvt. Ltd
- X Bosen AI Pvt. Ltd

General Infrastructural Services:

Incubation space, Conference Hall, Committee halls, Auditorium, Meeting Rooms, Cafeteria, Office Space, Guest House. GH,SH,FC,HOR.

Scientific Support Services:

a-IDEA, NAARM-TBI offers access to 6000+ ICAR scientists across India, providing strong technological mentoring for startups. It has strategic partnerships and 6500 sq.ft. of lab space with specialized facilities.

Advisory and Mentoring Services:

Mentoring covers various fields like food, finance, and technology. It includes one-on-one, e-mentoring, and executive mentoring, focusing on specialized guidance and employee development. Group mentoring is informal and outside formal training for entrepreneurs.

Incubator Name: ASPIRE-BioNEST

Focus Area: Lifesciences

Location: University of Hyderabad,
Gachibowli, Hyderabad
Telangana-500046

Website:
<https://bionest.uohyd.ac.in/>

Email:
drkondreddy@uohyd.ac.in


Contact No:
9542241333

About Incubator:

ASPIRE BioNEST is a deep-tech life science incubator spread over an area of 23,000 sq.ft. It provides, plug-and-play laboratory space for start-ups and nurtures innovation and entrepreneurship in Biotechnology, Healthcare, Pharmaceutical, Agritech and Allied areas.

Total Space Sq. Ft.: 23000

IMPACT



5 most successful incubatees:

- Bycus Therapeutics Pvt. Ltd
- UR Advanced Therapeutics
- Provis Biolabs Pvt. Ltd
- 30M Genomics Pvt. Ltd
- Vegen Therapeutics

General Infrastructural Services:

The facility can support 45 startups at any given point of time with 30 individual labs and 15 co-working spaces. About 45 of the start-ups incubated at the facility have women as founders and cofounders and 25 of the incubating start-ups are owned by faculty and alumni of the university. The excellent all-around growth of ASPIRE-BioNEST has enabled it to bag the "Best Emerging Bio incubator in the country" honour for the year 2021. Modern amenities such as reliable internet connectivity and optimal air conditioning, surveillance and house-keeping services enhance the overall research environment. Access to a well-stocked online library of University of Hyderabad further supports researchers in staying abreast of the latest scientific developments. The meeting and board rooms, fit with advanced audio-visual devices are conducive to discussions, presentations, and brainstorming sessions fostering a culture of collaborative innovation.

Scientific Support Services:

The common instrumentation facility of ASPIRE-BioNEST contains routinely needed basic equipment for supporting research at the lab scale. It includes a wide spectrum of analytical equipment ranging from spectrophotometers to microscopes, PCRs and centrifuges, facilitating precise and in-depth experimentation by the start-ups. The facility operates on a self-use basis, with 24/7 access facilitated through biometric credentials, ensuring uninterrupted workflow. A dedicated utility area equipped for sterilization of glassware, media, and equipment upholds the quality standards of experiments. Dedicated labs for microbial and animal cell culture, along with a Biosafety Level 2 BSL2 facility. A walk-in cold storage room for safeguarding temperature-sensitive samples, reagents, and materials. For botanical research, a well-maintained net house facilitates for plant growth under specific conditions. Furthermore, the newly inaugurated Center of Excellence, supported by Thermo Fisher Scientific, is equipped with high-end imaging systems, and FACS machine, strengthening the facility's instrumentation capacities and meeting the analytical demands of start-ups.

Advisory and Mentoring Services:

ASPIRE-BioNEST has a strong advisory board comprising of policy makers, academicians, industry experts, and venture capitalists. It also provides several soft services, such as IP protection, Accounts and Audit, Company secretaries, legal advisors etc., besides technical experts, who are best in class to help the start-ups.





Incubator Name: Association for Bio-inspired Leaders & Entrepreneurs at SASTRA-TBI

Focus Area: MedTech

Location: Anusandhan Kendra II, SASTRA Campus,
Thirumalaisamudram, Tamilnadu,
Thanjavur-613401

Website:
<https://ablest.sastra.edu>

Email:
ceo.ablest@sastra.ac.in


Contact No.:
9443309910

About Incubator:

The ABLEST, a theme-based incubator established with the support of BIRAC, DBT, and SASTRA, is housed in SASTRA's Hub for Research & Innovation SHRI with 7000 sq. ft. of dedicated space. ABLEST plays a pivotal role in nurturing start-ups across a wide spectrum of biotechnology domains, including therapeutics, diagnostics, preclinical evaluation, and innovative healthcare solutions. The primary goal of ABLEST is to help start-up entrepreneurs realize their dreams by providing state-of-the-art infrastructure, business advisory support, mentoring, IPR services, and financial assistance through SISFS. Facilities include a bio-innovation space, an RCGM-certified BSL-3 facility, a ISO 13485:2016-compliant clean room manufacturing facility for medical devices, molecular biology facilities, BSL-2 suites, a GLP-compliant animal facility, and other essential amenities. Since 2019, ABLEST has onboarded 41 innovative biotech ideas and supported the launch of seven products. With periodic mapping of critical success factors and systematic mentoring, ten products are under field trials, with two receiving pilot test licenses from CDSCO. The incubator has organized 90+ events with 3403 beneficiaries, filed seven IPs with three granted patents, and received the Best Incubation Centre award in Tier III Cities at Global Bio-India 2023 by DBT-BIRAC. Our support has helped startups in raising significant funding and created over 130 jobs. Our innovation-friendly ecosystem led to the launch of five products in the commercial space including a saliva collection kit, herbal mosquito repellents, a telepresence robot, Pashu Ayurveda for cows, & an AI-powered gait monitoring device.

Total Space Sq. Ft.: 7000

IMPACT



5 most successful incubatees:

- Krishams Healthcare OPC Pvt. Ltd
- ONEOMICS Private Limited
- CROBOT Technologies Private Limited
- BEARLY Technovations Private Limited
- Losjovenes Clinilogic Private Limited

General Infrastructural Services:

ABLEST centre have wet lab workbenches with equivalent linear feet ELF of work surface with chemically resistant lab bench to support the development of PoCs to prototype development. Major facilities include a RCGM-certified BSL-III virology facility, a ISO-13485:2016 compliant manufacturing facility for medical devices, BSL-II compliant mammalian cell culture, complete genomics workflow from nucleic acid extraction to Next-generation sequencing illumina platform Miseq and Individually ventilated cages for small animals at GLP-compliant animal facility, and other existing intense multidimensional research facilities and programmes at SASTRA Deemed University and DST supported FIRST facilities including 3D printing, IoT, VR, AR, Robotics and Drones.

Scientific Support Services:

ABLEST offers the following technical and business services to the Bio-Startups. • Incubation • General Infrastructure access • Scientific support services • Business Advisory and Mentoring services • IPR and Regulatory support • Information services including uninterrupted Wi-fi support for 24/7, Library, cloud facilities • Funding assistance through Start-up India Seed Fund Scheme & SPARSH

Advisory and Mentoring Services:

ABLEST provides comprehensive support to start-ups with deep tech innovations, focusing on areas such as point-of-care devices, medical devices, therapeutics, Agri-tech, and Vet-tech. We assist in developing Minimum Viable Products MVPs and facilitate networking with scientific mentors from SASTRA Deemed University, Tamil Nadu. Additionally, ABLEST offers access to experts from the School of Management and the School of Law within the host institute for valuable legal and business advices. ABLEST offers expert mentors who provide invaluable guidance and industry insights to startups. Combined with our extensive technical, and business expertise, our team delivers a 360° business perspective through personalized one-on-one mentoring, thereby supporting innovative deep-tech ventures at various stages of development.

Incubator Name: Atal Incubation Centre - Centre For Cellular and Molecular Biology

Focus Area: BioIndustrial

Location: Medical Biotechnology Complex,
CMB Annex 2, Genpact Road, IDA Uppal, Habsiguda,
Hyderabad, Telangana-500039

Website:
<https://aic.ccmb.res.in/>

Email:
ritika@ccmb.res.in


Contact No.:
9030131086

About Incubator

The Atal Incubation Centre- Centre for Cellular & Molecular Biology AIC-CCMB was instituted with a precise focus on propelling this objective and nurturing an emerging cadre of entrepreneurs. Established on June 14, 2017, as one of India's first 10 incubators under the Atal Innovation Mission, NITI Aayog, Government of India, AIC-CCMB has quickly become one the top incubator for biotechnology. We have supported more than 150 startups in the past 7 years, out of which more than 40 successfully reached the revenue stage.

Total Space Sq. Ft.: 20000

IMPACT



5 most successful incubatees:

- Athlon Tech Innovations Private Limited
- Magellan Life Sciences Pvt Ltd
- Oncosis Biotech Pvt Ltd
- Acrannolife Genomics Pvt Ltd
- PopVax Private Limited

General Infrastructural Services:




20k sqft plug & play, 24x7 secure lab and co-working facility equipped with best-in-class research equipment available for validating early stage technologies & deep science based innovations in life sciences. - Best-in-class shared equipment managed by a dedicated instrumentations team to keep minimum downtime. - Access to animal house models for regulated and ethical research on animal models including mice, rats, rabbits and hamsters in various fields. - Cell culture facility well equipped with laminar flow hoods, CO2 incubators, microscopes, electroporator, cold room, freezers, and cryopreservation containers. - Molds with hospitals where clinical immersions can be carried out - Access to premium softwares like Tracxn for competitor analysis and market reports. - High-speed internet, basic utilities, parking space, subsidized canteen facility for staff, 24x7 security etc. - Co-working spaces, workstations, meeting pods, privacy telephone booth, 30 seater conference room with video conferencing facilities - Sophisticated testing facilities - Technical support from CSIR Labs - An ecosystem of life-sciences talent pool - Access to information technology & data science capabilities

Scientific Support Services:

Facilities at AIC-CCMB: Prototyping facility with 3D Printer, Laser Cutter, 3D Modelling AutoDesk Fusion 360, Microfluidic Controller System, Nano Fibre Electrospinning unit, Soldering station and small machining tools, Cold storage facilities from 4° to -80° deep freezing, Cell culture facility for yeast and mammalian cells with Biosafety Cabinet Class II, CO2 Incubator and cryopreservation containers, Chromatography facility equipped with HPLC and FPLC, Centrifugation Facility with analytical ultracentrifuge, Other equipment like Real-time PCR, Spectrophotometer, Fluorometer, Rota Vapor, Inverted Microscope, Autoclave, Thermal Cycler, pH Meter, Conductivity Meter. Facilities available with host organization CSIR-CCMB: Advanced Microscopy and Imaging Facility, Next-Gen Sequencing and High-performance Computing Facility, Automated DNA Sequencing with automated capillary array-based DNA Sequencers Model 3730 and DNA Sequencer Model 3730d for high-throughput applications. High-performance Flow cytometer for Stem cell sorting with Bio-Safety cabinet Class-II Automated karyotyping facility, Mass Spectrometry MS based Proteomics Facility, Drosophila and Zebrafish facility, Animal house facility catering to regulated and ethical research on animal models including mice, rats, rabbits and hamsters, Micro Imaging Nuclear Magnetic Resonance Spectroscopy, DNA Microarray Facility, X-ray crystallography.

Advisory and Mentoring Services:

AIC-CCMB offers 360-degree support to empower startups throughout their growth journey. Scientists from CSIR-CCMB serve as scientific experts. We have a technical Advisory Group TAG of AICCCMB, consisting of eminent scientists including Director, CCMB viz: Dr. Vinay Nandicoori, Dr. Rakesh Mishra and Dr. Manjula Reddy alongside external technical and business experts for inputs and guidance. We provide essential contacts for IP, regulatory, company formation, and legal matters. CSIR-CCMB offers internal IP assistance led by Dr. Divya Singh, complemented by collaborations with external IP firms like Patentwire, Avidment, and VideAmilP, experts from NIPAM. Our strong mentorship network, coupled with engagement from CDSA and CDSCO members, ensures startups receive comprehensive regulatory guidance. Transfer AIC-CCMB facilitates the commercialization of intellectual property through a well-defined process covering disclosure, evaluation, protection, marketing, negotiation, and licensing. Streamlined Business Services AIC-CCMB partners with JSS Pro for accounting and legal services outsourcing. Startups can also access support for company formation, legal guidance and compliance adherence with the help of our network of qualified CAs and CS.



Incubator Name: Bannari Amman Institute of Technology - Technology Business Incubator

Focus Area: BioIndustrial

Location: Bannari Amman Institute of Technology - Technology Business Incubator, Sathyamangalam, Erode, Tamilnadu

Website: <https://bittbi.com/>

Email: bitt-tbi@bitsathy.ac.in


Contact No.: 04295226321

About Incubator:

Bannari Amman Institute of Technology - Technology Business Incubator BIT-TBI was established in 2007 by Bannari Amman Institute of Technology, Sathyamangalam, with financial support from the Department of Science and Technology, New Delhi, Government of India. The incubator primarily focuses on biotechnological applications in agriculture and rural industries. Over the years, BIT-TBI has successfully incubated more than 100 entrepreneurs, assisting them with seed funding exceeding 500 lakhs through various funding programs. The incubator is equipped with cutting-edge laboratories for technology development, TRL enhancement, co-working spaces, an IPR cell, mentor studios, and other essential amenities to support innovation and entrepreneurship.

Total Space Sq. Ft.: 18000

IMPACT



5 most successful incubatees:

- BASL Bio Labs
- Technowild Limited
- Phison agritech private Limited
- Nugenica Biotech Labs Private Limited
- Sri Biosys LLP

General Infrastructural Services:

The general infrastructural services at BIT-TBI include over 20 incubatee cubicles and a 3,000 sq. ft. co-working space, mentor and venture studios, seminar and conference halls, plug-and-play labs, and essential basic amenities.

Scientific Support Services:

The incubation and innovation labs span 3,000 sq ft, providing dedicated spaces for nurturing startups. A central research facility, covering 10,000 sq ft, supports cutting-edge research activities. The infrastructure includes over 10 modern, domain-specific labs designed to foster innovation across various sectors. Additionally, the facility features pre-processing and packaging areas, branding arenas, and a venture studio, all aimed at accelerating the growth and success of incubated ventures.

Advisory and Mentoring Services:

BIT-TBI offers a pool of mentors from various domains for personalized one-on-one mentoring, ensuring extensive mentoring hours. Additionally, young professionals are available to assist in technology development, and a strong industry network is in place to help startups scale their businesses effectively.

Incubator Name: Bhubaneswar City Knowledge Innovation Cluster BCKIC

Focus Area: Healthcare, AgriTech, CleanTech, Industry 4.0, Waste Management

Location: Bhubaneswar City Knowledge Innovation Cluster, C/o - Kalinga Institution of Industrial Technology, Bhubaneswar, Odisha

Website: <https://bckic.in/>

Email: ceo@bckic.in


Contact No.: 8249471927

About Incubator:

The Bhubaneswar City Knowledge Innovation Cluster BCKIC Foundation, established as a Section 8 company on February 18, 2022, is a flagship initiative led by the Office of the Principal Scientific Adviser to the Government of India, under the guidance of the Prime Minister's Science, Technology, and Innovation Advisory Council PM-STIAC. BCKIC is dedicated to seamlessly connecting research institutions, academia, industry partners, startups, MSMEs, NGOs, philanthropic foundations, state governments, and international organizations within a Hub & Spoke Model. It aims to address regional and global challenges through consortium-style collaborations, leveraging the complementary strengths of all stakeholders and harnessing the best available expertise and technical know-how through a unified platform. Operating under a formal umbrella structure while preserving internal autonomy, BCKIC creates a shared ecosystem that promotes collaboration among stakeholders for innovation, technology development, and deployment. Additionally, BCKIC is part of a network of six S&T Clusters in Bhubaneswar, Bengaluru, Delhi NCR, Hyderabad, Jodhpur, Pune, Chandigarh & Vishakhapatnam serving as global technology hubs that facilitate the entire spectrum from technology development to the commercialization of solutions, contributing to the growth of the social economy and livelihood generation.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Clinoh Health Innovations Private Limited
- Kalinga Renewable Energy Manufactures Karma Pvt Ltd
- Bariflo Cybernetics Private Limited
- Medtel Healthcare Pvt Ltd
- Invent Grid India Pvt Ltd

General Infrastructural Services:



The BCKIC, currently housed at KIIT TBI as the anchor center in a hub-and-spoke model, offers a comprehensive range of infrastructural facilities designed to foster innovation and entrepreneurship. Spread across a total area of 10,000 sq. ft, it accommodates over 100 seats. The facility is organized across three floors, each dedicated to specific focus areas. The ground floor features office space and meeting rooms for collaborative engagements. The first floor is tailored for deep tech innovations, providing state-of-the-art office spaces, incubation suites, and equipment required for cutting-edge research and development. The second floor focuses on societal innovations, equipped with validation labs for real-world testing and refinement of solutions. The overall infrastructure is well-distributed, with the facility offering 1,000 sq. ft for meeting rooms, 3,000 sq. ft for incubation suites, 2,000 sq. ft each for office spaces and validation labs, and another 1,000 sq. ft for additional infrastructural needs. This well-rounded setup is designed to support a vibrant ecosystem of innovators, researchers, and entrepreneurs working towards impactful technological and societal advancements.

Scientific Support Services:

The Scientific Facilities at BCKIC is an extensive and state-of-the-art ecosystem designed to support startups, researchers, and innovators across a wide range of fields, particularly in biotechnology, healthcare, and technology development. It offers a bio-incubation space with cutting-edge equipment such as biosafety cabinets, gas distribution systems, incubators, and freezers, along with specialized tools like real-time PCR machines and fluorescent microscopes. It also provides essential tools for molecular biology, including spectrophotometers, microcentrifuges, and thermomixers, facilitating research and development in biotechnology. Complementing this, Additionally, the Advanced Microfluidics and Biosensors Laboratory features specialized equipment like an oxygen plasma bonder and 3D printers, essential for cutting-edge research in microfluidics. The Analytical Lab houses high-end analytical instruments such as gas chromatography, high-performance liquid chromatography HPLC, and inductively coupled plasma optical emission spectrometers ICP-OES, making it ideal for chemical and biochemical analysis. The Protein Production Facility is dedicated to large-scale protein expression and purification, equipped with ultra-centrifuges, fermenters, and advanced protein purification systems like the AKTA FPLC. Similarly, the Molecular Biology Lab supports research with PCR thermocyclers, real-time PCR systems, and gel documentation systems, essential for molecular diagnostics and gene expression studies.

Advisory and Mentoring Services:

With a pool of 80+ authentic mentors engaged with varied backgrounds and sectors from both industry and academia, BCKIC conducts regular mentorship sessions focused on technology and business development for startups. Furthermore, startups are anchored with one or more mentors to monitor progress and provide guidance.





Incubator Name: BioNEST Agri Innovation Center, UASB

Focus Area: AgriTech

Location: Agri Innovation Centre,
University of Agricultural Sciences,
Bangalore, Karnataka-560065

Website:
<https://uasbgrinnovationcenter.in/>

Email:
agrinovationsgkv@gmail.com


Contact No.:
9880197154

About Incubator:

The University of Agricultural Sciences, Bangalore UASB has established an Agri Innovation Centre at GVKV campus, fostering innovation and entrepreneurship in agriculture. The centre caters to agriculture graduates, farmers, and individuals with innovative ideas. Its vision is to cultivate pioneering advancements, empower diverse individuals, offer guidance and support to agricultural entrepreneurs, and contribute significantly to India's agricultural startup ecosystem. The BioNEST Agri Innovation Centre, supported by BIRAC under the BioNEST scheme, has state-of-the-art laboratories, office space, and playhouse facilities for startups. UASB AIC, a section 8 company, has received funding from Startup India Seed Fund Scheme to provide financial assistance to start-ups. Four startups have been selected for funding. The centre has created facilities like molecular biology and biotechnology labs, common instrumentation lab, tissue culture facility, and industrial shed with food packaging facility. Since its inception, 60 incubatees have been on-boarded, focusing on Agri & allied sectors. AIC has also organized over 42 training programs on innovation and entrepreneurship and has been nominated as the knowledge partner for the E-YUVA center of UAS Dharwad by BIRAC. The Agri Innovation Centre aims to foster economic growth, empower individuals, and contribute to India's agricultural startup ecosystem. With its state-of-the-art facilities, funding, and training programs, it is a hub of creative ideas and initiatives in the agricultural sector.

Total Space Sq. Ft.: 11021

IMPACT



5 most successful incubatees:

- Cryogen Agri and Biotech Pvt Ltd
- Eco Green Products Pvt Ltd
- Beagle AgriTech Pvt Ltd
- Roots Goods Pvt Ltd
- AgriApp Technologies Pvt Ltd

General Infrastructural Services:

BioNEST Agri Innovation Centre boasts a dedicated 11,000 sq. ft. of built-up area specifically designed for incubation activities. The space is strategically divided as follows: Incubation Centre with Office Space & Lab Facilities: 7,254 sq. ft. allocated for incubation activities, including office space and state-of-the-art laboratory facilities. Mist Chamber: 600 sq. ft. dedicated to maintaining optimal humidity and temperature conditions for sensitive agricultural experiments. Net House: 2,500 sq. ft. reserved for controlled environment agriculture, allowing startups to test and grow crops in a protected environment. Food Processing-Industrial Shed: 667 sq. ft. equipped for small-scale food processing operations, enabling startups to develop and test food products. Facilities Offered to Incubatees: Common Instrumentation Lab: The BioNEST AIC has established three well-equipped common molecular biology and biotechnology instrumentation labs. These labs feature both basic and advanced equipment necessary for startups to engage in product development, testing, and validation. Mini Laboratory: For startups that have already established their operations, BioNEST AIC provides Mini Laboratories. These labs offer larger facilities where startups can bring their own instruments for extensive research and product development. Mini Chambers: Startups are provided with individual office spaces, fully furnished and equipped with high-speed internet. These chambers are ideal for client meetings, discussions, and day-to-day operations. Co-working Facility: BioNEST AIC offers a co-working space designed for startups focused on app development and other non-laboratory-based activities. Conference Room: A 100-seater conference room is available for organizing events, workshops, and seminars. Discussion Room: Dedicated spaces for one-on-one mentoring sessions and client discussions are provided to ensure that startups have the privacy and resources needed for productive meetings. Storage Facility: Startups are offered a secure storage area where they can keep raw materials and other essentials needed for their product development processes.

Scientific Support Services:

The BioNEST Agri Innovation Centre offers an array of scientific support services to incubatees. The services include: Technical Mentoring: Startups are paired with scientists from UASB who provide specialized technical guidance. Tissue Culture Facility: Provides state-of-the-art facilities for maintaining a repository for biological materials, serving as a storage and distribution hub for materials from student research. Cold Room Facility: Startups have access to cold room facilities designed for the storage of seeds, parental materials, and other sensitive biological specimens that require low-temperature conditions to maintain viability. Advanced High-End Equipment: We provide extensive range of advanced biotechnology equipment, critical for testing and validating innovations. The list of high-end instruments includes: BSZ2 Laminar Hood, Stereomicroscope, UV Spectrophotometer, Deep Freezers -80°C and -20°C, PCR Machines, Refrigerated Centrifuge, Neph Drop, Gel Electrophoresis, Laminar Air Flow Unit, Microscopes, Incubators, Hot Air Oven, Food Packaging Machine, Centrifuge with Various Biotar Adapters, Gel Documentation Unit, Water Bath with Temperature-Controlled Shaker, Steam Blancher, Flame Photometer, Muffle Furnace, BOD Incubator, Dry Bath Incubator, Rotary Evaporator, Mist Chambers. Specialized mist chambers are available, providing startups with the capability to maintain optimal humidity and temperature conditions necessary for conducting sensitive agricultural experiments. Greenhouse Facility: Startups are facilitated with access to greenhouses that allow for controlled environment agriculture, enabling the testing and cultivation of crops in a protected setting. Industrial Shed: Offers an industrial shed equipped with small-scale food processing operations, including facilities for product packaging.

Advisory and Mentoring Services:

Business Mentoring: BioNEST AIC has empanelled experienced business mentors from various industries and has established collaborations with organizations such as the SID, IISc Bangalore, BIRAC, AIC, Coffee Board, and NaVIC. ICR-NEVEDI Incubation Centre, Legal and Regulatory Advice: Startups are connected with legal and regulatory experts including company secretaries, chartered accountants, and PSAL certification agencies. Business Strategy and Planning: Assists startups in crafting robust business plans and growth strategies. This support encompasses market analysis, competitive positioning, and business model refinement, helping startups to strategically position themselves in the market. Funding and Investment Advisory: Offers guidance on securing funding, including grants, venture capital, and angel investors. Startups receive support in preparing pitch decks, financial projections, and investor presentations. Intellectual Property IP Management: Startups are advised on protecting and managing their intellectual property, including patents, trademarks, and copyrights. Also organizes sessions on IP management to ensure startups are well-informed about the processes. Market Access and Go-to-Market Strategy: Mentors provide critical assistance in helping startups understand their target markets, customer needs, and distribution channels. Startups receive guidance on developing effective go-to-market strategies, including pricing, marketing, and sales tactics to ensure successful product launches. Product Validation and Testing: Demonstration: Mentoring on the validation and testing of products to ensure they meet industry standards and customer expectations. This includes advice on conducting pilot studies, gathering and analyzing customer feedback. Facilitated for Product demonstration through Director of Research, UASB. Networking and Industry Connections: The Centre connects startups with industry leaders, potential customers, and other key stakeholders within the agriculture and biotechnology sectors. Startups benefit from networking opportunities through events, workshops, and conferences. Demo Day/Field Day: Organizes events such as demo days and field days to facilitate the launch of startups' products, providing them with a platform to showcase their innovations to a broader audience.

Incubator Name: BioNEST DMIHER

Focus Area: MedTech

Location: Datta Meghe Institute of Higher Education and
Research Deemed to Be University
Sawangi, Wardha, Maharashtra -442107

Website:
<https://bionestdmiher.com>

Email:
bionestdmiher@gmail.com


Contact No.:
9890417646

About Incubator:

The Bio-NEST DMIHER Centre is a leading bio incubator in central India, offering a comprehensive range of facilities and services to support startups in biotechnology, Medtech, and bio-pharma. It features advanced labs, including NABL-certified facilities, a Central Research Lab, and a clinical setting within a NABH-accredited 1500+ bed hospital. Startups benefit from pre-clinical testing services, an advanced simulation lab, and robust support for clinical trials through the ICMR INTENT network. The center provides expert advisory and mentoring through a network of clinicians, superspecialists, biostatisticians, and innovators, offering guidance on clinical development, data analysis, and business strategy. Additional services include regulatory and IP consultation, strategic business support, and assistance with grant submissions. Community engagement is a key focus, with the center actively participating in educational programs, outreach initiatives, and collaborative networks. Overall, the Bio-NEST DMIHER Centre delivers a holistic support system designed to accelerate innovation, ensure regulatory compliance, and drive successful startup commercialization in the life sciences and healthcare sectors. The center provides expert advisory and mentoring through a network of clinicians, superspecialists, biostatisticians, and innovators, offering guidance on clinical development, data analysis, and business strategy. Additional services include regulatory and IP consultation, strategic business support, and assistance with grant submissions. Community engagement is a key focus, with the center actively participating in educational programs, outreach initiatives, and collaborative networks. Overall, the Bio-NEST DMIHER Centre delivers a holistic support system designed to accelerate innovation, ensure regulatory compliance, and drive successful startup commercialization in the life sciences and healthcare sectors.

Total Space Sq. Ft.: 17000

IMPACT



5 most successful incubatees:

- PRECISUR PVT LTD.
- SINDKOLPO PRIVATE LIMITED
- Iva Medical Technology Private Limited
- ATIVEN TECHNOINVENTION PRIVATE LIMITED

General Infrastructural Services:

Bionest DMIHER, located in central India at Wardha and Nagpur, is a leading bio incubator designed to turn innovative ideas into successful products. We offer a comprehensive ecosystem tailored for startups in the life sciences and healthcare sectors. Incubation Facilities: Customizable Workspaces: Flexible offices, co-working spaces, and specialized labs designed to support both early-stage startups and growing ventures. Prototyping & MVP Development: Access to advanced equipment, including 3D printing and biomedical tools, for rapid prototyping and product development. Clinical Immersion: Hands-on experience in a 1500+ bed tertiary care hospital, offering direct interaction with patients and healthcare professionals. Available Resources: Pre-Clinical & Cadaveric Labs: Fully equipped labs for pre-clinical testing and research, including animal facilities and cadaveric labs, essential for product validation. Advanced Simulation Lab: High-fidelity mannequins and immersive environments for testing and refining healthcare solutions. Regulatory & IP Support: Guidance through the regulatory landscape, including clinical trials, certifications, and intellectual property management. Mentorship & Networking: Direct access to clinical mentors, industry experts, and academic leaders, with regular events to connect with partners and investors. Accredited Labs: On-site accredited laboratories for product testing, ensuring compliance with industry standards. Additional Services: Business Development: Strategic support in business planning, market analysis, and fundraising to accelerate growth. Resource Mobilization: Assistance in securing funding through grants and venture capital, along with building strategic partnerships. Legal Support: Expert legal advice and contract management to protect your innovations. Bionest DMIHER provides everything needed to propel startups from concept to market success, offering the resources, expertise, and environment to thrive in the competitive life sciences and healthcare industries.

Scientific Support Services:

Bionest DMIHER is a bio incubator that offers a comprehensive suite of scientific support services, advanced facilities, and strong community engagement to accelerate the growth of startups in the life sciences and healthcare sectors. Scientific Support Services: Clinical Trial Support: As part of the ICMR INTENT network, we provide end-to-end clinical trial support, from protocol development to data analysis, ensuring high clinical research standards. NABL-Accredited Hospital: Our NABL-accredited tertiary care hospital offers an ideal setting for clinical testing and real-world validation, giving startups access to critical healthcare resources. NABL-Certified Labs: Access to our NABL-certified labs ensures precise testing, rigorous quality control, and global standard compliance. Advanced R&D Facilities: Central Research Lab: Our state-of-the-art Central Research Lab is equipped with the latest technology for testing, validation, and research, transforming innovative ideas into market-ready products. Pre-Clinical Testing: We provide specialized pre-clinical testing services, including animal facilities and cadaveric labs, essential for thorough product development and safety assessments. Regulatory Consultation: Our regulatory experts guide startups through the complexities of clinical trials and product approvals, ensuring compliance with all necessary requirements. Additional Services: Grant Submission & IP Management: We assist with securing grants and protecting innovations through comprehensive intellectual property services, including patent filing and strategic IP management. Community Outreach: Engagement & Education: We actively engage with the community through educational programs, workshops, and health initiatives, fostering a culture of innovation and awareness. Collaborative Networks: We build strong partnerships with academia, industry, and healthcare institutions, creating opportunities for startups to collaborate and contribute to the broader community. Bionest DMIHER is dedicated to driving scientific innovation while making a positive impact on the community, providing startups with the resources and support needed to thrive in the competitive life sciences and healthcare industries.

Advisory and Mentoring Services:

The Bio-NEST DMIHER Centre offers a robust suite of advisory and mentoring services designed to accelerate the growth of startups and innovators in the biotechnology, Medtech, and bio-pharma sectors. Advisory & Mentoring Services: Expert Clinician Guidance: Our network of experienced clinicians provides invaluable insights into clinical development, offering tailored advice on translating innovative concepts into practical, patient-centered solutions. Their expertise ensures that your ideas align with real-world healthcare needs. Specialized Mentorship: Access to superspecialist centers means your startup benefits from the knowledge and experience of top-tier medical professionals and researchers. This specialized mentorship helps you navigate complex medical challenges, refine your product, and enhance its impact. Biostatistics & Data Analysis Support: Our biostatisticians offer expert consultation on study design, data analysis, and interpretation, ensuring your research is statistically robust and scientifically sound. This support is critical for developing credible and impactful innovations. Innovative-Led Insights: Engage with successful innovators with firsthand experience bringing products to market. Their mentorship covers everything from R&D to commercialization, providing you with practical strategies to overcome obstacles and scale your venture. Additional Support: Strategic Business Guidance: Beyond scientific advice, we provide strategic business mentoring, helping you craft a business model, identify market opportunities, and develop a go-to-market strategy that maximizes your innovation potential. Networking Opportunities: We facilitate connections with industry leaders, investors, and academic institutions, expanding your professional network and opening doors to collaboration, funding, and new markets. Regulatory & IP Consultation: Receive expert guidance on navigating regulatory requirements and protecting your intellectual property, ensuring your innovation is both compliant and safeguarded. The Bio-NEST DMIHER Centre's comprehensive advisory and mentoring services are designed to empower startups with the knowledge, connections, and strategic insights needed to thrive in the competitive biotechnology, Medtech, and bio-pharma landscapes.



Incubator Name: BioNEST, Panjab University, Chandigarh

Focus Area: Bioprocess technology, biopharmaceuticals, food and agricultural biotechnology

Location: BioNEST
New Hospital Building, Near Dental College,
South Campus, Panjab University, Chandigarh-160014

Website:
<https://bionest.puchd.ac.in/>

Email:
bionestpu@pu.ac.in


Contact No:
9914461545

About Incubator:

BioNEST Panjab University has always envisioned ideas turning into reality. We aim to promote start-up culture in India under Make-in India and Atma nirbhar Bharat campaign. By providing complete technology building platform. We have developed a pre-incubation space, incubation space and post incubation facility through funding received from BIRAC, New Delhi. The bio-incubation spaces are committed to deliver and provide, its incubatees and anchor associations, state-of-the-art infrastructure, technical, administrative, purchase, networking & scientific support. Complete technology building platform with state-of-the-art laboratories has been established and has resulted in tangibles. There are 26 start-ups/ Innovators incubated at BioNEST. Some has reached above TRL 4-5 and 2 start-ups have passed TRL-9. Five products have been successfully launched and 2 start-ups have received fund for validation & scale-up. 10 start-ups have received funding through BIG/ BIG like grants, 20-50 Lakhs each for developing POC's. We have 4 BIG awardees and 5 SAEN awardees. BioNEST-PU has facilitated Intellectual property protection for over 15 patents in last seven years. Start-ups incubated with us have received national/ international recognitions through national awards and international visits & trainings. This also acts as a pipeline of incubates in the system. A large amount of funding from industry for collaborative Research & Development for Proof-of-concept POC, Post-POC & scale-up studies & certain joint initiatives in the areas of Bioprocess engineering, Biopharmaceuticals with core focus on vaccine under healthcare segments has been taken.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Biobridge Healthcare Solutions Pvt Ltd.
- AKB Innovant Healthcare Pvt. Ltd.
- Microradical360 Pvt. Ltd.
- Trishveda Naturals Pvt. Ltd.
- Mritarch Assiduities Pvt. Ltd.

General Infrastructural Services:

1. Microbiology laboratory. 2. Molecular Biology Facility. 3. Analytical Facility with HPLC. 4. Scale-Up Facilities 7L, 25 L & 250 L 5. Cell Culture Facility 6. BSL-2 Facility 7. Plug & Play Facility 8. Open-Library 9. Mini Sterilization Unit 10. Scale-Up Facilities Upto 250 L 11. Manual Bottle Small Scale Packaging Unit. 12. Hot Desking- Office space for Start-ups. 13. Wet-Lab for Start-ups/ incubatees. 14. Cafeteria 15. Board room for meetings. 16. One-on-One interaction spaces. 17. LAN and Wi-Fi facilities

Scientific Support Services:

1. Purification of proteins through fully equipped proteomics platform
2. Analytical support for product identification
3. Characterization and authentication of products/ molecules
4. Bioprocess technology development
5. Process development
6. Standardization and scale-up of all types of bioprocesses up to 250 L
7. High-throughput screening of active compounds
8. Development of Cell banks
9. In-vitro testing of biologically active molecules for different pharmacological properties
10. Gene expression analysis
11. Turn-key projects for setting up large scale facility

Advisory and Mentoring Services:

1. Purification of proteins through fully equipped proteomics platform
2. Analytical support for product identification
3. Characterization and authentication of products/ molecules
4. Bioprocess technology development
5. Process development
6. Standardization and scale-up of all types of bioprocesses up to 250 L
7. High-throughput screening of active compounds
8. Development of Cell banks
9. In-vitro testing of biologically active molecules for different pharmacological properties
10. Gene expression analysis
11. Turn-key projects for setting up large-scale facility

Incubator Name: BioNEST-Banaras Hindu University BHU

Focus Area: BioTech, MedTech, AgriTech, BioEnergy, BioIndustrial, BioService

Location: BioNEST-BHU
4th Floor, CDC Building, Banaras Hindu University,
Varanasi-Uttar Pradesh

Website:
<https://bionestbhu.org/>

Email:
bionestbhu@bhu.ac.in


Contact No:
8076696601

About Incubator:

BioNEST-BHU, a bio-incubator facility is an initiative of InnoResTech Foundation, BHU, a Section 8 company under The Company Act 2013, created by the Institute of Science, Banaras Hindu University, Varanasi to foster entrepreneurship in the areas of Life Sciences, Biotechnology, Healthcare, Agriculture, Secondary Agriculture, Food Technology, and other allied areas. BioNEST-BHU is developed in about 10000 sqft area on the 4th floor of the Central Discovery Centre CDC building, BHU. BHU provides an excellent ecosystem for interdisciplinary translational research and its validation. BioNEST-BHU intends to translate the expertise, experience, and excellence of BHU researchers for welfare and wealth through innovation and entrepreneurship. BioNEST-BHU is consistently mentoring and nurturing bio-entrepreneurs/innovators having translational ideas to generate new opportunities for business and self-employment by leveraging the expertise of the faculty and equipment facility of BHU. BioNEST-BHU core team led by Prof. Rajeshwar P Sinha, Director & CEO, InnoResTech Foundation, BHU, and Coordinator Incharge consists of Prof. S.B. Agrawal Deputy Coordinator, Dr. Durgesh Narain Singh Scientific Officer, and Mr. Ravi Prakash Singh Technical Officer. To create awareness among faculties, students as well innovators BioNEST-BHU is consistently organizing seminars, webinars, ideathons, hackathons, and workshops, and training programs. Currently, a total of 38 startups are incubated in BioNEST-BHU. We connect startups/innovators to different stakeholders including Venture Capitalists, AIs, Industries, Patent attorneys, CA, etc

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Scitech Research and Technology Private Limited
- Dr. Abhishek Kumar Dwivedy
- Flavins Labs Private Limited
- Taumed Technology Private Limited
- Miron LLP

General Infrastructural Services:

1. Laboratories: BioNEST-BHU provides laboratory facilities 5000 square feet to innovators/startups for product development. In addition, innovators/startups associated with BioNEST-BHU have access to high-end equipment available in SATHI-BHU and BHU at the same rate fixed for BHU students
2. Office cum Workspace: As per requirement BioNEST-BHU provides office space (300 square feet to innovators/startups)
3. Other facilities: BioNEST-BHU provides access to meeting & conference rooms, internet/WiFi facility, Lobby and refreshment zone

Scientific Support Services:

1. Mentors: BHU has two campuses, 5 institutes, 16 faculties, 140 departments, 4 advanced centers, and 4 interdisciplinary schools. Innovators/Startups incubated at BioNEST-BHU have access to facilities for mentoring and all facilities available in BHU. We have a total pool of 78 mentors from all disciplines including Biotech, Life science, Healthcare, Agriculture, Nanotechnology, Food and dairy science, AI and data science, Environment and energy, Management study, and business mentors.
2. Access to High-end Equipment: In addition to instruments available in BioNEST-BHU lab, we also provide access to different high-end equipment available in BHU and IIT BHU
3. Access to Funding Opportunities: We are consistently contacting faculties, students, and startups to educate them about the types of grants /facilities available to start their own businesses with a single, novel idea. We are mentoring to write an application for the Biotechnology Ignition Grant BIG scheme, a flagship program of BIRAC, Govt. of India that provides INR 50 Lakhs for prototype developments. In the last three years, we encouraged and provided mentorship to more than 100 innovators for writing and submitting proposals for different grants. Despite a tough competition 13 applications worth 2.945 Cr has been awarded.
4. Technology Transfer and Licensing: BioNEST-BHU supports transferring research findings and technologies to industry partners.

Advisory and Mentoring Services:

1. Mentors: BHU has two campuses, 5 institutes, 16 faculties, 140 departments, 4 advanced centers, and 4 interdisciplinary schools. Innovators/Startups incubated at BioNEST-BHU have access to facilities for mentoring and all facilities available in BHU. We have a total pool of 78 mentors from all disciplines including Biotech, Life science, Healthcare, Agriculture, Nanotechnology, Food and dairy science, AI and data science, environment and energy, Management study, and business mentors.
2. Networking: BioNEST-BHU startups/innovators to different stakeholders including Venture Capitalists, AIs, Industries, Patent attorneys, CA, etc.



Incubator Name: BioNEST-UDSC, University of Delhi South Campus

Focus Area: Development of various bio actives for Industrial and Agricultural sectors & Development of mol.

Location: Biotech Building, University of Delhi, South Campus

Website:
<https://bionest.du.ac.in>

Email:
bionest@south.du.ac.in


Contact No.:
01124157371

About Incubator:

The Bio-incubator is established with the objective of supporting incubation for juvenile technologies developed by entrepreneur scientists. Our mission is to support Start-ups and Innovators in taking their Innovation from the laboratory bench to the market by providing infrastructure, mentoring and incubation support in the early stages of their entrepreneurial journey. The provided support aims to ultimately promote the translation of fundamental work to viable technologies and to facilitate the maturation and commercialization of technologies developed at the Bio-incubator. BioNEST-UDSC also aims to foster translational research, enabling the academic researcher to commercialize a viable process/ technology/ product. Our vision is to bridge the gap between academia and industry through our efforts.

Total Space Sq. Ft.: 8800

IMPACT



5 most successful incubatees:

- Bioheaven 360 Genotac Pvt Ltd
- Inte-e-labs Pvt Ltd
- Labex Recombinant Proteins Pvt Ltd
- Sodhani Biotech Pvt Ltd
- ESCO Global Pvt Ltd Absolute

General Infrastructural Services:

The BioNEST-UDSC is housed on the Ground Floor of the Biotech Building of University of Delhi, South Campus. It has state-of-the-art Infrastructure, with modern laboratories and equipment for Life Sciences research/technology and product development. Infrastructure being offered to Incubatees includes laboratory benches as well as laboratory modules to suit the needs of the Incubatees. Additional facilities includes High speed internet, campus library accesses, Central Instrument Facility CIF access, 24hr Power back, Meeting room, Cold room etc.

Scientific Support Services:

The BioNEST-UDSC provides scientific support by providing access to high end sophisticated instruments including micro/ultrafiltration unit, constant flow cell disruptor, sonicator, Fluorescence Microscope, table top lyophilizer, industrial scale freeze drier, mini spray drier, high performance liquid chromatography and gas chromatography, ultracentrifuge, BOD and COD incubators, PCR, Electroporator, Fermenters upto 240 lt working volume etc.

Advisory and Mentoring Services:

The BioNEST-UDSC is under guidance of experienced faculties of Department of Microbiology, South Campus, University of Delhi, who have vast experience in different fields of Microbiological research and development. Incubatees can seek their mentorship at any level of product development.

Incubator Name: BIRAC E-YUVA Centre, UAS Dharwad

Focus Area: AgriTech

Location: Department of Biotechnology, University of Agricultural Sciences, Dharwad

Website:
<https://acsl.uasd.edu/index.php/biotechnology/>

Email:
narayanmoger1313@gmail.com


Contact No.:
9480459906

About Incubator:

The Department of Biotechnology at UAS, Dharwad was started in 1998. It was supported by the forethought of the Vision Group on Biotechnology, Government of Karnataka to set up the state-of the-art molecular biology laboratories in 2002. BIRAC E-YUVA Centre formerly known as BIRAC - NInC - UIC was started in 2014 which is being supported and funded by Biotechnology Industry Research Assistance Council BIRAC till date has groomed nine individuals and five teams in laying down their foundations to bloom into being an Entrepreneur by providing State - of - the art Laboratories, Distinguished Mentors, Exclusive Infrastructure and a very rewarding atmosphere. Currently, we are supporting five teams of E-YUVA fellows UG Students from various institutes and four E-YUVA Innovation fellows who are working on their ideas and start their journey towards entrepreneurship in field of Agriculture and Biotechnology.

Total Space Sq. Ft.: 3550

IMPACT



5 most successful incubatees

- Dr. Basavaraj Girennavar
- Dr. K. R. Rajyashri
- Mr. Deepak Bajanthri
- Mr. Abhinav J. V.
- Mrs. Neeta P. Gai

General Infrastructural Services:

Office rooms, Video conferencing facility, Seminar halls, Community radio station, Hostel facility, Meeting rooms etc

Scientific Support Services:

Molecular Biology Laboratories, Common Instrumentation facility, Incubation facility for startups, Bioinformatics facility and e-LAB, Genome sequencing labs, Tissue culture labs, Hydroponics facility, Shade houses, Glass Houses, Green houses, large agricultural fields for large scale experiments, Orchards of different crops, plantations, Nanotechnology Labs, Soil testing Labs, Microbiology Labs, Pesticide analysis lab, Water quality checking labs, Textile labs, Food Technology Labs, Organic farming labs and fields, seed testing labs, Quality analysis lab, Gene Bank facility, Meteorological Lab, Weather stations, Agricultural Engineering Labs, Entomology Labs, Pathology Labs etc.

Advisory and Mentoring Services:

The centre is in the main campus of University of Agricultural Sciences Dharwad, since the University has strong network of Scientists of different disciplines of Agriculture, Alumni and research institutes & industries collaborations therefore the incubatees can have mentorships from any of the above-mentioned based on their need.



Incubator Name: BITS Goa Innovation Incubation & Entrepreneurship Society BGIIES BITS BIRAC BioNEST

Focus Area: Agriculture, education, energy, food processing, healthcare, mobility, waste management, water management

Location: BITS, Pilani K K Birla Goa Campus Near
NH 178, Bypass Road Zuarinagar Goa

Website:
<https://www.bgiies.com/>

Email:
bionest@goa.bits-pilani.ac.in

Contact No.:
9944545247

About Incubator:

BITS BIRAC BioNEST was initially set up under BIRAC BioNEST funding and supported startups in health care & environment. Since the year 2020, the incubator has been supported by BITS Goa Innovation Incubation & Entrepreneurship Society BGIIES, a Society under Societies Registration Act, 1860. The incubator supports the india startups in the ideation stage / pre-seed stage with the pre-incubation program & the startups in the MVP / seed stage with its incubation program. Currently, BGIIES is running Startup India Seed Fund Scheme under which 15 startups have benefited.

Total Space Sq. Ft.: 3500

IMPACT



5 most successful incubatees

- Greengrahi Solutions Pvt Ltd
- Greenshift Energy Pvt Ltd
- Intellicon technologies Pvt Ltd
- Magellan Life Sciences Pvt. Ltd.
- Technergio Private Limited

General Infrastructural Services:

7 Office Rooms with 28 Seats, AV Conference room with 20 Seating, Innovation Lab with 16 Workbenches and 44 Seats, Innovation Lab Cell Culture, Molecular Biology, Microbiology, Physicochemical Analysis, Sample Processing Areas, Access to BITS Pilani Goa Campus facilities, Labs, and equipment, Brainstorming Gardens for open air meetings and brainstorming, Other Infrastructure Facilities Printing, Pantry, Library

Scientific Support Services:

Access to in house support Faculty, Research scholars, Student interns

Advisory and Mentoring Services:

Mentors, Investors, Corporates, Alumni, Academia, Researchers, Funding agencies and Government

Incubator Name: BITS Pilani Hyderabad campus TBI Society

Focus Area: BioPharma & MedTech

Location: BITS Pilani Hyderabad campus TBI Society
TBI Birla Institute of Technology & Science

Website:
<http://www.tbi.bits-pilani.ac.in>

Email:
tbi@hyderabad.bits-pilani.ac.in


Contact No.:
+919584114787

About Incubator:

BITS Pilani Hyderabad campus houses a technology business incubator called BITS Pilani Hyderabad Campus TBI Society henceforth referred to as "TBI" or "the TBI" since 2012 to encourage innovative entrepreneurship, and to facilitate translation of knowledge or technology-driven innovations from within and outside the institute. TBI was initially established with the support of National Science and Technology Entrepreneurship Development Board NSTEDB, DST, Govt. of India and is currently being supported by the intramural budget. Right from its inception, TBI has major focus on fostering technology / knowledge-based start-ups in the areas of Pharma & Biopharma, ICT in Healthcare, Medical Devices, Biotechnology, MicroElectroMechanical Systems MEMS for Diagnostic devices and PoC healthcare. Being an incubator housed at academic institute with 12 different departments, TBI is welcoming for sector agnostic innovations. However, start-ups and innovators from Healthcare sector including Invitro Diagnostics IVD, MEMS, Pharma and Bio-Pharmaceuticals has always been predominant incubatees at TBI. TBI currently houses 21 startups for incubation and eight student pre-startups. TBI has incubated and supported 55 startups and around 20 student pre-startup in the past. Notably, 12 of TBIs present and past incubatees are the recipient of prestigious BIRAC Grants.

Total Space Sq. Ft.: 7800

IMPACT



5 most successful incubatees:

- Allalus Technology Pvt Ltd
- Azyom SpaceTech Pvt Ltd
- Chrome Innovations Pvt Ltd
- Azevel Healthcare Pvt Ltd
- Applied AeroLabs

General Infrastructural Services:

Current infrastructure at TBI is well suited to catering the early to mid-stage innovative start-ups by providing them with lab infrastructure, instrumentation facilities, office cubicles, co-working area, prototyping facility and access to the state-of-the-art instrumentation facility of the institute. The existing TBI is spanned over 7800 SFT and the details of the existing facility are as follows: TBI BioLab: TBI has a dedicated Biotech / Pharma lab of over 2,000 SFT with common instrumentation facility, chemical hoods, cell culture facility, bacteriological lab, refrigeration room, media room, wash & autoclave area and dedicated lab premises to host biotech and pharma/biopharma start-ups. TBI Office Premises: TBI has office premises comprising of 12 individual offices and co-working space with 34 hot-desks & chairs. TBI currently houses 15 incubatees start-ups and 10 student pre-incubatees teams. TBI office is equipped with a dedicated conference room, discussion room, brainstorming area, reception, pantry and utility area. Prototyping facility: TBI shares design and prototyping facility with Sandbox & Tinker's lab spanning over 3,000 SFT. The premises include prototyping devices and tools co-created with TBI support, readily accessible for incubatees start-ups and student innovators. Some of the prototyping tools at prototyping facility includes SLA Printer, 3D Printers, 35W Laser Engraving machine, DimiLite Digital microscope, 2D scanner, etc. In addition, the incubator and student innovators can also access the institute's highly equipped prototyping facility on need basis.

Scientific Support Services:

In addition to TBI BioLab & Prototyping facility, Incubatees at TBI are provided with access to institute facilities such as, Central Analytical Lab facility, Animal House facility, Clean Room facility, Departmental Facilities, and High-end Computational facility, which are detailed below: Central Analytical Laboratory (CAL): Comprehensive analytical laboratory equipped with sophisticated instruments for characterizing biomolecules, drugs and materials. NMR facility, facility for microscopy laser scanning confocal microscope, high resolution scanning electron microscope, cell sorter, flow cytometer and single crystal small molecule XRD are the essential highlights. Clean Room Facility: State of the art clean room facility equipped with advanced systems for MEMS-based systems and capabilities for bioprocessing. The class 100 & class 1000 facilities spread in 600 sq ft are equipped with an array of equipment to support MEMS based technology development. The facility is capable to support bio-processing such as IVD assembly and prototyping with upgradation for relevant ISO certifications. Central Animal Facility: CSIR approved Fully equipped animal house facility for preclinical research and testing, specifically in the areas of neuro-pharmacology, oncology and metabolic disorders. The live animal imaging facility, facilities to conduct research on behavioural pharmacology and a facility dedicated towards housing immunocompromised mice are the essential highlights. Facilities in the Department of Pharmacy: Well-equipped departmental facilities tailored for pharmaceutical research, formulation and development offers bio-entrepreneurs access to specialised equipment and expertise for drug discovery, formulation optimisation, and pharmacological studies. MMNE Lab: A collaborative effort across the various departments which consists of various fabrication, characterisation and testing facilities in the domain of Bio-MEMS and microfluidics for technology development in bio-chemical sensing. Collaborative Research: TBI facilitates collaborations with BITS faculty and other research institutions, enabling startups to leverage additional expertise and resources. This includes opportunities for joint research projects, access to specialized facilities, and research partnerships.

Advisory and Mentoring Services:

Empowering startups with expert guidance is at the heart of what we do at TBI. Our advisory and mentoring services are designed to provide entrepreneurs with the strategic insights, industry knowledge, and hands-on support they need to navigate the complexities of building and scaling a business. Office of Research and Innovation (ORI) The multifactorial objectives of the office range from motivating faculty members and start-ups in scouting for funding opportunities, IPR filing, industry connects and the Technology Transfer process. Technology Enabling Center (TEC) A Technology Enabling Centres TEC is established at BITS Pilani through initiatives of Technology Translation and Innovation TTI Division of the DST. BITS TEC brings together the regional academic institutes, R&D institutions, industry, MSMEs, start-ups, and incubators on a common platform for enabling research, innovation, technology development, improvement, and commercialization while leveraging its core strength of strong industry engagement. Mentoring network at TBI: Bio-entrepreneurs can leverage mentorship for guidance, advice, and strategic direction in navigating the complexities of entrepreneurship and commercialization. We connect our incubatees with a network of over 60 experienced mentors from diverse industries. TBI also has access to a team of chartered accountants and company secretary to extend their support to the biotech incubators, offering invaluable guidance on financial management, compliance and strategic planning. Faculty expertise in thrust areas: The institute has diverse faculty expertise spanning key areas of biotechnology, pharmacology, bioinformatics, and regulatory affairs. Bio-entrepreneurs can tap into faculty knowledge and research capabilities for technical guidance, mentorship, and collaborative research endeavours. Industry connects: Past and present ties and collaborations with industry partners and hospitals can facilitate networking opportunities, partnerships, and access to resources for the incubate startups. Workshops and Training Programs: TBI organizes regular workshops, seminars, and training programs led by industry veterans, thought leaders, and legal & financial experts.



Incubator Name: BSC BioNEST Bio-Incubator BBB, RCB, Faridabad

Focus Area: BioIndustrial

Location: NCR Biotech Science Cluster,
3rd Milestone, Faridabad-Gurugram
Expressway Faridabad - 121001

Website:
<https://bbb.rcb.res.in/>

Email:
bbb@rcb.res.in


Contact No.:
0129-2848-625/606

About Incubator:

BSC BioNEST Bio-Incubator BBB, a leading bio-incubation facility supported by DBT-BIRAC's BioNEST scheme, has become the preferred destination for aspiring bio-entrepreneurs looking to transform their innovative ideas into commercially viable products with significant medical and environmental impact. Situated within the NCR Biotech Science Cluster, BBB boasts a state-of-the-art 35,000 sq. ft. ecosystem equipped with central instrumentation, lab and culture facilities, and office suites. To date, it has supported 53 startups focused on areas such as diagnostics, healthcare, med-tech, industrial biotech, biopharma vaccines & therapeutics, and environmental and agro-food technologies. Startups at BBB benefit from a range of services, including IP support, business mentorship, strategic guidance, funding assistance, and access to a pool of mentors and the Advanced Technology Platform Centre. Recently recognized as an 'Associate BIRAC Partner,' BBB continues to draw in emerging innovators. Its programs align with national initiatives such as Skill India, Make in India, and Aatma Nirbhar Bharat, contributing to capacity building and self-reliance in the biotech sector. Additionally, the Bio-Incubator has secured funding under the Startup India Seed Fund Scheme SISFS from DPIIT, Government of India, to further bolster its entrepreneurial ecosystem. The Regional Centre for Biotechnology RCB has also been officially recognized and registered as a Host Institute HI under the Ministry of Micro, Small, and Medium Enterprises MSME Scheme. Leveraging this recognition, BBB has been actively supporting startups under the MSME scheme, reinforcing its dedication to fostering innovation and entrepreneurship within the biotechnology sector.

Total Space Sq. Ft.: 35000

IMPACT



5 most successful incubatees:

- Vanguard Diagnostics Pvt. Ltd.
- Dharaksha Ecosolutions Pvt. Ltd.
- Anziam Bio Pvt. Ltd.
- Translational Research and Innovations Pvt. Ltd.
- Incredible Devices Pvt. Ltd.

General Infrastructural Services:

BBB has huge infrastructure dedicated to serve startups. Incubation center has labs of different denominations for incubation. It offers shared lab benches as well as independent cubicles to incubates and Pls. Two Common Instrumental Facilities CIF and 3 culture rooms have been set up to support the startups. Dedicated office space, lab facilities, seminar and meeting rooms for hosting team meetings, client meetings, workshop, seminars, networking events and presentations are offered. BBB provides high speed internet access, Wi-Fi, printing, scanning support, IT services, administrative support services, attendance records, recruitment assistance, security services, ethical approvals etc.

Scientific Support Services:

BBB has dedicated lab spaces for startups to conduct experiments, develop prototypes and accelerate their research & development. These labs are equipped with necessary infrastructure such as workbenches, sinks, and safety equipment. Dedicated technical staff is involved in assisting startups in handling/ maintaining equipment's and execution of assays. BBB's Central Instrumentation Facility CIF is outfitted with both basic and advanced instruments to bolster interdisciplinary academic and entrepreneurial research pursuits in fields such as diagnostics, healthcare, med-tech, industrial biotech, biopharma vaccines & therapeutics, environmental and agro-food technologies.

Advisory and Mentoring Services:

BBB offers a pool of expert mentors specializing in Life Sciences and Biotechnology, along with business mentors and incubation experts who serve on our Mentor Board. We organize mentor mixer programs, networking events, and CXO meetings for our incubatees. Our incubator team has successfully guided numerous startups in preparing their BIRAC BIG proposals, providing support in gap analysis, unmet need identification, and solution refinement. BBB also facilitates mentorship and networking sessions focused on company formation, business strategies, funding options, and connecting with domain experts in Science and Technology.

Incubator Name: Career College Autonomous, Bhopal

Focus Area: BioService

Location: BHEL Square,
Sector A, Govindpura, Bhopal

Website:
<https://careercollegeindia.com>

Email:
eywahirac@careercollegeindia.com


Contact No.:
7869557217

About Incubator:

Career College, Bhopal was established in the year 1970 by Career Society, Bhopal which has completed its 53 glorious years of academic excellence. The College is affiliated to Barkatullah University, Bhopal and accredited A Grade in its third cycle by National Assessment and Accreditation Council NAAC. Shri. Vishnu Rajoria, Founder Chairman of Career College is an active social worker with a firm belief in social values and principles of equity, justice, honesty and uprightness. His hard work has made commendable contributions in the field of education. E-YUVA Centre has been established at Career College, Bhopal in the year 2021. It has been funded by Biotechnology Industry Research Assistance Council BIRAC which is a not-for-profit Public Sector Enterprise set up by Department of Biotechnology DBT, Government of India as an interface agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing nationally relevant product development needs. Career College entails research and entrepreneurship environment with well-equipped laboratories facility. Various projects sponsored by Government include Department of Biotechnology, Government of India, Madhya Pradesh Council of Science and Technology, Government of MP, University Grants Commission, Ministry of Education, Government of India, Biodiversity Board, etc. in addition to BIRAC, E-YUVA Scheme. Till date it has supported 15 projects under E-Yuva Scheme where the students have been working on ideas like, Herbal anti-tick spray, Tridax based wound healing ointment, Biochar, Wine-o-shine products, Sea weed Biofertilizers, Nanobandages, Gaugrass etc.

Total Space Sq. Ft.: 6300

IMPACT



5 most successful incubatees:

- Vaishnavi Sharma
- Divyanshi Makode
- Vishwam Jawade
- Prabuddh Awasthi
- Saurya Shrivastava

General Infrastructural Services:



The E-YUVA Centre is spread over 6300 sq area. It has well-maintained laboratories with basic and advanced instrumentation facilities. This includes Microbiology Lab, Molecular Biology Lab, Tissue Culture Lab, Biochemistry Lab, etc. Some of the advance instruments available at E-YUVA Centre are Thermal Cycler, Gel Documentation System, Biosafety cabinets, UV-Vis Spectrophotometer, Cooling Centrifuge Digital Microscope with digital transmitted-light inverted imaging system, BOD incubator etc.

Scientific Support Services:

In addition to providing robust intellectual property IP and business support, we offer targeted assistance for growth-oriented enterprises among our E-Yuva fellows. This support is designed to foster entrepreneurial spirit and facilitate business development. We regularly organize Entrepreneurship Awareness Camps in collaboration with esteemed institutions such as IISER Bhopal, AIIMS Bhopal, MPCON, EDII, CEDMAP, and CEPAT. These camps aim to equip participants with the knowledge and tools necessary to succeed in the entrepreneurial landscape. Furthermore, entrepreneurship development is a cornerstone of our curriculum at Career College, Bhopal. We are committed to integrating entrepreneurial education and resources into our programs, ensuring that students and aspiring entrepreneurs receive ongoing support and opportunities to cultivate their business acumen.

Advisory and Mentoring Services:

Our advisory and mentoring services draw on a diverse and distinguished network of experts to provide comprehensive support. This network includes renowned institutions such as B-NEST Bhopal, Riid, Mumbai, MANIT, IIT, Indore etc. as well as various esteemed national and international organizations. Our advisory committee is composed of specialists with extensive experience across multiple domains: Intellectual Property Rights IPR Experts: Offering guidance on protecting innovations and navigating the complexities of intellectual property law. Our IP Expert includes experts from UMM Matrix, Delhi, Smart City, Bhopal etc. Industry Partners: Providing insights into market trends, business development, and strategic partnerships. Our Industry Partner includes Bio-Nutrients, Aadarsh Pvt. Ltd. Amul Dairy, Fortscape etc. Successful Entrepreneurs: Sharing practical knowledge and personal experiences to guide new ventures through the challenges of entrepreneurship. This includes ours Startup experts from HARI Lifesciences, KAD Biotech, Delhi, Khadyot Natural, Falcrum services etc. Scientific Experts: Contributing cutting-edge research knowledge and technical expertise to support scientific and technological advancements. This includes experts from AIIMS, Bhopal, IISERB, MANIT, etc.



Incubator Name: BioNEST Centre - Centre for Cellular and Molecular Platforms

Focus Area: Lifescience, Agritech, MedTech, Healthcare

Location: GKVK campus,
Bellary Road, Bengaluru
Karnataka-560065

Website:
<https://www.ccamp.res.in/>

Email:
incubation@ccamp.res.in


Contact No.:
08067185055

About Incubator:

The Centre for Cellular and Molecular Platforms C-CAMP is India's premier research and innovation hub in the biosciences and one of the largest and most vibrant life sciences incubators in the country. C-CAMP has established several state-of-the-art technology platforms for facilitating cutting-edge research in the biosciences which have supported 250+ publications. C-CAMP has helped catalyze research translation and commercialization of more than 10 academic inventions as industry-ready technologies for further productization. C-CAMP has directly funded, incubated and mentored 450+ start-ups over half a decade and is connected to over 2000 start-ups and entrepreneurs across the country in healthcare, agriculture and environment. C-CAMP is an initiative supported by Govt of India agencies, including the Department of Biotechnology, Department of Science & Technology, NITI Aayog-AIM, Ministry of Electronics and Information Technology, Startup India, Principal Scientific Advisor's Office, Government of India and Department of IT, BT, S&T Government of Karnataka. It has collaborated with several national and international philanthropies to foster societal impact of cutting-edge technology and has several international partnerships spread across the US, UK, Netherlands, Denmark, Switzerland, Germany, Japan, Brazil and Israel.

Total Space Sq. Ft.: 16500

IMPACT



5 most successful incubatees:

- Zumutor Biologics Pvt. Ltd.
- Bugworks Research India Pvt Ltd
- Dozee
- Eyestem Pvt. Ltd
- Loopworm Pvt. Ltd.

General Infrastructural Services:

C-CAMPs Bio-incubator offers a plug & play model wherein we provide a fully equipped, dedicated lab space, with small and large table top equipment as well as access to high-end platform technologies, services and clean rooms/culture rooms, which allow the start-up companies to "start the ball rolling" from day one in terms of the research projects. Along with the small bench top equipment at hand on the benches, all the start-ups have open access to the present larger equipment in the common laboratory area as well as the large sophisticated equipment in the common equipment rooms. Start-ups needing to perform cell culture experiments also have access to the tissue culture rooms.

Scientific Support Services:

High End Technology Platforms Centre of Excellence for Agri Innovation MedTech Rapid Prototyping for Microfabrication and Microfluidics C-CAMP InDx: C-CAMP Indigenisation of Diagnostics

Advisory and Mentoring Services:

India AMR Innovation Hub Digital Health Platforms- India Digital Health Accelerator C-CAMP Technology Impact Program Karnataka Start Up Advancement Program K-SAP BIRAC Regional Entrepreneurship Centre Meet the Investor Series Office of Tech Transfer

Incubator Name: Centre for Medical Innovation and Entrepreneurship CMIE, All India Institute of Medical Sciences, Delhi

Focus Area: MedTech

Location: Centre for Medical Innovation and Entrepreneurship CMIE,
4th and 5th Floor, Research Block

Website:
<https://cmie-aiims.in/>

Email:
cmie@aiims.edu


Contact No.:
+919560257329

About Incubator:

Centre for Medical Innovation and Entrepreneurship CMIE – AIIMS , the AIIMS Bioincubator is established with an aim to create an ecosystem of Incubation of Medical Innovations for Entrepreneurship and Inclusive Development of Indian Healthcare. CMIE seeks to capitalize on indigenous academic innovations in the healthcare sector by enabling the results of research efforts carried out by such Faculty/Scientist/ Students/Residents/ Researchers of AIIMS, New Delhi. Along this line, CMIE – AIIMS also enables Indian startups working in healthcare area to leverage the mentorship and guidance of AIIMS clinical and non-clinical faculty, and also by giving them paid access to advanced laboratory equipment and resources at AIIMS. In its selection of Start-ups to associate with, the CMIE prioritizes their potential for social impact and commercial impact. CMIE has supported a total of 24 startups to date. CMIE has supported a total of 24 startups to date. Of these, 22 are currently incubated, while 2 have graduated. This includes 5 BIRAC's BIG awardees who are also faculty members of AIIMS Delhi. Additionally, 4 startups are part of a special incubation cohort focused on oncology.

Total Space Sq. Ft.: 13000

IMPACT



5 most successful incubatees:

- Mammet S Kalu - Trifluge Platforms Services Pvt. Ltd.
- Suchi Gupta - Tech Cell Innovations Pvt. Ltd.
- Ravi Kaushik - Aarth Research Pvt. Ltd.
- Prof. Asha Thakur - IISc Awardee
- Kunal Rai - Jyana Therapeutics

General Infrastructural Services:

The Centre for Medical Innovation & Entrepreneurship CMIE at AIIMS spans 13,000 sq. ft. across two campuses. The main AIIMS campus in Delhi offers 2,000 sq. ft., featuring meeting rooms, offices, board room and a basic laboratory setup. The NCI-AIIMS [Hajar] campus provides 11,000 sq. ft. of space, including meeting rooms, board room, offices, and co-working laboratories for 32 incubatees. This facility includes exclusive cubicles for larger teams, along with a break-out zone and pantry. The 2,500 sq. ft. co-working laboratory at Hajar accommodates 32 incubatees in 4- and 6-seater cubicles 150-220 sq. ft. each. The central laboratory is fully equipped with instruments, such as a multimode microplate reader, hypoxifier, laminar biosafety hood, fume hood, refrigerated laboratory centrifuge, CO2 incubator, inverted research fluorescence microscope with live-cell imaging, on-stage incubator, horizontal and vertical electrophoresis systems, Western blotting with imaging station, RT-PCR, thermal cycler, digital precision systems, gill meters, 48°C and 20°C freezers, mini-cool laboratory PC, high-speed and ultra centrifuges, water purification systems, shaking bioreactors, BOD incubator, and HPLC. In addition to these resources, incubatees have access to AIIMS's specialized facilities: • Core Central Research Facility (CCRF): Equipped with high-end instrumentation for genomics, proteomics, bioinformatics, bioanalytics, RNA-seq, microscopy, and flow cytometry, supporting research in genomics areas. • Sophisticated Analytical Instrumentation Facility (SAIF): Includes an electron microscope lab for ultrastructural analysis, with tools like a 200KV electron microscope, cryo-electron microscope, confocal microscope, and SEM. • Stem Cell Facility: A GMP-compliant facility supporting stem cell research. • Central Animal Facility (CAF): Access to various small rodents and animals, including Wistar and Sprague Dawley rats, Swiss Albino and Balb/c mice, C57BL/6 mice, New Zealand rabbits, and Drosophila Hartley guinea pigs.

Scientific Support Services:

CMIE provides extensive scientific support to drive the development and commercialization of deep tech innovations. Our services include business development, legal and corporate affairs, financial management, and guidance on IPR management and technology transfer. Advanced Research Facilities: Access to high-end instrumentation for genomics, proteomics, bioinformatics, microscopy, and RNA-seq. Specialized facilities include the Stem Cell Facility with GMP-compliant infrastructure, the Central Animal Facility for preclinical research, and the SAIF lab for advanced electron microscopy. Clinical Trials and Regulatory Support: • Clinical Trials: Expertise in designing, conducting, and managing trials with a focus on ethical and regulatory compliance. • Regulatory Studies: Guidance on navigating both national and international regulatory requirements. Technical and Business Mentorship: • Expert Mentoring: Diverse mentors in genomics, nanomedicine, surgical technology, medical imaging, point-of-care diagnostics, therapeutics, tissue engineering, emerging technologies, and digital pathology. • Business Development: Support for business modeling, validation, commercialization strategies, intellectual property management, and technology transfer. Educational and Networking Opportunities: • Workshops, Seminars, Webinars, and Bootcamps: Regular programs provide training in innovation, user-specific profiling, business development, and regulatory processes. • Networking: Opportunities to connect with industry leaders, researchers, and investors. Intellectual Property and Technology Transfer: Guidance on IP rights, patent filing, and technology transfer to protect innovations and aid commercialization. CMIE Healthcare Innovation Bootcamp Series: Our flagship 3-4 day program empowers healthcare innovators through immersive sessions. Participants develop skills in identifying healthcare challenges, validating ideas, and exploring commercial potential. The bootcamp emphasizes User-Specific Profiling (USP) to tailor solutions to end-user needs and provides insights into intellectual property, regulatory affairs, and market opportunities, ensuring that innovators create sustainable and competitive solutions. CMIE's integrated approach combines advanced facilities, expert mentorship, and robust business and technical services to advance biotech innovation from concept to market success.

Advisory and Mentoring Services:

The Centre for Medical Innovation & Entrepreneurship CMIE at AIIMS provides a comprehensive advisory and mentoring framework designed to support MedTech startups through every stage of their development. Expertise and Mentorship: Startups benefit from a diverse pool of expert mentors, including renowned clinicians and specialists from AIIMS. The advisory team covers a broad spectrum of fields such as genomics, nanomedicine, surgical technology, medical imaging, and point-of-care diagnostics, therapeutics, and emerging technologies. This multidisciplinary approach ensures that startups receive tailored guidance to address specific technical and business challenges. Clinical and Technical Support: CMIE offers access to AIIMS's extensive clinical resources, including specialized labs and a robust network of clinicians for clinical trials and user-specific profiling. This support extends to navigating regulatory requirements and designing clinical studies and validation studies. Business Development and IP Management: Startups receive comprehensive business development support, including assistance with business modeling, commercialization strategies, and technology transfer. Also, expert advice on intellectual property management ensures innovations are protected and effectively commercialized. Educational and Networking Opportunities: CMIE organizes workshops, seminars, and networking events, providing startups with training in regulatory processes, market alignment, and strategic growth. These opportunities foster connections with industry leaders and potential investors. By integrating diverse expertise with practical support, CMIE ensures that medtech startups are well-equipped to advance from concept to market success.



Incubator Name: Clean Energy International Incubation Centre

Focus Area: Clean Energy

Location: TATA Power – DDL,
Smart Grid lab, Sector 15, Rohini, N

Website:
<https://ceic.socialalpha.org/>

Email:
hriday@socialalpha.org

Contact No.:
9936415286

About Incubator:

The Clean Energy International Incubation Centre CEIC, which is Social Alpha's Energy Lab, is a joint initiative of Tata Trusts and the Government of India supported by Department of Biotechnology, BIRAC, Tata Power and Tata Power – Delhi Distribution Limited. CEIC has been set up for promoting innovations in the energy space and has become the first International Incubator in India under Mission Innovation. The Incubator is designed to offer complete "lab to market" incubation support to clean energy enterprises, both Indian and International, which can bring about deep and irreversible social and environmental impact. CEIC supports the incubatees by providing last-mile connectivity and end-use deployment of successful research outputs.

Total Space Sq. Ft.: 17000

IMPACT



5 most successful incubatees:

- Tan90 Thermal Solutions Pvt Ltd
- Accelero Vehicles India Private Limited
- Himalayan Sustainable Energy Solutions Private Ltd, Takachar
- Himalayan Rocket stove Pvt Ltd
- Ergon Mobility Private Limited

General Infrastructural Services:

Incubation infrastructure spans approximately 17,000 sq. ft at Smart Grid Labs, Tata Power, Rohini, Delhi, ensuring that the startups have access to affordable and quality workspaces without compromising on the accessibility of the location. The facility boasts access to world-class lab infrastructure in Meter Testing labs, Smart Grid, Communication Labs, Engineering Labs and Transformer Labs. The Centre also has state-of-the-art meeting rooms and video and audio-conferencing facilities.

Scientific Support Services:

The lab is well equipped with a plethora of test bench setup and product testing and validation facility that minimizes lab to market journey on solving complex socio-economic challenges. CEIC has established a high-end lab comprising a stack of software with the latest graphics for easy rendering and simulation with a dedicated high-end PC. The rapid prototyping lab provides low-format manufacturing and functional prototyping while the Measure and Simulation lab facility helps in analytical testing and validating the Prototype/Products. The Energy Storage / HALT- HASS lab caters to the new era of battery tech by assisting in the R&D of any new solutions electrical, mechanical and chemical parameters. The Battery Testing setup helps in Monitoring Systems for EV/Energy Storage Segment Cell and pack level testing. EMI-EMC Pre-compliance Set-up supports in getting compliant ready products for National and international markets, reducing the time and iteration efforts of taking relevant certifications like CE/IEC 61000-1-1/2/4. The Environment chamber, set up recently helps in evaluating a products performance under various temperature conditions, climate testing conducted in chambers.

Advisory and Mentoring Services:

Social Alpha Knowledge Services and mentoring has been a beacon in the Indian startup ecosystem, having conducted many sessions on varied topics. We have had a cumulative attendance of more than 2,000+ participants with topics varying from coding, sales, technology operations, sectoral, fundraising, pitching, and supply chain to internal operations.

Incubator Name: Crescent Innovation and Incubation Council

Focus Area: Biotech, Medtech, BioEnergy, BioIndustrial, BioService & Agritech

Location: Inside BS Abdur Rahman Crescent Institute of Science and Technology,
Seethakathi Estate, GST Road,

Website:
<https://www.ciic.ventures/>

Email:
ceciic@crescent.education


Contact No.:
9841478682

About Incubator:

Crescent Innovation and Incubation Council CIIC, is a not-for-profit, innovation arm of B.S. Abdur Rahman Crescent Institute of Science and Technology BSACIST, deemed to be a University. The goal of Crescent is to encourage "deep tech" entrepreneurs in the verticals of Life Sciences, industry 4.0, and Smart & Clean Mobility. In the past 5 years, we have incubated 130 startups and acted as a "One Stop Shop – Business Incubator BI". Our startups have received around Rs.260 Cr raised from the Government of India and private Investments. Around 1400+ jobs were created by our startups. Because of our unique positioning with a large number of partner academic institutions spread over Southern India that have approached CIIC for mentoring, we believe we are uniquely positioned to take entrepreneurship and innovation to Tier-2 and Tier-3 cities/towns and rural India. CIIC is recognized and funded by the Eight Union Ministries of India, with a total allocation of Rs.35 Cr. CIIC aims to support & render startups into profitable entities through the mission statement called Five 'M' – Mentor, Money, Market, Machineries & More value-added services. Transforming innovation into scalable business models with high productive impact and encouraging interdisciplinary advancement both nationally and internationally.

Total Space Sq. Ft.: 13000

IMPACT



5 most successful incubatees:

- Costal Aquacore Research Institute Pvt Ltd
- Aloe E-cell Pvt Ltd
- AcaDiCell Innovations International Pvt Ltd
- MedCuore Medical Solutions Pvt Ltd
- Rekindle Automations Pvt Ltd

General Infrastructural Services:



We have established facilities like - Molecular Biology Lab; Analytical Lab ; Microbiology Lab ; Plant Tissue Culture Lab ; Facility for Microalgal & Nano Biotechnology ; Facility of Precision Agriculture

Scientific Support Services:

Services Offered 1. Recombinant DNA technology - Gene Technology - Protein Expression 2. Phytochemical Extraction and Purification - Compound Characterization 3. Drug Discovery and Development 4. Cell Biology 5. Bioinformatics 6. Bioprocess - Upstream - Downstream Other Services - Testing services - Student Project/Internship - Contract Research - BioEntrepreneurship Programme - IPR/Technology Transfer - Scientific Writing and Publication

Advisory and Mentoring Services:

Crescent Innovation and Incubation Council CIIC, offer comprehensive advisory and mentoring services designed to propel startups and businesses to new heights. With a network of 50+ seasoned mentors specializing in Life Sciences and Business, we provide personalized guidance that spans from technical expertise to strategic business advice. Our mentors bring a wealth of knowledge and industry experience, empowering you to navigate challenges, refine your strategies, and accelerate your growth. Whether you're a budding startup or an established business looking to innovate, our mentoring services are tailored to support your unique journey. Advisory and intellectual property services are offered to the start-ups through the Centre for Intellectual Property as CIIC has an in-house patent Officer. For patents, patentability assessment, prior art search, drafting, and patent prosecution. Design registration filing and prosecution, and copyright advisory and filing support is also provided. A comprehensive list of services is provided below: Services: ? Patentability Assessment ? Drafting & Filing patent applications ? Prior Art Search ? Patent mapping ? Freedom to operate analysis ? Out-licensing inventions ? Technology sourcing & In-licensing ? Technology transfer ? Collaboration with academic labs for PoC/Validations or scale-up ? Linkages with other OTTs for joint licensing of technologies



Incubator Name: CSIR-CFTRI Incubation Centre

Focus Area: AgriTech

Location: CSIR-CFTRI Incubation Centre
Mysuru-570020

Website:
<https://bionest.cftri.res.in/>

Email:
https://bionest.cftri.res.in/


Contact No.:

About Incubator:

The incubator facility at CSIR-CFTRI is designed to nurture entrepreneurial talent in food bioprocessing and biotechnology research. The state-of-the-art facility supports advanced research, scale-up, and efficacy studies, pertaining to food bioprocessing and biotechnology. It creates an accessible avenue for startups and SMEs involved in postharvest technology and food technology. It facilitates startups to convert innovative concepts into commercially viable technologies.

Total Space Sq. Ft.: 20000

IMPACT



5 most successful incubatees:

- Mr Kevin Parekh
- Dr Kumuda
- Dr Yashwini B
- Dr Anudeep S
- Ms Yashwanthara Mohan Raj

General Infrastructural Services:

Quality of food is inextricably linked to health. Access to sufficient amounts of safe and nutritious food is the key to sustaining life and promoting good health. The Institute provide analytical services, which include the determination of proximate composition, nutritional analysis oils and fats, milk and milk products, sweets and confectionaries, analysis of food additives preservatives, synthetic colours, artificial sweeteners, antioxidants, etc., analysis of food contaminants heavy metals, pesticides, Aflatoxins, antibiotics, etc. and microbiological safety for food products. The institute has diverse equipment and machineries for pilot production of food products some of it was developed in-house as well. The same facility can be hired by any SMEs, Entrepreneur's etc. for carrying out manufacturing and for introducing new/existing products on a trial basis. The services provided by the Unit are boon to the small and Medium scale industries and new entrepreneurs. Major processing units housed in the facility include: Twin crew extrusion equipment, Cryogenic grinding system, Drying systems, Roasting systems and forming machinery. Added to it there is a Design Centre and Prototype Fabrication Units while assisting in the automation demands in the area of food processing. Also various Mini Pilot plants attached to the technology departments caters to the processing of grains, spices, baking, fruits and vegetables, Packaging and Meat processing.

Scientific Support Services:

CSIR-CFTRI can assist industry by undertaking projects of shorter durations with one-time activity such as testing & analysis, Technical assistance of advisory nature etc. The mode will be extremely friendly to MSMEs. Industries can get assistance in the consultancy mode. This include support for preparing the Detailed Project Report DPR, turn-key solution, Advisory support etc. Off-the-shelf purchase of technologies developed by CFTRI. Delivering specific solution in terms of R&D, Product development etc. Here also, the project will be for a short duration such as 9-12 month while meeting specific objectives as defined by the party.

Advisory and Mentoring Services:

We offer tailored business solutions that enhance quality, safety, and productivity while mitigating risks. With a global reach and local expertise, we specialize in inspection, testing, certification, and verification. Our core values underpin all services, driven by innovation to propel our start-ups businesses forward. Our unique global network delivers industry-specific independent results. In order to assist startups and entrepreneurs in meeting regulatory obligations, we offer essential guidance for scientific and manufacturing compliance, as well as legal registrations. Mentorship is a vital cornerstone for startups, offering pragmatic guidance and motivation. Industry veterans volunteer their extensive knowledge, covering crucial areas like go-to-market strategies, ingredient formulation, troubleshooting, infrastructure development, pitch and project crafting. Their collective wisdom empowers startups to thrive in a competitive industry.

Incubator Name: CSIR-IIIM BioNEST Bioincubation Centre IIIM-TBI

Focus Area: Fermentation Technology, Aromatic & Medicinal Plants, Medicinal Mushroom & Skill Development

Location: IIIM-Technology Business Incubator CSIR-Indian
Institute of Integrative Medicine

Website:
<https://www.iiimtbi.com/>

Email:
iiim.tbi@iiim.res.in


Contact No.:
7840028444

About Incubator:

BioNEST Bioincubation Centre IIIM-TBI is a technology based incubator that champions new business ideas, innovation and entrepreneurship in the field of Biotechnology and Life Sciences. It focuses on young people and small businesses, celebrating their vision and role in changing our society with their ideas, products and technology. IIIM -BioNEST Incubator provide in-house State-of-Art National Facility for small and medium scale manufacturers from North India and the UT of Jammu & Kashmir in particular to get their prototype ready under GMP/GLP conditions. In addition, TBI has in house facilities like QA-QC, Fermentation Technology, Animal House, cGMP, Kilo & Toxicology labs. The core strength of CSIR-Indian Institute of Integrative Medicine IIIM is in natural products based drug discovery. The CSIR-IIIM has state of the art infrastructure which is well equipped with advance machineries and high end equipments. The institution has developed in-house technologies in phyto-pharmaceuticals and herbal products.

Total Space Sq. Ft.: 9000

IMPACT



5 most successful incubatees:

- M/s JK Aroma Farmers Products Cooperation Ltd
- M/s Adoptive Biotech Pvt Ltd
- M/s Cham the Chaos
- M/s Velanutrion Nutaceuticals Pvt Ltd
- M/s Gaurico Products

General Infrastructural Services:

At present BioNEST Bioincubation Centre offers the following infrastructural support to startups:

- cGMP-Herbal drug manufacturing facility,
- NABL accredited Quality Assurance / Quality Control Laboratory,
- Kilo Laboratory for complex chemistry reactions and
- GLP standard in vivo Animal House for pre-clinical studies,
- Essential oil-based value-addition facility


Scientific Support Services:

At present BioNEST Bioincubation Centre offers the following scientific support services to startups:

- Technical Consultation: Expert advice on experimental design, protocol development, and troubleshooting,
- Protocol Development: Assistance in creating and optimizing experimental protocols, complete with standard operating procedures SOPs for laboratory work,
- Analytical Services: Comprehensive analytical testing and validation services for byproducts,
- Bioprocess Development: Support in developing and optimizing bioprocesses for production, purification, scale-up, and bioprocess advancement,
- Data Analysis and Interpretation: Assistance in analyzing and interpreting experimental data,
- Collaborative Research: Opportunities for collaborative research projects with academic and industry partners,
- Access to Scientific Literature: Access to an extensive collection of scientific journals, databases, and other research resources.

Advisory and Mentoring Services:

Core team from the BioNEST Incubator under the guidance of the scientists and technical officers of the institute offers a robust support system to startups. Core Team of BioNEST Incubator provides structured support and resources tailored to the specific needs of biotech startups, including business planning, funding advice and operational guidance. Management Team of BioNEST Incubator offers deep technical expertise, research guidance and practical insights into the biotech field. They offer guidance in R&D, product development and navigating scientific challenges which startups encounter during their journey. The overall role of the Advisory & Mentoring Team is to offer the following services: 1. Business Planning 2. Market Strategy 3. Funding and Investment 4. Regulatory Compliance 5. Research and Development 6. Technology Transfer 7. Networking Opportunities 8. Skill Development & Technical Training 9. Post-Incubation Support





Incubator Name: BioNEST@CSIR-IITR

Focus Area: BioEnergy

Location: Technology Development and
Innovation Centre TDIC CSIR-Indian
Institute of Toxicology Research Centre

Website:
<https://iitr.res.in/En/Index.aspx>

Email:
bio Nest.citar@iitr.res.in


Contact No.:
+91 77049 94437

About Incubator:

Technology Development and Innovation Centre is a unique bio-incubation and translational research programme, supported by the institutes Centre for Innovation and Translational Research CITAR. The centre intends to assist the development of the biotech entrepreneurial ecosystem by providing start-ups with a range of services, such as networking opportunities, access to communities and high-end instruments, as well as technical, marketing, and mentorship support. With the objective to offer researchers, innovators, and entrepreneurs from academia and industry, MSMEs access to cutting-edge platform technologies and apprenticeship in a holistic inclusive setting, the incubation facility offers about 20,000 square feet of built-up incubation space.

Total Space Sq. Ft.: 20000

IMPACT



5 most successful incubatees:

- Mr. Prajwal Gupta, M/s PI Chem Chemicals Pvt Ltd.
- Mr. Aman Kumar, M/s Nutty Village
- Mr. Sidhant Nishad, M/s Matiyari Technology Pvt. Ltd.
- Ms. Shobhita Sharma, M/s Trosas Technologies Pvt. Ltd.
- Dr. Ranjana Srivastava, M/s Nextec Lifesciences Pvt. Ltd.

General Infrastructural Services:

BioNEST @ CSIR-IITR is a dynamic and innovative initiative designed to foster biotechnology and life sciences entrepreneurship. Hosted within the Technology Development and Innovation Centre at CSIR-Indian Institute of Toxicology Research IITR Lucknow, this bioincubator provides a comprehensive range of infrastructural services to support start-ups/ companies/ entrepreneurs/ industry in the biotech sector. One of the key features of BioNEST @ CSIR-IITR is its state-of-the-art laboratory facilities, such as Advanced Imaging Facility, Analytical Facility, Computational Toxicology Facility high performance computing for toxicology chem/bioinformatics - The only facility for toxicology in India, Translational Research Facility and the Cell and Molecular Biology Facility and Industrial Labs. These facilities will also leverage the institute capabilities for nurturing innovative technology-based solutions for start-ups and industries which are crucial for conducting cutting-edge experiments and developing new products. In addition to laboratory space, BioNEST provides office space and meeting rooms designed to foster collaboration and innovation. These workspaces are equipped with high-speed internet, telecommunication facilities, and administrative support creating a conducive environment for entrepreneurs to focus on their research and business development activities.

Scientific Support Services:

BioNEST @ CSIR-IITR provides a comprehensive suite of scientific support services designed to assist in the advancement of biotechnology and life sciences. Key services include: 1. Technical Expertise: BioNEST @ CSIR-IITR offers access to a pool of scientists and researchers with expertise in molecular biology, toxicology, bioinformatics, and other relevant fields. This team provides critical guidance on experimental design, data interpretation, and troubleshooting, ensuring high-quality research outcomes. 2. Advanced Laboratory Facilities: The incubator is equipped with state-of-the-art laboratory infrastructure, including molecular biology tools like PCR machines, sequencing systems, cell culture facilities, and analytical instruments such as spectrophotometers and chromatographs. These facilities support a wide range of experiments and research activities. 3. Regulatory and Compliance Guidance: Navigating the complex landscape of biotechnology regulations can be challenging. BioNEST @ CSIR-IITR provides support to ensure compliance with national and international standards, including safety protocols, ethical guidelines, and regulatory approvals, which are crucial for advancing research and commercializing products. 4. Training and Workshops: To keep start-ups abreast of the latest developments and techniques, BioNEST @ CSIR-IITR organizes regular training sessions and workshops. These programs cover various aspects of biotechnology, from emerging technologies to best practices in research and development. 5. Collaboration Opportunities: BioNEST @ CSIR-IITR facilitates partnerships with other research institutions, universities, and industry leaders. These collaborations can enhance research capabilities, provide access to additional expertise, and open up new avenues for innovation and funding. 6. Data Management and Analysis: Support is provided for managing and analysing experimental data using advanced bioinformatics tools and software, which helps in making informed decisions and advancing research findings. 7. Funding Assistance: BioNEST @ CSIR-IITR aids start-ups in identifying and applying for grants and funding opportunities, providing crucial financial support for research and development activities.

Advisory and Mentoring Services:

BioNEST @ CSIR-IITR offers robust advisory and mentoring services designed to support biotech start-ups through their journey from concept to commercialization. Key services include: 1. Strategic Guidance: Mentors provide insights into business strategy, market positioning, and commercialization pathways. This helps start-ups refine their business models and navigate the competitive biotech landscape. 2. Technical Expertise: Experienced scientists offer technical advice on research and development. This includes guidance on experimental design, product development, and troubleshooting, ensuring scientific rigor and innovation. 3. Regulatory and Compliance Support: Mentors assist start-ups in understanding and meeting regulatory requirements. They provide advice on navigating complex regulatory landscapes, preparing for audits, and ensuring compliance with safety and ethical standards. 4. Funding and Investment Advice: BioNEST @ CSIR-IITR offers support in identifying potential funding sources, including grants, venture capital, and angel investors. Mentors help in crafting effective pitches and business plans to attract investors and secure financial support. 5. Networking Opportunities: Start-ups benefit from connections to a network of industry professionals, researchers, and potential collaborators. BioNEST facilitates introductions and fosters relationships that can lead to strategic partnerships and business development opportunities. 6. Commercialization Strategy: Guidance on translating research findings into market-ready products. This includes advice on intellectual property management, licensing agreements, and market entry strategies. 7. Operational Support: Mentors provide advice on optimizing operational processes, scaling up production, and managing resources effectively, helping start-ups build a solid foundation for growth.

Incubator Name: DBT-ILS BIOINCUBATOR INSTITUTE OF LIFE SCIENCES

Focus Area: Agri tech, Med tech, Industrial Biotechnology, Device and diagnosis, Food and wellness

Location: Institute of Life Sciences DBT-ILS
Neeladri Vihar, Chandrasekharpur, Bhubaneswar

Website:
<https://www.ils.res.in/>

Email:
nivedita@ils.res.in


Contact No.:
9556716477

About Incubator:

DBT-ILS Bioincubator at the Institute of Life Sciences was set-up on 12th April 2019 with the Support of the Science and Technology Department, Govt of Odisha followed by the support from the Biotechnology Industry Research Assistance Council BIRAC, a Government of India Enterprise under the Department of Biotechnology, GOI. DBT-ILS Bioincubator manages the innovation and entrepreneurial activities at the Institute of Life Sciences by incubating startup companies in various disciplines of science and technology. As a life sciences incubator, it nurtures innovation and entrepreneurship in agriculture, biotechnology, healthcare, pharmaceuticals, IT, and related fields of scaling technologies.

Total Space Sq. Ft.: 12000

IMPACT



5 most successful incubatees:

- MicrobioTx Health Pvt Ltd
- Sichern Techno Health Pvt Ltd
- ZuZidan Biotec OPC Pvt Ltd
- Netraum Ayurveda Pvt Ltd
- Sylene Wellness Pvt Ltd

General Infrastructural Services:


Dedicated laboratory space for wet lab experiments, with necessary equipment and facility, including a well established cell culture facility and a central facility will all advanced equipment and infrastructure. Facilities includes BSL III, proteomics, bioinformatics, animal house, next generation sequencing, green house, and zebrafish and tissue culture facilities. Depending on the requirements and relevance, the ILS bio incubator will have flexibility and operational facilitation for promoting innovation. Incubator ensures that the growing under it get all the benefited from it which includes financial, mentorship and infrastructural support throughout incubation. It also promises technical assistance from the trained professional in their areas of expertise

Scientific Support Services:

DBT-ILS Bioincubator offers a comprehensive range of scientific support services that are essential for the growth and success of startups. These services include access to state-of-the-art laboratory facilities equipped with advanced technology, allowing startups to conduct critical research and product development. We also provide technical support and training on specialized equipment and experimental techniques. Additionally, we connect startups with experienced professionals who guide them through scientific and regulatory challenges

Advisory and Mentoring Services:

DBT-ILS provides comprehensive advisory and mentoring services to startups, designed to support their growth and development. These services include personalized guidance from industry experts and seasoned entrepreneurs who offer strategic advice on business planning, market positioning, and scaling operations. Startups receive mentorship in critical areas such as product development, regulatory compliance, intellectual property management, and fundraising strategies. Additionally, our incubator facilitates connections with a network of professionals, investors, and potential partners, ensuring that startups have the resources and insights needed to navigate challenges and achieve long-term success.



Incubator Name: DERBI Foundation

Focus Area: MedTech

Location: Dayananda Sagar Innovation Campus,
A Block, 2nd Floor, Kudlu gate, Bangalore

Website:
<https://derbifoundation.com/>

Email:
info@derbifoundation.com


Contact No.:
9606022144

About Incubator:

The DERBI Foundation Dayananda Sagar Entrepreneurship Research and Business Incubation Foundation is a prominent incubation centre in Bangalore, India. Established in 2015. A Section 8 company, hosted by Dayananda Sagar Institutions, supported by the DST, MEITY, DPIIT, DBT, and Government of India & Government of Karnataka. Since its inception, DERBI has supported over 100 startups, predominantly in Healthcare, via its flagship Programs: PACE: 4-month program where startups and innovators are supported to validate their work with the backdrop of Stanford Biodesign, under customer needs, engage with clinical teams & patients in real-life settings and build a proof of concept. GALLOP: A 2-milestone-based incubation program that supports startups in validating their solutions, guiding the IP and regulatory pathway, providing GTM strategies, and offering seed funds. Incubated startups get access to DERBI's robust ecosystem of Hospitals, Physicians, health allied professionals & distributors and connect to sector-specific experts, apart from healthcare-focused investors. EMERGE: A 6-month customized acceleration program for late-stage healthcare startups curated for their growth through mentorship, streamlined go-to-market GTM activities, and access to opportunities in the healthcare ecosystem. DERBI offers holistic support by providing not only seed funds and grants but also deep mentoring, prototype development solutions, and pilot trials in real settings.

Total Space Sq. Ft.: 35000

IMPACT



5 most successful incubatees:

- PANKHTECH INDIA PRIVATE LIMITED
- AYATI DEVICES PRIVATE LIMITED
- PAINZIO HEALTH PRIVATE LIMITED
- SAVEMOM PRIVATE LIMITED
- DENOVO BIOINNOVATIONS PRIVATE LIMITED

General Infrastructural Services:

Co-working Space: -Fully air-conditioned State of the art infrastructure
-Individual cabins of varying sizes - 5-seaters to 18-seaters -Open seaters -Meeting rooms, Discussion Rooms, Teleconferencing Facilities
-Private Telephone Zones -Cafeteria IT Infrastructure : -Wired &Wi-fi enabled High-speed Internet -Telecom Facilities with individual numbers -Dedicated IT Support Engineer Server Room Facility -Voice and data connectivity

Scientific Support Services:

Connected DSU labs: -Applied Science Lab -Digital Media Lab -Prototyping Design Lab -Clean room & aerospace -Mouser innovation lab -Fabrication Lab -Access to High End Technology Research Centres -Autodesk Centre of Competence for Virtual Design -Centre of Competence for Automation Technologies -IBM Software Lab for Emerging Technologies -VMware IT Academy

Advisory and Mentoring Services:

One-on-one mentoring -Business model validation -Market research -Financial management -Marketing and sales -Technology and product development, -Business Support Services: Advanced workshops on -Accounting Services - Routine Bookkeeping and Invoice generation. -IPR Services- drafting and filing of patents or any other IP -Legal services -HR services- Talent Acquisition, Leave Management, Payroll management assistance to connect to qualified professionals at a subsidized tariff Concessions Tax Exemptions , Priority in Funding from Govt. As declared by the Govt. from time to time.

Incubator Name: DPSRU Innovation Incubation Foundation

Focus Area: Healthcare, pharmaceuticals, Agri, Wellness

Location: DPSRU Innovation Incubation Foundation Mehrauli - Badarpur Rd, Sector 3, Pushp Vihar, New Delhi

Website:
<https://diif.in>

Email:
diif@dpsru.edu.in


Contact No.:
9821675614

About Incubator:

DPSRU Innovation and Incubation Foundation DIIF is a section 8 company promoted by Delhi Pharmaceutical Sciences and Research University DPSRU in New Delhi, India. DIIF focuses on fostering innovation, entrepreneurship, and technology transfer in pharmaceuticals and healthcare. DIIF serves as a platform for students, researchers, and professionals to develop innovative ideas into viable businesses. It supports start-ups and early-stage ventures in healthcare by offering resources, mentorship, networking, and funding opportunities. The foundation encourages collaboration between academia, industry, and the public sector, facilitating knowledge and technology exchange. Workshops, seminars, and training programs promote an entrepreneurial mindset among students and researchers. DIIF also provides assistance with IP protection, market research, and commercialization strategies for innovative projects Key highlights: 33 start-ups mentored and supported BIRAC supported BioNest Incubator focused on Formulation and Validation. DTTE supported Incubation centre • 55 lakhs worth seed fund support given to start-ups • Industry sponsored research facilities • 100+ events and workshops conducted • 4 granted patents by Incubatee start-ups • 14 products commercialized • Start-ups have raised more than 10.5 Cr in grant in aid and equity • 6.5cr Funding from BIRAC and DTTE for Incubation support 5 Preincubatee Student Startup teams supported and mentored Undergraduate BIRAC Eyuva fellowship to PreIncubate student startup teams

Total Space Sq. Ft.: 6500

IMPACT



5 most successful incubatees:

- Nano Clean Global Pvt Ltd
- Nanosafe Solutions Pvt Ltd
- Neuramics Lab Pvt Ltd
- Cerebra Nutritech Pvt Ltd
- Inmito Meditech Pvt Ltd

General Infrastructural Services:


Facilities and Support to startups : At DIIF , we offer a comprehensive range of facilities to support the growth and success of entrepreneurs and startups. Our physical incubation office space provides state-of-the-art infrastructure for teams to work, meet, and collaborate with like-minded innovators. Additionally, we offer technical advisory services, introducing entrepreneurs to validated service providers and industry experts who provide mentorship and guidance on investment and funding opportunities, including access to BIRAC funding and support for follow-on investments. Our ecosystem also facilitates networking opportunities, enabling interactions and relationships with a vibrant community of innovators and our management team, supporting entrepreneurs throughout the entire business life cycle. The Biostat Centre at DIIF is a specialized research facility dedicated to pharmaceutical product development and testing, equipped with cutting-edge instruments and equipment. The centre provides a comprehensive range of services, from formulation development to quality control and testing, supporting innovators and startups in bringing their pharmaceutical products to market. For more information visit our website www.diif.in

Scientific Support Services:

At DPSRU Innovation Incubation Foundation, we offer comprehensive scientific support services to facilitate product development and deployment. Our expert team comprises regulators, marketers, doctors, IP specialists and more, providing invaluable insights and guidance throughout the product development lifecycle. State-of-the-Art Lab Facilities Our product development and validation lab is equipped with an extensive range of cutting-edge instruments, including: 1. HPTLC System 2. Particle Size Analysis 3. 3D Printing prototype 4. Autoclave 5. Trinocular Microscope with LED & Camera 6. Rheometer 7. Mini Spray Dryer 8. Lyophilizer 9. Spectro Fluorophotometer 10. Benchtop Microfluidizer 11. Tablet Dissolution Test Apparatus 12. Magnetic Stirrer with hot plate 13. Digital Balance 14. Probe Sonicator 15. HPLC Prep-HPLC Extraction System 16. Spherulizers 17. Extruders 18. Laminar airflow 19. Homogenizer 20. Moisture balance 21. Bath sonicator 22. Benchtop centrifuge 23. Rotary vacuum Evaporator 24. MPLC 25. Fluid bed granulator These advanced instruments enable us to support various scientific activities, such as: - Product formulation and development - Analytical testing and validation - Quality control and assurance - Regulatory compliance - Scale-up and manufacturing Expert Team Support Our team of experts works closely with entrepreneurs and innovators to: - Provide scientific guidance and mentorship - Conduct product testing and validation - Develop and implement quality control measures - Ensure regulatory compliance - Facilitate scale-up and manufacturing processes By leveraging our scientific support services and state-of-the-art lab facilities, innovators and entrepreneurs can accelerate their product development journey and bring their ideas to life.

Advisory and Mentoring Services:

The DPSRU Innovation Incubation Foundation offers comprehensive Advisory and Mentor Services to support entrepreneurs and innovators in their journey. Our expert team provides guidance and mentorship in various areas, including: - Investment guidance from industry experts and practitioners - Access to funding opportunities from BIRAC and support for follow-on rounds of investments - Regulatory compliance and market entry strategies - Business growth and expansion planning - Networking opportunities with fellow entrepreneurs, industry experts, and investors Our mentorship program is designed to provide personalized support and guidance to entrepreneurs, helping them navigate the challenges of starting and growing a successful business. Our mentors are experienced professionals with a deep understanding of the industry and a passion for innovation and entrepreneurship. With our Advisory and Mentor Services, entrepreneurs can: - Gain valuable insights and expertise from experienced professionals - Develop a robust business plan and strategy - Access funding and investment opportunities - Build a strong network of contacts and connections - Accelerate their business growth and success At DPSRU Innovation Incubation Foundation, we are committed to supporting entrepreneurs and innovators in their journey to success. Our Advisory and Mentor Services are an integral part of our incubation program, and we are dedicated to providing the best possible support to our startups



Incubator Name: Dr.Moopen's iNEST

Focus Area: MedTech

Location: Dr. Moopen's Medical College,
Naseera Nagar, Meppadi P O, Wayanad,
Kerala-673575

Website:
<https://www.drmoopensinest.com/>

Email:
contact@drmoopensinest.com


Contact No.:
8111880451

About Incubator:

Dr. Moopen's iNEST is a Healthcare Incubator supported by BIRAC BioNEST hosted at Dr. Moopen's Medical College, Wayanad. Dr. Moopen's iNEST is the India's first healthcare incubator in a standalone Medical College and hospital with a vision of Providing patient-centric healthcare and transforming patient experience by harnessing open innovation i.e. working with startups, industries, research and academia under asset-light business models. It is a professional translation facility that comprehensively supports start-ups first into the initial milestones with a fully functional infrastructure and a strong support network with a collaboration model between academia, research and industry acting as a translation lever. A strong focus on sourcing and building startups with high commercialization potential coupled with the in-house strength for minimizing the lab to market period hedges the risks of uncertainty/long gestation period. At Dr. Moopen's iNEST, we are dedicated to fostering innovation among students, doctors, healthcare innovators and startups. We provide comprehensive support to transform their innovative healthcare ideas into viable products, covering all stages from idea validation to market entry. Our Strengths: Strong Mentor Base in Healthcare Technologies Clinical Epidemiological research center with ICMR registered Clinical Trial Centre CDSCO Recognized Institutional Ethics Committee Network Healthcare Organisations of Aster DM Healthcare spanning 377 establishments in 15 countries Recognized Medical College with NABH Level 2 Accredited Hospital DSIR Recognised Advanced Research Laboratories with 3D Bioprinter, Stem cell & Tissue Engineering Digital Health Databank Ecosystem Enabling Data Centric AI Enabled Research Clinical Laboratories & Radiodiagnosis Unit, Clinical simulation lab

Total Space Sq. Ft.: 11000

IMPACT



5 most successful incubatees:

- Mr. Piyush - Next Big Innovations Pvt Ltd
- Mr. Suraj - Panlys nanotech Pvt Ltd
- Mr. Romy - Type 3 Civilization Pvt Ltd
- Mr. Vinod - Imaginering Minds Private Limited
- Mr. Mitesh - BRAINSPIRED LABS PVT LTD

General Infrastructural Services:

Office spaces: Coworking Space: A fully furnished coworking area for 12 individuals, equipped with high-speed internet, Cabin Space: Four fully furnished cabins, each with seating for one person. Digital Health Lab: A lab with 14 workstations, featuring high-end computers and supercomputing capabilities for incubatees. Meeting Room: A spacious, air-conditioned meeting room that accommodates up to 30 people, equipped with a projector. Audio Visual Room: A soundproof room with a 30-person capacity, ideal for recording audio and video content. Discussion Room: A small, fully equipped room with a projector and sound system, accommodating up to 8 people for discussions. Laboratory Facilities: Biomaterials Lab: Key facility for the development of biomaterials, particularly biopolymers and polymer composites. Membrane synthesis, wet spinning, and the design and development of novel polymers are among the primary activities. 3D Bioprinter Laboratory: Equipped with Advanced 3D Bioprinters, Cell Culture facilities for creating intricate biological structures & models and examinations. Molecular Biology: Facilities for RNA & DNA extraction, modifications, cloning, and gene expression studies. Animal House: Facility offers provisions for housing and breeding of rat, mice & rabbit as well as conducting experiments on them. The facility included animal rooms, holding and quarantine room, surgery/dissection theatre. Cell Culture Facility: A well-equipped Cell Culture Laboratory with a facility supporting primary cultures and cell cultures for stem cell line cultures for stem cell research, anti-cancer studies and toxicology/ biocompatibility studies. Proteomics Lab: Proteomics Lab equipped with facilities for protein isolation, expression studies, development & purification of antibodies. Biochemistry Lab: Biochemistry Lab is equipped with analytical instruments for protein assays and characterization including FTIR Spectroscopy, Refractometer & UV-Vis Spectrophotometer. Immunohistochemistry Lab: Facilities for Cryo-sectioning & tissue processing, microscopic imaging to study cytology & localization of various receptors & associated proteins at molecular and cellular levels.

Scientific Support Services:

Preclinical & Clinical Trial support Cytotoxicity analysis of Biomaterials, Hydrogels and Nanomaterials Gene Expression Studies Cell Culture studies Drug screening Analysis FTIR Analysis of samples Phytochemical Analysis Biomaterials & Nanomaterial synthesis Protein analysis 3D bioprinted Model Studies

Advisory and Mentoring Services:

Clinical Validation Business Development Guidance IPR Filing services Medical Device Regulatory Support Investment support Fundraising Guidance Company Registration services

Incubator Name: Entrepreneurship Development Center Venture Center

Focus Area: MedTech

Location: NCL Innovation Park,
Dr Homi Bhabha Rd, Pune, Maharashtra

Website:
<https://venturecenter.co.in/>

Email:
frontdesk@venturecenter.co.in


Contact No.:
+91-9172232215

About Incubator:

Venture Center, a section 8, not-for-profit company is the technology business incubator hosted by CSIR-National Chemical Laboratory in Pune. Venture Center is supported by DST, NSTEDB & BIRAC, DBT among other government organizations. Venture Center is today India's leading science business and inventive enterprises incubator, which is home to 70+ resident startups on campus at any time and has supported roughly 170+ resident startups since its inception on 10th January 2007. Overall Venture Center has supported 700+ startups & individual innovators via residential and non-residential programs and has mentees in more than 15 cities in India. Venture Center has built a rich network of 200+ mentors based in and out of India. Venture Center startups have successfully raised approx. 700 Cr as follow-on funding in the past eight financial years.. Venture Center has received various awards & recognitions like National Award for Technology Business Incubators received from the President of India in 2016, Asian AABI Incubator of the Year Award, 2018 and National Entrepreneurship Award under the Ecosystem Builder Category in 2019. Venture Center has been ranked as no. 1 Bioincubator by Biospectrum in 2021 and has recently been awarded for nurturing the best IP. Venture Center has built a strong and vibrant innovation ecosystem to support such a large and growing number of healthcare & bio-based startups.

Total Space Sq. Ft.: 53000

IMPACT



5 most successful incubatees:

- Mylab Discovery Solutions Pvt. Ltd.
- Jeevtronics Pvt. Ltd.
- BioPrime AgriSolutions Pvt. Ltd.
- Indius Medical Technologies Pvt. Ltd.
- Actorius Innovations and Research Pvt. Ltd.

General Infrastructural Services:


General infrastructural services at Venture Center include dedicated office suites, hot desking facility, meeting spaces, Venture Centre reception, mailbox facility and website development.

Scientific Support Services:

Scientific support services at Venture Center can be enlisted as follows: • Ready to use Shared Labs Chemistry & Material Science, BS1, BS2 & BS3 • Dedicated lab spaces • Elemental analysis • Chromatography analysis HPLC, GC, HPLC-UV, GC-TCD & GC-FID • Spectroscopy analysis FTIR, DLS, NIR, UV, Spectrofluorometer • Thermal analysis Thermogravimetry, Differential Scanning Calorimetry, Thermal Stability, Filler Content estimation, Measurement of Volatile components • Centre for Applications of Mass Spectrometry CAMS • Mechanical Testing services • Confocal Microscopy Services • Flow Cytometry Services • Cell proliferation and viability studies • Center for Biopharma Analysis • ISO certified Med Tech Clean room

Advisory and Mentoring Services:

Advisory and mentoring services under all incubation programs are available on request. Some of them can be listed as follows: • Business planning and sharpening the value proposition • Fund raising • Preparation for pitches • IP and technology strategy • Company operations and HR • Agreements • One-to-one mentoring via M Clinics • IP and licensing services by IPFACE • Advisory service for other upcoming incubators Incubation Practice School • Referrals and leads • Website development and maintenance • Basic client support services printing, business cards etc • Conference call services • HR Help Desk • Venture Center takes care of housekeeping, basic security, safety etc



Incubator Name: E-Yuva Center, Anna University, Chennai

Focus Area: BioIndustrial

Location: E-Yuva Center, Anna University,
CSIR Road, Taramani, Chennai

Website:
<http://www.uichannau.ac.in/>

Email:
uichau@gmail.com


Contact No:
9514867579

About Incubator:

E-YUVA Centre EYC, Anna University has been developed to nurture a culture of applied research and need-oriented societal or industry innovation among researchers. E-YUVA Centre has been funded by Biotechnology Industry Research Assistance Council BIRAC in collaboration with Anna University. This council has developed a focused strategic action plan to foster the culture of innovation and techno-entrepreneurship in Universities, leveraging the Cluster Innovation Centre CIC model. The Center has been developed to nurture a culture of applied research and need-oriented societal or industry innovation among researchers. This includes stakeholders in the entire value chain from idea discovery to proof-of-concept to prototype development/pilot studies to validation and commercialization. We provide pre-incubation and incubation supports to effective translate innovative ideas into products thereof. Such support will include Technical infrastructure, Technology trainings, IP management, Technology business management, access to Venture Capital finance for setting up the industry.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Dr. Priyanka Pothan, Relicus Bio Pvt. Ltd
- Mr. Muthu Dhanraj, Primas Bioscience Pvt. Ltd
- Dr. Dhinakar S. Kompala, Sudhin Biotech Pvt. Ltd
- Dr. Pavan Asalapuram, Xact Diagnostics Pvt. Ltd
- Dr. Chandra Sainathan, Theevanam Additives and Nutraceuticals Pvt. Ltd

General Infrastructural Services:

The center provides state-of-art infrastructure facility to all the incubatees who tries to develop their products and to all innovation fellows who wants to convert their idea into a proof-of-concept / prototype. High end bio-processing facilities include 300 L Bio-reactor, 5L/2L Bio-reactor, AKTA purification system, microfiltration unit, spray dryer, lyophilizer etc and analytical facilities such as GCMS/MS, HPLC, Microflex MALDI-TOF, Multimode Reader, RT-PCR etc are available for incubatees/innovation fellows. The center also has a dedicated cell-culture facility for incumbents. Apart from this laboratory workspace, all other minor equipment access, high-speed internet, meeting rooms, 24x7 access to the lab are provided to incubatees/innovation fellows.

Scientific Support Services:

Technical mentoring from University Professors & Industrial Experts, IP Facilitation, Technology Transfer & Technology Commercialization, fund raising support are provided to incubatees and E-Yuva/Innovation Fellows.

Advisory and Mentoring Services:

Technical mentoring from University Professors & Industrial Experts and business mentoring support from business experts are provided to incubatees & E-Yuva/Innovation Fellows.

Incubator Name: BIRAC E-YUVA CENTER, GIET UNIVERSITY

Focus Area: AgriTech

Location: E-YUVA Center, Department of Biotechnology,
GIETU, Gunnupur, Odisha-765022

Website:
<https://www.giet.edu/academics/e-yuva-center/>

Email:
birac.eyuva@giet.edu


Contact No:
7008450160

About Incubator:

E-YUVA Centre of GIET University was established in September, 2021 by the support of Biotechnology Industry Research Assistance Council BIRAC, DBT, Govt. of India to facilitate and promote bio-entrepreneurship in the academic campus. It is located amidst the foothills of beautiful Eastern Ghats range of southeastern Odisha known for its biodiversity and traditional knowledge. Housed within GIET University, a leading state private University, recognized and accredited by UGC, AICTE NAAC, NBA, DBT and DSIR. University has made a mark in the global scenario with its state-of-the-art infrastructure, quality education and modern facilities. The center has partnered with BioNest bio-incubator of Institute of Life Science, Bhubaneswar for mentorship and knowledge support. The aims of this Centre are to do purpose driven innovation by culturing and harvesting existing community information and applying academic knowledge in interdisciplinary research activity. Centers mission is to encourage young students and researchers to engage in translational research and need-oriented societal or industry entrepreneurial innovation through modern scientific practice. The main vision is to facilitate and promote bio-entrepreneurship in younger minds from rural and semi urban area for self-empowerment and nation building. Center through its E-YUVA scheme provides funding support through fellowship and research grant, technical and business mentoring through academic and industrial connects, orientation to entrepreneurial culture through entrepreneurial workshop, seminar and exhibition and exposure to bio-incubation hub through networking to students at various levels including undergraduates, post-graduates and post-doctoral.

Total Space Sq. Ft.: 3000

IMPACT



5 most successful incubatees:

- Mr. Palla Hemanth Kumar
- ECHRA INNOVATIONS PRIVATE LIMITED
- Biomom Organics Pvt. Ltd.
- Ms. Anwesa Jena
- Mr. Mahendra Kalyan Senapati

General Infrastructural Services:


Lyophilizer, HPLC, Fluorescent Microscope, Inverted Phase Contrast Microscope, RT PCR, PCR, 7 Lit Industrial Fermenter, Humidifier, Muffle Furnace, CO2 Incubator, Hot Air Oven, Vacuum Oven, -20 Freezer, Refrigerator, Aquarium Set, Biosafety Cabinet, Laminar Air Flow Chamber, Open Algal Culture Tank, pH Meter, Weighing Machine, DE oiling Machine, Microwave, Induction, Mixture & Grinder, Viscosity Meter, Tissue Homogeniser, Plant Tissue Culture Facilities, Green House, Dry Lab, Conference Room

Scientific Support Services:

Daily Scientific Test & Work progress Monitoring, Scientific Data analysis and Interpretation, Researcher Connection to Subject matter Experts, etc

Advisory and Mentoring Services:

IP Mentoring, Animal Cell culture, Viral Assay, Antimicrobial Assay, Tissue Culture Mentoring and Training, Dynamic Business Plan Development, Chemical Synthesis, Technology Transfer, as Advisory





Incubator Name: E-YUVA Centre, Adamas University Supported by BIRAC

Focus Area: Life Science and Related any domain

Location: ADAMAS University Adamas
Knowledge City, Barasat – Barrackpore Road,
P.O. – Jagannat

Website:
<https://incubation.adamasuniversity.ac.in/>

Email:
birac-e-yuva@adamasuniversity.ac.in


Contact No.:
7016636678

About Incubator:

E-YUVA Centre was established in Aug 2021 at Adamas University through the support of BIRAC, A Govt. of India enterprise. This is one of the 20 such centres in India fostering translational research, innovation and entrepreneurship. The scheme is mandated to promote a culture of applied research and need oriented Societal or industry entrepreneurial innovation among young students and researchers. The main vision of this centre is to stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry, addressing the needs of the largest section of society. The centre supports and nurtures innovators and entrepreneurs through R&D, Infrastructural Support, Mentorship. The support is extended from UG students to Post Doc Fellows in the form of E-YUVA Fellow and Innovation Fellow.

Total Space Sq. Ft.: 3500

IMPACT



5 most successful incubatees:

- Gene Prospera Biotech Pvt Ltd
- Protinet India Pvt Ltd
- Biocademia Nexus Technologies LLP
- Indus Agro and Foods Pvt Ltd
- SBH Electrolab Pvt Ltd

General Infrastructural Services

The E-YUVA Centre at Adamas University, established in August 2021 with support from the BIRAC, A Govt. of India Enterprise. The centre is the hub for fostering and nurturing innovation, entrepreneurship, and translational research, particularly in the field of life sciences and allied sector. It is one of twenty such centres across India. The centre is spread within an area of 3500 sq ft and located within the sprawling green campus of Adamas University extending over 100 acres, nestled in Barasat, West Bengal. The centre provides extensive scientific support services, including state-of-the-art laboratories related to biotechnology, microbiology, cell biology, insect biology and other advance scientific areas. These labs are equipped with advanced tools and techniques to support innovation-based research in various field such as food technology, molecular biology, microbiology, agriculture and aquaculture, clean and green environment, medical device and diagnostics and others. The centre and facilities are designed to assist and provide financial assistance in the form of fellowship scheme supported by BIRAC to the young researchers, innovators, and entrepreneurs, from undergraduate students to post-doctoral fellows, in conducting translational research and developing industry-oriented solutions. We also provide separate pre-incubation and incubation space along with smart classroom for conducting meetings, workshops, training program, etc. In addition to lab facilities, the E-YUVA Centre offers a comprehensive support system that includes intellectual property IP management, legal assistance, marketing, branding, networking and online compliance support. The centre also provides various skill development and entrepreneurship training programs and trained the youth for pitching competitions, hackathon and creating viable business plans and proposal. We have a big greenery campus, playground, basketball ground, cafeteria, food court, gym, bank, hostels, pharmacy, etc. Also, it has a 100-seater auditorium, a 100-seater video conference room, a most central library and central instrumental facilities with high end instruments.

Scientific Support Services:

E-YUVA Centre has a cell biology and general lab, a bio-innovation cum microbiology lab, an insect biology lab along with a 3D printing station were students, innovators, startups can do their innovating project work. These labs are equipped with instruments like BSL-2, CO2 incubator, UV-VIS spectrophotometer, inverted microscope, cooling centrifuge, Thermal cycler, PCR, BOD incubator, laminar airflow, hot air oven, Gel apparatus, double distillation water unit etc. to support translational research and innovations. The centre also has small equipment's like pH meter, autoclave, magnetic stirrer and hot plate, vacuum desiccator, weighing balance, rocker, dry and water bath to support the basic innovative work of the E-YUVA Fellows and other young minds/students. There is a pilot scale fish harvesting set up in insect biology lab to study the scientific component of the product developed by the fellows. For scientific analysis, R&D studies, quality checking and monitoring of the innovative prototypes and products developed by the fellows' various experiments like animal model study, field trials, survey are conducted on regular basis. Based on the data, proper scientific support and mentoring is given to fellow by the E-YUVA team as well as by the pool of scientific mentor of different domains. Ethical committee clearance and other supports are also provided to the fellows. Scientific supports in the form of exposure visit, internship, training and workshop are also provided to UG and PG students and research scholars of different institutions like University of Calcutta, Jadavpur University, Acharya College, Gurudas College, Serampore College, Swami Vivekananda, Brainware and JIS University. Faculties from different universities attended faculty development programs as well as capacity building program. Scientific and innovative work has been done collaboratively with startups like Andragogy Life Sciences, Synbiogenetics, Azoka Labs, Alona Life Sciences Pvt Ltd and with our in-house startups.

Advisory and Mentoring Services:

Many advisory and mentoring services on bio-innovation, translational research and entrepreneurship is provided by E-YUVA Centre. Awareness, orientation, outreach and mentoring sessions on E-YUVA Fellowship scheme and other schemes of BIRAC are conducted by the centre for young innovators, students, scholars and startups. E-YUVA and Innovation fellow, UG and PG students and innovators are trained under domain specific mentors about scientific analysis, start-up ideation, pitching for funding, business plan and proposal submission, IP filing, company registration, legal compliance, HR/Team management, fund management, branding and marketing etc. The centre has an expert mentor panel that includes professionals from various fields. Academy – innovation expert Dr. Amalash Mukhopadhyay, Prof. Rudra Prasad Saha, Industry specialist Dr. Subhalekshmi Ghosh, Dr. Swapnil Sinha, Dr. Soumyadip Roy, IP expert Dr. Sush Kumar Mitra & Dr. Mahipal Hem Choudhury, and many others are mentor of E-YUVA Centre. This multidisciplinary panel plays a crucial role in nurturing young innovators and helps in establishment of their own venture successfully. Mentor and advisory board of E-YUVA Centre also have experts related to business incubation, funding, technology transfer, community innovation, grassroot level entrepreneurs, academicians and scientists from renowned University and research institute. The expert panels involvement ensures that the projects and research undertaken at the centre are aligned with industry needs and societal demands. They also assist in bridging the gap between academia and industry by offering insights into real-world challenges and helping innovators to develop solutions that are both innovative and commercially viable. Dr. Saptarshi Chatterjee and Dr. Moumuni Saha are associated as mentor with different startups and incubation centers. Skill development and awareness programs for promoting a career and interest towards innovation & entrepreneurship is provided by the centre. Mentoring, guidance and incubation is also provided for different schools, NGOs and many other institutes.

Incubator Name: E-YUVA Centre, Panjab University, Chandigarh

Focus Area: Bioprocess technology, biopharmaceuticals, food and agricultural biotechnology

Location: New Hospital Building,
Near Dental College, South Campus,
Panjab University

Website:
<http://eyuva.puchd.ac.in/>

Email:
eyuva2021@pu.ac.in


Contact No.:
9914461545

About Incubator:

E-YUVA centre at Panjab University is situated in the South Campus, Sector 25 of Chandigarh. We aim in encouraging the youngsters to innovate for the new India- the Atma-nirbhar Bharat! Bringing together different verticals of research with a multi-disciplinary approach to problem-solving is our main motive. We are the pre-incubation platform for undergraduates, postgraduates and post-doctoral fellows. Promoting innovation and enthusing entrepreneurship at grass root level i.e., during graduation is our first priority. Keeping in view the ever- dynamic global scenario, we are motivated to encourage translational research which can be transformed to valuable products having large scale social impact. We are making our effort to boost young lot, guide them towards correct path, helping them to clear their vision towards their entrepreneurial journey. We provide them backbone for their scientific requirements take initiative to create facilities they require for their future goals. We provide them with infrastructure, technical, scientific, administrative and IP support. In addition to this, we are here to support, nurture, and provide a positive ecosystem where anyone can start working on their ideas and transform them into reality by moving to incubation and then post incubation.

Total Space Sq. Ft.: 2000

IMPACT



5 most successful incubatees:

- Moondeep Chauhan
- Shivanshi Vashist
- Shailendra Singh Khichi
- Shallu Goyal
- Shruti Nagarath

General Infrastructural Services:

1. Lab space of 2000 sq. ft. 2. Laboratory tables, chairs, stools. 3. Basic laboratory consumables.

Scientific Support Services:

1. Microbiology & Molecular Biology Facility 2. Analytical systems like spectrophotometry, liquid chromatography, electrophoresis, centrifugation etc. 3. Basic Culture Facility 4. Library 5. Wet Lab 6. Lab scale sterilization system

Advisory and Mentoring Services:

1. Mentoring session with Knowledge partner, subject experts and industry experts. 2. Training Innovation & E-YUVA fellows for Prior art search, filing their own IP, NBA application and Technology transfer etc. 3. Networking Platform by conducting Innovator-Investor sessions 4. Drafting of Grant proposals for Incubation & Post-incubation pathway 5. Market analysis 6. Turnover estimations and appreciating strategy



Incubator Name: E-YUVA Centre, PSGR Krishnammal College for Women

Focus Area: BioIndustrial

Location: Krishnammal College for Women,
Peelamedu, Coimbatore

Website:
<https://www.psgrkwc.ac.in/eyuva/>

Email:
grgbracey@psgrkcw.ac.in


Contact No:
9994033058

About Incubator:

BIRAC E-YUVA Centre @ PSGRKCW established in 2021 with the support from BIRAC, Department of Biotechnology, Government of India, has the vision to stimulate, foster and empower students with a culture of applied research and enhance need-oriented innovation capabilities for creating affordable solutions addressing the needs of the society. PSGR Krishnammal College for Women is the only Women's college among 20 BIRAC E-YUVA centres in India to be supported under this scheme. The centre is specialized in the domain of Industrial Biotechnology with the expected outcomes in Healthcare, Waste to Wealth, Food Technology, Alternate Packaging Materials, Enzyme Technology, and Microbial Oils. The centre has access to the in-house labs across the departments that are equipped with state-of-the-art facilities and high-end instruments for research work.

Total Space Sq. Ft.: 3000

IMPACT



5 most successful incubatees:

- SweetSpire Private Limited by Akshaya and Team
- GutHealth Bioline Pvt. Ltd. by Dr. Chayanika Sarma
- Vaso Credentialia Bhairavi Pharma Pvt.Ltd. by Dr. Maruvor Arasi

General Infrastructural Services:

The facility includes an Enzyme Purification Lab, a Fermentation Unit, a Main Laboratory, a Microbiology section, and a dedicated Innovation Fellows Workspace. It is also equipped with cutting-edge instruments such as an IR affinity with ATR, Potentiostat and Galvanostat with an integrated impedance analyzer, Zeiss Primostar 3, trinocular fluorescence microscope, Atomic Absorption Spectroscopy, UV-Vis spectrophotometer and HPLC.

Scientific Support Services:

PSGRKCW have collaborative partnerships with companies and institutions like Golden Jubilee Park for Women Society, Chennai, SS Cini Research LLP, Dr. RK Diabetic Foot and Podiatry Institute, StartupTN, Pinochle.AI LLC, Coimbatore, Viyen Biotech LLP, Coimbatore, VT Ecogreen Technologies Pvt Ltd, Coimbatore, Dr. Moopen's Medical College, Kerala, Saveetha Institute of medical sciences, Chennai, Biozone Research Technologies Pvt. Ltd., Microbiological Laboratory, PSG-Science & Technology Entrepreneurial Park, Technology Business Incubator- Agribusiness Incubation Society, Tamil Nadu Agricultural University, Institute of Forest Genetics and Tree Breeding, Sugarcane Breeding Institute, Bharathiar university, ICAR-Indian Agricultural Research Institute, Bioline Laboratory, AWE CARE Analytical and Research Laboratory, Centre for Bioscience and Nanoscience Research, Golden Jubilee Biotechnology Park for Women, Jananom Private Limited. We also have qualified interdepartmental faculties with several years of research experience perfectly poised to offer advice and support. PSGRKCW have received several research projects from government funding agencies such as DST, DBT, DRDO, ICSSR etc.

Advisory and Mentoring Services:

We have distinguished personnel from different domains offering mentoring services. Dr. D. Sudhakaran, General Manager, Golden Jubilee Park for Women Society, Chennai, Dr. C. Sheela Sasikumar, Managing Partner - SS Cini Research LLP, Director Research and Education- Dr. RK Diabetic Foot and Podiatry Institute, Dr. Mahendra Gandham, Technical Expert, Golden Jubilee Biotech Park for Women Society, Chennai, Mr. Dinesh Kumar, Associate Vice President -StartupTN, Dr. Kaushik Hatti, Chief Data Scientist, Rezilyens-Pinochle.AI LLC, Coimbatore, Dr. R. Ranjith Kumar, Chief Scientific Officer, Viyen Biotech LLP, Coimbatore, Dr. M S Lipin Dev, Director and Partner, VT Ecogreen Technologies Pvt Ltd, Coimbatore, Dr. K. Rijesh, CEO, BioNEST - Dr. Moopen's Medical College, Kerala are some of them providing constant support and assistance to the center. They are also part of the networking sessions organized by the center.

Incubator Name: E-YUVA Centre, University of Rajasthan

Focus Area: Biotechnology

Location: Centre for Converging Technologies,
University of Rajasthan, JLN Marg, Jaipur

Website:
<https://www.uniraj.ac.in/eyuva/>

Email:
uicbuniraj@gmail.com


Contact No:
9079303565

About Incubator:

The E-YUVA Encouraging Youth for Undertaking Value Added Innovative Translational Research Scheme funded by Biotechnology Industrial Research Assistance Council BIRAC aims to promote a culture of applied research and need-oriented societal or industry entrepreneurial innovation among young students and researchers. EYC was established as the University Innovation Cluster - Biotechnology UIC-B in 2015 with the help of generous funding from BIRAC. In 2021, UIC-B was upgraded by BIRAC to Empowering Youth for Undertaking Value Added Innovative Translational Research Centre E-YUVA Centre, where besides postdoctoral and postgraduate Innovation fellows, 25 undergraduate students are being supported as E-YUVA Fellows with fellowship and research grants to work on innovative projects. The aim of the E-YUVA Centre is to play the role of a facilitator to stimulate entrepreneurial activities within the University and establish networks with the industry. • To develop area specific technologies for the industries through R&D projects of student entrepreneur. • To develop and strengthen the Industry-Academia partnership for research sponsorships development • To provide Intellectual Property protection and management services and facilitate the technology transfer and commercialization.

Total Space Sq. Ft.: 3000

IMPACT



5 most successful incubatees :

- Joish Agrisciences Pvt Ltd
- GreeNano Technologies
- Ekicite Technologies

General Infrastructural Services:

Laboratory facilities to carry out routine bacterial culture, DNA & Protein isolation and analysis, extraction system, access to CCT and central facilities, Conference room, Office space to name a few.

Scientific Support Services:

Access to scientific instrumentation within the EYUVA Centre as well as those belonging to Centre for Converging Technologies and Central Facility of University of Rajasthan. Facilitation of access to scientific services outside the university system. Facilitation of scientific trainings within and outside the university system.

Advisory and Mentoring Services:

Scientific guidance and access to mentors within and outside the University of Rajasthan. Guidance and facilitation for IP filing, Business plan and business model mentoring, Marketing strategy mentoring.





Incubator Name: Federation of Asian Biotech Associations FABa

Focus Area: BioIndustrial

Location: Vindya-C4, 1st Floor, CIE,
International Institute of Information Technology
IIIT Prof. C R Rao Road, Hyderabad-500032

Website:
<https://biofab.org.in/index.html>

Email:
gandla.jagadeesh@gmail.com


Contact No.:
+918074648547

About Incubator:

Established in 2004, FABa is a global non-profit organization dedicated to fostering collaboration and innovation in the field of biology. With 22 international chapters, we actively bridge the gap between Industry, Academia, and Government. Key Initiatives: FABa Academy: Empowering the next generation of bio-leaders through specialized training programs for students and industry professionals. FABa Entrepreneurship: Supporting early-stage startups with mentorship and funding opportunities to accelerate their growth and impact. As one of the largest ecosystem enablers in the biology sector, FABa is committed to driving progress and shaping the future of the bio-economy.

Total Space Sq. Ft.:0

IMPACT



5 most successful incubatees:

- UR Therapeutics
- Prantae
- Proleri
- Arthro Biotech
- Tulsu Therapeutics

General Infrastructural Services:

FABa operates as a dynamic, virtual entity, unburdened by physical infrastructure. This allows us to maintain a lean and agile structure, fostering flexibility and adaptability. Leveraging technology and digital platforms, we seamlessly connect with partners and clients across India, transcending geographical limitations. Our extensive network of collaborations with incubators throughout the country positions us at the heart of the startup ecosystem. We act as a catalyst, facilitating access to crucial resources and opportunities for emerging ventures. From securing investments and forging strategic partnerships to navigating regulatory complexities and expanding into new markets, we empower startups to overcome challenges and achieve sustainable growth.

Scientific Support Services:

At FABa, our expertise in Life Sciences is comprehensive and multifaceted. We are deeply immersed in the dynamic fields of Biotechnology, Pharmaceuticals, Agri-tech, and Medical Devices, constantly exploring innovative solutions and strategies. Our team possesses a profound understanding of these sectors, enabling us to guide and support organizations through complex regulatory landscapes, accelerate research and development initiatives, and drive commercial success. We are committed to fostering collaboration and staying at the forefront of technological advancements to shape a healthier and more sustainable future.

Advisory and Mentoring Services:

beyond facilitating access to resources. Our Advisory and Mentorship services provide the strategic guidance and industry insights needed to navigate the complexities of the business landscape. Expert Advisory: Strategic Planning: We help develop comprehensive business strategies, aligning goals with market opportunities and regulatory requirements. Market Analysis and Entry: Gain in-depth understanding of target markets, competitive landscapes, and optimal entry strategies. Regulatory and Compliance: Navigate complex regulations and ensure compliance throughout the product development and commercialization journey. Financial Modeling and Fundraising: Develop robust financial models, attract investors, and secure funding for growth. Operational Optimization: Streamline processes, enhance efficiency, and maximize resource utilization for sustainable growth. Dedicated Mentorship: Personalized Guidance: Receive tailored mentorship from seasoned industry professionals with deep domain expertise. Knowledge Transfer: Gain valuable insights into industry best practices, emerging trends, and potential pitfalls. Network Expansion: Connect with key stakeholders, potential partners, and investors within the life sciences ecosystem. Leadership Development: Enhance leadership skills and cultivate a mindset of innovation and adaptability. Long-term Support: Benefit from ongoing mentorship and guidance as your venture evolves and matures. At FABa, we believe that knowledge and experience are invaluable assets. Through our Advisory and Mentorship services, we aim to empower entrepreneurs and innovators with the tools and insights they need to thrive in the dynamic life sciences arena.

Incubator Name: Foundation for CfHE

Focus Area: MedTech

Location: TIP Building,
IIT Hyderabad, Kandi Telangana-502285

Website:
<https://cfhe.iith.ac.in/>

Email:
office.cfhe@iith.ac.in


Contact No.:
7036406261

About Incubator:

CfHE is committed to evolving into a dynamic platform that unites engineers, scientists, clinicians, designers, and business administrators to drive innovation in healthcare. We are on a mission to achieve universal healthcare by igniting the entrepreneurship in our youth spirit in our youth, equipping them with focused education, training and top-notch mentorship. To catalyze healthcare innovation to bring about affordable solutions to address healthcare needs of India.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Beable Health Pvt Ltd
- Nemocare Wellness Pvt Ltd
- Hemac Healthcare Pvt Ltd
- Jivika Healthcare Pvt Ltd
- Kvyat Medical Pvt Ltd

General Infrastructural Services:

CfHE offers comprehensive infrastructural services that support innovation and development, including a state-of-the-art Prototyping & Manufacturing Facility. This facility houses a variety of specialized labs designed to meet diverse project needs: a Prototyping Lab for initial concept development, a Mechanical Lab for precision engineering, an Electronics & Precompliance Lab for testing and refinement, and a Heavy Machinery Lab equipped for large-scale manufacturing. These resources provide a robust foundation for turning innovative ideas into reality.

Scientific Support Services:

Our Fellowship Program is designed to guide innovators through the entire journey of transforming an idea into a tangible solution, starting from clinical immersion. Participants begin by identifying real-world problems in the healthcare setting, followed by a thorough need identification process. From there, the program supports ideation and prototyping, providing the tools and mentorship needed to develop ideas from scratch into impactful solutions. This comprehensive approach ensures that fellows are well-equipped to create innovations that address critical healthcare challenges.

Advisory and Mentoring Services:

Our Advisory and Mentoring Services provide comprehensive support across all aspects of innovation and development. This includes guidance on intellectual property IP management, business strategy, and technical expertise. We also offer access to our state-of-the-art lab facilities and provide mentorship at every stage of prototyping. Whether you're refining your idea or bringing a prototype to life, our expert advisors and mentors are here to ensure your success at every step of the process.



Incubator Name: Foundation for Innovation & Research in Science & Technology FIRST, IIT Kanpur

Focus Area: MedTech/AgriTech

Location: SIDBI Building, Indian Institute of Technology Kanpur, Kalyanpur, Kanpur, Uttar Pradesh 208016

Website:
<https://siicincubator.com/>

Email:
biocubatoratitk@gmail.com


Contact No:
8353995330

About Incubator:

FIRST, IITK is a startup for startups that supports every budding startup in its growth journey. It came into existence when in 2000 SIDBI approached IIT Kanpur to form an Incubation centre. The idea was to deepen the entrepreneurship and incubation culture of the institute. FIRST, IIT Kanpur aims to develop cutting-edge technologies grounded in science and engineering innovations to solve pressing problems of the country, focusing on the underprivileged strata. It provides the right space and opportunities for converting your startup ideas into products and business.

Total Space Sq. Ft.: 10549

IMPACT



5 most successful incubatees:

- Kanpur Flowercycling Pvt Ltd
- Noccarc Robotics Pvt Ltd
- Curadev Pharma Pvt Ltd
- Saptkrishi Scientifics Pvt Ltd.
- LCB Fertilisers Pvt Ltd.

General Infrastructural Services:

At FIRST IITK, we provide a comprehensive infrastructure to support startups throughout their product development journey. The in-house laboratories offer an ideal environment for cutting-edge research and development. Understanding the importance of a conducive workspace, there are dedicated seating areas for startups to focus on their product development. To facilitate seamless collaboration and strategic discussions, we offer well-equipped conference rooms along with high-speed internet access. With this robust infrastructure, FIRST IITK empowers startups to transform their ideas into reality.

Scientific Support Services:

FIRST IITK is a key hub for scientific innovation, providing startups with exceptional R&D infrastructure. The institute features a wide range of in-house laboratories that are equipped with cutting-edge instrumentation. This extensive scientific arsenal covers various disciplines, including analytical chemistry, clinical and environmental testing, food and beverage analysis, forensics, life sciences with a focus on metabolomics, genomics, and proteomics, materials characterization, and petrochemical analysis. Additionally, specialised labs for upstream and downstream processing meet the diverse needs of startups involved in product development. By providing access to such a rich scientific ecosystem, First IITK enables entrepreneurs to conduct thorough research, accelerate product development, and introduce groundbreaking solutions to the market.

Advisory and Mentoring Services:

In addition to modern infrastructure, the incubator offers valuable mentorship in technical and business areas. To promote a thriving startup community, FIRST actively participates in and manages government-funded programs such as NIDHI EIR, TIDE 2.0, and BIRAC's BIG, which provide startups with important funding opportunities. Startups receive expert guidance to develop their ideas into actual prototypes and improve their business strategies for successful market entry. This holistic approach, along with the institute's strong alumni network, gives startups the necessary tools and connections to navigate the entrepreneurial journey.

Incubator Name: Foundation for Innovation and Technology Transfer

Focus Area: MedTech

Location: Foundation for Innovation and Technology Transfer FITT, 3rd Floor, Research and Innovation Park

Website:
<https://fitt-iitd.in/web/home>

Email:
incubation@fitt-iitd.in


Contact No:
011 2685 7762

About Incubator:

Foundation for Innovation and Technology Transfer FITT at IIT Delhi has been the vanguard of knowledge transfer activities from academia since its inception in 1992. This techno-commercial organization from academia is counted amongst the successful such organizations. FITT provides superior program management services and is steadily increasing its operational landscape. The varied roles of FITT can be seen in enabling innovations and technopreneurship, business partnerships, technology development, consultancy, collaborative R&D, technology commercialization, development programs, corporate memberships etc. These roles are necessitated by the key agenda of the Foundation to showcase the Institute's "intellectual ware" to industry, and thereby unlock its knowledgebase and inculcate industrial relevance in teaching and research at IIT Delhi.

Total Space Sq. Ft.: 70000

IMPACT



5 most successful incubatees:

- Redroom Technology Sanfe
- Ramja Genesense
- Clensta International
- Machphy
- Wrig Nanosystems

General Infrastructural Services:



FITT at IIT Delhi Research and Innovation Park is planned to be a managed facility with focus on innovation and product development where IIT Delhi, industry, entrepreneurs and government agencies interact and enable creation of advanced technological solutions. This facility designed with dedicated office and lab spaces to accelerate research translation, provide avenues for IIT Delhi students and faculty to interact more closely with industry and bring to market technological breakthroughs through incubation. Amplify technological and societal impact of R&D at IIT Delhi and galvanize entrepreneurial aspirations. Further, FITT is supporting BioIncubation through the Biotechnology Business Incubation facility, setup under the BISS BioNEST program of BIRAC. The facility has been operational since the last quarter of 2014 and has incubated many biotech innovators, startups, and BIG-funded companies. In 2024, we are ready with our new and larger facility for Bio-NEST 2.0, spread across 22,000 square feet. This facility is dedicated to biotech and life science-based startups and is equipped with state-of-the-art equipment designed for conducting research in biotechnology, including an animal cell culture lab, synthesis lab, microbial culturing lab, omics lab, analytical labs, and more. In addition, the NIDHI-CoE has been operational since November 2021, providing access to specialized simulation software, electronics prototyping laboratory, and a mechanical prototyping laboratory, which are essential for the MedTech and diagnostics sectors within the biotech domain.

Scientific Support Services:

FITT at IIT Delhi offers a range of scientific support services to foster innovation and entrepreneurship. These services include access to advanced research facilities, technical consultancy, and specialized testing and analysis services. FITT collaborates with startups, industries, and research organizations, providing them with expert guidance, technology transfer opportunities, and intellectual property management. By leveraging the expertise and infrastructure of IIT Delhi, FITT aims to bridge the gap between academia and industry, promoting the commercialization of cutting-edge technologies and enhancing the innovation ecosystem in India. As a general practice, all startups are linked to a faculty member at the IIT Delhi to facilitate technical mentoring and connect with the Institute.

Advisory and Mentoring Services:

FITT at IIT Delhi provides comprehensive advisory and mentoring services to support innovators and entrepreneurs in navigating the complex journey of technology commercialization. These services include guidance from experienced mentors, strategic business advice, and support in market research, funding, acquisition, and intellectual property management. FITT connects startups and researchers with industry, regulatory experts and investors, helping them refine their business models, validation studies and scale their innovations effectively. Through these services, FITT plays a crucial role in fostering a vibrant innovation ecosystem by empowering entrepreneurs with the knowledge and resources.



Incubator Name: Golden Jubilee Biotech Park for Women Society

Focus Area: BioIndustrial

Location: Golden Jubilee Biotech Park for Women Society, Siruseri Village, Inside SIPCOT- IT Park

Website:
<https://www.biotechpark.co.in/>

Email:
gm@biotechpark.co.in


Contact No.:
9444346362

About Incubator:

Golden Jubilee Biotech Park for Women Society was established with a vision of encouraging and empowering Women Entrepreneurs almost 2 decades ago. This organization is supported by Department of Biotechnology, Govt. of India, Govt. of Tamil Nadu. We have established companies which have their R&D and manufacturing units within our campus. The Park began its commercial operations in 2001 and over the years has proved to be a successful and unique venture in women entrepreneur development in the Biotech Sector. The Park has been designed based on the principle of decentralized production supported by centralized services to develop the field of Biotechnology. BioNest: With BioNest – a state of the art Bio Incubation Centre facility coming up in Oct., 2017, which was inaugurated by then Dr.Harsh Vardhan - Minister of Health & Family welfare, the Park has become unique and the first of its kind in the country dedicated for aspiring women to realize their dream come true. Park supports truly from R&D to Commercialization. Manufacturing: Park has 20 Unit modules and having 100 occupancy with Women Entrepreneurs from different field in the arena of Life Science and manufactures varied products which are sold across India and abroad. Achievements: The Golden Jubilee Biotech Park for Women Society was awarded as one of the Best Incubators during the Tamil Nadu Startups & Incubators Meet 2022 event

Total Space Sq. Ft.: 5000

IMPACT



5 most successful incubatees:

- Mrs. Geetanjali Radhakrishnan
- Dr. Menaga Magendran
- Dr. Jyothirmayee Dash
- Dr. Rachna Dave
- Dr. Shamini Senthilkumar

General Infrastructural Services:

The BioNest facility consists of Wet Lab Space, Admin office space, minor equipments, major equipments such as HPLC, RTPCR, PCR, Fermenter, Fluorescence microscope etc., Other facilities like seminar hall, conference room are also available to support the startups.

Scientific Support Services:

Highly Qualified and experienced Technical Team will support the Startups.

Advisory and Mentoring Services:

Support provided: Technical skill training, Mentorship to startups – End to End, IP Assistance and Guidance, Networking, Funding and Funding Assistance, Clinical trials and Validation support, Competitive Landscaping, Support on Marketing and Distribution.

Incubator Name: iDeaNA-CDFD Technology Incubator

Focus Area: Life Sciences

Location: Centre for DNA Fingerprinting and Diagnostics, Inner Ring Road, Uppal, Hyderabad-500039

Website:
<http://incubator.cdfd.org.in/>

Email:
incubator@cdfd.org.in


Contact No.:
914027216225

About Incubator:

Situated in the eastern health corridor of Hyderabad, CDFD Technology Incubator is a business incubator under the aegis of Centre for DNA Fingerprinting and Diagnostics, an institute of BRIC, Department of Biotechnology, Ministry of Science & Technology, Government of India. It is dedicated to nurturing, promoting, and accelerating early-stage innovations and deep-tech startups in the field of life sciences and related disciplines. It provides complete handholding throughout the entrepreneurial journey from lab to market and thereafter by giving access to co-working lab and office space, high-end equipment, mentoring, networking, fundraising support, and assistance with business modeling, IP facilitation, & Technology Transfer.

Total Space Sq. Ft.: 20000

IMPACT



5 most successful incubatees:

- DrOmics Labs Pvt Ltd
- Bharath Advanced Therapeutics Pvt Ltd
- Utopia Therapeutics Pvt Ltd
- Turnit AI Pvt Ltd
- Promecens Entrosystems Pvt Ltd

General Infrastructural Services:

Co-working lab space, shared office amenities, desk space, subsidized canteen, high-speed WIFI, library, seminar hall, meeting & conference rooms for virtual and/or in-person meetings, and breakout areas.

Scientific Support Services:

CDFD Technology Incubator has state-of-the-art facilities for shared R&D which includes basic equipment and world-class computing infrastructure. It also offers a wide range of analytical services and high-end equipment including super resolution microscopes, flow cytometer, cell sorter, CD spectrometer, and others facilities like Next-Generation Sequencing, Tissue Culture, Experimental Animal Facility & Green House. Start-ups incubated at CDFD Technology Incubator also get access to renowned scientists from CDFD who work in diverse areas of modern biology.

Advisory and Mentoring Services:

CDFD Technology Incubator has constituted a mentor pool of several seasoned personnel from various fields including industry, academia, business, legal, technical, financial, regulatory, IP to provide tailored advice for navigating the day-to-day challenges, refining business strategies and thus accelerating success of the startups.



Incubator Name: IIT Guwahati Technology Innovation & Development Foundation BioNEST

Focus Area: Bioindustrial

Location: IIT Guwahati Research Park 4th Floor
IIT Guwahati Campus Amingaon Guwahati

Website:
<https://www.iitg.ac.in/bionest/>

Email:
ceo@bionestititgtdf.com


Contact No.:
8011743755

About Incubator:

IITG TIDF BioNEST, supported by BIRAC, Government of India, strategically located at the IIT Guwahati campus amid lush green rich flora of North East NE India with a vision to foster innovative research and entrepreneurial activities in Healthcare and Industrial biotechnology related areas. The main focus area of the facility is the incubation of a host of entrepreneurs to commercialize an array of healthcare products in the area of traditional and modern Biomaterials, Industrial Biotechnology and state-of-art frugal Diagnostics so as to establish a benchmark especially in NE. Since its inception since 2021, IITG BioNEST has supported over 55 companies, 8 of whom have already been graduated. Currently we have 47 incubatees. We provide 360 degrees support to an entrepreneur from venture building, product development and GTM. We have various funding schemes for startups especially curated to the needs of NE startups. Since 2021, we have generated a corpus of ~INR20Cr from Govt. and CSR funds for startup ecosystem development at NE. Till now our startups have raised INR8Cr from Govt. grants and PE. IITG BioNEST has emerged as the leading Bio-Incubator at NE.

Total Space Sq. Ft.: 12000

IMPACT



5 most successful incubatees:

- Fuloni LLP
- Human Biogenesis Pvt. Ltd.
- Medinovation Research and Consultancy Private Limited
- Symbica Pvt. Ltd.
- Synbiogenesis Pvt. Ltd.

General Infrastructural Services:

1 Incubation: IITG BioNEST has been established in an area of 12,000sq.ft. at IIT Guwahati Research Park IITGRP. BioNEST provides two types of incubation residential incubation and virtual incubation support. BioNEST has dedicated space of about 3500sq.ft. area for incubatee co-working office space and individual labs, equipped with high-speed internet, phone lines, modular furniture and access to other IITGRP amenities like cafeteria, conference room, seminar hall etc. 2 Laboratory/Makerspace: IITG TIDF BioNEST lab/makerspace is developed in 2,500sq.ft. area which houses: o Instrumentation Lab: Housing sophisticated equipment for molecular biology, microbiology, Plant tissue growth chambers to be used for product development activities in Agritech, Food tech, diagnostics, testing and validations. o Fabrication Lab: Housing equipment like 3D printers, PCB prototyping, Automatic biosensor machine, Lithography etc. o Analytical Lab: Housing instrumentation for regular lab work required during product prototyping o Agritech Lab: Housing equipment for supporting innovation in agri and food technology Growth chambers, fermenters, incubators etc. o Mammalian Tissue culture: For Drug discovery, Therapeutics and Drug screening

Scientific Support Services:

- Product Development support
- Collaboration support from IIT Guwahati 3 CRO connect

Advisory and Mentoring Services:

- Business Mentoring
- Regulatory Compliances
- Product Development
- Product Branding
- Founders Branding
- Finance Structuring

Incubator Name: IIT Madras HTIC MedTech Incubator

Focus Area: MedTech

Location: No:1, 5th floor, C Block, Phase 2, IIT-Madras Research Park, Kanagam Rd, Tharamani, Chennai, Tamil N

Website:
<https://htic.iitm.ac.in/mti/>

Email:
ceo.incubation@htic.iitm.ac.in


Contact No.:
9790932420

About Incubator:

Healthcare Technology Innovation Centre HTIC, a multi-disciplinary R&D centre, is a joint initiative of Indian Institute of Technology Madras IITM and Department of Biotechnology DBT, Government of India that brings together technologists, engineers, doctors and healthcare professionals, industry and government to develop healthcare technologies for the country. The vision of HTIC is to develop technologies that create impact and drive innovation in healthcare and be a leader known for technical excellence and collaborative spirit. The MedTech incubator is part of HTIC and supported by BIRAC. The MedTech Incubator's supported by BIRAC prime focus is to build a community of healthcare entrepreneurs who can deliver innovative, affordable and valuable MedTech solutions and products for the Indian society. The incubator provides wide-ranging support such as technical support, seed funding, business support services, infrastructure & equipment support to start-ups and entrepreneurs working at the intersection of healthcare and technology. The Incubator currently has 61 incubated start-ups and has supported over 250 pre-incubated start-ups in the last six years. In the next 5 years we hope to have another 50 to 75 start-ups.

Total Space Sq. Ft.: 18

IMPACT



5 most successful incubatees:

- Kornerstone Devices Pvt.Ltd
- Mocero Health solution Pvt. Ltd
- Swasthchain Pvt Ltd
- C3 MedTech Pvt Ltd
- MediSim VR Private limited

General Infrastructural Services:



The incubator provide infrastructure services to start-ups are workspace space in incubator and rental offices in IITMRP subsidizes. It also includes MedTech facility, workshops, Product Demo zones & Start-up Lounges

Scientific Support Services:

The incubator is part of IIT Madras Healthcare Technology Innovation Centre HTIC, a multidisciplinary research centre. The centre extends its support in providing access to its healthcare researchers and product experts to assist the startups in joint technology development, product/service development and clinical, design & market validation.

Advisory and Mentoring Services:

Mentoring services provided by Serial entrepreneurs, Investors, Domain experts, Industry Heads, IITM faculty & Investors partners VCs, Angels



Incubator Name: IIT Mandi Catalyst

Focus Area: BioIndustrial

Location: IIT Mandi North campus,
Salgi-175005, N Campus Rd, Khanahr,
Himachal Pradesh 175005

Website:
<https://www.iitmandicatalyst.in/index.html>

Email:
gm@iitmandicatalyst.in


Contact No.:
+91 95998 36232

About Incubator:

IIT Mandi Catalyst Catalyst is a section 8 company promoted by IIT Mandi in 2016 as Himachal Pradesh's first Technology Business Incubator TBI. Catalyst is emerging as the Himalayan Region's leading incubator, with a special emphasis on technological innovation. Over the past eight years, Catalyst has supported over 500 startups and committed more than INR 20 Crore in financial aid, contributing significantly to the startup ecosystem in the state. Our supported startups have garnered over 100 awards and generated employment for over 4,100 individuals, illustrating the impact and growth of the entrepreneurial community here. As one of the country's most active incubators and through the visionary leadership provided by IIT Mandi, Catalyst has created a startup-friendly support system to ensure the ideas of tomorrow don't die.

Total Space Sq. Ft.: 11000

IMPACT



5 most successful incubatees:

- WELLNESYS TECHNOLOGIES PRIVATE LIMITED
- Sunbots Innovations LLP
- BONV Technology Private Limited
- SKPL Antrepriz Solutions Private Limited
- NEMA AI Private Limited

General Infrastructural Services:

IIT Mandi Catalyst offers a range of general infrastructural services designed to support startups and entrepreneurs in their early stages. These services include state-of-the-art office spaces, high-speed internet, meeting rooms, and dedicated workstations to facilitate a conducive work environment. The incubator also provides access to labs and prototyping facilities equipped with advanced tools and technologies, which are essential for product development and testing. Additionally, Catalyst offers shared amenities like printing and scanning facilities, cafeteria services, and a peaceful, pollution-free campus setting. These infrastructural services aim to provide startups with the necessary resources and environment to innovate, collaborate, and grow effectively.

Scientific Support Services:

IIT Mandi Catalyst provides comprehensive scientific support services to assist startups in developing and refining their technological innovations. These services include access to advanced laboratories equipped with cutting-edge instruments for research, testing, and prototyping across various domains such as biotechnology, materials science, electronics, and mechanical engineering. This robust scientific support infrastructure empowers startups to accelerate their R&D processes and bring their innovations closer to market readiness. Catalyst facilitates connections with domain experts, offers guidance on intellectual property IP management, and supports startups in conducting pilot studies, clinical trials, and other crucial scientific validations.

Advisory and Mentoring Services:

IIT Mandi Catalyst offers robust mentoring and advisory services to guide startups through various stages of their entrepreneurial journey. These services include one-on-one mentorship sessions with experienced industry professionals, entrepreneurs, investors, and subject matter experts who provide valuable insights into business strategy, product development, market entry, and scaling. Additionally, startups have access to a network of advisors and alumni who offer tailored guidance on overcoming specific challenges.

Incubator Name: IIT Ropar - Technology Business Incubator Foundation

Focus Area: MedTech

Location: IIT Ropar Technology Business Incubator Foundation

Website:
<https://www.iitrprac.in/tbif/>

Email:
tbifoffice@iitrprac.in






Contact No.:
09417484881

About Incubator:

To strengthen the entrepreneurship & start-up ecosystem in the Indian Institute of Technology Ropar and the country at large, the institute has been running a technology business incubator at its campus, which is an independent section 8 Company, registered as IIT Ropar Technology Business Incubator Foundation TBIF. Established in 2016 under the NIDHI TBI Scheme of DST Govt of India, TBIF offers startups a 20,000 sq. ft. incubation facility to help start, scale up, and accelerate. With the aim of building a robust startup ecosystem within the state and beyond, IIT Ropar's TBIF strives to nurture and create value for startups, MSMEs, entrepreneurs, and other ecosystem partners. IIT Ropar - TBIF empowers local entrepreneurs, researchers, and students to build deep tech businesses covering a wide variety of technologies and innovations in the thrust areas like manufacturing, defence and security, IoMT, IoT, AI, ML, healthcare technologies, etc. Besides this, we have a dedicated student body called E-Cell, which acts as an extended arm of TBIF to cultivate an entrepreneurial culture within the students of the institute. TBIF provides startups access to networks, cutting-edge technology, central research facilities at IITR-PR, a well-knit network of technical and business mentors, an investor pool, government funding, etc.

Total Space Sq. Ft.: 20

IMPACT



5 most successful incubatees:

- Vanix Technologies Pvt. Ltd.
- Evigway Technologies Pvt. Ltd.
- Jyoma Solutions Pvt. Ltd.
- Roschcrete Technologies Pvt. Ltd.
- Sri Venkateshwara Indo Global Medicare Pvt. Ltd.

General Infrastructural Services:

20,000 sq. ft. of space, which includes common areas, design and die lab, specific office space for startups, a conference room, etc. Incubation seats at IIT Alumni Centre, Bangalore Access to the state-of-art facilities and resources of the institute Startups can utilize the institute's equipment/infra at internal rates 20-50x cheaper than rates for industry

Scientific Support Services:

30+ Mous done with various industries, institutes and army commands. Access to the state-of-art facilities and resources of the institute Startups can utilize the institute's equipment/infra/ labs at internal rates 20-50x cheaper than rates for industry 180+ faculty engaging as domain experts/mentors/ advisors/founders/consultants for mentoring startups.

Advisory and Mentoring Services:

We have industry stalwarts like Sanjeev Bikhchandani, Arindam Mukhopadhyay, Deb Mukherji and Mr Vikrant Varshney as mentors/advisors to help startups refine their business strategies and investment plans. 180+ faculty engaging as domain experts/mentors/advisors/ founders/consultants for mentoring startups. To mentor our defense and aerospace domain startups we have experts like Colonel Virbhadr Singh Rawat, Lieutenant General Surinder Singh Mahal, Major General Ashish Jindal, Major General Mandeep Singh, Commodore Mukesh Bhargava, Lieutenant Colonel Prashant Malik and Colonel Prabir Sengupta

Incubator Name: IITM Bioincubator

Focus Area: BioIndustrial

Location: IITM Bioincubator,
IITM Incubation cell, IITM Research park,
Taramani, Chennai

Website:
<https://bioincubator.iitm.ac.in/facilities.php>

Email:
merit_bioincubator@incubation.iitm.ac.in


Contact No.:
9952932141

About Incubator:

IITM Bioincubator is one of the world class bioincubators established with the support of BIRAC Gov. of India on 11th December 2014. It is housed in IIT Madras Research Park IITM RP, India's first and leading university-based innovation ecosystem and falls under the purview of IIT Madras Incubation Cell IITM IC. Its excellent ecosystem enables collaboration between the start ups, corporate houses, faculty and students of IIT Madras. Our objective is to promote biotechnology based innovation and entrepreneurship in India, fostering the development of globally competitive products by startups for successful commercialization. Our vision is to Our Vision to create a state of art facility, enabling translation of lab based discoveries to marketable products, nurturing innovation and entrepreneurship. The services we provide are a comprehensive support system to enable the entrepreneurial leap from Idea to Market Facilitating enhancement in technical skills and business mindset providing infrastructure for technology scale-up and pilot-scale validation providing a conducive networking platform for industry-academia collaboration providing an outreach platform to identify early adopters and customers

Total Space Sq. Ft.: 9000

IMPACT



5 most successful incubatees:

- Fibsol technologies Pvt Ltd
- Cisgen Biotech Discoveries Pvt Ltd
- ISMO Bio-photonics Pvt Ltd
- Theevanam additives and neutraceuticals Pvt Ltd
- QBiome research Pvt Ltd

General Infrastructural Services:

IITM Bioincubator has the following facilities 1. Phase -I, 3E-Block in IITM RP IITM Bioincubator with Wet lab Facility and shared cubicles 3000 sq ft. laboratory space, housing all the equipment Sitting arrangements and workstations allotted to individual companies Equipment facilities are shared by all the incubated companies A meeting room with videoconferencing facilities 2. Phase-II, 5C-Block in IITM RPIITM Bioincubator with Wet lab facility and individual cabins 8 Lab/office spaces for individual companies ~ 200 - 220sqft. each

Scientific Support Services:

Equipment to support work in the domain 1. Microbiology 2.Molecular biology 3.Bioprocess Engineering 4.Bio-analytics 5. Mammalian cell culture Also, Work Benches and Office space-Desks, storage, internet, telephone, printing, Meeting room Cold room, Clean-air room for cell culture, Room for Media preparation, autoclaving, and washing

Advisory and Mentoring Services:

A very structured mentoring and advisory service called IITM Entrepreneurship Forum IITMEF is provided to the startup incubated at IITMBI, providing a forum for startup leadership to seek advice/guidance from Mentors primarily on business-related matters: business model and plan, product-market fit, GTM strategy, etc. Startups interact one-on-one with mentors, discuss, and obtain feedback on business strategy, problems, opportunities, etc and Mentor will meet startups at a recommended frequency Incubator will make all efforts to identify suitable 'journey' business mentors for every incubatee. We will also facilitate interaction with domain experts when required. There is another structured mentoring service provided called CII - CSO Forum- where Chief Strategy Officers from leading organizations bring varied experience from major industries. The startups interact one-on-one with mentors, discuss, and obtain feedback on business strategy. Another structured programme is the VC-in-house where there is one-to-one mentoring session with Angel investors and VCs. Startups can expect to receive feedback on business strategies, startup finances, and fundraising /pitch deck.

Incubator Name: IKP Knowledge Park - Life Science Incubator

Focus Area: BioService

Location: Genome Valley,
Turkapally, Shamirpet, Medchal-Malkajgiri

Website:
<https://ikpknowledgepark.com/>

Email:
viswanatham@ikpknowledgepark.com


Contact No.:
+91 79896 46563

About Incubator:

The Life Science Incubator LSI, a division of IKP, is dedicated to empowering innovation in the life sciences sector. Our mission is to support startup companies, spinoffs, and scientist entrepreneurs, ultimately enhancing regional and national competitiveness. We offer state-of-the-art facilities to our incubatees, including lab space and shared equipment for early-stage innovators, as well as analytical facility services for comprehensive support. Our entrepreneurs work in diverse domains, such as pharmaceutical, chemistry, agriculture, food and nutrition, and industrial environmental biology. The LSI is situated within IKP Knowledge Park, a 200-acre premier Science Park that is home to esteemed companies like Daicel, AMRI, Biological E, Coromandel PI, and US Pharmacopeia. This thriving ecosystem provides our startups with the ideal environment to grow and develop. In addition to our facilities and ecosystem, we also offer comprehensive support to our incubatees. This includes tailored mentoring sessions with industry partners, experts, and our extensive mentor pool, regulatory support through the IKP Global Regulatory Forum IGRF, and IP and legal services through the IKP prime team.

Total Space Sq. Ft.: 400000

IMPACT



5 most successful incubatees:

- LAURUS Labs
- Enzibeta Biotech Pvt Ltd
- RAS Lifesciences Pvt Ltd
- Telluris Pvt Ltd
- Remidio Innovations Pvt Ltd

General Infrastructural Services:




- Ready-to-use lab space with utility lines, 2. Work benches, fume hoods, biosafety cabinets, 3. Shared common equipment facility 4. Tissue culture Lab 5. Analytical services NABL accreditation

Scientific Support Services:

IKP orchestrates a diverse range of events, workshops, hackathons, idea expositions, tech showcases, and pitch sessions to support and enhance the growth of startups. These multifaceted activities are tailored to meet the varied needs of emerging enterprises, providing them with crucial platforms for networking, knowledge exchange, and collaboration. Through large-scale conferences and more intimate meetups, IKP facilitates opportunities for startups to acquire practical skills, gain industry insights, and showcase their innovations. The organization's strategic location, hosting prominent companies such as USP Pharmacopoeia, Daicel, AMRI, Biological E, and Coromandel PI, further enriches the environment by enabling startups to engage in meaningful dialogue and resolve challenges swiftly. By connecting startups with established industry leaders and investors, IKP plays a pivotal role in nurturing entrepreneurial ventures and accelerating their development.

Advisory and Mentoring Services:

IKP offers comprehensive support to budding entrepreneurs and academicians through various stages of their ventures. Our services encompass assistance with proposal writing and pitch deck preparation for securing grants and funding. Additionally, we provide support in intellectual property filing, legal services, market access, and regulatory advisory. Our multifaceted approach is designed to address the diverse needs of startups and facilitate their growth and success.



Incubator Name: Incubation Centre IIT Patna

Focus Area: MedTech

Location: Indian Institute of Technology Patna,
Bihta, Patna, Bihar, 801103

Website:
<https://www.iciitp.com>

Email:
iciitp_ic@iitp.ac.in


Contact No.:
9031200867

About Incubator:

The Incubation Centre IC at IIT Patna is a result of collaboration between the Government of India and the Government of Bihar. The IC IITP is specifically focussed on incubating ventures in the Electronics Systems Design and Manufacturing ESDM and Medical Electronics. We provide world-class facilities for design, testing, prototyping and fabrication. The objective is to ensure that for ideas in medical electronics, the IC IITP is the place to turn the idea into reality. It is a registered as IC IITP society under Society Act Reg. No. 987, Year 2015-16. Focus area is of Electronic System Design and Manufacturing ESDM with a special focus on Medical Electronics. Objective is to Identify, nurture and translate technology ideas and innovation in the broad area of Electronic System Design and Manufacturing ESDM with a focus in Medical Electronics. IC IIT Patna recently got approval from BIRAC to run the BioNEST program. It aims to promote and support the innovation and entrepreneurship activities in the broad scope of Life sciences, MedTech and Biotech based ideas.

Total Space Sq. Ft.: 30000

IMPACT



5 most successful incubatees:

- Pushkar Shripad Bhagwat
- Rajnish Kumar
- Sobhan Chakraborty
- Ankur jaiswal
- Llewellyn Dsa

General Infrastructural Services:

Incubation Centre IIT Patna is setup in a dedicated 30,000 sq.ft areas in IIT Patna Campus. Incubation Centre IIT Patna will accommodate 100+ people incubatees and staff, and having world class facilities such technology labs, clean room, meeting and conference facility, cafeteria, library, recreation facility, co-working/individual office space and 4 guest rooms.

Scientific Support Services:

The IC IITP works with the vision to be the leading technology business incubator in the country in the area of Electronics Systems Design and Manufacturing ESDM and Medical Electronics. In line with this, IC IITP provides state of the art facilities to the incubated start-ups to give them a head start in business. All possible needs a start-up in ESDM area is taken care of from well-furnished office space to support for a successful commercial launch. Labs in IC IIT Patna are being used for technical and research purposes. Labs in IC IITP: 1 PCB based Electronic System Manufacturing, 2 PCB and Electronic System Testing and Measurement, 3 Fabrication facility/Clean room, 4 3D Printing.

Advisory and Mentoring Service:

The activities of the IC are governed by a governing council of eminent personalities from Government of India, Bihar Government, Industry, Academia and Investment Community. A pool of mentors 50 mentors from various areas such as academia, industry, investor, hospital etc. to support in business, technology, product development, entity registration, problem validation, product and service definition, patents and other aspects of business planning.

Incubator Name: Innovation and Incubation Centre for Entrepreneurship

Focus Area: MedTech

Location: IISER Bhopal Campus Bhauri Bypass Road,
Bhauri, Bhopal, Madhya Pradesh

Website:
<https://iice.iiserb.ac.in/>

Email:
office_iice@iiserb.ac.in


Contact No.:
07552692387

About Incubator:

IISER Bhopal has established a Technology Business Incubator Innovation and Incubation Centre for Entrepreneurship-IICE with support from DST NIDHI TBI Scheme. IICE is a Technology Business Incubator TBI, which provides 'Start to scale' support by providing office space, research support and mentorship for entrepreneurship and facilitates the conversion of research activity into entrepreneurial ventures. IICE aims to promote and support startups based on ideas in science and technology that either have the potential or have already resulted in a product, process or service that has commercial value and the potential for creating a positive impact on the society.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Plabeltech Pvt Ltd
- Intisen Technology Pvt Ltd
- Powermest Pvt Ltd
- Mbiosys Pvt Ltd
- Adit Bioscience Pvt Ltd

General Infrastructural Services:



- Furnished Office Space / Shared office space.
- Shared resources: Meeting rooms, Conference rooms, Pantry.
- Instrumentation Facility of the IICE
- Office facilities: Photocopier, Scanner, Projector, Audio-visual conferencing facilities.
- Laboratories with equipment and software tools.
- Facilitation for access to Instrumentation facility and labs of IISER Bhopal.
- Electricity, Water, High Speed Internet, and Server.
- Individual storage spaces with safety lockers

Scientific Support Services:

- Facilitation of Inter disciplinary research support.
- Facilitation of testing and validation of new technologies.
- Connection with mentors and experts.

Advisory and Mentoring Services:

- Mentoring, advisory from experts on legal, accounts, support for fund raising through government grants and investment.
- Trainings and workshops.
- Interaction with successful entrepreneurs, policy makers, and industry experts.
- Facilitation for industry connects.
- Showcasing opportunities.
- Inter-disciplinary expertise.
- Facilitation for investors network.



Incubator Name: Institute of Advanced Study in Science and Technology - BioNEST - IASST

Focus Area: BioService, BioTechnology, FoodTech, AgriTech, BioService

Location: SAIC Building,
Vigyan Path, Paschim Boragaon Guwahati

Website:
<https://srasta-iasst.org/bionest>

Email:
bionest.iasst@gmail.com

Contact No.:
9101764862

About Incubator:

BioNEST is an incubation centre under the aegis of Institute of Advanced Study in Science and Technology IASST which is one of the autonomous R&D Institutes under the Ministry of Science and Technology, Govt. of India and is a premier scientific research organization in the north-east region of India. The Institute is engaged in multidisciplinary research activities, both in fundamental and applied sciences, across frontier areas of science and technology. BioNEST IASST intends to support and nurture innovative start-ups in their pursuit to become scalable and sustainable business enterprises. We have supported around 65+ entrepreneurs who are working in sectors from Agriculture, Bioenergy, Health-tech, Cosmetics, Diagnostics, Prosthetics Bio-waste Management, and allied fields of Biotechnology.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Aranyam Innovations Pvt. Ltd.
- Amblygold Monoroma Foods Pvt. Ltd.
- Arling Symphony LLP.
- Chai Trails Pvt. Ltd.
- Tholux Pratishthan Pvt. Ltd.

General Infrastructural Services:

Lab Space: BioNEST-IASST is set up within IASST as a division with a key objective of nurturing start-up companies and entrepreneurs working in the areas of healthcare, agriculture, food/nutrition, bio-energy, industrial & environmental biotechnology, etc. The fully furnished dedicated lab space at BI includes: Four Exclusive labs incubate unit of 270 sq ft. There is a common facility which houses equipments used in Pharma/Biotech experimentation. Each incubate unit is provided with work bench and essential furniture etc. and each unit is fitted with uninterrupted power supply, telephone and Internet connection, fire protection and detection systems, utility lines and flexible ducting with centralized air conditioning. Considering the demand for shared facilities with specialized equipment support, an additional 610 sq ft. of incubation space [unfurnished laboratory space of varying sizes ranging from 75 to 200 sq ft.] and bootstrapping area of 19 seats approximately 450 sq ft. is available. Office Space: With an aim of enabling early start-ups with a "plug and play" feature, it provides access to a fully equipped office space with Photocopier, Scanner, Projector, video audio conferencing facilities. Exclusive Lab/office spaces for individual companies - 250 - 270 sq ft. each are designed for upcoming incubatees. The incubatees will have to bring their own lab and office equipment Seminar Room/Conference Room: A 6/8 seater meeting room with videoconferencing facilities is available with free WiFi facility. Besides this choices are available for availing the larger accommodation capacity Seminar rooms/conference rooms of IASST Campus. It is also equipped with excellent sound system and good system and portable Cell Culture Facility, Micro biology facility, Fermentation Facility, Sealing & Packaging facility is accessible to the incubatees. The Central Instrumental facility of IASST is also available to the incubatees at discounted price.

Scientific Support Services:

Technical Consultancy: These include road-maps to the technology, creation of strategy & due diligence. Emphasis will be given on consultancy of raw material availability, product development, design, scaling & packaging for prototypes, instrumentation, study design, scientific software, informatics, and scientific services. The incubation center helps in Product formulation, Product validation, Lab scale R&D and Process optimization.

Advisory and Mentoring Services:

Business Consultancy: These include value proposition of the technology, defining of markets or targeted industry or the customer needs, financial projections, milestones and risk planning and creating a business plan document. With decades of experience and belong to top-notch institutions of India and abroad. In-house experts will provide professional or expert advice in area such as Biomedicine, Biophysics, Biochemistry Biomedical Device, Biotechnology, Phytopharmacology, Nanotechnology, Bioprocess engineering etc. The Mentors of BioNEST IASST provide advice on how best to modify new technologies so that they become patentable and commercially viable in India. Fund Facilitator: We provide financial support to incubatees to encourage and foster technological entrepreneurship by connecting to funding bodies. Network/Linkages: BioNEST IASST provides networking with Domains Experts, Industry experts, Consultants, Venture Capitalist and other funding agencies. We help startup connects to various industries like Private and Government sector including Manufacturing. Legal Consultancy: Idea validation from a legal and regulatory standpoint, including advising on founder legacy issues and legal execution of the business idea is taken care by our Legal Consultant team. These include company incorporation, financial & accounting setup, HR processes, regulatory requirements, etc. IPR Consultancy: We primarily focus on patentability of an invention in a particular jurisdiction, Infringement issues, Technical Patent Drafting including suggested claims and ultimately guide the incubatees in protecting their innovations by connecting to attorneys. Training & Workshop : We conduct regular workshops, seminars and lectures in specific areas of biotechnology, instrumentation and entrepreneurship.

Incubator Name: i-RISE TECHNOLOGY BUSINESS INCUBATOR, IISER Mohali

Focus Area: Agnostic AgriTech, Biotech, Healthcare, AI-ML, IoT, Food Tech

Location: Technology Business Incubator,
IISER Mohali Knowledge city, Sector 81, Manauli

Website:
<https://www.iisermohali.com/>

Email:
ceotbi@iisermohali.ac.in

Contact No.:
9696218778


About Incubator:

i-RISE TBI at IISER Mohali is a leading technology business incubator dedicated to fostering innovation and entrepreneurship. Established to support startups, i-RISE TBI offers a comprehensive ecosystem that includes mentorship, funding opportunities, state-of-the-art facilities, and access to a vast network of industry experts and academic professionals. The incubator has been instrumental in guiding startups through their growth journey, from ideation to commercialization. Recognized for its excellence, i-RISE TBI has received funding from DPIIT under the Startup India Seed Fund Scheme and has been selected as a BIRAC SPARSH Center. The incubator has supported 40 startups, leading to the creation of over 80 job opportunities and the successful filing of 9 trademarks. It has also facilitated the granting of 6 patents, with 7 more in process. Noteworthy among its incubated startups, Breww Therapeutics Pvt Ltd showcased its innovative products at the WIPO General Assembly Meeting in Geneva and was chosen to interact with the Prime Minister of India at Startup Mahakumbha 2024. Additionally, Besure Buddy Cabs and The NRI Helpline were recognized with prestigious awards at the STPI Excellence Awards by STPI and TIE Chandigarh. Through its efforts, i-RISE TBI IISER Mohali continues to be a catalyst for innovation and a driving force in the startup ecosystem.

Total Space Sq. Ft.: 10000



IMPACT



5 most successful incubatees:

- BREWW THERAPEUTICS PVT LTD
- VERDANT IMPACT PVT LTD
- AGNENT TECHNOLOGIES
- BESURE BUDDY CABS PVT LTD
- FERMENTECH LABS PVT LTD

General Infrastructural Services:


TBI IISER Mohali has developed sophisticated research facilities and advanced office and lab infrastructure, to support its incubated startups. The i-RISE facility, which spans a total built-up area of 10,000 square feet within the IISER Mohali campus, serves as the hub for this innovation-driven ecosystem. This facility was inaugurated by Dr. Jitendra Singh, the Honorable Minister of State Independent Charge for the Ministry of Science and Technology and Ministry of Earth Sciences, highlighting its importance in the national innovation landscape. The infrastructure at i-RISE is meticulously designed to cater to the diverse needs of startups. It includes a conference room equipped with video conferencing capabilities, a common workstation, and dedicated office spaces for incubatees. The facility also boasts a seminar room, an activity room, a pantry, and storage rooms to ensure a well-rounded working environment. For research and development, i-RISE offers dedicated labs for startups, four open labs, a cell culture lab, a microbiology lab, and two analytical instrumental labs. These labs are outfitted with state-of-the-art equipment, such as GC-MS, HPLC, Real-Time PCR machines, Rota vapor, and centrifuges, among others. Additional key equipment includes UV photo spectrometers, fume hoods, -80°C freezers, BS II cabinets, laminar hoods, sonicators, vacuum ovens, water baths, autoclaves, and various incubators. The labs also feature advanced instruments like analytical weighing machines, shaking incubators, CO2 incubators, vacuum filtration units, orbital shakers, and more, ensuring that startups have access to the best tools for their research and product development needs. This comprehensive infrastructure at TBI IISER Mohali empowers startups to innovate, develop, and scale their operations, providing them with the essential resources to thrive in a competitive environment.

Scientific Support Services:

TBI IISER Mohali provides extensive scientific support services to foster innovation among budding entrepreneurs. The incubator features in-house lab facilities, including a microbiology lab, an instrumentation lab, and wet labs, offering the essential infrastructure for advanced research and development. In addition to physical resources, TBI IISER Mohali supports startups through training programs, boot camps, and awareness sessions that enhance both technical and business skills. Startups also receive legal and intellectual property IP support, along with access to the sophisticated equipment available at IISER Mohali. A key advantage is the mentorship and hands-on guidance provided by renowned IISER Mohali faculty and scientists, ensuring entrepreneurs receive expert advice and technical assistance. This comprehensive support ecosystem empowers startups to innovate, develop high-quality products, and successfully navigate the challenges of bringing their ideas to market.

Advisory and Mentoring Services:

TBI IISER Mohali offers comprehensive advisory and mentoring services across three key areas. Business Support: Startups receive assistance in idea and product validation, market validation, and refinement, along with guidance in team formation and venture development. Business mentorship is provided by domain experts, focusing on capacity and leadership development, revenue acceleration, and opportunities to conduct pilots with corporate partners. Technical Support: Startups benefit from mentorship by sector experts and IISER faculty, with tie-ups to technological partners and academic institutions like NAB, NIPER, IMTECH, and Punjab University. The incubator also offers an in-house pilot plant facility and supports validation and certification processes. Network Connect: TBI IISER Mohali facilitates connections across a diverse network that includes mentors, fellow startups, government organizations, academic institutions, investors, and corporate partners. This network is instrumental in providing startups with the resources, insights, and opportunities they need to thrive in a competitive landscape.





Incubator Name: JSSATE Science & Technology Entrepreneurs Park, Noida

Focus Area: BioIT | DeepTech

Location: JSS Academy of Technical Education,
C-20/1, Sector 62, Noida, Uttar Pradesh 201301

Website:
<https://www.jssstepnoida.org/>

Email:
bhuvna@jssstepnoida.org


Contact No.:
07305030428

About Incubator:

JSS ATE STEP, NOIDA a society registered under the Societies Registration Act 1860 and is India's first TBI, started in 2000, recognized by NSTEDB in 2004. JSS STEP nurtures post ideation stage ventures, in TRL 4 and above. Supported 300+ startups from different sectors and now under BioNEST supports BioIT startups with DeepTech innovations.

Total Space Sq. Ft.: 18000

IMPACT



5 most successful incubatees:

- Circuit Sutra Pvt. Ltd.
- Railyatri Stelling Technologies Pvt. Ltd.
- Arogyam Medisoft Pvt. Ltd.
- Agatsa Software Pvt. Ltd.
- Emuron Technologies Pvt. Ltd.

General Infrastructural Services:

1. Laboratories and Equipment Access to Advanced Labs: Startups, particularly in the domains of biotechnology, energy, manufacturing, or hardware, can access sophisticated laboratories and equipment for prototyping, product testing, and development. R&D Facilities: Research and development facilities that support innovation and technology enhancement, including software tools, 3D printers, testing equipment, and more. 2. Incubation Spaces Office and Workspace: Fully equipped office spaces with essential amenities such as internet, furniture, meeting rooms, and access to other shared resources. Co-working Spaces: Flexibility for startups to use co-working spaces that allow for collaboration, networking, and cost-effective operations. 3. Hospital Connections: JSSATE STEP Noida has a huge connection with pharmacy and hospitals which can be streamlined for field trials and expert mentorship for healthcare. The products can be validated through doctors and experts. 4. High-Speed Internet and IT Infrastructure: Reliable and high-speed internet connectivity along with essential IT infrastructure like cloud services, servers, and data management tools. Technology Tools and Platforms: JSS STEP often provides access to software tools, design platforms, and technical support for startups involved in AI, IoT, data analytics, and other tech-driven sectors. 5. IT Infrastructure Credits: Startups are given IT infra Credits from AWS, Zoho, MSG91, Microsoft Azure, Internshala.

Scientific Support Services:

Availability of more than 250 full-time, highly qualified faculty members from various departments like Computer Science, Information Technology, Electronics, and Business Management, and from JSS College of Pharmacy housed within the JSS ATE campus to mentor the biotech entrepreneurs in different aspects of technology development and deployment. JSS STEP has a huge network both nationally and internationally for research and innovation development. JSS STEP also facilitates in certification processes of different innovations.

Advisory and Mentoring Services:

JSS STEP has a mentor pool of more than 150 mentors from industry for technical, business, finance and legal advisory for startups. 36 Mentors in the sectors like - Biotechnology, Deep Science, Bio- Sensors, Molecular Biology, HealthCare, Doctors and Microbiology

Incubator Name: KIIT Technology Business Incubator

Focus Area: Healthcare, AgriTech, Industrial Biotechnology, Bio energy

Location: KIIT Technology Business Incubator,
Near KIIT School of Biotechnology,
AT/PO- Patia, KIIT University

Website:
<https://kiitincubator.in/>

Email:
mrutyunjay@kiitincubator.in


Contact No.:
7008099439

About Incubator:

KIIT Technology Business Incubator KIIT TBI set up as a not-for-profit, public-sector company in 2009, with generous support from the Government of India's Department of Science and Technology DST, it was recognized as a Centre of Excellence in 2020. KIIT-TBI has received funding and support from various government agencies such as DST, the Department of Biotechnology, the Biotechnology Industry Research Assistance Council, the National Science & Technology Entrepreneurship Development Board, the Ministry of Micro, Small and Medium Enterprises, the Technology Development Board, the Ministry of Food Processing Industries, the Ministry of Electronics and Information Technology and the Government of India. Particularly, to augment the biotech innovation quotient, in 2012 KIIT TBI BioNEST Bioincubator was established with generous support from the BIRAC. For more than a decade of collective efforts in nurturing innovation in biotech space, KIIT TBI has been awarded the best Bioincubator for last two years by the Bio spectrum. KIIT-TBI won the National Award for Technology Business Incubation in 2017 from the Union Minister for Science and Technology and Earth Sciences. The primary focus of KIIT-TBI has been to nurture start-ups, facilitate industry-academia interaction and to promote student entrepreneurship. Today, KIIT-TBI has established itself as a major innovation hub for technology ventures and a site for interfacing with the industry, academia, government bodies, and cross-border agencies.

Total Space Sq. Ft.:1

IMPACT



5 most successful incubatees:

- EnRx HealthTech Pvt Ltd
- Aavy Biosciences Pvt Ltd
- LarkAI Healthcare Pvt Ltd
- Tan 90 Thermal Pvt Ltd
- Inochi Care Pvt Ltd

General Infrastructural Services:

KIIT-TBI provides an ideal platform and environment with a world-class infrastructure covering around 1,30,000 sq. ft. of built-up space. The facility offers a wide range of incubation facilities and services, including: Office Space: KIIT TBI provides modern office space equipped with essential amenities to foster a productive work environment. Plug & Play Business Suites: KIIT TBI provides high-end plug-and-play incubation facilities for startups, innovators, and entrepreneurs. Meeting Rooms: State of the art meeting rooms are available for various engagements. These rooms are equipped with advanced audio-visual systems for seamless communication. IT Infrastructure: Robust IT infrastructure, including dedicated high-speed internet, cloud storage, and secure networks, ensures that employees & startups have the technological backbone needed to thrive. Dedicated IT Support helpdesk is available to resolve any technical issues. Conference Room: The incubator features conference designed for workshops, capacity building programs & training sessions. These rooms are equipped with advanced presentation technology to enhance the experience. Prototyping Facilities: The state-of-the-art labs include basic a digital fabrication lab providing an integrated platform for rapid prototyping, product design, and technology development. Networking Areas: Designated networking areas provide space for informal interactions, fostering community building & one to one engagement entrepreneurs. Regular networking events are organized to connect startups with industry experts & investors. Parking & Logistics: Ample parking facilities are available for incubator tenants, providing convenient access to the building. Additionally, the incubator offers logistical support for the storage of materials & products.

Scientific Support Services:

Scientific support services: CENTRAL BIOINSTRUMENTATION FACILITY: This state-of-the-art facility provides a comprehensive bio incubation space for startups. It includes essential equipment such as biosafety cabinets, gas distribution facilities, orbital shakers, incubators, thermometers, cold centrifuges, -80°C, -20°C freezers, weighing balances, microcentrifuges, spectrophotometers, Nanodrop, water baths, PCR machines, fluorescent microscopes, and more. ADVANCED MICROFLUIDICS AND BIOSENSORS LABORATORY: Equipped with specialized tools like oxygen plasma bender, 3D printer for molds, and spin coater. CELL CULTURE FACILITY: Featuring a BSL2 cell culture facility, CO2 incubators, ELISA plate readers, flow cytometry, fluorescence microscopy, confocal microscopes, and other essential tools. ANIMAL HOUSE FACILITY: Supporting regulated and ethical research on animal models, including specialized services like maintenance of tumors, immunization, and management of mutant mouse stocks. BIRAC Bioreactor Supported High-End Analytical Facility: Offering advanced testing and characterization facilities at nominal costs for startups. Prototype Development & Validation Services: Prototyping and 3D Printing Laboratory: Offer development of point-of-care diagnostic devices and 3D printing services. CDE Digital Health & Precision Agriculture: Provides digital cytology and pathology, applications of machine learning and AI in pathology and clinical diagnosis, and clinical data services. Advanced Microfluidics and Biosensors Laboratory: Engaged in the development of point-of-care devices, diagnosis, and Lab on a Chip applications. 3D Prototyping and Bioprinting Laboratory: Specialized in 3D bioprinting and applications in drug discovery, studying drug interactions, testing organ-on-a-chip, and bioreactors. Computational Laboratory: Dedicated to computational modeling and simulation of biomolecular systems, drug-protein and protein-protein interactions, and metabolic pathway analysis.

Advisory and Mentoring Services:

Advisory and mentoring services: With a pool of 200+ authentic mentors engaged with varied backgrounds and sectors from both industry and academia, KIIT TBI conducts regular mentorship sessions focused on technology and business development for startups. Furthermore, startups are anchored with one or more mentors to monitor progress and provide guidance. Tailored Mentorship & Handholding: Commercialization strategy, Market analysis, Customer need analysis SWOT, Product marketing, Branding and Communication, Investor need analysis, Pitch deck preparation, Technical Mentorship, Experimental Workflow, Risk/Challenges mitigation, Intellectual Property, Regulatory Compliances, Product Development, Scalability, Product User need analysis, Validation/Clinical Trials, Finance/Term sheet, Legal / Corporate affairs, Operations/HR



Incubator Name: MakerVillage

Focus Area: Electronic Hardware Incubator

Location: Maker Village,
Integrated Startup Complex,
Kalamassery, Kochi

Website:
<https://www.makervillage.in>

Email:
pm2.makervillage@iitmk.ac.in

Contact No:
0484-2976688

About Incubator:

Maker Village, the largest electronic hardware incubator in the country was started in 2015 as an Electronic System Design & Manufacturing ESDM project under the host institute IIITMK with MeitY & Govt of Kerala as operating partners. With its strong network of associations with industries, ESDM facilities, academic institutions, and R & D institutes, Maker Village has made significant advances in the country's startup landscape in a very brief period of time since its inception. In terms of infrastructure, hardware & software resources for designing, prototyping, small scale manufacturing, testing, technical & business support, and its associated services for the startup ecosystem, Maker Village now has a unique offering.

Total Space Sq. Ft.: 25000

IMPACT



5 most successful incubatees:

- Covid Wireless
- C ELECTRIC AUTOMOTIVE DRIVES PVT LTD
- Transight System Pvt Ltd
- Evelabs Pvt Ltd
- Navat Solar & Electric Boats

General Infrastructural Services:

The main aim of Maker Village is to mitigate the risk that start-ups face while manufacturing electronic/deep-tech hardware. The incubation ensures that the entrepreneur sets up the manufacturing process and then quickly scale the product by the time the incubation period comes to an end. The incubation offers not just relevant technological tools and a manufacturing pipeline but specialized tools like Laser cutting, industrial 3D printing, industrial PCB assembly line metal machining centres, testing and measurement lab, robotic development centre, DIY zone and state-of-the-art electronic & mechanical design and simulation packages. The incubator enables bringing technology as fast as possible for the entrepreneur so that instead of taking a long duration to develop a product, the entrepreneur can have the prototype ready during the course of the incubation period itself. The incubation is specifically designed to focus on setting up a manufacturing line for start-ups.

Scientific Support Services:

Maker Village has an exemplary structured Intellectual Property system and has contributed its best to the development of Intellectual Property subject. Maker Village also supports the start-ups for their business development by connecting them with industrial leaders, mentors, investors and solution providers. Maker Village supports the start-ups to attract various funds, both public and private. By conducting roadshows, seminars and conclaves, Maker Village facilitates the start-ups to get connected and selected for various funding schemes. Maker Village partnered with many private and public sector ventures to facilitate the accelerated growth of start-ups. The joint solutions integrate best-in-class ecosystem facilities, global accelerator programs, leading industries, academic institutes, industrial manufactures, technical solution providers, mentors and other services. Maker village leverage this strategic partnership to develop the global competitiveness of the start-ups.

Advisory and Mentoring Services:

1 Rema Devi Naval Physical & Oceanographic Laboratory NPOL 2 Ramakrishnan Venkataraman Director, Sales, Dassault Systems 3 Jayakrishnan Nair Retd Commander, Indian Navy 4 S K Shenoy Former Director, NPOL Kochi, DRDO 5 Pavan Kumar Vice President, Altair South Asia and Managing Director, Altair India 6 Dr. Hemang Shah Intellectual Property and Innovation Strategy Qualcomm India 7 Dr. Rajasree M S Vice Chancellor, APJ Abdul Kalam Technical University 8 Dr. Vinod Kumar Gopal Assistant Professor, Amrita Vishwa Vidyapeetham University, Kerala 9 Narendra Singh Negi Head and VP R&D of Electronics & Power Products, V-GUARD Industries Ltd., Kerala 10 Sreekanth V M Assistant General Manager, SFO Technologies, Kerala 11 C Balagopal Founding Managing Director, Peninsula Polymers Limited Now Torumo Pempol Ltd 12 Prof. S Rajeev Adjunct Faculty, IIM Bangalore 13 Dr. Jayasankar Prasad Director, ICFOS International Centre for Free and Open Source Software 14 Dr. Sam Thomas Professor, School of Management Studies, Cochin University of Science and Technology 15 Dr. Suresh Nair CTO, SFO Technologies & Founding Managing Director, Imobreeze Technologies Pvt. Ltd. 16 Prakash Bare Co-Founder GDA Technologies Inc 17 Dr. Ambedkar Dukkithathi Associate Professor, Computer Science and automation, IISc, Bangalore 18 Dr. Murali Thummarakudy Chief, Disaster Risk Reduction, UN Environment Programme. 19 Manav Gupta Founder and CEO of BRINC, Hong Kong 20 Rahul Bansal Gandhi Center for Inclusive Innovation, Imperial College London & Deputy Director, Climate-KIC. 21 Anil Joshi Founder and Managing Partner, Unicorn India Ventures 22 B V Naidu Chairman and CEO of Sagittar Ventures Pvt Ltd 23 Dr. Heriberto Saldivar Massimi Managing Director, Brinc Accelerator 24 Sidharth Narayanan Head, Ecosystem Development at Intel Corporation 25 Sanjay Somasundaran Head, Engineering & Hardware Product development, Robert Bosch Engineering and Business Solutions Pvt.Ltd. 26 Jatinder Singh Head, Business Development, IMEC India 27 Anilkumar B Company Secretary, Kochi Metro Rail Limited.

Incubator Name: Manipal Government of Karnataka Bioincubator - BioNEST

Focus Area: MedTech

Location: MAHE Advanced Research Centre,
behind MMMC, Manipal, Karnataka

Website:
<https://bioincubator.manipal.edu/>

Email:
ceo.bioincubator@manipal.edu


Contact No:
909577323

About Incubator:

Manipal-GoK Bioincubator, a Technology Business Incubator established in 2019, is supported by Manipal Academy of Higher Education MAHE , Karnataka Innovation and Technology Society KITS , Government of Karnataka, and DBT's Biotechnology Industry Research Assistance Council BIRAC . Spanning 20,000 sq. ft., this world-class facility offers cutting-edge incubation infrastructure, high-end instrumentation, and regulatory support. It focuses on Biopharma, Biomedical Devices, Medical & Dental Innovation, Biotechnology, Diagnostics, and Healthcare. The Bioincubator is dedicated to upscaling innovations and propelling them toward product commercialization. It provides comprehensive services, including mentorship, investment readiness support, technical assistance, business validation, and networking opportunities. Its mission is to create a robust entrepreneurship ecosystem that supports the transformation of innovative ideas into scalable, technology-based enterprises. The Bioincubators vision is to strategically implement and mentor early-stage ideas, offering affordable high-end incubation facilities to help them evolve into successful enterprises.

Total Space Sq. Ft.: 20000

IMPACT



5 most successful incubatees:

- Blackfrog Technologies Pvt.Ltd
- ElkonaX Innovative Solutions Pvt.Ltd
- TAD AIRCON Pvt.Ltd
- Cambrian Biotech Private Limited
- Seragen Biotherapeutics Pvt.Ltd

General Infrastructural Services:

M-GoK Bioincubator provides facilities based on the requirements of the start-up including a dedicated or Shared Incubation Facility for Tissue culture, Microfluidics, Microbiology, Fabrication Prototyping facility, Electronic testing, analytical testing Dedicated labs & Offices, Plug and play Workstations, Class 100 Clean Rooms, and provide linkages to MAHE facilities including Primary, secondary and tertiary Hospitals, Animal House, Biobank and central facilities, other MAHE resources and Facilities.

Scientific Support Services:

The Manipal-GoK Bioincubator offers extensive scientific support services to help startups transform innovative ideas into viable products. These include access to high-end instrumentation, advanced lab facilities for Biopharma, Biotechnology, and Biomedical Devices. The incubator provides technical assistance with experimental design, data analysis, and troubleshooting, along with regulatory and compliance support to navigate clinical trials and product approvals. Startups benefit from mentorship and advisory services, connecting with industry experts who offer guidance on scientific, technical, and business aspects. The Bioincubator also facilitates collaborative research opportunities with academic and industry partners, enhancing knowledge exchange and resource sharing. Additionally, support in intellectual property management and technology transfer helps startups protect and commercialize their innovations. Regular workshops and training programs are offered to keep startups updated on the latest technologies and industry trends, ensuring they are well-prepared for commercialization.

Advisory and Mentoring Services:

The Manipal-GoK Bioincubator provides comprehensive advisory and mentoring services to support startups in their journey from concept to commercialization. Expert Mentorship: Startups gain access to a network of experienced mentors from academia, industry, and research who offer personalized guidance on scientific research, technology development, and business strategy. These mentors help address specific challenges related to product development, scaling, and market entry. Business Strategy and Development: The incubator provides advisory support in refining business models, conducting market analysis, and enhancing competitive positioning. Startups receive assistance in identifying target markets, potential customers, and strategic partners, as well as in crafting effective go-to-market strategies. Investment Readiness: Startups are prepared for investor interactions through guidance on pitch deck creation, financial modeling, and valuation. The incubator also facilitates connections with potential investors, offering opportunities to pitch at events and network with venture capitalists and angel investors. Regulatory and Compliance Guidance: The incubator offers advisory services to help startups navigate regulatory landscapes, including product approvals, clinical trials, and intellectual property management, ensuring compliance with both national and international standards. Networking Opportunities: Startups benefit from access to a vast network of industry contacts, including potential collaborators, customers, and partners. Participation in industry events, workshops, and conferences is encouraged to enhance visibility and expand networks. These services empower startups at the Manipal-GoK Bioincubator to overcome challenges, scale operations, and achieve commercial success.



Incubator Name: Mazumdar Shaw Medical Foundation TBI

Focus Area: MedTech

Location: Bommasandra Industrial Area,
Hosur Road, Narayana Health City,
Bengaluru. 560099

Website:
<https://tbi.ms-mf.org>

Email:
tbi@ms-mf.org


Contact No.:
9900983936

About Incubator:

The Mazumdar Shaw Medical Foundation - Technology Business Incubator MSMF-TBI is located within Narayana Health City in Bengaluru. It is India's first corporate hospital-based startup incubator, fostering innovation in BioTech, MedTech, and HealthTech sectors. MSMF-TBI offers a collaborative environment for entrepreneurs, engineers, clinicians, and scientists to develop life-saving medical technologies. The incubator provides access to clinical immersion, design thinking, bio-implant design, and clinical validation. Recognized as a Technology Business Incubator by the Department of Science and Technology in 2014 and awarded the Birac BioNEST in 2019, MSMF-TBI supports startups with mentorship, funding opportunities, and a robust ecosystem for testing and developing new medical technologies. Under the BioNEST program, 30 healthcare startups have been onboarded, with eight completing clinical validation and five in progress. Strategic partnerships with over 20 hospital networks provide clinical mentorship, validation, and commercialization support. MSMF-TBI's efforts aim to bridge the gap between scientific research and practical healthcare applications, transforming innovative ideas into tangible healthcare solutions.

Total Space Sq. Ft.: 8000

IMPACT



5 most successful incubatees:

- CIMED
- OMIX RESEARCH AND DIAGNOSTICS LABORATORIES PRIVATE LIMITED
- YOSTRA LABS PRIVATE LIMITED
- JANITRI INNOVATIONS PRIVATE LIMITED
- SUNFOX TECHNOLOGIES PRIVATE LIMITED

General Infrastructural Services:

Conference Room, Meeting Rooms, Seating Space, Office Space, Cubicles, Cafeteria, Amphitheatre, Parking Space, 24x7 Hi-speed Wifi, Mechanical Fabrication Lab, Electronics Lab, Prototyping Lab, AIML Lab, Wet lab, & Cell-culture facilities

Scientific Support Services:

Product Development Support, Market Validation Support, Clinical Validation and Trials, Prototype development support.

Advisory and Mentoring Services:

IP, Legal, Regulatory, Clinical Mentoring, Clinical Validation and Trials, Go to Market, Commercialization Support.

Incubator Name: Padmashree Research and Innovation center

Focus Area: AgriTech

Location: Padmashree Institute of Management and Sciences No.149, Padmashree Campus, Kommaghatta, Sulikere Po

Website:
<http://www.pims.org.in>

Email:
Pimsprincipal@gmail.com


Contact No.:
9902863900

About Incubator:

Padmashree SPARSH Research and Innovation Centre is a hub for entrepreneurial incubation, dedicated to nurturing the next generation of innovators and business leaders. Located within the Padmashree Institute of Management and Sciences, Bangalore, the center offers a dynamic environment where aspiring entrepreneurs can turn their ideas into reality. Our state-of-the-art facilities, including advanced laboratories and cutting-edge equipment, provide the perfect setting for innovative research and product development. We emphasize a hands-on approach, guiding entrepreneurs from the ideation stage through to commercialization. Our focus on Farm to Fork and climate resilience ensures that our incubatees are working on solutions that are both innovative and sustainable. We provide mentorship from experienced scientists and industry experts, helping entrepreneurs to navigate the challenges of starting and growing a business. This support includes everything from technical training to business development, ensuring that our incubatees are well-equipped to succeed in the competitive market. Our incubation center is committed to fostering interdisciplinary collaboration, allowing entrepreneurs to explore new frontiers in biotechnology, plant tissue culture, nutrition, and nutraceuticals. We also offer industry-oriented services such as analytical testing and consultancy, further supporting our incubatees in their journey. Through our strong national and international collaborations, SPARSH not only provides a platform for innovation but also enhances the global impact of the research and businesses developed here. Padmashree SPARSH Research and Innovation Centre is more than just an incubator; it's a launchpad for future leaders in science and industry.

Total Space Sq. Ft.: 1000

IMPACT



5 most successful incubatees:

- Kausheya
- Inside out
- Nourish foods
- Senior adda
- Only Millet Gourmet foods

General Infrastructural Services:


Padmashree offers an extensive and advanced laboratory infrastructure designed to support high-quality research and hands-on training. Our state-of-the-art facilities include a Central Instrumentation Lab equipped with Atomic Absorption Spectrophotometers, High-Pressure Liquid Chromatographs HPLC, Gas Chromatographs GC, and Fast Protein Liquid Chromatography FPLC. Specialized labs include Advanced Tissue Culture, Animal Cell Culture, Proximate Analysis, Molecular Biology, Biochemistry, Nutraceuticals, Microbiology, Food Processing, and Food Sensory Evaluation. High-end equipment such as UV-Visible Spectrophotometers, NanoDrop Spectrophotometers, PCR machines, Gel Documentation Systems, and ELISA Plate Readers ensure precise and reliable results.

Scientific Support Services:

Padmashree is committed to fostering innovation and scientific advancement through a comprehensive array of resources and services. We have expert faculty members with industrial and post-doctoral experience providing top-tier guidance and mentorship. Our facilities include a workshop area and a library that supports prototyping, fabrication, and extensive research. The specialized laboratories cater to Proximate Analysis, Molecular Biology, Phytochemistry, Nutraceuticals, Microbiology, and Food Quality Management, along with Sensory Evaluation labs. Additionally, we have greenhouses and open fields for practical crop cultivation and field experiments.

Advisory and Mentoring Services:

Padmashree Research and Innovation Center provides a comprehensive advisory and mentoring platform to support researchers, and incubatees. With over 50 established MOUs, including partnerships with esteemed organizations like GKVK, CFTRI, IBAB, Bangalore Bio Innovation Centre, Biocore Academy, Merck, and TUV SUD South Asia Pvt Ltd., the center offers unparalleled access to industry expertise and practical insights. The center's advisory services are further strengthened by its team of 15+ doctorates, 8 of whom bring significant industry experience. These experts actively mentor incubatees, helping them navigate the complexities of innovation, technology transfer, and commercialization. Moreover, the center has collaborated with the Karnataka State Council for Science and Technology KSCST to establish an IP Facilitating Cell. This cell provides legal support and intellectual property mentorship, ensuring that researchers and innovators are well-equipped to protect and commercialize their work. Through this network of partnerships and experienced professionals, Padmashree Research and Innovation Center fosters innovation, guiding participants towards successful outcomes.



Incubator Name: Parul Innovation and Entrepreneurship Research Centre PIERC

Focus Area: Sector Agnostic

Location: Post Limda,
Waghodia, Gujarat

Website:
<https://www.pierc.org/>

Email:
edc@paruluniversity.ac.in


Contact No.:
7405149221

About Incubator:

Established in 2013, Entrepreneurship Development Cell EDC is one of the creative hubs of Parul University formed to support students and aspiring entrepreneurs in their entrepreneurial endeavors. EDC was established with an aim to foster the culture of Research, Innovation and Entrepreneurship in students and faculty members of the university. In 2015, the university registered a Section 8 company, Parul Innovation and Entrepreneurship Research Center PIERC as an incubator to formally extend its services and support to start-ups from Idea Stage to Growth Stage. PIERC comprises a dedicated team of Incubation Managers and staff members that work towards developing the start-up and entrepreneurship ecosystem of the university and region. With the support from PIERC, a large number of entrepreneurs have successfully taken their startups to new heights.

Total Space Sq. Ft.: 12250

IMPACT



5 most successful incubatees:

- Total Healthcare Solutions
- PlantPact Innovations Pvt Ltd
- Yield Pro Earth Pvt. Ltd
- WinHealthCare
- Kavulit Technologies Pvt Ltd DeCardio ECG Machine

General Infrastructural Services:

At PIERC, Parul University, we provide a robust set of general infrastructural services tailored specifically to support startups in their growth journey. Our comprehensive infrastructure offerings ensure that startups have the essential tools and environment to thrive. Workspace Facilities: Startups benefit from access to up to 7,000 square feet of modern office in 04 big Cities of Gujarat through Startup Studios at Surat, Ahmedabad, Rajkot and Vadodra. co-working, and lab spaces. These areas are designed to foster creativity and collaboration, featuring adaptable layouts that accommodate various team sizes and activities. Our facilities include private offices, open co-working areas, meeting rooms, and conference spaces, all equipped with ergonomic furniture and a conducive working environment. Digital Infrastructure: We equip startups with high-speed internet connectivity and state-of-the-art IT systems. Our digital infrastructure includes cybersecurity measures to protect sensitive data and management software that streamlines operations. Additionally, startups have access to virtual collaboration tools that facilitate seamless remote work and team interactions. Shared Resources: PIERC provides access to a range of shared resources essential for day-to-day operations. This includes high-quality printers, advanced technical equipment, and common areas designed for brainstorming and networking. By offering these shared resources, we ensure that startups can operate efficiently without the burden of acquiring and maintaining expensive equipment. Operational Support: We develop and implement operational guidelines that streamline the use of facilities and resources. Our guidelines cover aspects such as resource allocation, facility management, and administrative procedures, ensuring smooth and efficient operations for all startups. Scalability and Flexibility: Our infrastructure is designed to be scalable and flexible, accommodating the evolving needs of startups. We plan for future expansions and upgrades, allowing startups to grow and adapt their space and resources as their needs change.

Scientific Support Services:

At PIERC, Parul University, our scientific support services are designed to empower startups with the research and technical resources they need to drive innovation and development. Research and Development Facilities: Startups have access to advanced research and development labs equipped with cutting-edge technology and tools. Our facilities support a wide range of scientific experiments and technical development activities, fostering an environment conducive to high-impact research. Technical Expertise and Consultation: We provide startups with access to a network of over 50 industry experts and technical specialists. These professionals offer valuable consultation and guidance on complex scientific and technical challenges, helping startups navigate research methodologies, product development, and technical problem-solving. Grants and Funding Support: PIERC assists startups in securing research grants and funding. We offer support in identifying suitable grant opportunities, preparing detailed proposals, and managing the application process. Our aim is to help startups access financial resources necessary for advancing their scientific projects. Knowledge Transfer and Training: We organize seminars, workshops, and training sessions to facilitate knowledge transfer. These events are designed to keep startups informed about the latest scientific advancements and best practices. By providing ongoing education, we ensure that startups stay at the forefront of technological and scientific developments. Collaborative Research Opportunities: PIERC fosters partnerships with academic institutions, research organizations, and industry leaders. We facilitate collaborative research projects, enabling startups to leverage external expertise and resources to enhance their scientific endeavors. Resource Access: Startups benefit from access to shared scientific resources, including specialized equipment and research materials. This support helps reduce the cost and logistical burden of acquiring and maintaining high-end scientific tools. PIERC's scientific support services equip startups with the necessary infrastructure, expertise, and resources to advance their research and development efforts, driving innovation and success in their respective fields.

Advisory and Mentoring Services:

At PIERC, Parul University, our advisory and mentoring services are crafted to provide startups with the strategic guidance and support essential for their growth and success. Strategic Advisory: We offer expert advisory services to help startups navigate the complexities of business development. Our strategic advisory includes assistance with market analysis, business model refinement, and growth strategy formulation. Our team helps startups identify key opportunities and challenges, providing actionable insights to drive their business forward. Mentorship Program: PIERC connects startups with a network of over 100 seasoned mentors, including successful entrepreneurs, industry leaders, and academic experts. These mentors provide personalized guidance on various aspects of startup development, including business planning, product development, and market entry strategies. The mentorship programs are designed to address specific challenges and support startups in achieving their goals. Training and Workshops: We design and deliver up to 50 customized training programs and workshops annually. These sessions cover crucial entrepreneurial skills such as leadership, financial management, marketing, and innovation management. Our training programs are tailored to meet the needs of startups at different stages of their development, ensuring they acquire the skills necessary to succeed. Ongoing Support and Evaluation: Our advisory services include continuous support through regular check-ins and progress evaluations. We monitor the development of startups, providing ongoing advice and adjustments to strategies as needed. This hands-on approach ensures that startups remain on track and can effectively address emerging challenges. Networking Opportunities: We facilitate networking events and connections with potential investors, partners, and industry professionals. These opportunities help startups build valuable relationships and expand their business networks, enhancing their chances of success and growth.

Incubator Name: PILANI INNOVATION AND ENTREPRENEURSHIP DEVELOPMENT SOCIETY

Focus Area: MedTech

Location: BITS Pilani,
Pilani Raj. - 333031

Website:
<https://pieds-bitspilani.org/>

Email:
tbi@pieds-bitspilani.org


Contact No.:
8955479457

About Incubator:

Pilani Innovation and Entrepreneurship Development Society PIEDS was established in 2004 from a Department of Science and Technology, Government of India. Since then, PIEDS has been supported by various programs from different government ministries and departments, corporate organization including Corporate Social Responsibility Funds, and BITS Pilani alumni.

Total Space Sq. Ft.: 40000

IMPACT



5 most successful incubatees:

- Nawgati
- Sustvest
- Jarsh Safety
- Simplismart
- Petmojo

General Infrastructural Services:



PIEDS is located in a dedicated incubation centre called as Rakesh Kapoor Incubation Centre set up in 40,000 sq. Ft. of area. The centre has 150 co-working seats, more than 20 meeting and conference rooms

Scientific Support Services:

BITS Pilani has set up a dedicated Technology Transfer Office TTO under the Coordinator of the Intellectual Property Enablement and Commercialization vertical of the Research & Innovation Division. The TTO is a central function that acts as a bridge between the innovators and agencies wishing to commercialize the IP, and safeguards their interest NDAs, MTA, and other legal tools with proper procedures, in quick and faster manner.

Advisory and Mentoring Services:

Mentoring: Each startup is provided with 1-2 mentors for advise, help, connect regarding their plan of action. Our pool of mentors is startup founders and professionals, industry experts and VC and investment professionals.



Incubator Name: PSG-STEP: BioNEST

Focus Area: Agricultural Biotech, Environmental Biotech, Food Biotech, Industrial Biotech, Nano Biotech and Healthcare

Location: J Block 4th Floor,
PSG College of Technology, Coimbatore

Website:
<http://www.psgstep.org/>

Email:
step@psgtech.edu


Contact No.:
+91 6382376401 / +91 9944789225

About Incubator:

PSG-STEP: BioNEST Centre is a state-of-the-art research and innovation facility located in Coimbatore, Tamil Nadu, India. The BioNEST is established by PSG-STEP, PSG College of Technology with the support from BIRAC, Department of Biotechnology DBT, and Government of India. The center aims to provide a platform for researchers, innovators, and startups to work together in biosector. The facility has emerged as a hub for biotech startups and plays a crucial role in promoting entrepreneurship and innovation in the field of biotechnology.

Total Space Sq. Ft.: 6180

IMPACT



5 most successful incubatees:

- Aaral Exports
- Seragen Biotherapeutics Private Limited
- Elies Biotech Private Limited
- Ardor Biomed India Private Limited
- Immugenix Biosciences Private Limited

General Infrastructural Services:

: BioNEST have an Analytical Lab of 1,200 of sq.ft, Open Innovation Lab of 1,200 sq.ft, Individual Wet Labs of 1,200 sq.ft, Co-Working Space of 1,500 sq.ft and Common Space of 1,180 sq.ft.

Scientific Support Services:

- Facilitate incubatees to showcase their products in national and international platforms.
- Equipment and Testing facilities can be accessed by the industries in the region.
- Clinical validation support through PSG Institute of Medical Sciences and Research PSG IMSR & PSG Hospitals

Advisory and Mentoring Services:

- Legal and IPR Support
- Training Programs
- Access to Mentoring
- Investor / Industry Connect
- Networking Events

Incubator Name: RISE Foundation IISER

Focus Area: Affordable healthcare, Agri and allied

Location: RISE Foundation IISER
IISER Kolkata Campus Mohanpur Nadia

Website:
<https://www.risefoundationiiser.co.in>

Email:
coo@risefoundationiiser.co.in


Contact No.:
9678007196

About Incubator:

Research Innovation and Scientific Entrepreneurship RISE Foundation IISER is the Incubation Centre of IISER Kolkata. RISE incorporated as a Section 8 Company in the year 2018 and started its operation from the year 2022. RISE is a DST supported NIDHI TBI. The motto of RISE Foundation IISER is to nucleate and nurture deep-science based start-ups in particular, and for creating an ecosystem of science-based innovation and entrepreneurship development for the overall benefit of society in general. RISE is sector agnostics focusing mainly on Affordable Health Care, AI and Machine Learning based Solutions, Smart materials, Renewable Energy and Sustainability, Earth, Climate, and Space sciences and Agri and Allied areas. RISE support incubatees for the technical PoC and Prototype development, legal regulatory, IP, Company compliance, commercial business plan, brand building, revenue generation and financial grant writing, pitching, investor connect areas. At Present RISE is hosting 26 incubatees and many more in the pipeline.

Total Space Sq. Ft.: 20000

IMPACT



5 most successful incubatees:

- Monosha Biotech Pvt. Ltd.
- BomLife Pvt. Ltd.
- Bioinovatiq Lifescience Pvt. Ltd.
- Chemactiva Innovation Pvt. Ltd.
- Canfinis Therapeutics Pvt. Ltd.

General Infrastructural Services:

- Biotech space with Animal Cell Culture Facility
- Plant Tissue Culture space
- Optics and Photonics space with Dark Room
- Chemical Technology space for pharma, agri and polymer
- Training Room
- Incubatee Office Space
- Client Meeting Room
- Server room
- Incubation Support Station
- IT space and Library
- Fabrication Lab with Clean Room
- Ideation space
- Incubation Suits
- Conference Room
- Pantry
- Space for Microbial Culture

Scientific Support Services:

Access to IISER K equipment and the equipment of the institutions from Kalyani Innovation Network PoC and MVP Development Prototyping Service Technical assessment of the prototype

Advisory and Mentoring Services:

Technical Advisory by experts from IISER-Kolkata and collaborating Institutes. Access to equipment of IISER and R&D Organizations of network. Arrangement of Funding Seed funds/ Crowd-funding/ Post-incubation investment from Angel Investors/ VC Advisory on Company formation, IPR Protection & Transfer by CS/CA/ CDSCO. Regulatory compliances for therapeutic products by experts. Pre-incubation commercial assessment by Management Professionals, Test Marketing, Branding, Developing vendor and distribution channels by Commercial Partners / NGOs. Mentorship facility - Networking with the Ecosystem, Preparation for Seed Fund Application, Preparation for Pitching, Regulatory Affairs, Tech Production and Transfer 5 hours per month. Monitoring of projects and arrangement of appropriate mentors. Help in account maintenance, preparation of Utilization Certificate, purchase related matters. Coordination with various stakeholders for smooth execution of projects.



Incubator Name: Runway Incubator UPES, Dehradun

Focus Area: Deep Tech, Ayush & Health Tech, FinTech, Hospitality, Travel & Tourism, AgriTech

Location: UPES, Dehradun, Uttarakhand

Website:
<https://www.runwayincubator.com/>

Email:
nidhichan2007@rediffmail.com


Contact No.:
8130615833

About Incubator:

1st Floor, Energy Block, Energy Acres, UPES, BIDHOLI, via, Prem Nagar, Uttarakhand 248007

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Saurav Sinha
- Kuldeep Parashar
- Siddharth Gupta
- Priyanshu Jain
- Gaurav Dwivedi & Dr. Tridip Sinha

General Infrastructural Services:

The UPES Runway Incubator hosts state-of-the-art facilities designed to foster innovation and growth among startups. The incubator features a spacious co-working space with a capacity of 100 seats, where entrepreneurs can collaborate and network in a dynamic environment. Over 10 meeting rooms, including six equipped with smart TVs and two conference rooms, provide startups with the necessary technology and privacy for productive discussions and presentations. To promote a relaxed and collaborative atmosphere, the incubator offers a well-equipped common space with a coffee machine. A gym facility is also available to encourage physical well-being and work-life balance. High-speed Wi-Fi, printing facilities, and essential stationery are provided throughout the co-working space and meeting rooms to ensure startups have the tools they need to operate efficiently. For larger events, the incubator features a spacious auditorium with a seating capacity of over 500, making it an ideal venue for boot camps, workshops, conferences, and other gatherings. Additionally, startups requiring high-performance computing systems can access iMac systems upon request. Nestled in the scenic foothills of the Himalayas in Dehradun, spread over 40+ acres, offer an inspiring backdrop for innovation. The cutting-edge academic infrastructure, including multimedia-enabled classrooms, libraries, advanced computing centres, research centres, and other comfortable facilities. With full Wi-Fi connectivity, outdoor labs, moot courts, auditoriums, and amphitheatres, UPES Runway Incubator provides a dynamic environment that supports both academic learning and startup development, making it an ideal destination for higher education and entrepreneurship.

Scientific Support Services:

UPES Runway Incubator extends comprehensive support for sponsored research projects from government and corporate organizations, collaborations with Indian and international institutions, patents, technology transfer, and the establishment of startups. UPES Runway Incubator houses various centres and programs dedicated to research and innovation: • Central Instrumentation Centre CIC: Equipped with state-of-the-art facilities, CIC offers access to leading citation databases and peer-reviewed journals, facilitating high-quality research. • SEED Funding: An in-house financial support mechanism, SEED provides up to Rs. 15 lakhs for consumables, mini equipment, travel grants, software purchases, and other operational expenses. • SHODH: This program fosters a culture of innovation-driven entrepreneurship among students by encouraging innovative projects and entrepreneurial initiatives. • Centre of Interdisciplinary Research & Innovation CIDRI: CIDRI brings together experts from various fields, including basic sciences, engineering, AI, design, business, and law, to develop products with intellectual property rights and business plans. • Centre for Intellectual Property Rights: This center supports the drafting and filing of patents, trademarks, and copyright applications, promoting a deeper understanding of intellectual property rights. • Centre for Alternate Energy Research CAER: Focused on sustainable energy, CAER conducts advanced research on biofuel production from waste, plastic waste-to-energy conversion, and microalgae biofuels. • Waste-paper Recycling Laboratory: This lab addresses the massive global consumption and disposal challenges of paper products, focusing on innovative recycling solutions. • Centre for Energy, Environment, and Sustainability Studies CEES: A multidisciplinary think tank that promotes research in economics, environment, energy, globalization, trade, and sustainable development. • Machine Intelligence Research Centre MIR: MIR conducts high-end computing research in AI, offering support for applied AI work, fluid dynamics, virtual reality, and aerodynamics. • Medicinal and Aromatic Plant MAP Lab: Developed under the DST-funded project, this lab supports rural women farmers in cultivating medicinal and aromatic plants, equipped with advanced extraction and testing.

Advisory and Mentoring Services:

At UPES Runway Incubator, we recognize the pivotal role of mentorship in driving startup success. To provide our incubated startups with comprehensive support, we have forged partnerships with leading organizations and industry experts. Our collaborations with prominent organizations such as Startup Uttarakhand, TIE Dehradun, IIT Ropar AWaDI, Headstart, Techstars, WICCI, and PICO FLO offer startups unparalleled access to resources and a vast network of support. Startup Uttarakhand recognizes UPES as a key screening and incubation partner, providing startups with opportunities for government recognition. TIE Dehradun offers mentorship from seasoned entrepreneurs and investors, platform for startups to network, collaborate, and learn from peers and industry leaders while IIT Ropar AWaDI collaborates with us to provide joint programs, funding opportunities, and technical support through the establishment of a Cyber-Physical System CPS lab at UPES. Headstart and Techstars bring additional value to our startups through events, workshops, and pitching opportunities that connect them with global mentors and investors. WICCI and PICO FLO specifically focus on empowering women entrepreneurs, providing them with the necessary tools and networks to succeed. Our esteemed mentors, including R. Kannan Former Mission Director, AIM, NITI Aayog, Uday Chatterjee Lead Angel Investor, Paragendra P Singh Program Director, Anand IT Ropar, Rajneesh Kapoor Managing Partner, Indian Angel Network, Adit Parash Director Corporate Development, Freshworks, Mohit Satyansand Chairman, Liberty Institute, Shilpa Sharma Founder, Jaypore, and Sri Prakash President, TIE Dehradun Chapter, bring a wealth of experience and insights to the table. Their diverse backgrounds and expertise span various industries, ensuring that our startups receive tailored advice and guidance at every stage of their entrepreneurial journey. With the support of these partners and mentors, UPES Runway Incubator is dedicated to nurturing the next generation of innovators and entrepreneurs, helping them transform their ideas into successful, scalable businesses.

Incubator Name: SCTIMST-Timed

Focus Area: MedTech

Location: Biomedical Technology Wing,
Sree Chitra Tirunal Institute for Medical Sciences & Technology Trivani

Website:
<https://www.timed.org.in/>

Email:
timed@sctimst.ac.in


Contact No.:
9249402311

About Incubator:

SCTIMST-Timed is Technology Business Incubator set up by Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum An Institute of National Importance under Dept. of Science & Technology, Govt. of India for supporting startups and innovators developing medical devices and healthcare solutions to solve the unmet clinical needs of the country. SCTIMST-Timed was setup in 2015 and is exclusively focussing on MedTech and healthcare startups. It has supported over 50 startups and innovators through physical and virtual programs. 14 Social innovation fellows under SPARSH have been supported since 2018. Managing seed funding for startups since 2017

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Sascan Meditech Pvt Ltd
- Waferchips tehnosolutions Pvt Ltd
- Evelabs Technologies Pvt Ltd
- Alicorn Medical Pvt Ltd
- ByLin Medical Pvt Ltd

General Infrastructural Services:


Pilot Production facility for medical devices as per ISO class 7 clean rooms. Common scientific equipment such as precision weighing balance, dep freezers, ovens, autoclaves, centrifuges, microscope, fume hoods as well as high end PCs, 3D printers, laser cutter, digital storage oscilloscope, High end computers etc

Scientific Support Services:

IPR facilitation using paid databases, facilitation to library of host institute, testing services of host institute, regulatory experts of host institute.

Advisory and Mentoring Services:

Fund raising, pitching, business development, Technology Transfer and industry connect services



Incubator Name: SIDDAGANGA INCUBATION FOUNDATION

Focus Area: AgriTech

Location: Dr. Sree Shivakumara Swamajji Road,
Siddaganga Institute of Technology

Website:
<https://www.siddagangathi.com/>

Email:
manager@siddagangathi.com


Contact No.:
9900377666

About Incubator:

Siddaganga Incubation Foundation is a section non-profit entity hosted by Siddaganga Institute of Technology, Tumakuru, a tier city of Karnataka. Siddaganga Institute of Technology established in the year 1963 with 60 years of legacy and it has accredited by NAAC with A++ Grade. The foundation is funded by DST, under its NIDHI I TBI Scheme, and DPIIT, Startup India Seed Funding schemes to support rural innovators in the Agritech sector, addressing grassroots problems through technological solutions benefiting rural communities. More than 50 of the startup founders are located in the remote villages where access to resources for their innovations is limited. Through DST i-TBI Scheme we offer great exposure to founders, with One-to-One mentorship, access to fund, go to market, Business Strategy Development, 24/7 prototyping lab access to develop products and office space. The foundation has supported 21 startups, offered 10 grants, developed 18 partnerships, organized 80+ events and created 85 jobs through our startups in the last two years.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Dr. Sumalatha Aradhya
- Dr M A Rashmi
- Mr. DURGAPRASAD T
- Gorre Ashok
- Mr. Shrivasta

General Infrastructural Services:

Siddaganga Incubation Foundation has 10,000 sqft state-of-the-art infrastructure facility, which includes a 106-seat capacity, 6 discussion rooms, 1 training room, a cafeteria, and a relaxation area. This infrastructure was built with an investment of 1.8 crore from the host institution.

Scientific Support Services:

* The host institution has more than 100 labs and an exclusive Idea Lab to build prototypes of innovations. The Idea Lab is accessible 24/7 and equipped with major equipment such as a composite 3D printer, vinyl cutter, laser engraver, wood router, CNC milling machine, CNC lathe, 6-axis articulated robot, and many more.

Advisory and Mentoring Services:

SIF supports startups with business mentors who help validate business models, connect with various business units for pilot trials, and link to customers. We have partnered with KVK - IIHR, Navya Disha, and NABARD for market linkages. Technology and domain experts guide product development. We have collaborations with Auto Live, Continental, AWS, and Microsoft for startup support. Live field labs are available at Siddaganga Farms. Additionally, we connect startups to Venture Catalyst and angel networks for co-investment and follow-on funding. We offer support for company financials, projections, pricing, and more. Our investment partners include Arali Ventures, Startup Xseed, RevX Capital, and Yunus Social Fund, and we work with KPMG for financial analysis.

Incubator Name: Society for Innovation and Entrepreneurship SINE IIT Bombay

Focus Area: SINE is sector agnostic technology business incubator and incubated startups from IT, manufacturing.

Location: RBTIC Building,
Opp. VMCC, IIT Bombay

Website:
<https://sineiitb.org/>

Email:
pranita@sineiitb.org


Contact No.:
9820673603

About Incubator:

Society for Innovation and Entrepreneurship SINE, is an umbrella organisation at IIT Bombay for fostering entrepreneurship and nurturing tech start-ups. It administers a business incubator which provides 'Start to scale' support for technology based entrepreneurship and facilitates the conversion of research activity into entrepreneurial ventures.

Total Space Sq. Ft.: 69000

IMPACT



5 most successful incubatees:

- Ideaforge Technology Limited
- Atomeberg Technologies Pvt Ltd
- Immunoadaptive cell therapy Pvt Ltd
- Haystack analytics Pvt Ltd
- Webaroo Technology India Pvt Ltd

General Infrastructural Services:



SINE offers a dynamic ecosystem spanning over 69,000 square feet, designed to nurture and support startups and innovators. With a capacity to accommodate up to 90 startups simultaneously, SINE provides a vibrant and collaborative environment. The space includes a diverse range of options, from private offices ranging from 150 to 700 square feet totaling 51 offices to flexible co-working spaces 65+, and even dedicated open areas for lab work and prototyping. To foster a productive and inspiring atmosphere, SINE has thoughtfully created a 2,000 square foot recreational area where startup employees can relax, network, and recharge. Additionally, the facility boasts five startup booths, 13 meeting rooms, and a casual discussion area that can comfortably seat 60 people. For larger gatherings, SINE offers a seminar hall with a capacity of 104 and a conference room that can accommodate 24 participants. These spaces serve as venues for a variety of events organized by SINE and its resident startups, fostering knowledge sharing, collaboration, and networking opportunities. Whether you're seeking a private workspace, a collaborative co-working environment, or specialized facilities for research and development, SINE provides the ideal setting to turn your innovative ideas into reality.

Scientific Support Services:

SINE has established cutting-edge lab facilities across three key domains: the BIRAC BIONEST BioLab, an electronics lab, and a prototyping lab. These state-of-the-art laboratories are equipped with over 90 specialized instruments, providing startups with the essential tools and infrastructure needed to conduct groundbreaking research and development in their respective fields.

Advisory and Mentoring Services:

SINE boasts a robust network of in-house mentors who possess deep expertise in various domains, offering invaluable guidance and support to startups and innovators. To further enrich the mentoring experience, SINE also collaborates with a panel of esteemed external mentors who actively participate in guidance meetings, reviews, and progress assessments. Additionally, SINE leverages the insights and experience of industry professionals, engaging them to provide expert advice and mentorship to startups as they navigate their entrepreneurial journeys.



Incubator Name: Sona Incubation Foundation

Focus Area: AgriTech

Location: Sona Incubation Foundation
2nd Floor, Sri Valliappa Block,
Sona College of Technology

Website:
<https://www.sonaincubations.com/>

Email:
head@sonaincubations.com


Contact No.:
96778 86632

About Incubator:

Sona Incubation Foundation SIF is a vital center at Sona College of Technology dedicated to fostering an entrepreneurial ecosystem that specifically supports agritech and bio-based startups. By providing a range of resources and initiatives, SIF aims to nurture innovative ventures in the biotechnology and agricultural technology sectors, encouraging their growth and development. A significant funding opportunity available through SIF is the Startup India Seed Fund Scheme SISFS, which offers financial assistance for various stages of startup development, including proof of concept, prototype development, product trials, market entry, and commercialization. This funding is crucial for agritech and bio-based startups seeking to enhance their innovations and attract further investment from angel investors and venture capitalists. SIF is recognized by the Ministry of Micro, Small and Medium Enterprises MSME to facilitate the incubation of enterprises utilizing innovative technologies, particularly in the agritech and biotechnology fields. The foundation provides tailored physical infrastructure, technical support, and networking opportunities that address the unique needs of agritech and bio-based startups, enabling them to thrive in a competitive landscape.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Medford technologies private limited
- Mycolum Sona Pvt.Ltd
- shadivi nutrients private limited
- start insights private limited
- Naglin

General Infrastructural Services:

Sona Incubation Foundation SIF provides a range of general infrastructural services designed to support early-stage startups throughout their development journey. These services include: 1.Co-working Space: Startups have access to dedicated co-working spaces that foster collaboration and innovation among entrepreneurs. Meeting Rooms: SIF offers meeting rooms equipped for team discussions, client meetings, and presentations, subject to availability and booking procedures. 2.Event Spaces: Facilities for hosting workshops, seminars, and networking events are available, promoting engagement within the entrepreneurial community. 3.Technical Support: Startups receive assistance with technical challenges, ensuring they can effectively develop their products and services. 4.Networking Opportunities: SIF facilitates connections with industry experts, mentors, and potential investors, helping startups expand their professional networks. 5.Workshops and Training: A structured curriculum of workshops covering essential topics such as business model development, market research, and financial planning is provided to enhance the skills of the entrepreneurs.

Scientific Support Services:

SIF is committed to providing comprehensive scientific support to startups, particularly those working in the biotechnology and agritech sectors. This support is complemented by a robust ethical framework to ensure responsible development and commercialization of novel technologies. 1.Mentorship: Startups are paired with industry-specific mentors who provide guidance on refining business models, product development, and navigating regulatory requirements. These mentors have a strong scientific background and are well-versed in ethical considerations. 2.Workshops and Training: SIF organizes structured workshops covering critical topics such as ideation, customer discovery, prototyping, and product-market fit. These sessions equip startups with the knowledge needed to enhance their scientific and technical capabilities while emphasizing the importance of ethical practices. 3.Technical Assistance: Startups receive support in technical aspects of product development, including prototyping and testing, which is vital for ensuring that their innovations meet industry standards and adhere to ethical guidelines. 4.Access to Laboratory Facilities: Depending on availability, SIF may provide access to laboratory spaces and equipment necessary for agritech and biotech startups to conduct experiments and develop their products. These facilities operate under strict safety and ethical protocols. 5.Networking Opportunities: SIF connects startups with a network of industry experts, potential investors, and research institutions, facilitating collaborations that can enhance scientific research and development while promoting ethical practices. 6.Ethical Review Committee: SIF has established an Ethical Review Committee comprising domain experts, legal professionals, and ethicists. This committee is responsible for reviewing the ethical implications of startups projects and providing guidance on ethical practices. 7.Compliance Monitoring: SIF closely monitors startups adherence to ethical guidelines and regulatory requirements. Regular audits and progress reviews ensure that startups maintain the highest standards of ethical conduct throughout their development process.

Advisory and Mentoring Services:

Sona Incubation Foundation SIF offers comprehensive advisory and mentoring services to support early-stage startups in their development journey. These services are designed to guide entrepreneurs from the prototyping phase to creating market-ready solutions. Key components of the advisory and mentoring services include: 1.Curated Mentorship: Each startup is assigned a mentor with relevant industry experience. Mentors provide personalized guidance on refining business models, developing revenue strategies, and creating effective go-to-market plans. This tailored support helps startups identify their competitive advantages and target markets. 2.Group and One-on-One Mentoring: SIF conducts both group mentoring sessions and individual meetings, allowing startups to gain insights on various topics relevant to their growth. This flexible approach ensures that startups receive the support they need in a collaborative environment. 3.Workshops and Training Programs: The foundation organizes a series of structured workshops covering essential topics such as ideation, customer discovery, prototyping, business model development, and financial planning. These workshops equip startups with the knowledge and skills necessary for success. 4.Progress Monitoring: SIF closely monitors the progress of each startup, establishing clear milestones and providing ongoing guidance to ensure they stay on track toward achieving their goals.

Incubator Name: SPMVV- WOMEN BIOTECH INCUBATION FACILITY

Focus Area: BioService

Location: Sri Padmavati Mahila Visvavidyalayam,
Tirupati

Website:
<https://www.spmvwbif.com>

Email:
spmvwbif.backup@gmail.com


Contact No.:
8328433150

About Incubator:

SPMVV-WBIF is a BioNEST incubation facility funded by DBT, BiRAC, New Delhi in the year 2019. SPMVV-WBIF operates with the objective to promote Entrepreneurship among students, faculty, and Rural women in the areas of Life Sciences, Healthcare Sciences, Nutraceuticals, Food Biotechnology, Value added products, Biocomputing, AI, and Allied areas. And to improve their skills for better employment opportunities or to develop their business plans. SPMVV-WBIF helps prospective Entrepreneurs to transform their ideas into successful early-stage ventures.to women, SPMVV- WBIF is open to all for making use of the facility.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- CSL BIOTECH, TIRUPATI
- SRI DHARANI AGROTECH PVT.LTD, HYDERABAD
- ARMOR SHIELD HEALTH CARE INNOVATIONS, CHENNAI
- SAI GANGA PANAREA PVT LTD
- JAMA BOTANICS PVT.LTD

General Infrastructural Services:


Sri Padmavati Mahila Visvavidyalayam's Women Biotech Incubation Facility SPMVV-WBIF offers comprehensive infrastructural services tailored to foster innovation and entrepreneurship, particularly for women in biotechnology. The facility is designed with state-of-the-art infrastructure that supports a wide range of biotech-related activities, from research and development to product commercialization. The SPMVV-WBIF provides fully equipped laboratories with modern scientific instruments essential for advanced research in biotechnology, molecular biology, cell culture, and bioinformatics. These labs are designed to cater to the needs of startups, academic researchers, and industry professionals. The facility includes specialized equipment such as biosafety cabinets, incubators, centrifuges, and high-performance liquid chromatography HPLC systems, ensuring that incubatees have access to the tools necessary for cutting-edge research and innovation. In addition to the technical infrastructure, the incubation facility also offers office spaces, meeting rooms, and conference facilities. These spaces are equipped with high-speed internet, video conferencing capabilities, and other essential office amenities, creating a conducive environment for collaboration, business development, and networking. SPMVV-WBIF also provides support services, including access to a network of mentors, industry experts, and academic professionals, which helps in guiding startups through various stages of development. Furthermore, the facility organizes workshops, training programs, and networking events to enhance the entrepreneurial skills of incubatees. Overall, the general infrastructural services at SPMVV-WBIF are designed to empower women entrepreneurs and researchers, providing them with the necessary resources and support to transform innovative ideas into successful biotech ventures.

Scientific Support Services:

The SPMVV-Women's Biotechnology Incubation Facility SPMVV-WBIF offers a robust suite of scientific support services designed to foster innovation. These services are tailored to meet the diverse needs of academic researchers, startups, and industry partners. SPMVV-WBIF provides access to state-of-the-art laboratories equipped with advanced scientific instruments, enabling precise and high-quality research. The facility supports various domains including molecular biology, cell culture, biochemistry, and analytical chemistry. Researchers have the opportunity to work with specialized equipment such as PCR machines, spectrophotometers, cell counters, and incubators, all of which are essential for cutting-edge biotechnology research. In addition to equipment access, SPMVV-WBIF offers expert technical assistance, ensuring that researchers and entrepreneurs can efficiently utilize the available resources. The facility also provides training programs, workshops, and hands-on sessions to enhance the skills and knowledge of users, helping them stay updated with the latest technological advancements and methodologies in the field. SPMVV-WBIF's scientific support services are integral in bridging the gap between academic research and industrial application. By providing a collaborative environment and necessary tools, the facility enables the development of innovative solutions and the commercialization of research outcomes. This support not only accelerates research but also contributes to the growth of the biotechnology sector, making SPMVV-WBIF a pivotal player in the scientific community.

Advisory and Mentoring Services:

The Sri Padmavati Mahila Visvavidyalayam - Women Biotech Incubation Facility SPMVV-WBIF offers specialized advisory and mentoring services designed to empower women entrepreneurs in the biotechnology sector. These services are aimed at providing guidance, support, and resources to help innovators transform their ideas into successful ventures. The advisory services at SPMVV-WBIF encompass a wide range of expertise, including business strategy, market analysis, intellectual property management, and regulatory compliance. The facility provides access to seasoned professionals and industry experts who assist incubatees in navigating the complexities of the biotech industry. This guidance ensures that entrepreneurs are well-equipped to handle the various challenges associated with product development, commercialization, and scaling. Mentoring at SPMVV-WBIF is a personalized and continuous process, focusing on the individual needs of each entrepreneur. Experienced mentors offer insights into the intricacies of business management, fundraising, and networking, helping women entrepreneurs build a strong foundation for their ventures. This mentorship extends beyond business advice, fostering personal growth and leadership skills, which are crucial for success in the competitive biotech landscape. SPMVV-WBIF's commitment to fostering innovation and entrepreneurship among women is reflected in the success of its incubatees, who benefit from a nurturing environment that encourages creativity and collaboration. Through its comprehensive advisory and mentoring services, SPMVV-WBIF plays a pivotal role in shaping the future of women-led biotech startups, contributing to the broader goal of gender equality and economic empowerment in the industry.





Incubator Name: Sri Ramachandra Innovation & Incubation Centre at SRIHER

Focus Area: MedTech

Location: SRIHER (Deemed University)
No1 Shri Ramchandra Nagar,
Karambakkam, Porur, Chennai

Website:
<https://sriher.academy.ca/sriher-research/about-sriher/>

Email:
anand.sriic@gmail.com


Contact No.:
994562995

About Incubator:

About SRIIC Research at SRIHER is driven by the institutional and national vision to contribute to the prevention and alleviation of disease and disability, leading to the betterment of the health of our population. A network of sophisticated research laboratories provides world class facilities to faculty and students for engagement in clinical, biomedical, public health, pharmaceutical, health sciences, medical technology and healthcare management related research. There is special emphasis on multi-disciplinary and collaborative research where in faculty members drawn from different departments and divisions routinely take up high impact research to inform national and international health priorities. Several centers of excellence created through extra-mural support from Government of India including the ICMR Center for Advanced Research on Air Quality, Climate and Health and The DBT- Wellcome India Alliance funded Centers focused on Early Childhood Caries CECCre and Speech & Hearing Disorders in Children SRESHT and from International Organisations including the World Health Organisation Collaborating Center for Research and Training in Occupational and Environmental Health and the National Institute of Health Research UK Center for Environment and Non-Communicable Diseases are anchoring multiple field, hospital laboratory and hospital based research teams to examine priority health concerns in longitudinal cohorts.

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubatees:

- Biversity
- Ignobilis Terrain
- ISMO Biophotonics
- LEO Med
- Abahaya 3cd

General Infrastructural Services:

Co-working Office and Laboratory Spaces Hi-speed Wireless Network Access to In-house Research Laboratories and Expertise Access to Clinical Samples and Clinical Data Access to World Class Library and Scientific Journals

Scientific Support Services:

Sophisticated Instrumentation Laboratory GLP-certified Animal Experimentation Facility * CDSCO-approved, DCGI - Audited Clinical Trials Facility Institutional Ethics committee IEC for clinical research Institutional Bio-Safety Committee IBSC Institutional Animal Ethics Committee IAEC Institutional Committee for Stem Cell Research and Therapy ICSCRT

Advisory and Mentoring Services:

Business Plan Development Knowledge Transfer from successful companies Mentoring and handholding Arranging meets with Angel Investors Intellectual Property consultants Pharma Industry consultants Networking events

Incubator Name: Startups Valley TBI

Focus Area: AgriTech

Location: Amal Jyothi College of Engineering Kanjirappally,
Koovappally P.O. Kottayam D

Website:
<https://startupsvalley.in/>

Email:
sherinsamjose@amalyothi.ac.in


Contact No.:
9496805712

About Incubator:

An overriding objective of the venture is to achieve a transformation of minds of the students from being job-seekers to being entrepreneurs themselves, utilising the theoretical and practical lessons they get at the College. Creation of Technology-based incubates on a continuous basis Help to create value-added jobs and services Introduction of Entrepreneurial culture to the students and the common people Create effective networking for the development of technology-based start-ups Develop internationally accepted technologies Promote students to come up with commercially viable curriculum projects Create student entrepreneurs Create awareness about Technology Incubation and Commercialization of R & D products and processes Promote small and medium industries Thrust Areas- Rural technology Green Technology Information Technology Artificial Intelligence Automation of traditional systems through technology upgradation is the only way to uplift the rural people. Development of interdisciplinary technologies is essential for the overall development of the common people. In this region we have identified two categories of people technical experts and technically skilled people. We are concentrating for start-ups that can incorporate both categories. The second TBI sanctioned under Bio-NEST of BIRAC, govt. of India, focusses on biotechnology.

Total Space Sq. Ft.: 13500

IMPACT



5 most successful incubatees :

- Onesimon K K
- Dr. Sunnichan VGeorge
- Vineetha
- Thomas Varghese
- Ajin Omanakuttan

General Infrastructural Services:


Upon admission to Startups Valley TBI, the following infrastructural facilities and services may be offered to the incubate companies, Office Space, AC rooms with furniture, Telecomm facility and Internet, Shared Resources, Conference Room, Meeting Room, Libraries, Laser Printer, Photocopier, Scanner, Teleconferencing facilities, Cafeteria etc.

Scientific Support Services:

Prototyping facilities, R&D labs, Testing Labs

Advisory and Mentoring Services:

Business mentoring Technical Mentoring Investors connect



Incubator Name: TIDES, IIT ROORKEE

Focus Area: MedTech

Location: 2nd & 3rd Floor, Multi-Activity Center,
IIT Roorkee 247667

Website:
<https://tides.iitr.ac.in/>

Email:
bioincubation.tides@iitr.ac.in


Contact No.:
+91-1332-284419

About Incubator:

TIDES is running as a premier incubation centre since 2011, empowering tech startups with government-backed resources, including TBI-DST, TIDE-Meity, BioNEST-BIRAC, and ENGSI-EIL. TIDES also runs multiple programs such as NIDHI Seed Support System, NIDHI PRAYAS, SISFS, TIDE 2.0, and NIDHI EIR. Recognized by the Uttarakhand government and Central government, TIDES serves as a nodal agency for the state's startup scheme and acts as a partner incubator for the IDEX program. As SPARSH centre, TIDES will identify and support promising innovators, startups, and social enterprises addressing challenges in public health, food systems, and climate resilience. The support includes expert mentorship, cutting-edge resources, and strategic guidance to help them transform their ideas into impactful solutions.

Total Space Sq. Ft.: 2200

IMPACT



5 most successful incubatees:

- Humblx
- Log 9 Materials
- Indi Energy
- Flabs
- Ednam Solutions

General Infrastructural Services:

- Dedicated office spaces
- Conference room with audio video facility
- Dedicated Wi-Fi facility
- Department of Bioscience and Bioengineering
- Hospital
- Greenhouses
- Institute Instrumentation Center
- Rethink Tinkering Lab
- Access to lab and research facility of 23 departments of IIT Roorkee.
- Hostel facilities and other campus-based support facilities are available at IIT Roorkee.

Scientific Support Services:

TIDES business incubator hosted at Indian Institute of Technology, Roorkee, fosters innovation and entrepreneurship. IIT Roorkee, one of India's oldest and most prestigious engineering institutes, has a strong alumni network of distinguished business leaders. With over 550 faculty experts and 23 departments, the institute provides a robust foundation for technical skill development. Our incubation and pre-incubation programs offer cutting-edge facilities, corporate-quality office spaces, and mentoring from industry leaders, investors, and IIT Roorkee faculty.

Advisory and Mentoring Services:

TIDES has built an ecosystem of 15+ angel and institutional investors, 400+ industry experts and mentors. Our investor partners include prominent names such as Mumbai Angels, HDFC, 100X Ventures, Digital Ocean, Zetacapital, Soonicorn Ventures, Speciale Invest, IvyCamp, Venture Catalysts, Titan Capital, and Indian Angel Network. Additionally, our esteemed mentor pool includes influential figures from business and technology giants like Blum Ventures, Adani Group, Aditya Birla Group, Cargill, Tech Mahindra, Google, and HSBC Commercial Banking.

Incubator Name: TNAU E-YUVA Centre

Focus Area: AgriTech

Location: Department of Plant Biotechnology CPMB&B,
TNAU Coimbatore

Website:
<https://tnau.ac.in/site/cpmb/e-yuva/>

Email:
uitcna@tnau.ac.in


Contact No.:
9655883005

About Incubator:

E-YUVA centre in Tamil Nadu Agricultural University TNAU is supported by Biotechnology Industry Research Assistance Council BIRAC, a GOI enterprise. It started functioning in the year 2014 in the name "University Innovation Cluster". TNAU is one of the five prestigious institutions in the country initially selected for such activity for the first time in the history. In the year 2021 BIRAC upgraded the university innovation cluster into E-YUVA centre. The mandate of E-YUVA is to reach out to young students and fresh graduates to validate their ideas and take them to Proof-of-Concept in collaboration with industry. If India has to innovate, young researchers have to be nurtured and provided with all the key components of an innovation ecosystem. It is important that they should be given a right platform where their innovation research is completely de-risked and they are mentored not only on technical issues but also on enterprise creation, technology commercialization, intellectual property IP protection, regulatory and ethical affairs, marketing strategies, etc., E-YUVA programme is aimed to handhold the aspiring young entrepreneurs and budding student innovators, help to mobilize resources and connect them to various networks in order to understand what it takes to move the research forward and create an entrepreneur, transforming 'job seeker' to 'job provider'. E-YUVA centre provides this ecosystem.

Total Space Sq. Ft.: 4735

IMPACT



5 most successful incubatees:

- Dr. C. Sivananth, BIRAC Innovation Post Masters Fellow
- Akash M., Srinivasan G. Nivedhya N., Karpaga Illakkiya K. and Sangeetha L.
- Dr. R. Naganathan Suganthan, BIRAC Innovation Post Doctoral Fellow
- Dr. S. Naga Nandhini, BIRAC Innovation Post Doctoral Fellow
- Dr. P. R. Deepu Krishnan, BIRAC Innovation Post Doctoral Fellow

General Infrastructural Services:

TNAU E-YUVA centre offers ambient work environment to the E-YUVA fellows and Innovation fellows of the centre to work effectively.

Scientific Support Services:

TNAU E-YUVA centre is housed in the Directorate of Centre for Plant Molecular Biology and Biotechnology CPMB&B which is in existence for more than 25 years. It is a nationally acclaimed centre with all high end equipment facilities for biotechnology research. To name a few are HPLC, GCMS, LCMS, Real Time PCR, High end bioinformatics facility, transgenic green house facility, etc. Being located in this centre, the incubatees of E-YUVA centre are given access to all the labs in CPMB&B. Besides, TNAU EYC functions in the Hub & Spoke model by integrating different Centre/ Directorate/ Departments of TNAU along with the constituent colleges of TNAU. Instrumentation facility present across the University shall also be available for the innovators working in TNAU EYC. They can seek access to the laboratory/ testing facilities available in any department/ directorate based on their need. NABL accredited laboratories functioning at TNAU for testing food samples and pesticide residues are offering a special concession of 33 in the testing fee to the incubatees of TNAU.

Advisory and Mentoring Services:

For each and every project being carried out in TNAU E-YUVA centre, a scientific mentor is assigned and a project specific technical advisory committee is constituted with relevant external subject experts and industrial experts to guide them through out the project. With the well trained scientist pool, TNAU extends its expertise to render technical and business mentoring to the E-YUVA fellows and Innovation fellows. Apart from the scientists, the institute's law officer, patent attorneys and legal consultant will handhold the budding entrepreneurs in the legal activities of the startup such as company incorporation, entering into agreements / MoUs with other stakeholders for scaling up. Apart from all these, TNAU has a dedicated patent cell in supporting the fellows in IP filing.



Incubator Name: Translational Oncology Council TRON

Focus Area: Bioincubator

Location: Maharaniipeta,
Visakhapatnam, Andhra Pradesh

Website:
<https://troncouncil.com>

Email:
info@troncouncil.com


Contact No.:
9347131412

About Incubator:

VCR Park-supported Translational Oncology Council TRON BioNest incubator is a comprehensive state-of-the-art physical facility combined with access to core biotechnology-related expertise to greatly accelerate the development of novel cancer therapies and/or services by biotechnology startups. VCR Park with its visionary senior core management team, an expanded steering committee, a distinguished team of scientific technical experts to run the high-end biology laboratories, technological global access, and integrated global partnerships provides much-needed support to startups for translational science. Moreover, through its partnership with the local hospital, VCR Park-TRON BioNest provides access to clinical samples, assists in developing clinical trial protocols, helps in patient recruitment, and provides access to the market. The confidentiality of all incubatees is covered by NDA/MoU/MoA pertaining to their specific requirements with in-house secure data generation, storage and retrieval. Moreover, it fast-tracks the incubatees growth and helps them to scale appropriately towards building globally approved solutions and becoming a disruptive innovator.

Total Space Sq. Ft.: 12400

IMPACT



5 most successful incubatees:

- Enveda Therapeutics
- AUM Biosciences
- Acasta Health Pvt. Ltd.
- Prayasta
- Kibur Medical Inc.

General Infrastructural Services:

Bio-Waste management, Internet, UPS & Generator backup, Motion sensor lights, Public addressing system, Access control, Designated lab wash area, Storage space with racks, Board room, Meeting room, Dry pantry, Phone pod

Scientific Support Services:

Common shared lab facilities: 1. Cold Storage: ULT -80° & -20° freezers, 2-8° refrigerator, cryopreservation 2. Tissue Culture: Class-II biosafety cabinet, HeraCell CO2 incubator, Countess II FL Automated Cell Counter, EVOS imaging system 3. Microbiology: Heratherm incubator, refrigerated shaker, shaking water baths 4. Molecular biology: Kingfisher Duo Prime extraction, 96 well thermal cycler, Mini gel tank, Gel handcast station, Gel-doc imaging system, Nanodrop, TapeStation 4200, thermomixer 5. Proteomics: Minigel casting and running tank, PAGE gel apparatus, Western blot with wet transfer module, Multimode plate reader 6. Ancillary lab equipments: Merck-Millipore water system, Ice flaker machine, Ductless fume hood, Micro centrifuge, autoclave, analytical balance, hot air oven, vacuum pump, rocker 7. Mice Animal facility Charles River labs animals Advanced core lab facilities: 1. Multimode plate reader - Perkin Elmer Victor Nivo 2. Real-time PCR system - Invitrogen QuantStudio 5 3. IHC/ISH automated system - Roche Ventana Benchmark Ultra Discovery 4. NGS system - Illumina NextSeq 2000 5. High-content imaging system - Molecular Devices ImageXpress Micro Confocal 6. Fast-Protein liquid chromatography - Cytiva Akta Avant 150 7. Flow cytometry: Beckman Coulter CytoFlex LX Access to clinical samples Access to ethically consented clinical samples are available as per the incubatee specific requirement s . Institutional Biosafety Committee IBSC In-house IBSC for safe execution of BSL II level protocols/ experiments by all incubatees.

Advisory and Mentoring Services:

The senior management at VCR Park addresses the challenges faced by the most biotechnology startups by enabling the know-how and making state-of-the-art core lab facility, animal facility and access to ethically consented clinical samples available in Visakhapatnam with a focused approach towards the following areas: 1. Ideation, business plan development, entrepreneurship and mentoring program and Intellectual property evaluation and protection 2. Technical, clinical, scientific, regulatory, intellectual property, human resources and commercial due diligence 3. Knowledge and expertise to raise non-dilutive or private funding and budget management 4. Cost-effectiveness of advanced laboratory facilities 5. Analytical and Pre-clinical validation with regulatory compliance 6. In vitro research, In vivo research, clinical trials, access to niche markets, and adoption 7. Finding and obtaining funding assistance public as well as private and upscaling funding source suggestions from public sectors

Incubator Name: VENTURE Studio, Ahmedabad University

Focus Area: MedTech

Location: Ahmedabad University,
North Campus Navrangpura,
Ahmedabad 380009, Gujarat

Website:
<https://venturestudio.in>

Email:
arpit.shukla@ahduni.edu.in


Contact No.:
7795066012

About Incubator:

VentureStudio, Ahmedabad University's startup incubator, is dedicated to fostering and developing innovative entrepreneurial ventures by providing 360° support ranging from incubation, funding at different stages, personalized mentoring by domain experts, to cutting-edge facilities for product development, market access, and team building. Since its inception in 2011, it has stayed focused on its vision to support innovation-driven technology startups. In the last decade, the Centre has supported over 135 startups in diverse science & technology domains such as Healthcare, BioTechnology, Life Sciences, Medical Devices, Diagnostics, Engineering, Agriculture, Fintech, Hardware, Industry 4.0, Enterprise Software etc. The Centre is managed by a team of professionals with solid technology, industry, and investment expertise. This has led to a stellar track record of supporting more than 150 startups.

Total Space Sq. Ft.: 21500

IMPACT



5 most successful incubatees:

- Apna | Nirmith Parikh
- Pragmatech Healthcare | Anirban Palit
- Wide Need Pvt Ltd | Siddhant Tawarawala
- Biofics Pvt Ltd | Sunil Mahapatra
- Vidcare Innovations Pvt Ltd | Rohan Agarwal

General Infrastructural Services:



24x7 11,482 sq.ft. of incubation space including co-working area, conference & meeting rooms, cafeteria, equipped with telecom, high-speed internet and print-scan-copy facilities. Parking and recreational space. With startup seating for 84 people, it provides a great ecosystem where entrepreneurs live their dreams, share experiences and grow together

Scientific Support Services:

DST NIDHI Prayas Shala: The 3300 sq. ft. DST NIDHI Prayas Shala supported through grants from TBI, NSTEDB NIDHI Prayas and Ahmedabad University's investment houses a design cell, an additive rapid prototyping section, a subtractive manufacturing section and an opto-electronics section. In addition, it houses a co-working space with wi-fi and video-conferencing facilities.

Advisory and Mentoring Services:

BioNEST - 6500+ sq. ft. of lab space with internet access, centralized power backup, VRV and waste water treatment plant. Microbiology lab, Molecular biology lab and Wet lab facility. Separate cell culture area with CO2 incubators, Biosafety Cabinets and imaging tools. Chromatography lab with HPLC, FPLC and GC-FID. Additional high-end equipment including Lyophilizer, Microplate reader, Probe Sonicator, Electroporator, -80°C Freezer and many more.



Incubator Name: Veterinary Incubation Foundation @ TANUVAS

Focus Area: Veterinary Sector

Location: CUL Building, TANUVAS,
Madhavaram Milk Colony, Chennai

Website:
<https://vifanuv.org/>

Email:
vifanuv@gmail.com


Contact No:
9486949407

About Incubator:

Veterinary Incubation Foundation VIF @ TANUVAS is a Section 8 company located at Tamil Nadu Veterinary and Animal Sciences University, Chennai. VIF@ TANUVAS has been established with the financial support of Entrepreneurship Development and Innovation Institute EDII, Chennai, Government of Tamil Nadu, BIRAC-BioNEST, Govt. of India and State fund for Strengthening of VIF@ TANUVAS, Government of Tamil Nadu for nurturing start-up companies and entrepreneurs in the area of veterinary, animal sciences and allied sectors.

Total Space Sq. Ft.: 13500

IMPACT



5 most successful incubatees:

- Agromalin Farmtech Private Limited
- Chimertech Private limited
- Iyarkai Tech Lab Private Limited
- Dvara E Dairy Solutions Private Limited
- Eiyarkai Three Life Sciences LLP

General Infrastructural Services:

VIF@TANUVAS has dedicated office space and Co-working space for the incubatees. VIF@TANUVAS has sophisticated instruments for conducting research to develop novel technologies. Incubatees can use the lab facilities by paying the relevant cost at need basis. TANUVAS has sophisticated instruments such as Freeze dryer, Live imaging, Clean room facility, 2D Gel system, Confocal microscope, Flow cytometer, Cell culture lab, BSL-2 laboratory, BSL-3 laboratory, Small and large animal experimentation facility, Cell culture lab with ISO class 7 & 8 clean room facility. TANUVAS - Livestock farm complex hosts Piggery Unit, Sheep and Goat Units, Cattle and Buffalo Units, Farm Waste Management Unit, Fodder Unit and Animal Science Park.

Scientific Support Services:

TANUVAS has a well established clinical facility for studies in Endoscopy and Ultrasonography, Cardiology, Radiology and Physiotherapy, Arthroscopy and Orthopaedics, Ophthalmology, Operation Theatre Services, Canine Breeding, Large Animal Clinical Services. TANUVAS provide rats, mice, guinea pigs at Laboratory Animal Medicine LAM unit for clinical Trial and Validation. We also provide rabbits at the University Research Farm TANUVAS for the same. Dogs and Cats at the veterinary university peripheral Hospital and Clinical department at Madras Veterinary College will be facilitated to the incubatees for trial and validation. TANUVAS - Livestock farm complex hosts Piggery Unit, Sheep and Goat Units, EMU Unit, Farm Waste Management and Fodder Unit will be available for the Incubatees for Clinical Trial and Validation. Cattle and Buffalo available in the Institutional Livestock farm complex will be provided to the incubatees for Validation of non-invasive products.

Advisory and Mentoring Services:

VIF@TANUVAS helps startups with product development, testing and validation, mentoring and professional consultancy. Technical mentors are assigned to all the incubated startups as per the recommendations of the Project screening and Review Committee.

Incubator Name: VITTechnology Business Incubator VITBTI

Focus Area: ICT, MEDTECH, HEALTHCARE

Location: Vellore Institute of Technology,
Vellore, Tamil Nadu, India.

Website:
<https://vittbi.com>

Email:
vittbi@vit.ac.in


Contact No:
9566656777

About Incubator :

Incorporated in 2003, VITBTI is a Not-for-Profit Society that helps technology startups with all the necessary resources to evolve and grow as a mature business. VITBTI had its humble beginnings with the support from the Department of Science and Technology DST, Ministry of S&T, Govt. of India. Today, VITBTI is a multi-stakeholder organization extending access to knowledge, funding, infrastructure, mentoring and network to innovative technology startups through its active programs supported by DST, BIRAC BioNEST and MeitY TIDE 2.0

Total Space Sq. Ft.: 10000

IMPACT



5 most successful incubates:

- Sandal Kotawala - Alfaeus Technology Private Limited
- Tuhin Sharma - Illuminify Technologies Private Limited
- Anmol Saxena - Ashva Wearable Technologies Private Limited
- Ravi Kiran Manapuram - Tishyas Medical Device Development Solutions Private Limited
- Jyotirmayee Dash - Teralumen Solutions Pvt. Ltd

General Infrastructural Services :



VITBTI has created a State-of-the-art Product Innovation Centre that is accessible to the incubatees. Independent incubation office spaces, Co-working space, Conference room, Discussion rooms are available for incubatees. VITBTI also leverages all the resources that are available within the campus such as access to laboratories, machineries and other facilities.

Scientific Support Services :

Access to Electronics and Analytical Instrumentation Product Innovation Centres at VITBTI - Access to Laboratories and Research facilities of the host institution - Connects with domain expertise from within the institution and from VITBTIs network

Advisory and Mentoring Services :

VITBTI gives utmost importance to mentorship and believes that the shared wisdom from experience can alleviate probable challenges in the journey of an entrepreneur. VITBTI has one-on-one session with the incubatees at regular intervals to understand the progress, challenges and any other points of concern. This helps the innovators and startups to find solutions, get directions and gain confidence. VITBTI also offers mentoring support through a mentor pool consisting of senior faculty from within the University and as well from Entrepreneurs, Business Consultants, and Industry experts from its network. The incubatees are referred to relevant expertise as and when business coaching is required. These are deep engagement sessions that include guidance in business modeling and business plan preparation and a host of other advisory support.





Incubator Name: Innovation Starter

Focus Area: FoodTech, EduTech, BioTech, CleanTech, Telco, GreenTech

Location: 2 Apostol Karamitev Str.,
Sofia

Website:
<https://accelerator.bg/>

Email:
leona@innovationstarterbox.bg


Contact No.:
359882224123

About Incubator:

Innovation Starter Accelerator is an educational acceleration program for pre-seed startups. The accelerator is powered by the team of the first Bulgarian innovation agency – Innovation Starter, which operates the projects Innovation Explorer Forum and Innovation Academy as well as the support of corporate partners. Our vision is to focus on key high-priority sectors in the local economy with potential for disruptive and scalable innovation – including Healthcare, Education, Care for the elderly, Transport & logistics, Frontier digitalization, Food industry, Eco-innovation – and to support their transformation through professional innovation management in high-potential start-up businesses. Our end goal is to help these businesses growing to scale and cooperate with well-established companies and innovation leaders.

Total Space Sq. Ft.: 400

IMPACT



5 most successful incubatees:

- AgroVar Ltd.
- Vodoraslo Ltd.
- Melifera Ltd.
- HotFarm Ltd.
- Kelvin Health Ltd.

General Infrastructural Services:

Educational Services - acceleration program in partnership with Stanford University, mentorship program, consultancy innovation shared space financing.

Scientific Support Services:

Memorandum with 15 Bulgarian Universities.

Advisory and Mentoring Services:

Broad network of business mentors from all economic areas.

Incubator Name: Poznan Science and Technology Park

Focus Area: BioService

Location: Poland ul.
Rubiez 46, 61-612 Poznan

Website:
<https://ppnt.poznan.pl/en/>

Email:
ppnt@ppnt.poznan.pl


Contact No.:
0048618279700

About Incubator:

The Poznan Science and Technology Park PPNT in Poland is the first established in 1995 Polish hub for innovation and entrepreneurship, designed to foster the development of research, technology, and businesses in the region. In recent years, PPNT has focused on fostering innovation in key areas such as chemistry, biotechnology, information technology, and renewable energy. PPNT undertakes four main activities: • R&D activities: providing research services for companies, conducting contracted research, and technology incubation, which involves the preparation and testing of technologies based on university research results through 12 research centers. PPNT owns 23 patents and patent applications. • Start-up/Spin-off incubation: offering coaching, investment readiness programs, and investor forums. PPNT also acts as a seed investor. • Technology transfer and business consulting: scouting for technologies, offering consulting services, and assisting in technology transfer, as well as facilitating collaboration between science and business. • Infrastructure provision: Renting out equipped laboratories and office spaces and creating an innovation-friendly environment. Currently, there are 60 tenants at PPNT, including R&D centers of large companies, technology start-ups, innovative SMEs, and some research institutions.

Total Space Sq. Ft.: 30000

IMPACT



5 most successful incubatees:

- Biosynthesis
- Symbiosis
- Future Synthesis
- Polbiotech
- Nutopi

General Infrastructural Services:

The Biotechnology Centre specialises in a large scope of research and services for microbiological food products, animal feed, cosmetics, housekeeping products, as well as air, working surfaces and liquids. The laboratory will help create a product control system in terms of microbiological safety and reduce the risk of bacterial contamination. The Biotech Centre broad tailored training programme will ensure that all the client's expectations are met and exceeded. The Biotechnology Centre, together with its enormous scientific, technical and real-property resources, is the strategic partner for private companies, scientific and research institutes, as well as consortia.

Scientific Support Services:

A significant aspect of PPNTs history is its collaboration with academic institutions such as Adam Mickiewicz University and Poznan University of Technology. These collaborations have been crucial in creating a bridge between academic research and practical applications in industry. The park also established partnerships with various industrial entities, both domestic and international, to promote technology transfer and commercialization of research. PPNT gained international recognition as a member of the International Association of Science Parks and Areas of Innovation IASP. This membership allowed PPNT to exchange knowledge and best practices with other science parks worldwide and to attract foreign investors and companies to Poznan.

Advisory and Mentoring Services:

Overall, PPNTs mission is to create an ecosystem that supports the development and implementation of innovative solutions in various fields, including green transformation and digitalization. By providing comprehensive support for innovation, research, and development, PPNT plays a vital role in the economic growth and sustainability of the region.





DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology



INDUSTRY (Pg. No. 221-242)

Sponsors

Non-Sponsors

SMEs

CROs



SPONSORS		
Sl. No.	Company Name	PAGE NUMBER
1	Bharat Biotech International Limited	224
2	Biocon Group	224
3	Biological E Limited	225
4	Blockchain For Impact	225
5	Danaher	226
6	Gennova Biopharmaceuticals Ltd.	226
7	Hester Biosciences Limited	227
8	HigenoMB - HiMedia Laboratories Pvt. Ltd	227
9	Praj Matrix	228
10	Quantoom Biosciences	228
11	Serum Institue of India Pvt Ltd.	229
12	SOLIZE India Technologies Pvt. Ltd. and Dassault Systemes	229
13	Takeda Pharmaceuticals Company	230
14	Thermo Fisher Scientific	230
15	Univercells S.A / Quantoom	231
16	Virchow Biotech Private Limited	231

NON-SPONSORS		
Sl. No.	Company Name	PAGE NUMBER
1	ARAYMOND INDIA Pvt. Ltd	232
2	Asahi KASEI	232
3	Genetix Biotech Asia Pvt Ltd	233
4	HiMedia Laboratories Pvt Ltd	233
5	Premas Biotech Private Limited	234
6	Premas Life Sciences Pvt Ltd	234
7	Twist Bioscience	235
8	ZYTEX BIOTECH PVT LTD	235

SMEs		
Sl. No.	Company Name	PAGE NUMBER
1	Barcode Biosciences Pvt.ltd	236
2	Hi Tech Biosciences India Pvt. Ltd.	236
3	Provis Biolabs Pvt Ltd	237
4	Revelations Biotech Pvt. Ltd.	237
5	Sri Bioaesthetics Pvt Ltd	238
6	Ttk Healthcare Limited, Heart Valve Division	238

CROs		
Sl. No.	Company Name	PAGE NUMBER
1	BTL BIOTECHNO LABS PRIVATE LIMITED	239
2	Embio Limited	239
3	GNANLex Associates LLP	240
4	Oniosome Healthcare Pvt. Ltd	240
5	S. MAJUMDAR & CO.	241
6	Tacit MedTek Private Limited	241
7	Texnano Technologies Pvt. Ltd.	242



Name of Industry: Bharat Biotech International Limited



Contact Person:
Dr. Rajesh Thouta

Email:
drrajesh@outlook.com

Description of Exhibit

Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to deliver affordable, safe, and high-quality vaccines and biotherapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in the fight against disease, with a focus on emerging markets.

Organization Profile

For over 25 years, we have been creating innovative vaccines and bio-therapeutics that help patients around the world lead healthier lives. As a research-led company, we have successfully pursued scientific breakthroughs that help patients overcome challenging diseases. We operate the finest bacteriology and virology lab in the country. All our anti-viral, bacterial and recombinant vaccines are manufactured at our world-class manufacturing facilities, that conform to the standards set by global regulators.

Website URL

<https://www.bharatbiotech.com/overview.html>

Social Media Links

<https://www.facebook.com/bharatbiotech>

<https://www.linkedin.com/company/bharat-biotechil/>

<https://x.com/BharatBiotech>

Status of Commercialization

We received funding for a project titled Proposal for Facility Augmentation to Support COVID Vaccine Manufacturing. This support helped us meet the total vaccine demand of the Government of India, which further supplied vaccines to all the states and other countries.

Recent Achievements or Awards

We recently launched Hilchol®, our next-generation Oral Cholera Vaccine OCV, which is effective and safe yet has a simple manufacturing process. This will allow Bharat Biotech to scale up its production and meet the unmet needs of OCV in Cholera outbreak regions and other low—and middle-income countries.

Interested in in-licensing/adoption No

Address

Genome Valley, Turkapally, Shamirpet,
Hyderabad, Telangana 500078.

Year of establishment

01-06-1996

Theme of Exhibit

Industrial Biotechnology, Vaccines,
Therapeutics, APIs, Biopharmaceuticals,
Excipients, Public Health

Key Products/Services

Bharat Biotech creates innovative vaccines and bio-therapeutics trusted by physicians around the world. We own 220 patents, and our products help people in over 125 countries live to their fullest potential. Our manufacturing facilities are approved by the USFDA, KFDA and WHO. Our significant R&D investments have yielded several breakthroughs, including the world's first: India's first Indigenous COVID-19 vaccines: COVAXIN and iNCOVACC Typhoid Conjugate vaccine Rotavirus vaccine from a naturally attenuated strain. Eco-friendly recombinant Hepatitis-B vaccine free of caesium chloride and Thiomersal

Supported under Scheme of BIRAC

Mission COVID Suraksha

Name of Industry: Biocon Group



Contact Person:
Seema Ahuja

Email:
seema.ahuja@biocon.com

Description of Exhibit

Biocon will exhibit its products and services in this well-built 100 sqm Booth P9 at the Global Bio-India 2024. It will showcase its innovative products and services. You will have the opportunity to learn more about Biocon's vision and achievements, and to interact with its experts and representatives. Don't miss this chance to discover how Biocon can help you with your biotechnology needs.

Organization Profile

Biocon Limited, is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on Twitter: @bioconlimited for company updates.

Website URL

<https://www.biocon.com/>

Social Media Links

<https://x.com/bioconlimited>

<https://www.linkedin.com/company/biocon/>

<https://x.com/BioconBiologics>

<https://www.linkedin.com/company/bioconbiologics/>

Recent Achievements or Awards

Sustainability & CSR Malaysia Awards 2024, "Champion of Supply Chain" award by the Indian Supply Chain Management, India ISCM, 2 awards for Excellence in Quality Control Practices and Quality Culture Transformation at Pharma Quality Excellence Awards, one Platinum and two Golds at the 7th CII-IQ National Competition.

Address

Biocon Limited 20th KM, Hosur Road,
Electronic City, Bengaluru 560100,
Karnataka, India T +91 80 2808 2808 / +91
80 4014 4014

Year of establishment

29-11-1978

Key Products/Services

Generics, Biosimilars, Research Services

Name of Industry: Biological E Limited



Contact Person:
ALN Reddy

Email:
reddy.aln@biological-e.com

Description of Exhibit

Biological E Limited established in 1953, has a long and richly textured history in manufacturing and supplying vaccines 142 countries for global health. BE vaccine portfolio includes 12 licensed vaccines, 10 of which are pre-qualified WHO vaccines. BE's 14-valent Pneumococcal conjugate vaccine PCV-14 under review by WHO for prequalification. BE equipped with state-of-the-art R&D laboratories, manufacturing facilities, and more than 5,000 highly skilled employees, including around 350 scientists. BE facilities are complying with rigorous compliance standards established by USFDA/EMA/WHO/ANVISA-Brazil/TGA-Australia and other regulatory bodies. BE's integrated services platform encompasses Microbial, Conjugate, Cell Culture, mRNA, Nanotechnologies & Peptides.

Organization Profile

Biological E Limited established in 1953, has a long and richly textured history in manufacturing and supplying vaccines 142 countries for global health. BE vaccine portfolio includes 12 licensed vaccines, 10 of which are pre-qualified WHO vaccines. BE's 14-valent Pneumococcal conjugate vaccine PCV-14 under review by WHO for prequalification. BE equipped with state-of-the-art R&D laboratories, manufacturing facilities, and more than 5,000 highly skilled employees, including around 350 scientists. BE facilities are complying with rigorous compliance standards established by USFDA/EMA/WHO/ANVISA-Brazil/TGA-Australia and other regulatory bodies. BE's integrated services platform encompasses Microbial, Conjugate, Cell Culture, mRNA, Nanotechnologies & Peptides.

Website URL

<https://www.bharatbiotech.com/overview.html>

Social Media Links

<https://www.linkedin.com/company/biological-e-ltd>

<https://www.linkedin.com/company/biological-e-ltd>

<https://www.facebook.com/Biological-E-Limited-1374756706187061/>

Status of Commercialization

Product received India EUA on 28-December-2021 for primary vaccination for adults, on 21-February-2022 for primary vaccination in 12 – 17 years old adolescents, on 26-April-2022 for primary vaccination 5 – 12 years old children, CORBEVAX received WHO EUL on 15-January-2024 & delivered 400 million for global health.

Recent Achievements or Awards

YR 2023: The Directorate General of Foreign Trade, Department of Commerce, Ministry of Commerce and Industry, Government of India, has given us the Four-Star Export House status. YR 2022: Bagged 6th Rank in the 'Top 20 Biopharma Companies' survey conducted in May 2022 by Bio Spectrum.

Address

Road no 35, Jubilee Hills, Hyderabad - 500033.

Year of establishment

10-12-1953

Key Products/Services

Vaccines Speciality Generic Injectables CDMO/CMO for Vaccines & Biologics

Supported under Scheme of BIRAC

To develop a safe, immunogenic & stable vaccine for all populations against the novel coronavirus CO

Name of Industry: Blockchain For Impact



Contact Person:
Dr. Pooja Agrawal

Email:
pooja@blockchainforimpact.in

Description of Exhibit

Bringing together Institutes, Incubators and Medical INI foreground breaking healthcare solutions through biomedical innovation and research.

Organization Profile

BFI envisions investing its resources into biomedical research and innovation. The aim is to construct multi sectoral collaborations by developing a virtual network of researchers, innovators and industry experts to expedite biomedical innovation across the nation to tackle the challenges in the healthcare sector and stimulating concentrated efforts towards upstream research, primarily Translational Research to convert upcoming inventive research into actual products and services that can be applied to public welfare.

Website URL

<https://www.blockchainforimpact.in/>

Social Media Links

www.blockchainforimpact.in

<https://www.linkedin.com/company/blockchain-for-impact-bfi/>

https://x.com/BFI_Impact

<https://www.youtube.com/@BlockchainForImpact>

Accreditations received (if any)

Indian Institute of Science IISc Birla Institute of Technology and Science BITS , Pilani Centre for Cellular and Molecular Biology CCMB Foundation for Neglected Disease Research FNDR Indian Institute of Technology Bombay IIT B TCG Crest Venture Centre C-CAMP Atal Incubation Centre - CCMB AIC-CCMB IKP Knowledge Park IISc IIT Kanpur.

Differential pricing model implemented in providing services

Not for Profit

Future Plans and Initiatives

Biome 2.0 is set to launch this year in India. Launching Medical INI program with medical colleges.

National/Societal Relevance

BFI by means of collaborative partnering with prominent institutions actively working in the domain of translational research, is steadily constructing an elaborate network, where the researchers can connect with the innovators, other researchers, grantors, industrial experts, policy makers and startup initiatives, and build the foundation of biomedical innovation together without redundancy and at a much more rapid pace. This will help nations in improving healthcare outcomes and economic growth through innovation and research.

Address

In Covid Support FZE LLC A-24-01-01-13 Flamingo, Ajman, United Arab Emirates

Year of establishment

30-07-2023

Theme of Exhibit

Public Health

Unique value proposition of the facility

Support translational research by means of funding and resources. Fostering of collaborations between the medical, academia, industrial, entrepreneurial, public health sector.



Name of Industry: Danaher



Contact Person:
Ankur Gupta

Email:
agupta09@beckman.com

Description of Exhibit

A congregation of 4 Danaher opcos- Beckman Coulter Life Sciences, Cytiva, SCIEX and Molecular Devices on one platform, displaying biopharma workflow solutions.

Organization Profile

Danaher Corporation is an American global conglomerate founded in 1984, and the company designs, manufactures, and markets medical, industrial, and commercial products and services. Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Danaher partners with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Danaher Life Sciences and Biotechnology operating companies include Beckman Coulter Life Sciences, IDBS, Leica Microsystems, Molecular Devices, Phenomenex, SCIEX, Cytiva, and IDT.

Website URL

<https://lifesciences.danaher.com/>

Social Media Links

<https://www.linkedin.com/showcase/danaher-life-sciences/>

<https://www.linkedin.com/company/danaher/posts/?feedView=all>

<https://www.linkedin.com/company/cytiva/>

<https://www.linkedin.com/showcase/beckman-coulter-life-sciences-metai/?viewAsMember=true>

<https://www.linkedin.com/company/sciex/>

<https://www.linkedin.com/company/molecular-devices/>

Address

Danaher India DHR Holding India Pvt. Ltd.
3rd Floor, B- Wing, Art Guild House, Phoenix
Market City, Lal Bahadur Shastri Marg, Kurla,
Mumbai, Maharashtra 400070

Year of establishment

01-01-2024

Key Products/Services

Analytical Instrumentation - Biopharma
Workflow Solutions

Theme of Exhibit

Industrial Biotechnology, APIs,
Biopharmaceuticals, Excipients, Analytical
& Laboratory Services, Equipments,
Biomanufacturing

Name of Industry: Gennova Biopharmaceuticals Ltd.



Contact Person:
Ms. Ankita Bhargava

Email:
ankita.bhargava@gennova.co.in

Description of Exhibit

At Global Bio India 2024, Gennova Biopharmaceuticals will showcase its biologics portfolio, focusing on stroke, oncology, and mRNA therapies. Our exhibit will feature innovative biotherapeutics developed with advanced recombinant DNA technologies and state-of-the-art manufacturing practices. We proudly highlight our mRNA technology, being the only Indian company to develop thermostable mRNA vaccines. Our platform uses nano-lipid emulsions for efficient manufacturability and scalability. Attendees will also learn about our expertise in perfusion-based continuous manufacturing and our role as a leading partner in research and cGMP manufacturing.

Organization Profile

Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to developing, producing, and commercializing biotherapeutics to address life-threatening diseases across various indications. Gennova is transforming healthcare by creating efficient and effective solutions for manufacturing and successfully commercializing biotherapeutics in the cardiovascular, neurology, nephrology, and oncology segments. Incorporating recombinant DNA technologies and innovative bio-manufacturing practices, Gennova utilizes bacterial, mammalian, and mRNA-based production platforms and excels in perfusion-based continuous manufacturing. The company has commercialized nine products, including biosimilars, generics, and vaccines, and is recognized as a leading partner for research and cGMP manufacturing, particularly in vaccines.

Website URL

<https://gennova.bio/>

Social Media Links

1. LinkedIn: <https://www.linkedin.com/company/gennova-biopharmaceuticals>

2. Instagram: <https://instagram.com/gennova.bio?igshid=NTc4MTIwNjQ2YQ==>

3. X Twitter : <https://x.com/GennovaBio>

Status of Commercialization

Gennova Biopharmaceuticals developed India's first mRNA COVID-19 vaccine, GEMCOVAC®-19, and the Omicron-specific booster, GEMCOVAC®-OM. Both received Emergency Use Authorization from DCGL. GEMCOVAC®-OM is listed on the CoWIN portal and has been commercialized. These projects were supported by BIRAC under the Ind-CEPI mission and Mission COVID Suraksha.

Recent Achievements or Awards

1. BIRAC Innovator Award 2023 for the category - Outstanding Contribution to Pandemic Management
2. Asia Pacific Vaccine Excellence Award AVEA 2023
3. India Pharma World Awards 2022 By ET Healthworld.com
4. Biotech Product , Process Development & Commercialization Award 2019 DBT
5. IDMA MARGI Memorial Best Patent Award

Interested in in-licensing/adoption Yes

Please Specify

We are interested in next generation manufacturing.

Address

Plot No. P-1 & P-2, IT-BT Park, Phase-II,
M.I.D.C., Hinjawadi, Pune - 411057,
Maharashtra, INDIA

Year of establishment

19-06-2001

Key Products/Services

Top 3 products are as follows:

1. TENECTASE®
2. HAMSYL Junior
3. mRNA based vaccines

Supported under Scheme of BIRAC

BIPP, NBM, Mission COVID Suraksha

Name of Industry: Hester Biosciences Limited

HESTER

Contact Person:
Mr. Rajiv Gandhi

Email:
rajiv.gandhi@hester.in

Description of Exhibit

We will be highlighting about the company strengths and focus products vaccines and health products from the three divisions - poultry, ruminants and petcare.

Organization Profile

Hester Biosciences is one of the India's leading animal health company, manufacturing vaccines and health products since 1997. Hester has three divisions:

1. Poultry Healthcare division
2. Animal Healthcare division
3. Petcare division

- It is the world's largest manufacturer and supplier of PPR vaccine, having approximately 75 of the world market.
- It has over 70 market share in Goat Pox vaccine in India which is being used to immunise cattle against Lumpy Skin disease.
- It is the second largest poultry vaccine manufacturer, with approximately 35 market share in India.

Website URL

<https://www.hester.in/>

Social Media Links

Instagram-<https://www.instagram.com/hesterbiosciences?igsh=YnRreWw3ejhsbXZm>
 Facebook-<https://www.facebook.com/HesterBiosciencesLimited?mibextid=JRoKGI>
 YouTube-<https://youtube.com/@hesterbioscienceslimited8287?si=pXQK1AVVL2aVXlgr>
 TwitterX-<https://x.com/Hesterindia?t=Zu9gcsjRmrgS9vKUbWePgA&s=08>

Recent Achievements or Awards

Received the Best Animal Vaccine Company honor by The New Economy, UK, 2010 Completed the Worlds largest backyard poultry immunization program in collaboration with GALVmed in 2016 Contributed to the national immunization program against LSD by supplying highest number of Goat Pox vaccine doses in 2022.

Status of Commercialization

BSL-3 GMP manufacturing facility for manufacture of cell culture based viral vaccines DS commissioned and qualified. Facility available for manufacture of Live attenuated and inactivated based viral vaccine drug substance.

Interested in in-licensing/adoption Yes

Please Specify

We would be interested in mRNA based, viral vectored and recombinant live attenuated vaccine platforms.

Address

Hester Biosciences Limited Pushpak, 1st Floor, Panchavati Circle, Motilal Hirabhai Road Ahmedabad 380006 Gujarat, India

Year of establishment

19-04-1987

Key Products/Services

PPR Vaccine: For the immunisation of sheep and goats Gumboro I +: For the immunisation of Poultry against Infectious Bursal Disease VitaCoat Advance: Pioneering dermatitis therapy with revolutionary CoQ10 for Canine and Feline We Offer Comprehensive training on poultry disease and farm management using advanced diagnostic facilities and Sero-profiling for chicken flock.

Supported under Scheme of BIRAC

Mission Covid Suraksha

Name of Industry: HigenoMB - HiMedia Laboratories Pvt. Ltd

HiGenoMB
Unzipping Genes

Contact Person:
Mr Rajender Kumar

Email:
rthakur@himedialabs.com

Description of Exhibit

Automated Extraction kits DNA/RNA, PCR kits, Buffers & Reagents, Resins, Protein Purification Kits, Automated Nucleic Acid Extractors, RT-PCR System, Thermal Cyclers etc. Sequencing & Bioinformatics Services Raw materials & Molecular Biology Grade Chemicals Lab Consumables.

Organization Profile

HiGenoMB®, The Leading Molecular Biology Brand Manufacturing complete workflow solutions from Genomics, Proteomics to full range of Sequencing & Bioinformatics It encompasses the Molecular Biology Product Range of HiMedia Laboratories Pvt. Ltd. Comprising of -? Genomics - Automated Extraction kits DNA/RNA, PCR kits, Buffers & Reagents, Proteomics - Resins, Protein Purification Kits, Stains, Buffers & Reagents. Automation - Automated Nucleic Acid Extractors, RT-PCR System, Thermal Cyclers etc.

Sequencing & Bioinformatics Services. Raw materials & Molecular Biology Grade Chemicals. Teachings Kits, Growth Media & Lab Consumables

Website URL

<https://www.himedialabs.com/in/molecular-biology.html>

Social Media Links

<https://www.facebook.com/HiGenoMB/>

<https://www.linkedin.com/showcase/higenomb/>

Interested in in-licensing/adoption Yes

Address

Plot No. C40, Road No. 21Y, MIDC, Wagle Industrial Estate, Thane West - 400604, Maharashtra, India

Year of establishment

01-01-2006

Key Products/Services

Extraction Kits Chemicals Sequencing.



Name of the Institute: Praj Matrix



Founder and Co-founder(s):
Dr. Anand Ghosalkar

Email:
anandghosalkar@praj.net

About the Institute

With the goal of providing environment-friendly solutions for a future perfect world, Praj established Matrix – R&D centre in the very first decade of its inception. Praj Matrix is the common innovation engine for all business units of Praj Industries. Each business unit strives to stay ahead of competition through continuous investment in cutting-edge technology & product research carried out at Praj Matrix. Standing true to our vision of making the world a better place, Praj Matrix conducts research in the emerging areas of industrial biotechnology viz. 2nd generation biofuels, advanced biochemicals, advanced biofuels for road, aviation and marine sectors and health & wellness products.

Thrust Area

Industrial biotechnology for applications in technology development of advanced biofuels, advanced biochemicals, renewable chemicals and materials mainly bioplastics and other biochemicals for health and wellness applications through its two innovation platforms viz bio-mobility and bio-prism.

Website URL

https://www.praj.net/resources_page/rd-praj-matrix-the-innovation-center/.

Are you willing to Transfer/ Out-License your Technology No

Geographical Region Targeted

Primarily targeting biotech hubs in India, Middle East Southeast Asia, and Africa, with plans to expand into Europe and the Americas.

Specialized Equipment

Biomethanation Potential Testing, HTS Facility, Scale Up Facilities UpTo 5000 Ltrs.

Facilities available for Start-ups

Manufacturing Facilities ,
Lab renting facilities ,
3D printing and prototyping ,
Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities



Address

402/403/1098, Urawade, At. Pirangut, Tal. Mulshi, Dist. Pune 412 108, India.

Area of Expertise available

Climate change impact and one health (health of human, animals and our shared environment including AMR/ surveillance), Agriculture,

IP related support and Technology transfer/ Regulatory support

Name of the Institute: Quantoom Biosciences



Founder and Co-founder(s):
Antoine Nopere

Email:
a.nopere@quantoom.com

Organisation Profile

Quantoom Biosciences is leading the revolution in mRNA-based vaccines and therapeutics by offering turnkey solutions for mRNA-LNP manufacturing. Its cutting-edge Ntensify™ technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&D to commercial manufacturing. Launched in 2023, Ntensify™ has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate™ technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based drugs.

Thrust Area

Industrial biotechnology for applications in technology development of advanced biofuels, advanced biochemicals, renewable chemicals and materials mainly bioplastics and other biochemicals for health and wellness applications through its two innovation platforms viz bio-mobility and bio-prism.

Website URL

<https://quantoom.com/>

Social Media Links

<https://www.linkedin.com/company/quantoom-biosciences/>

Address

Rue de la Maitrise 11, 1400 Nivelles.

Theme of Exhibit

Vaccines

Year of establishment

01-06-2021

Key Products/Services

Ntensify mano Ntensify mini Ntensify midi

Name of the Institute: Serum Institute of India Ltd



About the Institute

Serum Institute of India Ltd. has established itself as the world's largest producer of Measles and DTP group of vaccines. It is estimated that two out of every three children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute. In fact, our range of products have been used in 170 countries across the globe.

Serum Institute of India was founded in 1966 with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man. The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Rabies vaccine, Combination vaccine etc. and latest introduction - HPV vaccine, so that not only Indian's, but the entire under-privileged children of the world.

It has been ranked as world's No. 1 biotech company (by no of doses). Serum Institute is associated with WHO and other International agencies for development of newer vaccines. They have a very strong pipeline of biologicals like monoclonals and for dengue and vaccines form many other diseases.

Name of the Institute: SOLIZE India Technologies Pvt. Ltd. and Dassault Systemes



Founder and Co-founder(s):
 Gourav Gupta

Email:
 gourav.g@solize.com

Organisation Profile

Please visit <https://www.3ds.com/> and <https://www.solize.com/india/> Please visit <https://www.3ds.com/products/biovia/> to know more about BIOVIA portfolio

Description of Exhibit

-A research platform with over 30years of peer-reviewed research with world-class in-silico techniques such as Molecular Mechanics, Free energy calculations, Biotherapeutics as a complete tool set to explore chemistry and biology of molecules. -Material modelling and simulation environment to allow researchers in Material Science and Chemistry to predict and understand the relationship of material atomic and molecular structure with its properties and behaviour Materials include catalysts, Biopolymers, Metals, alloys, Pharmaceuticals -An IP protected One-Lab to digitalise R&D, QA QC labs for regulatory compliance -Validated data science tools for scientific data analysis across Biology, Chemistry, Physics AI / ML/ Imaging.

Recent Achievements or Awards

-Dassault Systemes ranked No.4 for sustainability as per DOW Jones -Dassault Systemes Migal Galilee Research Institute collaborate to develop first vaccine against COVID-19 -Dassault Systemes collaborates with Sanofi to establish a virtual twin of their manufacturing facility to reduce 106 B USD cost & 61 MT of CO2 emission

Social Media Links

<https://www.linkedin.com/company/biovia/>

<https://www.linkedin.com/company/dassaultsystemes/>

<https://www.linkedin.com/company/solize-india/>

Website URL

<https://www.3ds.com/products/biovia/>

Partnerships and Collaborations

-University of Illinois NAMD -University of Cambridge CHARMM -Massachusetts Institute of Technology Boston Aggregation Propensity

Address

SOLIZE India Technologies Private Limited
 2nd Floor, Unit Nos. 201-B & 202, Brigade
 Opus, No. 70/401, Kodigehalli Gate, Hebbal,
 Bangalore- 560092.

Theme of Exhibit

Industrial Biotechnology ,
 Agriculture ,
 Vaccines ,
 Therapeutics ,
 IP/Technology Transfer ,
 APIs, Biopharmaceuticals, Excipients ,
 Analytical & Laboratory Services ,
 Regulations/Standards/Certifications ,
 Artificial Intelligence ,
 Bioservices ,
 Biomanufacturing

Key Products/Services

Molecular Modelling and Simulation
 for Biomolecules and Biomaterials,
 Laboratory Information Management,
 Manufacturing Operational Excellence
 Regulations/Standards/Certifications,
 Artificial Intelligence, Bioservices,
 Biomanufacturing



Name of Industry: Takeda Pharmaceuticals Company



Contact Person:
Ruchi Sagarwal

Email:
ruchi.sagarwal@takeda.com

Description of Exhibit

Exhibition will showcase Takedas Global presence and investments in India for the following areas 1- Digital Technology Solutions 2 Patient Support Services 3 - Biomanufacturing Partnership and R&D.

Organization Profile

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are.

Website URL

<https://www.takeda.com/>

Social Media Links

<https://www.linkedin.com/company/takeda-pharmaceuticals>

Recent Achievements or Awards

1 International Society for Pharmaceutical Engineering ISPE has awarded Takeda with top honours in the category Operations with the 2024 Facility of the Year Awards FOYA . Source: <https://www.takeda.com/newsroom/newsreleases/2024/ispe-facility-of-the-year-awards-in-category-operations/> 2 Takeda Named Global Top Employer for Seventh Consecutive Year

Address

6th floor, Tower C, DLF Cyber City, DLF Phase 2, Sector 24, Gurugram, Haryana 122002.

Year of establishment

12-06-1781

Key Products/Services

Takeda has a strong presence in India, the companys portfolio encompasses diverse therapeutic areas such as gastroenterology, oncology, rare diseases, neuroscience, and vaccines. Top 3 Global products Molecules: 1 Vedolizumab 2 Lanadylomab -Flyo 3 Brentuximab Vedotin

Name of Organisation: Thermo Fisher Scientific



Founder and Co-founder(s):
Rashmi Jha

Email:
rashmi.jha@thermofisher.com

Organisation Profile

Thermo Fisher Scientific is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Description of Exhibit

Thermo Scientific solutions are designed with your application in mind. We are focused on setting the standards for serving science by providing customers with an innovative and broad life sciences portfolio, a product offering that includes virtually everything needed for the laboratory, and a strong presence at the bench and focused on transforming the customer experience through tools and solutions that let you focus on your research processes and breakthroughs.

Recent Achievements or Awards

-Dassault Systemes ranked No.4 for sustainability as per DOW Jones -Dassault Systemes Migal Galilee Research Institute collaborate to develop first vaccine against COVID-19 -Dassault Systemes collaborates with Sanofi to establish a virtual twin of their manufacturing facility to reduce 106 B USD cost & 61 MT of CO2 emission

Social Media Links

<https://www.linkedin.com/company/thermo-fisher-scientific-india/>

Website URL

<https://www.thermofisher.com/in/en/home.html>

Address

SOLIZE India Technologies Private Limited 2nd Floor, Unit Nos. 201-B & 202, Brigade Opus, No. 70/401, Kodigehalli Gate, Hebbal, Bangalore- 560092.

Key Products/Services

Laboratory Equipment, Analytical Instruments, Chemicals & Consumables



Name of Industry: Univercells S.A.



Contact Person:
Rozi Kirakosian

Email:
r.kirakosian@univercells.com

Description of Exhibit

Univercells is a Belgian biotechnology company focused on developing cost-effective biomanufacturing solutions to make biotech drugs and vaccines more accessible. Founded in 2013, the company leverages its proprietary technologies to reduce the cost and complexity of biotech drug production.

Organization Profile

Univercells Group is a global group of biotech innovators, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere can get them.

Website URL

<https://www.univercells.com/>

Social Media Links

<https://www.linkedin.com/company/univercells>

Address

Av. Herrmann-Debroux 54.

Year of establishment

01-01-2013

Key Products/Services

Viral vectors and mRNA drug development partnerships and collaborations. Vaccine manufacturing equipment

Name of Organisation: Virchow Biotech Private Limited



Founder and Co-founder(s):
Murty sattiraju

Email:
murty@virchowbiotech.com

Organisation Profile

VBPL Incorporated in 2001, Virchow Biotech P Limited VBPL, the biopharmaceutical company of the group focuses on the manufacturing of a wide range of biologicals and bio-generics by genetic engineering, classical fermentation, or extraction technologies. VBPLs achievements include being the worlds first company to commercialize PDGF bio generics, Teriparatide, Pegylated Interferon, and Rasburicase. The product portfolio consists of 50 products with five other recombinant bio-generics in the pipeline. VBPLs cGMP facilities, accredited by various regulatory agencies from around the world, consist of 12 independent production suites with a total built-up area of 6, 00, 000 square feet.

Description of Exhibit

VBPL facilities are equipped to manufacture products ranging from oral biologicals, recombinant monoclonal antibodies, medical devices, and parenteral biopharmaceuticals in various forms of presentations like vials, cartridges, prefilled syringes and blow-fill seal products. Such diversified manufacturing capabilities provide vital and timely support to customers relying on VBPL for their clone to market strategies. VBPL also undertakes contract manufacturing of biologicals for various customers around the world.

Recent Achievements or Awards

-Dassault Systemes ranked No.4 for sustainability as per DOW Jones -Dassault Systemes Migal Galilee Research Institute collaborate to develop first vaccine against COVID-19 -Dassault Systemes collaborates with Sanofi to establish a virtual twin of their manufacturing facility to reduce 106 B USD cost & 61 MT of CO2 emission

Website URL

<http://virchowbiotech.com/>

Address

Survey no.172 part, Gagillapur, Quthbullapur, Telangana 500043.

Key Products/Services

Classical Biologicals Depot Formulations
Nano formulations Miscellaneous
Generics Contract Manufacturing Vaccines

Theme of Exhibit

Devices & Diagnostics, Vaccines,
Therapeutics, Bioservices,
Biomanufacturing

Organisation Type

Industry/Pharmaceutical/Biopharma/
Medtech



Name of Industry: ARaymond India Pvt Ltd



Contact Person:
Gaurav Sahoonja

Email:
Gaurav.Sahoonja@araymond.com

Description of Exhibit

We are showcasing our Disposable Drug Delivery Pen Device, designed for self-administration by diabetic patients. This device, developed for Liraglutide, is already commercialized in India. Additionally, we are exhibiting the RayDyLyo® Cap, an innovative all-plastic push-fit cap for vial closure. Unlike traditional aluminum crimp caps, RayDyLyo® allows pre-assembly of the stopper in the cap, simplifying the production process and accelerating time to market for pharmaceutical companies.

Organization Profile

ARaymond has been present in India since 2007 with production plants in Pune, Chennai and a regional office near Delhi. The company designs and manufactures plastic and metal fastening solutions and Quick Connectors. ARaymond India's plant is supported by a fully equipped quality testing lab. A significant proportion of the products manufactured by ARaymond India are sold to OEMs, tiers, and other customers in India for various applications on Industrial markets.

Website URL

<https://www.araymond.com/en/presence-in-the-world/araymond-india>

Social Media Links

<https://in.linkedin.com/company/araymond-india>

Address

Gat No. 259, 276/8B, Nighoje, Taluka-Khed,
Maharashtra 410501

Year of establishment

30-11-2007

Key Products/Services

CDMO Pen device RayDyLyo cap

Organisation Type

Industry/Pharmaceutical/Biopharma/
Medtech

Name of Industry: Asahi Kasei



Contact Person:
Mohammad Asif Ahmad

Email:
ahmad.as@asahi-kasei.in

Description of Exhibit

Asahi KASEI's Microza Division in Biopharma specializes in advanced filtration solutions tailored for biopharmaceutical applications. With a focus on precision and reliability, Microza's hollow fiber membrane technology ensures high-purity separation and concentration processes, critical for producing safe and effective biopharmaceutical products. The division supports various stages of drug development, from research to large-scale production, offering robust and scalable solutions. Committed to innovation, Microza enables enhanced process efficiency and product quality, making it a trusted partner in the biopharma industry.

Organization Profile

Asahi KASEI is a global leader in diverse fields, including materials, homes, and health care. With a rich history of innovation, the company offers cutting-edge solutions in electronics, chemicals, fibers, and construction materials. In healthcare, Asahi KASEI is renowned for its advanced medical devices and biopharmaceutical filtration systems. Committed to sustainability and improving quality of life, Asahi KASEI continually drives innovation across industries. With a strong global presence, the company leverages its expertise to meet the evolving needs of society, ensuring safety, comfort, and environmental responsibility.

Website URL

<https://www.asahi-kasei.com/>

Social Media Links

<https://www.linkedin.com/company/asahi-kasei/>

Address

The Capital, Office No:1502-B, Plot NO.C
70, G Block BKC, Bandra East, Mumbai,
Maharashtra 400051, India

Year of establishment

01-01-1925

Key Products/Services

TFF MF UF

Name of Industry: Genetix Biotech Asia Pvt. Ltd.



Contact Person:
Ms. Deepthi Vashishtha

Email:
deepthi@genetixbiotech.com

Description of Exhibit

Genetix POC GeneNAT-300 and GeneNAT-340 real-time PCR analyzers with never-seen-before turn-around time TAT and minimal hands-on time deliver accurate error-free results at unparalleled speed. The PCO system is based on microfluidic-chip-based detection involving two-color detection, enabling multiplexing. It has a small footprint and requires no maintenance it may operate on a portable battery and it employs an intuitive, user-friendly interface, minimal hands-on requirements.

Organization Profile

Leading healthcare and diagnostics company Genetix Biotech Asia Pvt. Ltd. is primarily focused on fleet deployment, molecular kit development, and research and development. We take great satisfaction in introducing the most cutting-edge and reasonably priced technology to the Indian life science, diagnostics, and healthcare markets in order to improve outreach to both the general public and businesses and research facilities. Our company is built upon four verticals: medical technology and equipment, bioprocess, life science goods, & diagnostics. Our team comprises highly qualified professionals, including 15 Ph.D. holders. We are a valuable vendor, not only for R&D and technical support.

Website URL

<https://genetixbiotech.com/>

Social Media Links

<https://www.linkedin.com/company/genetix-biotech-asia-p-ltd./mycompany/>

Recent Achievements or Awards

1. Times of India: Excellence in Biotech Spectrum, Conclave 2024.

Address

71/1, First Floor Nagargarh road, Shivaji Marg,

Year of establishment

10-10-2001

Key Products/Services

GeneNAT-300/340 Genetix P4 nucleic acid extraction system Microfluidic chips compatible with the real time PCR analyzer

Name of Industry: HiMedia Laboratory Pvt. Ltd.



Contact Person:
Dr. Vishal G Warke

Email:
vwarke@himedialabs.com

Description of Exhibit

HiMedia's CellBio Facility offers advanced cell culture solutions, providing services like custom media formulation, sterile filtration, and cell-based assays. The facility also supports large-scale media production, media optimization, and provides technical assistance, catering to research, pharmaceutical, and biotech industries with high-quality, reliable cell culture products and services.

Organization Profile

HiMedia's Cell Bio division specializes in providing high-quality, innovative solutions for cell culture and related research. With state-of-the-art facilities, it offers custom media formulation, media optimization, and large-scale production tailored to the needs of the biotech, pharmaceutical, and academic sectors. The CellBio division is committed to supporting advanced research through its sterile filtration services, cell-based assays, and technical consultation. Leveraging decades of industry expertise, HiMedia CellBio ensures reliable, high-performance products that accelerate scientific discoveries and enhance productivity across various applications in cell biology, immunology, and regenerative medicine.

Website URL

<https://www.himedialabs.com/>

Social Media Links

<https://www.linkedin.com/showcase/80221115/admin/dashboard/>

Accreditations received (if any)

HiMedia holds accreditations like WHO GMP, USFDA cGMP for its production plants, ISO 9001 for quality management, and NABL accreditation for its labs. The company's DSIR-recognized R&D labs ensure innovative solutions. HiMedia has served over 5,000 clients worldwide, including pharmaceutical giants, research institutions, and biotech companies.

Differential pricing model implemented in providing services

HiMedia CellBio implements a differential pricing model based on client categories, offering competitive rates for academic institutions, tiered pricing for startups, and premium services for large pharmaceutical and biotech companies. Discounts are provided for bulk orders, long-term contracts, and repeat clients, ensuring affordability and accessibility across all sectors.

Future Plans and Initiatives

HiMedia CellBio plans to expand its global footprint, launch new cell culture products, and enhance automation in custom media production.

National/Societal Relevance

HiMedia CellBio contributes to national health and research by providing high-quality, affordable cell culture solutions critical for diagnostics, vaccine development, and drug research. The facility supports India's biotech growth, enhances research capabilities, and strengthens healthcare innovations, aligning with the nation's goals for scientific advancement and self-reliance.

Address

C40, Neheru Nagar, Wagle Industrial Estate, Thane West, Thane, Maharashtra 400604.

Year of establishment

08-09-1982

Unique value proposition of the facility

HiMedia CellBio Facility's unique value proposition lies in its comprehensive end-to-end solutions, featuring state-of-the-art equipment, custom media production, and stringent quality control under WHO GMP and USFDA cGMP standards. Strategically located for easy access to global markets, the facility's DSIR-recognized R&D labs drive innovation. A customer-centric governance model ensures tailored.

Current Status of Facility

Functional

Partnerships and Collaborations

HiMedia CellBio collaborates with leading research institutions, biotech companies, and academic organizations like CSIR, ICMR, and DBT.



Name of Industry: Premas Biotech Pvt Ltd



Contact Person:
Prabuddha Kundu

Email:
prabuddha.kundu@premasbiotech.com

Description of Exhibit

At Global Bio India we seek to: Partner, License or collaborate for development and licensing collaborations on novel preclinical candidates: • Fully human Anti-PD-L2 antibody immune checkpoint • Influenza vaccine VLP candidate Universal vaccine design, in animal trials • Thermo-stable mRNA-VLP candidate Influenza • Thermo-stable mRNA-VLP candidate RSV Furthermore, our product portfolio contains: • Growth factors • Cytokines GMP Grade IL-2 • Enzymes • Recombinant CRM197.

Organization Profile

PREMAS Biotech, based in Gurgaon, India, is a leading Contract Research and Manufacturing Services CRAMS organization with 19 years of experience. Recognized by DSIR and ISO 9001:2015 certified, we offer flexible, cost-effective solutions for therapeutic and vaccine development. With a GMP-certified facility, PREMAS has delivered over 750 proteins and supported multiple clinical pipeline projects. Our expertise spans process development, scale-up, and tech transfer for biotherapeutics and vaccines. Known for on-time deliveries, strong processes, and customer satisfaction, PREMAS uses lean manufacturing principles to ensure high-quality service and continuous improvement in our collaborations.

Website URL

<https://www.premasbiotech.com/>

Social Media Links

<https://www.linkedin.com/company/premasbiotech/mycompany/>

Status of Commercialization

Under Development, Phase-I

Address

Plot 79, Sector 4, IMT Manesar, Gurgaon

Year of establishment

28-11-2005

Key Products/Services

1. Gene to IND, Process Development, GMP Production of clinical lots. 2. Protein Therapeutics 3. Vaccine Technologies, VLP, D-Crypt Platform.

Scheme of BIRAC

Covid vaccine, VLP, Genique Lifesciences.

Name of Industry: Premas Life Sciences Pvt. Ltd.



Contact Person:
Srishti Kushwaha

Email:
srishtikushwaha@premaslifesciences.com

Description of Exhibit

Premas Life Sciences, established 18years ago, is a pioneering company in the field of life sciences, dedicated to advancing scientific research and healthcare through innovative technologies. With a strong focus on providing cutting-edge solutions, Premas collaborates with global leaders to offer a diverse portfolio of products and services, including next-generation sequencing, genomics, and proteomics. Our commitment to excellence is reflected in its support for research institutions, biotech companies, and healthcare providers. Through our new brand, Uncoded, Premas aims to make multi-omics accessible and affordable, continuing its legacy of empowering the scientific community in India and beyond.

Organization Profile

At the exhibit, Premas Life Sciences will proudly showcase its cutting-edge products, reflecting our collaborations with some of the world's most innovative technology providers. Our partnerships with renowned brands like Illumina, 10x Genomics, Twist Bioscience, Olink, Bionano, Covaris, Beckman Coulter, and Bioptrics empower us to bring the latest advancements in genomics, cell biology, proteomics, and automation to India. This exhibit will highlight these collaborations and the launch of our new brand, Uncoded, which focuses on making multi-omics more accessible and affordable. Discover how Premas continues to drive scientific excellence and innovation in India and beyond.

Website URL

<https://www.premaslifesciences.com/>

Social Media Links

LinkedIn: <https://www.linkedin.com/company/premas-lifesciences/>

Facebook: <https://www.facebook.com/connectpls/>

Twitter: <https://twitter.com/PremasLifeSc>

YouTube: https://www.youtube.com/channel/UCBI_X0gv00UllFW9pZzYWyg

Address

E - 49/5, Second Floor, Okhla Phase II, New Delhi, Delhi 110020.

Year of establishment

10-08-2006

Key Products/Services

Genomics, Proteomics and Multi-Omics



Name of Industry: Twist Bioscience



Contact Person:
Tiong Han Yeo

Email:
tyeo@twistbioscience.com

Description of Exhibit

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.

Organization Profile

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist manufactures synthetic DNA-based products, including synthetic genes, tools for NGS preparation, and antibody libraries for drug discovery and development.

Website URL

<https://www.twistbioscience.com/>

Social Media Links

<https://twitter.com/TwistBioscience>

<https://www.linkedin.com/company/twist-bioscience/>

<https://www.youtube.com/twistbioscience>

Address

Twist Bioscience HQ 681 Gateway Blvd
South San Francisco, CA 94080

Year of establishment

01-01-2013

Key Products/Services

DNA Synthesis DNA Libraries Biopharma solutions.

Name of Industry: Zytex Biotech Pvt. Ltd.



Contact Person:
Rajesh Poojari

Email:
rajesh.poojari@zytex.com

Description of Exhibit

Zytex, today, is one of the leading producers of bacillus in India and poised to become a global player.

Organization Profile

Zytex was established in 1996 with its first venture into manufacturing of textile enzymes. Fermentation research started in the company in 2004 with a focus on bacillus technology. In 2009, Zytex Biotech Pvt. Ltd. set up a world class fermentation plant.

Website URL

<https://www.zytex.com/>

Social Media Links

<https://www.facebook.com/ZytexBiotech/>

<https://in.linkedin.com/company/zytex>

Address

702 B, Polaris, Off Marol Maroshi Rd, behind
Sangeet Plaza, Marol, Andheri East, Mumbai,
Maharashtra 400059

Year of establishment

17-03-2006

Key Products/Services

Bacillus coagulans Bacillus subtilis PB Kit
65 Incryl Xplorer glory.



Name of Industry: BARCODE BIOSCIENCES PVT.LTD



Contact Person:
Dr. RAMPRASAD KUNCHAM

Email:
ramprasad@barcodebiosciences.com

Description of Exhibit

Oligonucleotides are short sequences of nucleotides, typically ranging from 2 to 50 bases in length. They can be synthesized to have specific sequences for use in various molecular biology and genetic research applications. Commonly used as primers in PCR and as probes in hybridization assays, oligonucleotides are vital for amplifying, detecting, and analyzing nucleic acids. They are also utilized in gene synthesis, antisense therapy, and CRISPR gene editing. Due to their ability to bind selectively to complementary DNA or RNA sequences, oligonucleotides are essential tools for diagnostics, therapeutic developments, and fundamental research in genomics and biotechnology.

Organization Profile

Barcode Biosciences Pvt. Ltd., based in Bangalore, is a pioneering company in the field of molecular biology and genomics. Specializing in advanced DNA sequencing and analysis, the company offers a range of services including genetic testing, biomarker discovery, and custom oligonucleotide synthesis. With a focus on precision and innovation, Barcode Biosciences supports research in healthcare, agriculture, and environmental science. The company's state-of-the-art facilities and expert team enable it to deliver high-quality, reliable results, contributing to advancements in personalized medicine and scientific research. Their commitment to excellence positions them as a key player in the biosciences sector in India.

Website URL

<https://www.barcodebiosciences.com/>

Social Media Links

<https://www.linkedin.com/in/barcode-biosciences-555498217>

Address

Barcode Biosciences Pvt Ltd No. 90&91, 3rd and 4th Floor 6th Cross, MCECHS layout Dr. Shivaram Karanth Nagar Bangalore-560077 INDIA

Year of establishment

05-04-2021

Key Products/Services

DNA/RNA Oligonucleotides PCR Primers/ Probes Sanger Sequencing services

Name of Industry: Hi Tech BioSciences India Pvt. Ltd.



Contact Person:
Mr. Mahendra Savadikar

Email:
mms@htblindia.com

Description of Exhibit

A leading probiotic manufacturer in India, we specialize in developing and offering high-quality probiotic products, including active ingredients and market-ready solutions, adhering to the highest international standards. Our product portfolio caters to diverse applications and target consumer groups globally, ensuring cost-effective and effective solutions that meet our clients' needs. Our biocatalysis deck, comprises of comprehensive, end-to-end services, from enzyme identification and engineering to production and process scale-up. We manufacture small-volume, high-value chiral intermediates, delivering tailored solutions for specific applications. Our commitment to innovation and excellence drives our success in every project, setting new benchmarks in the industry.

Organization Profile

Hi Tech BioSciences India Pvt Ltd. HTBS is an Indian biotechnology company specializes in providing sustainable solutions for health and the environment. HTBS focuses on: 1 Developing products and technologies for microbiome modulation to enhance health, nutrition, and productivity in humans, animals, and agriculture, & 2 Biocatalysis solutions for sustainable chemical synthesis. HTBS operates a DSIR-approved R&D Centre in Pune, equipped with state-of-the-art laboratory and pilot plant facilities for microbiology, molecular biology, protein chemistry, fermentation technology, and biocatalysis process development. The company also has two GMP-compliant manufacturing facilities in Pune and Supa for probiotics, nutraceuticals, and chemical intermediates.

Website URL

<http://www.htblindia.com>

Social Media Links

<https://www.linkedin.com/company/hi-tech-biosciences-india-private-limited/>

Status of Commercialization

TRL-5 to TRL-8.

Recent Achievements or Awards

1. Licensing of technology for manufacturing of D-Mandelic Acid from Racemic Mandelonitrile using nitriles enzyme 2. Scale-up of cascade biocatalysis technology for NUS, Singapore, 3. Launching of Bacillus clausii spore suspension for paediatric diarrhoea 4. Probiotic products for Chronic Kidney Disease, Feminine Hygiene, IBS, Oral Hygiene, etc.

Address

C-2, Unit 102+103, Saudamini Complex, S. No. 101/1, Bhusari Colony, Paud Road, Kothrud, Pune 411038 Maharashtra India.

Year of establishment

24-04-2007

Key Products/Services

1. Ready to Market Finished Products in various oral dosage forms, such as suspension, capsules, sachets, etc. 2. Active Probiotic Ingredients for human health, animal health & nutrition and agriculture. 3. Contract Research & Customized biocatalysts, enzymes & solutions for biocatalysis processes.

Supported under BIRAC Scheme

SBIRI

Theme of Exhibit

Industrial Biotechnology, Others, APIs, Biopharmaceuticals, Excipients

Name of Industry: Provis Biolabs Private Limited

Provis

Contact Person:
Pavan Avula

Email:
customersupport@provisbiolabs.com

Description of Exhibit

At Global Bio India, Provis Biolabs Pvt. Ltd. showcases its cutting-edge portfolio of high-quality recombinant proteins, enzymes, and therapeutic peptides. Specializing in GMP-compliant manufacturing, we offer solutions for biopharmaceuticals, including recombinant proteins, enzymes, and BioAPIs. Our services include end-to-end technology development, OEM production, and advanced GMP manufacturing. Visit our exhibit to explore collaboration opportunities, engage with our experts, and discover how our innovative solutions can meet your industry needs.

Organization Profile

Provis Biolabs is a life sciences company based in Hyderabad, India. Founded in the year 2019 with a vision to be integrated research driven company offering products and services to global life sciences industry. Provis began its budding scientific journey by setting up R&D lab at Aspire-Bio-Nest, University of Hyderabad. Provis is WHO-GMP, GLP, ISO 9001-2015, Halal and Kosher certified company. We have developed and commercialized 5 products and 10 products in various stages of development. Provis is in the process of expanding R&D operations and establishing state-of-the-art, large-scale fermentation-based manufacturing facility to serve its global ambitions.

Website URL

<https://www.provisbiolabs.com/>

Social Media Links

<https://www.linkedin.com/company/provis-biolabs-private-limited>

<https://www.youtube.com/watch?v=djRHF2UTRE>

Address

Prashanthi Nagar, Kukatpally Hyderabad – 500 072, Telangana, India

Year of establishment

12-09-2019

Key Products/Services

Trypsin, Carboxypeptidase B, L-Asparaginase

Theme of Exhibit

APIs, Biopharmaceuticals, Excipients, Biomanufacturing

Name of Industry: Revelations Biotech Pvt. Ltd, Hyderabad


REVELATIONS

Contact Person:
Dr. Ravi Chandra Beeram

Email:
ravi@revelationsbio.com

Description of Exhibit

Revelations developed futuristic nature derived healthy sugar reduction solutions involving a sweet prebiotic fiber FOSLIFE, an intensely sweet tasting protein Brazzein 500 times sweeter than sugar and a zero-calorie rare sugar Allulose. While the world is caught in sugar pandemic, Revelations came up with completely indigenous solutions which offer a host of health benefits while offering the clean sweetness. Revelations solutions are well adopted by the food industry worldwide by major food companies. Revelations technologies not only provide the healthy sweetening solutions but also scale and assured supply at cost almost at par with cane sugar prices.

Organization Profile

Revelations Biotech Pvt Ltd is sugar reduction solutions provider focusing on nature derived solutions harnessed through cutting edge biotechnology involving recombinant DNA technology, genome editing, synthetic biology, metabolic engineering and precision fermentation. The company develops and manufactures low calorie or zero calorie healthy alternate sweeteners of natural origin which are scientifically proven and validated to offer a host of health benefits. Revelations could demonstrate that these solutions are not only highly scalable but also cost effective and are readily adoptable by industry.

Website URL

<http://www.revelationsbio.com/>

Social Media Links

<https://www.linkedin.com/company/revelations-biotech-private-limited/>

Status of Commercialization

Revelations has already commercialized FOSLIFE and is about to commercialize a few more products.

Recent Achievements or Awards

1st Prize at IKMC, 2011

Address

Plot No 153 A&D, Phase-2, IDA, Cherlapally, Hyderabad TS 500051

Year of establishment

15-10-2008

Key Products/Services

FOSLIFE- A healthy sweet soluble function prebiotic fiber of fructo-oligosaccharides BRAZZEIN- An intensely sweet tasting protein which is over 500 times sweeter than sugar ALLULOSE- A sweet tasting zero calorie rare sugar

Supported under Scheme of BIRAC

BIPP



Name of Industry: SRI BIOAESTHETICS PVT LTD



Contact Person:
Dr KRK REDDY

Email:
drkrkreddy2017@gmail.com

Description of Exhibit

SRIBIO stands as a premier manufacturing hub for Agro-biologicals, blending cutting-edge technology, research-driven innovation, and a steadfast commitment to sustainability. Positioned at the forefront of modern agriculture, the company offers effective solutions to address farmers evolving challenges while prioritizing environmental stewardship. Central to SRIBIO's ethos is its dedication to sustainability, integrating eco-friendly production practices, waste reduction strategies, and renewable energy sources to minimize its environmental impact.

Organization Profile

Sri Bio Aesthetics Pvt. Ltd. SRIBIO is a leading manufacturer of agro-biological products focused on sustainable agricultural solutions. The company specializes in bio-pesticides, Bio stimulants, bio-fertilizers, Animal probiotic and other biological products designed to enhance crop productivity, plant and animal health, environmental sustainability. SRIBIO offers cost-effective solutions to modern agricultural challenges, enabling farmers to grow healthy crops while reducing dependency on chemical fertilizers and pesticides, thus ensuring the production of chemical-free food and protecting the environment. Additionally, the company R&D efforts are well-regarded and supported by entities such as the Department of Biotechnology DBT - Biotech Industry Research Assistance Council.

Website URL

<https://sribioaesthetics.com/>

Social Media Links

<https://www.linkedin.com/in/sri-bioaesthetics-pvt-ltd-6428ba251>

Status of Commercialization

For financial year 2023-24, production figures of few major products include 2,17,864 Kgs of Indi roots, 2,740 Kgs of Kriya, 830 Kgs of Kriya Micro rain, 6,540 Kgs of Kriya Plus, 1,020 Kgs of Micro Magnum, 660 liters of Novophos, 192 Kgs of Organogold SP, and 2,856 Kgs of Spectrum Bio

Recent Achievements or Awards

FCO, CIBRC, GMP, ISO, FSSAI, IBSC, NATIONAL BIODIVERSITY APPROVAL

Address

Plot No: G-49, TSSIC, MEDICAL DEVICE
PART, SULTANPURA, SANGAREDDY,
HYDERABAD.

Year of establishment

25-07-2016

Key Products/Services

INDIROOTS KRIYA PLUS HALOCHECK
NOVOPHOS BIO SPECTRUM MICRO
MAGNUM

Supported under Scheme of BIRAC

BIRAC BIG, PACE

Name of Industry: TTK Healthcare Limited, Heart Valve Division



Contact Person:
Dr. Anupama Raj

Email:
anupama@ttkhealthcare.com

Description of Exhibit

The TTK Chitra – Titanium Heart Valve Model TC2 is a rigid tilting disc mechanical heart valve substitute consisting of three components i a metal frame of Titanium alloy coated with Titanium Nitride, ii Ultra High Molecular Weight Polyethylene disc and iii sewing ring made of Polyethylene Terephthalate fabric, which is fixed around the metal frame. Model TC2 valve has completed its single center pilot study on 40 subjects conforming to the requirements of ISO 5940 and the Medical Device Rules, 2017 of CDSCO. This single center pilot study has been successfully completed with the financial support of NBM-BIRAC.

Organization Profile

TTK Healthcare, Heart Valve Division, has over 28 years of expertise in manufacturing and marketing heart valves. The TTK Chitra Heart Valve has been designed and developed by Sree Chitra Tirunal Institute for Medical Sciences and Technology SCTIMST, an institute of National importance under the Department of Science and Technology, Government of India. TTK Chitra Heart Valves are being used in over 400 cardiac centers across India with over 1,60,000 implantations since 1994. It's the first Indian made heart valve and one of the most affordable heart valves in the world.

Website URL

<https://www.ttkchitraheartvalves.com/>

Address

Plot No. A-28, KINFRA Apparel Park,
St. Xaviers College P.O., Thumba,
Thiruvananthapuram Kerala.

Year of establishment

21-05-1958

Key Products/Services

TTK Chitra Heart Valves

Name of Industry: BTL Biotechno Labs Private Limited



Contact Person:
Bharat

Email:
support@biotechnolabs.com

Description of Exhibit

BTL Biotechno Labs Pvt. Ltd. is a trusted provider of cutting-edge DNA solutions, offering cost-effective synthetic biology services. We support applications in diagnostics, precision medicine, and protein production. Our services include oligo and gene synthesis, protein expression, peptide synthesis, antibody discovery, and nanocarrier design for the Indian scientific community.

Organization Profile

We, BTL Biotechno Labs Pvt. Ltd. based in New Delhi, India are committed to being the most reliable supplier for life science research products in the entire Indian market. Our motive is to offer the highest quality products and custom biological services, including gene synthesis, antibody discovery, peptide synthesis, vector designing, nanocarriers, multiplex ELISA, recombinant protein synthesis, lateral flow assay development, and more. We prioritize expert technical support and the provision of up-to-date, accurate data to the research community, ensuring our offerings are both user-friendly and consistently reliable in performance.

Website URL

<https://www.biotechnolabs.com>

Social Media Links

<https://www.linkedin.com/company/33995809/admin/dashboard/>

Accreditations received (if any)

We serve more than 10000 clients in India.

Differential pricing model implemented in providing services

BTL Biotechno Labs Pvt. Ltd. offers a range of biological custom services, including gene synthesis, antibody discovery, peptide synthesis, vector designing, nanocarriers, multiplex ELISA, recombinant protein synthesis, and lateral flow assay development. Pricing varies for each service and is tailored based on the specific requirements and orders of each client.

Future Plans and Initiatives

BTL Biotechno Labs Pvt. Ltd. plans to expand globally, providing high-quality biological custom services to support researchers worldwide.

National/Societal Relevance

We provide biological custom services to academia, the health sector, pharmaceutical companies, and CROs, supporting their efforts in advancing life science research.

Address

620, Ansal Chamber - II, Bhiakji Cama Place,
New Delhi - 110066

Year of establishment

04-05-2017

Unique value proposition of the facility

Innovative Scientific Designs

Current Status of Facility

Under Development

Name of Industry: Embio Limited



Contact Person:
Aadya Malladi

Email:
aadya@embio.co.in

Description of Exhibit

We have capability of upstream process development, scale up and high cell density fermentation, whole cell biotransformation in yeast and bacteria, Downstream processing using counter current extraction, chromatography including adsorption, ion exchange, gel filtration, full-fledged Organic chemistry division for substrate synthesis and Semisynthetic derivative preparations and dedicated Analytical Development lab.

Organization Profile

Embio is a leading global player in the domain of controlled substances, advanced intermediates and chiral molecules for more than 30 years and has demonstrated an impeccable track record in compliance and credibility in this space. Embio's State of the Art manufacturing facility approved by US-FDA, PMDA, KFDA, COFEPRIS & WHO-GMP.

Website URL

<https://www.embio.co.in>

Accreditations received (if any)

Plant has accreditation from US-FDA, PMDA, KFDA, COFEPRIS, WHO-GMP and R & D has accreditation from ISO 9001-2015.

Differential pricing model implemented in providing services

Pricing is based on type of process and scale of operation. We offer concessional pricing for startups and institutional clients.

Future Plans and Initiatives

Our new facility is coming up at Dahej, Gujarat.

National/Societal Relevance

A technology developed by CDRI Lucknow in 1990 was improved by genetic engineering at MHRD institute in 2010 and scaled up by BIRAC SBIRI program in 2012. This technology is commercialized in 2019 leading to DBT National Award for process commercialization.

Address

E-21, MIDC industrial estate, Mahad, Dist.
Raigad, Maharashtra, 402302

Year of establishment

20-01-1986

Unique value proposition of the facility

We have capability of In-house development of GMO based biotransformation processes, Biotransformation capability from 10L up to 4 KL, Integration of chemistry & biotechnology for semisynthetic operations, Pilot plant for biotech & chemistry divisions, Functional IBSC-DSIR recognised lab with biosafety framework.

Current Status of Facility

Functional



Name of Industry: GNANLex Associates LLP



Contact Person:
Dr. Srividya Ravi

Email:
srividya@gnanlex.net

Description of Exhibit

Gnanlex Associates LLP specializes in all types of Intellectual Property Rights, chiefly focusing on Patents, Trademarks, Copyrights and Designs. Our services encompass search, filing, prosecution, enforcement, opposition, litigation and legal services. Gnanlex partners with IQzyme to provide services in ISO, CE marking and CDSCO consultations for medical devices and diagnostics.

Organization Profile

GNANLEX provides support for filing, prosecuting and enforcing Patents, Trademarks, Designs, Copyrights, and for drafting Agreements, Contracts and legal documents such as Complaints, Petitions, Reply, Rejoinder, Affidavits and Undertakings as well as help Start-ups and Incubators in their IP Matters.

Website URL

<https://www.gnanlex.net/>

Social Media Links

<https://in.linkedin.com/company/gnanlex-associates>

<https://in.linkedin.com/company/iqzyme-medtech-pvt-ltd>

Differential pricing model implemented in providing services

Gnanlex recognizes the unique position and requirement of start-ups and individual inventors. Therefore, Gnanlex works on the IP strategy for such applicants and handholds them throughout the process of securing IP protection globally, while simultaneously providing them a unique pricing model and advice on leveraging various schemes and grants.

Accreditations received (if any)

Gnanlex is a well decorated firm receiving World IP Forum - Influential and Visionary Leader. Our clients include fortune 500 companies, multinational companies, nationally funded research and educational institutions as well as start-ups, individuals and MSMEs.

Current Status of Facility

Functional.

Future Plans and Initiatives

Gnanlex envisions to be the most preferred national IP service provider. IQzyme aims to have a global footprint.

Address

Office No. 333 & 335, V-Mall, Asha Nagar, Sai-Dham, Thakur Complex, Kandivali, East, Mumbai- 400 101, Maharashtra.

Year of establishment

11-05-2015

Unique value proposition of the facility

Gnanlex Associates LLP is a law firm completely dedicated to Intellectual Property Rights. The firm provides end-to-end services in all forms of IPRs and is a one-stop solution for protection, enforcement and valorization of all creations. Similarly, IQzyme provides turnkey project consultation including regulatory support and certifications for medical products.

Name of Industry: Oniosome Healthcare Pvt. Ltd.



Contact Person:
Dr. Sarvesh Malviya

Email:
sarveshjain1@gmail.com

Description of Exhibit

Oniosome Healthcare P Ltd. is a Specialty Contract Research and Services Organization delivering the best end-to-end solutions to global pharmaceutical industry catering niche segment comprising of nano formulations, lyophilized, oncology injectables and other liquid and solid formulations.

Organization Profile

Oniosome has been engaged in the development of innovative Products for Pharmaceutical Companies interested to commercialize such Products. As a DSIR Approved unit focusing on Solutions pertaining to the areas: Solubility, Dissolution profile, Analytical validation, Development of lyophilized product, Stability study, Physical properties evaluation, Impurities, Compatibility Studies, Commercial Formulation Development.

Website URL

<https://oniosome.com/>

Social Media Links

<https://www.facebook.com/ZytexBiotech/>

<https://in.linkedin.com/company/zytex>

Accreditations received (if any)

DSIR, FDA, GLP, ISO

Future Plans and Initiatives

Oniosome Has initiated the another facility in Ahmedabad comprising the formulation and development, scale up, technology transfer and Analytical services

Address

Oniosome Healthcare Private Limited Plot No F-103 Phase 7, Industrial area SAS Nagar, Mohali-160055 PUNJAB INDIA

Year of establishment

11-05-2010

Unique value proposition of the facility

Committed manpower and dedicated facilities as evident from facilities set-up, investment in R&D and manpower deployed. Support to commercialize of products and accelerate market entry. Product Development based on innovative technologies. Process optimization, troubleshooting and analytical method. In-vitro Product Evaluation Support in Technology transfer; IPR/ Patent.

Current Status of Facility

Functional.

Name of Industry: S. Majumdar & Co.



Contact Person:
Amrita Majumdar

Email:
cal@patentindia.com

Description of Exhibit

Provides services in respect of Intellectual Property Laws IP, including filing and prosecution of patent applications, oppositions, revocations, patentability and infringement opinion freedom to operate FTO analysis in all areas of technology. Filing and prosecution of TM applications, availability searches and opinion on adoption and litigation.

Organization Profile

S. Majumdar & Co. SMC0 was founded in 1993 and which has since established itself as a leading Intellectual Property Firm manned with Lawyers with expertise in all areas of Intellectual Property Laws IP, authorized to represent client across all judicial and quasi-judicial forums. The Firm has professionals well-versed in engineering, telecommunications, software, electronics, chemistry, pharmaceuticals, life sciences. It also has a robust team handling IP litigations, across the country.

Website URL

<https://www.majumdarip.com/>

Social Media Links

<https://in.linkedin.com/company/s-majumdar-&-co-patent-&-trademark-attorneys>

Accreditations received (if any)

Clientele includes both domestic and foreign from various sectors. The firm represents Defence Research and Development Organisation DRDO ? Department of Atomic Energy DAE ? Department of Science and Technology DST ? Department of Biotechnology DBT ? Indian Council of Medical Research ICMR ? Indian Council of Agricultural Research ICAR ? Steel Authority of India SAIL ? Premier Engineering Institutes

Current Status of Facility

Functional

Differential pricing model implemented in providing services

Schedule of charges will be shared on request

Future Plans and Initiatives

To assist the industry with their IP needs

National/Societal Relevance

One of the top IP firms

Address

5 Harish Mukherjee Road, Kolkata,
Pin code - 700025

Year of establishment

15-11-1993

Unique value proposition of the facility

Firm has offices in strategic locations including Kolkata, New Delhi and Mumbai

Name of Industry: TACIT MEDTEK PRIVATE LIMITED



Contact Person:
Maya Singh

Email:
maya.singh@tacitmedtek.com

Description of Exhibit

USFDA 510 K filing CE Marking ISO 13485, MDSAP and ICMED Certification SaMD Registration India-Medical Device Import License MD-15 India Medical device Manufacturing License MD-5 & MD-9 CDSCO Registration BIS certifications.

Organization Profile

Tacit MedTek is a consulting company that provides regulatory guidance and quality compliance services to various manufacturers in the healthcare industry. We serve our clients by providing turnkey services, system implementation, training, licensing, regulatory approvals, and certifications. Tacit MedTek is a vibrant and customer-focused company that provides healthcare product manufacturers across the globe with US, EU & Indian medical device regulatory consultants services.

Website URL

<https://tacitmedtek.com/>

Social Media Links

LinkedIn- <https://www.linkedin.com/company/tacit-medtek/>

Instagram-<https://www.instagram.com/tacitmedtek?igsh=MTF2ejV4endmeG9lcA==>

Facebook- <https://www.facebook.com/tacitmedtek?mibextid=ZbWKwL>

Twitter X - https://x.com/TacitMedTek?t=y42b_Aj_7vUCYYV3Y1K8fQ&s=09

Differential pricing model implemented in providing services

Payment for medical devices is influenced by their risk classification, with higher risk classes necessitating increased fees. Additionally, the quality and completeness of documentation play a crucial role. Incomplete or inadequate documentation can result in extended processing times and additional costs.

Future Plans and Initiatives

We plan to launch a training program to Guide manufacturers and students regulatory strategy and quality compliance in medical devices.

National/Societal Relevance

Tacit MedTek plays a crucial role in enhancing the healthcare industry by providing expert regulatory guidance and quality compliance services to medical device manufacturers. Our impact is significant in several key areas: Strengthening Healthcare Product Compliance: We help manufacturers navigate complex regulatory environments in the US, EU, and India, ensuring that medical devices meet stringent safety and efficacy standards. This ensures high-quality, compliant products for patients. Supporting Make in India: We are working with various Indian Start-up companies and helping them for system implementation, training, licensing, regulatory approvals, and certifications to facilitate the entry of innovative medical devices into both global and local markets. This not only supports business growth but also enhances the availability of advanced technologies in India, improving healthcare outcomes. Enhancing Healthcare Infrastructure: By assisting manufacturers in obtaining and maintaining necessary certifications and approvals, we strengthen the healthcare infrastructure and improve overall healthcare delivery through adherence to high standards of quality and safety. Economic Impact: Our services drive economic growth by enabling market expansion and scaling operations for manufacturers. This contributes to job creation and stimulates economic development within the healthcare sector. Education and Training: We offer training programs that equip manufacturers with the necessary knowledge to navigate regulatory requirements, enhancing industry standards and practices. Commitment to Excellence: Tacit MedTek's dedication to regulatory excellence fosters a culture of safety and innovation, ensuring that healthcare products comply with both international and local regulations, thus supporting the delivery of effective healthcare solutions worldwide. In summary, Tacit MedTeks expertise supports regulatory compliance, market access, and economic growth, ensuring high-quality medical devices are available to meet the needs of patients and healthcare providers globally.

Address

Office No-240, 2nd Floor, Oak Tower,
Paramount Golf Mart, UPSIDC Site C,
Gulistanpur, Greater Noida, Uttar Pradesh
201306

Year of establishment

11-04-2023

Unique value proposition of the facility

Tacit MedTek excels in regulatory consulting by offering tailored services from system setup to license approvals across the US, EU, and India. Our expert team, customer-focused approach, and advanced tools ensure accurate, timely assistance, helping clients meet global standards and succeed in international markets.

Current Status of Facility

Functional

Accreditations received (if any)

We have worked for clients globally including US, UK, China, India and various others. We have completed various projects in the field of pharmaceuticals, cosmetics and Medical Devices. We have provided support to various Medical Device start-ups. We have helped our clients to obtain manufacturing license, test license, and Import license. We have also assisted our clients with global market entry, including US FDA 510 k filings, helping clients sell products worldwide.



Name of Industry: Texnano Technologies Pvt Ltd



Contact Person:
Shantikumar Nair

Email:
nairshanti@gmail.com

Description of Exhibit

Facilities: R&D Biomolecular Labs 36,000 sq ft GMP Bio-manufacturing Lab 18,000 sq ft GLP small animal and large animal labs: 20,000 sq ft biorepository 5000 sq ft scientific and bio-manufacturing know-how Services: Laboratory molecular testing cell culture in vitro testing GMP bio-Manufacturing small animal testing. and product validation.

Organization Profile

Non-Profit Section 8 Company. Site of operations: Amrita Research center. Delhi and Amrita Center for Nanoscience and Molecular Medicine, Kochi, Kerala. Both sides are attached to Amrita Hospitals - a 1000-bed multi-specialty hospital in Kochi and a 2600-bed multi-specialty hospital in Delhi so that company can provide direct translational pathway to hospital and clinical trials and clinical validation. Unique features include GMP Biomanufacturing capability with expertise, incubation opportunities and joint development opportunities, advanced laboratory testing and validation services and clinical services All in one place.

Website URL

<https://texnano.in>

Social Media Links

<https://www.linkedin.com/company/texnano/>

Differential pricing model implemented in providing services

Pricing slabs based on: for-profit clients, non-profit clients and government clients. Texnano being a non-profit, prices will be much less than commercial rates.

Future Plans and Initiatives

Cell Therapy Products, AI in Medical applications, Bioelectronic devices.

National/Societal Relevance

Capacity building for make in India biomedical product development Incubation Support for startups at affordable rates Training/internships for students.

Address

Amrita Research Center Mata
Amritanandamayi Marg Sector 88
Faridabad Haryana 121002

Year of establishment

19-07-2020

Unique value proposition of the facility

This is a non-profit dedicated to affordable biomedical product development and capacity building. Terms of service include pay-preservice mode with complete confidentiality and IP protection or partnership mode with IP sharing or some combination of the two. Services are offered in Faridabad Delhi NCR and Kochi, Kerala.

Current Status of Facility

Functional

Accreditations received (if any)

Accreditations product-wise 4 clients served





DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology



ACADEMIA EXPO

(Pg. No. 244-265)

Global Bio India 2024: List of Participants

S.No.	IBRIC Institutes	Page Number
1.	Centre for DNA Fingerprinting and Diagnostics (BRIC-CDFD), Hyderabad	245
2.	Institute For Stem Cell Science and Regenerative Medicine (BRIC-INSTEM), Bengaluru	246
3.	Institute of Bioresources and Sustainable Development (BRIC-IBSD), Imphal	246
4.	Institute of Life Sciences (BRIC-ILS), Bhubaneswar	247
5.	International Centre For Genetic Engineering and Biotechnology (ICGEB), New Delhi	247
6.	National Agri-Food Biotechnology Institute (BRIC - NABI), Punjab	248
7.	National Brain Research Centre (BRIC-NBRC), Gurugram	248
8.	National Centre for Cell Science (BRIC-NCCS), Pune	249
9.	National Institute of Animal Biotechnology (BRIC - NIAB), Hyderabad	249
10.	National Institute of Biomedical Genomics (BRIC - NIBMG), Kalyani	250
11.	National Institute of Immunology (BRIC - NII), New Delhi	250
12.	National Institute of Plant Genome Research (BRIC-NIPGR), New Delhi	251
13.	Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Thiruvananthapuram	251
14.	Regional Centre for Biotechnology (RCB), Faridabad	252
15.	Translational Health Science and Technology Institute (BRIC- THSTI), Faridabad	252
Research Institutions/Universities/NGOs		
1.	Amity University	253
2.	Atmiya University (E-Yuva Center)	253
3.	Bangalore Bioinnovation Centre	254
4.	CSIR-Central Drug Research Institute, Lucknow (CDRI)	254
5.	CSIR Indian Institute Of Chemical Biology	255
6.	CVJ Centre for Synthetic Biology and Bio-manufacturing	255
7.	Electron Microscope Facility, SAIF-AIIMS New Delhi	256
8.	Indian Institute of Technology Delhi	256
9.	Indian Institute of Technology Guwahati	257
10.	Institute for Applied Research and Innovation InARI	257
11.	Integral University	258
12.	Interactive Research School for Health Affairs, BVDU	258
13.	Jawaharlal Nehru University Participants: School of Biotechnology	259
14.	JSS College of Pharmacy	259
15.	La Trobe University	260
16.	Mauritius Institute of Biotechnology Ltd	260
17.	National Research Development Corporation, New Delhi	261
18.	Sadguru Netra Chikitsalaya, Shri Sadguru, Seva Sangh Trust	261
19.	Sathyabama Institute of Science and Technology	262
20.	Shiv Nadar Institution of Eminence Deemed to be University Delhi/NCR	262
21.	Shriram Institute for Industrial Research Gurugram	263
22.	SRM Institute of Science & Technology	263
23.	University of Birmingham	264

Name of the Institute : Centre for DNA Fingerprinting and Diagnostics (CDFD)



Contact Person
Dr. Varsha, Staff Scientist-VI

Email
director@cdfd.org.in; scom@cdfd.org.in

About the Institute

CDFD is an autonomous institute under the Department of Biotechnology, Govt. of India. This is one of the leading institutions in India which provides services and training in the areas of DNA profiling and diagnostic testing for genetic diseases, and also spearheads basic research in diverse areas of modern molecular biology. Both services and research activities run parallel and enrich each other. This combination of high-calibre services and research at the Centre has emerged as a unique model that strives for academic excellence knitted with social relevance. We have publications in international peer reviewed journals of high repute like Nature, Science, etc. and also have patents to our credit. The contributions of CDFD scientists have been recognized with several accolades, honors and awards. These include the Padma Shree, Shanti Swarup Bhatnagar prize, fellowships of all the three national academies, and several others. The Centre currently houses more than hundred research scholars working for their PhD degree. CDFD offers outstanding outreach activities by hosting visits from educational institutions nationwide and by organising Open Days and several other outreach activities. This provides students with valuable exposure to the advanced research being conducted at CDFD.



Area of Expertise available

microbiology, disease biology, cell biology, computational biology, developmental biology, genetics, and genomics

Facilities available for Start-ups

CDFD Technology Incubator has state-of-the-art infrastructure and the high-end equipment for shared R&D in the field of life sciences and related disciplines. The start-ups get access to CDFD's strong network of hospitals, universities, academic institutes, govt./private organisations and other innovation ecosystem enablers. iDeaNA-CDFD Technology Incubator has constituted a mentor pool of several seasoned personnel from various fields to provide tailored advice for navigating the day-to-day challenges.



Name of the Institute : Institute for Stem Cell Science
and Regenerative Medicine, Bangalore



Contact Person (for GBI 2024)
Dr. Ketan Thorat, Scientist D, iBRIC-inStem (ketant@instem.res.in)
Dr. Sabuj Bhattacharyya, Scientist C, iBRIC-inStem (sabujb@instem.res.in)

Email
info@instem.res.in

About the Institute

iBRIC-inStem's scientific program is primarily allied to areas of stem cell research that bolster translational and regenerative medicine. Our programs include focused research in cardiovascular disease, metabolic disorder, barrier dysfunction and brain development and disorders. On the one hand, teams working to decipher the metabolic regulation of cell fate examine the effect of varying environmental conditions on cellular behaviour with special focus on stem cells. On the other, models for investigating neurodevelopmental, cardiac and gut disorders are developed by groups focused on disease physiology. Additionally, a few research groups also pursue chemical biology approaches to generate therapeutic leads and support scaffolds for stem cell-based therapies. In the pursuit of modern medical interventions for genetic disorders such as hemoglobinopathies by our unit at Vellore – the Centre for Stem Cell Research (CSCR) – a gene therapy clinical trial for haemophilia is underway. Further novel approaches to prime editing in hematopoietic cells have been devised to correct sickle cell disease and thalassemia.

Support received from BIRAC (If any) (100 Words)

inStem has been a recipient of several competitive BIRAC grants including Biotechnology Ignition Grants (BIGs), BIRAC-PACE, and Mission COVID Suraksha. Currently the BIRAC supported projects are focused at pre-clinical evaluation of promising drugs for a rare syndromic cardiomyopathy in children; creation of animal models for enabling COVID-19 vaccine and therapeutics development; understanding the pathogenesis and long-term effects of SARS-CoV-2 variants to enable the development of new antiviral modalities; and creation of pre-clinical Indian ancestral-specific human organoids and novel knock-in rat models to study inheritable heart failure. Several technologies developed.



Thrust Area (100 Words)

- Cardiovascular development and disease mechanisms
- Chemical Biology Approaches for Stem Cells and Therapeutics
- Mechanisms Regulating Barrier Tissue Homeostasis
- Modelling neurodevelopment and disease
- Metabolic Regulation of Cell Fate
- Gene Therapy for Rare and Genetic disorders

Area of Expertise available

- Stem Cell Biology and Regeneration
- Developmental Biology
- Stem cell-based embryo and organ models to study health and diseases
- Biomaterials for unmet clinical needs
- Chemical Biology
- Gene Therapy
- Research Ethics and Integrity
- Regulatory Compliances in Life Science Research
- Cryo Electron Microscopy
- Multimics
- Genome editing in small animals

Specialized Equipment

- Stem Cell Facility
- Next Gen. Genomics
- Sanger Sequencing
- Mass Spectrometry - Proteomics
- Mass Spectrometry - Lipidomics & GC-MS
- Mass Spectrometry - Metabolomics
- Mass Spectrometry - Glycomics
- Central Imaging & Flow Cytometry Facility
- Electron Microscopy
- NMR Spectroscopy
- Animal Care Resource Centre
- Mouse Genome Engg. Facility
- Transgenic Fly Facility
- X-Ray Crystallography
- Biosafety Facility (BSL-2 labs active and ABSL-3 in making)
- Stem Cell Facility (# of user labs)
- C. elegans Facility
- CryoEM facility

Facilities available for Start-ups

The institute is nested within the Bangalore Life Science Cluster that involves Centre for Cellular and Molecular Platforms (C-CAMP) a leading start-up incubator. Operating within this thriving research and innovation ecosystem, inStem researchers have access to C-CAMP expertise for translation of their innovations.

The institute also regularly consults the Office of Technology Transfer (OTT) at C-CAMP to facilitate the filing of intellectual property (IP). The institute is one of the firsts to develop a comprehensive policy to encourage development and commercialization of inventions and innovations from inStem. This policy offers a clear pathway for academic innovations to be translated into market.

Name of the Institute : BRIC- Institute of Bioresources and Sustainable
Development, Imphal, Manipur



Contact Person
Prof. Pulok Kumar Mukherjee, Director

Email
pulokm@gmail.com

About the Institute

Institute of Bioresources and Sustainable Development is the only institute in North Eastern Region of India in the ambit of Biotechnology Research and Innovation Council (BRIC) under the Department of Biotechnology, Ministry of Science and Technology, Govt. of India established at Imphal, Manipur. For the development of bioresources and other outreach activities, BRIC-IBSD has established three Centres in NER including Gangtok in Sikkim, Shillong in Meghalaya and at Aizawl in Mizoram. Since inception, BRIC-IBSD has been engaged in research activities and numerous outreach programmes to fulfil the mission for "Bioresources development and their sustainable use through biotechnological interventions for the socio-economic growth of the North Eastern Region". This region falls under Indo-Burma biodiversity Hotspot which is one of the biodiversity Hotspots of the world and very unique in terms of bioresources including plants, microbes, animals with diversity of indigenous people, their traditional knowledge.

BRIC-IBSD has been engaged in research activities and numerous outreach programmes for the development of bioeconomy from bioresources. BRIC-IBSD is committed for integration of multi-disciplinary, inter-disciplinary and multi-stakeholder research on bioresources of NER. IBSD is working on different research areas to promote the bioresources of NER and integrated study for their scientific validation, value addition to propel innovations, discoveries and inventions for catalysing the growth of industry in the region for livelihood generation and boosting bioeconomy from bioresources.

Support received from BIRAC (if any)

For the promotion of Start-ups in NER, BRIC-IBSD has setup Bioincubators Nurturing Entrepreneurship for Scaling Technologies (BioNEST) incubator at Shillong to develop women bio-entrepreneurship through orchid floriculture in Meghalaya with support from Biotechnology Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Govt. of India. Major focus of this programme is capacity building and training of women bio-entrepreneurs from different parts of Ri-Bhoi, Aspirational District of Meghalaya. Under this programme, 100 women entrepreneurs have been trained and encouraged for orchids cultivation and propagation. This project is implemented through a Hub & Spokes model at Umsning Block of Ri-Bhoi district of Meghalaya and provided with Dendrobium orchids planting materials and infrastructure.



Thrust Area

For the development of integrated multi-disciplinary research and innovation programs, BRIC-IBSD is synergizing different research areas including phytopharmaceutical mission, ethnobotany, ethnopharmacology & drug discovery, medicinal plant resources, microbial resource, animal resources and water quality management & surveillance to boost the bioeconomy with the development of processes/ products/ technologies from the bioresources of NER.

Area of Expertise available

- Phytopharmaceuticals, ethnobotany, ethnopharmacology & drug discovery
- Microbial resources including fermented foods
- Medicinal plant resources
- Animal resources including edible insects
- Water quality management & surveillance

Facilities available for Start-ups

- BioNEST Incubator
- Phytopharmaceutical Laboratory
- Microbial Repository Centre
- Genomics facility
- Central Instrumentation Facility (CIF)
- Hydro Distillation Units for mass scale extraction of essential oils from aromatic plants

Specialized Equipment

Next generation sequencers (MiSeq, NextSeq), Confocal Microscope, LC-MS-MS, GC-MS, DNA Sequencer, RT-PCR, HPLC system, HPTLC, Bioanalyzer, AktaPrime system, SureScan microarray scanner, Flash chromatography, Multimode extraction system, Microplate reader, Plant growth chambers, Plant tissue culture, UV-VIS spectrophotometer, Incubator, Freeze Drying System, Bio-incubator, Biosafety cabinet, BOD incubator, Molecular imager/Gel Doc, Compound microscope, Phase contrast microscope, Thermal cycler (PCR), Electrophoresis Unit, circulator water bath, Ice Flaking Machine, Bench top UV Trans-illuminator, Laminar Air Flow bench (horizontal), Laminar Air Flow bench (vertical), LOM-150 Refrigerated shaker incubator, Micro Centrifuge, Microbial colony counter, Multichamber Incubator, Rotary evaporator, Shaking Incubator, walk-in plant growth chamber, Oil extraction systems, Shaking water bath, deep freezers, Gradient PCR, Ultra Low Deep freezer (-86 °C), Ultrasonic water bath, Water bath, Water purification system, Water Quality meter Aquared AP 200, Horizontal gel electrophoresis unit, Experimental fields and farms, polyhouses, nethouses.

Name of the Institute : BRIC-Institute of Life Sciences



Contact Person (for GBI 2024)
 Dr. Debabrata Biswas

Email
 scienceoutreach@ils.res.in

About the Institute

BRIC-ILS is established with the overall mandate to work for the betterment of Human Health and Welfare. The vision and mission of the institute are to conduct fundamental and translational research in the frontier areas of Life Sciences, to develop globally competitive human resources through training in cutting-edge areas of biology and to disseminate scientific knowledge to the general public and the student community.

Support received from BIRAC (If any)

BIRAC has supported ILS in the last few years by funding individual PI-centric projects and platform facilities. BIRAC has so far funded 2 projects under the PACE scheme and 1 project under the BIG grant. With support from BIRAC under COVID-19- SURAKHYA MISSION, a comprehensive immunogenicity platform is established for product development for viral diseases. BIRAC has supported a National Level Animal Biosafety Level -3 (ABSL-3) for small animal breeding, rearing and conducting COVID-19 related experiments.



Thrust Area

The research activity of BRIC-ILS focuses on basic, applied, translational, and interdisciplinary areas. The ongoing research activities are aimed at strengthening institutional innovation and aligning our research with the DBT-recognized thematic sectors of Bio-manufacturing. BRIC-ILS has identified several short-term and long-term research initiatives to facilitate precision therapeutics for biomedical application and climate-resilient agriculture.

Area of Expertise available

Infection and Immunity
 Cancer Biology
 Plant Biotechnology
 Interdisciplinary Biology

Specialized Equipment

- Flow Cytometry - CyTOF, Cytex Aurora, LSR Fortessa, MoFlo Astrios
- Genomics Facility - NovaSeq 6000, NextSeq 550
- Microscopy - SEM, TEM, Apotome, STED Confocal, High Content Cx7 LR
- ABSL3 & BSL3
- Proteomics Facility -TSQ Quantis plus Triple Quadrupole Mass Spectrometer

Facilities available for Start-ups

- Bio-incubator
- Biorepository
- Bio-validation
- Animal House facility
- Zebrafish facility
- Genomics
- Proteomics & Metabolomics
- Protein Crystallography
- Green House
- Imaging facility

Name of the Institute : International Centre for Genetic Engineering and Biotechnology (ICGEB New Delhi)



Contact Person
 Dr Ramesh V. Sonti

Email
 director@icgeb.res.in

About the Institute

The International Centre for Genetic Engineering and Biotechnology (ICGEB) in New Delhi is a premier research institute dedicated to advancing biotechnology for global health, agriculture, and environmental sustainability. As one of three global ICGEB centres, it plays a crucial role in fostering scientific research and international collaboration in the life sciences. ICGEB New Delhi is renowned for its cutting-edge research in biotechnology. Our work spans a broad spectrum, from developing innovative vaccines and therapeutics to pioneering advancements in plant biotechnology and biofuel production. With state-of-the-art laboratories and a dynamic research environment, the centre is at the forefront of scientific discoveries, addressing some of the world's most pressing challenges such as food insecurity, climate change and disease burden. What distinguishes ICGEB New Delhi is its commitment to nurturing young scientists. Through extensive training programs, workshops, and collaborative projects, it empowers youth and researchers from around the globe, promoting a spirit of innovation and scientific inquiry. This vibrant scientific community, driven by a shared commitment to excellence, continues to make significant contributions to the global scientific landscape. ICGEB New Delhi also serves as a hub of international cooperation, building partnerships that transcend borders. Its efforts are integral to the global endeavour to improve human health, protect the environment, and enhance agricultural productivity, making it a cornerstone of scientific progress in the developing world.

Support received from BIRAC (If any)

Following projects were supported by BIRAC at ICGEB 1. Project Title: Development of saracatinib based immunomodulatory regimens for treatment of MDR tuberculosis Period: 17.2.2023 TO 16.12.2024 2. Project Title: Preclinical development of a broadly neutralizing SARS-COV-2 specific human monoclonal antibody Period: 12.3.2024 to 11.3.2026 3. Project Title: Translational research consortia TRC for Chikungunya virus. Period: 30.5.2019 to 29.6.2024

Specialized Equipment/Facility

TEM & Ultramicrotomy, NMR, X-ray crystallography, BSL3-Virology, Tuberculosis Aerosol Challenge Facility, animal house, ICP-MS facility, Super Resolution Facility, Laser Scanning Confocal facility, Flow cytometer, GC FID facility, Green Houses etc.



Thrust Area (100 Words)

Infectious Diseases: Research in this area focuses on understanding the molecular mechanisms of infectious diseases, developing vaccines, and creating therapeutic strategies to combat diseases such as malaria, dengue, chikungunya and tuberculosis.

Plant Biology and Biotechnology:

This area is dedicated to enhance crop yield and stress resilience using biotechnological tools. It also includes research on plant-microbe interactions and the development of biofortified crops. **Human Health and Molecular Medicine:** Our labs work on identifying the genetic and molecular basis of diseases, including cardiovascular diseases. **Structural and Computational Biology:** This thrust area focuses on understanding the structure and function of biomolecules using advanced techniques like X-ray crystallography and NMR.

Biotechnology for Environmental Sustainability: Research in this area includes developing biofuels, bioremediation strategies, and environmentally friendly bioproducts. The focus is on harnessing biological systems to address environmental challenges and promote sustainability.

Translational Bioinformatics:

This area focuses on leveraging computational tools and data-driven approaches to translate biological research into practical healthcare applications, particularly in genomics and medicine.

Area of Expertise available

In Molecular medicine, including the development of vaccines, therapeutics including monoclonal antibodies and small molecules, structure-aided drug design, and diagnostics. Systems biology, synthetic biology, and biomanufacturing, including carbon capture and 1G, 2G, 3G, and 4G biofuels. NMR and X-ray crystallography. Plant biotechnology including transgenics, genome editing, and genomics-assisted breeding. Big data analysis, artificial intelligence and bioinformatics

Facilities available for Start-ups

All listed facilities are available

Name of the Institute : BRIC-NABI



Contact Person
Dr. Meena Krishania

Email
edoffice@nabi.res.in; ashwani.p@nabi.res.in; meena@ciab.res.in

About the Institute

As an autonomous R&D Institute under the Department of Biotechnology, Government of India, our institute stands at the forefront of cutting-edge research, seamlessly integrating agricultural, food, and nutritional biotechnology with advanced biomanufacturing. Our mission is to pioneer innovative solutions that elevate the quality of food and nutrition while fostering sustainability through eco-friendly practices. We focus on:

1. Utilizing biotechnological strategies to enhance yield and nutritional value.
2. Leveraging renewable resources.
3. Eliminating harmful chemicals.
4. Selecting optimal raw materials to minimize waste.
5. Designing innovative processes and effective models for sustainable production.
6. Recycling and repurposing production and post-consumption waste.

Our institute boasts strong collaborations with prestigious national and international organizations and industries. Strategically located within the agri-food cluster in the "Knowledge City" of Mohali, Punjab, we work alongside neighboring institutes to drive forward our vision of a sustainable and nutritionally secure future.

Support received from BIRAC (If any) (100 Words)

BIONEST incubator

Thrust Area (100 Words)

- Bio-based Chemicals and Enzymes
- Functional Foods and Smart Proteins
- Carbon Capture and Utilization
- Climate-Resilient Agriculture

Area of Expertise available

Chemical Engineers, Biochemical Engineers, Chemists and food technologists, biotechnologists, microbiologists, nutritionist and agricultural specialists etc

Specialized Equipment

- Bioprocessing facility (fermenter and downstream process)
- Proteomics and Metabolomics (GC, MS/MS; LC, HPLC- UPLC with MS and Triple Q-TOF; MALDI-TOF-TOF; QTRAP; HPTLC; LA-ICP-MS, NIR and FTIR etc)
- Animal cell culture facility
- Param Smriti - Super computer
- SPEEDY SEEDS- speed breeding facility

Facilities available for Start-ups

1. BIONEST incubator and research labs (support from BIRAC)
2. SPEEDY SEEDS
3. Gene editing centre
4. Super computer
5. Animal house
6. Bioprocessing infra
7. Advanced Proteomics, metabolomics and ionomics

Name of the Institute : NBRC



Contact Person
Bhvani Sahu, Anindya Ghosh Roy, Seepika

Email
director@nbrc.ac.in

About the Institute

The National Brain Research Centre (NBRC) is dedicated to advancing our understanding of brain function in both health and disease. It conducts interdisciplinary neuroscience research, trains skilled human resources, and promotes neuroscience in India through a network of institutions nationwide. Recognized as an Institute of Excellence by the Government and a deemed-to-be University, NBRC offers Master's and PhD degrees in neuroscience and holds a leading position in the field. With state-of-the-art laboratories and facilities comparable to any international institution, NBRC's multidisciplinary team of scientists explores all aspects of neuroscience, from molecules to the mind, using various in vivo and in vitro models, as well as human studies. Their research spans multiple sub-disciplines, including Cellular and Molecular Neuroscience, Systems Neuroscience, Cognitive Neuroscience, Computational Neuroscience, and Translational Research. NBRC scientists have developed several innovative technologies, such as non-invasive techniques like Magnetic Resonance Spectroscopy (MRS) to detect early signs of dementia, behavioral assessment tools for Dyslexia in Indian languages (DALI), and drugs to reduce brain inflammation caused by viral infections. In future, NBRC aims to embark on a more ambitious project to develop expertise in studying neurodevelopmental disorders which includes Autism and Intellectual deficiency syndrome using clinical and preclinical approaches.

Thrust Area (100 Words)

The key focus area of NBRC is brain research in both basic and clinical contexts. Current research at NBRC includes studies on mild cognitive impairment (MCI), metabolic regulation of glial cell carcinoma, molecular mechanisms of flavivirus and Zika virus infections, nerve regeneration, the role of long non-coding RNA in stress and memory function maintenance, nerve secretion, neuroinflammation, and brain organoid development. Additionally, NBRC is embarking on a consortia-based project to develop biomarkers for Autism Spectrum Disorder (ASD) and to understand the comorbidity issues related to ASD using pre-clinical models and cohort data.

Area of Expertise available

MRI and MEG imaging and data analysis, multiphoton imaging and data analysis,

Specialized Equipment

fMRI, MEG, dual laser multiphoton system, confocal microscopes, neuro-lucida facility

Facilities available for Start-ups

Animal House facility for Rodents and non-human Primate

fMRI with data analysis and server storage facility

MEG with data analysis and server storage facility

Dual Laser Multiphoton System

Confocal and other microscopy facility

C. elegans culture facility

Tissue Culture facility



Name of the Institute : National Centre for Cell Science (NCCS)



Contact Person
Dr. Jyoti Rao

Email
jyoti@nccs.res.in, nccstalks@gmail.com

About the Institute

The Biotechnology Research and Innovation Council - National Centre for Cell Science (BRIC-NCCS) has a tripartite mandate encompassing:

- (i) Basic research in cell biology
- (ii) Human resource development
- (iii) Serving as a national repository for animal cell lines.

For more than 35 years, BRIC-NCCS has been contributing to India's excellence in biomedical science through cutting-edge interdisciplinary research in cell biology.

Support received from BIRAC (If any)

Support has been received under the BIRAC-NBM Project for the Establishment of a GMP-compliant National Repository for banking, safe deposit and supply of characterized mammalian cells for use in biopharma.

Specialized Equipment

• Bio-Imaging Facility 1. Zeiss LSM 880 Confocal Microscope with AiryScan and Elyra P1 – High Resolution system. 2. Thermo Scientific CellInsight CX7 LZR – Confocal based High Content Screening System 3. Leica TCS SP5 II Confocal Microscope 4. Olympus FV 3000 with Olympus Super resolution 5. Olympus Spin SR10 • Flow Cytometry Facility, Cytex Aurora, FACS Canto II, FACS Aria III SORP, MoFlo Astrios EQ • Bioinformatics Facility, GPU computing HP Proliant SL6500, SGI Altix XE 1300 Cluster, HPZ820 High End work station iMAC, HP Elite 8200 CMT PC, HP Z800 High End Workstation • Proteomics Facility * Orbitrap Fusion Tribrid LC-MS/MS system. * Triple ToF 6600+ system * 6500 Q-Trap LC-MS/MS system (Sciex) • DNA Sequencer, ABI 3730 DNA sequencer, Illumina Miseq • X ray Diffraction Facility • Surface Plasmon Resonance Facility • Scanning Electron Microscope • In vivo imaging



Thrust Area

BRIC-NCCS has 21 research groups that work in one or more of the research areas listed under 'areas of expertise'.

The research at NCCS is aimed at addressing challenging questions about human health, especially those related to cancer, diabetes, infectious diseases, functioning of the immune system, regeneration of bone and other tissues, gut microorganisms in health and disease, stem cell biology, etc. Through achieving the proximal goal of understanding the basic biology of cells, NCCS aspires to contribute towards improving diagnostic methods and treatment regimens / therapeutics for the management of diseases, in the long run.

Area of Expertise available

- A. Research Areas:
1. Biology of cancer and other non-communicable diseases.
 2. Pathogenesis and cellular response.
 3. Stem cells and regeneration.
 4. Neuroscience.
 5. The human microbiome and microbial taxonomy.
 6. Cell organization and function
 7. Genome architecture and regulation
 8. Regulatory RNAs and gene expression
 9. Macromolecular structure and cell function
- B. Cell repositories for animal cell lines and microbial cultures: We supply animal cell cultures and microbial cultures, and provide associated services and training, such as cell line authentication, mycoplasma testing, deposition of microbial cultures for patent purposes and of cell lines, microbial identification tests, etc.
- C. Capacity building: Through academic programmes including the PhD programme, summer internships, research project training and training workshops.

Facilities available for Start-ups

Services and usage of central facilities and animal cell repositories are available on a chargeable basis.

Details are available on the BRIC-NCCS website. QR codes to the facilities and user charges webpage are given below:



Name of the Institute : BRIC- National Institute of Animal Biotechnology (NIAB), Hyderabad



Contact Person
Harjit Singh

Email
sm@niab.org.in

About the Institute

NIAB, is aimed to harness novel and emerging biotechnologies and create knowledge in the cutting edge areas for improving animal health and productivity. The Institute's research focus is on animal health and production with an special emphasis on Reproductive Biotechnology, infectious biology, Genomics, transgenesis, stem cell biology, nutrition, Nano biology and bioinformatics. The Institute aims at translational research leading to genetic enhancement of Indian Livestock species and basic research towards development of novel vaccines, diagnostics various organoids and improved therapeutic molecules for farm animals. NIAB is focusing on basic as well as translational science and capacity building in the area of animal biotechnology

Support received from BIRAC (if any)

BIRAC has funded extra mural projects to the scientists



Thrust Area

NIAB is aimed to harness novel and emerging technologies and take up research in contemporary areas for improving animal health and productivity. The ultimate aim is the improvement of animal health as well as qualitative and quantitative enhancement in livestock and poultry products for human consumption and hence food security. NIAB's mission is to contribute to a sustainable and globally competitive livestock-based economy through cutting-edge research & development. Its vision is to demonstrate excellence in science, and to develop technology and solutions in animal biotechnology, leading to eventual commercialization.

Area of Expertise available

Animal Biotechnology

Facilities available for Start-ups

NIAB incubation facility consist of approx. 250000 sq feet built up area which can be given to start ups. There are few minor equipment's which will be part of the facility and other major instruments under Central Instrument Facility are also available on payment of charges.



Name of the Institute : BRIC-National Institute of Biomedical Genomics



Contact Person
Debasish K. Mondal

Email
dkm1@nibmg.ac.in

About the Institute

The National Institute of Biomedical Genomics (NIBMG) has been established as an autonomous institution by the Government of India, under the aegis of the Department of Biotechnology. This is the first institution in India explicitly devoted to research, training, translation & service and capacity-building in Biomedical Genomics. It is located in Kalyani, West Bengal, India, near Kolkata.

The research focus of the institute is to understand the molecular basis of disease using genomics and integrative biology, as well as functionalization of genomic leads. Such knowledge is translated for enhanced prediction, prevention and cure and also provides us with the insight into mechanism of disease development and progression. NIBMG laboratories are equipped with high end instruments and state of art facilities. The huge 30 acre campus of the Institute has academic blocks, student and faculty housing, guest houses, conference centre and other facilities.



Thrust Area

Biomedical genomics in context of Cancer, Host-pathogen interaction, complex disorders along with Statistical genomics and computational biology

Area of Expertise available

The strength of NIBMG is in its unique combination of genomics based and allied multi-omics wet and dry lab high-throughput facilities for big data generation, analysis and integration for solving human biomedical problems of prediction, diagnosis and prognosis. NIBMG is the hub of technological expertise in genomics and associated platform technologies including organoid and metagenomics fields. Some of the expertise include genomics data generation and analysis, proteomic analysis, pre-clinical testing of small molecules for cancer cure/prevention, understanding host-microbiome interaction, statistical and computational genomics,

Facilities available for Start-ups

Genomics facility, High performance computing facility, Proteomics facility, Human microbiome facility, Bacteriological facility, radioactivity facility, BSL3 facility, and access to instruments such as Bioplex, confocal microscope, FACS, DD-PCR and Ultracentrifuge

Name of the Institute : National Institute of Immunology



Contact Person
Dr Debasish Mohanty

Email
director@nii.ac.in

About the Institute

Since its inception in 1986, the National Institute of Immunology (NII) has been at the forefront of unravelling the intricacies of this immune system for human health and wellbeing. NII is one of the foremost institutions under the Biotechnology Research and Innovation Council of the Department of Biotechnology dedicated to conducting cutting-edge research in immunology. In the past four decades, there has been significant progress in our ongoing efforts to develop new lines of research at NII. Today, researchers at NII are trying to address interdisciplinary research questions in areas of biological sciences spanning from immunology, infectious and chronic disease biology, molecular and cellular biology, chemical biology, and structural biology to computational biology. We at NII have access to scientific and technical facilities of international standards, which has made cutting-edge research in emerging areas like genomics, proteomics, systems biology, and computational biology possible. Bringing together interdisciplinary research themes to better understand the immune system, NII is committed to developing better diagnostics, treatments, and vaccines against diseases. In the past year, research carried out at NII has given rise to innovations that find applications from vaccine development to immunotherapeutics to the treatment of cancers, neurodegenerative disorders, and infectious diseases. The research excellence of NII is reflected in the national and international acclaim won by our scientists and students for their contributions to the field of immunology. NII recognizes that developing research ecosystems that produce high-quality research requires interventions to build capacity. NII runs an academic program for doctoral research and offers training to undergraduate and postgraduate students through various programs. Additionally, NII invests in activities that promote understanding of the frontiers of biomedical research and build opportunities for collaborative science. To foster scientific temper and interest in science and technology among the youth, NII conducts an array of programs that help people especially young students connect with new scientific advances. NII is committed to make scientists accessible as role models to make science more appealing to students as well as bridge the gap between science and society.

Support received from BIRAC (If any)

BIRAC funds a number of projects at NII focused on the development of vaccines and therapeutics against infectious diseases like dengue and malaria. In one of the BIRAC-funded projects, a Translational Research Consortium has been set up to establish platform technologies to support prophylactic and therapeutic strategies for dengue (discovery to proof-of-concept). BIRAC has also facilitated studies on multi-stage malaria vaccine candidates for the prevention of Plasmodium falciparum infection. Notably, BIRAC has supported the development of a novel vaccine evaluation platform to support SARS-CoV-2 vaccine development in resource-limiting settings.



Thrust Area (100 Words)

The National Institute of Immunology (NII) is one of the foremost institutions under the Biotechnology Research and Innovation Council of the Department of Biotechnology, Govt of India dedicated to conducting cutting-edge research in immunology and allied sciences. Bringing together interdisciplinary research themes to better understand the immune system, NII is committed to developing better diagnostics, treatments, and vaccines against diseases and promoting human health.

Area of Expertise available

- Basic Immunology
- Infectious Diseases
- Autoimmune and Inflammatory Diseases
- Vaccines and Immunotherapy
- Genetics
- Cell Signalling
- Cancer Biology
- Nano-biotechnology
- Structural Biology
- Computational Biology
- Chemical Biology and Biochemistry
- Aging Research
- Metabolic Disorders

Specialized Equipment

- Transmission Electron Microscopy
- Scanning Electron Microscopy
- Biomolecular NMR Facility
- X-Ray Crystallography
- Confocal Microscopy (Zeiss LSM 980 Meta System with Airyscan and Live Cell Imaging)
- Flow Cytometry
- Mass Spectrometry
- Cross Flow Filtration
- Fast Protein Liquid Chromatography
- Array System / Bio Plex-200
- Small Animal Imaging System with X-Ray
- Micro-computed tomography (CT) Imaging System
- NanoString Platform
- 10xChromium Single cell platform
- Seahorse XFe24 Metabolic Analyzer
- MinION Nanopore Sequencer
- Nextseq2000 from Illumina

Facilities available for Start-ups

The specialized equipment available under the SAHAJ scheme at NII are available for use by the start-ups.

Details: <https://www.nii.res.in/en/major-infrastructure-research>

Name of the Institute : National Institute of Plant Genome Research (NIPGR), New Delhi, India



Contact Person
Director, NIPGR New Delhi

Website URL
<https://www.birmingham.ac.uk/contact>

Email
director@nipgr.ac.in

About the Institute

The National Institute of Plant Genome Research (formerly known as National Centre for Plant Genome Research) is an autonomous institution aided by the Department of Biotechnology, Government of India. The Institute's establishment coincides with the 50th anniversary of India's independence as well as birth anniversary of Prof. (Dr.) J. C. Bose. The formal announcement was made on November 30th 1997. This Institute has already placed India among the major contributors to plant genomics. It is hoped that in coming years, the ongoing efforts of NIPGR will allow India to emerge as one of the most important national and international resource institutes for material, knowledge and technologies in the areas of functional, structural, evolutionary and applied genomics of plants, including crop plants.



Thrust Area (100 Words)

To conduct high-quality research in frontier areas of plant genomics and molecular biology, with the aim of having practical application in crop improvement. By utilizing molecular biology and omics approaches along with tissue culture and genetic engineering technology, the aim is to identify important genes/proteins/metabolites and manipulate these for generating plants with improved agronomic characters, biotic/abiotic stress tolerance and enhanced nutritional value.

Area of Expertise available

Plant genomics, plant breeding, metabolomics, plant molecular biology, plant developmental biology, proteomics and structural biology

Specialized Equipment

Mass spectroscopy, Confocal microscopy, ICP-MS, GC-MS, LC-MS/MS, HPTLC, U-HPLC, NextSeq 550, IntelliCube/ LGC Array, Octopure

Name of the Institute : Rajiv Gandhi Centre for Biotechnology (RGCB)



Contact Person
Prof. Chandrabhas Narayana, Director


Email
director@rgcb.res.in

About the Institute

The Rajiv Gandhi Centre for Biotechnology (RGCB), located in Thiruvananthapuram, is a pioneering institution renowned for its cutting-edge advancements in biotechnology. With a primary focus on genomics, proteomics, structural biology, and bioinformatics, RGCB leads the way in health biotechnology, genetic engineering, and nano-platform disease diagnostics, fueling the growth of a knowledge-based economy. Upholding values of excellence, integrity, and professional growth, RGCB fosters a culture of innovation and continuous learning. Through interdisciplinary research programs spanning various areas such as cancer, cardiovascular disease, regenerative biology, and neurobiology, RGCB unravels cellular and molecular disease mechanisms, driving breakthroughs in drug development and healthcare solutions. By offering PhD and postdoctoral programs, the institute plays a pivotal role in nurturing scientific talent and promoting entrepreneurship in biotechnology. RGCB provides essential support to researchers through state-of-the-art facilities and services including training programs, research consultancy, molecular platforms, histology core facility, proteomics, metabolomics, genomics, bioimaging, and advanced microscopy. Collaborating with Kerala Startup Mission, RGCB offers incubation support to biotech start-ups, further fostering innovation in the sector. With a commitment to "Discoveries for a Better Tomorrow," RGCB spearheads bio-manufacturing initiatives and remains dedicated to scientific research, evident through its extensive publication record. The institute's partnership with the Government of Kerala to establish a Centre of Excellence in Microbiome underscores its pivotal role in shaping the future of biotechnology. RGCB's relentless pursuit of excellence and innovation firmly establishes it as a global leader in biotechnological research and development.

Support received from BIRAC (If any)

The details of the projects supported under BIRAC-BIG is given below: 1. Portable Testing Kit: • Innovative solution - portable testing kit for analyzing methanol and formaldehyde in samples within 2 minutes • Technology developed - drop cast sample and reagents on a paper chip; color change and smartphone capture for quantification. 2. DENV Vaccine Development: • Challenges - genetic diversity, antibody dependent enhancement. • Salient features - targeting and engineering multi subunit antigens, consensus based sequence selection.



Area of Expertise available

The Rajiv Gandhi Centre for Biotechnology (RGCB) focuses on key thrust areas including health biotechnology, spice genetic engineering, and advanced disease diagnostics. Through innovative research in genomics, proteomics, structural biology, and bioinformatics, RGCB drives advancements in biotechnology for disease diagnostics, therapeutics, cancer treatment, and genetic disorder management. The institute excels in capacity building, education, and fostering entrepreneurship, leading to the establishment of spin-off ventures and startup initiatives. By promoting collaborations with industry partners, academia, and healthcare entities, RGCB contributes significantly to regional and global biotechnology and healthcare progress, shaping the future of healthcare and biotechnology through innovation and scientific expertise.

Specialized Equipment

- Biosafety Level-3 (BSL-3) Facility
- UltraFlex Xtreme MALDI-TOF/TOF (Bruker Daltonics)
- Synapt G2 HDMS Q-TOF connected with nanoAquity UPLC system (Waters)
- Orbitrap Eclipse Tribrid MS connected with UltiMate 3000 RSLCnano UHPLC or vanquish UHPLC system (Thermo Fisher Scientific)
- TSQ Altis Plus Triple Quadrupole MS connected with vanquish UHPLC system (Thermo Fisher Scientific)
- High Speed Flowcytometer Sorter System: (FACS Aria III)
- Transmission Electron Microscope (TEM) Thermo Scientific Talos F200i S(TEM)

Facilities available for Start-ups

- Analytical Chemistry Laboratory
- Phytochemistry Facility Laboratory
- DNA Sequencing Laboratory
- BioProcess Development and DSP Laboratory
- Tissue Culture Laboratory
- Common Facility Laboratory
- Central Histology Core Facility
- Raman Confocal Facility
- DBT-SAHAJ National Facility for Mass Spectrometry based Proteomics, Metabolomics and Lipidomics
- Central Bioimaging & Confocal Microscopy
- Central Flow Cytometry Core Facility
- Laboratory Medicine & Molecular Diagnostics (LMMD)
- Medical Laboratory Services (MLS)
- Molecular Forensic & DNA Technologies (MFDIT)



Name of the Institute : Regional Centre for Biotechnology



Contact Person
Dr. Anil Thakur

Email
director@rcb.res.in, anil.thakur@rcb.res.in

About the Institute

Regional Centre for Biotechnology (RCB) is an academic institution established by the Department of Biotechnology, Govt. of India with regional and global partnerships synergizing with the programmes of UNESCO as a Category II Centre. The primary focus of RCB is to provide world class education, training and conduct innovative research at the interface of multiple disciplines to create high quality human resource in disciplinary and interdisciplinary areas of biotechnology in a globally competitive research milieu. In 2016, RCB was recognised as an Institution of National Importance by the Parliament of India

Support received from BIRAC (If any)

RCB received a BioNEST grant for establishing the Bioincubator facility to support and nurture startups.



Thrust Area

The research at RCB covers various themes that come under the purview of Biotechnology which include, Infectious Disease Biology, Molecular Medicine, Cancer & Cell Biology, Agricultural Biotechnology, Systems & Synthetic Biology, & Structural Biology.

Area of Expertise available

Biotechnology, Cell Biology, Molecular Biology, Structural Biology, Bioinformatics, Genomics, Immunology, Cancer Biology, & Synthetic Biology.

Facilities available for Start-ups

BSL-3, Flow Cytometry, Mass Spectrometry, Optical Microscopy, Electron Microscopy, Mass Spectrometry, Genomics, Molecular Interactions, & Protein Purification facilities.

Specialized Equipment

BD Influx Cell Sorter, FACS analyzers, High Resolution 5600Plus Electrospray mass spectrometer, MALDI TOF TOF SYSTEM, MicroScale Thermophoresis (MST): Monolith NT.115, Biolayer interferometry (BLI): Octet Red 96e, DNA Sequencer: ABI 3500 Genetic Analyzer, Droplet Digital™ PCR: BIORAD ddPCR™, High Content Imaging (ImageXpress Microconfocal System), Super Resolution Microscope: Carl Zeiss Elyra PS.1, Laser Scanning Confocal Microscope: Carl Zeiss LSM 880, Electron Microscope – TEM, SEM, Cryo electron Microscope.

Name of the Institute : Translational Health Science and Technology Institute



Contact Person
Prof G Karthikeyan, Executive Director

Email
ed@thsti.res.in

About the Institute

BRIC-Translational Health Science and Technology Institute (BRIC-THSTI), an institute of Department of Biotechnology, is situated in NCR Biotech Science Cluster, Faridabad, Haryana. It brings together diverse scientific minds - physicians, biologists, chemists, mathematicians, and more - to translate innovative concepts into tangible healthcare products. The institute has fostered robust connections with academia and industry, creating a powerful network. THSTI has developed capabilities in indigenous vaccines, monoclonal antibodies, in vitro diagnostic kits, biotherapeutics, drug discovery and provides a scientific atmosphere for clinical research healthcare advancements.

Support received from BIRAC (if any)

BIRAC has significantly contributed to THSTI's research efforts by funding a variety of projects. These projects span diverse areas such as infectious diseases, vaccine development, maternal health, and genetic research. Notably, BIRAC-funded initiatives have supported the development of COVID-19 diagnostic tools, animal models for disease research, and platforms for studying pregnancy outcomes. Such collaborations have strengthened THSTI's capabilities in translational research and its ability to address critical healthcare challenges.



Thrust Area

Infectious Diseases (Viral and bacterial infections), Non communicable diseases with a focus on NAFLD, Product development viz., Vaccines Therapeutics, Diagnostics, Antimicrobial Resistance (AMR), Immunobiology & immunotherapeutics, Drug Design and Discovery, Biomaterials, Computational and Mathematical Biology, Maternal and Child Health

Area of Expertise available

Vaccines, Monoclonal antibodies, Therapeutics, Virus research, Diagnostics, Microbiome, Antimicrobial Resistance (AMR), Tuberculosis, Immunobiology & immunotherapeutics, Drug Design and Discovery, Biomaterials, Computational and Mathematical Biology, Maternal and Child Health, Clinical trials

Facilities available for Start-ups

Bioassay laboratory, BSL-3, Biorepository facility, Experimental animal facility, Data Management Centre, Multi OMICS facility, Immunology Core Laboratory, Vaccine design and development centre

Specialized Equipments

Annexure I

Name of the Institute : AMITY UNIVERSITY



Contact Person
Additional Director, DITT, Amity

Website URL
<http://saifaiims.com>

Email
mkanojia@amity.edu

About the Institute

UNIVERSITY – One of India's Leading Research & Innovation Driven Universities, NAAC A+ Accredited

Amity University in Delhi NCR is India's #1 ranked private not-for-profit University and has been ranked among the top 3% universities globally by QS and Times Higher Education, the world's leading university ranking organisations.

Amity's strong focus on research and innovation earned the honour of National Intellectual Property Award for being the top Indian Academic Institution for Patents and Commercialisation by the Indian Intellectual Property Office of the Ministry of Commerce & Industry, Govt. of India. Amity's faculty have filed over 1,840 patents, with 184 granted patents, and are engaged in more than 500 high-end government funded as well as international research projects and have authored over 900 books and published over 30,000 research papers in top ranked research journals.

Amity has academic & research partnerships with over 250 leading Universities globally, has its own campuses in 12 countries and established over 35 hi-end Research Centres in diverse areas. Amity has also been listed as one of the top universities in India by Atal Ranking of Institutions on Innovation Achievements (ARIIA), Ministry of Education (MoE), Govt. of India.

At Amity, the guiding motto for research is to take every innovation to commercial scale or finding pragmatic solutions to real-life problems. Over 40 innovations developed at Amity have already been commercially scaled up and are being used by leading organizations.

Support received from BIRAC

Several projects are completed with the support of BIRAC like:

Interaction of Nano-embedded Piriformospora Indica with the plant of medicinal importance, Brassica oleracea var Bortytis (Broccoli)

Novel approach to reduce zinc malnutrition in rural woman and children through agronomic bio-fortification of food crops.

Pilot Scale production of Plant Promoting Fungus piriformospora Indica a step forward towards commercialization.

Home based portable device integrated with smartphone app for simultaneous monitoring of glucose, HbA1c Glycated Hemoglobin and GA Glycated Albumin

Thrust Area

Nanotechnology, Material Sciences, Applied Sciences, Nanomedicine, Click Chemistry, Nuclear Science & Technology, Molecular Medicine, Stem Cell, Translational Research, Virology & Immunology, Food & Agriculture Neurosciences, Pharmaceutical Sciences, Public Health, Hospital Administration Defence technology, Cancer biology, genome engineering, hydrogen fuel, drug discovery and development, robotics, biofuels, herbal and natural products.

Area of Expertise available

Nanomedicine, Phyto chemistry, plant molecular biology, proteomics, structural biology, Artificial intelligence, Pharmaceutical sciences, Click chemistry, Advance materials, Microbial technology, Food technology, Bioinformatics, Marine Biology, Cancer biology, Molecular medicine, Enzyme technology, Biochemical engineering

Specialized Equipment

Mass spectroscopy, Confocal microscopy, GC-MS, HPLC, UPLC, XRD, FTIR, FACS, SEM, AFM, Tabletop NMR,

Facilities available for Start-ups

DITT: Directorate of Innovation and Technology Transfer

DST-Amity TEC provides preincubation services and helps startups in enabling their technologies.

Amity Innovation Incubator offers a range of incubation services to nourish entrepreneurial talent such as - Business Planning, Company formation, Legal & IPR assistance, Managerial Support, and Technology Support.

IPR Cell

Amity Design Centre

Entrepreneurship cell



Name of the Institute : ATMIYA University



Contact Person
Dr. Nishant Gopalan

Website URL
<https://atmiyauni.ac.in>

Email
eyuva@atmiyauni.ac.in

About the Institute

Established on April 13, 2018, under the Gujarat Private University Act 11, 2018, ATMIYA University emphasizes to train young minds in consonance with the doctrines of higher education and human values. The aim of this University is to spread eternal happiness and to create a happy society in letter and spirit. The motto Suhardam Sarva Bhootanam is an expression of willingness to attain harmony with each creation of the Almighty! His Divine Holiness Hariprasad Swamiji Maharaj, the present spiritual successor of Lord Swaminarayan is the mentor of ATMIYA University. With His blessings, His Divinity P.P.Tyagvallabh Swamiji has envisioned Atmiya University to be a global leader in showing the path to enshrine Jeevan Vidya into every domain area of higher education, in the pursuit of transformative outcomes of education for living life to the fullest. For this, over the years, He has invested His sweat and toil and that of His team, to create state-of-the-art learning facilities and spaces. The ultimate goal is to attain 'Atmiyata' Oneness.

Support received from BIRAC (if any)

E-Yuva Centre



Thrust Area

Spread over 23.5 acres of salubrious, divine yet busy campus, the ATMIYA University hosts the following: Value Education for Consciousness Development/Madyastha Darshan Faculty of Engineering & Technology Faculty of Health Science Faculty of Business & Commerce Faculty of Sciences Faculty of Humanities & Social Sciences While focusing on these thrust areas, Atmiya University consistently strive to work with the 17 Sustainable Development Goals prescribed by the UN.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Climate change impact and one health (health of human, animals and our shared environment including AMR/surveillance), Agriculture, IP related support and Technology transfer/Regulatory support, Others

Area of Expertise Others

ESG through Madhyastha Darshan

Facilities available for Start-ups

Incubator, Manufacturing Facilities, Lab renting facilities, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities Next-generation sequencing facilities

Name of the Institute : Bangalore Bioinnovation Centre



Contact Person
Dr. Mohamed Adil A.A

Website URL
<https://www.bioinnovationcentre.com/>

Email
director@bioinnovationcentre.com

About the Institute

Bangalore Bioinnovation centre BBC , jointly established in 2014 by department of Electronics, IT, BT, S & T, Government of Karnataka and Department of Biotechnology, Government of India as Not for profit organization, focused on nurturing innovation, entrepreneurship and skill development in life sciences domain. BBC provides cutting edge infrastructure specialized equipment, mentorship, networking opportunity, funding support to startups in life sciences focusing in healthcare, Medtech, pharmaceutical, allied medicine, integrated veterinary medicine, sustainability, clean and climate tech, Agriculture, agri tech, food tech, blue economy, Bio IT & SAAS, BIO electronics and industrial biotechnology for startups in TRL, CRL and MRL. BBC also obtained BIRAC Bionest scheme in Medtech in 2018. The present area is around 60,000sqft and new area under construction is 1,60,000 sqft within the campus. BBC is also the implementation partner for BIRAC BIG grants and seed funds. Total 280+ startups are associated with BBC and 51 startups have graduated. BBC also houses international startups from various countries. BBC also houses Bangalore Biobank, Bangalore DNA data bank, EHR and EMR Banks. Support received from BIRAC (if any)

Support received from BIRAC (if any)

1. Establishment of the centre from DBT.
2. BIRAC BIONEST 2018



Thrust Area

Medical Biotechnology, Agricultural Biotechnology, Industrial Biotechnology, Environmental Biotechnology, Food and Nutritional Biotechnology, Bioinformatics, Marine Biotechnology, Ipr, Ethics and Biosafety, Arid and Desert Biotechnology.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science) , Climate change impact and one health (health of human, animals and our shared environment including AMR/surveillance) , Agriculture , Biostatistics/data science and AI & ML , Clinical validation/ Clinical trials and GLP/cGCP/cGMP certifications, IP related support and Technology transfer/ Regulatory support , Others

Facilities available for Start-ups

Incubator, Manufacturing Facilities, Lab renting facilities, CTRI registered Ethics committee, Cloud computing platforms/ Servers, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities, Next-generation sequencing facilities

Name of the Institute: CSIR-Central Drug Research Institute, Lucknow



Contact Person
Director, CSIR-CDRI, Lucknow

Email
director@cdri.res.in

About the Institute

CSIR-CDRI is a premier biomedical research institute focused on the discovery and development of drugs, affordable technologies and diagnostics for diseases of relevance to India. Since its inception in 1951, the Institute has played a key role in the growth of the Indian Pharmaceutical Industry.

Institute has end-to-end drug discovery and development research capabilities which include structure-guided drug design, medicinal chemistry, in vitro screening, pharmacology, pharmacokinetics, formulation development and toxicology. The Institute works with clinical partners for Phase 1 and Phase 2 clinical studies.

The Institute offers services in the areas of medicinal and process chemistry, structural biology, toxicology, pharmacokinetics, formulation development and analytical chemistry.

Vision

To drive discovery and development of cutting edge and affordable healthcare technologies

Mission

Discovery and development of therapeutics for nationally important diseases with global impact, understanding fundamental disease biology and training future drug researchers

Mandate

- To develop new drugs for controlling diseases of national relevance
- To systematically explore the Indian flora & fauna for therapeutic potential
- To serve as a national nodal centre to convert 'hits' into 'new drug candidates'
- To provide co-working platform, process technologies and consultancy to pharma industry
- To conduct cutting-edge research in disease biology and to translate the results into bio-therapeutics to face challenges of the future
- To develop human resource specializing in diverse areas of drug discovery and development

For more details please visit: www.cdri.res.in

Support received from BIRAC (if any)

Supported projects:

1. Development of small molecule Inhibitor of PCSK-9- a new target for LDL receptor and atherosclerotic Cardiovascular disease.
2. Therapeutic targeting of neutrophil extracellular traps nets in Pulmonary fibrosis.
3. Development of Novel Small molecule SMAC Mimetics as Cancer Therapeutics.



Thrust Area

- Microbial Infections
- Viral infections
- Parasitic infections
- Neurological Disorders
- Metabolic disorders
- Endocrine Disorders
- Cancer
- Reproductive health

Area of Expertise available

Drug Discovery and Development

Specialized Equipment

- Bioprocessing facility (fermenter and downstream process)
- Proteomics and Metabolomics (GC, MS/MS; LC, HPLC- UPLC with MS and Triple Q-TOF, MALDI-TOF; QTRAP; HPTLC; LA-ICP-MS, NIR and FTIR etc)
- Animal cell culture facility
- Param Smriti - Super computer
- SPEEDY SEEDS- speed breeding facility

Facilities available for Start-ups

Common Research and Technology Development Hub - UP FDA Approved Drug Testing Facility

Formulation, Analytical and Bioanalytical R&D Services

- Pharmaceutical formulations
- Quality by design
- Stability studies
- Form 37 GLP DTL
- Bioanalytical site for PK, BA/BE,
- Form 29/CT-10 GMP site
- Consultancy and troubleshooting
- Regulatory filing

for more Information please email to: amit_misra@cdri.res.in

GLP Test Facility for Pharmaceuticals

for more Information please email to: tfm.cdri@cdri.res.in ; head.bdu@cdri.res.in

Biological Screening

CSIR-CDRI has developed a large number of Biological Assays and Screening Protocols to carry out biological activity studies of compounds against various diseases.

Researchers willing to get any of the tests carried out may email at: bio-screen@cdri.res.in

National Laboratory Animal Centre

- NLAC, national resource center in India established in 1952.
- House rodents and non-rodents (mouse, rat, hamster, gerbil, mastomys, guinea pig, rabbit, & monkey)

for more Information please email to: rajdeep.guha@cdri.res.in

Sophisticated Analytical Instrument Facility

- Established in 1974 with support of Department of Science & Technology
 - Provides sophisticated analytical services to scientists and other users from academic institutes, R&D laboratories and industries
 - Organizes short term courses / workshops
- for more Information please visit: <https://www.saiilucknow.org/>

Name of the Institute : CSIR-Indian Institute of Chemical Biology



Contact Person
Prof. Vibha Tandon

Email
director@iicb.res.in

About the Institute

The Institute was established in 1935 as the first non-official centre in India for biomedical research and was included within the aegis of CSIR in 1956. CSIR-IICB today is engaged in research on diseases of national importance and biological problems of global interest, employing sophisticated state-of-the-art technology in keeping with the rapid and unprecedented momentum that life science research has gained globally over the last 50 years.

CSIR-IICB is one of the major laboratories in India which initiated, right from its inception, multidisciplinary concerted efforts for conducting basic research on infectious diseases, specifically leishmaniasis and cholera, along with the development of technologies for the diagnosis, immunoprophylaxis, and chemotherapy of the diseases. The institute has developed an oral vaccine for cholera, herbal products for controlling gastric ulcer, empirical treatment for vitiligo, diagnostic kits for malignancy and hormonal disorders, fungal enzymes of industrial importance, radiopharmaceuticals for evaluation of the functional status of renal and hepatobiliary systems and a device for early detection of Parkinson's disease.

Efforts are now on to convert the knowledge gained over the years through high quality basic research into wealth.

Support received from BIRAC (if any)

Various ongoing projects being run with the support of DBT/BIRAC, including:

1. Hemostat – A Lifesaving Bandage for Faster Bleeding Arrest (BT/AIR0711/PACE-17/19)
2. Phase II/III clinical trials of an indigenously developed hepatitis E vaccine and evaluating its immune correlates



Thrust Area

Development of technologies for the diagnosis, immune-prophylaxis, and chemotherapy of the diseases. A neurobiology group is involved in research on the development of the vertebrate brain and also the genesis of human movement disorders. Bioactive substances from natural sources and chemically synthesized new molecules are being explored as potential drugs.

Other areas being actively pursued are gastric hyperacidity and ulcer, muscular dystrophy and related disorders, macromolecular structure function analysis, development of targeted drug delivery systems, sperm biology and protein chemistry and enzymology.

Area of Expertise available

The scientific staff has expertise in a variety of areas including chemistry, biochemistry, cell biology, molecular biology, neurobiology and immunology which promotes productive interdisciplinary interaction.

Facilities available for Start-ups

Expert mentorship available with state of the art analytical facilities for carrying out cutting edge research in the areas of chemistry, phyto-pharmaceuticals, biochemistry, cell biology, molecular biology, neurobiology and immunology with in-house Animal House and Central Instrumentation facilities.

Specialized Equipment

1. Atomic Force Microscope (AFM)
2. BD FACS Fortessa, 5 Laser
3. Chemidock Imaging System (Azure Bio System)
4. Circular Dichroism Spectropolarimeter (CD)
5. Dynamic Light Scattering
6. Spectrometer (DLS)
7. Fast Protein Liquid Chromatography (FPLC)
8. FTIR Spectrometer, GC MS
9. Matrix-assisted Laser Desorption / Ionization (MALDI)
10. NMR 600 MHz Spectrometer
11. ORBITRAP ANALYZER
12. Super Resolution Confocal Microscope
13. UV-Visible Spectrophotometer
14. Fluorescence Correlation Spectroscopy, etc

Name of the Institute : CVJ Centre for Synthetic Biology and Bio-manufacturing




Contact Person
Dr. Pawan K Dhar, Executive Director

Email
director@cvjsynbio.org

About the Institute

The CVJ Centre for Synthetic Biology and Biomanufacturing CSB is a collaborative initiative between Synthite Industries and Cochin University of Science and Technology CUSAT . The Centre has been established to honour one of India's pioneering entrepreneurs, Mr. C.V. Jacob, the founder of Synthite Industries. CSB operates as an independent registered society dedicated to advancing education, research, and entrepreneurship in the rapidly growing fields of Synthetic Biology and Biomanufacturing. CSB is nucleated on the philosophy of building capacity, building expertise and building enterprise by transforming synthetic biology and biomanufacturing space leading to socially useful solutions.



Thrust Area

Synthetic Biology, Biofoundry, Biomanufacturing

Area of Expertise available

Synthetic Biology, Biofoundry, Biomanufacturing

Facilities available for Start-ups

Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities, Next-generation sequencing facilities

Name of the Institute : Electron Microscope Facility, SAIF-
AIIMS New Delhi

Contact Person
Prof. Tapas Chandra Nag

Website URL
<http://saifaiims.com>

Email
tapas_nag@yahoo.com

About the Institute (250 Words)

An Electron Microscope Facility was established in 1971 in the Department of Anatomy, All India Institute of Medical Sciences AIIMS, New Delhi, by Prof. TC Anand Kumar. Recognizing its role and the need to create an electron microscopy center, the Department of Science and Technology DST, Government of India, upgraded this facility as a Regional Electron Microscope Facility in 1983. This center is presently known as Sophisticated Analytical Instrument Facility SAIF – AIIMS, New Delhi. It provides services to academic researchers in various disciplines, from biological, biomedical, and nanobiological to material sciences, from all over India to assist them in their research utilizing electron microscopy. Besides, it organizes regular training programs for researchers and scientists for manpower development in electron microscopy. The facility has scanning and cryo-transmission electron microscopes with EDS, a biological atomic force microscope, a confocal laser scanning microscope and state-of-the-art biological sample preparation equipment such as ultramicrotomes, a sputter coater, a critical point drier and a Zeta particle size analyzer. It has experienced technical and scientific staff to organize services for users and facility management. The Centre has many collaborative research activities with scientists in organizations and industries. It aims to develop new cutting-edge technologies based on multidisciplinary and translational research relevant to national goals. It would promote research collaborations with scientists from small and medium-scale industries for increased solutions to research objectives and innovations in products for use by society.



Thrust Area (100 Words)

- 1 Identifying new viruses and sub-viral agents that modulate immune response in human and experimental models.
- 2 Development of methodologies to delineate the pathogenesis of various neoplasms and their dynamic interactions at the organelle and molecular level by using the high-resolution ultrastructural, molecular and 3D organization of organelles and macromolecules.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science)

Specialized Equipment

Transmission Electron Microscope, Scanning Electron Microscope, Atomic Force Microscope, Confocal Laser Scanning Microscope

Facilities available for Start-ups

Incubator

Name of the Institute : Indian Institute of Technology Delhi



Contact Person
Dr Satish Kumar Dubey, Associate Professor SeNSE, IIT Delhi, Hauz khas, New Delhi- 110016, Delhi India

Website URL
<https://home.iitd.ac.in/>

Email
satishdubey@sense.iitd.ac.in

About the Institute

Indian Institute of Technology Delhi is one of the 23 IITs created to be Centres of Excellence for training, research and development in science, engineering and technology in India. Established as College of Engineering in 1961, the Institute was later declared as an Institution of National Importance under the "Institutes of Technology Amendment Act, 1963" and was renamed as "Indian Institute of Technology Delhi". It was then accorded the status of a Deemed University with powers to decide its own academic policy, to conduct its own examinations, and to award its own degrees. Since its inception, over 60000 have graduated from IIT Delhi in various disciplines including Engineering, Physical Sciences, Management and Humanities & Social Sciences. Of these, nearly 5070 received Ph.D. degrees. The number of students who graduated with B.Tech. degree is over 15738. The rest obtained Master's Degree in Engineering, Sciences and Business Administration. These alumni today work as scientists, technologists, business managers and entrepreneurs. There are several alumni who have moved away from their original disciplines and have taken to administrative services, active politics or are with NGOs. In doing so, they have contributed significantly to building of this nation, and to industrialization around the world.

Support received from BIRAC (if any)

Grant-in-Aid assistance to IIT Delhi, CDAC Kolkata, CSTM Kolkata and AIIMS Nagpur for the project entitled "Development of AI-enabled field portable microscope for detection of Filariasis" supported under Grand Challenges India GCI - Diagnostics for Neglected Tropical Disease NTD -Lymphatic Filariasis LF program. The project objective is to realize an AI enabled microscope for the diagnosis of the filariasis in Point of Care PoC settings. As the proposed solution can work for hematology applications, it is useful to diagnosis of other disease like malaria, sickle cell anemia etc. is cost-effective, It can be executed with minimum human resources.



Thrust Area (100 Words)

Teaching and Research

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science),

Biostatistics/data science and AI & ML,

IP related support and Technology transfer/ Regulatory support

Facilities available for Start-ups

Incubator, CTRI registered Ethics committee, 3D printing and prototyping

Specialized Equipment

Nano- Imprint Lithography, Electron Beam Lithography, Characterization facilities

Name of the Institute : Indian Institute of Technology Guwahati



Contact Person
Prof.S.Kanagaraj

Email
kanagaraj@iitg.ac.in

About the Institute

Indian Institute of Technology Guwahati, the sixth member of the IIT fraternity, was established in 1994. The academic programme of IIT Guwahati commenced in 1995. At present the Institute has eleven departments, seven inter-disciplinary academic centres and five schools covering all the major engineering, science, healthcare, management and humanities disciplines, offering B.Tech., B.Des., M.A., M.Des., M.Tech., M.Sc., MBA and Ph.D. programmes. Within a short period of time, IIT Guwahati has been able to build up world class infrastructure for carrying out advanced research and has been equipped with state-of-the-art scientific and engineering instruments. Besides its laurels in teaching and research, IIT Guwahati has been able to fulfil the aspirations of people of the North East region to a great extent since its inception in 1994. IIT Guwahati is the only academic institution in India that occupied a place among the top 100 world universities – under 50 years of age – ranked by the London-based Times Higher Education THE in the year 2014 and continues to maintain its superior position even today in various International Rankings. IIT Guwahati gained rank 32 globally in the 'Research Citations per Faculty' category and overall 364 rank in the QS World University Rankings 2024 released recently. IIT Guwahati has retained the 7th position among the best engineering institutions of the country in the 'India Rankings 2023' declared by the National Institutional Ranking Framework NIRF of the Union Ministry of Education.



Thrust Area

Biomedical Devices, Biomaterials, Prosthetic and Orthotic Devices, Biodesign program, Implants etc

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Biostatistics/data science and AI & ML, Others

Facilities available for Start-ups

Incubator, CTRI registered Ethics committee, Next-generation sequencing facilities

Name of the Institute : Institute for Applied Research and Innovation InARI



Contact Person
Saranya Kanukollu

Email
saranya@neuome.com

About the Institute

Bridging Academia and Industry for a Brighter Biotech Future At Institute for Applied Research and Innovation InARI – we are redefining the future of biotechnology education and industry engagement. Our journey began with a visionary goal: to complement university education by transforming students into job-ready professionals who excel not only in science but also in the management, marketing, and business development aspects of biotechnology and life sciences. Since our inception, InARI has partnered with over 20 leading companies/Institutes, addressing real-world challenges and creating a dynamic environment where students can apply their academic knowledge to practical, industry-driven problems. Our interdisciplinary team of senior scientists and industry experts work tirelessly as mentors, guiding students through every step of their professional development. At InARI, we believe that true innovation comes from the fusion of scientific inquiry and business acumen. Our programs are designed to provide hands-on experience, fostering a deep understanding of both the scientific and commercial landscapes of the biotech industry. This unique approach ensures that our students are not just proficient scientists but also strategic thinkers and effective leaders.



Thrust Area

Our goal is to transform innovative ideas into viable products and services, driving economic growth and improving lives globally. At InARI, we are dedicated to transforming students into job-ready professionals by immersing them in real-world challenges companies face in the biotechnology and life sciences sectors. Problem-Based Learning Pedagogy. The Institute for Applied Research and Innovation –where seasoned senior scientists converge to mentor and mould the biotech leaders of tomorrow. Our interdisciplinary team brings decades of collective expertise, spanning the breadth of biotechnology and life sciences. Beyond advancing scientific frontiers, our mentors empower students to navigate the complexities of the biotech.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Agriculture, Biostatistics/data science and AI & ML, Clinical validation/Clinical trials and GLP/cGCP/cGMP certifications, IP related support and Technology transfer/Regulatory support

Facilities available for Start-ups

Incubator, Lab renting facilities, TRI registered Ethics committee, Cloud computing platforms/Servers, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities

Name of the Institute : Integral University



Contact Person
Alvina Farooqui

Website URL
<https://www.iul.ac.in/>

Email
alvina@iul.ac.in

About the Institute

Integral University is situated in Lucknow, a city known for its culture, etiquette, monuments and role in the freedom struggle. Lucknow is the capital city of the largest state of India, and has a population of about 4.6 million. Lucknow is the capital city of Uttar Pradesh and it has always been a multicultural city. Integral University has a unique culture of inclusiveness, diversity, personal and intellectual integrity and value-based education. The curriculum has a strong focus on individual growth and the development of essential tools so that its students make a mark in the corporate world and the field of technology. These are solidly supported by a highly qualified and trained team of accomplished faculty and robust academic infrastructure. It was established under the Act Number 9 of 2004 by the State Government. The University is duly approved by the University Grants Commission UGC under section 2 f and 12B of the UGC Act, 1956, Medical Council of India, Pharmacy Council of India, Indian Nursing Council, Council of Architecture, Bar Council of India, Indian Association of Physiotherapists, National Council for Teacher Education, UP State Medical Faculty. The University maintains a decent and decorous atmosphere in the campus. The campus is highly disciplined and ragging-free, with all modern amenities for pursuit of higher education and sports. The campus provides state-of-the-art hostel accommodation, with the capacity to host 2600 students in the hostels, and houses a 550-bedded hospital, as part of the Medical College, with state-of-the-art medical facilities.



Thrust Area (100 Words)

Biotechnology, food technology, Agricultural Biotechnology, cancer biology, Allied health sciences, Bioinformatics, Industrial Biotechnology, Environmental technology, Artificial intelligence and machine learning.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Climate change impact and one health (health of human, animals and our shared environment including AMR/surveillance), Agriculture, Biostatistics/data science and AI & ML, Clinical validation/Clinical trials and GLP/cGCP/cGMP certifications, IP related support and Technology transfer/Regulatory support

Facilities available for Start-ups

Incubator, Manufacturing Facilities, Lab renting facilities, CTRI registered Ethics committee, Cloud computing platforms/Servers, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities

Specialized Equipment

HPLC, LC-MS, FTIR, CONFOCAL MICROSCOPE, ICPMS, XRD, LYOPHILIZER, PCR

Name of the Institute : Interactive Research School for Health Affairs, Bharati Vidyapeeth Deemed to be University



Contact Person
Dr. Harshad Padmanabh Patil

Email
harshad.patil@bharativedyapeeth.edu

About the Institute

Interactive Research School for Health Affairs IRSHA is a unique constituent unit of Bharati Vidyapeeth. The institute is mandated to conduct biomedical research in priority areas of human health. The core area of research encompasses Mother and child health, Cancer, Obesity- Diabetes, Herbal medicine and Communicable Diseases. The institute strives to foster a balance between the pursuit of basic knowledge and applying outputs of research for societal benefits. There is equal emphasis on student learning that is reflected in the vibrant and robust post-doctoral program that aims to impart research training to the next generation. IRSHA has received competitive grants from funding Agencies like DBT, ICMR, DST, Ayush and Wellcome Trust. The services of the Institute have been availed by many leading pharmaceutical industries. The institute is working in collaboration with the institutes on university campus like Medical, Ayurveda, Homeopathy, Dental colleges, Rajiv Gandhi Institute of IT & BT, Environmental sciences etc. It has also developed strong networks with National and International Institutes working in similar research areas. IRSHA looks to the future with a vision to develop and position itself as a premium research organization in the country and is committed to striving for channelizing its core strengths in the pursuit of excellence.

Support received from BIRAC (if any)

National Immunogenicity and Biologics Evaluation Center, NIBEC, was established in the year 2019, jointly by IRSHA-BVDU and the DBT/BIRAC-National Biopharma Mission. The primary mandate of the centre was to standardize, validate, get accreditation of the front line tests to evaluate immunogenicity of vaccines in clinical trial. A State of art facility was established having BSL-2 and BSL-3 laboratories. In 2021, NIBEC received additional funds under Mission COVID Suraksha for capacity enhancement of NIBEC for assessing the immunogenicity of SARS-CoV-2 vaccines. Various tests for dengue, chikungunya and SARS-CoV-2 have been accredited by NABL under ISO 17025.



Thrust Area

1. Communicable Diseases 2. Mother and Child health 3. Innovative Nutrition 4. Integrative Health

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Agriculture

Facilities available for Start-ups

Incubator, Lab renting facilities

**Name of the Institute : Jawaharlal Nehru University Participants:
School of Biotechnology**



Contact Person
Dr. Jaydeep Bhattacharya

Email
jaydeep@jnu.ac.in

About the Institute

Jawaharlal Nehru University is one of the premier Institute in India. Jawaharlal Nehru University was established in 1969.

The School of Biotechnology (SBT) is one of the schools in JNU. It was founded in 1985 as the first human resource centre of Biotechnology by the Department of Biotechnology, Ministry of Science and Technology, Government of India. The school is equipped with faculty members having graduated from reputed academic institutions and universities of our country and abroad with diverse and interdisciplinary backgrounds aligning with national strategic development policies and their demands. Various elective courses floated by experienced faculty of the school enables the students to choose and get specialized in the area of their research interest. The school has been awarded UGC-SAP, DST-FIST, and DBT-BUILDER programs in participation with other schools of the university. SBT's mission is to expand its reach and to nurture innovative minds through education, professional development, and advancements in biotechnology knowledge.

Support received from BIRAC (If any)

1. A low cost portable microfluidics embedded on chip rRT-PCR and microelectrode array coupled point-of care optoelectronic device for large scale screening of emerging viral disease like SARS COV2. 2. Bioengineered meso porous dialysis Nano Beads for the specific removal of excess Body Toxins, water and ions from Kidney failure patients



Thrust Area

Nanobiotechnology, Low cost point of care device for healthcare, Biomanufacturing, Molecular Farming, Cancer Biology, Bioprocess Engineering

Area of Expertise available

Nanobiotechnology, Instrumentation, Optogenetics, Bioprocess Engineering, Plant Biotechnology, Infectious disease biology, Cancer Biology, Human Molecular Genomics, Protein Chemistry, Chemical Biology, Bioinformatics, Environmental Biotechnology, Molecular and Cellular basis of Viral Oncogenesis, Molecular and Cell Biology of Rare Diseases, Microbiome Biotechnology

Facilities available for Start-ups

Electron Microscopy, AFM, NMR, FACS, Lithography, Microscopy facility, Cell Culture facility on charge basis

Specialized Equipment

Electron Microscopy, AFM, NMR, FACS, Maskless Lithography, Microscopy facility, Cell Culture facility,

Name of the Institute : JSS College of Pharmacy



Contact Person
Dr. T.M. Pramod Kumar

Website URL
<https://jssuni.edu.in/jsscollegeofpharmacymysuru/cpm-home.html>

Email
pramodkumar@jssuni.edu.in

About the Institute

Jagadguru Sri Dr. Shivarathri Rajendra Mahaswamijalavaru, the 23rd pontiff of Sri Suttur Veerasimhasana Math was the architect and founder president of JSS Mahavidyapeetha, which came into being in 1954. With the divine inspiration of Sri Swamiji, the JSS College of Pharmacy was started in the year 1973. JSS College of Pharmacy is a constituent college of JSS AHER, Mysore. The institution offers B. Pharm 4 years , Pharm. D 6 years , Pharm.D PB 3 years , M.Pharm 2 years in twelve specializations and Ph. D. The college is recognized by Government of Karnataka and approved by Pharmacy Council of India PCI , New Delhi and All India Council for Technical Education AICTE , New Delhi. It is accredited to National Board of Accreditation NBA , AICTE, New Delhi. The institute is presently ranked as the top 6th pharmacy college in the country by NIRF, MHRD, Govt. of India and has consistently remained in the top 10 positions in NIRF ranking.



Thrust Area

Pharmaceutical Biotechnology, Pharmaceuticals, Centre for Excellence in Regulatory Sciences, Pharmacology, Pharmaceutical Chemistry, Pharmaceutical Analysis, Pharmacognosy, Quality Assurance, Industrial Pharmacy, Pharmacy Practice

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science)

Facilities available for Start-ups

Incubator, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities



Name of the Institute : La Trobe University



Contact Person
Sid Jain

Email
sid.jain@latrobe.edu.au

About the Institute

For over 50 years, La Trobe University has transformed individuals and societies. Ranked among the world's top 250 universities QS World University Rankings 2025, La Trobe fosters collaborations and partnerships to support the innovation and translation of research for real-world impact. La Trobe Industry drives the University's engagement with industry, government, academia and the community. Partnerships provide students, alumni, and entrepreneurs with learning opportunities to grow and thrive in their communities. Facilities including the new La Trobe Digital Innovation Hub and Bio Innovation Hub, support businesses in their growth and transformation through technology, AI, PC2 laboratories, an ecosystem of academics and researchers, a talent pipeline, and more.



Thrust Area

Biotechnology, biomedicine, agriculture, agritechology, food, nutrition, allied health, sport science, business, entrepreneurship, regional/rural, digital transformation, digital technology, AI, machine learning, medical innovation

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science, Climate change impact and one health (health of human, animals and our shared environment including AMR/surveillance), Agriculture, Biostatistics/data science and AI & ML, Clinical validation/Clinical trials and GLP/cGCP/cGMP certifications, IP related support and Technology transfer/Regulatory support

Facilities available for Start-ups

Incubator, Manufacturing Facilities, Lab renting facilities, CTRI registered Ethics committee, Cloud computing platforms/Servers, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities

Specialized Equipment

La Trobe University Research Platforms - Bioimaging Platform, Genomics Platform, Proteomics and Metabolomics Platform, Statistics Consultancy Platform, La Trobe Animal Research and Teaching Facility,

Name of the Institute : Mauritius Institute of Biotechnology Ltd



Contact Person
Nandini- Gooly-Gopalla

Email
nandini.gopalla@miblmu.com

About the Institute

Mauritius aspires to rise as a regional Centre of Excellence in the field of Biotechnology by capitalizing on sustained and consolidated growth in established sectors while setting the scene for new segments. The Mauritius Institute of Biotechnology Ltd MIBL has been set up by Government to spearhead the development on Medical Biotech, Marine Biotech, Industrial Biotech, Environmental Biotech and Agricultural Biotech sectors. MIBL acts as an institutional catalyst and facilitates projects in the field of biotechnology. MIBL is also mandated to invest in such projects.

Other Facility

Government funding and Partnership facilitation

Thrust Area (100 Words)

Biotechnology - Medical Biotech, Marine Biotech, Industrial Biotech, Environmental Biotech and Agricultural Biotech

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Agriculture, IP related support and Technology transfer/Regulatory support, Others

Facilities available for Start-ups

Incubator, Lab renting facilities, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities, Next-generation sequencing facilities

Name of the Institute : National Research Development Corporation



Contact Person
VK Jain

Website URL
<https://nrdcindia.com/>

Email
vkjain@nrdc.in

About the Institute

National Research Development Corporation NRDC was established in 1953 by the Government of India, with the primary objective to promote, develop and commercialize the technologies / know-how / inventions / patents / processes originating from various national R&D institutions / Universities. NRDC is fully owned by Government of India and is registered under the Companies Act, 1956, and is now being administered under Section 8 of the Companies Act, 2013. NRDC is presently under the administrative control of the Department of Scientific & Industrial Research DSIR, Ministry of Science & Technology MoS&T, Bharat Sarkar.



Thrust Area

Technology transfer

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science) ,

Agriculture ,

IP related support and Technology transfer/ Regulatory support

Facilities available for Start-ups

Incubator, Lab renting facilities, 3D printing and prototyping, Cell culture/ tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities

Name of the Institute : SADGURU NETRA CHIKITSALAYA, SHRI SADGURU SEVA SANGH TRUST - Ophthalmology Clinical Trial Network,



Contact Person
Dr.Poonam Jangid

Website URL
<https://sadgurustrust.org/index.php>

Email
poonamjangid@ioctn.org

About the Institute

Shri Sadguru Seva Sangh Trust SSSST Founded in 1968 by Param Pujya Ranchhodasji Maharaj. This trust is a humanitarian organization emphasizing selfless service and righteousness. Renowned for initiatives like Food for the Hungry and Clothes for the Destitute, It is one of the largest Rural Eyecare Institutions which got recognized worldwide as the 'Best Rural Eyecare Model' in the region. Sadguru Netra Chikitsalaya, a premier Tertiary Eye Care Hospital and Post Graduate Institute of Ophthalmology, boasts a unique value proposition. With a 54-year legacy, it has earned national and international acclaim for its commitment to eliminating curable blindness in rural central and northern India. As one of India's largest NGOs in the field, it has served over 20.1 million beneficiaries. The hospital specializes in all ophthalmic subspecialties, equipped with cutting-edge technology and modern facilities, ensuring high-quality, affordable eye care. Its extensive network of 110 Vision centres across Uttar Pradesh and Madhya Pradesh reaches a million patients annually. The hospitals 26 state-of-the-art modular operation theatres and team of 150+ ophthalmologists facilitate over 150,000 surgeries each year. With over 2000 staff members and more than 200 publications, Sadguru Netra Chikitsalaya remains at the forefront of ophthalmic care and research.

Support received from BIRAC (if any)

Sadguru Netra Chikitsalaya is a collaborative site of the Ophthalmology Clinical Trial Network, supported by NBM BIRAC. It is part of a multicentric ophthalmology network and received a grant of 162.97 lakh. With support of BIRAC SNC developed training modules for clinical research and established an IP storage facility on-site, equipped with deep freezers ranging from -80°C to 2°C to 8°C. A fully equipped laboratory has been set up in accordance with Good Clinical Practice GCP standards. We have also established the necessary processes and infrastructure to meet GCP requirements, with archival facilities available on-site.



Thrust Area

Sadguru Netra Chikitsalaya has been dedicated to eliminating curable blindness in rural central and northern India for over 54 years. It functions as a modern Tertiary Eye Care Hospital, offering advanced ophthalmological services. The hospital conducts numerous eye surgeries and provides various clinical services. Additionally, it hosts training programs to develop healthcare professionals in ophthalmology, emphasizing knowledge and awareness to prevent blindness.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Agriculture, Biostatistics/data science and AI & ML, Clinical validation/Clinical trials and GLP/cGCP/cGMP certifications, IP related support and Technology transfer/ Regulatory support, Others

Facilities available for Start-ups

Incubator, Lab renting facilities, CTRI registered Ethics committee, Cloud computing platforms/Servers, 3D printing and prototyping, Cell culture/ tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities, Next-generation sequencing facilities

Specialized Equipment

At SNC, developed training modules for clinical research and an IP storage facility available at site, which includes deep freezers with temperature r

Name of the Institute : SATHYABAMASAT



Contact Person
Vice Chancellor

Website URL
<https://www.sathyabama.ac.in/>

Email
vc@sathyabama.ac.in

About the Institute

Sathyabama is a prestigious institution which excels in the fields of Engineering, Science and Technology for more than three successful decades. It offers multidisciplinary academic programmes in various fields of Engineering, Science, Technology, law, Dental Science, Pharmacy, Nursing, Management, Arts and Science and Allied Health Sciences. It is established under Sec.3 of UGC Act, 1956 and is been Accredited with 'A++' Grade by the National Accreditation and Assessment Council. The Institution has been Graded as Category I University by UGC under the UGC Categorization of Universities only for Grant of Graded Autonomy Regulations, 2018. The Institution persistently seeks and adopts innovative methods to improve the quality of higher education and is responsive to the changes taking place in the field of education on a global scale. The Institution has a team of dynamic and outstanding faculty, innovative pedagogical practices, state of the art infrastructure and world class Research Facilities. Sathyabama has been ranked in 51st position by the National Institutional Ranking Framework NIRF, Government of India among the Universities in India for the year 2024 and ranked one among the top 100 Universities for eight consecutive years. Sathyabama is ranked among the Top 5 Institutions in the Country for Innovation by ATAL ranking of Institution for Innovation Achievements, Govt. of India. Times Higher Education and QS has ranked Sathyabama among the top Institutions worldwide. In addition, Sathyabama launched "SATHYABAMASAT" in association with ISRO.

Support received from BIRAC (if any)

Support received from BIRAC if any : Sathyabama Institute of Science and Technology has received funding support from BIRAC under PACE scheme for the project Production, characterization and scaling-up of earthworm coelomic fluid based serum-free cell culture medium for animal cell culture Ref. No.BT/AIR0846/PACE-18/19 for the year 2020 to 2022



Thrust Area (100 Words)

Artificial Intelligence and Machine Learning Robotics and 3D printing and prototyping Cell culture/tissue culture Stem cell research and regenerative medicine Marine Biology and Climate Change Remote sensing and GIS Vector Borne Disease and Control Drug Discovery and Development Nanomaterial synthesis and Bioimplants

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Climate change impact and one health (health of human, animals and our shared environment including AMR/surveillance), Agriculture, Biostatistics/data science and AI & ML, IP related support and Technology transfer/ Regulatory support

Facilities available for Start-ups

Incubator, Manufacturing Facilities, Lab renting facilities, CTRI registered Ethics committee, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities

Specialized Equipment

XPS, Nikon Confocal Microscopy with NSPARC technology, Cell Vivo organoid incubator, 3D Bioprinter, Flow Cytometry

Name of the Institute : Shiv Nadar Institution of Eminence Deemed to be University Delhi/NCR



Contact Person
Dr.Sanjeev Galande

Email
sanjeev.galande@snu.edu.in

About the Institute

The Shiv Nadar Institution of Eminence is a multidisciplinary, student-centric research university established in 2011 by Shiv Nadar, one of India's foremost philanthropists and a pioneer of the technological revolution. It has four Schools, viz., Engineering, Natural Sciences, Humanities and Social Sciences, Management & Entrepreneurship, and the Academy of Continuing Education. We were the first university in the country to offer a 4-year multidisciplinary research degree. Today, we are continuing as trailblazers with new kinds of curriculum championed by faculty drawn from some of the top institutions in the country and the world. With low faculty-student ratios, their in-depth attention to students leads to high levels of student success. Vision To become a globally recognized research university committed to excellence in teaching, discovery and innovation, scholarship, and service so as to expand the scope of human understanding and contribute to the betterment of the world. Mission • To develop and educate the path-shapers of tomorrow, capable of responsible and ethical leadership. • To support research, scholarly, and creative endeavors that contribute to the creation of new knowledge at the frontiers of specialized areas, as well as at the interface of diverse disciplines. • To establish research and teaching programs to address the most pressing problems of India and the global community.



Thrust Area

Shiv Nadar Institution of Eminence Deemed to be University, Delhi/NCR, is a multidisciplinary institution offering a wide range of disciplines. It aims to become one of the leading research-led universities in the world, with key thrust areas including Molecular and Systems Biology, Regeneration Biology, Translational Biology, Chemical Biology, Computational Chemistry, Materials Chemistry, Materials Science, Computational and Mathematical Physics, Particle and Dark Matter Physics, Astrophysics, Soft Matter Physics, Sustainable Infrastructure Systems, Urban Network Systems, Computational Mechanics, Green Technologies, Smart Materials and Advanced Manufacturing, Artificial Intelligence, Machine Learning, Data Science, and Big Data Analytics to name a few.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Climate change impact and one health (health of human, animals and our shared environment including AMR/surveillance), Agriculture, Biostatistics/data science and AI & ML, Clinical validation/ Clinical trials and GLP/cGCP/cGMP certifications, IP related support and Technology transfer/ Regulatory support

Facilities available for Start-ups

Incubator, Manufacturing Facilities, Lab renting facilities, CTRI registered Ethics committee, Cloud computing platforms/ Servers, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities

Specialized Equipment

To name a few, specialized equipment includes Gas Chromatography/Gas Chromatography-Mass Spectrometry GC/GC-MS, Matrix-Assisted Laser Desorption/Ionization MALDI, Liquid Chromatography-Mass Spectr

Name of the Institute : SHRIRAM INSTITUTE FOR INDUSTRIAL RESEARCH



Contact Person
Ms Sukanya Dikshit

Website URL
<https://sriramgurugram.org/>

Email
sukanyadikshit@dcmsr.com

About the Institute

Shriram Institute, Gurugram is a derivative branch of the Shriram Institute for Industrial Research, an establishment with a storied legacy initiated by the distinguished Sir Shriram in 1947 and commencing operations in 1950. Emphasizing the imperative for India to advance by assimilating and innovating upon existing technologies through research, Sir Shriram laid the foundation for the institutes direction. The institutes robust framework is supported by its competent staff, a seasoned and expert Governing Board, alongside inventive management strategies. Shriram Institute has expanded its focus in Materials Science to include innovative fields like Blood bags, Cactus Latex products, Biomaterials, Aerospace materials, Electronic Polymers, Advanced Adhesives, Composites, Specialty Chemicals, Renewable resources, Radiation technologies, Herbal Products, Waste Utilization, and Technical Consultancy. Being a distinguished client at Shriram Institute For Industrial Research, Gurugram means you'll consistently engage with your dedicated account manager and specific laboratory representatives. Our ethos is centered on forging a close-knit relationship with our clients, often becoming perceived as an integral part of their team. One of our major focuses is on skill upgradation and training, and we are committed to providing state-of-the-art training infrastructure in Civil and Hydrogen labs and delivering comprehensive programs designed to empower individuals with the latest industry-relevant skills, ensuring they are well-equipped to meet the evolving demands of Industry 5.0. Our expert team of highly qualified PhD level Nanotechnologists, Engineers, Validation & Regulatory Professionals have been delivering industry leading laboratory services here for 7 decades.

Support received from BIRAC (if any)

Projects applied for - BIO-NEST & BIO-FOUNDRY



Thrust Area

Shriram Institute for Industrial Research Gurugram focuses on application-oriented research across several key areas, including clean energy, nanomaterials, infrastructure, and electrochemical technologies. The institute's Clean Energy Lab specializes in hydrogen production, storage, and nanomaterial synthesis for sustainable energy. Its Infrastructure Lab offers material strength and durability testing, while the Electrochemical and Fuel Cell Lab focuses on fuel cell material development and testing. Additionally, the Nanomaterials Lab conducts advanced water and environmental quality analysis using cutting-edge nanotechnology. SRIFIR provides comprehensive validation services, consultancy, and specialized training across these sectors?

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Climate change impact and one health (health of human, animals and our shared environment including AMR/surveillance), Agriculture, IP related support and Technology transfer/Regulatory support, Others

Area of Expertise Others

Infrastructure & New Materials
Nanomaterials & Polymers

Facilities available for Start-ups

Incubator, Manufacturing Facilities, Lab renting facilities, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities, Next-generation sequencing facilities

Specialized Equipment

XRD, BET, FTIR, HPLC, Prep HPLC, GC-MS, DSC, STA, UV-Vis & ICP-OES.

Name of the Institute : SRM Institute of Science & Technology



Contact Person
Dr. Shantanu Patil

Email
director.dei@srmist.edu.in

About the Institute

SRM Institute of Science and Technology SRMIST is one of India's premier educational institutions, renowned for its innovation-driven academic and research environment. Located in Chennai, Tamil Nadu, SRMIST offers a wide array of undergraduate, postgraduate, and doctoral programs across various disciplines, including engineering, medicine, management, humanities, and sciences. SRMIST is distinguished by its strong focus on research and development, fostering collaborations with leading global universities and industry partners. The institution is home to several centers of excellence, including those in advanced manufacturing, healthcare innovation, and nanotechnology, which drive cutting-edge research that addresses real-world challenges. A significant feature of SRMIST is its vibrant startup ecosystem, nurtured through initiatives like the Directorate of Entrepreneurship and Innovation and the BIRAC Bio-nest at SRM Medical College Hospital & Research Centre. These platforms provide aspiring entrepreneurs with the necessary support to transform their ideas into successful ventures, particularly in the biotechnology and healthcare sectors. SRMIST's commitment to global engagement is evident in its extensive network of international collaborations and student exchange programs. The institutes global outlook is also reflected in its diverse student body, which represents over 50 countries. At Global Bio India 2024, SRMIST aims to showcase its contributions to the biotech industry, particularly in the fields of healthcare innovation and clinical validation. Through its interdisciplinary approach, SRMIST continues to shape the future of education, research, and innovation on both national and global stages.

Support received from BIRAC (if any)

BIRAC Bio-NEST to showcase the SRMIST contributions to the biotech industry, particularly in the fields of healthcare innovation and clinical validation, and SRM Centre for Clinical Trials & Research received funding from BIRAC and successfully conducted the COVAXIN Clinical Trials Phases 1, 2, and 3.



Thrust Area

State-of-the-art research facility in medical college, healthcare innovation, clinical validation, clinical trials, ethical and rigorous maintenance of patient confidentiality during trials, industrial biotechnology, agriculture, and intellectual property & tech transfer support.

Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science), Agriculture, Biostatistics/data science and AI & ML, Clinical validation/Clinical trials and GLP/cGCP/cGMP certifications, IP related support and Technology transfer/Regulatory support.

Facilities available for Start-ups

Incubator, Lab renting facilities, CTRI registered Ethics committee, Cloud computing platforms/Servers, 3D printing and prototyping, Cell culture/tissue culture / Biosafety Level 3 and 4 (BSL-3 and 4) facilities

Specialized Equipment

HRTEM, HRTEM, XRD, Teecan, and etc. SRM Facilities: <https://www.srmist.edu.in/research/scif/scif-facilities/> Carl Zeiss Elyra PS.1, Laser Scanning Confocal Microscope: Carl Zeiss LSM 880, Electron Microscope - TEM, SEM, Cryo electron Microscope.



Name of the Institute : University of Birmingham WMHTIA



Contact Person
Business Engagement

Website URL
<https://www.birmingham.ac.uk/contact>

Email
wmhtia@contacts.bham.ac.uk

About the Institute (250 Words)

The WMHTIA is focused on helping companies with the challenges of commercialising their products. Uniting 20 partners across academia, industry and NHS under one cohesive programme - we provide companies access to services and expertise that are essential in critically developing technologies. The WMHTIA is funded by the Department for Science, Innovation and Technology, in partnership with Innovate UK and the West Midlands Combined Authority.

Support received from BIRAC (If any) (100 Words)

To attend GBI

Thrust Area (100 Words)

Health Tech, Healthcare,


Area of Expertise available

Healthcare (public health/medicine/therapeutics/diagnostics/devices/vaccines/basic science)

Facilities available for Start-ups

Incubator







DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology



STATES

(Pg. No. 266-271)



STATES		
Sl. No.	Company Name	PAGE NUMBER
1	Gujarat State Biotechnology Mission	268
2	Kerala Lifesciences Industries Parks P Ltd & Kerala State Council for Science , Technology and Environment	268
3	Punjab Biotechnology Incubator	269
4	Science & Technology Department,Government of Odisha	269
5	Startup-Bihar	270
6	Tamil Nadu	270
7	Telangana Life Sciences Foundation	271
8	Uttarakhand Council for Biotechnology	271



Name of Organisation : Gujarat State Biotechnology Mission



Contact Person
Mr. Hadmat Gadhavi

Website
<https://btm.gujarat.gov.in/>

Email
mnbtm7@gujarat.gov.in

Description of Exhibit

Apart from the institutions built by the state Government, in the form of GSBTM, GBRC, STBI and GBU the state government has come up with Biotechnology Policy 2022-27, reiterating the commitment of Gujarat to promote rapid and inclusive growth in the biotechnology sector in Gujarat. The Policy offers several attractive incentives to companies setting up operations in the state. This policy will provide 25 CapEx support, 15 OpEx support for 5 years, 7 Interest Subsidy for 5 years and many such incentives with a special support for Mega/ Special/ Ecosystem Strengthening Projects.

Organisation Profile

The Gujarat State Biotechnology Mission, established in 2004, serves as the facilitation arm of the Government of Gujarat for biotechnology. Its primary focus is to strengthen the research, business, and human resource pillars of biotechnology within the state. The Mission achieves this by providing funding, creating infrastructure, and developing institutional frameworks to support the overall growth of biotechnology. The state has introduced various schemes and programs that offer funding for research projects, financial incentives, and venture support for the biotechnology industry, as well as capacity-building initiatives for human resources.

Name of Organisation : Punjab Biotechnology Incubator



Contact Person
Dr. Ajit Dua

Website
<https://www.pbttilabs.com>

Email
ceo.dst.sasn@punjab.gov.in

Description of Exhibit

Government of Punjab as State Partner

Organisation Profile

Punjab Biotechnology Incubator PBTI, was jointly established by DBT-Gol and Department of Science, Technology and Environment GoP in 2005 as a registered society under Presidentship of Chief Secretary to GoP. PBTI is steering the development of Biotechnology Sector in Punjab. The State-of-the-Art facility of PBTI is spread over 60,000 sq. ft. area from where it is providing Advanced Analytical services, Contractual Research/Advisory Services, Knowledge & Upskilling services and Incubation services. To further expand the support for innovation in Life Sciences/ Biotechnology sector in Punjab State Government has transferred additional 4 acre land to PBTI for establishment of Global Innovation Hub.



Name of Organisation : Science & Technology Department,
Government of Odisha



Contact Person
Dr. Sashi Kanta Dash

Website
<https://st.odisha.gov.in/>

Email
deputydirector.btdst@gmail.com

Description of Exhibit

Science & Technology Department, Government of Odisha - The Land of New Opportunity.

Organisation Profile

Science & Technology Department,
Government of Odisha

Name of Organisation : Department of Industries,
Startup-Bihar



Contact Person
SHIVENDRA KUMAR

Website
<https://startup.bihar.gov.in/>

Email
startup-bihar@gov.in

Description of Exhibit

1.GrainX Full-Stack intelligent Crop management and e-commerce platform
2.Brihati Natural Food Pvt.Ltd. Our startup will provide health, lifestyle, and biomarker-based precision nutrition
3.GHAASPAAT Microgreens using Hydroponics
4.SMARTWAY ELECTRONICS PVT. LTD Oximeters and IR Thermometer
5.Minus Degree Manufacturers private limited. Innovative products made from plastic waste, like building materials, Home accessories, furniture, and gifts with our unique process.

Organisation Profile

Startup Bihar is an initiative aimed at transforming Bihar into a hub of innovation and entrepreneurship. The program focuses on fostering a supportive ecosystem for startups by providing access to funding, mentorship, and resources. It encourages aspiring entrepreneurs to turn their ideas into viable businesses, contributing to the states economic growth. By partnering with industry experts, government bodies, and educational institutions, Startup Bihar creates opportunities for skill development and innovation. The initiative is key to empowering local talent, boosting employment, and positioning Bihar as a dynamic player in the national startup landscape.



Name of Organisation : TICEL Bio Park Ltd.



Contact Person
Mr. P. Poongumaran

Website
<https://ticelbiopark.com/>

Email
md@ticelbiopark.com

Description of Exhibit

TICEL Bio Park will showcase the infrastructure with different Phases across Tamil Nadu. TIH provide co-working & cubicles spaces for incubation and instrumentation support to the startups. Biotechnology Core Instrumentation Facility BTCIF is a clean room facility complies with BSL-II with lab modules for Microbiology, Biochemistry, Molecular Biology, Cell culture & Bioprocess. TICEL has been undertaking services like of the CRO/CMO projects. It facilitates setting up a R&D, Pilot scale production of biopharmaceuticals, GMP & GLP facility. Startup TN services to the startup ecosystem in Tamil Nadu which empowers entrepreneurs by providing resources, mentorship, and opportunities to scale their ventures.

Organisation Profile

TICEL Bio Park Ltd. was established in 2004 by Govt. of Tamil Nadu at Chennai. It provides space facilities, equipment and testing facilities for biotech ecosystem. The TICEL Innovation Hub TIH has individual cubicles and co-working spaces for startups. TIH supports skill development program/joint certification program for the researchers and college students. StartupTN is the nodal agency of the GoTN, driving the growth of the states startup ecosystem through strategic initiatives, robust support systems, and fostering innovation across various sectors with a mission to make Tamil Nadu a global startup hub.

Name of Organisation : Telangana Life Sciences Foundation



Contact Person
Nikhila Karnam

Website
<https://lifesciences.telangana.gov.in/>

Email
pa5-hpc-icc@telangana.gov.in

Description of Exhibit

We will be showcasing the Telanganas life sciences ecosystem, Clusters like Genome Valley, Medical Devices Park and other initiatives in the sector.

Organisation Profile

TLSF incorporated by Government of Telangana is established with the objective of development of infrastructure and visibility for life sciences and med-tech industries in the state of Telangana and with a view to assist socio economic development of the state. The State of Telangana commissioned Medical Devices Park, Genome Valley, pharma villages others and is engaged in a plethora of functions, including incubation, mentoring, supporting and handholding of various life sciences companies.

Name of Organisation : Uttarakhand Council for Biotechnology



Contact Person
Dr. Manindra Mohan

Website
<https://ucb.ac.in/>

Email
manmicro59@gmail.com

Description of Exhibit

Exhibition of UCB activities and promotion of Biotechnological research

Organisation Profile

Uttarakhand Council for Biotechnology UCB is situated at Haldi, Pantnagar district Udham Singh Nagar, Uttarakhand established in February, 2003 as State Biotechnology Program SBP . In year 2014, SBP renamed as Uttarakhand Council for Biotechnology UCB under the Department of Science and Technology, Govt. of Uttarakhand. Now, UCB is working under Department of Agriculture, Govt. of Uttarakhand 07.08.2019. The UCB is fulfilling all the research, development and extension activity in state regarding Biotechnology.

Name of Organisation : Kerala Lifesciences Industries Parks P Ltd & Kerala State Council for Science , Technology and Environment



Contact Person
Sumi S Kumar

Website
<https://www.bio360.in/> <https://kscste.kerala.gov.in/>

Email
amadmsciencepark@gmail.com

Description of Exhibit

Kerala is rapidly emerging as a key player in the life sciences sector, leveraging its rich biodiversity and skilled workforce. The state offers significant growth and opportunities in biotechnology, biomedical sciences, bioinformatics, pharmaceuticals, nutraceuticals, ayurveda and genomics. Key agencies like Kerala State Council for Science, Technology and Environment KSCSTE and Kerala Lifesciences Industries Parks KLIP have been propagating the life science sector through sector specific schemes and incentives. Organisations like Kerala Biotechnology Commission, Jawaharlal Nehru Tropical Botanical Garden and Research Institute, Kerala Forest Research Institution and Bio 360 Life Science Park has been instrumental in providing the right ecosystem for the sector.

Organisation Profile

Kerala's strong research and development ecosystem positions it as a hub for life sciences and biotechnology advancement. The Kerala State Council for Science, Technology and Environment KSCSTE , drives scientific knowledge and policy development. JNTBGRI, KFRI, the Kerala Biotechnology Commission support biotechnology R&D and entrepreneurship and upcoming three Science Parks fosters Research and Development, International Partnerships. Kerala Lifesciences Industries Park under Kerala State Industry Development Cooperation serves to promote startups and life science industry. It houses core testing facilities and R&D institutions in the field of Life Sciences. The park provides the infrastructure facility to facilitate the translation of research into quality accredited products by setting up manufacturing facility.

Partners

Ecosystem Enablers



INVEST INDIA

#startupindia



Event Partners



FICCI



Pursuing
Infinite
Opportunities



**DELHI
NCR**

FOSTERING ENTREPRENEURSHIP



Session Partners



International Facilitation Partner



GBI

GLOBAL
BUSINESS
INNOVATION
CONSULTING - EXCELLENCE BELIEVED



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology



Biotechnology Industry Research Assistance Council
Central Public Sector Enterprise (CPSE), Under Department of Biotechnology (DBT)
Ministry of Science and Technology, Government of India
5th Floor, NSIC Business Park, NSI Bhawan, Okhla Industrial Estate, New Delhi - 110020